Cardiovascular
Genetics and
Genomics for
the Cardiologist
EDITED BY
Victor J. Dzau, MD
James B. Duke Professor of Medicine
Director, Mandel Center for Hypertension
and Atherosclerosis Research
Chancellor for Health Affairs
Duke University
Durham, NC, USA
Choong-Chin Liew, PhD
Professor Emeritus, Department of Laboratory
Medicine and Pathobiology,
University of Toronto
Toronto
Ontario, Canada
and (formerly) Visiting Professor of Medicine
Brigham and Women’s Hospital
Harvard Medical School
Boston, MA, USA
© 2007 by Blackwell Publishing
Blackwell Futura is an imprint of Blackwell Publishing
Blackwell Publishing, Inc., 350 Main Street, Malden, Massachusetts 02148-5020, USA
Blackwell Publishing Ltd, 9600 Garsington Road, Oxford OX4 2DQ, UK
Blackwell Science Asia Pty Ltd, 550 Swanston Street, Carlton, Victoria 3053, Australia
All rights reserved. No part of this publication may be reproduced in any form or by any
electronic or mechanical means, including information storage and retrieval systems, without
permission in writing from the publisher, except by a reviewer who may quote brief passages
in a review.
First published 2007
1
2007
ISBN: 978-1-4051-3394-4
Library of Congress Cataloging-in-Publication Data
Cardiovascular genetics and genomics for the cardiologist / edited by Victor J. Dzau,
Choong-Chin Liew.
p. ; cm.
Includes bibliographical references and index.
ISBN-13: 978-1-4051-3394-4 (alk. paper)
ISBN-10: 1-4051-3394-5 (alk. paper)
1. Cardiovascular system–Diseases–Genetic aspects. 2. Cardiovascular
system–Molecular aspects. 3. Genomics. I. Dzau, Victor J. II. Liew, Choong-Chin.
[DNLM: 1. Cardiovascular Diseases–genetics. 2. Cardiovascular Diseases–therapy.
3. Genomics. WG 120 C26745 2007]
RC669.C2854 2007
616.1′042–dc22
2007005634
A catalogue record for this title is available from the British Library
Commissioning Editors: Steve Korn and Gina Almond
Development Editors: Vicki Donald and Beckie Brand
Editorial Assistant: Victoria Pittman
Production Controller: Debbie Wyer
Set in 9.5/12pt Minion by Graphicraft Limited, Hong Kong
Printed and bound in Singapore by Fabulous Printers Pte Ltd
For further information on Blackwell Publishing, visit our website:
www.blackwellcardiology.com
The publisher’s policy is to use permanent paper from mills that operate a sustainable forestry
policy, and which has been manufactured from pulp processed using acid-free and elementary
chlorine-free practices. Furthermore, the publisher ensures that the text paper and cover board
used have met acceptable environmental accreditation standards.
Blackwell Publishing makes no representation, express or implied, that the drug dosages in
this book are correct. Readers must therefore always check that any product mentioned in
this publication is used in accordance with the prescribing information prepared by the
manufacturers. The author and the publishers do not accept responsibility or legal liability
for any errors in the text or for the misuse or misapplication of material in this book.
Contents
Contributors, v
Foreword, vii
Introduction, ix
1 The gene in the twenty-first century, 1
Choong-Chin Liew, Victor J. Dzau
Part I Cardiovascular single gene
disorders
2 Monogenic hypercholesterolemia, 19
Ruth McPherson
3 Hypertrophic cardiomyopathy, 30
Ali J. Marian
4 Dilated cardiomyopathy and other
cardiomyopathies, 55
Mitra Esfandiarei, Robert Yanagawa,
Bruce M. McManus
5 The long QT syndrome, 83
Sabina Kupershmidt, Kamilla Kelemen,
Tadashi Nakajima
Part II Cardiovascular polygenic
disorders
6 Atherosclerosis, 113
Päivi Pajukanta, Kiat Tsong Tan,
Choong-Chin Liew
7 Heart failure, 137
Markus Meyer, Peter VanBuren
8 The implications of genes on the pathogenesis,
diagnosis and therapeutics of hypertension,
166
Kiat Tsong Tan, Choong-Chin Liew
Part III Therapies and applications
9 Gene therapy for cardiovascular disease:
inserting new genes, regulating the expression
of native genes, and correcting genetic defects,
195
Ion S. Jovin, Frank J. Giordano
10 Stem cell therapy for cardiovascular disease,
225
Emerson C. Perin, Guilherme V. Silva
11 Pharmacogenetics and personalized medicine,
250
Julie A. Johnson, Issam Zineh
12 The potential of blood-based gene profiling for
disease assessment, 277
Steve Mohr, Choong-Chin Liew
Index, 301
Colour plates are found facing p. 20
iii
Contributors
Victor J. Dzau, MD
Duke University
Medical Center
Durham, NC, USA
Mitra Esfandiarei, PhD
James Hogg iCAPTURE Centre
Providence Health Care Research
Institute UBC St. Paul’s Hospital
Vancouver, BC, Canada
Frank J. Giordano, MD
Cardiovascular Gene Therapy Program
Yale University School of Medicine
New Haven, CT, USA
Julie A. Johnson, PharmD
Departments of Pharmacy Practice and Medicine
(Cardiovascular Medicine)
Colleges of Pharmacy and Medicine, and Center for
Pharmacogenomics
University of Florida
Gainesville, FL, USA
Ion S. Jovin, MD
Cardiovascular Gene Therapy Program
Yale University School of Medicine
New Haven, CT, USA
Kamilla Kelemen, MD
Departments of Anesthesiology, and Division of Clinical
Pharmacology
Vanderbilt University School of Medicine
Nashville, TN, USA
Sabina Kupershmidt, PhD
Assistant Professor
Anesthesiology Research Divison
Vanderbilt University
Nashville, TN, USA
Choong-Chin Liew, PhD
GeneNewsCorporation
Toronto, ON, Canada
Ali J. Marian, MD
Center for Cardiovascular Genetic Research
The Brown Foundation Institute of Molecular Medicine
The University of Texas Health Science Center
Texas Heart Institute at St. Luke’s Episcopal Hospital
Houston, TX, USA
Bruce M. McManus, MD, PhD, FRSC
The James Hogg iCAPTURE Centre for Cardiovascular and
Pulmonary Research
St. Paul’s Hospital/Providence Health Care
Department of Pathology and Laboratory Medicine
University of British Columbia
Vancouver, BC, Canada
Ruth McPherson, MD, PhD, FRCPC
Departments of Medicine and Biochemistry
University of Ottawa Heart Institute
Ottawa, ON, Canada
Markus Meyer, MD
Departments of Medicine and Molecular Physiology and
Biophysics
University of Vermont
College of Medicine
Burlington, VT, USA
Steve Mohr, PhD
GeneNews Corporation
Toronto, ON, Canada
Tadashi Nakajima, MD, PhD
Department of Anesthesiology
Vanderbilt University School of Medicine
Nashville, TN, USA
Päivi Pajukanta, MD, PhD
Department of Human Genetics
David Geffen School of Medicine at UCLA
Los Angeles, CA, USA
Emerson C. Perin, MD, PhD
New Cardiovascular Interventional Technology
Texas Heart Institute
Baylor Medical School
Houston, TX, USA
v
vi
Contributors
Guilherme V. Silva, MD
Robert Yanagawa, BSc, PhD
Stem Cell Center
Texas Heart Institute
Baylor Medical School
Houston, TX, USA
The James Hogg iCAPTURE Centre for Cardiovascular and
Pulmonary Research
St. Paul’s Hospital/Providence Health Care
Department of Pathology and Laboratory Medicine
University of British Columbia
Vancouver, BC, Canada
Kiat Tsong Tan, MD, MRCP, FRCR
Department of Radiology
University of Bristol
Bristol, UK
Peter VanBuren, MD
Departments of Medicine and Molecular Physiology and
Biophysics
University of Vermont
College of Medicine
Burlington, VT, USA
Issam Zineh, PharmD
Departments of Pharmacy Practice and Medicine
(Cardiovascular Medicine)
Colleges of Pharmacy and Medicine, and Center for
Pharmacogenomics
University of Florida
Gainesville, FL, USA
Foreword
In medicine, new developments seem to creep
along until they add up to a momentous shift, such
as those created by the development of X-ray technology, the discovery of penicillin, or the advent of
open heart surgery. More recently, dramatic shifts
in clinical practice have stemmed from the development of minimally invasive surgical techniques
and the identification of lifestyle factors that significantly affect disease risk, particularly for heart disease and diabetes. But perhaps no development of
the last decade will prove more revolutionary to
medicine as we know it today than the completion
of the Human Genome Project in 2003. This international effort provided not just the sequence of
our genetic building blocks, but a raft of new technologies and computational abilities that made the
project possible.
Research done “the old fashioned way” – without
the technologies of the Human Genome Project –
already has resulted in treatment advances that
target the genetic problems of “single-gene” cardio-
vascular conditions. With our genetic sequence
known and these technologies available, however,
researchers’ hunt for genetic factors underlying
common, genetically complex diseases will be significantly accelerated. It is a natural extension that
this research will bring new treatment, prevention
and diagnostic strategies to medicine. As a result,
tomorrow’s medical graduates will be well-versed
in genetics, and today’s practicing physicians will
need to be as well.
This book will allow cardiologists and others to
“catch up” with the genetic revolution and to prepare for the impact the Human Genome Project
will have on the practice of cardiovascular medicine. Get ready. Change is coming, and in many
cases it’s already here.
Peter Agre, MD, Nobel Laureate 2003
Vice Chancellor for Science and Technology
Duke University Medical Center
Durham, NC, USA
vii
Introduction
Until recently, a modest knowledge of genetics has
been more than adequate for the day to day practice
of clinical medicine and cardiology. However, this
situation is rapidly changing. Advances in genetics
and genomics over the past two decades, including
the sequencing of the human genome, are shaping
medicine to a greater extent than any other basic
science endeavor. Indeed, the past 20 years of
research has witnessed genetics becoming a foundational science. Information on genes, genetics,
genetic testing, genomics, pharmacogenetics and
related subjects has moved from highly specialized
publications to the general medical literature.
Genomics and genetic science is changing the practice of medicine in fundamental ways. In cardiovascular medicine, the genetic basis of several forms of
dyslipidemia, hypertension, diabetes, cardiomyopathies and vascular diseases have been identified.
Pharmacogenetic studies have demonstrated the
influence of genetics on the effectiveness and safety
of drugs in anticoagulants and congestive heart failure and other disorders.
Most cardiologists receive limited education in
genetics and genomics during their training. Thus,
there is an unmet need for education in genetics
and genomics for the clinician. This textbook will
serve to introduce the concepts of cardiovascular
genetics and genomics to cardiologists and to prepare them for the new science that promises to
reshape the way that cardiology is practiced. The
book is organized into first, a mainly historic
overview of genetics and genomics concepts, and a
specific application of blood-based microarray
technology; second, the single-gene cardiovascular
disorders; third, polygenic cardiovascular disorders; and the last section deals with genetic and
genomic-based cardiovascular therapeutics.
Chapter 1 aims to introduce some of the basic
concepts of genetics and genomics in a historic
context. What is a gene? How did ideas about the
gene change over the twentieth century? What are
the principles of the structure and function of the
gene? We conclude the chapter with a discussion of
genes of particular interest to the cardiologist.
The next part of the book is devoted to the singlegene cardiovascular disorders. Classically, monogenic
disorders are those in which the disease phenotype
is brought about by a defect in a single gene. The
single-gene disorders are exemplified in Chapter 2
by monogenic hypercholesterolemia in which patients exhibit a severe phenotype of high plasma
levels of low density lipoprotein, together with xanthoma tissue deposits, early onset atherosclerosis
and in some cases premature death. Chapter 2
describes how our understanding of the genetic and
molecular mechanisms underlying these rare disorders has been applied to developing therapeutic
approaches for hypercholesterolemia. Familial
hypercholesterolemia is the most common form of
monogenic hypercholesterolemia. It was the study
of this gene defect that led to the identification of
low density lipoprotein receptor pathways and to
the development of the statin drug class, an important therapeutic advance in cardiovascular disease.
This chapter also discusses other less well-known
examples of monogenic hypercholesterolemias that
have shed light on various aspects of intracellular
protein trafficking and cellular cholesterol handling.
Chapter 3 is a comprehensive description of the
genetic and clinical aspects of hypertrophic cardiomyopathy. Identification of the genetic mutations underlying this disorder represents a historic
landmark in cardiovascular disease genetics. The
cause of hypertrophic cardiomyopathy was for
decades a mystery following its first recognition as
a clinical entity in the 1950s. It was not until the
1990s when the disorder was identified with a
mutation in the beta myosin heavy chain gene that
ix
x
Introduction
it was subsequently elucidated as a disorder of the
sarcomeric proteins. Yet another longstanding puzzle
of hypertrophic cardiomyopathy has been that the
clinical manifestations of the disorder vary strikingly even within members of the same family with
identical mutations. This chapter places the causal
single-gene mutations within the context of modifier
genes, gene–gene interactions, environmental and
other factors as well as diseases such as hypertension. All have effects on the phenotypic manifestations making hypertrophic cardiomyopathy a truly
complex – yet “single-gene” – disorder.
Chapter 4 provides an overview of the large
number of single-gene cardiomyopathies other than
hypertrophic cardiomyopathy. Dilated cardiomyopathy, restrictive cardiomyopathy and arrhythmogenic right ventricular cardiomyopathy represent
a vast array of disturbances in numerous genes,
having differing effects on protein function, all of
which yield cardiomyopathy as their final common
expression. Advances in molecular genetics have
led to tools to identify single-gene defects underlying many of the cardiomyopathies. Understanding
how mutations in genes affect cardiac function may
further the search for potential targets for therapeutic intervention.
Long QT syndrome is discussed in Chapter 5.
Long QT is a major cause of sudden cardiac death,
including sudden infant death syndrome. Long QT
is yet another puzzling disorder whose etiology was
finally illuminated over the course of a series of
genetic studies. These investigations, carried out
during the 1990s, have led to an understanding of
long QT as predominantly an ion channelopathy
and to insights into cardiac electrophysiology and
into mechanisms leading to arrhythmias. Knowledge of specific mutations has led to rational drug
and other therapies for long QT. Acquired long
QT is also a syndrome of great interest, and the
pharmaceutical industry faces major challenges in
identifying drug-induced life-threatening repolarization abnormalities.
The next section of the book deals with the cardiovascular polygenic disorders hypertension,
atherosclerosis and heart failure. These are diseases
and disorders that involve multiple genes interacting with epigenetic and environmental factors to produce the disease phenotype. Polygenic disorders are
actually syndromes or complex disorders, described
phenotypically rather than on a mechanistic basis.
Polygenic multifactorial diseases are much more
common in populations than are the single-gene
disorders which are mostly very rare. Onset in polygenic disorders is usually delayed until later in life.
Polygenic diseases/disorders are highly complex,
involving multiple genes, gene pathways and interactions. Their complexity renders them much
harder to understand at the molecular level.
Chapter 6 addresses atherosclerosis, one of the
most complex of the polygenic cardiovascular disorders and the most common cause of mortality
in the western world. Atherosclerosis involves the
actions of perhaps 400 genes, which, together with
multiple risk factors, determine the likelihood of
atherosclerosis. The identification of atherosclerosis
as an inflammatory disease, coupled with detailed
molecular biology studies of the atherosclerotic
process, have provided numerous clues to novel
diagnostic, prognostic and therapeutic approaches.
Work is also underway in determining further
polymorphisms in genes that are specifically associated with atherosclerosis.
Chapter 7 is an introduction to the complexities
of heart failure. Heart failure involves a multitude
of genes: from the initial myocardial insult through
the remodeling process that leads to heart failure.
An understanding of gene regulation is key to understanding heart failure and this chapter describes
the roles of neurohormonal factors, proteins in
myocardial calcium handling, interstitial alterations, energy metabolism, apoptosis, reactive oxygen species and myriad other processes. Gene array
studies are beginning to contribute to an understanding of heart failure, and to the identification of
diagnostic or prognostic biomarkers. In the future,
a patient’s genetic profile may help to tailor individualized therapies in chronic heart failure.
An overview of the genes in hypertension is the
subject of Chapter 8. Blood pressure is a polygenic
trait with genetic and environmental factors as
well as age contributing to the phenotype. Many
studies have been undertaken to identify the genes
of essential hypertension but with little success.
However, studies of different forms of monogenic
hypertension have identified the involvement of
specific genes and have led to advances in understanding the pathophysiology of this condition.
Most such disorders are caused by mutations of
Introduction xi
genes involved in renal sodium handling. A large
number of patients have not achieved optimal
blood pressure control or have side effects from
medications. Pharmacogenomics and personalized
medicine approaches hold promise in overcoming
the challenges of hypertension management.
The next section deals with future therapeutic
advances in cardiovascular disease promised by
studies in genetics and genomics. Ultimately, the
aim of gene science as applied to the practice of
medicine is to produce clinically applicable results
in the form of new medications, new vaccines, new
technologies, new diagnostic and prognostic tests.
It is predicted that significant practical changes
will occur in medical practice in a short time
period based on advances in pharmacogenetics and
pharmacogenomics.
Chapter 9 examines the fundamental concepts,
potentials and challenges of gene therapy. It also
provides an updated review of cardiovascular gene
therapy, specifically, in angiogenesis in peripheral
vascular disease and ischemic coronary heart disease, strategies in heart failure, cardiac rhythm
disturbances and atherosclerosis. Gene therapy
research advanced dramatically in the past decade
and now includes techniques to carry out targeted
corrections of DNA mutations, engineered transcriptional factors to regulate endogenous gene
expression as well as technologies to silence gene
expression. Although still in its infancy, gene therapy holds promise as an effective approach to treat
common diseases and potentially cure monogenic
cardiovascular disorders.
Chapter 10 on stem cell therapy for cardiovascular disease explores exciting new evidence that
the adult heart may harbour endogenous healing
mechanisms. This concept has led to an intense
interest in stem cell therapy to reverse the processes
of heart disease by harnessing the heart’s capacity to
heal itself. This chapter reviews the basics of stem
cells, provides an overview of animal studies, delivery mechanisms and early human clinical studies in
cardiovascular stem cell therapy. The search con-
tinues for an ethically acceptable, easily accessible,
high yield source of stem cells and for optimal
means of delivering cells to therapeutic targets.
Several strategies in humans have been tested clinically in the immediate post-myocardial infarction
phase as well as in the chronic phase of ischemic
heart disease but these studies are still in the very
early stages of investigation. Many issues remain
before the full potential of stem cell therapy can be
realized.
Chapter 11 concerns the emerging new field of
pharmacogenetics and pharmacogenomics. An
important tool for the practice of personalized
medicine, pharmacogenetics characterizes the
effects of genetic variations on an individual’s
responses to specific drugs. Drug therapy in cardiovascular disease is frequently made on an empirical
or on a protocol-driven basis. Thus, pharmacogenetic strategies should reduce the number of
patients who fail specific courses of treatment or
experience side effects. This chapter provides an
up-to-date review of pharmacogenetic influences
of genetic polymorphisms on statin and nonstatin
therapy of hyperlipidemia, hypertension, heart failure, thrombosis and arrhythmia. Warfarin is likely
to be the first of the cardiovascular disorders whose
utilization might be improved by pharmacogenetic
strategies; already there is a warfarin-dosing algorithm. In most cases though, it is likely to be 10–15
years before pharmacogenetic information can be
used to guide the use of therapeutics in cardiovascular disease. Chapter 12 highlights the potential of
blood-based microarray diagnostics, or bloodomics,
a methodology that is transforming microarray and
leading the way to a systems based biology.
In summary, this book presents cardiovascular
disease in the context of the genetics and genomics.
Such a book is long overdue. We are proud to have
been involved in the editing of this book and we
hope that it will be of service to cardiologists of the
twenty-first century.
C.C. Liew and V.J. Dzau
1
CHAPTER 1
The gene in the twenty-first
century
Choong-Chin Liew, PhD, & Victor J. Dzau, MD
Introduction
When the word was first used in 1909, “gene” was a
hypothesis necessary to explain puzzling observations about heredity. As the century progressed, the
hypothesis began to acquire reality as the structure
and functions of the gene were gradually elucidated.
Earlier and simpler concepts became superseded as
evidence led to better understanding of the gene.
Today the gene is recognized to be a highly complex
entity. The genomics revolution is well underway
but there is much that remains for twenty-first century science to learn before the potential of molecular biology and technology can be fully realized.
The search for the gene
Much of the science that laid the foundation for the
genetics and genomics revolution took place in the
very near past; 1900 is the date often considered to
be the beginning of modern genetics. In that year,
three botanists working on plant hybridization,
independently, in three different countries, published their rediscovery of Gregor Mendel’s (1822–
1884) rules of inheritance, first presented in 1865
and then largely forgotten [1]. Carl Correns (1864–
1933) in Germany, Hugo de Vries (1848–1935) in
the Netherlands and Erich von Tschermak (1871–
1962) in Austria each published their findings in
the Berichte der Deutsche Botanischen Gesellschaft
(Proceedings of the German Botanical Society)
[2–4]. The botanists recognized that Mendel’s concept of dominant and recessive traits could be used
to explain how traits can skip generations, appearing and disappearing through the years. Hugo de
Vries named the transmitted substances “pangens”;
he later coined the term “mutation” to signify the
appearance of a new pangen [5].
Cambridge evolutionist William Bateson (1861–
1926) translated Mendel into English and worked
vigourously to promote Mendel’s ideas in the
English-speaking scientific world. Bateson himself
coined the term “genetics” in 1906 [6]. The word
“gene” was not introduced until 1909, when Wilhelm
Johannsen (1857–1927), a Danish botanist, offered
this term in preference to earlier terms [7].
A next major step towards an elucidation of
the gene came with the discovery that genes have
physical locations on chromosomes in studies on
Drosophila carried out by Thomas Hunt Morgan
(1866–1945) and his colleagues at the zoology department of Columbia University [8,9]. Morgan’s
student, Alfred Sturtevant (1891–1970) was able to
show that the gene for a trait was localized in a fixed
location or locus arranged “like beads on a string”
in his often quoted metaphor [10]. Later, Calvin
Bridges was able to visualize this arrangement
using light microscopy to show in detail the parallel
bands on the chromosomes of the salivary gland
cells of larval fruit flies [11].
In 1927, another of Morgan’s students, Herman
J. Muller (1890–1967) proved in studies at the
University of Texas, Austin, that ionizing radiation
from X-rays and other mutagens could be used to
create genetic mutations in fruit flies, and that
some of these mutations were able to pass to offspring [12].
Muller believed as early as the 1920s that genes
were “the basis of life” [13]. However, it was not
until the 1940s that researchers began to work out
1
2 CHAPTER 1 The gene in the twenty-first century
the physical and material properties of genes. In
1944, Rockefeller University researchers, Oswald
Avery (1877–1955), Colin MacLeod (1909–1972)
and Maclyn McCarty (1911–2005) demonstrated
that it was DNA that was the carrier of genetic
information [14]. In 1952, Alfred Hershey (1908–
1997) and his laboratory assistant Martha Chase
(1928–2003) confirmed Avery’s findings [15].
Against this background can be understood the
importance mid-century of James Watson (b. 1928)
and Francis Crick’s (1916–2004) double helix. In
their landmark paper, published in Nature in 1953,
Watson and Crick presented for the first time a
comprehensible model of a unit of heredity [16].
Briefly, their double helix is composed of two long
polymers of alternating sugar-phosphate deoxyribose molecules, like the sides of a twisted spiral ladder. To these molecules Watson and Crick attached
the ladder’s rungs, four nucleotide bases: adenine
and guanine (A and G) and cytosine and thymine
(C and T). The property of each base is such that
it attracts and bonds to its complementary base
forming arrangements known as base pairs: “A” can
only pair with “T” and “C” can only pair with “G.”
The DNA bases are loosely attached to each other
by weak bonds; they are released from each other
by disrupting the bonds. Thus, every time a cell
divides it copies its DNA program, in the human
cell, it copies its entire three billion base pair
human genome.
Once the structure of the gene was described the
molecule could take its place in the scientific ontology of the twentieth century. With the double
helix, classic genetics began to shift to molecular
genetics [8].
Gene function
Studies of gene function proceeded largely independently of investigations into gene structure. The
first clue to the biologic behaviour of the gene in the
organism came in 1902, with the work of London
physician Archibald Garrod (1857–1936) [17]. In
his famous paper published in the Lancet in 1902,
Garrod hypothesized that alkaptonuria was a consequence of some flaw in body chemistry that disrupts one of the chemical steps in the metabolism
of tyrosine [18]. He explained alkaptonuria as a
recessive disorder, using the terms of the new
Mendelian genetics and conjectured that it is an
absence of the enzyme involved that leads to alkaptonuria and other “inborn errors of metabolism”
[19].
Garrod’s hypothesis was given experimental
support in an important series of studies on Neurospora crassa carried out at Stanford University by
George Beadle (1903–1989) and Edward Tatum
(1909–1975) between 1937 and 1941 [20]. Because
biochemical processes are catalyzed by enzymes and
because mutations affect genes, reasoned Beadle
and Tatum, then genes must make enzymes: the
“one-gene-one-enzyme” hypothesis, later made
famous by Beadle.
The hypothesis was further developed in studies
on sickle cell anemia. In 1949, the hereditary basis
of the disorder was shown by James Neel (1915–
2000) [21]. Also in 1949, Linus Pauling (1901–1994)
and Harvey Itano showed that the disease was linked
to a modification in hemoglobin, such that the hemoglobin in sickled cells carries a charge different to
the charge of the molecule in normal cells [22].
Eight years later, Vernon Ingram (1924–2006)
and Francis Crick demonstrated that this difference
was caused by the replacement of a single amino
acid, glutamic acid, by another, valine, at a specific position in the long hemoglobin protein [23].
Sickle cell anemia was the first disease explicitly
identified as a disorder flowing from a derangement at the molecular level, or as Pauling himself
put it, “a molecular disease” [22].
Understanding of gene function sped up once
Watson and Crick had elucidated the structure of
the double helix. As summarized in Crick’s famous
central dogma of 1958, information flows from
DNA to RNA to protein [24]. The central dogma
captured the imagination of biologists, the public and the media in the 1960s and 1970s [25].
“Stunning in its simplicity,” Evelyn Fox Keller
writes, the central dogma allows us to think of the
cell’s DNA as “the genetic program, the lingua
prima, or perhaps, best of all, the book of life” [25].
The gene since 1960
By 1960, the definition of a gene was that implied
by the central dogma: a gene is a segment of DNA
that codes for a protein [26]. The first significant
challenge to that definition arose with the work of
CHAPTER 1
microbiologists Francois Jacob (b. 1920) and
Jacques Monod (1910–1976) of the Institut Pasteur
in Paris [27].
Monod and Jacob’s operon model explained
gene function in terms of gene cluster. However,
such a model adds levels of complexity to the gene
and makes it more difficult to determine precisely
what is a gene. What should be included in one
gene? Its regulatory elements? Its coding elements?
What are the boundaries of the gene? [25]. Furthermore, the Monod/Jacob gene loses some of its
capacity for self-regulation: on the operon model
the gene acts, not autonomously, but in response to
proteins within the cell and between the cell and its
environment [28].
Although Monod famously asserted that what
was true for Escherichia coli would be true for the
elephant, in fact the operon model of gene regulation characterizes prokaryotes (simple unicellular
organisms without nuclei). In eukaryotes (animals
and plants whose cells contain nuclei), gene regulation is far more complicated. Later research showed
that in some cases, regulatory elements were scattered at sites far away from the coding regions of
the gene; in other cases, regulator genes were found
to be shared by several genes; gene regulation
included further levels of control including positive control mechanisms, attenuation mechanisms,
complex promoters, enhancers and multiple polyadenylation sites, making it even more difficult to
clarify the boundaries of the gene (for discussion on
difficulties in defining the gene see [25,29–31]).
Later, in 1970, Howard Temin (1934–1994) and
David Baltimore (b. 1938) also posed challenges to
the one way DNA-to-protein pathway implicit in
the central dogma. In their work on viruses that can
cause cancer they discovered an enzyme, reverse
transcriptase, which uses RNA as the template to
synthesize DNA [32,33].
Another unexpected finding to shake the central dogma occurred with the discovery of the split
gene. In 1977, Phillip Sharp (b. 1944) at the Massachusetts Institute of Technology and Richard
Rogers (b. 1943) at Cold Spring Harbor Laboratory
showed that not all genes are made of one continuous series of nucleotides. Their electron microscopy comparisons of adenovirus DNA and mRNA
showed that some genes are split, or fragmented
into regions of coding pieces of DNA interrupted
The gene in the twenty-first century
3
by stretches of non-coding DNA [34,35]. Walter
Gilbert (b. 1932) of Harvard University later coined
the terms “exon” and “intron” to describe these
regions [36].
Split genes can be spliced, or alternatively
spliced, in different ways: exons can be excised out,
some introns can be left in, or the primary transcript can be otherwise recombined (for review see
[37]). The proteins thereby produced are similar
although slightly different isoforms. Split genes
play havoc with the straightforward one-gene-oneenzyme hypothesis. As Keller has pointed out “one
gene – many proteins” is an expression common in
the literature of molecular biology today [25].
Other nontraditional genes discovered (or become accepted by the research community) since
the 1960s include transposons, moveable genes that
travel from place to place in the genome of a cell
where they affect the expression of other genes discovered by Barbara McClintock [38]; nested genes,
whose exon sequences are contained within other
genes; and pseudogenes which are “dead” or nonfunctional gene remnants, overlapping genes, repeated genes and other gene types (these and other
“nonclassical” genes are reviewed in [30]).
Most recently, with the discovery of nonprotein coding RNAs, the idea that genes necessarily
make proteins at all has been called into question.
As far back as 1968, Roy Britten and David Kohne
published a paper in Science reporting that long
stretches of DNA do not seem to code for proteins
at all [39]. Large areas of genome – hundreds to
thousands of base pairs – seemed to consist of
monotonous nucleotide sequence repetition of DNA.
Such noncoding DNA, which includes introns
within genes and areas between coding genes, represents a surprising fraction of the genomes, at least
genomes of higher organisms. In humans, 98% of
human DNA appears not to code for anything.
Only a tiny percentage – about 2% – of the three
billion base pairs of the human genome corresponds to the 20,000–25,000 protein coding genes
tallied by the International Human Genome Sequencing Consortium [40]. Much of it consists of
repeated DNA; some elements are repeated over
100,000 times in the genome with no apparent purpose. Such noncoding elements were long dismissed
as parasitic or “junk” DNA: a chance by-product of
evolution with no discernible function.
4 CHAPTER 1 The gene in the twenty-first century
Table 1.1 Recently discovered noncoding RNA families and their functions.
Family
Processes affected
miRNAs
microRNAs
translation/regulation
siRNAs
small interfering RNAs
RNA interference/gene silencing
snRNAs
small nuclear RNAs
RNA processing/spliceosome components
st RNAs
small temporal RNAs
temporal regulation/translation
snoRNAs
small nucleolar RNAs
cis-antisense RNAs
ribosomal RNA processing/modification
transcription elongation/RNA
processing/stability/mRNA translation
Adapted from Storz et al. [44].
Since the sequencing of the human and other
genomes, however, and with the availability of
transcriptomes and novel genomic technologies
such as cDNA cloning approaches and genome
tiling microarrays, researchers have begun to explore intronic and intragenic space. Increasingly
since 2001 it appears that far from being junk, these
stretches of DNA are rich in “gems” [41]: small
genes that produce RNAs, called noncoding RNAs
(reviewed in [42–44]) (Table 1.1).
Noncoding RNAs are not messenger RNAs,
transfer RNAs or ribosomal RNAs, RNA species
whose functions have long been known. They vary
in size from tiny 20–30 nucleotide-long microRNAs
to 100–200 nucleotide-long nonprotein coding
RNAs (ncRNAs) in bacteria to more than 10,000
nucleotide-long RNAs involved in gene silencing.
Many of these intriguing ncRNAs are highly conserved through evolution, and many seem to have
important structural, catalytic and regulatory properties [45].
Noncoding RNAs were thought at first to be
unusual; however, over the past 5 years increasing
numbers of these intriguing elements have been
emerging. The number of ncRNAs in mammalian
transcriptomes is unknown, but there may be tens
of thousands; it has been estimated that some 50%
of the human genome transcriptome is made up of
ncRNAs [46].
The function of these elements is only beginning
to be explored; and their structural features are
beginning to be modeled [47]. Nonprotein coding
RNAs seem to be fundamental agents in primary
molecular biologic processes, affecting complex
regulatory networks, RNA signaling, transcription
initiation, alternative splicing, developmental timing, gene silencing and epigenetic pathways [44].
One class of ncRNAs has been the focus of much
research attention. MicroRNAs are hairpin-shaped
RNAs first discovered in Caenorhabditis elegans
[48,49]. These tiny, approximately 22 nucleotide
elements seem to control aspects of gene expression in higher eukaryote plants and animals. Many
microRNAs are highly conserved through evolution; others are later evolutionary elements. For
example, of some 1500 microRNAs in the human
genome [46], 53 are unique to primates [50]. Each
microRNA may regulate as many as 200 target
genes in a cell, or one-third of the genes in the
human genome [51].
In animals, microRNAs appear to repress translation initiation or destabilize messenger RNA.
In animals, microaRNAs so far characterized seem
to be involved in developmental timing, neuronal
cell fate, cell death, fat storage and hematopoietic
cell fate [49]. The potential effects of these RNA
elements on gene expression have led to the hypothesis that these elements may be involved in
disease processes. For example, microRNAs have
been suggested to be involved in cancer pathogenesis, acting as oncogenes and tumor suppressors
[52]. Calin et al. [53] recently reported a unique
microRNA microarray signature, predicting factors associated with the clinical course of human
chronic lymphocytic leukemia.
In 2006 Andrew Fine of Stanford University and
Craig Mello of the University of Massachusetts
Medical School shared the Nobel Prize in Physiology or Medicine for their work in RNA interference gene silencing by double-stranded RNA.
CHAPTER 1
The Human Genome Project
By this first decade of the twenty-first century the
simple “bead on a string,” “one-gene-one-enzyme”
concept of the gene has given way to a far more
detailed understanding of genes and gene function.
In addition, there has been a fundamental shift in
scientific emphasis since 2000 from gene to the
genome: the whole complement of DNA of an
organism and includes genes as well as intergenic
and intronic space [25,30,54].
In February 2001, two independent drafts of the
genome sequence were published simultaneously
in the journals Science [55] and Nature [56]. The
work highlighted in Science had been carried out by
Celera, Rockville, Maryland, a company founded
by Craig Venter; that in Nature was work by the
International Human Genome Sequencing Consortium. The Human Genome Project, the culmination of decades of discussion, had officially begun in
1990 by the US National Institutes of Health and
US Department of Energy. Completing the sequencing project and determining the location of the
protein encoding genes opened a new “era of the
genome” in the biologic sciences. Hopes have continued high that the project would provide the tools
for a better and more fundamental level of understanding of human genetic diseases, of which there
are some 4000 known, as well as providing new insights into complex multifactorial polygenic diseases.
Also in 2001, our team working at the University
of Toronto was the first to describe the total number of genes expressed in a single organ system, the
cardiovascular system [57]. This work had developed out of our 1990s research project using the
expressed sequence tag (EST) strategy to identify
genes in human heart and artery. We sequenced
more than 57,000 ESTs from 13 different cardiovascular tissue cDNA libraries and in 1997 published a comprehensive analysis of cardiovascular
gene expression, the largest existing database for a
single human organ [58].
Even when the first draft of the genome was published in 2001 – still incomplete and with many
gaps – researchers were surprised at the small number of genes in the human genome: approximately
30,000–40,000 genes and far fewer than the original
(and often quoted) 100,000 genes that had been
informally calculated by Walter Gilbert in the 1980s
The gene in the twenty-first century
5
Table 1.2 Genes in the genome.
Organism
Number of
genes
Maize (Zea mays)
50,000
Mustard (Arabidopsis thaliana)
26,000
Human (Homo sapiens)
20,000–25,000
Nematode worm (Caenorhabditis elegans)
19,000
Fruit fly (Drosophila melanogaster)
14,000
Baker’s yeast (Saccharomyces cerevisiae)
6000
Bacterium (Escherichia coli)
3000
Human immunodeficiency virus
9
Adapted from Functional and Comparative Genomics
Factsheet. Human Genome Project. http://www.ornl.gov/
sci/techresources/Human_Genome/faq/compgen.shtml#
compgen and Human Genome Program, US Department of
Energy, Genomics and Its Impact on Science and Society:
A Primer, 2003. http://www.ornl.gov/sci/techresources/
Human_Genome/publicat/primer2001/index.shtml
[59]. When in 2004 the almost completed final
sequence of the genome appeared in Nature, our
species’ total gene count was further reduced to
20,000–25,000 [40]. Furthermore, when compared
with the genomes of other organisms, humans
seem to have surprisingly few genes: only about
twice as many genes as fruit flies; and only half as
many genes as the corn plant (Table 1.2).
Certainly a challenge for the Human Genome
Project and a major challenge in the transition from
structural to functional genomics was to identify
the entire set of human genes in the genome. About
98% of the DNA in the genome does not code for
any known functional gene product and only 2%
encodes protein producing genes. In 1991, Mark
Adams and J. Craig Venter and colleagues at the
National Institutes of Health [60] had proposed the
EST approach to gene identification. In this approach individual clones are randomly selected
from cDNA libraries representing the genes expressed in a cell type, tissue or organ of interest.
Selected clones are amplified and sequenced in a
single pass from one or both ends, yielding partial
gene sequences known as ESTs. These are then
compared with gene sequences in existing nucleotide databases to determine whether they match
known genes, or whether they represent uncharacterized genes.
6 CHAPTER 1 The gene in the twenty-first century
Venter and his colleagues used automated fluorescent DNA sequencing technology to increase the
efficiency and scale of EST generation; they were
able to rapidly generate ESTs representing over 600
cDNA clones randomly selected from a human
brain cDNA library [60]. More than half of these
were human genes that had previously been
unknown. Venter argued that this strategy could
lead to the identification and tagging of 80–90%
of human genes in a short period of time and
at dramatically less cost than complete genome
sequencing, a full decade before the proposed date
of completion of the human genomic nucleotide
sequence [61]. At about the same time at our laboratory at the University of Toronto we launched
the first human heart EST project as we began our
catalog of the complete set of genes expressed in the
cardiovascular system [58,62,63].
The EST approach ultimately overcame skepticism [64,65] and became recognized as an important and powerful strategy complementing
complete genome sequencing. It has been found
that ESTs are an efficient vehicle for new gene discovery; ESTs provide information on gene expression
levels in different cells/tissues and EST sequences
can be used to design PCR primers for physical
mapping of the genome. ESTs may also be useful in
the search for new genes involved in genetic disease.
Chromosomal localization of ESTs increases the
ability to identify novel disease genes. Such positional candidate strategies were used, for example,
to identify novel candidates for a familial Alzheimer’s disease gene [66].
Early EST-based strategies for gene expression
investigation were expensive and labor-intensive.
Another important technology to emerge from the
Human Genome Project, microarray technology
enables data similar to EST data to be produced for
thousands of genes, simultaneously, in a single
experiment. Indeed, while ESTs have been useful
for monitoring gene expression in different tissues
or cells, their primary utility is now to provide
materials for cDNA microarrays [67]. By tagging
and identifying thousands of genes, EST repositories presently serve as the primary source of cDNA
clones for microarrays.
The two types of microarray systems in widespread use are the photolithographic synthesis of
oligodeoxynucleotides directly on to silicon chips
and an X-Y-Z robotic system, which spots DNA
onto coated standard glass microscope slides or
nylon membranes [67–70]. Microarray will be discussed more fully in Chapter 2. DNA microarray
technology can profile and compare thousands of
genes between mRNA populations simultaneously.
The DNA microarray is also a novel tool to pinpoint differences in expression between single
genes on a large scale. A series of transcript profiling
experiments can be analyzed to determine relationships between genes or samples in multiple dimensions. A set of expression fingerprints, or profiles,
similarities and differences in gene expression are
used in order to group different mRNA populations or genes into discrete related sets or clusters.
Clusters of co-regulated genes often belong to the
same biologic pathways, or the same protein complex, whereas the clusters of mRNA populations are
defined by their “expression fingerprint” providing
a means to define differences between samples.
Thus, the microarray is a powerful technique.
For example, a molecular profile of cancer has
been a subject for cDNA microarray analysis. Perou
et al. [71] compared transcript profiles between cultured human mammary epithelial cells subjected to
a variety of growth factors or cytokines and primary
breast tumors. Interestingly, a correlation between
two subsets of genes with similar expression patterns in vitro and in the primary tumors was found,
suggesting that these genes could be used for tumor
classification. Other transcriptomal cancer studies
have also yielded findings, such as new candidate
genes that may now be further investigated in population based studies [72–74].
Microarrays are also increasingly being used to
investigate gene expression in heart failure – a condition that has complex etiologies and secondary
adaptations that make it difficult to study at the
level of cellular and molecular mechanisms [75].
A few cardiovascular-based microarray studies have
been published. For example, Friddle et al. [76] used
microarray technology to identify gene expression
patterns altered during induction and regression of
cardiac hypertrophy induced by administration of
angiotensin II and isoproterenol in a mouse model.
The group identified 55 genes during induction or
regression of cardiac hypertrophy. They confirmed
25 genes or pathways previously shown to be
altered by hypertrophy and further identified 30
CHAPTER 1
genes whose expression had not previously been
associated with cardiac hypertrophy or regression.
Among the 55 genes, 32 genes were altered only
during induction, and eight were altered only during regression. This study used a genome-wide
approach to show that a set of known and novel
genes was involved in cardiac remodeling during
regression and that these genes were distinct from
those expressed during induction of hypertrophy.
In the first reported human microarray study in
end stage heart failure, Yang et al. [77] used high
density oligonucleotide arrays to investigate failing
and nonfailing human hearts (end stage ischemic
and dilated cardiomyopathy). Similar changes were
identified in 12 genes in both types of heart failure,
which, the authors maintain, indicate that these
changes may be intrinsic to heart failure. They
found altered expression in cytoskeletal and myofibrillar genes, in genes involved in degradation
and disassembly of myocardial proteins, in metabolism, in protein synthesis and genes encoding
stress proteins.
Our “CardioChip” microarray, an in-house
10,848-element human cardiovascular-based expressed sequence tag glass slide cDNA microarray,
has also proved highly useful in helping elucidate
molecular and genetic events leading to end stage
heart failure. Our group used the CardioChip to
explore expression analysis in heart failure [78,79].
We compared left ventricle heart transplant tissue
with nonfailing heart controls and found some
100 transcripts that were consistently differentially
expressed in dilated cardiomyopathy samples by
more than one and a half times.
Microarrays have revolutionized our approach
to studying the molecular aspects of disease. The
whole genome scan opens a window through which
we can monitor molecular pathways of interest
and determine how gene expression changes in
response to various stimuli (such as drug therapy).
These comparisons offer the ability to study disease
as it evolves over different time points and to compare patients with different epigenetic risk factor
profiles and under different environmental influences. By examining tissue biopsies or cell samples,
researchers can identify a whole-genome “portrait”
of gene expression, extract candidate genes and
conduct targeted follow-up studies that directly
relate to specific cellular functions. Current micro-
The gene in the twenty-first century
7
array studies typically utilize tissue samples, and of
necessity rely on tissue biopsy. In many cases, however, such as in the cardiovascular studies above,
tissue samples can only be obtained in very late
stage disease, at transplant or after death. The need
for a simple noninvasive cost-effective method to
replace tissue biopsy to identify early stage disease is
clear. Hence, research interest has begun to turn to
investigating the use of blood based gene expression profiling. Blood samples have a number of
advantages over tissue samples, in particular that
blood can be obtained early during disease development and causes little discomfort to patients.
There is a growing body of evidence that the blood
contains substantial bioinformation and that biomarkers derived from blood RNA may provide an
alternative to tissue biopsy for the diagnosis and
prognosis of disease [80]. Recent studies have shown
that blood cell gene expression profiles reflect individual characteristics [81,82], and alterations in
blood cell transcriptomes have been found to
characterize a wide range of diseases and disorders
occurring in different tissues and organs, including
juvenile arthritis [83], hypertension [84–86], colorectal cancer [87], chronic fatigue syndrome [88]
and neuronal injuries [89,90]. Circulating blood
cells also show distinctive expression patterns under
various environmental pressures and stimuli, such
as exercise [91], hexachlorobenzene exposure [92],
arsenic exposure [93] and smoking [94].
Such research findings provide convincing support to the hypothesis that circulating blood cells
act as a “sentinels” which detect and respond to
microenvironmental changes in the body. Our laboratory, Gene News Corp., in Toronto has developed
a methodology to establish the Sentinel Principle™.
We have profiled gene expression from peripheral
blood and we have identified mRNA biomarkers
for different diseases. In an initial study, blood
samples were drawn from patients with coronary
artery disease and gene expression compared with
healthy control samples [95]. Differentially expressed
genes identified in the circulating blood successfully discriminated the coronary patients from
healthy control subjects [95]. We have also used the
principle to discriminate successfully between
patients with schizophrenia and those with bipolar
disorder and between patients and controls [96],
which findings have been verified in later studies
8 CHAPTER 1 The gene in the twenty-first century
[97]. Our group has also identified biomarkers in
blood that have utility in identification of early
osteoarthritis [98] and bladder cancer [99].
The new technologies of the Human Genome
Project allow us to view the entire genome of an
organism and permit better characterization of disease as a dynamic process. Although at an early stage
as yet, the possibility of using blood samples as the
basis for microarray studies of biology and disease
opens up new vistas of research for the future.
Conclusions
The twentieth century opened with the start of the
search for the gene. The concept grew in stature and
importance with the double helix and the central
dogma. However, research since 1960 has led to
changes in traditional ideas about the gene. No
longer is the gene the autonomous self-replicating
unit of inheritance of 1953; rather it requires the
assistance of a host of accessory regulatory proteins
[25]. Indeed, when in 1986 Walter Gilbert proposed the “RNA world hypothesis”: that RNA,
which can self-replicate, must be the primary molecule in evolution, the traditional gene even lost
its ascendancy over other molecules as “the basis
of life” [100].
Since 2001, the date of the first draft of the
Human Genome Project, and since the release of
the genome sequencing projects of other organisms, floods of new genome data have been generated and novel technologies have been developed to
attempt to make sense of that data. High throughput microarray technology has provided a “new
kind of microscope” [101] for post genomic analysis. It is now possible to look at thousands of base
pair sequences simultaneously. The one gene at a
time paradigm has been replaced, or at least supplemented, with a more holistic model of the gene in
its surrounding molecular landscape.
For example, the central dogma presupposes
a correspondence between genes and complexity
and one of the big surprises of the Human Genome Project has been the scarcity of genes in the
genome. The human genome contains in fact very
few protein coding genes and fewer than many
“simpler” organisms, a mere one-quarter to onefifth of the original estimates [40]. To begin to
explain the paradoxical genome data, researchers
have had to shift their emphasis away from genes
and proteins and towards gene regulation. Why do
humans have so few genes [102] has been replaced
by the question: How do so few genes create such
complexity?
Clearly, it is not genes themselves, per se, that
confer complexity. Rather complexity occurs as a
result of gene–gene interactions and programs –
molecular pathways that modulate development.
Alternative splicing is one possible mechanism that
might allow the cell to produce numerous proteins
from one basic gene, and the mechanisms, pathways and regulators governing alternative splicing
and spliceosomes are the subject of intensive research investigation. In addition, the large amount
of noncoding DNA in genomes suggests that noncoding DNA may have functional biological activity [103]. In particular, ncRNAs may prove to be
the programmers controlling complexity [42].
Science in the post genome era recognizes that
gene activity does not occur in isolation. Rather, a
full understanding of the development, the disease
and decay of organisms will be found when the
“genes,” including the protein gene, the RNA gene
or any other genes that might be discovered, are
considered together with gene regulatory factors,
gene–gene interactions, gene–cell interactions, epigenetic factors and signaling pathways in gene
expression. Understanding signaling pathways in
gene expression is a major research focus.
Gene function is beginning to be understood
in different ways, with different ways to pose the
problems. For example, rarely today do we speak of
a gene as causing a particular disease or giving rise
to a specific trait; diseases, even the so-called single
gene diseases, and traits are, rather, understood to
be the results of hundreds and even thousands of
genes operating in complex regulatory networks.
This is especially true in cardiology, where such
complex multifactorial diseases as coronary artery
disease, heart failure, hypertension and atherosclerosis are caused by genetic factors together with a
host of environmental and other factors. Even in
the case of the “single” gene diseases, such as hypertrophic cardiomyopathy, dilated cardiomyopathy
and other disorders considered to be the result of
mutations of a single gene, it is becoming increasingly clear that such disorders are actually far
more complex than previously thought [104–107].
CHAPTER 1
Already with microarray and other novel technologies, holistic approaches to investigating the
health and disease of organisms are becoming possible. As Evelyn Fox Keller put it, the twenty-first
century will be “the century of the genome” [25].
A closer look at some genes of
importance in cardiology
Cardiac myosin heavy chain genes
A family of genes of major importance in cardiology are the myosin heavy chain genes [108].
Myosin, the contractile protein of muscle, makes
up the thick filaments of cardiac and skeletal
muscle. Conventional myosin contains two heavy
chains (220,000 kDa) which form the helical coiled
rod region of the molecule and four light chains
(26,000 and 18,000 kDA) which form the pairshaped head regions. Striated muscle contraction is
generated by interaction between myosin and thin
filament actin. Upon fibre activation the myosin
head binds to actin, which slides a short distance
along the thick filament. Linkage is broken by
adenosine triphosphate (ATP) hydrolysis whereupon actin and myosin dissociate. By this process
the filaments are pulled along each other, rachetlike, in the classic sliding filament motion.
Myosin heavy chain genes are highly conserved
and structurally similar [109–111]. Mammalian
myocardial genes are large and complex, spanning
approximately 24 kb and split into 40–41 exons
and approximately the same number of introns, of
various sizes [112]. Two isoforms of myosin heavy
chain gene are expressed in myocardial cells, αMYH and β-MYH, extending over 51 kb on chromosome 14 in humans; α-MYH and β-MYH are
separated intragenically by about 4.5 kb; similar in
overall structure, their sequences in the 5′ flanking
regions are quite different, suggesting independent
regulation of these genes [113].
The α and β cardiac heavy chain genes are
tandemly linked, and are arranged in order of their
expression during fetal development. The β-MHC
is located 5′ upstream of the α-MHC sequence and
is expressed first during heart development, followed by α-MHC gene expression. Despite the fact
that there is almost 93% sequence identity between
α-MYH and β-MYH, their ATPase activity differs
by twofold suggesting functional differences.
The gene in the twenty-first century
9
Table 1.3 Response to stimuli of cardiac myosin heavy
chain genes.
a-MYH
b-MYH
+ Thyroid (T3)
Upregulated
Downregulated
– Thyroid (T3)
Downregulated
Upregulated
Exercise
Upregulated
Downregulated
Pressure
Downregulated
Upregulated
Aging
Downregulated
Upregulated
Adapted from Weiss & Leinwald [108].
α-MYH and β-MYH isoforms are tissue specific and differentially developmentally regulated
(reviewed in [114]). Thus, α-MYH and β-MYH are
both expressed at high levels throughout the cells of
the developing fetal heart tube at about 7.5–8 days
post coitum [115]. As ventricular and atrial chambers begin to form, isoform expression patterns
begin to diverge: β-MYH begins to be restricted
to ventricular myocytes in humans, and α-MHC
levels diminish in ventricular cells, but continue to
be expressed in adult human atrial cells [116].
Cardiac myosin heavy chain gene expression and
proportion of α-MYH and β-MYH expressed is
regulated by a number of factors, including thyroid
hormone during development, pressure or volume
overload, diabetes, catecholamine levels and aging
(Table 1.3) [108,114]. Regulatory elements in cardiac myosin heavy chain genes have been studied
extensively (reviewed in [108]).
Disease mutations associated with MYH genes
include, most notably, hypertrophic cardiomyopathy. Hypertrophic cardiomyopathy, a primary disorder of the myocardium and an important cause
of heart failure, was first associated with mutations
in the β myosin heavy chain gene in 1990 when a
missense mutation in R403Q was identified [117].
Subsequently, more than 80 mutations linked with
hypertrophic cardiomyopathy have been identified
in the β myosin heavy chain gene, and the list continues to grow [118].
In addition to mutations in the β myosin heavy
chain gene, researchers have identified hundreds
of mutations in at least 10 other genes, all encoding for proteins involved in the cardiac contractile
apparatus including α-myosin heavy chain gene,
cardiac myosin binding protein C, cardiac troponin
T2, C and I, α-tropomyosin, myosin regulatory and
10
CHAPTER 1
The gene in the twenty-first century
essential light chains, actin and titin [119]. Because
all of the genes identified as being causal in primary
hypertrophic cardiomyopathy encode for the sarcomeric proteins, primary hypertrophic cardiomyopathy is now widely recognized as a disorder of the
sarcomere [105].
Primer of genes and genomics
DNA
The deoxyribonucleic acid (DNA) of a living
organism contains all of the genetic information
necessary to construct a specific organism and to
direct the activity of the organism’s cells.
DNA is a very long, twisted, double stranded
molecule made up of two chains of nucleotides.
Each DNA nucleotide contains one of the four
DNA bases: guanine (G), adenine (A), thymine (T)
and cytosine (C). These bases are arranged side by
side (for example, AAGTTAAG) and it is their
sequence arrangement that will determine the protein constructed by the gene.
Gene
The basic unit of heredity, a gene is an ordered
sequence of DNA nucleotides that can be decoded
to produce a gene product. The overwhelming
majority of genes of the human genome are protein-coding genes; noncoding genes produce RNA
molecules, mainly involved in gene expression.
Gene expression
Gene expression is the complex process by which
information in the gene is transcribed into RNA
and translated into proteins. Gene expression is
carried out in two stages: transcription and translation. During transcription genetic information is
transcribed into an mRNA copy of a gene, which
must then be translated into a protein.
Although each cell of the human body contains a
complete genome and set of 20,000–25,000 genes,
only a subset of these genes are expressed or turned
on, depending on cell type. Such cell-specific gene
expression determines whether a cell will be a brain
cell, a heart cell or a liver cell, for example. Some
genes that carry out basic cellular functions are
expressed all the time in all the cells – they are called
housekeeping genes. Others are expressed only
under certain conditions, such as when activated by
signals such as hormones. Researchers study changes
in gene expression to gain understanding as to how
cells behave in response to changes in stimuli.
Gene structure
The gene is a structured molecule comprising exons,
introns and regulatory sequences. The region of
the gene that codes for a gene product (usually a
protein) is called the exon; between the exons are
sequences of noncoding DNA, called introns.
Introns must be edited out of the gene during transcription and before translation of the protein.
Stretches of DNA indicate the beginning and end
of genes. Coding begins with the initiation codon
or start codon “ATG” and ends with termination or
stop codons: TAA, TAG or TGA.
Genome
Genome is a word compound of “gene” and “chromosome.” A genome is the complete DNA required
to build a living organism, and an organism’s genome is contained in each of its cells. Some genomes
are small, such as bacterial genomes which may
contain less than a million base pairs and some are
very large: the human genome comprises about
three billion base pairs.
Human Genome Project
The Human Genome Project is an international
consortium to sequence all of the three billion base
pairs of the human genome. The Human Genome
Project formally commenced in 1990, led by the US
Department of Energy and the National Institutes
of Health. The project was completed in April 2003
with the announcement that the human genome
contains some 20,000–25,000 genes.
The benefits of the Human Genome Project are
beginning to make themselves felt. As a result of the
research project, powerful and novel technologies
and resources have been developed which will lead
eventually to an understanding of biology at the
deepest levels. Major advances in diagnosis and
treatment of many diseases, and disease prevention
is expected as a result of Human Genome Project
efforts.
How many genes in the human genome?
As of October 2004, the latest estimate from the
Human Genome Project is that the human gen-
CHAPTER 1
ome contains some 20,000–25,000 protein-coding
genes.
Genomics
Genome is a word combining “gene” and “chromosome”, and the genome includes the entire set of
an organism’s protein coding genes and all of the
DNA sequences between the genes. Genomics uses
the techniques of molecular biology and bioinformatics to study not just the individual genes of an
organism but of the whole genome.
Metabolomics
By analogy with genomics and proteomics, metabolomics is the large-scale study of the all the
metabolites of an organism. Understanding the
metabolome offers an opportunity to understand
genotype–phenotype and genotype–environment
interactions.
Microarray
Microarray is an enabling technology that allows
researchers to compare gene portraits of tissue
samples at a snapshot in time. A microarray is a
slide or membrane to which is attached an orderly
array of DNA sequences of known genes. The
researcher pipettes samples of mRNA onto the
slide, containing unknown transcripts obtained
from a tissue of interest. mRNA has the property
that it is complementary to the DNA template of
origin. Thus, mRNA binds or hybridizes to the slide
DNA and can be calculated by computer to provide
a portrait or snapshot of which genes are active in
the sample.
By monitoring and comparing thousands of genes
at a time – instead of one by one – a microarray gene
chip data can be used to see which genes in a tissue
are turned on or expressed and which are turned off.
Microarray gene expression profiling
Understanding gene function is crucially important to understanding health and disease. Most of
the common and serious diseases afflicting humans
are polygenic: that is, it takes hundreds if not thousands of genes interacting with each other and with
the environment to cause such diseases as cancer
and heart disease. By monitoring and comparing
thousands of genes at a time – instead of one by one
– microarray gene expression profiling can be used
The gene in the twenty-first century
11
to determine which genes in a tissue are turned on
and which are turned off – and how actively the
genes are producing proteins.
Such gene “portraits” can identify patients with
early stage diseases as compared to no disease or late
stage disease, to distinguishing patients with different
diseases, or patients with different stages of disease
for disease prognosis, drug effect monitoring and
other clinical applications. As microarray technology advances researchers will be able to ask increasingly probing and important biologic questions.
Mutation
A mutation is a change in the DNA sequence of a
gene. If the mutation is significant, then the protein
produced by the gene will be defective in some way
and unable to function properly. Not all mutations
are harmful; some may be beneficial and some may
have no discernible effect.
There are different types of mutations: base
substitution, in which a single base is replaced by
another: deletion, in which base(s) are left out; or
insertion in which base(s) are added.
Mutations can be caused by radiation, chemicals
or may occur during the process of DNA replication. Some mutations can be passed on through
generations.
Protein
A protein is a large molecular chain of amino acids.
Proteins are the cell’s main structural building
blocks and proteins are involved in all cellular
functions. Information in the gene encodes for the
protein and most of the genes of living organisms
produce proteins. Humans are calculated to have
about 400,000 proteins, far more than our 20,000
or so genes.
Proteomics
An understanding of cellular biology depends
fundamentally on understanding protein structure
and behaviour. Proteomics is the large-scale comprehensive study of the proteome, the complement
of all of the proteins expressed in a cell, a tissue or
an organism. Proteomics uses technology similar
to genomics technologies, such as protein microarrays, to explore the structure and function of
proteins and protein behaviour in response to
changing environmental signals.
12
CHAPTER 1
The gene in the twenty-first century
RNA
The relationship between a gene and its protein
is not straightforward. DNA does not construct
proteins directly; rather, genes set in motion
intermediate processes that result in amino acid
chains. The main molecule involved in this process
is called ribonucleic acid (RNA). RNA nucleotides
contain bases: adenine (A) uracil (U) guanine (G)
and cytosine (C). Thus, RNA is chemically very
similar to DNA, except that RNA has a uracil base
rather than thymine.
The process of producing a protein from DNA
template begins in the cell nucleus via the intermediary messenger (m) RNA. mRNA copies the
relevant piece of DNA in a process called transcription. The short, single-stranded mRNA transcript is then transported out of the cell nucleus
by transfer RNA and into the cytoplasm where it
is translated into a protein by the ribosome.
(Ribosomal RNA (rRNA), is involved in constructing the ribosomes.) Since the 1990s many new noncoding RNA genes have been discovered, such as
microRNA.
Single nucleotide polymorphism
A single nucleotide polymorphism (SNP) is a base
alteration in a single nucleotide in the genome.
Unlike mutations, which are rare, single nucleotide
polymorphisms are common alterations in populations, occurring in at least 1% of the population.
SNPs make up 90% of all human genetic variation
and occur every 100–300 human genome bases. In
time researchers hope to be able to develop SNP
patterns that can be used to test individuals for disease susceptibility or drug response.
Further information
National Center for Biotechnology Information. A Science Primer. http://www.ncbi.nlm.nih.gov/About/primer/
genetics_molecular.html
National Institutes of Health. NIGM. Genetics Basics
http://publications.nigms.nih.gov/genetics/science.html
Welcome Trust. Gene Structure. http://genome.wellcome.ac
.uk/doc_WTD020755.html
Human Genome Project. http://www.google.ca/search?
q=%22%22+what+is+a+gene%22+&hl=en&lr=&c2coff=
1&start=30&sa=N
Microarrays http://www.ncbi.nlm.nih.gov/About/primer/
microarrays.html
Introduction to proteomics: http://www.childrenshospital
.org/cfapps/research/data_admin/Site602/mainpageS602
P0.html
Bio-pro. Proteomics http://www.bio-pro.de/en/life/thema/
01950/index.html
The human metabolome project http://www.metabolomics
.ca/
References
1 Mendel G. Experiments in Plant Hybridization (1865)
Read at the meetings of the Brünn Natural History
Society, February 8 and March 8, 1865. (Available
online at www.mendelweb.org)
2 Correns C. Mendel’s law concerning the behavior of
progeny of varietal hybrids. (Trans: Piernick LK) Electronic Scholarly Publications. 2000. http://www.esp.org/
foundations/genetics/classical/holdings/c/cc-00.pdf
(Originally: Mendel’s Regel über das Verhalten der
Nachkommenschaft der Rassenbastarde. Ber Dtsch
Botanisch Gesellschadt 1900; 18: 158–168.)
3 De Vries H. Concerning the law of segregation of hybrids.
(Trans: Hannah A.) Electronic Scholarly Publications.
2000 (http://www.esp.org/foundations/genetics/classical/
holdings/v/hdv-00.pdf) (originally: Das Spaltungsgesetz
der Bastarde. Ber Dtsch Botanisch Gesellschaft 1900; 18:
83–90.)
4 Tschermak E. Concerning artificial crossing in Pisum
sativum. Genetics 1950: 35: 42–47. (Originally: Über
Künstliche Kreuzung bei Pisum sativum. Ber Dtsch
Botanisch Gesellschaft 1900; 18: 232–239.)
5 De Vries H. Intracellular pangenesis. Including a paper
on Fertilization and Hybridization. (Trans: Gager CS.)
Open Court Publishing, Chicago, 1910. http://www.
esp.org/books/devries/pangenesis/facsimile/title3.html
6 Bateson W. The progress of genetic research. In: Report
of the Third International Conference on Genetics 1906.
Royal Horticultural Society. London. 1907; 90–97.
7 Johannsen W. Elemente der Exakten Erblichkeitslehre.
Gustav Fischer, Jena, 1909.
8 Carlson EA. Mendel’s legacy: the origin of classical genetics. Cold Spring Harbor Laboratory Press, Cold Spring
Harbor, New York, 2004.
9 Sturtevant AH. A History of Genetics. Harper and Row,
New York, 1965.
10 Sturtevant AH. The linear arrangement of six sex linked
traits in drosophila, as shown by their mode of association. J Exp Zool 1913; 14: 43–59.
11 Bridges CE. Salivary chromosome maps: with a key
to the banding of the chromosomes of Drosophila
melanogaster. J Hered 1935; 26: 60–64.
12 Muller HJ. Artificial transmutation of the gene. Science
1927; 66: 84–87.
CHAPTER 1
13 Muller HJ. The gene as the basis of life. Proc Int Cong
Plant Science 1929; 1: 897–921.
14 Avery OT, MacLeod CM, McCarty M. Studies on the
chemical nature of the substance inducing transformation of pneumoccocal types. J Exp Med 1944; 79:
137–158.
15 Hershey AD, Chase M. Independent functions of viral
proteins and nucleic acid in growth of bacteriophage.
J Gen Physiol 1952: 36: 39–56.
16 Watson JD, Crick FHC. Molecular structure of nucleic
acids. Nature 1953; 171: 737–738.
17 Olby RC. The Path to the Double Helix. Macmillan,
London, 1974.
18 Garrod AE. The incidence of alkaptonuria: A study in
chemical individuality. Lancet 1902; ii: 1616–1620.
19 Garrod AE. Inborn Errors of Metabolism, 2nd edn. Henry
Frowde and Hodder & Stoughton, London, 1923.
20 Beadle G, Tatum E. Genetic control of biochemical reactions in Neurospora. Proc Natl Acad Sci USA 1941; 27:
499–506.
21 Neel JV. The inheritance of sickle cell anemia. Science
1949; 110: 64–66.
22 Pauling L, Itano H, Singer SJ, Wells I. Sickle cell anemia,
a molecular disease. Science 1949; 110: 543–548.
23 Ingram VM. Gene mutations in human haemoglobin:
the chemical difference between normal and sickle-cell
haemoglobin. Nature 1957; 180: 326–328.
24 Crick FHC. On protein synthesis. Symp Soc Exp Biol
1958; XII: 139–163.
25 Keller EF. The Century of the Gene. Harvard University
Press, Cambridge, 2000.
26 Morange M. Century of the gene. Isuma. Can J Policy
Res 2001; 2: 22–27.
27 Jacob F, Monod J. Genetic regulatory mechanisms in
the synthesis of proteins. J Mol Biol 1961; 3: 318–356.
28 Morange M. What history tells us. The operon model
and its legacy. J Biosci 2005; 30: 313–316.
29 Morange M. The Misunderstood Gene. Harvard University Press, Cambridge, 2001.
30 Portin P. The concept of the gene: Short history and present status. Q Rev Biol 1993; 68: 173–223.
31 Maas WK. Gene Action. Oxford University Press,
Oxford, 2001.
32 Temin HM, Mizutani S. RNA-dependent DNA polymerase in virions of Rous sarcoma virus. Nature 1970:
226: 1211–1213.
33 Baltimore D. RNA dependent DNA polymerase in
virions of RNA tumor viruses. Nature 1970; 226:
1209–1211.
34 Chow LT, Gelinas RE, Broker TR, Roberts RJ. An amazing sequence arrangement at the 5′ ends of adenovirus 2
messenger RNA. Cell 1977; 12: 1–8.
35 Berget SM, Moore C, Sharp PA. Spliced segments at the
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
The gene in the twenty-first century
13
5′ terminus of adenovirus 2 late mRNA. Proc Natl Acad
Sci USA 1977; 74: 3171–3175.
Gilbert W. Why genes in pieces? Nature 1978; 271: 501.
Lopez AJ. Alternative splicing of pre-mRNA: Developmental consequences and mechanisms of regulation.
Annu Rev Genet 1998; 32: 279–305.
McClintock B. The origin and behavior of mutable loci
in maize. Proc Natl Acad Sci USA 1950; 36: 344–355.
Britten RJ, Kohne DE. Repeated sequences in DNA.
Science 1968; 161: 529–540.
International Human Genome Sequencing Consortium. Finishing the euchromatic sequence of the human
genome. Nature 2004; 431: 931–945.
Gibbs WW. The unseen genome: gems among the junk.
Sci Am 2003; 289: 46–53.
Mattick JS. The hidden genetic program of complex
organisms. Sci Am 2004; 4: 60–67.
Eddy SR. Non-coding RNA genes and the modern RNA
world. Nat Rev Genet 2001; 2: 919–929.
Storz G, Altuvia S, Wassarman KM. An abundance of
RNA regulators. Annu Rev Biochem 2005; 74: 199–217.
Eddy SR. Computational genomics of noncoding RNA
genes. Cell 2002; 109: 137–40.
Mattick JS. The functional genomics of noncoding
RNA. Science 2005; 309: 1527–1528.
Noller HF. RNA structure: reading the ribosome. Science 2005; 309: 1508–1514.
Zamore PD, Haley B. Ribo-gnome: the big world of
small RNAs. Science 2005; 309: 1519–1524.
Ambros V. The functions of animal microRNAs. Nature
2004; 431: 350–355.
Bentwich I, Avniel A, Karov Y et al. Identification
of hundreds of conserved and nonconserved human
microRNAs. Nat Genet 2005; 37: 766–770.
Lewis BP, Burge CB, Bartel DP. Conserved seed pairing,
often flanked by adenosines, indicates that thousands
of human genes are microRNA targets. Cell 2005; 120:
15–20.
Chen CZ. MicroRNAs as oncogenes and tumor suppressors. N Engl J Med 2005; 353: 1768–1771.
Calin GA, Ferracin M, Cimmino A et al. A microRNA
signature associated with prognosis and progression in
chronic lymphocytic leukemia. N Engl J Med 2005; 353:
1793–1801.
Falk R. Long live the genome! So should the gene. Hist
Philos Life Sci 2004; 26: 105–121.
Venter JC, Adams MD, Myers EW et al. The sequence of
the human genome. Science 2001; 291: 1304–1351.
International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human
genome. Nature 2001; 409: 860–921.
Dempsey AA, Dzau VJ, Liew CC. Cardiovascular genomics: Estimating the total number of genes expressed in
14
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
CHAPTER 1
The gene in the twenty-first century
the human cardiovascular system. J Mol Cell Cardiol
2001; 33: 1879–1886.
Hwang DM, Dempsey AA, Wang RX et al. A genomebased resource for molecular cardiovascular medicine:
toward a compendium of cardiovascular genes. Circulation 1997; 96: 4146–4203.
Pennisi E. The human genome. Science 2001; 291:
1177–1180.
Adams MD, Kelley JM, Gocayne JD et al. Complementary DNA sequencing: expressed sequence tags and
human genome project. Science 1991; 252: 1651–1656.
Roberts L. Gambling on a shortcut to genome sequencing. Science 1991; 252: 1618–1619.
Liew CC. A human heart cDNA library: the development of an efficient and simple method for automated
DNA sequencing. J Mol Cell Cardiol 1993; 25: 891–894.
Liew CC, Hwang DM, Fung YW et al. A catalogue of
genes in the cardiovascular system as identified by
expressed sequence tags (ESTs). Proc Natl Acad Sci USA
1994: 91: 10645–10649.
Roberts L. Genome patent fight erupts. Science 1991:
254: 184–186.
Marshall E. The company that genome researchers love
to hate. Science 1994; 266: 1800–1802.
Levy-Lahad E, Wasco W, Poorkaj P, et al. Candidate
gene for the chromosome 1 familial Alzheimer’s disease
locus. Science 1995; 269: 973–977.
Schena M, Shalon D, Davis RW et al. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 1995; 270: 467–470.
Lockhart DJ, Dong H, Byrne MC et al. Expression monitoring by hybridization to high-density oligonucleotide
arrays. Nat Biotechnol 1996; 14: 1675–1680.
Bowtell DDL. Options available – from start to finish –
for obtaining expression data by microarray. Nat Genet
1999; Supplement 21: 25–32.
Lipshutz RJ, Fodor SPA, Gingeras TR et al. High density
synthetic oligonucleotide arrays. Nature Genetics. 1999;
Supplement 21: 20–24.
Perou CM, Jeffrey SS, van de Rijn M et al. Distinctive
gene expression patterns in human mammary epithelial
cells and breast cancers. Proc Natl Acad Sci USA 1999;
96: 9212–9217.
Rhodes DR, Chinnaiyan AM. Integrative analysis of the
cancer transcriptome. Nat Genet 2005; 37 Supplement:
S31–S37.
Segal E, Friedman N, Kaminski N et al. From signatures
to models: understanding cancer using microarrays.
Nat Genet 2005; 37 Supplement: S38–S45.
Mohr S, Leikauf GD, Keith G, Rihn BH. Microarrays as
cancer keys: an array of possibilities. J Clin Oncol 2002;
20: 3165–3175.
Liew CC, Dzau VJ. Molecular genetics and genomics of
heart failure. Nat Rev Genet 2004; 5: 811–825.
76 Friddle CL, Koga T, Rubin EM, Bristo J. Expression
profiling reveals distinct sets of genes altered during
induction and regression of cardiac hypertrophy Proc
Natl Acad Sci USA 2000; 97: 6745–6750.
77 Yang J, Moravec CS, Sussman MA. Decreased SLIM1
expression and increased gelsolin expression in failing
human hearts measured by high-density oligonucleotide arrays. Circulation 2000; 102: 3046–3052.
78 Barrans JD, Stamatiou D, Liew CC. Construction of a
human cardiovascular cDNA microarray: portrait of a
failing heart. Biochem Biophys Res Commun 2001; 280:
964–969.
79 Barrans JD, Allen PD, Stamatiou D et al. Global gene
expression profiling of end stage dilated cardiomyopathy using a human cardiovascular based cDNA microarray. Am J Pathol 2002; 160: 2035–2043.
80 Liew CC. Expressed genome molecular signatures of
heart failure. Clin Chem Lab Med 2005; 43: 462–469.
81 Whitney AR, Diehn M, Popper SJ et al. Individuality
and variation in gene expression patterns in human
blood. Proc Natl Acad Sci USA 2003; 100, 1896–1901.
82 Radich JP, Mao M, Stepaniants S et al. Individualspecific variation of gene expression in peripheral blood
leukocytes. Genomics 2004; 83: 980–988.
83 Barnes MG, Aronow BJ, Luyrink LK et al. Gene expression in juvenile arthritis and spondyloarthropathy: proangiogenic ELR+ chemokine genes relate to course of
arthritis. Rheumatol (Oxf) 2004; 43: 973–979.
84 Okuda T, Sumiya T, Mizutani K et al. Analyses of differential gene expression in genetic hypertensive rats by
microarray. Hypertens Res 2002; 25: 249–255.
85 Chon H, Gaillard CA, van der Meijden BB et al. Broadly
altered gene expression in blood leukocytes in essential
hypertension is absent during treatment. Hypertension
2004; 43: 947–951.
86 Bull TM, Coldren CD, Moore M et al. Gene microarray
analysis of peripheral blood cells in pulmonary arterial
hypertension. Am J Respir Crit Care Med 2004; 170:
827–828.
87 DePrimo SE, Wong LM, Khatry DB et al. Expression
profiling of blood samples from an SU5416 Phase III
metastatic colorectal cancer clinical trial: a novel strategy for biomarker identification. BMC Cancer 2003; 3: 3.
88 Whistler T, Unger ER, Nisenbaum R, Vernon SD.
Integration of gene expression, clinical, and epidemiologic data to characterize chronic fatigue syndrome.
J Transplant Med 2003; 1: 10.
89 Tang Y, Lu A, Aronow BJ, Sharp FR. Blood genomic
responses differ after stroke, seizures, hypoglycemia,
and hypoxia: blood genomic fingerprints of disease. Ann
Neurol 2001; 50: 699–707.
90 Tang Y, Nee AC, Lu A et al. Blood genomic expression
profile for neuronal injury. J Cereb Blood Flow Metab
2003; 23: 310–319.
CHAPTER 1
91 Connolly PH, Caiozzo VJ, Zaldivar F et al. Effects of
exercise on gene expression in human peripheral blood
mononuclear cells. J Appl Physiol 2004; 97: 1461–1469.
92 Ezendam J, Staedtler F, Pennings J et al. Toxicogenomics of subchronic hexachlorobenzene exposure in
Brown Norway rats. Environ Health Perspect 2004; 112:
782–791.
93 Wu MM, Chiou HY, Ho IC et al. Gene expression of
inflammatory molecules in circulating lymphocytes
from arsenic-exposed human subjects. Environ Health
Perspect 2003; 111: 1429–1438.
94 Ryder MI, Hyun W, Loomer P, Haqq C. Alteration of
gene expression profiles of peripheral mononuclear blood
cells by tobacco smoke: implications for periodontal
diseases. Oral Microbiol Immunol 2004; 19: 39–49.
95 Ma J, Liew CC. Gene profiling identifies secreted protein
transcripts from peripheral blood cells in coronary
artery disease. J Mol Cell Cardiol 2003; 35: 993–998.
96 Tsuang MT, Nossova N, Yager T et al. Assessing the
validity of blood-based gene expression profiles for the
classification of schizophrenia and bipolar disorder: a
preliminary report. Am J Med Genet B Neuropsychiatr
Genet 2005; 133: 1–5.
97 Glatt SJ, Everall IP, Kremen WS et al. Comparative
gene expression analysis of blood and brain provides
concurrent validation of SELENBP1 upregulation in
schizophrenia. Proc Natl Acad Sci USA 2005; 102:
15533–15538.
98 Marshall KW, Zhang H, Yager T et al. Blood-based
biomarkers for detecting mild osteoarthritis in the
human knee. Osteoarthritis Cartilage 2005; 13: 861–871.
99 Osman I, Bajorin D, Sun TT et al. Novel blood biomarkers of human urinary bladder cancer. Clin Cancer Res
2006; 12: 3374–3380.
100 Gilbert, W. Origin of life: The RNA world. Nature 1986;
319: 618.
101 Brown PO. Website (http://biochemistry.stanford.edu/
research/brown.html)
102 Pennisi E. Why do humans have so few genes? Science
2005; 309: 80.
103 Ruddle F. Hundred-year search for the human genome.
Annu Rev Genomics Hum Genet 2001; 2: 1–8.
104 Hughes SE. The pathology of hypertrophic cardiomyopathy. Histopathology 2004; 44: 412–427.
105 Seidman JG, Seidman C. The genetic basis for cardiomyopathy: from mutation identification to mechanistic
paradigms. Cell 2001; 104: 557–567.
The gene in the twenty-first century
15
106 Towbin JA, Bowles NE. The failing heart. Nature 2002;
415: 227–233.
107 Bonne G, Carrier L, Richard P. Familial hypertrophic
cardiomyopathy: from mutations to functional defects.
Circ Res 1998; 83: 580–593.
108 Weiss A, Leinwald LA. The mammalian myosin heavy
chain gene family. Annu Rev Cell Dev Biol 1996; 12:
417–439.
109 Liew CC, Jandreski MA. Construction and characterization of the α form of a cardiac myosin heavy chain
cDNA clone and its developmental expression in the
Syrian hamster. Proc Natl Acad Sci USA 1986; 83:
3175–3179.
110 Jandreski MA, Liew CC. Construction of a human
ventricular cDNA library and characterization of a βmyosin heavy chain cDNA clone. Hum Genet 1987; 76:
47–53.
111 Jandreski MA, Sole MJ, Liew CC. Two different forms of
β-myosin heavy chain are expressed in human striated
muscle. Hum Genet 1987; 77: 127–131.
112 Strehler EE, Strehler-Page MA, Perriard JC et al.
Complete nucleotide and encoded amino acid sequence
of a mammalian myosin heavy chain gene. Evidence
against intron dependent evolution of the rod. J Mol Biol
1986; 190: 291–317.
113 Yamauchi-Takihara K, Sole MJ, Liew J et al. Characterization of human cardiac myosin heavy chain
genes. Proc Natl Acad Sci USA 1989: 86: 3504–3508.
114 Morkin E. Control of cardiac myosin heavy chain gene
expression. Microsc Res Tech 2000; 50: 522–531.
115 Lyons GE, Ontell M, Cox R et al. The expression of
myosin genes in developing skeletal muscle in the
mouse embryo. J Cell Biol 1990; 111: 1465–1476.
116 Lompre AM, Nadal-Ginard B, Mahdavi V. Expression
of the cardiac ventricular α- and β-myosin heavy chain
genes is developmentally and hormonally regulated.
J Biol Chem 1984; 259: 6437–6446.
117 Geisterfer-Lowrence AA, Kass S, Tanigawa G et al. A
molecular basis for familial hypertrophic cardiomyopathy a β cardiac myosin heavy chain gene mis-sense
mutation. Cell 1990; 62: 999–1006.
118 Seidman C. For an updated list go to: Sarcomere Protein
Gene Mutation Database. (http://genetics.med.harvard
.edu/~seidman/cg3/)
119 Ahmad F, Seidman JG, Seidman C. The genetic basis for
cardiac remodeling. Annu Rev Genomics Hum Genet
2005; 6: 185–216.
Cardiovascular single
gene disorders
14q32
14q31
Chromosome 14
14q24
b-Myosin heavy chain (MYH7)
chromosome localization
14p13
14p12
14p11+2
14p11+1
14q11+1
14q11+2
14q12
14q13
14q21
14q22
14q23
I
PART I
b-Myosin heavy chain (MYH7)
genomic organization
Untranslated region
Coding region
Myosin N terminal SH-3-like domain
Myosin motor domain, type 2
Intermediate filament domain
Myosin tail 1 domain
b-Myosin heavy chain (MYH7)
protein domains
The chromosomal localization, genomic organization and protein domains of the human b-myosin heavy chain (MYH7).
The mRNA sequence of the human b-myosin heavy chain was first sequenced and characterized in 1990 by Liew et al. [1].
The genomic sequence and organization of the human b-myosin heavy chain was first identified and characterized in
1989 by Yamauchi-Takihara et al. [2].
1. Liew CC, Sole MJ, Takihara KY et al. Complete sequence and organization of the human cardiac b-myosin heavy chain
gene. Nucleic Acids Res 1990; 18: 3647–3651.
2. Yamauchi-Takihara K, Sole MJ, Liew J, Ing D, Liew CC. Characterization
of human cardiac myosin heavy chain genes.
.
Proc Natl Acad Sci USA 1989; 86: 3504–3508.
2
CHAPTER 2
Monogenic hypercholesterolemia
Ruth McPherson, MD, PhD, FRCPC
Introduction
Plasma concentrations of low-density lipoprotein (LDL) cholesterol are directly related to the
incidence of coronary artery disease (CAD). Approximately half of interindividual variation in LDLcholesterol is attributable to genetic factors [1,2].
The major part of this is believed to be oligogenic,
the cumulative result of variations in several genes,
or polygenic, resulting from a large number of
genetic variants, each contributing a small effect.
Plasma concentrations of LDL-cholesterol are also
strongly influenced by environmental factors including diet and lifestyle as well as a number of
endogenous and exogenous hormonal influences
and various disease states. Very high plasma concentrations of LDL-cholesterol may be the consequence of rare monogenic disorders with severe
clinical sequelae including tissue deposition of
cholesterol, producing cutaneous xanthomas and
premature atherosclerosis. Early diagnosis of these
disorders is essential both to permit the prompt
application of vigorous cholesterol lowering therapies required for CAD prevention and to alert the
clinician to the need to screen first degree relatives.
Insights gained from the study of rare monogenic causes of hypercholesterolemia have also
contributed significantly to our knowledge of intracellular protein trafficking and cellular cholesterol
metabolism [3–5]. This review focuses on recent
developments in our understanding of the genetic
and molecular etiology of known Mendelian disorders of LDL-cholesterol metabolism (Table 2.1)
and indicate how this knowledge been applied to
develop effective therapies for both rare and common forms of hypercholesterolemia.
Overview of LDL metabolism
Cholesterol is a structural component of vertebrate plasma membranes and is a precursor for
steroid hormone synthesis. Cholesterol is transported in plasma in the form of lipoproteins with
unesterified cholesterol as a surface component
and cholesteryl esters packaged in the core of
spherical lipoproteins. The liver synthesizes and
secretes very low-density lipoprotein (VLDL), which
are triglyceride-rich lipoproteins, containing one
molecule of apoB. The triglycerides and phospholipids of circulating VLDL are hydrolyzed by lipases
at vascular endothelial surfaces, leaving a cholesterol-enriched VLDL remnant, which may be
removed directly by the liver or converted to LDL, a
process that involves remodeling by hepatic lipase
and cholesteryl ester transfer protein (CETP). LDL
particles are largely cleared from the circulation by
the liver after binding to LDL receptors by receptor
mediated endocytosis (Plate 2.1) [5]. When LDL
receptors are absent or dysfunctional, LDL accumulates in the plasma and eventually crosses into
the subendothelial space, where following oxidation or other types of enzymatic modification, it
may be taken up by macrophage scavenger receptors, leading to foam cell formation [6].
Domain organization of the LDL
receptor
The protein domain structure of the LDL receptor (LDLR) is illustrated in Plate 2.2. This receptor
is a glycoprotein of 839 amino acids with a single
transmembrane domain. Seven LDL receptor type
A (LA) molecules at the amino terminal end are
responsible for lipoprotein binding via apoB or
apoE [7]. Mutations in apoB (esp Arg3500Gln)
19
20
PART I
Cardiovascular single gene disorders
Table 2.1 Monogenic disorders of LDL-cholesterol (LDL-C) metabolism.
Gene defect
Causative
Molecular etiology
sequence variants
Prevalence
LDL-C concentration
(heterozygotes)
Autosomal dominant
FH
LDLR
>1000
19p13.1–13.3
Impaired synthesis or
~1/500
7–10 mmol/L in
secretion or function
heterozygous FH
of LDLR
15–30 mmol/L in
homozygous FH
FDB
APOB
Most due to single
Impaired interaction of
2p23–24
missense mutation
apoB with LDLR
~1/1000
6–8 mmol/L in
heterozygous FBD
Arg3500Gln
FH3
PCSK9
S127R
Gain of function mutations
~1/2500
1p32
F216L
leading to decreased cell
8–25 mmol/L
Variable
surface expression of LDLR
Autosomal recessive
ARH
ARH
>10
1p35–36.1
Sitosterolemia
Impaired LDLR mediated
~1/5 × 106
10–14 mmol/L
~1/5 × 106
Variable
endocytosis
ABCG5 or
>25 require 2
Increased absorption of
ABCG8
mutations in either
plant sterols
ABCG5 or ABCG8
ARH, autosomal recessive hypercholesterolemia; FDB, familial defective apoB; FH, familial hypercholesterolemia;
LDLR, LDL receptor.
impair the interaction of LDL with the LDLR
leading to familial dysbetalipoproteinemia (FDB).
Adjacent to this is a region with homology to the
epidermal growth factor precursor (EGFP) consisting of two EGF like repeats, a YWTD domain and
a third EGF repeat. This region of the LDLR is implicated in the release of internalized lipoproteins
in acidic endosomes at low pH [8]. Interspersed
between the EGFR and the plasma membrane is a
region rich in serine and threonine which undergoes N-linked glycosylation. This O-linked sugar
domain is followed by the transmembrane domain
and a 50 AA cytoplasmic tail required for required
for receptor localization in clathrin coated pits and
a NPxY motif required for receptor internalization
[9] (reviewed in [10]).
Cellular itinerary of the LDLR
Following synthesis, the LDLR undergoes folding
in the endoplasmic reticulum, a process facilitated
by the molecular chaperone, receptor associated
protein (RAP) [11]. PCKS9 is a serine protease
which appears to function in the post translational
regulation of LDLR processing [12–14]. Gain of
function mutations in PCKS9 result in decreased
LDLr cell surface expression and have been identified as a rare cause of autosomal dominant hypercholesterolemia [15]. The LDLR is secreted from
the endoplasmic reticulum as a 120-kDa protein
which undergoes extensive O-linked glycosylation
in the Golgi to form the mature 160 kDa receptor,
which is transported to the cell surface. The LDLR
binds with high affinity to apoB and apoE containing lipoproteins at the cell surface. Receptor
lipoprotein complexes enter the cell via clathrin
coated pit mediated endocytosis, a process that
requires the NPXY sequence in the cytoplasmic tail.
ARH-1 encodes a protein with a PTB domain capable of binding the NPXY sequence in the LDLR, a
canonical clathrin binding sequence, LLDLE and
a sequence recognized by the β2 adaptin subunit of
AP-2, a major structural component of clathrin
coated pits [16]. Mutations in ARH-1 have been
identified as a cause of autosomal recessive hypercholesterolemia (ARH) [17]. Following clathrin
coated pit mediated endocytosis, LDLR and cargo
CHAPTER 2
are delivered to acidic endosomes, where the low
pH leads to release of the LDLR which recycles to
the plasma membrane. The released lipoproteins
traffic to lysosomes where the cholesteryl ester is
hydrolyzed to free cholesterol and the protein
moiety degraded. There is continual uptake and
recycling of each LDLR with or without bound
lipoproteins every 10–30 minutes with about 100
passages before degradation [10].
Familial hypercholesterolemia
Familial hypercholesterolemia (FH) was first
brought to clinical attention almost 70 years ago
when Müller described the familial clustering of
a syndrome of cutaneous xanthomas, elevated
cholesterol and premature CAD and proposed that
this might be caused by a single gene defect. In the
1960s, Frederickson et al. [18] demonstrated impaired LDL metabolism in patients with FH and
other investigators indicated a genetic link to a
locus on chromosome 19. These studies eventually
culminated in the discovery by Brown & Goldstein
[5] that FH is the result of mutations in the LDL
receptor gene.
Clinical diagnosis
Various paradigms for the diagnosis of heterozygous FH have been developed by different groups
including the US MedPed Program, the UK Simon
Broome Register Group and the Dutch lipid Clinic
Network (reviewed in [19,20]). Because total
cholesterol levels increase with age, the cutpoints
for diagnosis of FH in individuals with a family
history of FH in a first degree relative range from
>220 mg/dL (5.7 mmol/L) for a family member
<20 years of age to >290 mg/dL (7.5 mmol/L) for
those >40 years of age [21]. DNA based evidence of
a mutation in the LDLR or APOB gene, the presence of clinical stigmata of FH including tendon
xanthomas, inferior corneal arcus at an early age
and a family history of CAD in a first degree relative
before the age of 50 years will facilitate the diagnosis.
In adults with heterozygous FH, plasma cholesterol levels are typically 9–11 mmol/L (350–430 mg/
dL). Tendon xanthomas are rarely present until
after 20 years of age. In untreated FH, CAD typically presents in the fifth decade in males and in the
sixth decade in females. CAD onset can be much
Monogenic hypercholesterolemia 21
earlier in patients with other risk factors such as
cigarette smoking or high plasma levels of lipoprotein (a), justifying early screening for both conventional and emerging risk factors [20].
Homozygous FH presents in childhood with
cutaneous planar or tuberous xanthomas, tendon
xanthomas and dense corneal arcus. Cholesterol concentrations are typically >600 mg/dL (15 mmol/L)
and can be as high as 1000–1200 mg/dL (25–30
mmol/L). Atheroma of the aortic root and aortic
valve develops by puberty with evidence for an
aortic valvular gradient, angiographic narrowing of
the aortic root and coronary osteal stenosis. Without treatment, sudden death or acute myocardial
infarction typically occurs before the age of 30
years. The age of onset of CAD is dependent in part
on the contributing mutations in the LDLR and
degree of residual LDLR function (see below).
Prevalence
Heterozygous frequency of FH was typically estimated from the observed homozygous frequency
assuming Hardy–Weinberg equilibrium. This approach may be flawed because genetic counseling
has made couples who are both affected with heterozygous FH aware of the risk for their offspring.
The prevalence of functional mutations in the
LDLR gene causative of FH is estimated at approximately 1 in 500 in most North American and
European populations but higher in certain groups
such as South African Ashkenazi Jews (1 in 72),
Lebanese Christians (1 in 85), Africaners (1 in 100),
Tunisians (1 in 165) and French Canadians (1 in
270) as a result of founder effects (reviewed in
[20]). A founder effect occurs when a subpopulation is formed through the immigration of a small
number of individuals followed by population
expansion. If certain of the founders had FH, these
same, and limited number of mutations would
be enriched in their descendents. For example,
amongst French Canadians, 11 LDLR mutations
account for 90% of FH, the most prevalent being a
receptor negative mutation resulting from a 15-kb
deletion [22,23].
In other populations, the prevalence of FH is
apparently lower; for example, 1 in 950 in Denmark
and 1 in 900 in Japan. Homozygous FH is proportionally rare, with a reported incidence of about 1
in 106 in North America.
22
PART I
Cardiovascular single gene disorders
Table 2.2 LDL receptor (LDLR) mutations in familial hypercholesterolemia.
Mutation
General location
Functional effects
Class 1
Disruptions of promoter sequence nonsense,
No protein synthesis (null alleles)
frameshift or splicing mutations
Class 2
Primarily in the ligand-binding domain and
Disrupt transport of the LDLR from the ER to Golgi
EGF precursor regions
Class 3
Ligand binding and EGF precursor regions
Interfere with cell surface binding of the LDLR to LDL
Class 4
Cytoplasmic domain or cytoplasmic and
Inhibit the clustering of the LDLR on the cell surface
membrane spanning domains
Class 5
EGF precursor region
Prevent the release of LDL in endosome and thus
impair recycling of the LDLR to the cell surface
(Class 6)
C-terminal end of the cytoplasmic tail
Interferes with the proper sorting of the LDLR towards
towards the NPXY sequence (G823D)
the basolateral membrane in polarized cells
EGF, epidermal growth factor; ER, endoplasmic reticulum.
Genetic variants
The LDLR gene maps to the short arm of chromosome 19 at 19p13.1–p13.3, spans 45 kb and has 18
exons. As of September 1, 2005 over 1000 LDLR
variants have been identified in subjects with FH
although not all have been proven to be functional.
Gene variants are compiled online at two websites: http://www.ucl.ac.uk/fh/ [24] and www.umd
.necker.fr/LDLR/research.html [25].
Functional mutations in the LDLR gene have
been characterized according to their functional
effects in human fibroblasts (Table 2.2; Plate 2.3)
[26,27]. Null alleles and mutations in the ligand
binding region (exons 2–6) demonstrate high penetrance and are prevalent in patients referred for
DNA diagnosis. Exon 4 codes for repeat 5, which
is required for both LDL binding via apoB and
VLDL uptake via apoE and mutations in this region produce a particularly severe phenotype [28].
Approximately 5% of patients with FH have been
identified to have various deletions or duplications
in the LDLR gene, primarily in introns 1–8 and
intron 12, associated with a high frequency of Alu
sequences in these areas [29].
Treatment of heterozygous FH
Heterozygous FH responds well to strategies designed to upregulate the normal LDLR allele. The
development of HMG-CoA reductase inhibitors
(statins) was a direct result of the discovery that FH
resulted from mutations in the LDLR gene and that
expression of LDLR is regulated by cellular sterol
via a sterol regulatory element (SRE) in its 5′ flanking sequence [4,30,31]. Statins decrease hepatic
cholesterol synthesis, which leads to an increase in
cell surface LDL receptors as well as decrease in
VLDL secretion and hence reduced LDL production. Current recommendations advocate statin
therapy in children with FH as young as 10 years
and are supported by evidence of premature CAD
in untreated patients [32]. Statin monotherapy can
lower LDL-cholesterol by as much as 50% in FH.
Combination therapy is required for many patients. Ezetimibe inhibits endogenous and dietary
cholesterol absorption via an effect of the intestinal
cholesterol transporter, NPCL1, and can reduce
LDL-cholesterol by a further 20–25% [33,34].
Niacin is also a useful second or third agent, particularly in FH patients with low plasma levels
of HDL-cholesterol or high plasma concentrations
of lipoprotein (a).
Treatment of homozygous FH
Homozygous FH responds relatively poorly to
statin and/or ezetimibe therapy although responses
vary dependent upon the causative mutations and
residual LDLR activity. Atorvastatin 80 mg/day
reduced LDL-cholesterol by 18% in receptor negat-
CHAPTER 2
ive and 41% in receptor defective patients [35].
Currently, the treatment of choice for homozygous FH is LDL apheresis, a process by which LDL
particles and lipoprotein (a) are selectively removed
from the body by extracorporeal binding to heparin (heparin extracorporeal LDL precipitation system, HELP), or dextran sulfate (dextran-sulfate
cellulose absorption, DSA) or direct absorption
of lipoproteins using hemoperfusion (DALI). LDLcholesterol lowering efficacy ranges from 77% to
84%. Additional benefits include reduction of
lipoprotein (a), various adhesion molecules, Creactive protein and improved endothelial function
[36,37]. LDL apheresis clearly elicits regression of
xanthomas and attenuates atherosclerosis progression. Typically, LDL apheresis is performed at biweekly intervals with patients being maintained on
maximally tolerated doses of lipid lowering agents.
Where LDL apheresis is not available, plasmapheresis can be a useful alternative [38].
In children with homozygous FH, statin therapy
should be introduced by the age of 1 year and
titrated up to 1–2 mg/kg/day atorvastatin [35].
LDL apheresis is typically initiated at the age of
6 years or earlier [36,37]. To maintain adequate
blood flow rates, creation of an arteriovenous
fistula is normally required (reviewed in [39]).
Gene therapy would appear to be a logical approach in a single gene disorder. However, success
has been hampered by the inability to achieve high
level and long-term expression of the LDLR gene in
liver and by the safety of viral vectors [40–42]. Liver
transplantation to provide functional LDL receptors is the most definitive therapy currently available for homozygous FH but the surgical risks and
need for lifelong immunosuppression have limited
its popularity. However, improved surgical techniques and evidence of favorable outcomes of
liver/cardiac transplants in adults [43] and livingdonor liver transplants in children [44] suggest that
this may become the intervention of choice in the
future.
Familial defective apoB-100
A second relatively common cause of severe autosomal dominant hypercholesterolemia is familial
defective apoB (FDB). This disorder was first
identified in patients who presented similarly to
Monogenic hypercholesterolemia 23
FH, had reduced LDL apoB turnover rates by
kinetic analyses but normal LDLR expression and
function in isolated fibroblasts. FDB usually results from a missense mutation (Arg3500Gln) in
the LDLR binding domain of apoB [45,46]. Other,
less frequent mutations in apoB have been reported
to cause FDB. The prevalence of FDB is approximately 1 in 1000 in individuals of Northern
European descent and somewhat less in other
populations. Patients with heterozygous FDB
present with plasma cholesterol levels in the 275–
350 mg/dL (7–9 mmol/L) range and hence somewhat lower than those typical of patients with FH.
FDB homozygotes have cholesterol concentrations
comparable to that of FH heterozygotes and a more
benign course as compared to homozygous FH,
with onset of clinical CAD commonly not until the
fifth decade of life [47].
LDL from subjects with FDB have a 90%
decrease in affinity for the LDLR and LDL clearance
is markedly impaired. Kinetic studies indicate that
LDL production is also decreased likely because of
decreased VLDL secretion and increased clearance
of apoE-rich VLDL remnants, mediated by both
the LDLR and LDL receptor related protein (LRP)
[48]. The genetic diagnosis of the Arg3500Gln variant is straightforward but other causative mutations have been described. Treatment is similar to
that of FH with reliance on statin therapy, which
both decreases VLDL production and enhances
clearance of VLDL remnants. A second agent such
as ezetimibe is frequently required for optimal lipid
control [33].
PCKS9 nonsense mutations (FH3)
More recently, an additional cause of autosomal
dominant FH, FH3 was discovered. Abifadel et al.
[15] further mapped a region on chromosome 1
that had previously been linked to FH in a large
Utah kindred, in 23 French families in whom LDLR
or APOB sequence variants were excluded. In a
region containing 41 genes, they identified PCKS9
(NARC-1) as a candidate gene and identified two
missense mutations, S127R and F216L resulting in
gain of function. In alter studies S127R and D374Y
were shown to result in decreased cell surface
expression of the LDLR [2]. In a later study, a third
causative mutation, D374Y in the PCKS9 gene was
24
PART I
Sig
Pep
1
Cardiovascular single gene disorders
Prodomain
30
Catalytic
P domain
143
S127R
474
F216L
Y142X
D374Y
C-terminal
573
692
E670G
C679X
Figure 2.1 Schematic representation of PCKS9. The
domain structure of PCKS9 includes a signal peptide of
30 amino acids (aa), a pro-peptide domain (aa 30–143),
a catalytic domain (aa 143–474), containing the catalytic
triad of aspartate (D), histidine (H) and serine (S) as well
as a highly conserved arginine (N). This is followed by
a P domain (aa 474–573) and the C-terminal domain
(aa 573–692), which is cysteine rich. PCKS9 is synthesized
as a zymogen and undergoes autocatalytic processing
in the endoplasmic reticulum (ER). The cysteine-rich
C-terminal domain is required for autoprocessing and a
C-terminal deletion has been shown to impair the exit
of PCKS9 from the ER [52]. The missense mutations (S127R,
F216L, D374Y) are causative of severe hypercholesterolemia
whereas the nonsense mutations (Y142X, C679X) have
been associated with hypocholesterolemia. E670G has been
associated with moderate increases in LDL-cholesterol.
Adapted from [26] with permission from the Annual
Review of Genetics, volume 24 © 1990 by Annual Reviews
www.annualreviews.org.
identified in a Norwegian family [49] and in Utah
kindreds [50]. Subjects with the S127R and F216L
mutations displayed LDL-cholesterol levels which
were two- to fivefold higher than age-matched controls, thus similar to FH [15]. Response to statin
treatment was reportedly often inadequate [51].
PCKS9 (NARC-1) encodes neural apoptosisregulated convertase 1 [52], a 691 amino acid
protein belonging to the proteinase K family of
subtilases, which is predominantly expressed in
liver and intestine. The domain structure of PCKS9
(Fig. 2.1) includes a signal peptide of 30 amino
acids (aa), a pro-peptide domain (aa 30–143), a
catalytic domain (aa 143–474), containing the
catalytic triad of aspartate (D), histidine (H) and
serine (S) as well as a highly conserved arginine (N).
This is followed by a P domain (aa 474–573) and
the C-terminal domain (aa 573–692), which is cysteine rich. PCKS9 is synthesized as a zymogen and
undergoes autocatalytic processing in the endoplasmic reticulum. The cysteine-rich C-terminal
domain is required for autoprocessing and a Cterminal deletion has been shown to impair the exit
of PCKS9 from the ER [52].
PCKS9 functions in the post translational regulation of LDLR processing, reducing LDLR number
[3,14,53]. Adenoviral mediated overexpression of
Pcks9 in mice [14,53,54] results in near complete
depletion of LDL receptors whereas inactivation
of the catalytic unit is without effect. Secreted
PCSK9 decreases the number of LDL receptors in
hepatocytes [4]. Other effects of autosomal dominant
PCKS9 mutations include decreased zymogen processing of PCKS9 and reduced LDLR density [54].
In kinetic studies, subjects with the S127R mutation were shown to have a 30% decrease in LDL
apoB fractional catabolic rate, not dissimilar to that
observed in subjects heterozygous for mutations in
the LDLR gene. However, the most marked effect
of S127R mutation was to increase VLDL apoB
production rate by threefold and LDL apoB production by twofold [55], with evidence suggestive
of direct synthesis of LDL by the liver. Secreted
lipoproteins also had an abnormal composition
with an elevated cholesteryl ester : triglyceride ratio,
which would be expected to decrease their affinity
for lipoprotein lipase. It has been speculated that
PCKS9 may be involved in the post translational
degradation of nascent VLDL [56]. Taken together,
these studies suggest that PCKS9 normally functions to both increase VLDL and LDL production
and attenuate cellular uptake of LDL. Mutations
causative of an autosomal dominant form of hypercholesterolemia appear to result in “gain of function” [12,57,58,59].
Other sequence variants in PCKS9 have been
shown to act in a non-Mendelian fashion. PCKS9
genetic variants have been linked to LDL-cholesterol levels in Japan [58] and in the TexGen study
E670G in the C-terminal region was linked to
plasma cholesterol concentrations [59]. Homozygotes for the rare allele (GG) had 20% higher
plasma LDL-cholesterol compared with EE homozygotes. Conversely, other PCKS9 sequence variants
CHAPTER 2
(Y142X and C679X) resulting in “loss of function”
have recently been associated with low plasma
concentrations of LDL-cholesterol in AfricanAmericans, apparently accounting for this phenotype in 11% of subjects with LDL-cholesterol
concentrations <58 mg/dL (1.5 mmol/L) [60].
Haplotype analyses suggested that each of these
nonsense mutations arose from a single ancestor,
indicating a founder effect. The mutation coding
for Y142X, (426C to A) in exon 3 introduces a stop
codon, which is predicted to delete the last 80% of
the protein. A second nonsense mutation, (2037 C
to A) introduces a stop codon at residue 679
(C679X) and is predicted to truncate the protein by
14 amino acids. Studies on the effect of inactivation
of PckS9 on cellular processing of the LDLR and on
LDL metabolism in vivo are required to clarify the
relationship between these nonsense mutations
and LDL cholesterol concentrations. Cohen et al.
recently reported that three mutations in PCSK9
were associated with significant reductions in LDLcholesterol concentrations and incident coronary
heart disease (CHD) in the Atherosclerosis Risk
in Communities (ARIC) study. Among AfricanAmerican subjects, two nonsense mutations (Y142X
and C679X) were associated with a 28% reduction
in mean LDL-cholesterol concentrations and an
88% reduction in coronary heart disease (CHD).
Among white subjects in the same study, 3.2% had
a missense variant in PCSK9 (R46L); R46L carriers
had a 15% reduction in LDL-cholesterol levels and
a 47% reduction in the risk of CHD[5].
PCKS9 is regulated by sterols and expression is
decreased by dietary cholesterol (Maxwell KN JLR
2003). Conversely, statins increase PCKS9 expression [61], an effect which may attenuate the LDL
lowering effects of these agents [62]. Although a
number of questions regarding the function of
PCKS9 in the regulation of LDLR processing and in
VLDL and LDL secretion remain unanswered, the
identification of sequence variants resulting in both
gain and loss of function have highlighted its
unique and important role in LDL metabolism.
Autosomal recessive
hypercholesterolemia
Khachadurian and Uthman [63] described a
Lebanese family in 1973 including four members
Monogenic hypercholesterolemia 25
with severe hypercholesterolemia and tendon
xanthomas typical of homozygous FH but with
near-normal LDLR function in their cultured
fibroblasts. A similar phenotype was later identified
in a group of Sardinian patients, who were also
found to have decreased LDL apoB fractional
catabolic rate [64]. The disorder, termed autosomal
recessive hypercholesterolemia (ARH), did not segregate with either the LDLR or ApoB genes and
exhibited an autosomal recessive inheritance, with
the parents of affected subjects having normal or
slightly elevated LDL-cholesterol values.
ARH is brought about by mutations in ARH, a
novel adaptor protein that functions in the internalization of LDLR and cargo. Ten mutations have
been identified and all are predicted to introduce
premature stop codons, either as a result of a point
mutation or frameshift yielding no detectable ARH
protein [65,66]. Interestingly, LDLR function is
normal in ARH fibroblasts but is impaired in
lymphocytes, macrophages and hepatocytes [67].
LDLR protein is present in these cells in normal
amounts but is abnormally distributed with most
of the receptor residing on the plasma membrane,
where it binds LDL avidly but fails to internalize
and degrade its cargo [68,69].
ARH contains a phosphotyrosine binding (PTB)
domain similar to that found in several adaptor
proteins including numb, Disabled-1 (Dab-1),
Disabled-2 (Dab-2) and GULP. All of these bind
directly to the acidic phospholipids phosphatidylinositol 4,5-biphosphate {PtdIns(4,5)P2} as well as
to NPXY motifs in the cytoplasmic domain of signaling receptors and have a role in endocytosis or
cell signaling. Of interest, Dab-2 colocalizes with
the LDLR on the plasma membrane and binds to
the FDNPVY internalization sequence of the LDLR
[70], raising the possibility that Dab-2 may compensate for ARH deficiency and enable normal LDL
endocytosis in ARH fibroblasts. The PTB domain
of ARH-1 binds the NPXY sequence in the LDLR
[70,71]. The distal segment of ARH also contains a
canonical clathrin binding sequence, LLDLE, which
permits direct interaction with the terminal domain
of clathrin. Finally, ARH contains a sequence recognized by the β2 adaptin subunit of AP-2, a major
structural component of clathrin coated pits. Thus,
ARH-1 functions as an adaptor protein to link the
LDLR to endocytic machinery by simultaneously
26
PART I
Cardiovascular single gene disorders
binding to the NPxY sequence of the receptor cytoplasmic tail, clathrin and the AP-2 adaptor [72].
Retroviral expression of normal ARH in the immortalized lymphocytes of affected subjects was
shown to restore LDLR internalization [67].
Clinical phenotype of ARH
ARH is apparently uncommon, with the largest
series of affected subjects identified in Sardinia and
Italy. There is notably marked heterogeneity in disease phenotype with total cholesterol levels varying
between 350 and 1050 mg/dL (9–27 mmol/L) with
near-normal triglyceride concentrations (reviewed
in [65,66]). Large bulky tuberous, tendinous and/
or planar xanthomas are typically present from
early childhood. The pathophysiology of accelerated xanthoma formation in ARH is not clear but
may represent accelerated uptake of modified LDL
by scavenger receptors. Atherosclerosis and CAD
appear in early adulthood but aortic stenosis is a
somewhat less prominent feature compared with
patients with homozygous FH.
Patients with ARH generally respond well to
lipid-lowering medication in contrast to patients
with homozygous FH [17]. This may be related to
preserved LDLR activity in ARH fibroblasts. Combination therapy is most effective and decreases in
total cholesterol of 70–75% have been reported
with 80 mg atorvastatin in combination with 16 mg
cholestyramine [65]. LDL apheresis remains an
option for patients with an inadequate response to
pharmacologic therapy.
The discovery of ARH has provided important
insight into the LDLR endocytic pathway. This remains an intriguing disorder in part because of the
cell specificity of its effects on LDLR function. ARH
is also unusual in that there is significant heterogeneity in terms of severity of the clinical phenotype. This rare genetic disorder demonstrates that
our current understanding of the clathrin mediated
LDLR endocytic pathway is as yet incomplete.
Sitosterolemia
Noncholesterol sterols such as sitosterol are normally present in trace amounts in normal individuals. Sitosterol, like cholesterol, is taken up into
enterocytes in the proximal intestine. Although
20–80% of dietary cholesterol is incorporated
into chlylomicrons, <5% sitosterol is normally
absorbed and that which is absorbed is rapidly resecreted into bile. Patients with sitosterolemia have
markedly increased intestinal absorption of sitosterol and impaired resecretion of this sterol into
bile [73]. Sitosterolemia is caused by over 25 mutations in either ABCG5 or ABCG8. These are ABC
half-transporters and are encoded by two adjacent
genes. Affected subjects have at least two mutations
in either of ABCG5 or ABCG8 [74–77].
Clinical presentation
Patients with sitosterolemia typically have 50-fold
elevations in plasma and tissue concentrations of
plant and shellfish sterols [73,78,79]. Although
variable, LDL-cholesterol concentrations are significantly elevated especially in childhood and can be
similar to those of FH (~300 mg/dL or 8 mmol/L)
[80]. Planar xanthomas are frequent and untreated
patients develop aortic stenosis and premature
CAD. The plasma cholesterol level in sitosterolemia
is very responsive to dietary cholesterol intake and
to bile acid sequestrant therapy, which increases
the resecretion of cholesterol into bile in the form
of bile acids. Ezetimibe, which inhibits the intestinal cholesterol transporter NPCL1, is particularly
effective [33,81].
Conclusions
Although rare, the various types of monogenic hypercholesterolemia discussed above are important and
treatable causes of premature cardiovascular disease. Their study has also contributed significantly
to our knowledge of lipoprotein metabolism and
atherosclerosis and have provided important
insights into intracellular protein trafficking and
cellular cholesterol metabolism [3–5]. The early
studies of FH patients led to identification of the
LDLR pathway and ultimately the development of
statins, one of the most important clinical advances
for the primary and secondary prevention of
cardiovascular disease. More recent studies of the
etiology of hypercholesterolemia in patients with
mutations in PCKS9 and ARH have highlighted the
complexity of the LDLR secretory and endocytic
pathways.
CHAPTER 2
References
1 Dubuc G, Chamberland A, Wassef H. Davignon J, Seidah
NG, Bernier L, Prat A. Statins upregulate PCSK 9, the gene
encoding the proprotein convertase neural apoptosisregulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2004; 24:
1454–1459.
2 Cameron J, Holla OL, Ranheim T, Kulseth MA, Berge KE,
Leren TP. Effect of mutations in the PCSK 9 gene on the
cell surface LDL receptors. Hum Mol Genet 2006; 15:
1551–1558.
3 Maxwell KN, Breslow JL. Adenoviral-mediated expression of PCSK 9 in mice results in a low-density lipprotein
receptor knockout phenotype. Proc Natl Acad Sci USA
2004; 101: 7100–7105.
4 Lagace TA, Curtis De, Garuti R, McNutt MC, Park SW,
Prather HB, Anderson NN, Ho YK, Hammer RE, Horton
JD. Secreted PCSK 9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J Clin
Invest 2006; 116: 2995–3005.
5 Cohen JC, Boerwinkle E, Mosely TH, Hobbs HH.
Sequence variations in PCSK 9, low LDL, and protection
against coronary heart disease. N Engl J Med 2006; 354:
1265–1272.
6 Greaves DR, Gordon S. Thematic review series: the
immune system and atherogenesis. Recent insights into
the biology of macrophage scavenger receptors. J Lipid
Res 2005; 46: 11–20.
7 Russell DW. Protein domains of the low density lipoprotein receptor. Acta Med Scand Suppl 1987; 715: 39–44.
8 Davis CG, van Driel IR, Russell DW, Brown MS,
Goldstein JL. The low density lipoprotein receptor.
Identification of amino acids in cytoplasmic domain
required for rapid endocytosis. J Biol Chem 1987; 262:
4075–4082.
9 van Driel IR, Davis CG, Goldstein JL, Brown MS. Selfassociation of the low density lipoprotein receptor mediated by the cytoplasmic domain. J Biol Chem 1987; 262:
16127–16134.
10 Beglova N, Blacklow SC. The LDL receptor: how acid
pulls the trigger. Trends Biochem Sci 2005; 30: 309–317.
11 Gent J, Braakman I. Low-density lipoprotein receptor
structure and folding. Cell Mol Life Sci 2004; 61: 2461–
2470.
12 Attie AD, Seidah NG. Dual regulation of the LDL receptor: some clarity and new questions. Cell Metab 2005; 1:
290–292.
13 Maxwell KN, Fisher EA, Breslow JL. Overexpression of
PCSK9 accelerates the degradation of the LDLR in a postendoplasmic reticulum compartment. Proc Natl Acad Sci
USA 2005; 102: 2069–2074.
Monogenic hypercholesterolemia 27
14 Park SW, Moon YA, Horton JD. Post-transcriptional regulation of low density lipoprotein receptor protein by
proprotein convertase subtilisin/kexin type 9a in mouse
liver. J Biol Chem 2004; 279: 50630–50638.
15 Abifadel M, Varret M, Rabes JP et al. Mutations in PCSK9
cause autosomal dominant hypercholesterolemia. Nat
Genet 2003; 34: 154–156.
16 He G, Gupta S, Yi M, Michaely P, Hobbs HH, Cohen JC.
ARH is a modular adaptor protein that interacts with the
LDL receptor, clathrin, and AP-2. J Biol Chem 2002; 277:
44044–44049.
17 Arca M, Zuliani G, Wilund K et al. Autosomal recessive
hypercholesterolaemia in Sardinia, Italy, and mutations
in ARH: a clinical and molecular genetic analysis. Lancet
2002; 59: 41–47.
18 Fredrickson DS, Levy RI, Lees RS. Fat transport in
lipoproteins: an integrated approach to mechanisms and
disorders. N Engl J Med 1967; 276: 273–281.
19 Austin MA, Hutter CM, Zimmern RL, Humphries SE.
Familial hypercholesterolemia and coronary heart disease: a HuGE association review. Am J Epidemiol 2004;
160: 421–429.
20 Austin MA, Hutter CM, Zimmern RL, Humphries SE.
Genetic causes of monogenic heterozygous familial
hypercholesterolemia: a HuGE prevalence review. Am J
Epidemiol 2004; 160: 407–420.
21 Williams RR, Hunt SC, Schumacher MC et al. 1993.
Diagnosing heterozygous familial hypercholesterolemia
using new practical criteria validated by molecular genetics. Am J Cardiol 72: 171–176.
22 Couture P, Morissette J, Gaudet D et al. Fine mapping of
low-density lipoprotein receptor gene by genetic linkage
on chromosome 19p13.1–p13.3 and study of the founder
effect of four French Canadian low-density lipoprotein
receptor gene mutations. Atherosclerosis 1999; 143: 145–
151.
23 Leitersdorf E, Tobin EJ, Davignon J, Hobbs HH.
Common low-density lipoprotein receptor mutations in
the French Canadian population. J Clin Invest 1990; 85:
1014–1023.
24 Heath KE, Gahan M, Whittall RA, Humphries SE. Lowdensity lipoprotein receptor gene (LDLR) world-wide
website in familial hypercholesterolaemia: update, new
features and mutation analysis. Atherosclerosis 2001; 154:
243–246.
25 Villeger L, Abifadel M, Allard D et al. The UMD-LDLR
database: additions to the software and 490 new entries to
the database. Hum Mutat 2002; 20: 81–87.
26 Hobbs HH. Russell DW, Brown MS, Goldstein JL. The
LDL receptor locus in familial hypercholesterolemia:
Mutational analysis of a membrane protein. Annu Rev
Genet 1990; 24: 133–170.
28
PART I
Cardiovascular single gene disorders
27 Hobbs HH, Brown MS, Goldstein JL. Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Hum Mutat 1992; 1: 445–466.
28 Gudnason V, Day INM, Humphries SE. Effect on plasma
lipid levels of different classes of mutations in the lowdensity lipoprotein receptor gene in patients with familial
hypercholesterolemia. Arterioscler Thromb 1994; 14: 1717–
1722.
29 Yamamoto T, Davis CG, Brown MS et al. The human
LDL receptor: a cysteine-rich protein with multiple Alu
sequences in its mRNA. Cell 1984; 39: 27–38.
30 Goldstein JL, Brown MS. Regulation of the mevalonate
pathway. Nature 1990; 343: 425–430.
31 Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS,
Valle D, eds. The Metabolic and Molecular Basis of Inherited
Disease. McGraw-Hill, Inc., New York, 1995: 1981–2030.
32 Gotto AM. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized
controlled trial. J Pediatr 2005; 146: 144–145.
33 Patel SB. Ezetimibe: a novel cholesterol-lowering agent
that highlights novel physiologic pathways. Curr Cardiol
Rep 2004; 6: 439–442.
34 Yamamoto A, Harada-Shiba M, Endo M et al. The effect
of ezetimibe on serum lipids and lipoproteins in patients
with homozygous familial hypercholesterolemia undergoing LDL-apheresis therapy. Atherosclerosis 2006; 186:
126–131.
35 Marais AD, Firth JC, Blom DJ. Homozygous familial
hypercholesterolemia and its management. Semin Vasc
Med 2004; 4: 43–50.
36 Pokrovsky S, Straube R, Afanasieva O, Kukharchuk V,
Konovalov G. Lp(a) apheresis for the treatment of severe
CHD patients with Lp(a) hyperlipidemia. Ther Apher
Dial 2005; 9: A40.
37 Hershcovici T, Schechner V, Orlin J, Harell D, Beigel Y.
Effect of different LDL-apheresis methods on parameters
involved in atherosclerosis. J Clin Apher 2004; 19: 90–97.
38 Thompson GR, Miller JP, Breslow JL. Improved survival
of patients with homozygous familial hypercholesterolaemia treated with plasma exchange. Br Med J (Clin Res
Ed) 1985; 291: 1671–1673.
39 Thompson GR. LDL apheresis. Atherosclerosis 2003; 167:
1–13.
40 Grossman M, Wilson JM. Frontiers in gene therapy: LDL
receptor replacement for hypercholesterolemia. J Lab
Clin Med 1992; 119: 457–460.
41 Rader DJ, Cohen J, Hobbs HH. Monogenic hypercholesterolemia: new insights in pathogenesis and treatment.
J Clin Invest 2003; 111: 1795–1803.
42 Grossman M, Rader DJ, Muller DW et al. A pilot study of
ex vivo gene therapy for homozygous familial hypercholesterolaemia. Nat Med 1995; 1: 1148–1154.
43 Alkofer BJ, Chiche L, Khayat A et al. Liver transplant
combined with heart transplant in severe heterozygous
hypercholesterolemia: report of the first case and review
of the literature. Transplant Proc 2005; 37: 2250–2252.
44 Shirahata Y, Ohkohchi N, Kawagishi N et al. Livingdonor liver transplantation for homozygous familial
hypercholesterolemia from a donor with heterozygous
hypercholesterolemia. Transpl Int 2003; 16: 276–279.
45 Boren J, Ekstrom U, Agren B, Nilsson-Ehle P, Innerarity
TL. The molecular mechanism for the genetic disorder
familial defective apolipoprotein B100. J Biol Chem 2001;
276: 9214–9218.
46 Boren J, Lee I, Zhu W, Arnold K, Taylor S, Innerarity TL.
Identification of the low density lipoprotein receptorbinding site in apolipoprotein B100 and the modulation
of its binding activity by the carboxyl terminus in familial
defective apo-B100. J Clin Invest 1998; 101: 1084–1093.
47 Myant NB. Familial defective apolipoprotein B-100: A
review, including some comparisons with familial hypercholesterolaemia. Atherosclerosis 1993; 104: 1–18.
48 Schaefer JR, Scharnagl H, Baumstark MW et al.
Homozygous familial defective apolipoprotein B-100:
Enhanced removal of apolipoprotein E-containing VLDLs
and decreased production of LDLs. Arterioscler Thromb
Vasc Biol 1997; 17: 348–353.
49 Leren TP. Mutations in the PCSK9 gene in Norwegian
subjects with autosomal dominant hypercholesterolemia. Clin Genet 2004; 65: 419–422.
50 Timms KM, Wagner S, Samuels ME et al. A mutation in
PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree. Hum Genet 2004; 114: 349–
353.
51 Naoumova RP, Tosi I, Patel D et al. Severe hypercholesterolemia in four British families with the D374Y
mutation in the PCSK9 gene. Long-term follow-up and
treatment response. Arterioscler Thromb Vasc Biol 2005;
25: 2654–2660.
52 Seidah NG, Benjannet S, Wickham L et al. The secretory
proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci USA 2003; 100: 928–933.
53 Maxwell KN, Breslow JL. Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein
receptor knockout phenotype. Proc Natl Acad Sci USA
2004; 101: 7100–7105.
54 Benjannet S, Rhainds D, Essalmani R et al. NARC1/PCSK9 and its natural mutants: zymogen cleavage and
effects on the low density lipoprotein (LDL) receptor and
LDL cholesterol. J Biol Chem 2004; 279: 48865–48875.
55 Ouguerram K, Chetiveaux M, Zair Y et al. Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9. Arterioscler
Thromb Vasc Biol 2004; 24: 1448–1453.
CHAPTER 2
56 Jirholt P, Adiels M, Boren J. How does mutant proprotein convertase neural apoptosis-regulated convertase 1
induce autosomal dominant hypercholesterolemia? Arterioscler Thromb Vasc Biol 2004; 24: 1334–1336.
57 Attie AD. The mystery of PCSK9. Arterioscler Thromb
Vasc Biol 2004; 24: 1337–1339.
58 Shioji K, Mannami T, Kokubo Y et al. Genetic variants in
PCSK9 affect the cholesterol level in Japanese. J Hum
Genet 2004; 49: 109–114.
59 Chen SN, Ballantyne CM, Gotto AM Jr, Tan Y, Willerson
JT, Marian AJ. A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is
a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis. J Am Coll Cardiol 2005; 45: 1611–1619.
60 Cohen J, Pertsemlidis A, Kotowski IK, Graham R, Garcia
CK, Hobbs HH. Low LDL cholesterol in individuals of
African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet 2005; 37: 161–165.
61 Dubuc G, Chamberland A, Wassef H et al. Statins upregulate PCSK9, the gene encoding the proprotein
convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler Thromb
Vasc Biol 2004; 24: 1454–1459.
62 Rashid S, Curtis DE, Garuti R et al. Decreased plasma
cholesterol and hypersensitivity to statins in mice lacking
Pcsk9. Proc Natl Acad Sci USA 2005; 102: 5374–5379.
63 Khachadurian AK, Uthman SM. Experiences with the
homozygous cases of familial hypercholesterolemia. A
report of 52 patients. Nutr Metab 1973; 15: 132–140.
64 Zuliani G, Vigna GB, Corsini A, Maioli M, Romagnoni F,
Fellin R. Severe hypercholesterolaemia: unusual inheritance in an Italian pedigree. Eur J Clin Invest 1995; 25:
322–331.
65 Soutar AK, Naoumova RP, Traub LM. Genetics, clinical
phenotype, and molecular cell biology of autosomal
recessive hypercholesterolemia. Arterioscler Thromb Vasc
Biol 2003; 23: 1963–1970.
66 Soutar AK, Naoumova RP. Autosomal recessive hypercholesterolemia. Semin Vasc Med 2004; 4: 241–248.
67 Eden ER, Patel DD, Sun XM et al. Restoration of LDL
receptor function in cells from patients with autosomal
recessive hypercholesterolemia by retroviral expression
of ARH1. J Clin Invest 2002; 110: 1695–1702.
68 Garcia CK, Wilund K, Arca M et al. Autosomal recessive
hypercholesterolemia caused by mutations in a putative
69
70
71
72
73
74
75
76
77
78
79
80
81
Monogenic hypercholesterolemia 29
LDL receptor adaptor protein. Science 2001; 292: 1394–
1398.
Jones C, Hammer RE, Li WP, Cohen JC, Hobbs HH,
Herz J. Normal sorting but defective endocytosis of the
low density lipoprotein receptor in mice with autosomal
recessive hypercholesterolemia. J Biol Chem 2003; 278:
29024–29030.
Mishra SK, Watkins SC, Traub LM. The autosomal recessive hypercholesterolemia (ARH) protein interfaces
directly with the clathrin-coat machinery. Proc Natl Acad
Sci USA 2002; 99: 16099–16104.
Michaely P, Li WP, Anderson RG, Cohen JC, Hobbs HH.
The modular adaptor protein ARH is required for low
density lipoprotein (LDL) binding and internalization
but not for LDL receptor clustering in coated pits. J Biol
Chem 2004; 279: 34023–34031.
Wilund KR, Yi M, Campagna F et al. Molecular mechanisms of autosomal recessive hypercholesterolemia.
Hum Mol Genet 2002; 11: 3019–3030.
Salen G, Shefer S, Nguyen L, Ness GC, Tint GS, Shore V.
Sitosterolemia. J Lipid Res 1992; 33: 945–955.
Graf GA, Cohen JC, Hobbs HH. Missense mutations in
ABCG5 and ABCG8 disrupt heterodimerization and
trafficking. J Biol Chem 2004; 279: 24881–24888.
Heimer S, Langmann T, Moehle C et al. Mutations in the
human ATP-binding cassette transporters ABCG5 and
ABCG8 in sitosterolemia. Hum Mutat 2002; 20: 151.
Lee MH, Lu K, Hazard S et al. Identification of a gene,
ABCG5, important in the regulation of dietary cholesterol absorption. Nat Genet 2001; 27: 79–83.
Patel SB, Salen G, Hidaka H et al. Mapping a gene
involved in regulating dietary cholesterol absorption. The
sitosterolemia locus is found at chromosome 2p21. J Clin
Invest 1998; 102: 1041–1044.
Hidaka H, Nakamura T, Aoki T et al. Increased plasma
plant sterol levels in heterozygotes with sitosterolemia
and xanthomatosis. J Lipid Res 1990; 31: 881–888.
Bhattacharyya AK, Connor WE. Beta-sitosterolemia and
xanthomatosis. A newly described lipid storage disease in
two sisters. J Clin Invest 1974; 53: 1033–1043.
Wang J, Joy T, Mymin D, Frohlich J, Hegele RA.
Phenotypic heterogeneity of sitosterolemia. J Lipid Res
2004; 45: 2361–2367.
Salen G, Von Bergmann K, Lutjohann D et al. Ezetimibe
effectively reduces plasma plant sterols in patients with
sitosterolemia. Circulation 2004; 109: 966–971.
3
CHAPTER 3
Hypertrophic cardiomyopathy
Ali J. Marian, MD
Introduction
Hypertrophic cardiomyopathy (HCM) is a primary
disease of the myocardium with unique and fascinating clinical and pathologic manifestations [1].
HCM was first described by French pathologist
Liouville [2] in 1869 as cardiac contraction below
the aortic valve. In 1907, German pathologist
Schmincke described the condition in two adult
women as diffuse muscular “hyperplasia” at the left
ventricular outflow tract [3]. Schmincke made the
astute suggestion that outflow tract hypertrophy
obstructs left ventricular ejection, which leads to
further cardiac hypertrophy and hence, a vicious
cycle. The disease as a clinical entity, however,
remained largely unrecognized until the second
half of the twentieth century, when detailed pathologic phenotypes, familial inheritance and the phenotype of sudden cardiac death (SCD) were described
[4–6]. In the last 50 years, advances in modern
diagnostic tools led to characterization of specific
cardiac phenotypes and emphasized the heterogeneous nature of the disease. In the 1960s, HCM was
described primarily as a hemodynamic entity characterized by outflow tract obstruction. Braunwald
coined the term “idiopathic hypertrophic subaortic
stenosis” (IHSS) to describe the phenotype [7]. Subsequently, in 1964 Braunwald et al. [8,9] published
the most comprehensive report up to then on the
clinical, hemodynamic and angiographic aspects of
HCM in 64 patients. In the same year, Morrow et al.
[10] described septal myectomy through a transaortic approach as an effective method for reduction of left ventricular outflow tract gradient in 10
of the above 64 patients. Collectively, these reports
established HCM as a hemodynamic entity and
surgery as the treatment of choice.
30
The initial reports on the utility of echocardiography in the diagnosis of HCM were published in
late 1960s and were soon followed by echocardiographic findings of asymmetric septal hypertrophy
[11,12]. The term asymmetric septal hypertrophy
(ASH) was frequently used to emphasize the predominant involvement of the interventricular septum in patients with HCM [13,14]. Advances in
Doppler echocardiography in the late 1970s and
early 1980s led to a better understanding of the
physiology of the left ventricular flow dynamics
[15,16]. Accordingly, Doppler echocardiography
became the desirable tool for assessment and quantification of left ventricular outflow tract obstruction, supplanting the routine use of cardiac
catheterization [17,18]. Doppler echocardiography
also led to a better appreciation of diastolic dysfunction in HCM [18].
The discovery of the first causal gene and mutation for HCM by Geisterfer-Lowrance et al. [19] in
1990 heralded the dawning of the molecular era.
Since then, over a dozen genes and several hundred
mutations have been identified and the genetic
basis of HCM is all but delineated [20]. In 1995,
Sigwart [21] described a new catheter-based intervention for the treatment of outflow tract obstruction in HCM. The procedure, accomplished through
injection of ethanol into the main septal branches
of left anterior descending coronary artery, has
emerged as an effective method for reduction of the
outflow tract gradient and has raised considerable
debate on the choice of method for alleviation
of outflow tract obstruction in HCM [22,23]. In
addition, implantable defibrillators have emerged
as effective tools in preventing SCD in high-risk
patients [24]. Despite these advances, the pharmacologic treatment of HCM has remained largely
CHAPTER 3
unchanged during the past three decades. Conventional pharmacologic therapies are limited to
the use of beta-blockers, calcium-channel blockers,
disopyramide and amiodarone, the latter in a subset of patients with serious cardiac arrhythmias.
Recent experimental studies have raised the
potential utility of statins and inhibitors of renin–
angiotensin–aldosterone system (RAAS) in prevention and regression of cardiac phenotype HCM
[25–27]. However, the potential utility of these
novel therapeutic and preventive interventions in
humans has to await large-scale clinical studies.
The current research emphasis is to decipher the
molecular pathogenesis of the HCM phenotype, to
develop methods for genetic screening and diagnosis, to develop accurate risk stratification based
on genetic and clinical tools, and to identify novel
drug targets in order to develop pharmacologic
intervention targeted to molecules involved in the
pathogenesis of HCM. It is hoped that within the
next few years, clinicians will be able to utilize and
apply the recent advances to the care of patients
with HCM. The ultimate goal of correcting the
genetic defect has to await the development of
specific strategies whereby a single base pair could
be changed.
Definition
HCM is a primary disease of the myocardium characterized by cardiac hypertrophy in the absence
of an increased external load and a hyperdynamic
left ventricle with a small chamber. The above
definition, based on the clinical detection of “primary” cardiac hypertrophy, is neither specific nor
sufficiently sensitive for the accurate diagnosis of
HCM. For example, by strict definition, the presence of systemic hypertension excludes the diagnosis of HCM. However, systemic hypertension
is a common disease and hence could be present
concomitantly in patients with HCM and even
contribute to the phenotypic expression of HCM.
Thus, the presence of hypertension, or similarly
other overload conditions alone, is not sufficient to
exclude HCM. In such situations, the extent, severity and the type of cardiac hypertrophy as well as
other features, such as a hyperdynamic left ventricle, a small left ventricular cavity and the presence
of outflow tract obstruction should be considered.
Hypertrophic cardiomyopathy 31
Similarly, the term “unexplained cardiac hypertrophy” is often used to define HCM. However,
“unexplained cardiac hypertrophy” could also occur in phenocopy conditions, defined as a clinical
phenotype grossly similar to HCM. Examples of
HCM phenocopy include storage diseases, mitochondrial diseases, triplet repeat syndromes and
many others [28]. It is often difficult to distinguish
clinically between the phenocopy and true HCM, as
gross phenotype is quite similar [29]. Features such
as hyperdynamic left ventricle and small left ventricular chamber size would suggest true HCM. In
contrast, the presence of a depressed global cardiac
systolic function, conduction defects or involvement of other organs, such as deafness, neurologic
abnormalities and skeletal myopathy would suggest
a phenocopy. Endomyocardial biopsy and histologic examination is likely to provide a diagnosis
that is more robust. Myocyte disarray is considered
the pathologic hallmark of true HCM and is
expected to be absent in HCM phenocopy. In contrast, special staining of the myocardial sections
would help in the diagnosis of storage diseases.
Finally, the pathogenesis of true HCM and HCM
phenocopy are likely to differ considerably, as
shown in HCM phenocopy caused by mutations in
the γ2 subunit of adenosine monophosphate kinase [30–32]. The latter is characterized by cardiac
hypertrophy because of deposition of glycogen in
the heart, conduction defect and pre-excitation
pattern on electrocardiogram (ECG) [33]. The distinction between true HCM and phenocopy is
likely to gain clinical significance with the development of specific genetic and molecular treatment
for HCM and its phenocopy.
Thus, clinical diagnosis, which is primarily based
on the echocardiographic finding of cardiac hypertrophy, has considerable shortcomings. It is expected
that genetic-based diagnosis will supplant clinical
diagnosis of HCM upon further advances in molecular genetic techniques. An important value of
genetic-based diagnosis is in the preclinical diagnosis of mutation careers, which could have
considerable implications, not only for an early
diagnosis and risk stratification, but also for the implementation of preventive measures. Nonetheless,
clinicians should bear in mind that genetic-based
diagnosis, while robust in identification of those
with causal mutations, does not accurately predict
32
PART I
Cardiovascular single gene disorders
the severity of clinical phenotypes. The management of patients should take into consideration not
only the causal mutations and modifier genetic factors, but also the phenotypic expression of disease.
Prevalence
HCM is a relatively common disease with an estimated prevalence of approximately 1 in 500 in the
general population [34,35]. The estimate is based
on the presence of left ventricular wall thickness
of 15 mm or greater on an echocardiogram in
23–35-year-old individuals [34]. The estimate is
considered relatively conservative as many cases
with HCM have a milder degree of cardiac hypertrophy and many mutations are nonpenetrant
in the above age group. Accordingly, one would
expect a higher prevalence if those with milder
degrees of cardiac hypertrophy and an older population are included in the estimate. In addition,
those with hypertension are commonly excluded in
estimating the prevalence of HCM, which could
lead to underestimation of the true prevalence. In
contrast, inclusion of those with HCM phenocopy
could lead to overestimation. Thus, determination
of the true prevalence of HCM will require largescale molecular epidemiologic studies.
Phenotypic manifestations
Patients with HCM exhibit a diverse array of clinical, morphologic and pathologic phenotypes. A
significant number of patients with the clinical
diagnosis of HCM are asymptomatic or minimally
symptomatic. The most common symptoms are
dyspnea, chest pain, palpitations, dizziness and
lightheadedness. Syncope is an infrequent but a
serious symptom that merits full investigation. It is
often associated with serious cardiac arrhythmias
and heralds SCD [36–38]. Atrial fibrillation and
nonsustained ventricular tachycardia are the most
common cardiac arrhythmias and are associated
with adverse clinical outcome [39,40]. Electrocardiographic findings of Wolff–Parkinson–White
(WPW) syndrome are present in a small percentage
of patients with HCM and their presence raises the
possibility of a phenocopy [30–33].
SCD is often the first manifestation of HCM
in apparently young healthy individuals [41,42].
HCM is the most common cause of SCD in young
competitive athletes, accounting for almost half of
all cases of SCD in athletes younger than 35 years of
age in the USA [41,42]. The risk of SCD is greater
during or immediately after exercise. While there is
no reliable predictor, several clinical, pathologic
and genetic factors have been identified as potential
predictors of the risk of SCD in patients with HCM
(Table 3.1). Overall, the positive predictive value of
each marker is relatively low. Therefore, the global
risk, derived from the combination of all known
risk factors, should be considered in counseling,
risk stratification and management of patients with
HCM [38,43]. In the absence of two or more risk
factors for SCD, HCM is considered a relatively
benign disease. The estimated annual mortality of
patients with HCM is about 1% in the adult population [44–46].
Cardiac hypertrophy is the quintessential phenotype of HCM and the basis for the clinical diagnosis. Cardiac hypertrophy is concentric but
commonly asymmetric, predominantly involving
the interventricular septum. In approximately onethird of cases, cardiac hypertrophy is symmetric or
shows an atypical feature, such as the predominant
involvement of the apex, lateral wall or the posterior wall. HCM has been classified into four
categories according to the site and the extent of
involvement of the left ventricular walls [47]. In
apical HCM, hypertrophy is localized to the apex of
the heart, which is an uncommon form, with the
unique feature of giant T-wave inversion in the precordial leads on the ECG [48]. It has a relatively
benign prognosis, with a 15-year survival rate of
approximately 95% in the North American population [49]. Because of concentric nature of hypertrophy, the left ventricular cavity size is small and
left ventricular ejection fraction, a global index of
systolic function, is increased or at least preserved.
Cardiac diastolic function is impaired and left ventricular end-diastolic pressure is elevated, which is the
primary reason for symptoms of heart failure. In a
small fraction of patients with HCM, the phenotype evolves into that of a dilated heart with gradual
decline in the left ventricular ejection fraction (i.e.,
evolving into dilated cardiomyopathy, DCM).
A characteristic phenotype of HCM is increased
left ventricular ejection fraction (LVEF), which is
often interpreted as evidence of enhanced myocardial
CHAPTER 3
Hypertrophic cardiomyopathy 33
Table 3.1 Potential risk factors for sudden cardiac death (SCD) in patients with hypertrophic cardiomyopathy (HCM).
Predictor
Comments
Prior episode of aborted SCD
A major risk factor and mandates ICD implantation
Family history of SCD
ICD implantation is recommended if more than 1 SCD in the family.
History of syncope
A major risk factor in the presence of family history of SCD [38] or ventricular
Sustained and repetitive non-
A major risk factor requiring ICD implantation. Negative predictive value of
Additional risk factors should be considered If only 1 SCD in the family
arrhythmias on Holter monitoring [181] requiring ICD implantation
sustained ventricular tachycardia
EP studies is greater than the positive predictive value [181]
Cardiac hypertrophy
Severe hypertrophy increases the risk of SCD [38,65]. It is also associated with
Early onset of clinical
Early penetrance is associated with a higher incidence of SCD [42]
the risk of syncope [37]
manifestations (young age)
Causal mutations, including
double mutations
Variable according to individual mutations and genetic background
[74,75,94,126–131]
Modifier genes
The DD genotype of the angiotensin-converting enzyme 1 gene is associated
Outflow tract gradient
Severe outflow tract gradient is associated with a higher mortality [160]
Severe interstitial fibrosis and
Fibrosis could predisposes to ventricular arrhythmias [67]
with the risk of SCD [101]
myocyte disarray
Abnormal blood pressure
Could cause syncope because of exercise induced hypotension [42]
response to exercise
Presence of myocardial ischemia
Significance unclear in adult population
EP, Electrophysiology; ICD, internal cardioverter-defibrillator.
contractility. LVEF is a load-independent index
and alone is not robust evidence of myocardial contractility. It may be increased in patients with HCM
simply because of a smaller left ventricular enddiastolic volume resulting from concentric hypertrophy and the resulting smaller afterload [50,51].
Assessment of myocardial contractile function by
load-independent indices suggests reduced myocardial contractility and relaxation [52–54]. Given
the diversity of HCM mutations and their diverse
functional effects, the impact of the causal mutations
on myocardial contractile performance are expected
to vary, some leading to enhanced and others to
reduced myocardial contractile performance. For
example, mutations that enhance Ca2+ sensitivity of
the myofibrils for ATPase activity or force generation could increase myocardial contractile performance, and vice versa [55–57]. Similarly, the
impact of mutations on actin–myosin interactions
could determine the effects on global systolic function [58–61]. Mutations that reduce actin–myosin
interactions are expected to impair global cardiac
systolic function. In contrast, mutations that reduce the inhibitory effects of cardiac troponin I on
actin–myosin interactions would be expected to
increase the ejection fraction.
Cardiac myocyte disarray, defined as malaligned,
distorted and often short and hypertrophic myocytes oriented in different directions, is the pathologic hallmark of HCM (Plate 3.1). Other pathologic
features of HCM include myocyte hypertrophy,
interstitial fibrosis, thickening of media of intramural coronary arteries and, sometimes, malpositioned mitral valve with elongated leaflets. Myocyte
disarray often comprises >20% of the ventricle, as
opposed to <5% of the myocardium in normal
hearts [62,63]. It is more prominent in the interventricular septum, but commonly found throughout the myocardium [63]. Cardiac hypertrophy,
interstitial fibrosis and myocyte disarray are associated with the risk of SCD, mortality and morbidity
in patients with HCM [64–67].
34
PART I
Cardiovascular single gene disorders
Molecular genetics
HCM is a genetic disease with an autosomal dominant mode of inheritance. An autosomal recessive
form has also been described but is uncommon
[68]. It is familial in approximately half to twothirds of cases and sporadic in the remainder
[69,70]. Familial aggregation of HCM was first
described more than 50 years ago [4]. However, the
molecular genetic basis of HCM was unknown
until the seminal report of the R403Q mutation in
the β-myosin heavy chain (MyHC) in a family with
HCM by Geisterfer-Lowrance et al. in 1999 [19].
This seminal discovery was a watershed and led to
subsequent identification of over 400 causal mutations in more than a dozen different genes, all
encoding the sarcomeric proteins (Table 3.2).
Accordingly, HCM is considered a disease of mutant sarcomeric proteins [71]. It is important to
note that identification of a genetic variant in a
patient with HCM alone does not establish causality. To fulfill the Koch postulates for causality and
exclude the possibility of polymorphism, it is necessary to show co-segregation of the mutation with
the phenotype, its absence in the general population and its functional and biologic effects [72].
The true mutation usually changes a highly con-
served amino acid sequence, leading to a premature
truncation or reducing the expression level of the
protein.
Causal genes
Over a dozen genes encoding for sarcomeric proteins have been identified in patients and families
with HCM (Table 3.2). The prevalence of causal
genes and mutations varies among different populations. Overall, the collective results of genetic
epidemiologic studies suggest that approximately
two-thirds of the causal genes for HCM have been
identified [73–78]. The most common causal genes
are MYH7, MYBPC3, TNNT2 and TNNI3, which
encode the MyHC, myosin binding protein-C
(MyBP-C), cardiac troponin T and I, respectively
[73–76,79,80]. Collectively, mutations in the above
four genes account for approximately two-thirds of
all cases of HCM [73–75]. Mutations in MYH7 and
MYBPC3 are the most common, each accounting
for approximately 30% of cases of HCM [73–75].
Over 100 different mutations in the β-MyHC have
been identified, the vast majority of which are missense mutations located in the globular head of βMyHC. Mutations in the hinge and rod domain of
β-MyHC have also been described but, in general, are less common [81–83]. Similarly, over 100
Table 3.2 Causal genes for hypertrophic cardiomyopathy (HCM).
Gene
Gene symbol
Locus
Frequency
b-Myosin heavy chain [19]
MYH7
14q12
~30%
Myosin binding protein-C [182,183]
MYBPC3
11p11.2
~30%
Cardiac troponin T [71]
TNNT2
1q32
~5%
Cardiac troponin I [184]
TNNI
19p13.2
~5%
a-tropomyosin [71]
TPM1
15q22.1
<5%
Cardiac a-actin [85]
ACTA
11q
<5%
Essential myosin light chain [185]
MYL3
3p21.3–p21.2
<5%
Regulatory myosin light chain [185]
MYL2
12q23.q24.3
<5%
Titin [84]
TTN
2q24.3
<5%
Tcap (Telethonin or titin-cap) [91]
TCAP
17q12
Rare
Cardiac myosin light peptide kinase [90]
MYLK2
20q13.3
Rare
a-Myosin heavy chain (association) [134]
MYH6
14q12
Rare
Cardiac troponin C (association) [88]
TNNCI
3p21.3–3p14.3
Rare
Caveolin 3 (association) [93]
CAV3
3p25
Rare [93]
Phospholamban (association) [92]
PLN
6p22.1
Rare [92]
Citations refer to the first report of the mutations.
CHAPTER 3
different mutations in MYBPC3 have been identified which are scattered through the genes [74,75].
Mutations in TNNT2 and TNNI3 are less common
and together account for another 10–15% of the
cases of HCM [73,76,78]. Mutations in TPM1,
encoding α-tropomyosin; TTN, encoding titin;
ACTC, encoding cardiac α-actin; MYL3 and MYL2,
encoding essential and regulatory light chains,
respectively, have also been identified in patients
and families with HCM [71,78,84–87]. Rare mutations in TNNC1, encoding cardiac troponin C [88];
MYH6, encoding α-MyHC [89]; MYLK2, encoding
myosin light chain kinase [90]; TCAP, encoding
telethonin [91]; PLN, encoding phospholamban
[92]; and CAV3, encoding caveolin 3 [93] have
been reported in patients with HCM.
The vast majority of HCM mutations are point
or missense mutations that affect a highly conserved amino acid. A small fraction of the mutations
are insertion/deletion or splice junction mutations,
which are commonly found in MYBPC3 [74,94].
Insertion/deletion mutations induce frame-shift
and lead to premature truncation of the MyBP-C
protein. Thus, such mutations impart significant
functional impairment of the expressed protein. In
addition, deletion mutations in troponin T involving the splice donor sites have been reported that
could lead to truncation of the encoded protein
[71]. The frequency of each specific HCM mutation is low and hence no single mutation predominates. Accordingly, the mutations are referred to as
“private mutations.” A few suggestive hot spots for
mutations, such as codons 403 and 719 in MYH7,
have been noted [95,96]. Finally, double mutations
have been reported in a small fraction of patients
with HCM [97,98].
Modifier genes
Patients with HCM exhibit variable clinical manifestations [1]. The variability in the phenotype is
observed among individuals with different causal
mutations as well as among individuals with identical causal mutations [99]. Even members of a single
family, who share the same causal mutation as well
as a significant portion of the genome, exhibit considerable variability in the phenotypic expression
of HCM. The molecular basis for the interindividual variability in the phenotypic expression of
HCM is largely unknown. Causal mutations, while
Hypertrophic cardiomyopathy 35
important contributors to the phenotype, do not
fully account for the variability in the phenotypic
expression of HCM. The presence of multiple
mutations could account for a small part of the
variability [97,98]. However, multiple mutations
are uncommon and alone are insufficient to
explain the variability in the phenotype [97,98]. It is
likely that environmental factors, such as heavy
physical exercise, particularly isometric exercises, contribute to the phenotypic expression of
HCM. However, their contribution remains largely
unknown.
Single nucleotide polymorphisms (SNPs) are
important determinants of the interindividual variability in the phenotypic expression of single gene
disorders, as they are in determining the susceptibility to disease, response to therapy and clinical
outcome. Accordingly, the phenotypic expression
of HCM, a classic single-gene disorder with a
Mendelian inheritance, is determined not only by
the causal mutations, but also by the genetic background in which the mutations occur. SNPs in
genes implicated in cardiac growth and hypertrophy are the prime candidates to affect phenotypic
expression of HCM and hence are referred to
modifier mutations or genes [100]. Unlike the
causal mutations, modifier genes are neither necessary nor sufficient to cause HCM. Instead, functional variants of the modifier genes affect the
severity of phenotype, such as the magnitude of
cardiac hypertrophy and/or the risk of SCD. In
view of complexity of the molecular biology of cardiac hypertrophic response, a large number of
SNPs are expected to affect the phenotypic expression of HCM, each imparting a relatively small
effect. The identities of the modifier genes have
remained largely unknown. The gene encoding the
angiotensin-converting enzyme 1 (ACE-1) is a
potential modifier gene as its variants have been
associated with the severity of cardiac hypertrophy
and the risk of SCD [101–103]. Several other candidate modifiers have also been identified [104];
however, the results have been largely provisional
pending replication and confirmation through
experimentation.
Genetic basis of HCM phenocopy
The phenotype of “unexplained cardiac hypertrophy” is not unique to HCM caused by mutant
36
PART I
Cardiovascular single gene disorders
Table 3.3 Genes known to cause hypertrophic cardiomyopathy (HCM) phenocopy.
Gene
Gene symbol
Chromosome
Frequency
Protein kinase A, g subunit [30,32]
PRKAG2
7q22–q31.1
1–2% [186]
a-Galactosidase A [187]
GLA
Xq22
3% [108]
Unconventional myosin 6 [188]
MOY6
6q12
Rare
Lysosome-associated membrane protein 2 [118]
LAMP2
Xq24
1–2% [118,189]
Mitochondrial genes [190]
MTTG, MTTI
MtDNA
Rare
Frataxin (Friedreich ataxia) [191]
FRDA
9q13
Rare
Myotonin protein kinase (myotonic dystrophy) [192]
DMPK, DMWD
19q13
Uncommon
Protein tyrosine phosphatase, nonreceptor type 11 [113]
PTPN11
12q24
Uncommon, higher
in children [46]
sarcomeric proteins but also occurs in a variety
of other conditions, such as storage diseases, mitochondrial disorders and triplet repeat syndromes.
The prevalence of phenocopy in patients with the
diagnosis of HCM is unclear but expected to be
higher in children because of the early age of manifestations of many diseases that mimic true HCM.
In one report, 28.8% of patients with the diagnosis
of HCM had Noonan syndrome [46]. A list of conditions causing HCM phenotype and the causal
genes and mutations are listed in Table 3.3.
A prototypic example of HCM phenocopy is
Fabry disease, an autosomal recessive lysosomal
storage disease characterized by the deficient activity of α-galactosidase A (α-Gal A), also known as
ceramide trihexosidase [105,106]. The phenotype
results from the deposits of glycosphingolipids
in multiple organs, including the heart [107].
Fabry disease is caused by mutations in GLA gene
on chromosome Xq22, which encodes lysosomal
hydrolase α-Gal A protein [107]. Phenotypically, it
is characterized by angiokeratoma, renal insufficiency, proteinuria, neuropathy, transient ischemic
attack, stroke, anemia, corneal deposits and HCM
phenocopy [107]. Cardiac manifestations of Fabry
disease include hypertrophy, which is often indistinguishable from true HCM, high QRS voltage,
conduction defects, cardiac arrhythmias, valvular
regurgitation, coronary artery disease, myocardial
infarction and aortic annular dilatation [29,108].
The disease predominantly affects males; female
carriers could exhibit a milder form [29]. The diagnosis is established by measuring α-Gal A levels and
activity in leukocytes. The estimated prevalence of
Fabry disease in adult population with the clinical
diagnosis of HCM is approximately 3% [108]. The
distinction between true HCM and Fabry disease is
important because the latter can be treated with
enzyme replacement therapy using human α-Gal A
(agalsidase α) or recombinant human α-Gal A
(agalsidase β) [105,106,109,110].
Another phenocopy is a glycogen storage disease
caused by mutations in the PRKAG2 gene [30–33].
The gene encodes the γ2 regulatory subunit of AMPactivated protein kinase (AMPK), which is considered the energy biosensor of the cell. Mutations in
PRKAG2 lead to cardiac hypertrophy, conduction
defects and WPW [30–32]. Cardiac hypertrophy
results predominantly from the storage of glycogen
in myocytes. Hence, it differs considerably from
true HCM.
HCM phenocopy also occurs in trinucleotide
repeat syndromes, a group of genetic disorders
caused by expansion of naturally occurring GCrich triplet repeats in genes [111]. Friedreich ataxia
is an example of trinucleotide repeat syndrome that
causes HCM phenocopy. It is an autosomal recessive neurodegenerative disease caused by expansion
of GAA repeat sequences in the intron of FRDA
[112]. Cardiac involvement could manifest as
either a hypertrophic or a dilated heart.
HCM phenocopy also occurs in patients with
Noonan syndrome, an uncommon autosomal
dominant disorder characterized by dysmorphic
facial features, pulmonic stenosis, mental retardation, bleeding disorders and cardiac hypertrophy.
The causal gene in approximately half of cases is
protein-tyrosine phosphatase, nonreceptor type 11
(PTPN11) gene [113,114]. LEOPARD syndrome
(lentigines, electrocardiographic conduction abnor-
CHAPTER 3
malities, ocular hypertelorism, pulmonic stenosis,
abnormal genitalia, retardation of growth, and
deafness) is an allelic variant of Noonan syndrome.
Defective mitochondrial oxidative phosphorylation pathways could lead to a phenotype mimicking HCM. Kearns–Sayre syndrome (KSS) is an
example of a mitochondrial disease that causes
HCM phenocopy [115]. It is characterized by a
triad of progressive external ophthalmoplegia, pigmentary retinopathy and cardiac conduction defects,
and, less frequently, cardiac hypertrophy. Cardiac
hypertrophy could occur in a variety of metabolic
diseases, such as Refsum disease, glycogen storage
disease type II (Pompe disease), Danon disease,
Niemann–Pick disease, Gaucher disease, hereditary
hemochromotasis and CD36 deficiency [116–119].
Genetic and non-genetic
determinants of phenotype
The clinical phenotype of HCM is the consequence
of the cardiac response to mutant sarcomeric proteins. Hence, a variety of genetic and non-genetic
factors are expected to influence expression of the
clinical phenotype in HCM (Fig. 3.1). Thus, the
ensuing phenotype, whether it is hypertrophy,
interstitial fibrosis or SCD, is determined not only
by causal mutations, but also by modifier SNPs,
interactions between genes (epistasis), transcrip-
Causal
mutation
En
vi
Phenotype in
hypertrophic
cardiomyopathy
is
Ep
is
tas
ifier
Mod s
e
gen
Epigenetic
s
ro
nm
en
t
t
Pos ioal
ipt al
r
n
nsc
tra slatio ns
o
n
tra ficati
di
mo
Figure 3.1 Determinants of cardiac phenotype in
hypertrophic cardiomyopathy (HCM). While causal
mutations are important determinants of the severity of
the phenotypes, several others factors shown in the figure
contribute to phenotypic expression and severity of the
morphologic and clinical phenotypes in HCM.
Hypertrophic cardiomyopathy 37
tional and post transcriptional regulation of gene
expression, post translational modification of proteins and environmental factors. Thus, the clinical
phenotype of HCM, a single gene disorder, is in fact
a complex phenotype and hence variable and
diverse among affected individuals. The presence of
a remarkable interindividual variability in the phenotypic expression of HCM restricts generalization
of the findings in a particular subset of patients or
extension of the results across subgroups. Accordingly, as in any other risk assessment or prediction
of the phenotype, all components that contribute
to the phenotypic expression of HCM should be
considered as well as the limitations of applying the
group data to an individual patient.
The topography of the causal mutations, and
hence their impact on the structure and function
of the respective proteins, is expected to be an
important determinant of the ensuing phenotype.
This point is illustrated in the case of mutations in
β-MyHC, cTnT and cTnI, which could cause either
HCM or DCM [120,121]. The basis of the divergence of the phenotypes resulting from mutations
in a single gene remains unknown but likely pertains
to the effect of the mutation on protein structure
and function [57,122,123]. One could speculate
that mutations that enhance Ca2+ sensitivity of the
myofibrillar force generation or diminish the inhibitory effect of cTnI on actin–myosin interactions
to cause HCM [57,122,123]. In contrast, mutations
that reduce Ca2+ sensitivity of the myofibrillar force
generation or increase the inhibitory effect of cTnI
on actin–myosin interaction to cause DCM [57,122–
125]. Thus far, no systematic genotype–phenotype
correlation study, based on topographic classification of the mutations, has been performed. It is
also noteworthy that no phenotype is specific to a
genotype and there is considerable overlap in the
phenotypic expression of HCM caused by different
mutations. Similarly, because the ensuing clinical
phenotype in HCM is a complex trait, “benign” or
“malignant” phenotype could be observed for any
HCM mutation.
Despite the presence of considerable variability
in the phenotype expression of HCM and the limitations of the genotype–phenotype correlation
studies, the data suggest that the causal mutations
as well as the modifier genetic factors exert a significant impact on expression of cardiac hypertrophy
38
PART I
Cardiovascular single gene disorders
and the risk of SCD [74,75,101,102,126–131]. In
general, mutations in β-MyHC are associated with
a high penetrance, an early onset of clinical phenotype, extensive hypertrophy and a relatively higher
incidence of SCD than those in MyBP-C [94,132].
The phenotype in the latter group is generally characterized by a low penetrance, late onset of clinical
phenotype, mild cardiac hypertrophy and a lower
risk of SCD [74,94,132]. The relatively low penetrance of a mutation indicates that a phenotypically
normal individual could express the clinical phenotype later in life [133]. Thus, unless genetic testing
is performed to exclude the mutation, those at risk
should be evaluated periodically. The phenotype
imparted by mutations in cTnT, cTnI and αtropomyosin, while variable, is generally characterized by a mild degree of cardiac hypertrophy, but a
higher incidence of SCD and extensive myocyte
disarray [67,130]. Concerning the impact of the
modifier genes, the existing data suggest ACE-1 DD
genotypes are associated with more extensive
hypertrophy and a higher risk of SCD [101–103].
Another determinant of cardiac phenotype in
HCM is the presence of double mutations [98] and
concomitant diseases, such as hypertension. Hypertension provides extra stimulus for cardiac hypertrophic growth and so could increase the penetrance
and accelerate the phenotypic expression of HCM.
“Hypertensive hypertrophic cardiomyopathy of
the elderly” is considered a form of HCM caused by
low penetrant mutations, often in MyBP-C, whose
phenotypic expression is enhanced because of concomitant hypertension [94,134]. It is also unclear
whether heavy physical exercise, particularly isometric exercises, could enhance phenotypic expression of cardiac hypertrophy in HCM. Because
hypertrophy is the response of the heart to the
genetic defect, one could speculate that factors that
promote cardiac growth enhance phenotypic expression of HCM. Despite the lack of conclusive
data, because HCM is the most common cause of
SCD in young competitive athletes [41], patients
with HCM are advised not to participate in competitive or contact sports.
Genetic screening
There is considerable interest in genetic screening
of those at risk for HCM mutations. The interest,
expressed by patients and physicians alike, is primarily based on the potential utility of genetic testing
in preclinical diagnosis of mutation careers. Family
members who do not carry the causal mutation and
thus are not at the risk of HCM could be identified.
In addition, members who carry the mutation and
hence are at risk of developing HCM could be diagnosed early, prior to and independent of the clinical
phenotype [135]. Despite the need and in spite of
identification of the majority of the causal genes for
HCM, routine genetic screening has not been feasible. In addition, the clinical utility of genetic testing
in risk stratification and treatment, despite its plausibility, remain to be established.
A number of issues have impeded the development and application of routine genetic screening
in HCM. The diversity of the causal mutations and
the low frequency of each specific causal mutation
are the major limiting factors. In addition, routine
genetic testing will require systematic screening
of all known causal genes, which at best could lead
to identification of the causal mutation in approximately two-thirds of cases. Furthermore, the
genetic screening technique would need to be
highly sensitive and specific and not very expensive.
The current gold standard technique is direct
sequencing of the genomic DNA, which has an
excellent sensitivity and specificity. In the case of
HCM, it would be necessary to sequence at least all
coding exons and the exon–intron boundaries of a
dozen sarcomeric genes, assuming no phenocopy.
The current state of sequencing technology is not
conducive to routine genetic screening because of
the labor intensive and expensive nature of the task.
Hence, implementation of genetic screening on a
routine basis would require the development of
new screening methods. An alternative approach
is to screen the coding exons and exon–intron
boundaries of the most common causal genes for
HCM. The approach is costly, labor intensive with
the current technology, but feasible. It could lead to
detection of the causal mutations in about 60% of
cases. Screening technology is rapidly evolving.
One could anticipate that within the next few years,
advanced mutation-screening techniques will become available and applied on a routine basis to
screen individuals at risk of developing HCM.
The primary utility of genetic testing would be in
the accurate diagnosis of those at risk of the disease
CHAPTER 3
(mutation carriers) and normal individuals (noncarriers). The utility of genetic testing in prognostication and identification of those at risk of SCD
remains to be established and has to await largescale clinical studies. The significance of identifying
the causal mutations as the determinants of the
clinical phenotypes cannot be overemphasized. In
addition, information on the modifier genes, which
remain largely unrecognized, as well as environmental factors and others would be necessary for
accurate clinical management and counseling of
patients with HCM. Thus, an integrated approach
that utilizes genetic and nongenetic predictors
should be used in counseling and treating those
with HCM mutations.
Pathogenesis
Elucidation of the molecular genetic basis of HCM
afforded the opportunity to perform a series of
mechanistic experiments to delineate the molecular pathogenesis. The effects of the HCM mutations
on protein, cell and organ structure and function
have been studied through a large number of in
vitro and in vivo studies. Over a dozen genetically
modified animal models of HCM have been generated, which in part or fully recapitulate the phenotype of human HCM (Table 3.4). Collectively, the
results have provided considerable insight into the
pathogenesis of HCM and have led to partial
understanding of the links between the causal
genetic defect and the ensuing phenotypic expression of hypertrophy, fibrosis and myocyte disarray.
The sequence of events from the genetic defect to
the clinical phenotype could be simplified into
three major stages: the initial functional phenotypes; intermediary molecular phenotypes; and the
ensuing morphologic phenotypes [136]. A change
in the protein sequence (i.e., causal mutation) by
changing the secondary structure or charge of the
encoded protein affects interactions of the mutant
protein with other protein components of the sarcomeres. The defective interaction affects the function of the entire multiprotein sarcomeric units.
The resulting functional defects are diverse, which
is reflective of the diversity of the causal genes and
mutations. They include reduced ATPase activity
of the myofibrils [137], impaired actin–myosin
cross-bridging [138], enhanced Ca2+ sensitivity of
Hypertrophic cardiomyopathy 39
myofibrils in the generation of contractile force
[55]. A partial list of the initial functional phenotype is given in Table 3.5. Altered functional abnormalities of sarcomeres and myofibrils lead to
expression and activation of intermediary molecular
phenotypes, such as intracellular signaling molecules. The changes in gene expression and signaling
activation instigates cardiac morphologic and histologic response, such as hypertrophy and fibrosis
(Fig. 3.2). In addition, certain sarcomeric proteins,
such as titin and sarcomere-associated proteins are
directly involved in regulating muscle gene expression [139]. Mutations could also interfere with
regulation of gene expression by the sarcomeric
proteins. At organ level, impaired myocardial contraction and relaxation as well as impaired bioenergetics have been implicated in mediating cardiac
hypertrophic response in HCM [140–143]. Tissue
Doppler velocities of myocardial contraction and
relaxation are reduced in human subjects with HCM
mutations prior to the development of cardiac
hypertrophy [52]. Similarly, the ratio of cardiac
phosphocreatine (PCr) to adenosine triphosphate
(ATP) in the heart is reduced in patients with HCM
mutations [144]. Thus, a number of initial defects
alone or collectively at protein, myofibrillar or organ
level, contribute to the development of evolving
cardiac hypertrophy in HCM. Accordingly, cardiac
hypertrophy, the clinical hallmark of HCM, and
interstitial fibrosis are considered secondary phenotypes because of activation of intermediary molecules and hence potentially reversible.
The pathogenesis of myocyte disarray, the pathologic hallmark of HCM, is unknown. Myocyte
disarray is an early phenotype, independent of
hypertrophy and fibrosis [137]. Observations in a
mouse model expressing human cTnT-Q92 mutation
implicate impaired myocyte–myocyte attachment
at adherens junctions, as a potential mechanism for
myocyte disarray [145]. The extracellular domains
of cadherins form the intercellular bonds between
the adjacent myocytes. Meanwhile, the cytoplasmic
domains of cadherins attach to cytoskeletal actin
through β-catenin and other effector proteins.
Excess phosphorylation of β-catenin reduces complexing with N-cadherin at the adherens junctions,
impairing proper alignment of the myocytes and
hence myocyte disarray [137]. Several other alternative pathways could be responsible for myocyte
40
PART I
Cardiovascular single gene disorders
Table 3.4 Genetically engineered animal models of hypertrophic cardiomyopathy (HCM).
Knock out/in models
a-MyHC-Q403 mice
Phenotype
Myocyte disarray, interstitial fibrosis, hypertrophy mild and late, enlarged left atrium,
premature death, neonatal dilated cardiomyopathy in homozygous mice [193], systolic and
diastolic dysfunction, increased contractile performance in very early life, heterogeneous
ventricular conduction, inducible ventricular tachycardia, reduced crossbridge kinetics,
increased force generation of single myosin molecules and [Ca2+]I sensitivity, reduced [PCr],
and increased [Pi], increased actin-activated ATPase activity [138,180,193–202]
a-MyHC knock out mice
Embryonic lethality in –/–, +/– show fibrosis, sarcomere disarray, impaired contractility and
relaxation [148]
a-Tropomyosin knock-out
Embryonic lethality in homozygotes, no phenotype in heteozygotes, normal cardiac function
[150,203]
Transgenic mice
a-MyHC-Q403/DAA468-527 Myocyte disarray, interstitial fibrosis, ventricular hypertrophy in female and dilatation in
male mice, Increased ANF expression [204,205]
a-MyHC-DLCBD
Myocyte disarray, hypertrophy (only in homozygote), valvular thickening, decreased Ca2+
sensitivity and diastolic dysfunction [206]
cTnT-DC-terminus
Myocyte disarray, interstitial fibrosis, myocyte atrophy and drop out, cardiac atrophy,
premature death, systolic and diastolic dysfunction [207]
cTnT-Q92
Myocyte disarray, interstitial fibrosis, myocyte drop out, cardiac atrophy, systolic and diastolic
dysfunction, enhanced myofibrillar Ca2+ sensitivity [55,208,209]
cTnT-N179
Normal, normal survival, no hypertrophy, increased Ca2+ sensitivity of ATPase activity and
force generation, increased rate of contraction and relaxation, lower maximum force/
cross-section area and ATPase [210]
MyBP-C-DC-terminus
Truncated MyBP-C
Myocyte disarray, sarcomere dysgenesis, interstitial fibrosis, no cardiac hypertrophy [211]
Neonatal dilated cardiomyopathy in homozygous mice expressing <10% of the truncated
protein, disarray, minimal or mild hypertrophy, decreased contractility and diastolic
dysfunction [212,213]
ELC-V149 (human gene)
Papillary muscle hypertrophy, altered stretch-activation response [214]
ELC-V149 (mouse cDNA)
Normal, no hypertrophy, increased Ca2+ sensitivity and impaired relaxation [215]
a-Tropomyosin-N175
Myocyte disarray and hypertrophy, impaired contractility and relaxation. Increased Ca2+
sensitivity and decreased relaxation [216,217]
cTnI-G146
Myocyte disarray, interstitial fibrosis, premature death. Increased Ca2+ sensitivity,
hypercontractility and diastolic dysfunction [218]
Transgenic rat
cTnT-DExon 16
Normal, no cardiac hypertrophy, systolic and diastolic dysfunction, After 6 months of exercise
hypertrophy, myofibrillar disarray [219]
Transgenic rabbit
b-MyHC-Q403
Cardiac hypertrophy, myocyte disarray, interstitial fibrosis, increased mortality and SCD,
systolic and diastolic dysfunction, preserved global systolic function, reduced myocardial
contraction and relaxation velocities [220,221]
cTnI-G146
Subtle defects including mycoyte disarray, fibrosis, altered connexin43 organization and
leftward shift in the force-pCa2+ curves [222]
[Ca2+]I, intracellular Ca2+ concentration; cTnT, cardiac troponin T; cTnI, cardiac troponin I; ELC, essential light chain; LCBD,
light chain binding domain; MyBP-C, myosin binding protein C; MyHC, myosin heavy chain; [PCr], phosphocreatinine; ↑ [Pi],
inorganic phosphate; −/−, null (homozygous for the deletion); +/−, heterozygous.
CHAPTER 3
Table 3.5 Partial list of initial functional and biologic
defects caused by hypertrophic cardiomyopathy (HCM)
mutations.
Altered Ca+ and pH sensitivity of myofibrillar force
generation [56,124,222–225]
Altered Ca+ and pH sensitivity of myofibrillar ATPase
activity [56,57,226]
Impaired bioenergetics, higher energy cost (ATPase/force)
and reduced free energy of ATPase activity
[56,144,227,228]
Altered kinetics of actin–myosin cross-bridge cycling
Hypertrophic cardiomyopathy 41
experiments in mice suggest haplo-insufficiency
could change sarcomere structure and function as
well as myocardial dysfunction but may be gene
specific [148–150]. Ablation of α-tropomyosin does
not lead to discernible morphologic or functional
abnormalities in heterozygous mouse [149,150],
whereas heterozygosity of α-MyHC ablation leads
to a cardiomyopathic phenotype [148]. Thus, the
null mutations may lead to HCM only when compensatory mechanisms fail to overcome the haploinsufficiency.
[224,229,230]
Altered phosphorylation, protein folding and proteolytic
susceptibility [223,231–234]
Impaired interaction with other sarcomeric proteins
[190,225,235]
Sarcomere dysgenesis and poor assembly [101,211,233,236]
disarray in HCM including activation of the integrin/wnt signaling pathway by increased extracellular matrix proteins [146].
A number of the causal mutations in HCM are
splice-junction or frame-shift mutations that lead
to null alleles. Thus, the mutant sarcomeric proteins are not expressed or if expressed are not
expected to be incorporated into myofibrils. The
net effect is “haplo-insufficiency,” which is particularly relevant to frame-shift or insertion/deletion mutations in the MyBP-C protein [73,74,147].
Whether null alleles could cause HCM because of
haploinsufficiency remains unclear. Gene-targeting
Treatment
The focus in the management of patients with
HCM is on determining the risk of SCD, intervening to reduce the risk and the alleviation of
symptoms. Fortunately, the vast majority of patients with HCM are at a relatively low risk of SCD
and are asymptomatic or minimally symptomatic. In such patients, only periodic follow-up and
assessment by ECG and two-dimensional and
Doppler echocardiography is recommended. In an
asymptomatic patient who is at high risk for SCD,
typically defined by the presence of two or more
major risk factors (Table 3.1), an internal cardioverter-defibrillator (ICD) should be implanted
and has been shown to be effective [24]. Otherwise,
there is no pharmacologic or nonpharmacologic
intervention to prevent or slow the evolution of
HCM phenotype.
Treatment options of symptomatic patients comprise pharmacologic therapy, ICD implantation in
↑ Stress
Nucleus
Figure 3.2 Pathogenesis of hypertrophic
cardiomyopathy (HCM) phenotype.
Mutations in sarcomeric protein by
altering sarcomere function (initial
defects) lead to myocyte stress
(mechanical, biochemical and/or
bioenergetics stress), which induce
enhanced gene expression and the
ensuing cardiac hypertrophic and
fibrotic responses.
∆Force generation
↓ATPase activity
↑Ca2+ sensitvity
Intermediary
phenotypes
↑Gene expression
Fibrosis
Myocyte hypertrophy
/disarray
Initial
phenotypes
Others
Distal
phenotypes
42
PART I
Cardiovascular single gene disorders
patients at high-risk of SCD and, in those with
significant outflow tract obstruction, surgical myectomy and transcatheter septal ablation. Pharmacologic treatment includes the use of beta-blockers,
verapamil, disopyramide, low-dose diuretics and
amiodarone, the latter primarily for treatment of
atrial and ventricular arrhythmias. Treatment with
beta-blockers is preferred in patients with outflow
tract gradient at rest. Verapamil is generally not
recommended in such patients because of the risk
of hypotension resulting from vasodilatation.
Patients with symptoms of palpitations should
undergo Holter monitoring and, if needed, electrophysiologic studies to determine the etiology and
provide appropriate therapy. New onset atrial
fibrillation is not well tolerated in those with severe
hypertrophy or outflow tract obstruction. It often
requires electrical cardioversion. Patients with
chronic or intermittent atrial fibrillation should be
anticoagulated in order to reduce to risk of systemic
embolization and stroke. Beta-blockers, verapamil
or amiodarone are used for treatment of patients
with chronic or paroxysmal atrial fibrillation.
Syncope is a major risk factor for SCD and requires extensive investigation and proper treatment.
It often indicates serious ventricular arrhythmias
and, less frequently, exercise-induced hypotension.
Patients with syncope should undergo Holter monitoring, electrophysiologic studies and, if needed,
tilt table testing. Patients with repetitive bursts
of nonsustained ventricular tachycardia on Holter
monitoring and those with sustained ventricular
tachycardia are candidates for automatic ICD
implantation, regardless of the presence or absence
of symptoms. Ventricular arrhythmias are the main
cause of SCD in patients with HCM [24]. Implantation of an ICD as a preventive measure in patients
at high risk of SCD reduces the risk of SCD [24]. An
algorithm showing our current approach to management of HCM patients is shown in Fig. 3.3.
Unexplained cardiac hypertrophy
Phenocopy
True HCM
Low risk for SCD
High risk for SCD
No ICD
ICD
Asymptomatic/
minimally symptomatic
Periodic follow-up
Symptomatic
Dyspnea
Chest pain
Syncope
Hypotension
Medical therapy
Responsive
Significant LVOT gradient No LVOT gradient
Surgical
Ethanol septal
myomectomy
ablation
Refractory
DDD pacing
(also if surgery
or septal
ablation not an
option)
V arrhythmias
Medical therapy
Refractory
Refractory
Palpitation
ICD
Amiodarone
Other antiarrhythmic
drug
SVT/A Fib
Acute
Chronic
Cardioversion
Medical therapy
RF ablation
Anti-coagulation
Treat as diastolic heart failure
Figure 3.3 An algorithm for
management of patients with
hypertrophic cardiomyopathy (HCM).
A Fib, atrial fibrillation; DDD, dual
chamber pacing; ICD, internal
cardioverter-defibrillator; LVOT, left
ventricular outflow tract; RF, radiofrequency ablation; SCD, sudden
cardiac death; SVT, supra-ventricular
tachycardia; V, ventricular.
CHAPTER 3
Hypertrophic cardiomyopathy 43
Table 3.6 Comparison of surgical myectomy and ethanol septal ablation.
Surgical myectomy
Ethanol septal ablation
Approach
Cardiopulmonary bypass
Cardiac catheterization
Hospital stay
5–7 days
1–2 days
Perioperative mortality
1–5%
1–5%
Procedural success
>95%
>85%
Short-term symptomatic relief
Excellent
Excellent
Long-term symptomatic relief
Excellent
Excellent
Long-term safety
Established
Risk of ventricular arrhythmias
Impact on survival
Unknown
Unknown
Septal infarction/fibrosis
None
Present
Recurrence of LVOT gradient
Rare
Uncommon
Repeat procedure
Rare
Uncommon
Atrioventricular block requiring permanent pacemaker
~2%
~20%
Late ventricular arrhythmias
Rare
Uncommon
Postoperative atrial fibrillation
Uncommon
Rare
Significant aortic regurgitation
Rare
None
Ventricular septal defect
Rare
None
Correction of concomitant problems
Amenable
NA
LVOT, left ventricular outflow tract; NA, not applicable.
A small group of patients with HCM do not
respond to medical therapy and remain significantly symptomatic (New York Heart Association
Functional class III and IV for heart failure). These
patients are candidates for invasive therapeutic
interventions if they exhibit interventricular septal
thickness of 15 mm or greater and significant
outflow tract gradient obstruction (>50 mmHg at
rest). The most commonly used invasive interventions are surgical myectomy and transcoronary
septal ablation. While there are no prospective randomized studies to compare the clinical outcomes
after surgical myectomy and percutaneous transcoronary septal ablation, several observational
studies have shown efficacy of both techniques in
reducing left ventricular outflow tract gradient and
reduction of symptoms [151–157]. Nonetheless,
there is considerable debate regarding the superiority of each intervention [158,159]. Overall, there is
a general agreement on the suitability of transcoronary septal ablation as an alternative and effective
option in symptomatic patients who are not candidates for surgical myectomy. Neither surgical
myectomy nor transcoronary septal ablation is
considered a cure for HCM. Close monitoring,
follow-up and treatment of these patients are
warranted. The advantages and disadvantages of
these two techniques are summarized in Table 3.6.
Surgical myectomy (myomectomy)
The focus of surgical myectomy is to reduce
outflow tract obstruction, a determinant of morbidity and mortality of patients with HCM [160].
Surgical myectomy is indicated in a small group
of patients who have significant outflow tract
obstruction at rest (typically >50 mmHg gradient)
and are refractory to pharmacologic therapy.
Surgical myectomy is the procedure of choice in
HCM patients who have concomitant coronary
artery disease or valvular disorders. The procedure
involves resection of a small portion of the interventricular septum, commonly restricted to the
base of the septum, through a transaortic approach
(Morrow procedure) [161]. Mitral valve repair,
placation and replacement are performed during
surgery in those with significant mitral regurgitation. The overall surgical mortality is 1–5%
[151,153,162,163]. It is somewhat higher in elderly
patients and in those with concomitant surgeries,
such as coronary bypass or valve surgery. Surgical
myectomy is very effective in reducing or abolishing the outflow tract gradient and improving
44
PART I
Cardiovascular single gene disorders
symptoms. The long-term results have been remarkable for sustained symptomatic relief, a low recurrence rate requiring a second intervention and
excellent survival, almost matching that of the natural history of HCM [151,153,156,158,162–164].
However, the impact of surgical myectomy on
reducing cardiovascular mortality and the risk of
SCD remains to be established.
Transcoronary septal ablation
Transcoronary septal ablation is performed by
injecting a small amount of pure ethanol (1–3 mL)
into the main septal perforators of the left anterior
descending artery [21]. It is an effective treatment
option for partial ablation of the hypertophic
interventricular septum and reduction of the left
ventricular outflow tract gradient [154,165,166].
Injection of ethanol or microspheres into the septal
branches induces local myocardial necrosis, emulating surgical myectomy. The procedure is best
reserved for symptomatic patients who are refractory to medical therapy, have an interventricular
septal thickness of 15 mm or greater and a left ventricular outflow tract gradient of 50 mmHg or
more. In patients who have significant exertional
dyspnea and a thick interventricular septum but
no significant gradient at rest, exercise echocardiography could be used to provoke gradient. The
merit of dobutamine-induced outflow tract gradient as an indication for septal ablation is uncertain.
Progressive left ventricular remodeling occurs
in conjunction with enlargement of the left ventricular outflow tract following transcatheter septal
ablation [159,167]. The remodeling could lead to
continued improvement of symptoms. The procedure is well tolerated, with a relatively low perioperative morbidity and mortality [166]. A relatively
high early and late mortality has been reported
[153,168]. A major complication is the development of advanced conduction defect requiring permanent pacemaker implantation in approximately
20% of patients [168–170]. There is also a concern
regarding the possibility of ventricular arrhythmias resulting from localized myocardial necrosis.
This potentially serious complication appears to be
uncommon, albeit documented, and could account
for the higher late mortality reported [168,171–
173]. Overall, the intermediary follow-up data for
transcoronary septal ablation are remarkable for an
acceptable recurrence rate, but long-term followup data are not yet available [166].
Dual chamber pacing
Dual chamber pacing is a treatment modality
reserved for rare situations where medical therapy
fails and surgical myectomy or transcatheter septal
ablation are not considered options. It reduces left
ventricular outflow tract gradient by modifying
left ventricular excitation pattern causing dyssynchronous depolarization of left ventricular contraction. Optimal timing of the AV interval is
considered crucial for the effectiveness of the pacing strategy. Initial observational studies showed
a significant improvement in symptoms along with
a major reduction in outflow tract obstruction
[174]. However, subsequent randomized multicenter studies showed a significant placebo effect without discernible improvement in exercise tolerance
[175,176]. The poor results of two randomized
clinical studies have reduced the overall enthusiasm
in the clinical utility of dual chamber pacing in the
treatment of patients with HCM [175,176]. Thus,
dual chamber pacing is no longer recommended,
except in severely symptomatic patients who are
not candidates for either surgical or transcatheter
septal ablation.
Potential new therapeutic
approaches
Current pharmacologic interventions in human patients, largely restricted to the use of beta-blockers
and verpamil, are empiric and none has been
shown to reduce mortality or induce regression of
cardiac hypertrophy, fibrosis or disarray in patients
with HCM. Advances in the molecular genetics and
biology of HCM have provided new therapeutic
targets, which have been tested in animal models of
HCM with encouraging results.
Experimental studies in a transgenic rabbit
model, which recapitulate the phenotype of human HCM, have shown the potential utility of
3-hydroxy-3-methyglutaryl-coenzyme A (HMGCoA) reductase inhibitors (statins) in prevention,
attenuation and reversal of evolving phenotypes in
HCM [26,27]. Statins exert considerable antihyper-
CHAPTER 3
trophic effects by blocking geranyl geranylation
of RhoA and Rac1, essential mediators of cardiac
hypertrophic response [177]. In a randomized
study in transgenic rabbits with established HCM
phenotype, treatment with simvastatin reduced left
ventricular mass, wall thickness, myocyte size and
normalized interstitial fibrosis [26]. In addition,
indices of cardiac diastolic function and filling
pressure were improved significantly. The potential
utility of statins in prevention of HCM phenotype
has also been assessed in a prospective randomized
study [27]. Treatment of transgenic rabbit early
and prior to the development of cardiac phenotype prevented evolution of cardiac hypertrophy
by reducing activation of hypertrophic signaling
molecule [27]. Studies in other animal models of
cardiac hypertrophy and heart failure have corroborated the potential beneficial effects of statins in
prevention and attenuation of hypertrophy and
fibrosis [177,178]. Clinical studies in humans are
ongoing to test the potential utility of statins in the
attenuation of cardiac phenotypes and symptoms
in HCM.
Another potential therapeutic target for treatment for human HCM is inhibition of RAAS.
Studies in genetic mouse models of HCM have supported the potential utility of angiotensin II receptor blockade by losartan and mineralocorticoid
receptor blockade by aldosterone in complete resolution of interstitial fibrosis [25,145]. The findings are noteworthy and merit further investigation
in human patients because conventionally these
agents are not recommended in patients with
obstructive HCM.
There has been significant controversy regarding
the utility of calcineurin inhibitors in the treatment
and prevention of cardiac hypertrophy in a variety
of conditions [179]. A recent study in α-MyHCQ403+/– mice showed that treatment with FK506
or cyclosporine, inhibitors of calcineurin, worsened
cardiac and myocyte hypertrophy, myocyte disarray and interstitial fibrosis and increased mortality
[180]. Pretreatment with diltiazem, an L-type Ca2+
channel blocker, prevented the exaggerated cardiac
hypertrophic response to inhibitors of calcineurin
[180]. These findings have reduced the overall
enthusiasm for the potential utility of calcineurin
inhibitors in HCM.
Hypertrophic cardiomyopathy 45
Acknowledgments
Supported by grants from the National Heart,
Lung, and Blood Institute, Specialized Centers
of Research P50-HL54313, RO1 HL68884, and a
TexGen grant from Greater Houston Community
Foundation.
References
1 Maron BJ. Hypertrophic cardiomyopathy: a systematic
review. JAMA 2002; 287: 1308–1320.
2 Liouville H. Retrecissement cardiaque sous aortique.
Gazette Med Paris 1869; 24: 161–165.
3 Schmincke A. Ueber linkseitige muskulose conusstenosen. Dtsche Med Wochnschr 1907; 33: 2082.
4 Davies LG. A familial heart disease. Br Heart J 1952; 14:
206–212.
5 Brock R, Fleming PR. Aortic subvalvar stenosis; a report
of 5 cases diagnosed during life. Guys Hosp Rep 1956;
105: 391–408.
6 Teare D. Asymmetrical hypertrophy of the heart in
young adults. Br Heart J 1958; 20: 1–8.
7 Braunwald E, Ebert PA. Hemogynamic alterations in
idiopathic hypertrophic subaortic stenosis induced by
sympathomimetic drugs. Am J Cardiol 1962; 10: 489–
495.
8 Braunwald E, Lambrew CT, Rockoff SD, Ross J Jr,
Morrow AG. Idiopathic hypertrophic subaortic stenosis. 1. A description of the disease based upon an analysis
of 64 pateints. Circulation 1964; 30 (Supplement 4):
3–119.
9 Pierce GE, Morrow AG, Braunwald E. Idiopathic hypertrophic subaortic stenosis. 3. Intraoperative studies of
the mechanism of obstruction and its hemodynamic
consequences. Circulation 1964; 30 (Supplement 4):
152.
10 Morrow AG, Lambrew CT, Braunwald E. Idiopathic
hypertrophic subaortic stenosis. 2. Operative treatment
and the results of pre- and postoperative hemodynamic
evaluations. Circulation 1964; 30 (Supplement 4): 120–
151.
11 Moreyra E, Segal BL. [Echocardiographic study in subaortic muscular stenosis patients]. Prensa Med Argent
1968; 55: 767–773.
12 Moreyra E, Elein JJ, Shimada H, Segal BL. Idiopathic
hypertrophic subaortic stenosis diagnosed by reflected
ultrasound. Am J Cardiol 1969; 23: 32–37.
13 Henry WL, Clark CE, Epstein SE. Asymmetric septal
hypertrophy. Echocardiographic identification of the
pathognomonic anatomic abnormality of IHSS. Circulation 1973; 47: 225–233.
46
PART I
Cardiovascular single gene disorders
14 Shah PM, Gramiak R, Kramer DH. Ultrasound localization of left ventricular outflow obstruction in hypertrophic obstructive cardiomyopathy. Circulation 1969;
40: 3–11.
15 Joyner CR, Harrison FS Jr, Gruber JW. Diagnosis of
hypertrophic subaortic stenosis with a Doppler velocity
flow detector. Ann Intern Med 1971; 74: 692–696.
16 Boughner DR, Schuld RL, Persaud JA. Hypertrophic
obstructive cardiomyopathy. Assessment by echocardiographic and Doppler ultrasound techniques. Br Heart J
1975; 37: 917–923.
17 Maron BJ, Gottdiener JS, Arce J, Rosing DR, Wesley YE,
Epstein SE. Dynamic subaortic obstruction in hypertrophic cardiomyopathy: analysis by pulsed Doppler
echocardiography. J Am Coll Cardiol 1985; 6: 1–18.
18 Takenaka K, Dabestani A, Gardin JM et al. Left ventricular filling in hypertrophic cardiomyopathy: a pulsed
Doppler echocardiographic study. J Am Coll Cardiol
1986; 7: 1263–1271.
19 Geisterfer-Lowrance AA, Kass S, Tanigawa G et al. A
molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense
mutation. Cell 1990; 62: 999–1006.
20 Marian AJ. Recent advances in genetics and treatment of
hypertrophic cardiomyopathy. Future Cardiol 2005; 1:
341–353.
21 Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 1995; 346:
211–214.
22 Hess OM, Sigwart U. New treatment strategies for
hypertrophic obstructive cardiomyopathy: alcohol ablation of the septum: the new gold standard? J Am Coll
Cardiol 2004; 44: 2054–2055.
23 Maron BJ, Dearani JA, Ommen SR, et al. The case for
surgery in obstructive hypertrophic cardiomyopathy.
J Am Coll Cardiol 2004; 44: 2044–2053.
24 Maron BJ, Shen WK, Link MS et al. Efficacy of
implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med 2000; 342: 365–373.
25 Lim DS, Lutucuta S, Bachireddy P et al. Angiotensin II
blockade reverses myocardial fibrosis in a transgenic
mouse model of human hypertrophic cardiomyopathy.
Circulation 2001; 103: 789–791.
26 Patel R, Nagueh SF, Tsybouleva N et al. Simvastatin
induces regression of cardiac hypertrophy and fibrosis
and improves cardiac function in a transgenic rabbit
model of human hypertrophic cardiomyopathy. Circulation 2001; 104: 317–324.
27 Senthil V, Chen SN, Tsybouleva N et al. Prevention of
cardiac hypertrophy by atorvastatin in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circ
Res 2005; 97: 285–292.
28 Elliott P, McKenna WJ. Hypertrophic cardiomyopathy.
Lancet 2004; 363: 1881–1891.
29 Chimenti C, Pieroni M, Morgante E et al. Prevalence of
Fabry disease in female patients with late-onset hypertrophic cardiomyopathy. Circulation 2004; 110: 1047–
1053.
30 Gollob MH, Green MS, Tang AS et al. Identification of a
gene responsible for familial Wolff–Parkinson–White
syndrome. N Engl J Med 2001; 344: 1823–1831.
31 Gollob MH, Seger JJ, Gollob TN et al. Novel PRKAG2
mutation responsible for the genetic syndrome of ventricular preexcitation and conduction system disease
with childhood onset and absence of cardiac hypertrophy. Circulation 2001; 104: 3030–3033.
32 Blair E, Redwood C, Ashrafian H et al. Mutations in the
gamma(2) subunit of AMP-activated protein kinase
cause familial hypertrophic cardiomyopathy: evidence
for the central role of energy compromise in disease
pathogenesis. Hum Mol Genet 2001; 10: 1215–1220.
33 Arad M, Benson DW, Perez-Atayde AR et al. Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy.
J Clin Invest 2002; 109: 357–362.
34 Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki
TT, Bild DE. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA
Study. Coronary Artery Risk Development in (Young)
Adults. Circulation 1995; 92: 785–789.
35 Miura K, Nakagawa H, Morikawa Y et al. Epidemiology
of idiopathic cardiomyopathy in Japan: results from a
nationwide survey. Heart 2002; 87: 126–130.
36 Kofflard MJ, ten Cate FJ, van der Lee C, van Domburg RT.
Hypertrophic cardiomyopathy in a large communitybased population: Clinical outcome and identification
of risk factors for sudden cardiac death and clinical deterioration. J Am Coll Cardiol 2003; 41: 987–993.
37 Nienaber CA, Hiller S, Spielmann RP, Geiger M, Kuck
KH. Syncope in hypertrophic cardiomyopathy: multivariate analysis of prognostic determinants. J Am Coll
Cardiol 1990; 15: 948–955.
38 Elliott PM, Poloniecki J, Dickie S et al. Sudden death in
hypertrophic cardiomyopathy: identification of high
risk patients. J Am Coll Cardiol 2000; 36: 2212–2218.
39 Olivotto I, Cecchi F, Casey SA, Dolara A, Traverse JH,
Maron BJ. Impact of atrial fibrillation on the clinical
course of hypertrophic cardiomyopathy. Circulation
2001; 104: 2517–2524.
40 Monserrat L, Elliott PM, Gimeno JR, Sharma S, PenasLado M, McKenna WJ. Non-sustained ventricular
tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients.
J Am Coll Cardiol 2003; 42: 873–879.
CHAPTER 3
41 Maron BJ, Shirani J, Poliac LC, Mathenge R, Roberts
WC, Mueller FO. Sudden death in young competitive
athletes. Clinical, demographic, and pathological profiles.
JAMA 1996; 276: 199–204.
42 McKenna W, Deanfield J, Faruqui A, England D,
Oakley C, Goodwin J. Prognosis in hypertrophic cardiomyopathy: role of age and clinical, electrocardiographic and hemodynamic features. Am J Cardiol 1981;
47: 532–538.
43 Marian AJ. On predictors of sudden cardiac death in
hypertrophic cardiomyopathy. J Am Coll Cardiol 2003;
41: 994–996.
44 Cannan CR, Reeder GS, Bailey KR, Melton LJ III, Gersh
BJ. Natural history of hypertrophic cardiomyopathy. A
population-based study, 1976 through 1990. Circulation
1995; 92: 2488–2495.
45 Maron BJ, Olivotto I, Spirito P et al. Epidemiology of
hypertrophic cardiomyopathy-related death: revisited
in a large non-referral-based patient population. Circulation 2000; 102: 858–864.
46 Nugent AW, Daubeney PEF, Chondros P et al. Clinical
features and outcomes of childhood hypertrophic cardiomyopathy: Results from a national population-based
study. Circulation 2005; 112: 1332–1338.
47 Maron BJ, Wolfson JK, Ciro E, Spirito P. Relation of
electrocardiographic abnormalities and patterns of left
ventricular hypertrophy identified by 2-dimensional
echocardiography in patients with hypertrophic cardiomyopathy. Am J Cardiol 1983; 51: 189–194.
48 Sakamoto T, Tei C, Murayama M, Ichiyasu H, Hada Y.
Giant T wave inversion as a manifestation of asymmetrical apical hypertrophy (AAH) of the left ventricle.
Echocardiographic and ultrasono-cardiotomographic
study. Jpn Heart J 1976; 17: 611–629.
49 Eriksson MJ, Sonnenberg B, Woo A et al. Long-term
outcome in patients with apical hypertrophic cardiomyopathy. J Am Coll Cardiol 2002; 39: 638–645.
50 Furubayashi K. Hemodynamic characteristics of hypertrophic and congestive cardiomyopathies. Jpn Circ J
1981; 45: 1014–1024.
51 Hirota Y, Furubayashi K, Kaku K et al. Hypertrophic
nonobstructive cardiomyopathy: a precise assessment
of hemodynamic characteristics and clinical implications. Am J Cardiol 1982; 50: 990–997.
52 Nagueh SF, Bachinski L, Meyer D et al. Tissue Doppler
imaging consistently detects myocardial abnormalities
in patients with familial hypertrophic cardiomyopathy
and provides a novel means for an early diagnosis prior
to an independent of hypertrophy. Circulation 2001;
104: 128–130.
53 Beyar R. Hypertrophic cardiomyopathy: functional
aspects by tagged magnetic resonance imaging. Adv Exp
Med Biol 1995; 382: 293–301.
Hypertrophic cardiomyopathy 47
54 Nagueh SF, McFalls J, Meyer D et al. Tissue Doppler
imaging predicts the development of hypertrophic
cardiomyopathy in subjects with subclinical disease.
Circulation 2003; 108: 395–398.
55 Solaro RJ, Varghese J, Marian AJ, Chandra M. Molecular mechanisms of cardiac myofilament activation:
modulation by pH and a troponin T mutant R92Q.
Basic Res Cardiol 2002; 97 (Supplement I): 102–110.
56 Hernandez O, Szczesna-Cordary D, Knollmann BC
et al. F110I and R278C troponin T mutations that cause
familial hypertrophic cardiomyopathy affect muscle contraction in transgenic mice and reconstituted human
cardiac fibers. J Biol Chem 2005; 280: 37183–37194.
57 Chang AN, Harada K, Ackerman MJ, Potter JD. Functional consequences of hypertrophic and dilated cardiomyopathy causing mutations in alpha-tropomyosin.
J Biol Chem 2005; 280: 34343–34349.
58 Cuda G, Fananapazir L, Epstein ND, Sellers JR. The in
vitro motility activity of beta-cardiac myosin depends
on the nature of the beta-myosin heavy chain gene
mutation in hypertrophic cardiomyopathy. J Muscle Res
Cell Motil 1997; 18: 275–283.
59 Deng Y, Schmidtmann A, Kruse S et al. Phosphorylation
of human cardiac troponin I G203S and K206Q linked
to familial hypertrophic cardiomyopathy affects actomyosin interaction in different ways. J Mol Cell Cardiol
2003; 35: 1365–1374.
60 Palmer BM, Fishbaugher DE, Schmitt JP et al. Differential cross-bridge kinetics of FHC myosin mutations
R403Q and R453C in heterozygous mouse myocardium. Am J Physiol Heart Circ Physiol 2004; 287: H91–
H99.
61 Fujita H, Sugiura S, Momomura S, Omata M, Sugi H,
Sutoh K. Characterization of mutant myosins of
Dictyostelium discoideum equivalent to human familial hypertrophic cardiomyopathy mutants. Molecular
force level of mutant myosins may have a prognostic
implication. J Clin Invest 1997; 99: 1010–1015.
62 Maron BJ, Roberts WC. Quantitative analysis of cardiac
muscle cell disorganization in the ventricular septum of
patients with hypertrophic cardiomyopathy. Circulation
1979; 59: 689–706.
63 Maron BJ, Anan TJ, Roberts WC. Quantitative analysis
of the distribution of cardiac muscle cell disorganization
in the left ventricular wall of patients with hypertrophic
cardiomyopathy. Circulation 1981; 63: 882–894.
64 Shirani J, Pick R, Roberts WC, Maron BJ. Morphology
and significance of the left ventricular collagen network
in young patients with hypertrophic cardiomyopathy
and sudden cardiac death. J Am Coll Cardiol 2000; 35:
36–44.
65 Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P,
Maron BJ. Magnitude of left ventricular hypertrophy
48
66
67
68
69
70
71
72
73
74
75
76
77
78
PART I
Cardiovascular single gene disorders
and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 2000; 342: 1778–1785.
Varnava AM, Elliott PM, Baboonian C, Davison F,
Davies MJ, McKenna WJ. Hypertrophic cardiomyopathy: histopathological features of sudden death in
cardiac troponin T disease. Circulation 2001; 104: 1380–
1384.
Varnava AM, Elliott PM, Mahon N, Davies MJ,
McKenna WJ. Relation between myocyte disarray and
outcome in hypertrophic cardiomyopathy. Am J Cardiol
2001; 88: 275–279.
Olson TM, Karst ML, Whitby FG, Driscoll DJ. Myosin
light chain mutation causes autosomal recessive cardiomyopathy with mid-cavitary hypertrophy and restrictive physiology. Circulation 2002; 105: 2337–2340.
Greaves SC, Roche AH, Neutze JM, Whitlock RM, Veale
AM. Inheritance of hypertrophic cardiomyopathy: a
cross sectional and M mode echocardiographic study of
50 families. Br Heart J 1987; 58: 259–266.
Maron BJ, Nichols PF III, Pickle LW, Wesley YE,
Mulvihill JJ. Patterns of inheritance in hypertrophic
cardiomyopathy: assessment by M-mode and twodimensional echocardiography. Am J Cardiol 1984; 53:
1087–1094.
Thierfelder L, Watkins H, MacRae C et al. Alphatropomyosin and cardiac troponin T mutations cause
familial hypertrophic cardiomyopathy: a disease of the
sarcomere. Cell 1994; 77: 701–712.
Marian AJ, Roberts R. On Koch’s postulates, causality
and genetics of cardiomyopathies. J Mol Cell Cardiol
2002; 34: 971–974.
Richard P, Charron P, Carrier L et al. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of
mutations, and implications for a molecular diagnosis
strategy. Circulation 2003; 107: 2227–2232.
Erdmann J, Raible J, Maki-Abadi J et al. Spectrum
of clinical phenotypes and gene variants in cardiac
myosin-binding protein C mutation carriers with hypertrophic cardiomyopathy. J Am Coll Cardiol 2001; 38:
322–330.
Charron P, Dubourg O, Desnos M et al. Clinical features
and prognostic implications of familial hypertrophic
cardiomyopathy related to the cardiac myosin-binding
protein C gene. Circulation 1998; 97: 2230–2236.
Mogensen J, Murphy RT, Kubo T et al. Frequency and
clinical expression of cardiac troponin I mutations in
748 consecutive families with hypertrophic cardiomyopathy. J Am Coll Cardiol 2004; 44: 2315–2325.
Van Driest SL, Jaeger MA, Ommen SR et al. Comprehensive analysis of the beta-myosin heavy chain gene
in 389 unrelated patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2004; 44: 602–610.
Van Driest SL, Ellsworth EG, Ommen SR, Tajik AJ,
79
80
81
82
83
84
85
86
87
88
89
Gersh BJ, Ackerman MJ. Prevalence and spectrum of
thin filament mutations in an outpatient referral population with hypertrophic cardiomyopathy. Circulation
2003; 108: 445–451.
Andersen PS, Havndrup O, Bundgaard H et al. Genetic and phenotypic characterization of mutations in
myosin-binding protein C (MYBPC3) in 81 families
with familial hypertrophic cardiomyopathy: total or
partial haploinsufficiency. Eur J Hum Genet 2004; 12:
673–677.
Torricelli F, Girolami F, Olivotto I et al. Prevalence and
clinical profile of troponin T mutations among patients
with hypertrophic cardiomyopathy in tuscany. Am J
Cardiol 2003; 92: 1358–1362.
Marian AJ, Yu QT, Mares A Jr, Hill R, Roberts R,
Perryman MB. Detection of a new mutation in the
beta-myosin heavy chain gene in an individual with
hypertrophic cardiomyopathy. J Clin Invest 1992; 90:
2156–2165.
Blair E, Redwood C, de Jesus OM et al. Mutations of the
light meromyosin domain of the beta-myosin heavy
chain rod in hypertrophic cardiomyopathy. Circ Res
2002; 90: 263–269.
Hougs L, Havndrup O, Bundgaard H et al. One third of
Danish hypertrophic cardiomyopathy patients have
mutations in MYH7 rod region. Eur J Hum Genet 2004;
13: 161–165.
Satoh M, Takahashi M, Sakamoto T, Hiroe M, Marumo
F, Kimura A. Structural analysis of the titin gene in
hypertrophic cardiomyopathy: identification of a novel
disease gene. Biochem Biophys Res Commun 1999; 262:
411–417.
Mogensen J, Klausen IC, Pedersen AK et al. Alphacardiac actin is a novel disease gene in familial hypertrophic cardiomyopathy. J Clin Invest 1999; 103: R39–R43.
Flavigny J, Richard P, Isnard R et al. Identification of
two novel mutations in the ventricular regulatory
myosin light chain gene (MYL2) associated with familial
and classical forms of hypertrophic cardiomyopathy.
J Mol Med 1998; 76: 208–214.
Andersen PS, Havndrup O, Bundgaard H et al. Myosin
light chain mutations in familial hypertrophic cardiomyopathy: phenotypic presentation and frequency
in Danish and South African populations. J Med Genet
2001; 38: E43.
Hoffmann B, Schmidt-Traub H, Perrot A, Osterziel KJ,
Gessner R. First mutation in cardiac troponin C, L29Q,
in a patient with hypertrophic cardiomyopathy. Hum
Mutat 2001; 17: 524.
Carniel E, Taylor MRG, Sinagra G et al. α-Myosin heavy
chain: A sarcomeric gene associated with dilated and
hypertrophic phenotypes of cardiomyopathy. Circulation 2005; 112: 54–59.
CHAPTER 3
90 Davis JS, Hassanzadeh S, Winitsky S et al. The overall
pattern of cardiac contraction depends on a spatial gradient of myosin regulatory light chain phosphorylation.
Cell 2001; 107: 631–641.
91 Hayashi T, Arimura T, Itoh-Satoh M et al. Tcap gene
mutations in hypertrophic cardiomyopathy and dilated
cardiomyopathy. J Am Coll Cardiol 2004; 44: 2192–2201.
92 Minamisawa S, Sato Y, Tatsuguchi Y et al. Mutation of
the phospholamban promoter associated with hypertrophic cardiomyopathy. Biochem Biophys Res Commun
2003; 304: 1–4.
93 Hayashi T, Arimura T, Ueda K et al. Identification and
functional analysis of a caveolin-3 mutation associated
with familial hypertrophic cardiomyopathy. Biochem
Biophys Res Commun 2004; 313: 178–184.
94 Niimura H, Bachinski LL, Sangwatanaroj S et al.
Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. N Engl J Med 1998; 338: 1248–1257.
95 Anan R, Greve G, Thierfelder L et al. Prognostic implications of novel beta cardiac myosin heavy chain gene
mutations that cause familial hypertrophic cardiomyopathy. J Clin Invest 1994; 93: 280–285.
96 Dausse E, Komajda M, Fetler L et al. Familial hypertrophic cardiomyopathy. Microsatellite haplotyping
and identification of a hot spot for mutations in the
beta-myosin heavy chain gene. J Clin Invest 1993; 92:
2807–2813.
97 Van Driest SL, Vasile VC, Ommen SR et al. Myosin
binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy. J Am Coll
Cardiol 2004; 44: 1903–1910.
98 Blair E, Price SJ, Baty CJ, Ostman-Smith I, Watkins H.
Mutations in cis can confound genotype–phenotype
correlations in hypertrophic cardiomyopathy. J Med
Genet 2001; 38: 385–388.
99 Marian AJ. On genetic and phenotypic variability of
hypertrophic cardiomyopathy: nature versus nurture.
J Am Coll Cardiol 2001; 38: 331–334.
100 Marian AJ. Modifier genes for hypertrophic cardiomyopathy. Curr Opin Cardiol 2002; 17: 242–252.
101 Marian AJ, Yu QT, Workman R, Greve G, Roberts R.
Angiotensin-converting enzyme polymorphism in hypertrophic cardiomyopathy and sudden cardiac death.
Lancet 1993; 342: 1085–1086.
102 Lechin M, Quinones MA, Omran A et al. Angiotensin-I
converting enzyme genotypes and left ventricular hypertrophy in patients with hypertrophic cardiomyopathy.
Circulation 1995; 92: 1808–1812.
103 Tesson F, Dufour C, Moolman JC et al. The influence of
the angiotensin I converting enzyme genotype in familial hypertrophic cardiomyopathy varies with the disease
gene mutation. J Mol Cell Cardiol 1997; 29: 831–838.
Hypertrophic cardiomyopathy 49
104 Brugada R, Kelsey W, Lechin M et al. Role of candidate
modifier genes on the phenotypic expression of hypertrophy in patients with hypertrophic cardiomyopathy.
J Investig Med 1997; 45: 542–551.
105 Wilcox WR, Banikazemi M, Guffon N et al. Long-term
safety and efficacy of enzyme replacement therapy for
Fabry disease. Am J Hum Genet 2004; 75: 65–74.
106 Eng CM, Guffon N, Wilcox WR et al. Safety and efficacy
of recombinant human alpha-galactosidase A: replacement therapy in Fabry’s disease. N Engl J Med 2001; 345:
9–16.
107 Desnick RJ, Brady R, Barranger J et al. Fabry disease,
an under-recognized multisystemic disorder: Expert
recommendations for diagnosis, management, and
enzyme replacement therapy. Ann Intern Med 2003;
138: 338–346.
108 Sachdev B, Takenaka T, Teraguchi H et al. Prevalence of
Anderson–Fabry disease in male patients with late onset
hypertrophic cardiomyopathy. Circulation 2002; 105:
1407–1411.
109 Schiffmann R, Murray GJ, Treco D et al. Infusion of
alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc Natl
Acad Sci USA 2000; 97: 365–370.
110 Frustaci A, Chimenti C, Ricci R et al. Improvement in
cardiac function in the cardiac variant of Fabry’s disease
with galactose-infusion therapy. N Engl J Med 2001; 345:
25–32.
111 Cummings CJ, Zoghbi HY. Trinucleotide repeats:
mechanisms and pathophysiology. Annu Rev Genomics
Hum Genet 2000; 1: 281–328.
112 Palau F. Friedreich’s ataxia and frataxin: molecular
genetics, evolution and pathogenesis. Int J Mol Med
2001; 7: 581–589.
113 Tartaglia M, Mehler EL, Goldberg R et al. Mutations in
PTPN11, encoding the protein tyrosine phosphatase
SHP-2, cause Noonan syndrome. Nat Genet 2001; 29:
465–468.
114 Tartaglia M, Kalidas K, Shaw A et al. PTPN11 mutations
in Noonan syndrome: molecular spectrum, genotypephenotype correlation, and phenotypic heterogeneity.
Am J Hum Genet 2002; 70: 1555–1563.
115 Ashizawa T, Subramony SH. What is Kearns–Sayre syndrome after all? Arch Neurol 2001; 58: 1053–1054.
116 Mihalik SJ, Morrell JC, Kim D, Sacksteder KA, Watkins
PA, Gould SJ. Identification of PAHX, a Refsum disease
gene. Nat Genet 1997; 17: 185–189.
117 Raben N, Plotz P, Byrne BJ. Acid alpha-glucosidase
deficiency (glycogenosis type II, Pompe disease). Curr
Mol Med 2002; 2: 145–166.
118 Charron P, Villard E, Sebillon P et al. Danon’s disease as
a cause of hypertrophic cardiomyopathy: a systematic
survey. Heart 2004; 90: 842–846.
50
PART I
Cardiovascular single gene disorders
119 Guertl B, Noehammer C, Hoefler G. Metabolic cardiomyopathies. Int J Exp Pathol 2000; 81: 349–372.
120 Watkins H, McKenna WJ, Thierfelder L et al. Mutations in the genes for cardiac troponin T and alphatropomyosin in hypertrophic cardiomyopathy. N Engl J
Med 1995; 332: 1058–1064.
121 Li D, Czernuszewicz GZ, Gonzalez O et al. Novel cardiac
troponin T mutation as a cause of familial dilated cardiomyopathy. Circulation 2001; 104: 2188–2193.
122 Morimoto S, Yanaga F, Minakami R, Ohtsuki I. Ca2+sensitizing effects of the mutations at Ile-79 and Arg-92
of troponin T in hypertrophic cardiomyopathy. Am J
Physiol 1998; 275: C200–C207.
123 Morimoto S, Lu QW, Harada K et al. Ca2+-desensitizing
effect of a deletion mutation Delta K210 in cardiac troponin T that causes familial dilated cardiomyopathy.
Proc Natl Acad Sci USA 2002; 99: 913–918.
124 Harada K, Potter JD. Familial hypertrophic cardiomyopathy mutations from different functional regions
of troponin T result in different effects on the pH and
Ca2+ sensitivity of cardiac muscle contraction. J Biol
Chem 2004; 279: 14488–14495.
125 Lu QW, Morimoto S, Harada K et al. Cardiac troponin
T mutation R141W found in dilated cardiomyopathy
stabilizes the troponin T-tropomyosin interaction and
causes a Ca2+ desensitization. J Mol Cell Cardiol 2003;
35: 1421–1427.
126 Watkins H, Rosenzweig A, Hwang DS et al. Characteristics and prognostic implications of myosin
missense mutations in familial hypertrophic cardiomyopathy. N Engl J Med 1992; 326: 1108–1114.
127 Fananapazir L, Epstein ND. Genotype–phenotype correlations in hypertrophic cardiomyopathy. Insights provided by comparisons of kindreds with distinct and
identical beta-myosin heavy chain gene mutations.
Circulation 1994; 89: 22–32.
128 Epstein ND, Cohn GM, Cyran F, Fananapazir L.
Differences in clinical expression of hypertrophic cardiomyopathy associated with two distinct mutations in
the beta-myosin heavy chain gene. A 908Leu–Val mutation and a 403Arg–Gln mutation [see comments].
Circulation 1992; 86: 345–352.
129 Marian AJ, Mares A Jr, Kelly DP et al. Sudden cardiac
death in hypertrophic cardiomyopathy. Variability in
phenotypic expression of beta-myosin heavy chain
mutations. Eur Heart J 1995; 16: 368–376.
130 Watkins H, McKenna WJ, Thierfelder L et al. Mutations in the genes for cardiac troponin T and alphatropomyosin in hypertrophic cardiomyopathy. N Engl J
Med 1995; 332: 1058–1064.
131 Tesson F, Richard P, Charron P et al. Genotype–phenotype analysis in four families with mutations in betamyosin heavy chain gene responsible for familial
132
133
134
135
136
137
138
139
140
141
142
143
144
hypertrophic cardiomyopathy. Hum Mutat 1998; 12:
385–392.
Charron P, Dubourg O, Desnos M et al. Genotype–
phenotype correlations in familial hypertrophic cardiomyopathy. A comparison between mutations in the
cardiac protein-C and the beta-myosin heavy chain
genes. Eur Heart J 1998; 19: 139–145.
Maron BJ, Niimura H, Casey SA et al. Development of
left ventricular hypertrophy in adults in hypertrophic
cardiomyopathy caused by cardiac myosin-binding
protein C gene mutations. J Am Coll Cardiol 2001; 38:
315–321.
Niimura H, Patton KK, McKenna WJ et al. Sarcomere
protein gene mutations in hypertrophic cardiomyopathy of the elderly. Circulation 2002; 105: 446–451.
Marian AJ, Roberts R. To screen or not is not the question: it is when and how to screen. Circulation 2003; 107:
2171–2174.
Marian AJ. Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy.
Lancet 2000; 355: 58–60.
Nagueh SF, Chen S, Patel R et al. Evolution of expression of cardiac phenotypes over a 4-year period in the βmyosin heavy chain-Q403 transgenic rabbit model of
human hypertrophic cardiomyopathy. J Mol Cell Cardiol 2004; 36: 663–673.
Blanchard E, Seidman C, Seidman JG, LeWinter M,
Maughan D. Altered crossbridge kinetics in the
alphaMHC403/+ mouse model of familial hypertrophic
cardiomyopathy. Circ Res 1999; 84: 475–483.
Lange S, Xiang F, Yakovenko A et al. The kinase domain
of titin controls muscle gene expression and protein
turnover. Science 2005; 308: 1599–1603.
Marian AJ, Zhao G, Seta Y, Roberts R, Yu QT. Expression of a mutant (Arg92Gln) human cardiac troponin T,
known to cause hypertrophic cardiomyopathy, impairs
adult cardiac myocyte contractility. Circ Res 1997; 81:
76–85.
Nagueh SF, Lakkis NM, Middleton KJ, Spencer WH III,
Zoghbi WA, Quinones MA. Doppler estimation of left
ventricular filling pressures in patients with hypertrophic cardiomyopathy. Circulation 1999; 99: 254–261.
Rust EM, Albayya FP, Metzger JM. Identification of a
contractile deficit in adult cardiac myocytes expressing
hypertrophic cardiomyopathy-associated mutant troponin T proteins. J Clin Invest 1999; 103: 1459–1467.
Watkins H, Seidman CE, Seidman JG, Feng HS,
Sweeney HL. Expression and functional assessment of a
truncated cardiac troponin T that causes hypertrophic
cardiomyopathy. Evidence for a dominant negative
action [see comments]. J Clin Invest 1996; 98: 2456–2461.
Crilley JG, Boehm EA, Blair E et al. Hypertrophic cardiomyopathy due to sarcomeric gene mutations is
CHAPTER 3
145
146
147
148
149
150
151
152
153
154
155
156
characterized by impaired energy metabolism irrespective of the degree of hypertrophy. J Am Coll Cardiol 2003;
41: 1776–1782.
Tsybouleva N, Zhang L, Chen SN et al. Aldosterone,
through novel signaling proteins, is a fundamental
molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy. Circulation 2004; 109: 1284–1291.
Frame S, Cohen P. GSK3 takes centre stage more than 20
years after its discovery. Biochem J 2001; 359: 1–16.
Rottbauer W, Gautel M, Zehelein J et al. Novel splice
donor site mutation in the cardiac myosin-binding
protein-C gene in familial hypertrophic cardiomyopathy. Characterization of cardiac transcript and protein.
J Clin Invest 1997; 100: 475–482.
Jones WK, Grupp IL, Doetschman T et al. Ablation of
the murine alpha myosin heavy chain gene leads to
dosage effects and functional deficits in the heart. J Clin
Invest 1996; 98: 1906–1917.
Blanchard EM, Iizuka K, Christe M et al. Targeted ablation of the murine alpha-tropomyosin gene. Circ Res
1997; 81: 1005–1010.
Rethinasamy P, Muthuchamy M, Hewett T et al. Molecular and physiological effects of alpha-tropomyosin
ablation in the mouse. Circ Res 1998; 82: 116–123.
van der Lee C, ten Cate FJ, Geleijnse ML et al. Percutaneous versus surgical treatment for patients with
hypertrophic obstructive cardiomyopathy and enlarged
anterior mitral valve leaflets. Circulation 2005; 112:
482–488.
Nagueh SF, Ommen SR, Lakkis NM et al. Comparison
of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 2001; 38: 1701–1706.
Ralph-Edwards A, Woo A, McCrindle BW et al. Hypertrophic obstructive cardiomyopathy: Comparison of
outcomes after myectomy or alcohol ablation adjusted
by propensity score. J Thorac Cardiovasc Surg 2005; 129:
351–358.
Firoozi S, Elliott PM, Sharma S et al. Septal myotomy–
myectomy and transcoronary septal alcohol ablation in
hypertrophic obstructive cardiomyopathy. A comparison of clinical, haemodynamic and exercise outcomes.
Eur Heart J 2002; 23: 1617–1624.
Qin JX, Shiota T, Lever HM et al. Outcome of patients
with hypertrophic obstructive cardiomyopathy after
percutaneous transluminal septal myocardial ablation
and septal myectomy surgery. J Am Coll Cardiol 2001;
38: 1994–2000.
Heric B, Lytle BW, Miller DP, Rosenkranz ER, Lever
HM, Cosgrove DM. Surgical management of hypertrophic obstructive cardiomyopathy. Early and late
results. J Thorac Cardiovasc Surg 1995; 110: 195–206.
Hypertrophic cardiomyopathy 51
157 Kimmelstiel CD, Maron BJ. Role of percutaneous septal
ablation in hypertrophic obstructive cardiomyopathy.
Circulation 2004; 109: 452–456.
158 Maron BJ, Dearani JA, Ommen SR et al. The case for
surgery in obstructive hypertrophic cardiomyopathy.
J Am Coll Cardiol 2004; 44: 2044–2053.
159 Hess OM, Sigwart U. New treatment strategies for
hypertrophic obstructive cardiomyopathy: Alcohol ablation of the septum: the new gold standard? J Am Coll
Cardiol 2004; 44: 2054–2055.
160 Maron MS, Olivotto I, Betocchi S et al. Effect of left ventricular outflow tract obstruction on clinical outcome in
hypertrophic cardiomyopathy. N Engl J Med 2003; 348:
295–303.
161 Morrow AG, Reitz BA, Epstein SE et al. Operative treatment in hypertrophic subaortic stenosis. Techniques,
and the results of pre and postoperative assessments in
83 patients. Circulation 1975; 52: 88–102.
162 Merrill WH, Friesinger GC, Graham TP Jr et al. Longlasting improvement after septal myectomy for hypertrophic obstructive cardiomyopathy. Ann Thorac Surg
2000; 69: 1732–1735.
163 Schonbeck MH, Brunner-La Rocca H, Vogt PR et al.
Long-term follow-up in hypertrophic obstructive cardiomyopathy after septal myectomy. Ann Thorac Surg
1998; 65: 1207–1214.
164 Schulte HD, Bircks WH, Loesse B, Godehardt EA,
Schwartzkopff B. Prognosis of patients with hypertrophic obstructive cardiomyopathy after transaortic
myectomy. Late results up to twenty-five years. J Thorac
Cardiovasc Surg 1993; 106: 709–717.
165 Seggewiss H. Current status of alcohol septal ablation
for patients with hypertrophic cardiomyopathy. Curr
Cardiol Rep 2001; 3: 160–166.
166 Faber L, Meissner A, Ziemssen P, Seggewiss H.
Percutaneous transluminal septal myocardial ablation
for hypertrophic obstructive cardiomyopathy: long
term follow up of the first series of 25 patients. Heart
2000; 83: 326–331.
167 Mazur W, Nagueh SF, Lakkis NM et al. Regression of left
ventricular hypertrophy after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. Circulation 2001; 103: 1492–1496.
168 Minamino T, Gaussin V, DeMayo FJ, Schneider MD.
Inducible gene targeting in postnatal myocardium by
cardiac-specific expression of a hormone-activated Cre
fusion protein. Circ Res 2001; 88: 587–592.
169 Qin JX, Shiota T, Lever HM et al. Conduction system
abnormalities in patients with obstructive hypertrophic
cardiomyopathy following septal reduction interventions. Am J Cardiol 2004; 93: 171–175.
170 Chang SM, Lakkis NM, Franklin J, Spencer WH III,
Nagueh SF. Predictors of outcome after alcohol septal
52
171
172
173
174
175
176
177
178
179
180
181
182
PART I
Cardiovascular single gene disorders
ablation therapy in patients with hypertrophic obstructive cardiomyopathy. Circulation 2004; 109: 824–827.
McGregor JB, Rahman A, Rosanio S, Ware D, Birnbaum
Y, Saeed M. Monomorphic ventricular tachycardia: a
late complication of percutaneous alcohol septal ablation for hypertrophic cardiomyopathy. Am J Med Sci
2004; 328: 185–188.
Boltwood CM Jr, Chien W, Ports T. Ventricular tachycardia complicating alcohol septal ablation. N Engl J
Med 2004; 351: 1914–1915.
Kaplan SR, Gard JJ, Carvajal-Huerta L, Ruiz-Cabezas
JC, Thiene G, Saffitz JE. Structural and molecular
pathology of the heart in Carvajal syndrome. Cardiovasc
Pathol 2004; 13: 26–32.
Fananapazir L, Epstein ND, Curiel RV, Panza JA,
Tripodi D, McAreavey D. Long-term results of dualchamber (DDD) pacing in obstructive hypertrophic
cardiomyopathy. Evidence for progressive symptomatic
and hemodynamic improvement and reduction of left
ventricular hypertrophy. Circulation 1994; 90: 2731–
2742.
Kappenberger L, Linde C, Daubert C et al. Pacing in
hypertrophic obstructive cardiomyopathy. A randomized crossover study. PIC Study Group. Eur Heart J
1997; 18: 1249–1256.
Maron BJ, Nishimura RA, McKenna WJ, Rakowski H,
Josephson ME, Kieval RS. Assessment of permanent
dual-chamber pacing as a treatment for drug-refractory
symptomatic patients with obstructive hypertrophic
cardiomyopathy. A randomized, double-blind, crossover study (M-PATHY). Circulation 1999; 99: 2927–2933.
Delbosc S, Cristol JP, Descomps B, Mimran A, Jover B.
Simvastatin prevents angiotensin II-induced cardiac
alteration and oxidative stress. Hypertension 2002; 40:
142–147.
Takemoto M, Node K, Nakagami H et al. Statins as
antioxidant therapy for preventing cardiac myocyte
hypertrophy. J Clin Invest 2001; 108: 1429–1437.
Dorn GW. Calcineurin inhibition in hypertrophy: back
from the dead! Circulation 2001; 104: 9–11.
Fatkin D, McConnell BK, Mudd JO et al. An abnormal
Ca2+ response in mutant sarcomere protein-mediated
familial hypertrophic cardiomyopathy. J Clin Invest
2000; 106: 1351–1359.
Fananapazir L, Chang AC, Epstein SE, McAreavey D.
Prognostic determinants in hypertrophic cardiomyopathy. Prospective evaluation of a therapeutic strategy
based on clinical, Holter, hemodynamic, and electrophysiological findings. Circulation 1992; 86: 730–740.
Bonne G, Carrier L, Bercovici J et al. Cardiac myosin
binding protein-C gene splice acceptor site mutation is
associated with familial hypertrophic cardiomyopathy.
Nat Genet 1995; 11: 438–440.
183 Watkins H, Conner D, Thierfelder L et al. Mutations in
the cardiac myosin binding protein-C gene on chromosome 11 cause familial hypertrophic cardiomyopathy.
Nat Genet 1995; 11: 434–437.
184 Kimura A, Harada H, Park JE et al. Mutations in the
cardiac troponin I gene associated with hypertrophic
cardiomyopathy. Nat Genet 1997; 16: 379–382.
185 Poetter K, Jiang H, Hassanzadeh S et al. Mutations in
either the essential or regulatory light chains of myosin
are associated with a rare myopathy in human heart and
skeletal muscle. Nat Genet 1996; 13: 63–69.
186 Murphy RT, Mogensen J, McGarry K et al. Adenosine monophosphate-activated protein kinase disease
mimicks hypertrophic cardiomyopathy and Wolff–
Parkinson–White syndrome: Natural history. J Am Coll
Cardiol 2005; 45: 922–930.
187 Sawada K, Mizoguchi K, Hishida A et al. Point mutation
in the alpha-galactosidase A gene of atypical Fabry disease with only nephropathy. Clin Nephrol 1996; 45:
289–294.
188 Mohiddin SA, Ahmed ZM, Griffith AJ et al. Novel association of hypertrophic cardiomyopathy, sensorineural
deafness, and a mutation in unconventional myosin VI
(MYO6). J Med Genet 2004; 41: 309–314.
189 Yang Z, McMahon CJ, Smith LR et al. Danon disease as
an underrecognized cause of hypertrophic cardiomyopathy in children. Circulation 2005; 112: 1612–1617.
190 Lu QW, Morimoto S, Harada K et al. Cardiac troponin
T mutation R141W found in dilated cardiomyopathy
stabilizes the troponin T-tropomyosin interaction and
causes a Ca2+ desensitization. J Mol Cell Cardiol 2003;
35: 1421–1427.
191 Rotig A, de Lonlay P, Chretien D et al. Aconitase and
mitochondrial iron-sulphur protein deficiency in Friedreich ataxia. Nat Genet 1997; 17: 215–217.
192 Igarashi H, Momoi MY, Yamagata T, Shiraishi H,
Eguchi I. Hypertrophic cardiomyopathy in congenital
myotonic dystrophy. Pediatr Neurol 1998; 18: 366–369.
193 Fatkin D, Christe ME, Aristizabal O et al. Neonatal cardiomyopathy in mice homozygous for the Arg403Gln
mutation in the alpha cardiac myosin heavy chain gene.
J Clin Invest 1999; 103: 147–153.
194 Geisterfer-Lowrance AA, Christe M, Conner DA et al. A
mouse model of familial hypertrophic cardiomyopathy.
Science 1996; 272: 731–734.
195 Kim SJ, Iizuka K, Kelly RA et al. An alpha-cardiac
myosin heavy chain gene mutation impairs contraction
and relaxation function of cardiac myocytes. Am J
Physiol 1999; 276: H1780–H1787.
196 Georgakopoulos D, Christe ME, Giewat M, Seidman
CM, Seidman JG, Kass DA. The pathogenesis of familial hypertrophic cardiomyopathy: early and evolving
effects from an alpha-cardiac myosin heavy chain mis-
CHAPTER 3
197
198
199
200
201
202
203
204
205
206
207
208
sense mutation [see comments]. Nat Med 1999; 5:
327–330.
Berul CI, Christe ME, Aronovitz MJ et al. Familial
hypertrophic cardiomyopathy mice display gender differences in electrophysiological abnormalities. J Interv
Card Electrophysiol 1998; 2: 7–14.
Berul CI, Christe ME, Aronovitz MJ, Seidman CE,
Seidman JG, Mendelsohn ME. Electrophysiological
abnormalities and arrhythmias in alpha MHC mutant
familial hypertrophic cardiomyopathy mice. J Clin
Invest 1997; 99: 570–576.
Bevilacqua LM, Maguire CT, Seidman JG, Seidman CE,
Berul CI. QT dispersion in alpha-myosin heavy-chain
familial hypertrophic cardiomyopathy mice. Pediatr Res
1999; 45: 643–647.
Gao WD, Perez NG, Seidman CE, Seidman JG, Marban
E. Altered cardiac excitation-contraction coupling in
mutant mice with familial hypertrophic cardiomyopathy. J Clin Invest 1999; 103: 661–666.
Tyska MJ, Hayes E, Giewat M, Seidman CE, Seidman
JG, Warshaw DM. Single-molecule mechanics of
R403Q cardiac myosin isolated from the mouse model
of familial hypertrophic cardiomyopathy. Circ Res 2000;
86: 737–744.
Spindler M, Saupe KW, Christe ME et al. Diastolic dysfunction and altered energetics in the alphaMHC403/+
mouse model of familial hypertrophic cardiomyopathy.
J Clin Invest 1998; 101: 1775–1783.
Jin JP, Wang J, Ogut O. Developmentally regulated
muscle type-specific alternative splicing of the COOHterminal variable region of fast skeletal muscle troponin
T and an aberrant splicing pathway to encode a mutant
COOH-terminus. Biochem Biophys Res Commun 1998;
242: 540–544.
Vikstrom KL, Factor SM, Leinwand LA. Mice expressing
mutant myosin heavy chains are a model for familial
hypertrophic cardiomyopathy. Mol Med 1996; 2: 556–
567.
Vikstrom KL, Bohlmeyer T, Factor SM, Leinwand LA.
Hypertrophy, pathology, and molecular markers of cardiac pathogenesis. Circ Res 1998; 82: 773–778.
Welikson RE, Buck SH, Patel JR et al. Cardiac myosin
heavy chains lacking the light chain binding domain
cause hypertrophic cardiomyopathy in mice. Am J
Physiol 1999; 276: H2148–H2158.
Tardiff JC, Factor SM, Tompkins BD et al. A truncated
cardiac troponin T molecule in transgenic mice suggests
multiple cellular mechanisms for familial hypertrophic
cardiomyopathy. J Clin Invest 1998; 101: 2800–2811.
Tardiff JC, Hewett TE, Palmer BM et al. Cardiac troponin T mutations result in allele-specific phenotypes in
a mouse model for hypertrophic cardiomyopathy. J Clin
Invest 1999; 104: 469–481.
Hypertrophic cardiomyopathy 53
209 Oberst L, Zhao G, Park JT et al. Dominant-negative
effect of a mutant cardiac troponin T on cardiac structure and function in transgenic mice. J Clin Invest 1998;
102: 1498–1505.
210 Miller T, Szczesna D, Housmans PR et al. Abnormal
contractile function in transgenic mice expressing a
familial hypertrophic cardiomyopathy-linked troponin
T (I79N) mutation. J Biol Chem 2001; 276: 3743–3755.
211 Yang Q, Sanbe A, Osinska H, Hewett TE, Klevitsky R,
Robbins J. A mouse model of myosin binding protein C
human familial hypertrophic cardiomyopathy. J Clin
Invest 1998; 102: 1292–1300.
212 McConnell BK, Jones KA, Fatkin D et al. Dilated cardiomyopathy in homozygous myosin-binding proteinC mutant mice. J Clin Invest 1999; 104: 1235–1244.
213 McConnell BK, Fatkin D, Semsarian C et al. Comparison of two murine models of familial hypertrophic
cardiomyopathy. Circ Res 2001; 88: 383–389.
214 Vemuri R, Lankford EB, Poetter K et al. The stretchactivation response may be critical to the proper functioning of the mammalian heart. Proc Natl Acad Sci USA
1999; 96: 1048–1053.
215 Sanbe A, Nelson D, Gulick J et al. In vivo analysis of an
essential myosin light chain mutation linked to familial
hypertrophic cardiomyopathy. Circ Res 2000; 87: 296–
302.
216 Muthuchamy M, Pieples K, Rethinasamy P et al. Mouse
model of a familial hypertrophic cardiomyopathy mutation in alpha-tropomyosin manifests cardiac dysfunction. Circ Res 1999; 85: 47–56.
217 Evans CC, Pena JR, Phillips RM et al. Altered hemodynamics in transgenic mice harboring mutant tropomyosin linked to hypertrophic cardiomyopathy. Am J
Physiol Heart Circ Physiol 2000; 279: H2414–H2423.
218 James J, Zhang Y, Osinska H et al. Transgenic modeling
of a cardiac troponin I mutation linked to familial hypertrophic cardiomyopathy. Circ Res 2000; 87: 805–811.
219 Frey N, Franz WM, Gloeckner K et al. Transgenic rat
hearts expressing a human cardiac troponin T deletion
reveal diastolic dysfunction and ventricular arrhythmias. Cardiovasc Res 2000; 47: 254–264.
220 Marian AJ, Wu Y, Lim DS et al. A transgenic rabbit
model for human hypertrophic cardiomyopathy. J Clin
Invest 1999; 104: 1683–1692.
221 Nagueh SF, Kopelen HA, Lim DS et al. Tissue Doppler
imaging consistently detects myocardial contraction
and relaxation abnormalities, irrespective of cardiac
hypertrophy, in a transgenic rabbit model of human
hypertrophic cardiomyopathy. Circulation 2000; 102:
1346–1350.
222 Sanbe A, James J, Tuzcu V et al. Transgenic rabbit model
for human troponin I-based hypertrophic cardiomyopathy. Circulation 2005; 111: 2330–2338.
54
PART I
Cardiovascular single gene disorders
223 Gomes AV, Harada K, Potter JD. A mutation in the Nterminus of troponin I that is associated with hypertrophic cardiomyopathy affects the Ca2+-sensitivity,
phosphorylation kinetics and proteolytic susceptibility
of troponin. J Mol Cell Cardiol 2005; 39: 754–765.
224 Kruger M, Zittrich S, Redwood C et al. Effects of the
mutation R145G in human cardiac troponin I on the
kinetics of the contraction-relaxation cycle in isolated
cardiac myofibrils. J Physiol (Lond) 2005; 564: 347–357.
225 Doolan A, Tebo M, Ingles J et al. Cardiac troponin I
mutations in Australian families with hypertrophic cardiomyopathy: clinical, genetic and functional consequences. J Mol Cell Cardiol 2005; 38: 387–393.
226 Szczesna-Cordary D, Guzman G, Zhao J, Hernandez O,
Wei J, Diaz-Perez Z. The E22K mutation of myosin
RLC that causes familial hypertrophic cardiomyopathy
increases calcium sensitivity of force and ATPase in
transgenic mice. J Cell Sci 2005; 118: 3675–3683.
227 Chandra M, Tschirgi ML, Tardiff JC. Increase in tension-dependent ATP consumption induced by cardiac
troponin T mutation. Am J Physiol Heart Circ Physiol
2005; 289: H2112–H2119.
228 Javadpour MM, Tardiff JC, Pinz I, Ingwall JS. Decreased
energetics in murine hearts bearing the R92Q mutation
in cardiac troponin T. J Clin Invest 2003; 112: 768–775.
229 Palmiter KA, Tyska MJ, Haeberle JR, Alpert NR,
Fananapazir L, Warshaw DM. R403Q and L908V
mutant beta-cardiac myosin from patients with familial
hypertrophic cardiomyopathy exhibit enhanced mechanical performance at the single molecule level. J Muscle
Res Cell Motil 2000; 21: 609–620.
230 Palmer BM, Fishbaugher DE, Schmitt JP et al.
231
232
233
234
235
236
Differential cross-bridge kinetics of FHC myosin mutations R403Q and R453C in heterozygous mouse myocardium. Am J Physiol Heart Circ Physiol 2004; 287:
H91–H99.
Kremneva E, Boussouf S, Nikolaeva O, Maytum R,
Geeves MA, Levitsky DI. Effects of two familial hypertrophic cardiomyopathy mutations in α-tropomyosin,
Asp175Asn and Glu180Gly, on the thermal unfolding of
actin-bound tropomyosin. Biophys J 2004; 87: 3922–
3933.
Kobayashi T, Dong WJ, Burkart EM, Cheung HC,
Solaro RJ. Effects of protein kinase C dependent phosphorylation and a familial hypertrophic cardiomyopathy-related mutation of cardiac troponin I on structural
transition of troponin C and myofilament activation.
Biochemistry 2004; 43: 5996–6004.
Vang S, Corydon TJ, Borglum AD et al. Actin mutations
in hypertrophic and dilated cardiomyopathy cause
inefficient protein folding and perturbed filament formation. FEBS J 2005; 272: 2037–2049.
Barta J, Toth A, Jaquet K, Redlich A, Edes I, Papp Z.
Calpain-1-dependent degradation of troponin I mutants found in familial hypertrophic cardiomyopathy.
Mol Cell Biochem 2003; 251: 83–88.
Li MX, Wang X, Lindhout DA, Buscemi N, VanEyk JE,
Sykes BD. Phosphorylation and mutation of human
cardiac troponin I deferentially destabilize the interaction of the functional regions of troponin I with troponin C. Biochemistry 2003; 42: 14460–14468.
Wang Q, Moncman CL, Winkelmann DA. Mutations in
the motor domain modulate myosin activity and myofibril organization. J Cell Sci 2003; 116: 4227–4238.
4
CHAPTER 4
Dilated cardiomyopathy and
other cardiomyopathies
Mitra Esfandiarei, PhD, Bobby Yanagawa, PhD, &
Bruce M. McManus, MD, PhD, FRSC
Introduction
Cardiomyopathy or “sickness” of the heart muscle
is a condition characterized by diastolic or systolic
cardiac dysfunction in which the main abnormality
lies in the myocardium itself. This group of disorders is responsible for acute and chronic heart
failure and arrhythmias and, secondarily, disability
and death [1]. The origins and pathogenesis of
heart muscle disease are diverse, often reflecting
a collision of genetic and environmental factors,
or ecogenetics. Certain cardiomyopathies remain
completely unexplained from an etiologic or mechanistic standpoint.
Classification
Cardiomyopathies have been traditionally divided
into two main categories: primary (idiopathic) diseases of unknown causes and secondary diseases
of known causes or associated with disorders of
other systems. In defining the cardiomyopathies
clinically, it is useful to recognize the varied pathophysiology that is expressed. Both the primary and
secondary categories have three possible functional
states:
1 Hypertrophic: hyperdynamic, characterized by
massive left ventricular hypertrophy, predominantly in the septal region, variable dynamic outflow
tract obstruction, diastolic and systolic dysfunction, and a familial propensity.
2 Dilated: congestive, ventricular dilatation, systolic dysfunction, often resulting in systolic heart
failure, and less common familial tendency.
3 Restrictive: constrictive, stiff muscle and/or endocardial scarring and associated diastolic dysfunction.
To designate a cardiomyopathy as primary, acquired diseases of heart valves, coronary arteries,
pericardium and aorta, and congenital cardiac
defects must be excluded. Myocardial storage diseases and secondary endocardial diseases also must
be sought and excluded as major causes of cardiac
dysfunction.
In secondary cardiomyopathies, the cause of
myocardial abnormalities is known and may be a
manifestation of a systemic disease process [1].
Although therapy at times may be similar for primary and secondary myocardial diseases, treatment
is often distinctly different and the specific diagnosis may carry a very different prognosis. In 1995,
the World Health Organization/International Society and Federation of Cardiology (WHO/ISFC)
Task Force recommended that the cardiomyopathies be classified into specific cardiomyopathies and
primary cardiomyopathies [2]. This reorganization
was necessitated by the discovery of new entities,
not included in the 1980 WHO classification.
The specific cardiomyopathies include heart
muscle diseases associated with myocarditis, termed
inflammatory cardiomyopathy, as well as ischemic,
valvular, hypertensive diseases and those diseases
associated with cardiac or systemic disorders, such
as amyloidosis and hemochromatosis. The primary
cardiomyopathies are intrinsic to myocardium and
include dilated cardiomyopathy (DCM), arrhythmogenic right ventricular cardiomyopathy (ARVC)
and unclassified cardiomyopathies. Restrictive
55
56
PART I
Cardiovascular single gene disorders
cardiomyopathies can be classified as both primary
and secondary. Unclassified cardiomyopathies include left ventricular noncompaction, mitochondrial
cardiomyopathies and endocardial fibroelastosis.
Characterization of
cardiomyopathies
A normal healthy adult has a heart weight that correlates with his/her body size. The adult male heart
weight is in the range 250–350 g, while the adult
female heart is in the range 200–300 g. The normal
diastolic thickness of the right ventricular muscle
is <0.5 cm and that of the left <1.5 cm [3]. Ventricular thicknesses that are above these normal levels
indicate hypertrophy and increased mass, while
measurements below this index but with enlarged
chambers imply dilatation. However, dilated hearts
wherein the ventricular walls are of normal thickness still may have a marked increase in myocardial
mass.
The myocardium has a spiral layered organization formed by a syncytial-like arrangement of cardiac myocytes [4]. Myocytes are elongated and
joined to one another by intercellular junctions
(mediating cellular adhesion and transmission of
electrical impulses), accompanied by a rich supply
of larger blood vessels and capillaries, and embedded
in a dilated yet strong matrix of connective tissue
[5]. The array of contractile elements between two
adjacent Z-bands is known as a sarcomere and constitutes the contractile unit of cardiac muscle [3].
Z-bands are responsible for prominent crossstriations seen at the junction of sarcomeres and are
usually well aligned within a cell. The intercalated
discs at the cell junctions are typically undulant in
conformation.
Contractile material occupies about 50% of the
cytoplasm of myocytes and forms a continuous
mass, which is separated into myofibrils of varying
size by the interfibrillar matrix [3]. This cellular
matrix contains mitochondria, sarcoplasmic reticulum, T tubules and glycogen particles, as well
as other structures. Myofibrils are highly ordered
arrays of contractile elements.
Age-related increases in heart weight relate to
the presence of cardiac pathology. In the atria, a
progressive increase in the amount of endocardial
elastic tissue and collagen is observed with age, in
addition to a proportionate decrease in muscle
mass and an increase in fat [6]. Thus, the endocardium in the atria and over the atrial surface of
the atrioventricular (AV) valves becomes thicker
and more opaque. Not only is there proliferation
of collagen, but also progressive fragmentation,
disorganization and irregularity as shown with various stains [7]. The ventricles show a small but
significant increase in collagen, and the amount of
myocyte lipofuscin pigment increases substantially
with age [8]. Basophilic myofiber degeneration is
also strongly age-associated, appearing as amorphous, at times bubbly, basophilic masses in myocyte
cytoplasm upon hematoxylin and eosin staining.
Thickening and nodularity along the lines of apposition of the valve cusps and leaflets is prominent,
as well as lipid accumulation appearing in the basal
anterior mitral leaflet. The collagen of the aortic valve
and mitral ring undergoes changes with maturity.
Lipid begins to accumulate and calcification is
often seen with maturity and senescence.
In the postnatal period, cardiac myocytes are
typically believed to be terminally differentiated,
nondividing cells. While recent discussions have
suggested that myocytes may under certain conditions undergo cell division, in general the responses
of myocytes to physiologic or pathologic stimuli include altered synthesis of DNA, RNA and protein,
the evolution of increased myocyte heterogeneity
[9], and modified enzymic and metabolic profile.
The question clearly remains as to when a myocyte in the heart becomes “sick.” Thus, an increase
in size of myocytes, commonly termed hypertrophy,
may be an appropriate or inappropriate response to
injury, leading to compensated or decompensated
function. The relationship between hypertrophic
and atrophic changes and altered ventricular mechanical geometry remains to be understood.
When myocardial injury leads to frank cell
drop-out, the process involves one of the cell death
pathways. By convention, the types of necrosis are
usually designated coagulation (coagulative necrosis), contraction band (coagulative myocytolysis)
and vacuolar degeneration (colliquative myocytolysis) [10]. The most common form of myocyte
necrosis, coagulation type, is typically associated
with myocardial ischemia and represented by the
loss of striations, hypereosinophilia, drop-out of
stainable nuclei and a generally amorphous appear-
CHAPTER 4
ance of dead tissues and cells. The loss of contractile
capability leads to alterations in neighboring viable
myocytes as well as in the geometry of the pumping
chambers. The extent of loss resulting from coagulative necrosis will determine the ultimate degree of
heart failure and the eventuation of circulatory
instability. Contraction bands are more often associated with the margins of myocardial infarcts, as
well as with ischemia-reperfusion injury [11].
The evolution of hypertrophy and atrophy of
cardiac myocytes in a myopathic heart muscle represents the divergent pathways that a myocyte
may take in response to injury. Thus, a myocyte
may be lost through a process of diminished synthesis of cell constituents or may become enlarged
through enhanced synthesis. The variability in
myocyte size and configuration, as well as that of
the nuclei, should be a signal, in part, to the nature
of an injury or insult. Efforts to distinguish these
responses have generally not been successful at the
light microscopic level in the chronically failing or
cardiomyopathic heart muscle. However, highresolution image cytometry may be useful in beginning to understand the stereotypic and idiosyncratic
responses of cardiac myocytes to injury, and the
relationship between distinctive nuclear features
and measures of cardiac myocyte function, gene
expression or metabolism [12]. Myofibrillar and
cytoskeletal changes in cardiac myocytes are also
being studied in depth [13]. An understanding of
these relationships represents one of the remaining
important goals in myocardial diseases.
The myocardial interstitium has an intimate
relationship with the cardiac myocytes that it envelopes. Much work has been done to define the
evolution of aberrant cardiac matrix and the impact of such matrix on cardiac diastolic and systolic
function [14]. Undoubtedly, an increased amount
or altered nature of cardiac connective tissue impacts
on the relationship between individual and groups
of myocytes, thereby changing the electrical and
physiologic status of the myocardium in question.
Appreciation of interactions between matrix and
myocytes will be linked to the emergent understanding of cardiac myocyte gap junctions [15,16].
Familial dilated cardiomyopathy
Idiopathic dilated cardiomyopathy (IDCM) is a
primary myocardial disease, often of unknown
Dilated cardiomyopathy 57
cause, characterized by predominant left ventricular or biventricular dilatation and impaired
myocardial contractility [17]. The pathophysiologic features of DCM include increased ventricular
volume with ventricular wall thinning and moderate to severe reduction of contractile function [18].
In contrast, hypertrophic cardiomyopathy (HCM)
is characterized by markedly thickened ventricular walls and distinctive histopathologic features,
notably myocyte disarray with interstitial fibrosis,
accompanied by hyperdynamic contractile function with reduced ventricular volumes. IDCM is
the most common cause of congestive heart failure
in the young, with an estimated prevalence of at
least 36.5 per 100,000 in the USA. Among patients with IDCM, at least 30% of deaths are sudden,
usually attributed to ventricular tachyarrhythmias
[19]. The 5-year survival is <50% [20]. Approximately 50% of cardiac transplants are consequent to
IDCM.
Familial DCM is defined as the presence of
IDCM in two or more family members, as determined from a thorough family history. A positive
clinical history of DCM in relatives of probands has
yielded a prevalence of <10% of familial disease.
However, the incidence of familial DCM is likely
underestimated given the diversity of presentations
and variability in penetrance leading to many early
cases being unrecognized and virtually undetected
clinically [18,21]. In fact, when first degree relatives
of probands were assessed by physical examination, 12-lead electrocardiography and transthoracic
echocardiography, regardless of the presence of
symptoms, up to 35% were found to have DCM
[18,22,23]. Overall, it is estimated that roughly 30%
of individuals with IDCM have a significant familial, heritable component [24,25]. The incidence of
IDCM has been estimated to be 5–8 cases per
100,000 per year [17,26–28], accounting for 10,000
deaths in the USA annually [29]. Affected individuals may have a relatively benign course, or
develop progressive heart failure or experience sudden death from severe heart failure or ventricular
arrhythmias. In general, the 5-year survival following a diagnosis of congestive cardiac failure in
patients with familial DCM is 50% [17].
Molecular genetics, particularly linkage analysis,
continues to facilitate the identification of genes
and/or candidate genes responsible for the various
58
PART I
Cardiovascular single gene disorders
Table 4.1 Gene mutations and chromosomal locations in dilated cardiomyopathy (DCM).
Gene
Chromosomal
Phenotype
Inheritance
Duchenne/Becker type muscular
X-linked
Reference
location
Dystrophin
Xp21
61,64–72
dystrophy, X-linked DCM
Emerin
Xq28
Emery–Dreifuss muscular dystrophy
X-linked
Tafazin
Xq28
Barth syndrome
X-linked
37,73,75
Desmin
–
DCM
Autosomal dominant
35,36,48–52
Lamins A/C
1q11–q23
Emery–Dreifuss muscular dystrophy
Autosomal dominant
39
Lamins A/C
1p1–q21
DCM, conduction system disease
Autosomal dominant
a, b, g, d Sarcoglycans
–
DCM, limb girdle muscular dystrophy
Autosomal dominant
Actin
15q14
DCM
Autosomal dominant
94
Actin
2q31
DCM
Autosomal dominant
98
Actin
9q13–q22
DCM
Autosomal dominant
99
Actin
1q32
DCM
Autosomal dominant
97
Actin
10q21–q23
Mitral valve prolapse
Autosomal dominant
100
Actin
1p1–1q1
DCM, conduction system disease
Autosomal dominant
101
Actin
3p22–p25
DCM, conduction system disease
Autosomal dominant
102
Actin
2q14–q22
DCM, conduction system disease
Autosomal dominant
106
Actin
6q23
DCM, conduction system disease
Autosomal dominant
103
Actin
1q11–q21
DCM, limb girdle muscular dystrophy
Autosomal dominant
105
Actin
6q12–q16
DCM
Autosomal dominant
104
Actin
14q12
DCM
Autosomal dominant
81
forms of DCM [30,31]. The pattern of inheritance
of familial DCM is variable and is most commonly
autosomal dominant; but X-linked, autosomal recessive and mitochondrial inheritance also exist
[32–34]. It has also become clear that these diseases
are highly heterogeneous, with multiple genes
identified for each of the major forms of cardiomyopathy. They exhibit marked clinical variability
and can present alone, with conduction-system disease (sinus bradycardia, atrioventricular conduction
block, atrial tachyarrhythmias) or with skeletal
myopathy.
Grunig et al. [22] analysed the pedigrees of 445
consecutive patients with angiographically proven DCM and found that in 48 cases the patient
(10.8%) had at least one additional first degree relative with DCM. The phenotypic groups identified in
the 48 cases of familial DCM include DCM with
muscular dystrophy, juvenile DCM with a rapidly
progressive course in male relatives without muscular dystrophy, DCM with segmental hypokinesia
of the left ventricle, DCM with conduction defects
and DCM with sensorineural hearing loss. Gene
mutations known to cause dilated cardiomyopathy
124,125
40
107–112
include defects in the cytoskeletal proteins dystrophin [32], desmin [35,36], tafazzin [37,38] and
lamins A/C [39,40], which cause ventricular dysfunction with conduction system diseases, as well
as myocardial and skeletal muscle dysfunction.
Table 4.1 summarizes mutations in known genes as
well as published mutations in chromosomal loci
that result in DCM.
Desminopathy
Desmin is the key intermediate-filament protein
(type III) of cardiac and skeletal muscle supporting
the structural arrangement of myofibrils by linking
sarcomeres to the sarcolemma membrane [41,42].
In the heart, desmin is particularly abundant in the
Purkinje fibers [43] and in cardiomyocytes, where
it forms a double-banded structure at intercalated
discs, at regular intervals along the sarcolemma
[44,45]. Desmin filaments exist at the periphery of
the Z-disc in striated muscle, where they keep adjacent myofibrils in lateral alignment [41]. It forms a
three-dimensional scaffold around the myofibrillar
Z-disc and interconnects the contractile apparatus
with the subsarcolemmal cytoskeleton, the nuclei
CHAPTER 4
and other organelles. A single gene on human chromosome 2q35 encodes this muscle-specific protein
[46].
Desminopathies present with heterogeneous clinical phenotypes, which may include cardiomyopathy, skeletal myopathy, respiratory insufficiency,
neuropathy and smooth muscle disorders. The
characteristic features of desminopathies are a loss
of function caused by disorganization of the desmin filament network and the accumulation of
misfolded desmin or alpha-B-crystallin to form
toxic insoluble aggregates [47]. The observed clinical variation is in part dictated by type of desmin
mutation. Indeed, 21 different mutations causing
myopathy have been identified on the desmin gene.
The most common mutations are those of helix
1B (encoded by exons 4–6) on residues 155–250.
Severe disease, with a multisystem disorder involving skeletal, cardiac and smooth muscle, was
found in a homozygous boy with a large deletion
(7-amino acid, Arg173-Glu179) in the desmin gene
[48]. In seven cases associated with skeletal and cardioskeletal myopathy, residues in helix 2B (337,
345, 357, 360, 370, 385 and 389) were replaced by
proline, which disrupted the coiled-coil geometry
[36,49–52]. Two mutations have been identified in
the nonhelical tail domain, one at Lys449Thr and
the other at Ile451Met in familial DCM [35,36].
Besides desmin, a gene implicated in desminrelated myopathy is the desmin-associated protein
alpha-B-crystallin. Alpha-B-crystallin is a 22-kDa
heat shock protein with molecular chaperone activity. A missense mutation in the alpha-B-crystallin
chaperone gene on chromosome 11q22.3–q23.1 is
known to cause hypertrophic cardiomyopathy [53].
Dystrophinopathies
Dystrophin, a member of the spectrin superfamily
of proteins, is a key linker protein between the
sarcolemma of the myocyte and the contractile
apparatus, the sarcomere [54]. The dystrophin–
glycoprotein complex (DGC) is a large multimeric
complex specific to muscle cells [55]. In addition to
providing a structural link between subcortical
actin and the extracellular matrix, the DGC also
appears to be involved in signaling with components such as neuronal nitric oxide synthase, dystrobrevin and syntrophin. In its full-length form,
the dystrophin gene encodes a 427-kDa protein
Dilated cardiomyopathy 59
that is composed of an amino-terminal globular
domain, and 24 spectrin repeats that make up the
rod region of the dystrophin molecule [54]. At its
carboxyl terminus, dystrophin binds to dystroglycan and the syntrophins providing mechanical stability to the plasma membrane [56,57].
Dystrophinopathies include Duchenne muscular
dystrophy, Becker muscular dystrophy and X-linked
dilated cardiomyopathy caused by mutations in the
destrophin gene on chromosome Xp21.1 [58,59].
All patients with dystrophin deficiency are at risk
for the development of Duchenne muscular dystrophy and should be screened regularly. Dystrophin
deficiency leads to a disruption of the transmembrane complex and loss of integrity at the
sarcolemma.
Duchenne and Becker muscular dystrophy
Duchenne and Becker muscular dystrophies are
severe X-linked genetic muscular diseases affecting
approximately 1 in 3500 live male births and are the
most common, childhood onset, muscular dystrophies [60]. Cardiac myopathy in Duchenne muscular
dystrophy (DMD) may be severe and progressive,
with life-threatening heart failure and/or arrhythmias,
or may be asymptomatic for many years without
clinical features. Mutations that cause DMD are
typically deletions that are “out of frame” resulting
in a dysfunctional protein [61]. The standard diagnostic evaluation for cardiac involvement, the echocardiogram, is a noninvasive method of evaluating
left ventricular (LV) size and systolic function,
allowing one to analyze a variety of more subtle
parameters [62].
Becker muscular dystrophy (BMD) is also an
X-linked DCM characterized with later onset and
a slower progression of skeletal and cardiac myopathy. The prevalence of BMD is almost one-tenth
of the frequency of DMD [59]. There are reports
that a more severe form of BMD is associated with
mutations in the promoter region (5′ aminoterminal end) of the dystrophin gene [59]. Thus far,
several mutations in the dystrophin gene have been
identified at the mRNA level in BMD patients
[63–72].
Barth syndrome
The cardiac manifestations of Barth syndrome
include left ventricular dilatation, endocardial
60
PART I
Cardiovascular single gene disorders
fibroelastosis or a dilated hypertrophied left ventricle caused by mutations in the gene G4.5 on
chromosome Xq28, which encodes the protein
tafazzin [37]. The function of the tafazzin protein is
unknown, but mutations in the G4.5 gene appear
to be responsible for a diverse spectrum of cardiac
disease with unique clinical phenotypes, including
classic DCM, endocardial fibroelastosis and left
ventricular noncompaction (LVNC) with or without clinical features of Barth syndrome (isolated
LVNC). Recently, an autosomal recessive mutation
at 3q26.33 in the DNAJC19 gene was found to
cause a Barth-like syndrome, which includes early
onset dilated cardiomyopathy with conduction
defects, in the Canadian Dariusleut Hutterite population [73].
X-linked dilated cardiomyopathy
The X-linked DCM (X-LDCM) is a heterogeneous
inherited cardiomyopathy and has been shown to
be an allelic disorder to DMD, BMD and Barth syndrome [32,74,75]. X-LDCM occurs mostly in males
during adolescence or early adulthood, with a
rapidly progressive clinical course. The infantile
form of X-LDCM and Barth syndrome typically
presents in male infants and is characterized by
neutropenia, 3-methylglutaconic aciduria, mitochondrial dysfunction and growth retardation
[76]. X-LDCM is associated with increased serum
creatine kinase (CK), cardiac phenotype, without
clinical signs of skeletal myopathy and is caused by
mutations in the dystrophin gene [77,78]. Several
types of mutations including the deletion of the
dystrophin muscle-promotor region [75], a stop
mutation and alternative splicing of exon 29 [79]
and a point mutation in the 5′ splice site of dystrophin gene have been reported in Barth syndrome [80].
first shown to cause primary familial DCM, which
was subsequently confirmed in another family
[81,85]. The autosomal recessive TnI A2V mutation at the N terminus has been also shown to cause
DCM [82]. HCM resulting from a mutation in TnT
has a distinctive phase of dilatation [86]. Troponin
mutation R141W may cause calcium desensitization through stabilization of the troponin and
T-tropomyosin interaction leading to DCM [87].
Recently, a TnC mutation at G159D was reported
to trigger DCM [84].
The functional consequences in DCM are different and less well understood than in HCM.
However, the sarcomere mutations that have been
shown to cause dilated cardiomyopathy are likely
to diminish the mechanical function of cardiac
myocytes. TnT mutation ∆K210 is located in a
domain responsible for calcium-sensitive TnC
binding and in an experimental setting had a calcium desensitizing effect on force generation in isolated cardiomyocytes [87–89]. Three of these basic
residues (lysine 208, 209 and 210) participate in
forming a tight binary complex with TnC, possibly
by means of complementary interactions with a
ring of acidic residues located on the surface of TnC
[90–92]. Loss of TnT lysine residue 210 should
reduce these ionic interactions and diminish activation of calcium-stimulated actomyosin ATPase,
just as occurs with mutagenesis of TnC acidic
residues [92], leading to a significant reduction
in contraction force. The Gly to Asp substitution
(G159D) on TnC gene causes DCM and reduces
the rate of force development [84]. Decreased calcium sensitivity leads to reduced force generation,
impinging on systolic cardiac function and stroke
volume, and ventricular dilatation. Notably, none
of the mutations in cardiac TnT that cause hypertrophic cardiomyopathy alters lysine residues in
the calcium-sensitive TnC-binding domain.
Troponin mutations
Troponin is a sarcomeric protein with a central role
in calcium regulation during contraction. The troponin complex consists of T (TnT), I (TnI) and C
(TnC) subunits. Evidence exists for mutations in
all three subunits being causative for cardiomyopathies. Although mutations in the troponin gene
are mainly associated with HCM, mutations for
TnT, TnI and TnC have been also shown to cause
DCM [81–84]. The TnT mutation at ∆K210 was
Myosin and actin mutations
The location of cardiac myosin mutations that
cause DCM suggests that such mutations impair
contractile function. In this regard, Ser532Pro
maps within an α-helical structure of the lower
50 kDa domain in myosin that contributes to the
tight binding of actin [93]. This mutation disrupts
stereospecific interactions between myosin and
actin critical for initiating the power stroke of
CHAPTER 4
contraction. Demonstration that mutations in cardiac β-myosin heavy chain and cardiac TnT, along
with two previously reported mutations in cardiac
actin, cause DCM implicates mutations in other
sarcomeric genes in causing this disorder [94–96].
Mutations in the gene encoding cardiac actin
(15q14) have been shown in two unrelated families
diagnosed with familial DCM [94]. To date, disease
loci have been defined on chromosomes 1p1–1q1,
6q23, 3p22–25, 6q12–16, 1q32, 2q11–22, 2q31, 9q13–
22, 10q21–23 and 14q11.2–13 [81,94,97–106].
Laminin-2 (merosin) mutations
Laminin-α2 is an extracellular matrix protein
that acts with dystrophin and dystroglycan to
mechanically link the actin cytoskeleton and the
extracellular matrix. Mutations in the gene encoding the α2 chain of laminin-2 produce congenital
muscular dystrophy [107]. As this gene is also
expressed in the nervous system, laminin-α2 mutations can produce central and peripheral nervous
system defects in addition to a severe skeletal
muscular dystrophy and a mild cardiomyopathic
phenotype [108].
Sarcoglycanopathies
Sarcoglycans are dystrophin-associated glycoproteins, which function to stabilize the interaction
between α- and β-dystroglycan [109]. There are six
sarcoglycan genes described so far: α, β, γ, δ, ε and
ζ. Of them, α, β, γ and δ form a subcomplex in striated muscle and mutations in either one of the
sarcoglycan genes results in different forms of a
limb-girdle muscular dystrophy (LGMD-2D, -2E,
-2C and -2F, respectively) [110–114].
Titin mutations
Titin, an abundant and giant sarcomeric protein,
spans a significant part of the sarcomere and its
mutations underlie a form of autosomal dominant
DCM. At its N terminus, titin binds α-actinin at the
Z-band, while it interacts with myosin-binding
protein C and myomesin in the M domain [115].
Titin is composed of a number of immunoglobulin
domains that are thought to provide elastic recoil to
the muscle and participate in passive tension [115].
There are at least two splice forms of titin, one of
which (N2BA) provides greater stiffness. The two
major splice forms, N2B and N2BA, have varying
Dilated cardiomyopathy 61
expression in pathologic states such as DCM and
pressure-overload hypertrophy [116,117]. The differential ratio of titin isoforms likely results from
adaptive or maladaptive changes in gene expression
in response to increased load.
In addition to the changes in functional titin
splice forms, inherited mutations in titin may lead
to cardiac and skeletal muscle myopathies. Genetic
mutations in titin have been reported in several
cases of familial DCM [118,119]. A variety of mutations has been described in these families including
missense and splice site mutations. Very recently,
mutations in the titin gene have been reported in
patients with tibial muscular dystrophy [120].
Mutations in titin affect the terminal feature of this
giant protein and alter one of the predicted binding sites for the calcium-activated protease, calpain. Autosomal recessive mutations in calpain-3,
a muscle-specific form of calpain, cause a relatively common form of muscular dystrophy [121].
Calpain-3-associated LGMD is not thought to be
associated with cardiomyopathy and appears to be
more involved in regulating the passive stiffness of
the myocyte sarcomere. Siu et al. [98] mapped
familial DCM in three generations with autosomal
dominant transmissions of DCM to chromosome
2q31. Interestingly, although the titin gene resides
in this region, it did not co-segregate with disease in
affected individuals.
Emery–Dreifuss muscular dystrophies
Lamins A/C are intermediate filament proteins,
located in inner nuclear membrane, with a central
rod-like structure flanked by amino- and carboxylterminal globular domains. Missense mutations
scattered along the length of the lamins A/C
sequence have now been described in DCM subjects in the absence of skeletal muscle disease. Like
other intermediate filament proteins, lamins A/C
aggregate into parallel, coiled-coil structures that
can assemble into a higher order, head-to-tail
filament. Overall, lamins are thought to provide
structure to the nuclear membrane and can directly
bind chromatin [122].
Genetic defects in lamins A/C (1p1–q21) were
first discovered in association with an autosomal
dominantly inherited Emery–Dreifuss muscular
dystrophy (EDMD) phenotype [39]. The autosomal dominant and recessive variants are presented
62
PART I
Cardiovascular single gene disorders
with isolated DCM, conduction-system disease,
lipodystrophy and other phenotypes.
EDMD is a genetically heterogeneous X-linked
disorder characterized by muscle weakness, contractures, AV nodal heart block and cardiomyopathy [123,124]. X-linked EDMD is caused by
mutations in the STA gene encoding the nuclear
protein emerin, a 34-kDa protein of the inner
nuclear membrane. Emerin associates with the
membrane through its carboxyl terminus and contains an LEM (Lamina-associated polypeptide-2,
Emerin, MAN1 antigen) domain that binds directly
to chromatin. Thus, emerin participates directly in
a link from the nuclear membrane cytoskeleton
(nucleoskeleton) to chromatin itself suggesting a
role in the regulation of DNA synthesis or gene
expression [123].
Cardiac involvement in EDMD is characterized
by AV conduction defects, which start with sinus
bradycardia, prolongation of the PR interval on
electrocardiography (ECG), and evolution to heart
block, atrial flutter and complete atrial paralysis [123].
A recent report describes two brothers with a relatively severe variant of EDMD who developed cardiac
symptoms in the first decade of life and evidence of
left ventricular hypokinesia in the second decade of
life [125]. Cardiac involvement in EDMD was described recently by Boriani et al. [126] who reported
the long term follow-up of 10 EDMD patients.
Arrhythmogenic right ventricular
cardiomyopathy
Arrhythmogenic right ventricular cardiomyopathy (ARVC), formally known as right ventricular
dysplasia (ARVD), is a disease of myocardium
associated with cardiac dysfunction with frequent
familial occurrence and a manifestation of arrhythmic sudden death in young adolescents and athletes. The introduction of the condition dates back
to 1960, when Dalla Volta et al. [127,128], for the
first time, reported patients with “auricularization
of the right ventricular pressure curve” and referred
to the disease as “sclerosis of the right ventricle after
a myocardial infarction without coronary obstruction.” It was only later that Vedel et al. [129] established the term “arrhythmogenic right ventricular
dysplasia” in 1978. Afterward, Marcus et al. [130]
reported 24 adult cases of ARVC/D with sustained
ventricular tachycardia of right ventricular origin.
Because of its nature as a progressive myocardial
disease of unknown etiology, ARVC has been included among cardiomyopathies by the Task Force
of WHO/ISFC [2,131,132]. The prevalence of disease is unknown because of asymptomatic, nondiagnosed or misdiagnosed cases. In the general
population, the prevalence varies from 1 in 5000 to
1 in 10,000 people [133,134]. Several groups have
reported an approximate male : female ratio of 3 : 1
in ARVC [135,136]. ARVC has been indicated as
the cause of up to 20% of sudden death, particularly
among young competitive athletes [137,138]. The
incidence of familial cases is in the range 15–50% in
the published literature [130,132,139–141].
The typical clinical presentation consists of ventricular arrhythmias with the left bundle branch
block (LBBB) pattern, a morphology indicating
right ventricular origin; and ECG depolarization/
repolarization changes mostly in the right precordial lead [56,130,142]. Pathologically, ARVC is characterized by acquired progressive degeneration,
fatty or fibro-fatty replacement and patchment-like
thinning of right ventricular myocardium causing
dilatation of the right ventricle and ventricular
tachycardia (VT) or ventricular fibrillation (VF)
[132,142]. Among other manifestations are subtle
wall aneurysms of the infundibular, apical and subtricuspid areas known as “triangle of dysplasia”
and, in advanced cases, bi-ventricular pump failure
caused by left ventricular involvement [132,136,
143–145].
At the microscopic level, within the subepicardial and deeper layers of right ventricular myocardium, abnormal fatty or fibro-fatty tissues
surround the normal strand of fibers causing the
slow conduction and ventricular arrhythmias in
ARVC patients. The fibro-fatty cardiomyopathic
variant is associated with considerable thinning of
right ventricular free wall and reaches from epicardium to the endocardium [136,146].
In order to establish a universal diagnostic
guideline, the Study Group on ARVC of the Working Group Myocardial and Pericardial Disease
of the European Society of Cardiology and of the
Scientific Council on Cardiomyopathies of the
ISFC proposed the standardized major and minor
diagnostic criteria encompassing structural, histologic, electrocardiographic, arrhythmic and genetic
factors. Diagnosis of ARVC must be based on the
CHAPTER 4
presence of two major criteria, or one major plus
two minor criteria, or four minor criteria [135,147,
148]. Assessment of structural, functional and histologic alterations can be performed with echocardiography, magnetic resonance imaging (MRI),
ultrafast computed tomography (CT), conventional or radionuclide angiography (right ventricular angiography as the gold standard), invasive
electrophysiologic study (EPS) and endomyocardial biopsy [136,143,148]. The existence of adipose
and fibrous tissue between or around surviving
myocardial fibers is the gold standard for pathologic diagnosis of ARVC [148,149].
Therapy must be directed towards prevention
of sudden cardiac death (SCD) and/or treatment
of heart failure, if present. In patients with nonlifethreatening and well-tolerated ventricular arrhythmias, pharmacologic therapy could be the
first choice. In case of life-threatening ventricular
arrhythmias, nonpharmacologic treatment such
as implantable cardioverter-defibrillator (ICD),
radiofrequency ablation and surgery can be effective [150–157]. Nevertheless, heart transplantation
is the final therapeutic alternative for unmanageable congestive heart failure or untreatable ventricular arrhythmias.
ARVC is considered among idiopathic cardiomyopathies because of unknown etiology and
pathogenesis. For the last decade, the etiology of
ARVD has been in the center of scientific debate
and advanced research. Myocyte apoptosis, inflammatory response to viral myocarditis, genetically
determined dystrophy (atrophy) and some metabolic or structural defects have been proposed as
potential mechanisms for progressive loss of right
ventricular myocardium and fibro-fatty replacement in ARVC [132,158–160]. Regardless of suggested mechanisms and apart from a few cases,
familial occurrence and genetic defects have been
reported with largely autosomal dominant traits,
variable and incomplete penetrance, and polymorphic phenotypic expression in ARVC patients
[142,161–163].
Based on several familial linkage studies, nine
loci have been associated with ARVC/D. In recent
years, loci for autosomal dominant forms have
been identified and mapped to chromosomes
14q23–q24 (ARVC/D1), 1q42–q43 (ARVC/D2),
14q12–q22 (ARVC/D3), 2q32 (ARVC/D4), 3p23
Dilated cardiomyopathy 63
(ARVC/D5), 10p12–p14 (ARVC/D6) and 12p11
(ARVC/D9) [133,157,164–169]. In addition, autosomal recessive forms of ARVC have been linked to
chromosomes 10q22 (ARVC/D7) and 6p23–p24
(ARVC/D8) [170,171]. The existence of several loci
for the autosomal dominant forms, and the absence
of any linkage to above loci in almost 50% of familial cases of ARVC provide strong indications for
higher genetic heterogeneity. Recent studies have
identified some involved genes including desmoplakin, plakophilin-2 (pkp2), cardiac ryanodine
receptor 2 (RyR2) and transforming growth factors
β1, 2, 3 (TGF-β1, 2, 3). Genes for other loci are yet
to be determined. Table 4.2 summarizes related loci
and identified gene mutations in various types of
ARVC.
Cardiac ryanodine receptor 2 mutations
Mutation in RyR2 has been associated with
arrhythmogenic right ventricular cardiomyopathy
type 2 (ARVC2, OMIM 600996), and was the first
gene mutation identified through the mapping
studies in patients with ARVC. The disease locus
was mapped to chromosome 1q42–q43 [165,168].
The same mutation has been also reported in familial polymorphic ventricular tachycardia [172] and
catecholaminergic ventricular tachycardia [153].
ARVC2 is distinctive by the presence of peculiar
polymorphic effort-induced ventricular arrhythmias, a high penetrance, a 1 : 1 male : female ratio,
and less pronounced fibro-fatty substitution than
in other ARVDs [142]. RyR2 is the cardiac counterpart of RyR1, the ryanodine receptor expressed in
skeletal muscle cells. In cardiomyocytes, RyR2 can
be activated by calcium and has a pivotal role in
electromechanical (excitation–contraction) coupling by controlling calcium release from sarcoplasmic reticulum (SR) into the cytosol. RyR2 has
a tetrameric structure consisting of four identical
565 kDa monomers. Within the cell, RyR2 binds to
four FK506 binding proteins (FKBP12.6, also
known as calstabin-2), a necessary interaction for
a stabilized and coordinated gating of calcium
channel (coupled gating) [173–175].
Studies in four independent families with recurrence of ARVD2 cases have revealed single nucleotide polymorphisms (SNPs) in exons 15, 28, 37
and 59 of the RyR2 gene [172]. Using polymerase
chain reaction (PCR), single-strand conformation
64
PART I
Cardiovascular single gene disorders
Table 4.2 Gene mutations and chromosomal locations in arrhythmogenic right ventricular cardiomyopathy (ARVC).
Gene
Chromosomal
Phenotype
Inheritance
Reference
133
location
TGF-b3
14q23–q24
ARVC-1, excessive fibrosis
Autosomal dominant
RyR2
1q42–q43
ARVC-2, effort-induced arrhythmias
Autosomal dominant
165,168,177
–
14q12–q22
ARVC-3
Autosomal dominant
164
–
2q32.1–q32.3
ARVC-4
Autosomal dominant
166
–
3p23
ARVC-5
Autosomal dominant
167
–
10p12–p14
ARVC-6
Autosomal dominant
169
–
10q22
ARVC-7
Autosomal recessive
170
Desmoplakin
6p23–p24
ARVC-8, impaired filament
Autosomal recessive
149,171,178,179,181
Autosomal dominant
157
Autosomal recessive
192,193
interaction, dilation
Plakophilin-2
12p11
ARVC-9, disarrayed cytoskeleton,
rupture of cardiac walls
Plakoglobin
17p21
Naxos disease, diffuse palmoplantar
keratoderma, woolly hair, ventricular
arrhythmias
RyR2, ryanodine receptor 2; TGF-b3, transforming growth factor b3.
polymorphism (SSCP) analysis, denaturing highperformance liquid chromatography (dHPLC) and
direct sequencing, Laitinen et al. [172] succeeded in
identifying invariable transmission of four of these
sequence changes (R176Q, T2504M, N2386I and
L433P) along family generations. These mutations
occur in highly conserved cytoplasmic domain of
the RyR2 protein, which is crucial for FKBP12.6
binding and proper calcium gating, causing afterdepolarization, leading to arrhythmias in ARVC
patients. At the structural level, imbalanced intracellular calcium homeostasis and massive calcium
release from SR could lead to apoptotic and/or
necrotic myocardial cell death and degeneration of
cardiac muscle, a common histologic feature of
ARVC disease [160,172,176]. Recently, a missense
mutation in exon 3 (230C→T, A77V) of the RyR2
gene has been associated with both ARVC2 and catecholaminergic polymorphic ventricular tachycardia in a family with a history of sudden death, a
potential indication of differing phenotypic expressions of the same disease [177]. These findings
underscore the importance of parallel application
of tissue examination, electrophysiologic assessment and genetic examination among family members of affected ARVC patients.
Desmoplakin mutations
Desmoplakin (DSP) was the second gene identified in association with an autosomal recessive of
ARVC type 8 [178]. DSP is the most abundant protein in desmosomes and a key constituent of the
innermost desmosomal plaque. The C terminus
of desmoplakin binds to intermediate filament
desmin, whereas the N terminus contains the putative PKC phosphorylation site, as well as binding
sites for another desmosomal protein, plakoglobin
[179]. Desmosomes are highly organized cell–cell
adhesion junctions that form mechanical coupling
between cellular intermediate filaments and the
membrane of neighboring cells. The adhesive function of desmosomes is highly dependent on the
proper functioning of desmosomal components
wherein mutations could cause cellular detachment resulting in cell death and impaired regenerative capacity of tissue in response to mechanical
stresses [180].
Norgett et al. [171] reported the first recessive
mutation in DSP in members of three Ecuadorian
families with Carvajal disease, who were homozygous for a single nucleotide deletion (7901delG)
mapped to chromosome 6p23–p24. All affected
individuals presented with clinical manifestations
CHAPTER 4
of dilated left ventricular cardiomyopathy, woolly
hair and keratoderma [171]. Thereafter, a missense
mutation (C1176G; AGC→AGG; S299R) in exon 7
of the DSP gene was reported for the first time in a
family of 26 members affected by an autosomal
dominant form of ARVC (ARVC8) spanning four
generations [178]. The study disclosed that the
mutation affects the N terminal region of DSP.
Notably, in those patients, the mutation was tolerated by epidermal tissue and left ventricular
myocardium, because there was no report of skin
disorders or left ventricular involvement [178].
However, Bauce et al. [181] reported on left ventricular involvement in half of the ARVC8 cases
while studying 38 individuals belonging to four
families carrying different DSP mutations including three missense and one mutation in intron–
exon splicing region. Their findings indicate that
ARVC8 disorders are highly associated with sudden
death as the first clinical manifestation. Primary
left-sided (left ventricular) variants of ARVC have
been increasingly reported on postmortem examination with fibro-fatty replacement restricted to
the left ventricle [182]. Recently, a heterozygous
single adenine insertion (2034insA) in DSP gene
has been shown in a large family with autosomal
dominant left-sided ARVC [149].
Of note, mutations in DSP C terminus have also
been associated with skin disorders such as autosomal dominant form of striate palmoplantar keratoderma II (SPPK2) and autosomal recessive form
of skin fragility woolly hair syndrome (SFWHS)
without any presentation of cardiac involvement
[183,184].
Plakophilin-2 mutations
Plakophilins (pkp1, -2 and -3) are a family of 42amino acid armadillo-repeat containing proteins
that are located in the outer dense plaque of desmosomes and in the nucleoplasm [185]. Plakophilins
have important roles as intermediate proteins linking cadherins with DSP and intermediate filaments.
Plakophilin-2 (pkp2) is prominent in cardiac cells
and exists in two splice forms, 2a and 2b [186]. Using co-immunoprecipitation and yeast two-hybrid
assays, Chen et al. [187] have shown pkp2 interactions with multiple desmosomal components
including DSP, plakoglobin, desmoglein 1 and 2,
and desmocollin 1a and 2a. The role of plakophilin
Dilated cardiomyopathy 65
in embryogenesis, heart morphogenesis and junctional architecture has also been demonstrated in
studies using pkp2 null mice [157].
In a study by Gerull et al. [157], heterozygous
mutations in the pkp2 gene were identified in 32 of
120 unrelated individuals of western European
descent with ARVC type 9 (ARVC9). In total, 25
pkp2 mutations, including 12 insertion-deletion
mutations, six nonsense mutations, four missense
mutations and three splice site mutations were identified and mapped to chromosome 12p11 [157].
It has been shown that in the absence of pkp2,
DSP dissociates from desmosomal plaque of cardiac cells and forms granular aggregates within the
cytoplasm [157]. Mutant pkp2 protein impairs desmosomal assembly and cardiac cell–cell junction
leading to intercellular disruption during mechanical stress or exercise. This probably explains
the high prevalence of ARVC among competitive
athletes [157].
Transforming growth factor-β3 mutations
Mutation in transforming growth factor-β (TGFβ3) gene has been associated with ARVC type 1.
ARVC1 locus was the first one identified and
mapped to chromosome 14q23–q24 [133]. TGFβ1, -2 and -3 are pleiotropic cytokines with crucial
roles in the process of wound repair and tissue
remodeling following injury. TGF-β3 is involved in
cardiac morphogenesis, mesenchymal differentiation, fibrous skeleton development, angiogenesis
and trophoblast differentiation during hypoxia
[188]. The regulatory role of the TGF-β family of
proteins in heart morphogenesis has been studied
using various knockout mice models [188].
Beffagna et al. [189] have reported mutations in
5′ untranslated region (5′UTR) and 3′UTR regions
of the TGF-β3 gene in familial ARVC1 leading to a
twofold increase in TGF-β3 synthesis. TGF-β3 has
been shown to induce fibrosis in various tissues by
increasing the expression of components of extracellular matrix and suppression of expression of
matrix metalloproteinases [28,190]. On the basis of
these findings, it is suggested that mutations in
UTR regions of TGF-β3 may lead to extensive
replacement of cardiac cells by fibrous tissue leading to disruption of electrical and mechanical signals within the heart. Members of the TGF-β family
have been also shown to regulate the expression of
66
PART I
Cardiovascular single gene disorders
desmosomal proteins such as plakoglobin, indicating a role for these growth factors in cell–cell junction assembly and stability [191].
Plakoglobin mutations
Plakoglobin (JUP, DSPIII, γ-catenin) was initially
identified during mapping studies for Naxos disease. Naxos disease was first described in the Greek
island of Naxos by Coonar et al. [192] as a familial
cardiocutaneous syndrome with clinical presentations of diffuse, nonepidermolytic palmoplantar
keratoderma, woolly hair, a high incidence of ventricular arrhythmias and sudden death in children
or young adults. Further studies in nine families
with 21 positive cases of disease led to mapping of
the gene to chromosome 17p21 [192]. A homozygous two base pair (TG) deletion in the plakoglobin
gene causes a frame-shift and premature translation termination leading to expression of a truncated form of plakoglobin [193].
Plakoglobin is located in cytosol, desmosomes
and adherens junctions and, like other desmosomal
proteins, has a fundamental role in cell–cell junction assembly through its C terminal domain [194].
Within the cytoplasm, plakoglobin also interacts
with cadherins in adherens junctions and actin in
sarcomeres [195]. A hypothesis is that mutation
in plakoglobin protein could cause defects in the
intercellular junctions and the intracellular cytoskeleton network leading to remodeling of gap
junctions and impaired electrical coupling and
conduction within myocardium [196].
Restrictive cardiomyopathy
According to the revised WHO Task Force, restrictive cardiomyopathy (RCM) is a myocardial disorder characterized by restrictive filling and reduced
diastolic volume, with rapid early filling and slow
late filling of either or both ventricles, with normal
or near-normal systolic function [2,197]. Wall
thickness may remain normal or increase, depending on the precipitating condition. RCM is the least
common type of cardiomyopathy and is classified
as primary and secondary [198].
Primary RCM includes endomyocardial fibrosis,
Löffler endocarditis and idiopathic RCM of unknown etiology [199]. Idiopathic RCM occurs in
the absence of a precipitating condition and is often
characterized by noninfiltrative interstitial fibrosis
of myocardium, skeletal myopathy and autosomal
dominant transmission. The secondary form of
RCM is often caused by precipitating pathologic
conditions classified as myocardial infiltrative diseases including amyloidosis, sarcoidosis, Gaucher
disease and Hurler disease; myocardial storage diseases such as hemochromatosis, Fabry disease and
glycogen storage disease; and endomyocardial complications including hypereosinophilic syndrome,
endomyocardial fibrosis, carcinoid, metastatic malignancy, radiation damage and anthracycline toxicity. Cardiac amyloidosis is the most prevalent and
most thoroughly investigated entity of the secondary form of RCM [200].
In RCM patients, increased stiffness of the myocardium causes excessive pressure within either or
both ventricles in order to preserve cardiac output.
When only the right ventricle is affected, common
clinical profiles include peripheral edema, ascites,
hepatomegaly and elevated jugular venous pressure
with inspiration (Kussmaul sign). With involvement of the left ventricle, exertional dyspnea, fatigue, exercise intolerance and evidence of pulmonary
edema are common presentations [197,199,201,202].
Idiopathic RCM is usually associated with distal
skeletal myopathy and manifestations of AV block,
skeletal muscle weakness and a moderate increase
in heart weight [203,204]. On microscopic examination, patchy endocardial fibrosis and frequent
fibrosis of sinoatrial and AV nodes may be observed
[203,205].
In cardiac amyloidosis, clinical presentations
consist of biatrial dilatation and enlargement, right
and/or left ventricular hypertrophy and thrombi in
the atrial appendages. On histologic examination,
the myocardium may present a rubbery texture as
well as a waxy appearance. Complete heart block
resulting from fibrosis of the AV and sinoatrial
nodes necessitating permanent pacing has been
reported [203,206]. Patchy endocardial fibrosis and
deposition of insoluble amyloid protein fibrils
within the myocardial interstitium or vessel walls
are also present [205]. There are reports of eosinophilic deposits in cardiac valves, intramyocardial
coronary arteries and within myocardial interstitium [207].
Endomyocardial fibrosis and Löffler’s endocarditis (eosinophilic cardiomyopathy) are considered
with forms of RCM associated with eosinophilia
CHAPTER 4
[208]. Studies in animal models indicate that parasitic infection could result in myocardial accumulation of eosinophils causing damage [54,209]. In
patients diagnosed with Löffler disease, valve fibrosis may lead to valvular regurgitation and AV
valve stenosis that requires valvular replacement
[210,211].
The first diagnostic dilemma is the distinction
between RCM and constrictive pericarditis, as they
have similar clinical signs and symptoms but different treatment options [212,213]. Recent reports
have suggested that tissue Doppler imaging (TDI)
and pulsed wave Doppler echocardiography (PWD)
are more reliable methods in early detection of
cardiac dysfunction in patients with amyloidosis
[214,215]. Noninvasive Tc-99m pyrophosphate
myocardial single photon emission computed
tomography (SPECT) has also been successfully
used by Casset-Senon et al. [216]. Endomyocardial
biopsy is a valuable tool for the diagnosis of cardiac
amyloidosis, where cardiac myocytes are surrounded by amyloid deposits forming the so-called
“honeycomb” pattern [217–219].
The prognosis of RCM is generally poor except
for those with reversible precipitating conditions
such as hemochromatosis. The majority of individuals affected with RCM develop progressive
deterioration as a result of congestive heart failure
[220,221]. Specific therapies are considered according to the underlying cause. In patients with
cardiac sarcoidosis, cardiac transplantation is the
ultimate therapeutic alternative. However, there
are reports of recurrence of sarcoid granulomas in
the transplanted heart [15].
Cumulative evidence confirms familial occurrence
of both autosomal dominant and recessive forms
of RCM [204,206,211,222]. Two small studies have
shown increased prevalence among girls in childhood [223,224]. Fitzpatrick et al. [203] reported an
autosomal dominant restrictive cardiomyopathy
associated with skeletal myopathy in an Italian family spanning five generations. A familial cardiomyopathy with variable hypertrophic and restrictive
presentations affecting three generations of family
members with common human leukocyte antigen
(HLA) haplotype was documented by Feld and Caspi
[225]. There are also reports of RCM associated
with desmin accumulation in families with evidence of autosomal dominant inheritance [226,227].
Dilated cardiomyopathy 67
Cardiac troponin I mutations
The contractile structure of cardiomyocyte comprises highly organized arrangements of myosin
and actin filaments and associated troponin–
tropomyocin complexes, all which form sarcomere
units. More than 200 mutations in genes for sarcomeric proteins such as α- and β-myosin heavy
chains, myosin-binding protein C, cardiac TnT and
TnI, α-cardiac actin, cardiac titin/connectin and αtropomyosin have been reported in various forms
of cardiac cardiomyopathies [228]. Troponin is
a key player in cardiac contraction and relaxation
by preventing the interaction between actin and
myosin heads to guarantee muscle relaxation and
encompasses three subunits, TnC, TnI and TnT,
each with a distinct structure and function.
TnI blocks the contractile interaction between
actin and myosin through its inhibitory region
[229,230]. In the presence of sufficient amount of
calcium, TnI regulatory domain binds to the N terminal domain of TnC, leading to removal of TnI
inhibitory action of muscle contraction. Mutation
in the TnI gene could result in cardiac malfunction,
particularly diastolic dysfunction, and has been
associated with both restrictive and hypertrophic
forms of cardiomyopathy [84].
A linkage study in 33 members of a family presenting with RMC and hypertrophic cardiomyopathy revealed a disease-causing mutation in a highly
conserved region of cardiac troponin I (TNNI3)
gene [83]. Further mutational analysis identified nucleotide substitution (87A→G) on exon 8
(D190H; lod score 4.8). Additional studies by the
same group in nine unrelated patients who had
been diagnosed with idiopathic RCM revealed that
six patients were carriers of the same TNNI3 mutations [83]. These findings indicate that idiopathic
RCM may be considered a clinical expression of
hereditary sarcomeric contractile protein disease.
To date, six novel missense mutations in human
TnI have been identified in RCM patients [83,231].
Desmin mutations
Defects in desmin and other desmin-related
filaments, such as alpha-B-crystallin and plectin,
result in myofibril fragility and impaired contraction [41,42]. Mice lacking desmin develop cardiac
and skeletal myopathy, indicating an important
role for desmin in muscle function [232,233]. In
68
PART I
Cardiovascular single gene disorders
humans, mutation in desmin has been associated
with a distinct myopathy (desmin myopathy), which
is often accompanied by cardiomyopathy. Desminrelated myopathy is considered a dominantly
inherited familial disorder, which is characterized
by aggregation of desmin in skeletal or cardiac
muscle fibers, proximal muscle weakness and cardioskeletal myopathy associated with arrhythmias
and restrictive heart failure [36]. Missense A337P
mutation on exon 5 and missense A360P and
N3931 mutations on exon 6 have been identified in
two separate families [234]. A homozygous deletion of 21 nucleotides in the desmin gene has been
also reported in a family with a history of cerebrovascular attacks [48].
Transthyretin (prealbumin) mutations
Among different types of amyloidosis, cardiac
involvement is more common in primary amyloidosis. Primary amyloidosis is a hereditary disorder
caused by the deposition of immunoglobulin light
chains, while secondary amyloidosis is a result of
deposition of proteins other than immunoglobulin.
A familial pattern has been observed in both types.
Inherited forms of cardiac amyloidosis, which is
associated with cardiomyopathic features, may be
caused by mutation in serum protein transthyretin
(TTR, prealbumin), which is produced mainly in
liver. To date, over 80 different mutations have
been reported in association with amyloid disease
[235,236]. Lafitte et al. [237] have reported the cardiac manifestations in a French family of five sisters
and one brother, three of whom presented with
amyloidosis with deposits of transthyretin and
apolipoprotein A1 resulting from a genetic mutation. A novel variant of the transthyretin gene
encoding 59Thr→Lys associated with autosomal
dominant hereditary systemic amyloidosis has
been reported in Italian kindred in whom cardiac
involvement was the major feature [238].
Fabry disease
Fabry disease is an X-linked systemic lysosomal
storage disorder caused by lysosomal α-galactosidase A deficiency resulting in accumulation of
glycosphingolipids such as globotriaosylceramide
within brain, heart, kidney, skin and vasculature
[239]. Almost 60% of males with Fabry disease present with cardiac abnormalities such as valvular
dysfunction, left ventricular hypertrophy and conduction blocks [230,240]. To date, more than 300
mutations in α-galactosidase gene on the long arm
of the X chromosome (Xq22.1) have been reported,
mostly in single families [240]. Polymorphism of
interleukin-6, eNOS, methylenetetrahydrofolate
reductase (MTHFR), prothrombin, protein Z and
factor V have also been associated with various
manifestations of Fabry disease [241–246].
Unclassified cardiomyopathies
Mitochondrial cardiomyopathies
Mitochondria serve important functions in energy
production in the form of adenosine triphosphate
(ATP) via the pyruvate dehydrogenase complex,
citrate cycle, β-oxidation, respiratory chain and
oxidative phosphorylation, as well as in the mediation of the endogenous pathway of apoptosis
[247]. The mitochondrion is especially important
to the proper function of the adult myocardium,
which has a continuous and enormous demand for
energy to fulfill its function as a circulatory pump
and to maintain ion homeostasis. Thus, the heart is
particularly susceptible to disorders of mitochondrial function. The constituents of mitochondria
are encoded largely by nuclear genes but also by
mitochondrial DNA (mtDNA), which follows a
maternal inheritance. The mitochondrial genome
encodes 13 protein subunits of the electron transport chain, 22 transfer RNAs and two ribosomal
RNAs [247]. The first nuclear mutation leading to a
mitochondrial cardiomyopathy was discovered
in 1992 [248]. Since then, over 100 point mutations have been found [249]. Mitochondriopathies
caused by nuclear DNA mutations follow a
Mendelian pattern of inheritance, either autosomal
recessive, autosomal dominant or X-linked.
Mitochondrial cardiomyopathies were first
described in 1958 by Kearns and Sayre [250].
Mitochondrial myopathy is defined as “muscle
disease characterized by structurally or numerically abnormal mitochondria and/or abnormally
functioning mitochondria” [251–253]. Several
mtDNA disorders, including Kearns–Sayre syndrome, Leber hereditary optic neuropathy and Leigh
syndrome result in a global impairment of mitochondrial respiratory function. Proteins most
frequently affected by mutations are those of the
respiratory chain and oxidative phosphorylation.
CHAPTER 4
Cardiac muscle involvement may be predominant
or minor in the clinical disease spectrum. In early
childhood, heart involvement may present with
congestive failure, cardiomegaly and lactic acidosis.
Hearts with mitochondriopathy typically show
biventricular hypertrophy and increased weight.
Occasionally, there may be ventricular dilatation or
endocardial fibroelastosis [254,255].
Ultrastructural findings in clinically significant
cases are generalized, and include qualitative as
well as quantitative mitochondrial changes. These
morphologic abnormalities of mitochondria are
usually, if not always, present in affected tissues
when the mitochondrial disease is caused by a
defect of the respiratory chain (the large majority of
which are from mutations of the mtDNA, rather
than nuclear DNA) [34]. Defects of substrate transport or utilization, on the other hand, often lack
abnormalities of mitochondrial morphology [256].
The striking pathologic finding is fusiform swelling
of cardiac myocytes with perinuclear cytoplasmic
granulation and clearing of myofibrils. The accumulation of the structurally and functionally aberrant mitochondria is thought to be responsible for
the enlargement of the myocardium [257]. Increased
numbers and pleomorphism of mitochondria are
seen on electron microscopic examination. Myofibrils are displaced by the mitochondrial hyperplasia. Qualitative abnormalities of the mitochondria
include an abundance of tubular and vesicular
cristae, concentrically arranged (“fingerprint”)
cristae, and stacked arrays of cristae.
In a recent report, the incidence of mitochondrial cardiomyopathies was estimated to be 4–5 in
100,000 live births, but may be as high as 1 in
5000–10,000 live births [258,259]. More than 95%
of the mitochondriopathies are caused by nuclear
DNA mutations, of which only a few have been
identified thus far. On the other hand, less than 5%
of mitochondriopathies are caused by mutations
in mtDNA. Mutations involving nuclear DNA are
transmitted by traditional Mendelian modes and
primarily cause defects in substrate transport and
utilization [260,261]. The prevalence of mtDNA
mutations in adults is estimated to be 1 in 50,000
[262]. Mutations in mtDNA can be germline or
somatic and have a mutation rate of several times
that of nuclear DNA, probably because of a failure of proofreading by mtDNA polymerases. Any
Dilated cardiomyopathy 69
mutations in a 16.6-kb ring structure located in the
matrix of the mitochondrion are transmitted by
maternal inheritance [263]. Typically, “mitochondrial cardiomyopathy” refers to abnormalities
resulting from mtDNA mutations. These include
deletions, most often encompassing several electron transport chain subunit coding regions, duplications and point mutations involving transfer
RNA coding regions [264].
Mutations of mtDNA, through the process of
mitotic segregation of mitochondria during embryogenesis, can show selective organ or tissue distribution. When heart is a dominant focus, clinical
presentation is usually with concentric less common asymmetric septal hypertrophic cardiomyopathy, with decreased systolic function [257]. The
Kearns–Sayre syndrome prominently features conduction disturbances [264]. “Pure” cardiomyopathy
most often presents in infancy, but initial presentation in older patients has been reported [265].
Mitochondriopathies are typically multisystem
disorders, which predominantly manifest in childhood in tissues with high oxygen consumption
such as skeletal muscle, brain and myocardium.
Mitochondriopathies are extremely phenotypically
heterogeneous with symptoms including myalgia,
fatigue, weakness, muscle cramps, muscle stiffness,
double vision, sensory disturbances, deafness, wasting and ptosis [266]. Combinations of clinical features
such as deafness, cardiomyopathy and diabetes
together with encephalopathy and myopathy are
highly susceptible of mitochondriopathy [267]. The
combination of myopathy and deafness is also highly
suggestive of mitochondriopathy, wherein the patients present with short stature, deafness and ptosis
[262]. Myopathy with or without lactic acidosis is
also the most common presenting feature [266].
Mitochondriopathy should be also considered
when dealing with an unexplained association of
manifestations with progressive course, involving
seemingly unrelated organs [258]. A known pathogenic mutation in a symptomatic individual is
regarded as diagnostic. Beyond that, the diagnostic
approach to a patient with suspected mitochondriopathy requires an integral approach, incorporating clinical, electrophysiologic, imaging, histologic,
biochemical and genetic investigations [262,268].
Mitochondrial disorders most often result in
hypertrophic cardiomypathy as in the case with
70
PART I
Cardiovascular single gene disorders
such disorders as Leber hereditary optic neuropathy, Complex I deficiency, Leigh syndrome,
Friedreich ataxia and fatty acid oxidation disorders.
However, such diseases may also result in dilated
cardiomyopathy. Cardiomyopathy, typically with
symmetrical hypertrophy, occurs with deficiency of
carnitine, an essential co-factor for mitochondrial
fatty acid oxidation. Most forms of systemic carnitine deficiency relate to defects in various enzymes
of beta-oxidation. Primary systemic carnitine deficiency, a rare autosomal recessive disorder, causes
a dilated cardiomyopathy that reverses with carnitine administration [262,268]. It is noteworthy
that mitochondrial ultrastructure in this and other
disorders of beta-oxidation, such as carnitine palmitoyltransferase II deficiency and long chain acyl
coenzyme A dehydrogenase (LCAD) deficiency, is
reported as normal [269].
Mutations in the mitochondrial genome frequently result in skeletal myopathy coincident with
cardiac defects, including DCM, HCM and conduction defects. Similarly, inborn errors in several
steps in the mitochondrial fatty acid oxidation
pathway often manifest as a hypertrophic cardiomyopathic phenotype [270–272]. Cardiomyopathy in these patients usually appears during
childhood and often presents as sudden onset heart
failure, pulmonary edema and ventricular arrhythmia brought on by metabolic stress such as periods
of fasting during infectious illness. A chronic
cardiomyopathic phenotype may also develop.
Together, these inherited metabolic cardiomyopathic disorders highlight the sensitivity of the
heart to alterations of mitochondrial function.
Leigh syndrome
Leigh syndrome, also known as subacute necrotizing encephalomyopathy is a neuropathologically
defined multisystem disorder of infancy [267].
Leigh syndrome is caused by mutations in mtDNA
or nuclear DNA genes encoding for pyruvate dehydrogenase complex or respiratory chain components [267,268]. Complex IV (COX) is composed
of 13 subunits and functions as the terminal complex of the electron-transport chain. COX-deficient
Leigh syndrome is caused by mutations in the
SURF1, NDUFS or SDHA genes [267]. Several distinct autosomal recessive mutations in COX have
been associated with Leigh syndrome. The genes
responsible are the COX assembly factors SURF1,
SCO1, SCO2 and COX10 [273,274]. In addition,
Leigh syndrome, French-Canadian type, is a human cytochrome c-oxidase deficiency, which was
recently mapped to chromosome 2p16-21 [275].
Although most often associated with hypertrophic
cardiomyopathy, Leigh syndrome may also result
in a DCM phenotype.
Kearns–Sayre syndrome
Kearns–Sayre syndrome (KSS) is caused by sporadic, single large deletions or duplications in the
mtDNA leading to a global impairment of mitochondrial respiratory function resulting in DCM
[252,256]. KSS is a subtype of chronic progressive external ophthalmoplegia (CPEO) characterized
by pigmentary retinopathy, cardiac conduction
defects, cerebellar ataxia and an onset of less than
20 years [250]. The prognosis of KSS is rather poor
as patients rarely survive beyond 30 years of age.
Myopathy, encephalopathy, lactacidosis and
stroke-like episodes (MELAS)
MELAS is an early onset encephalomyopathy [276].
Typical features comprise stroke-like episodes with
hemiparesis, hemianopsia, migraine, nausea and
vomiting. Additional features are deafness, diabetes, seizures, dementia, ataxia, cortical blindness,
optic atrophy, pigmentary retinopathy, dilative
cardiomyopathy, myopathy (87% of cases), exercise intolerance, lactic acidosis and short stature
(55% of cases) [259,277].
Several hypotheses exist for the mechanisms
relating mitochondrial dysfunction to cardiomyopathy. First, reduced ATP production caused by
mitochondrial oxidative deficit could lead to a state
of energy deprivation, especially relevant in genetic
forms of mitochondrial myopathy [278]. Second,
production of reactive oxygen species (ROS) may
be causative in the development of mitochondrialinduced metabolic cardiomyopathy [279]. Third,
unabated mitochondrial proliferation could alter
expression of structural and sarcomeric proteins
[280,281].
Glycogen storage diseases
Disorders of metabolism account for a significant proportion of “idiopathic” cardiomyopathy
in children [282]. Certain inherited disorders of
CHAPTER 4
metabolism present with a clinical picture predominated by heart disease, while in other forms
extracardiac involvement, especially nervous system and liver, dominates cardiac consequences.
Conditions significantly affecting the heart may
involve endocardium, connective tissues and myocardium; heart dysfunction may result from valvular, coronary artery or myocardial disease. The
morphologic pattern of cardiomyopathy resulting
from inherited metabolic diseases can be hypertrophic, dilated or restrictive, with or without superimposed endocardial fibroelastosis [283].
In terms of cardiomyopathies, inherited metabolic disorders weigh more importantly in infants
and children than in adults [284]. Although this
group of disorders predominantly affects central nervous system and hepatic function, expression
may primarily involve the heart. Servidei et al. [283]
classified the hereditary metabolic cardiomyopathies into four groups: glycogen storage diseases,
disorders of lipid metabolism, disorders of mitochondrial metabolism and “others” (including mucopolysaccharidoses and other storage disorders).
The gross morphology of cardiomyopathies
in storage disorders can be dilated or restrictive,
although hypertrophic is the most common pattern [285]. The classic infantile form (GSD IIa) of
Pompe disease, (acid α-1,4-glucosidase, or acid
maltase, deficiency) characteristically causes biventricular cardiomegaly and leads to cardiorespiratory failure before 1 year of age [286]. The
autosomal recessive inherited lack of lysosomal
acid α-1,4-glucosidase results in lysosomal accumulation of morphologically normal glycogen,
mainly as β-particles, in numerous cell types, but
chiefly in cardiac myocytes, skeletal muscle cells
and hepatocytes. Excessive cytoplasmic and nuclear
accumulations of glycogen also occur. Cardiomegaly, macroglossia, muscular weakness and
hypotonia develop in early infancy [286]. The heart
in a patient with infantile Pompe disease shows
marked biventricular hypertrophy, with weight up
to 6 times normal. Cardiomegaly may be evident at
birth, and is progressive. Endocardial fibroelastosis
of the left ventricle may be prominent [287]. The
left ventricle and papillary muscles are most strikingly thickened. Light microscopy shows swelling
of cardiac myocytes with central vacuolation and
peripheral displacement of myofilaments.
Dilated cardiomyopathy 71
Isolated left ventricular noncompaction
cardiomyopathy
Left ventricular noncompaction cardiomyopathy
(LVNC) is a rare congenital myocardial disorder
resulting in multiple trabeculations in the left
ventricular myocardium caused by disruption or
failure of the compaction process of the myocardial trabeculae during early fetal development
[288,289]. LVNC is generally characterized by
hypertrophic and dilated left ventricle with a clinical presentation of reduced systolic function associated with a poor prognosis [290,291].
There is evidence that LVNC is a heterogeneous
genetic disorder. A point mutation in the gene
G4.5, which encodes the tafazzin protein, has been
identified in a family with X-linked isolated LVNC,
suggesting that LVNC is likely allelic with Barth
syndrome [292]. Mutations in ZASP gene, a novel
cardiac and skeletal muscle specific Z-line protein
and α-dystrobrevin have been also reported in
families with LVNC, left ventricular dysfunction
and variable forms of congenital heart diseases
[293,294]. Deletion of the gene encoding FK binding potein 12 (FKBP12) has been shown in a noncompaction disorder in mice [295,296]. However,
to date there is no report of the same mutation
in human cases of LVNC [296]. Recently, SasseKlaassen et al. [297] proposed that isolated LVNC
in the adult is an autosomal dominant disorder in
the majority of patients. An autosomal dominant
familial transmission of LVNC has been reported
and mapped to chromosome 11p15 by the same
group [298].
Conclusions
New advances in molecular genetics have provided
effective tools for identification of single gene
defects in various forms of cardiomyopathy complications [299,300]. Understanding how mutations in different genes alter cardiac function may
further our search for potential targets for therapeutic interventions. In general, DCM disorders
are mostly caused by defects in the cytoskeleton
components causing disruption in muscle force
transmission [299]. RCM cases, on the other hand,
are frequently linked to abnormal sarcomere proteins impairing force production [83], while ARVC
abnormalities are brought about by impaired
72
PART I
Cardiovascular single gene disorders
cytoskeletal proteins implicated in cell–cell junction [178,193].
Thus far, idiopathic cardiomyopathy has been
the diagnosis of exclusion, and the classification of
inherited cardiomyopathies is mainly based on
phenotypic manifestations. However, as we gain
a better understanding of the complex genetic
etiology of such diseases, we may have better classification parameters by taking into account the
underlying gene mutations.
Current challenges that limit the value of genetic
testing for cardiomyopathies include the vast number of genes and mutations causing clinical disease.
This situation is compounded by the fact that the
majority of patients have mutations, which are yet
undefined. In addition, sensitive, reproducible,
rapid, inexpensive and high throughput DNA testing is required. Nevertheless, as we increase our
understanding of genes and diseases, genetic testing
will begin to take a more central role in the management of patients. Genetic counseling is a communication process that includes education for medical
and psychosocial issues, as well as therapy for
patients and their families. Currently, no established guidelines exist for when to refer a patient for
genetic counseling. Thus, there is a great need for
cardiologists who have expertise in genetics and
vice versa who can become guiding experts in the
genetics and genomics of cardiomyopathy. The
horizon still beckons.
References
1 Kapoor AS. The spectrum of cardiomyopathies. In:
Kapoor AS, Schroeder J, Yacoub M, eds. Cardiomyopathies and Heart-Lung Transplantation. McGraw-Hill,
Inc., New York, 1991, 3–28.
2 Richardson P, McKenna W, Bristow M et al. Report of
the 1995 World Health Organization/International
Society and Federation of Cardiology Task Force on the
definition and classification of cardiomyopathies. Circulation 1996; 93: 841–842.
3 Silver M, Silver M. Examination of the heart and of cardiovascular specimens in surgical pathology. In: Silver
M, Gotlieb A, Schoen F, eds. Cardiovascular Pathology.
Churchill Livingstone, New York, 2001, 1–29.
4 Fox CC, Hutchins GM. The architecture of the human
ventricular myocardium. Johns Hopkins Med J 1972;
130: 289–299.
5 Veinot J, Ghadially F, Walley V. Light microscopy and
ultrastructure of the blood vessels and heart. In: Silver
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
M, Gotlieb A, Schoen F, eds. Cardiovascular Pathology.
Churchill Livingstone, New York, 2001, 30–53.
Davies MJ, Pomerance A. Quantitative study of ageing
changes in the human sinoatrial node and internodal
tracts. Br Heart J 1972; 34: 150–152.
Lester W. Age-related cardiovascular changes. In: Silver
M, Gotlieb A, Schoen F, eds. Cardiovascular Pathology.
Churchill Livingstone, New York, 2001, 54–67.
Lenkiewicz JE, Davies MJ, Rosen D. Collagen in human
myocardium as a function of age. Cardiovasc Res 1972;
6: 549–555.
Campbell SE, Korecky B, Rakusan K. Remodeling of
myocyte dimensions in hypertrophic and atrophic rat
hearts. Circ Res 1991; 68: 984–996.
Baroldi G. Anatomy and quantification of myocardial
cell death. Methods Achiev Exp Pathol 1988; 13: 87–113.
Itoh S, Yanagishita T, Mukae S, Konno N, Katagiri T.
Study on reperfusion injury on sarcoplasmic reticulum
in acute myocardial ischemia. Jpn Circ J 1992; 56:
384–391.
Huhn KM, Palcic B, Wilson JE, McManus BM.
Cytometric analysis of ventricular myocyte nuclei in
idiopathic dilated cardiomyopathy: a tool for evaluation
of disease progression? Eur Heart J 1995; 16 (Supplement O): 97–99.
Simpson DG, Sharp WW, Borg TK, Price RL, Samarel
AM, Terracio L. Mechanical regulation of cardiac
myofibrillar structure. Ann N Y Acad Sci 1995; 752:
131–140.
Weber KT, Sun Y, Katwa LC. Local regulation of extracellular matrix structure. Herz 1995; 20: 81–88.
Kanter HL, Saffitz JE, Beyer EC. Cardiac myocytes
express multiple gap junction proteins. Circ Res 1992;
70: 438–444.
Davis LM, Kanter HL, Beyer EC, Saffitz JE. Distinct gap
junction protein phenotypes in cardiac tissues with disparate conduction properties. J Am Coll Cardiol 1994;
24: 1124–1132.
Dec GW, Fuster V. Idiopathic dilated cardiomyopathy.
N Engl J Med 1994; 331: 1564–1575.
Michels VV, Moll PP, Miller FA et al. The frequency of
familial dilated cardiomyopathy in a series of patients
with idiopathic dilated cardiomyopathy. N Engl J Med
1992; 326: 77–82.
Tamburro P, Wilber D: Sudden death in idiopathic
dilated cardiomyopathy. Am Heart J 1992; 124: 1035–
1045.
Fuster V, Gersh BJ, Giuliani ER, Tajik AJ, Brandenburg
RO, Frye RL. The natural history of idiopathic dilated
cardiomyopathy. Am J Cardiol 1981; 47: 525–531.
Redfield MM, Gersh BJ, Bailey KR, Ballard DJ,
Rodeheffer RJ. Natural history of idiopathic dilated cardiomyopathy: effect of referral bias and secular trend.
J Am Coll Cardiol 1993; 22: 1921–1926.
CHAPTER 4
22 Grunig E, Tasman JA, Kucherer H, Franz W, Kubler W,
Katus HA. Frequency and phenotypes of familial dilated
cardiomyopathy. J Am Coll Cardiol 1998; 31: 186–194.
23 Keeling PJ, Gang Y, Smith G et al. Familial dilated cardiomyopathy in the United Kingdom. Br Heart J 1995;
73: 417–421.
24 Felker GM, Thompson RE, Hare JM et al. Underlying
causes and long-term survival in patients with initially
unexplained cardiomyopathy. N Engl J Med 2000; 342:
1077–1084.
25 Towbin JA, Bowles NE. The failing heart. Nature 2002;
415: 227–233.
26 Bagger JP, Baandrup U, Rasmussen K, Moller M,
Vesterlund T. Cardiomyopathy in western Denmark. Br
Heart J 1984; 52: 327–331.
27 Williams DG, Olsen EG. Prevalence of overt dilated cardiomyopathy in two regions of England. Br Heart J
1985; 54: 153–155.
28 Codd MB, Sugrue DD, Gersh BJ, Melton LJ. Epidemiology of idiopathic dilated and hypertrophic cardiomyopathy. A population-based study in Olmsted County,
Minnesota, 1975–1984. Circulation 1989; 80: 564–572.
29 Gillum RF. Idiopathic cardiomyopathy in the United
States, 1970–1982. Am Heart J 1986; 111: 752–755.
30 Mestroni L, Rocco C, Vatta M, Miocic S, Giacca M.
Advances in molecular genetics of dilated cardiomyopathy. The Heart Muscle Disease Study Group. Cardiol
Clin 1998; 16: 611–621, vii.
31 Bachinski LL, Roberts R. New theories. Causes of dilated
cardiomyopathy. Cardiol Clin 1998; 16: 603–610, vii.
32 Towbin JA, Hejtmancik JF, Brink P et al. X-linked
dilated cardiomyopathy. Molecular genetic evidence of
linkage to the Duchenne muscular dystrophy (dystrophin) gene at the Xp21 locus. Circulation 1993; 87:
1854–1865.
33 Suomalainen A, Paetau A, Leinonen H, Majander A,
Peltonen L, Somer H. Inherited idiopathic dilated cardiomyopathy with multiple deletions of mitochondrial
DNA. Lancet 1992; 340: 1319–1320.
34 Kelly DP, Strauss AW: Inherited cardiomyopathies. N
Engl J Med 1994; 330: 913–919.
35 Li D, Tapscoft T, Gonzalez O et al. Desmin mutation
responsible for idiopathic dilated cardiomyopathy. Circulation 1999; 100: 461–464.
36 Dalakas MC, Park KY, Semino-Mora C, Lee HS,
Sivakumar K, Goldfarb LG. Desmin myopathy, a skeletal
myopathy with cardiomyopathy caused by mutations in
the desmin gene. N Engl J Med 2000; 342: 770–780.
37 Bione S, D’Adamo P, Maestrini E, Gedeon AK, Bolhuis
PA, Toniolo D. A novel X-linked gene, G4.5 is responsible for Barth syndrome. Nat Genet 1996; 12: 385–389.
38 D’Adamo P, Fassone L, Gedeon A et al. The X-linked
gene G4.5 is responsible for different infantile dilated
cardiomyopathies. Am J Hum Genet 1997; 61: 862–867.
Dilated cardiomyopathy 73
39 Bonne G, Di Barletta MR, Varnous S et al. Mutations in
the gene encoding lamin A/C cause autosomal dominant Emery–Dreifuss muscular dystrophy. Nat Genet
1999; 21: 285–288.
40 Fatkin D, MacRae C, Sasaki T et al. Missense mutations
in the rod domain of the lamin A/C gene as causes of
dilated cardiomyopathy and conduction-system disease. N Engl J Med 1999; 341: 1715–1724.
41 Lazarides E, Hubbard BD: Immunological characterization of the subunit of the 100 A filaments from muscle
cells. Proc Natl Acad Sci USA 1976; 73: 4344–4348.
42 Gard DL, Lazarides E. The synthesis and distribution of
desmin and vimentin during myogenesis in vitro. Cell
1980; 19: 263–275.
43 Thornell LE, Eriksson A. Filament systems in the
Purkinje fibers of the heart. Am J Physiol 1981; 241:
H291–H305.
44 Ferrans VJ, Roberts WC, Shugoll GI, Massumi RA, Ali
N. Plasma membrane extensions in intercalated discs of
human myocardium and their relationship to partial
dissociations of the discs. J Mol Cell Cardiol 1973; 5:
161–169.
45 Tokuyasu KT. Visualization of longitudinally-oriented
intermediate filaments in frozen sections of chicken cardiac muscle by a new staining method. J Cell Biol 1983;
97: 562–565.
46 Viegas-Pequignot E, Li ZL, Dutrillaux B, Apiou F,
Paulin D. Assignment of human desmin gene to band
2q35 by nonradioactive in situ hybridization. Hum
Genet 1989; 83: 33–36.
47 Goebel HH. Desmin-related neuromuscular disorders.
Muscle Nerve 1995; 18: 1306–1320.
48 Munoz-Marmol AM, Strasser G, Isamat M et al. A dysfunctional desmin mutation in a patient with severe
generalized myopathy. Proc Natl Acad Sci USA 1998; 95:
11312–11317.
49 Dagvadorj A, Goudeau B, Hilton-Jones D et al. Respiratory insufficiency in desminopathy patients caused by
introduction of proline residues in desmin c-terminal
alpha-helical segment. Muscle Nerve 2003; 27: 669–675.
50 Goudeau B, Dagvadorj A, Rodrigues-Lima F et al.
Structural and functional analysis of a new desmin variant causing desmin-related myopathy. Hum Mutat
2001; 18: 388–396.
51 Sjoberg G, Saavedra-Matiz CA, Rosen DR et al. A missense mutation in the desmin rod domain is associated
with autosomal dominant distal myopathy, and exerts a
dominant negative effect on filament formation. Hum
Mol Genet 1999; 8: 2191–2198.
52 Sugawara M, Kato K, Komatsu M et al. A novel de novo
mutation in the desmin gene causes desmin myopathy
with toxic aggregates. Neurology 2000; 55: 986–990.
53 Vicart P, Caron A, Guicheney P et al. A missense
mutation in the alpha-B-crystallin chaperone gene
74
54
55
56
57
58
59
60
61
62
63
64
65
66
67
PART I
Cardiovascular single gene disorders
causes a desmin-related myopathy. Nat Genet 1998; 20:
92–95.
Hoffman EP, Brown RH Jr, Kunkel LM. Dystrophin: the
protein product of the Duchenne muscular dystrophy
locus. Cell 1987; 51: 919–928.
Rando TA. The dystrophin–glycoprotein complex,
cellular signaling, and the regulation of cell survival in
the muscular dystrophies. Muscle Nerve 2001; 24: 1575–
1594.
Chamberlain JS, Corrado K, Rafael JA, Cox GA, Hauser
M, Lumeng C. Interactions between dystrophin and the
sarcolemma membrane. Soc Gen Physiol Ser 1997; 52:
19–29.
Lapidos KA, Kakkar R, McNally EM. The dystrophin
glycoprotein complex: signaling strength and integrity
for the sarcolemma. Circ Res 2004; 94: 1023–1031.
Cox GF, Kunkel LM. Dystrophies and heart disease.
Curr Opin Cardiol 1997; 12: 329–343.
Finsterer J, Stollberger C. The heart in human dystrophinopathies. Cardiology 2003; 99: 1–19.
Beggs AH. Dystrophinopathy, the expanding phenotype. Dystrophin abnormalities in X-linked dilated cardiomyopathy. Circulation 1997; 95: 2344–2347.
Monaco AP, Bertelson CJ, Liechti-Gallati S, Moser H,
Kunkel LM. An explanation for the phenotypic differences between patients bearing partial deletions of the
DMD locus. Genomics 1988; 2: 90–95.
Mori K, Manabe T, Nii M, Hayabuchi Y, Kuroda Y,
Tatara K. Myocardial integrated ultrasound backscatter
in patients with Duchenne’s progressive muscular dystrophy. Heart 2001; 86: 341–342.
Roberts RG, Passos-Bueno MR, Bobrow M, Vainzof M,
Zatz M. Point mutation in a Becker muscular dystrophy
patient. Hum Mol Genet 1993; 2: 75–77.
Hagiwara Y, Nishio H, Kitoh Y et al. A novel point
mutation (G-1 to T) in a 5′ splice donor site of intron 13
of the dystrophin gene results in exon skipping and is
responsible for Becker muscular dystrophy. Am J Hum
Genet 1994; 54: 53–61.
Bartolo C, Papp AC, Snyder PJ et al. A novel splice site
mutation in a Becker muscular dystrophy patient. J Med
Genet 1996; 33: 324–327.
Patria SY, Alimsardjono H, Nishio H, Takeshima Y,
Nakamura H, Matsuo M. A case of Becker muscular
dystrophy resulting from the skipping of four contiguous exons (71–74) of the dystrophin gene during mRNA
maturation. Proc Assoc Am Physicians 1996; 108: 308–
314.
Shiga N, Takeshima Y, Sakamoto H et al. Disruption of
the splicing enhancer sequence within exon 27 of the
dystrophin gene by a nonsense mutation induces partial skipping of the exon and is responsible for Becker
muscular dystrophy. J Clin Invest 1997; 100: 2204–2210.
68 Fajkusova L, Lukas Z, Tvrdikova M, Kuhrova V, Hajek J,
Fajkus J. Novel dystrophin mutations revealed by analysis of dystrophin mRNA: alternative splicing suppresses the phenotypic effect of a nonsense mutation.
Neuromusc Disord 2001; 11: 133–138.
69 Cagliani R, Fortunato F, Giorda R et al. Molecular analysis of LGMD-2B and MM patients: identification of
novel DYSF mutations and possible founder effect in
the Italian population. Neuromusc Disord 2003; 13:
788–795.
70 Tuffery-Giraud S, Saquet C, Chambert S, Claustres M.
Pseudoexon activation in the DMD gene as a novel
mechanism for Becker muscular dystrophy. Hum Mutat
2003; 21: 608–614.
71 Adachi K, Takeshima Y, Wada H, Yagi M, Nakamura H,
Matsuo M. Heterogous dystrophin mRNA produced by
a novel splice acceptor site mutation in intermediate
dystrophinopathy. Pediatr Res 2003; 53: 125–131.
72 Beroud C, Carrie A, Beldjord C et al. Dystrophinopathy
caused by mid-intronic substitutions activating cryptic
exons in the DMD gene. Neuromusc Disord 2004; 14:
10–18.
73 Davey KM, Parboosingh JS, McLeod DR et al. Mutation
of DNAJC19, a human homolog of yeast inner mitochondrial membrane co-chaperones, causes DCMA
syndrome, a novel autosomal recessive Barth syndrome-like condition. J Med Genet 2006; 43: 385–393.
74 Berko BA, Swift M. X-linked dilated cardiomyopathy. N
Engl J Med 1987; 316: 1186–1191.
75 Muntoni F, Cau M, Ganau A et al. Brief report: deletion
of the dystrophin muscle-promoter region associated
with X-linked dilated cardiomyopathy. N Engl J Med
1993; 329: 921–925.
76 Barth PG, Valianpour F, Bowen VM, et al. X-linked cardioskeletal myopathy and neutropenia (Barth syndrome):
an update. Am J Med Genet A 2004; 126: 349–354.
77 Mestroni L, Giacca M. Molecular genetics of dilated cardiomyopathy. Curr Opin Cardiol 1997; 12: 303–309.
78 Ferlini A, Sewry C, Melis MA, Mateddu A, Muntoni F.
X-linked dilated cardiomyopathy and the dystrophin
gene. Neuromusc Disord 1999; 9: 339–346.
79 Franz W, Hermann R, Cremer M et al. Novel stop mutation and alternative splicing of exon 29 in th dystrophin
gene associated with rapid progressive familial dilated
cardiomyopathy. Abstract at the European Society of
Human Gentics. Med Genetik 1995; 2: 192.
80 Milasin J, Muntoni F, Severini GM et al. A point mutation in the 5′ splice site of the dystrophin gene first
intron responsible for X-linked dilated cardiomyopathy. Hum Mol Genet 1996; 5: 73–79.
81 Kamisago M, Sharma SD, DePalma SR et al. Mutations
in sarcomere protein genes as a cause of dilated cardiomyopathy. N Engl J Med 2000; 343: 1688–1696.
CHAPTER 4
82 Murphy RT, Mogensen J, Shaw A, Kubo T, Hughes S,
McKenna WJ. Novel mutation in cardiac troponin I
in recessive idiopathic dilated cardiomyopathy. Lancet
2004; 363: 371–372.
83 Mogensen J, Kubo T, Duque M et al. Idiopathic restrictive cardiomyopathy is part of the clinical expression of
cardiac troponin I mutations. J Clin Invest 2003; 111:
209–216.
84 Mogensen J, Murphy RT, Shaw T et al. Severe disease
expression of cardiac troponin C and T mutations in
patients with idiopathic dilated cardiomyopathy. J Am
Coll Cardiol 2004; 44: 2033–2040.
85 Hanson EL, Jakobs PM, Keegan H et al. Cardiac troponin T lysine 210 deletion in a family with dilated cardiomyopathy. J Card Fail 2002; 8: 28–32.
86 Fujino N, Shimizu M, Ino H et al. A novel mutation
Lys273Glu in the cardiac troponin T gene shows high
degree of penetrance and transition from hypertrophic
to dilated cardiomyopathy. Am J Cardiol 2002; 89:
29–33.
87 Lu QW, Morimoto S, Harada K et al. Cardiac troponin
T mutation R141W found in dilated cardiomyopathy
stabilizes the troponin T-tropomyosin interaction and
causes a Ca2+ desensitization. J Mol Cell Cardiol 2003;
35: 1421–1427.
88 Morimoto S, Lu QW, Harada K et al. Ca2+-desensitizing
effect of a deletion mutation Delta K210 in cardiac troponin T that causes familial dilated cardiomyopathy.
Proc Natl Acad Sci USA 2002; 99: 913–918.
89 Jha PK, Mao C, Sarkar S. Photo-cross-linking of rabbit
skeletal troponin I deletion mutants with troponin C
and its thiol mutants: the inhibitory region enhances
binding of troponin I fragments to troponin C. Biochemistry 1996; 35: 11026–11035.
90 Leszyk J, Collins JH, Leavis PC, Tao T. Cross-linking of
rabbit skeletal muscle troponin subunits: labeling of
cysteine-98 of troponin C with 4-maleimidobenzophenone and analysis of products formed in the binary
complex with troponin T and the ternary complex with
troponins I and T. Biochemistry 1988; 27: 6983–6987.
91 Leszyk J, Dumaswala R, Potter JD, Collins JH. Amino
acid sequence of bovine cardiac troponin I. Biochemistry
1988; 27: 2821–2827.
92 Houdusse A, Love ML, Dominguez R, Grabarek Z,
Cohen C. Structures of four Ca2+-bound troponin C at 2.0
A resolution: further insights into the Ca2+-switch in the
calmodulin superfamily. Structure 1997; 5: 1695–1711.
93 Rayment I, Holden HM, Whittaker M et al. Structure
of the actin-myosin complex and its implications for
muscle contraction. Science 1993; 261: 58–65.
94 Olson TM, Michels VV, Thibodeau SN, Tai YS, Keating
MT. Actin mutations in dilated cardiomyopathy, a heritable form of heart failure. Science 1998; 280: 750–752.
Dilated cardiomyopathy 75
95 Richard P, Isnard R, Carrier L et al. Double heterozygosity for mutations in the beta-myosin heavy chain and in
the cardiac myosin binding protein C genes in a family
with hypertrophic cardiomyopathy. J Med Genet 1999;
36: 542–545.
96 Fatkin D, Christe ME, Aristizabal O et al. Neonatal cardiomyopathy in mice homozygous for the Arg403Gln
mutation in the alpha cardiac myosin heavy chain gene.
J Clin Invest 1999; 103: 147–153.
97 Durand JB, Bachinski LL, Bieling LC et al. Localization of
a gene responsible for familial dilated cardiomyopathy
to chromosome 1q32. Circulation 1995; 92: 3387–3389.
98 Siu BL, Niimura H, Osborne JA et al. Familial dilated
cardiomyopathy locus maps to chromosome 2q31.
Circulation 1999; 99: 1022–1026.
99 Krajinovic M, Pinamonti B, Sinagra G et al. Linkage of
familial dilated cardiomyopathy to chromosome 9.
Heart Muscle Disease Study Group. Am J Hum Genet
1995; 57: 846–852.
100 Bowles KR, Gajarski R, Porter P et al. Gene mapping of
familial autosomal dominant dilated cardiomyopathy
to chromosome 10q21–23. J Clin Invest 1996; 98:
1355–1360.
101 Kass S, MacRae C, Graber HL et al. A gene defect that
causes conduction system disease and dilated cardiomyopathy maps to chromosome 1p1–1q1. Nat Genet
1994; 7: 546–551.
102 Olson TM, Keating MT. Mapping a cardiomyopathy
locus to chromosome 3p22–p25. J Clin Invest 1996; 97:
528–532.
103 Messina DN, Speer MC, Pericak-Vance MA, McNally
EM. Linkage of familial dilated cardiomyopathy with
conduction defect and muscular dystrophy to chromosome 6q23. Am J Hum Genet 1997; 61: 909–917.
104 Sylvius N, Tesson F, Gayet C et al. A new locus for autosomal dominant dilated cardiomyopathy identified on
chromosome 6q12–q16. Am J Hum Genet 2001; 68:
241–246.
105 van der Kooi AJ, van Meegen M, Ledderhof TM,
McNally EM, de Visser M, Bolhuis PA. Genetic localization of a newly recognized autosomal dominant limbgirdle muscular dystrophy with cardiac involvement
(LGMD1B) to chromosome 1q11–21. Am J Hum Genet
1997; 60: 891–895.
106 Jung M, Poepping I, Perrot A et al. Investigation of a
family with autosomal dominant dilated cardiomyopathy defines a novel locus on chromosome 2q14–q22.
Am J Hum Genet 1999; 65: 1068–1077.
107 Miyagoe-Suzuki Y, Nakagawa M, Takeda S. Merosin
and congenital muscular dystrophy. Microsc Res Tech
2000; 48: 181–191.
108 Gilhuis HJ, ten Donkelaar HJ, Tanke RB et al. Nonmuscular involvement in merosin-negative congenital
76
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
PART I
Cardiovascular single gene disorders
muscular dystrophy. Pediatr Neurol 2002; 26: 30–
36.
Straub V, Duclos F, Venzke DP et al. Molecular pathogenesis of muscle degeneration in the delta-sarcoglycandeficient hamster. Am J Pathol 1998; 153: 1623–1630.
Ben Hamida M, Ben Hamida C, Zouari M, Belal S,
Hentati F. Limb-girdle muscular dystrophy 2C: clinical
aspects. Neuromuscul Disord 1996; 6: 493–494.
Lim LE, Duclos F, Broux O et al. Beta-sarcoglycan: characterization and role in limb-girdle muscular dystrophy
linked to 4q12. Nat Genet 1995; 11: 257–265.
Bonnemann CG, Modi R, Noguchi S et al. Beta-sarcoglycan (A3b) mutations cause autosomal recessive muscular dystrophy with loss of the sarcoglycan complex.
Nat Genet 1995; 11: 266–273.
Duclos F, Broux O, Bourg N et al. Beta-sarcoglycan:
genomic analysis and identification of a novel missense
mutation in the LGMD2E Amish isolate. Neuromuscul
Disord 1998; 8: 30–38.
Noguchi S, McNally EM, Ben Othmane K et al.
Mutations in the dystrophin-associated protein gammasarcoglycan in chromosome 13 muscular dystrophy.
Science 1995; 270: 819–822.
Li H, Linke WA, Oberhauser AF et al. Reverse engineering of the giant muscle protein titin. Nature 2002; 418:
998–1002.
Neagoe C, Kulke M, del Monte F et al. Titin isoform
switch in ischemic human heart disease. Circulation
2002; 106: 1333–1341.
Wu Y, Bell SP, Trombitas K et al. Changes in titin isoform expression in pacing-induced cardiac failure give
rise to increased passive muscle stiffness. Circulation
2002; 106: 1384–1389.
Gerull B, Gramlich M, Atherton J et al. Mutations of
TTN, encoding the giant muscle filament titin, cause
familial dilated cardiomyopathy. Nat Genet 2002; 30:
201–204.
Itoh-Satoh M, Hayashi T, Nishi H et al. Titin mutations
as the molecular basis for dilated cardiomyopathy.
Biochem Biophys Res Commun 2002; 291: 385–393.
Van den Bergh PY, Bouquiaux O, Verellen C et al. Tibial
muscular dystrophy in a Belgian family. Ann Neurol
2003; 54: 248–251.
Jia Z, Petrounevitch V, Wong A et al. Mutations in calpain 3 associated with limb girdle muscular dystrophy:
analysis by molecular modeling and by mutation in mcalpain. Biophys J 2001; 80: 2590–2596.
Goldman RD, Gruenbaum Y, Moir RD, Shumaker DK,
Spann TP. Nuclear lamins: building blocks of nuclear
architecture. Genes Dev 2002; 16: 533–547.
Helbling-Leclerc A, Bonne G, Schwartz K. Emery–
Dreifuss muscular dystrophy. Eur J Hum Genet 2002; 10:
157–161.
124 Bione S, Maestrini E, Rivella S et al. Identification of a
novel X-linked gene responsible for Emery–Dreifuss
muscular dystrophy. Nat Genet 1994; 8: 323–327.
125 Talkop UA, Talvik I, Sonajalg M et al. Early onset of
cardiomyopathy in two brothers with X-linked Emery–
Dreifuss muscular dystrophy. Neuromuscul Disord 2002;
12: 878–881.
126 Boriani G, Gallina M, Merlini L et al. Clinical relevance
of atrial fibrillation/flutter, stroke, pacemaker implant,
and heart failure in Emery–Dreifuss muscular dystrophy: a long-term longitudinal study. Stroke 2003; 34:
901–908.
127 Dalla Volta S, Battaglia G, Zerbini E: “Auricularization”
of right ventricular pressure curve. Am Heart J 1961; 61:
25–33.
128 Corrado D, Basso C, Thiene G et al. Spectrum of clinicopathologic manifestations of arrhythmogenic right
ventricular cardiomyopathy/dysplasia: a multicenter
study. J Am Coll Cardiol 1997; 30: 1512–1520.
129 Vedel J, Frank R, Fontaine G et al. Recurrent ventricular
tachycardia and parchment right ventricle in the adult.
Anatomical and clinical report of 2 cases. Arch Mal
Coeur Vaiss 1978; 71: 973–981.
130 Marcus FI, Fontaine GH, Guiraudon G et al. Right ventricular dysplasia: a report of 24 adult cases. Circulation
1982; 65: 384–398.
131 Giles TD. New WHO/ISFC classification of cardiomyopathies: a task not completed. Circulation 1997; 96:
2081–2082.
132 Basso C, Thiene G, Corrado D, Angelini A, Nava A,
Valente M. Arrhythmogenic right ventricular cardiomyopathy. Dysplasia, dystrophy, or myocarditis? Circulation 1996; 94: 983–991.
133 Rampazzo A, Nava A, Danieli GA et al. The gene for
arrhythmogenic right ventricular cardiomyopathy maps
to chromosome 14q23–q24. Hum Mol Genet 1994; 3:
959–962.
134 Norman MW, McKenna WJ. Arrhythmogenic right
ventricular cardiomyopathy: perspectives on disease.
Z Kardiol 1999; 88: 550–554.
135 Fontaine G, Fontaliran F, Hebert JL et al. Arrhythmogenic right ventricular dysplasia. Annu Rev Med 1999;
50: 17–35.
136 Kayser HW, van der Wall EE, Sivananthan MU, Plein S,
Bloomer TN, de Roos A. Diagnosis of arrhythmogenic
right ventricular dysplasia: a review. Radiographics 2002;
22: 639–648; discussion 649–650.
137 Shen WK, Edwards WD, Hammill SC, Bailey KR,
Ballard DJ, Gersh BJ. Sudden unexpected nontraumatic
death in 54 young adults: a 30-year population-based
study. Am J Cardiol 1995; 76: 148–152.
138 Corrado D, Thiene G, Nava A, Rossi L, Pennelli N.
Sudden death in young competitive athletes: clinico-
CHAPTER 4
139
140
141
142
143
144
145
146
147
148
149
150
151
pathologic correlations in 22 cases. Am J Med 1990; 89:
588–596.
Laurent M, Descaves C, Biron Y, Deplace C, Almange C,
Daubert JC. Familial form of arrhythmogenic right
ventricular dysplasia. Am Heart J 1987; 113: 827–829.
Buja GF, Nava A, Martini B, Canciani B, Thiene G. Right
ventricular dysplasia: a familial cardiomyopathy? Eur
Heart J 1989, 10 (Supplement D): 13–15.
Wlodarska EK, Konka M, Kepski R et al. Familial form
of arrhythmogenic right ventricular cardiomyopathy.
Kardiol Pol 2004; 60: 1–14.
Nava A, Canciani B, Daliento L et al. Juvenile sudden
death and effort ventricular tachycardias in a family
with right ventricular cardiomyopathy. Int J Cardiol
1988; 21: 111–126.
Frances RJ. Arrhythmogenic right ventricular dysplasia/cardiomyopathy. A review and update. Int J Cardiol
2006; 110: 279–287.
Dokuparti MV, Pamuru PR, Thakkar B, Tanjore RR,
Nallari P. Etiopathogenesis of arrhythmogenic right
ventricular cardiomyopathy. J Hum Genet 2005; 50:
375–381.
Lindstrom L, Nylander E, Larsson H, Wranne B. Left
ventricular involvement in arrhythmogenic right ventricular cardiomyopathy: a scintigraphic and echocardiographic study. Clin Physiol Funct Imaging 2005; 25:
171–177.
Fontaine G, Fontaliran F, Frank R. Arrhythmogenic
right ventricular cardiomyopathies: clinical forms and
main differential diagnoses. Circulation 1998; 97: 1532–
1535.
McKenna WJ, Thiene G, Nava A et al. Diagnosis of
arrhythmogenic right ventricular dysplasia/cardiomyopathy. Task Force of the Working Group Myocardial
and Pericardial Disease of the European Society of
Cardiology and of the Scientific Council on Cardiomyopathies of the International Society and Federation
of Cardiology. Br Heart J 1994; 71: 215–218.
Corrado D, Basso C, Nava A, Thiene G. Arrhythmogenic right ventricular cardiomyopathy: current diagnostic and management strategies. Cardiol Rev 2001; 9:
259–265.
Norman M, Simpson M, Mogensen J et al. Novel mutation in desmoplakin causes arrhythmogenic left ventricular cardiomyopathy. Circulation 2005; 112: 636–642.
Leclercq JF, Coumel P. Characteristics, prognosis and
treatment of the ventricular arrhythmias of right ventricular dysplasia. Eur Heart J 1989; 10 (Supplement D):
61–67.
Movsowitz C, Callans DJ, Schwartzman D, Gottlieb C,
Marchlinski FE. The results of atrial flutter ablation in
patients with and without a history of atrial fibrillation.
Am J Cardiol 1996; 78: 93–96.
Dilated cardiomyopathy 77
152 Wichter T, Borggrefe M, Haverkamp W, Chen X,
Breithardt G. Efficacy of antiarrhythmic drugs in
patients with arrhythmogenic right ventricular disease.
Results in patients with inducible and noninducible
ventricular tachycardia. Circulation 1992; 86: 29–37.
153 Priori SG, Aliot E, Blomstrom-Lundqvist C et al. Task
Force on Sudden Cardiac Death of the European Society
of Cardiology. Eur Heart J 2001; 22: 1374–1450.
154 Fontaine G, Tonet J, Gallais Y et al. Ventricular tachycardia catheter ablation in arrhythmogenic right ventricular dysplasia: a 16-year experience. Curr Cardiol Rep
2000; 2: 498–506.
155 Fontaine G, Prost-Squarcioni C. Implantable cardioverter defibrillator in arrhythmogenic right ventricular
cardiomyopathies. Circulation 2004; 109: 1445–1447.
156 Guiraudon GM, Klein GJ, Sharma AD, Yee R,
Guiraudon CM. Surgical therapy for arrhythmogenic right ventricular adiposis. Eur Heart J 1989, 10
(Supplement D): 82–83.
157 Gerull B, Heuser A, Wichter T et al. Mutations in the
desmosomal protein plakophilin-2 are common in
arrhythmogenic right ventricular cardiomyopathy. Nat
Genet 2004; 36: 1162–1164.
158 James TN. Normal and abnormal consequences of
apoptosis in the human heart. From postnatal morphogenesis to paroxysmal arrhythmias. Circulation 1994;
90: 556–573.
159 Hofmann R, Trappe HJ, Klein H, Kemnitz J. Chronic
(or healed) myocarditis mimicking arrhythmogenic
right ventricular dysplasia. Eur Heart J 1993; 14:
717–720.
160 Valente M, Calabrese F, Thiene G et al. In vivo evidence
of apoptosis in arrhythmogenic right ventricular cardiomyopathy. Am J Pathol 1998; 152: 479–484.
161 Rakovec P, Rossi L, Fontaine G, Sasel B, Markez J,
Voncina D. Familial arrhythmogenic right ventricular
disease. Am J Cardiol 1986; 58: 377–378.
162 Nava A, Scognamiglio R, Thiene G et al. A polymorphic
form of familial arrhythmogenic right ventricular dysplasia. Am J Cardiol 1987; 59: 1405–1409.
163 Canciani B, Nava A, Toso V, Martini B, Thiene G. A
casual spontaneous mutation as possible cause of the
familial form of arrhythmogenic right ventricular cardiomyopathy (arrhythmogenic right ventricular dysplasia). Clin Cardiol 1992; 15: 217–219.
164 Severini GM, Krajinovic M, Pinamonti B et al. A new
locus for arrhythmogenic right ventricular dysplasia on
the long arm of chromosome 14. Genomics 1996; 31:
193–200.
165 Rampazzo A, Nava A, Erne P et al. A new locus
for arrhythmogenic right ventricular cardiomyopathy
(ARVD2) maps to chromosome 1q42–q43. Hum Mol
Genet 1995; 4: 2151–2154.
78
PART I
Cardiovascular single gene disorders
166 Rampazzo A, Nava A, Miorin M et al. ARVD4, a new
locus for arrhythmogenic right ventricular cardiomyopathy, maps to chromosome 2 long arm. Genomics
1997; 45: 259–263.
167 Ahmad F, Li D, Karibe A et al. Localization of a gene
responsible for arrhythmogenic right ventricular
dysplasia to chromosome 3p23. Circulation 1998; 98:
2791–2795.
168 Bauce B, Nava A, Rampazzo A et al. Familial effort polymorphic ventricular arrhythmias in arrhythmogenic
right ventricular cardiomyopathy map to chromosome
1q42–43. Am J Cardiol 2000; 85: 573–579.
169 Li D, Ahmad F, Gardner MJ et al. The locus of a novel
gene responsible for arrhythmogenic right-ventricular
dysplasia characterized by early onset and high penetrance maps to chromosome 10p12–p14. Am J Hum
Genet 2000; 66: 148–156.
170 Melberg A, Oldfors A, Blomstrom-Lundqvist C et al.
Autosomal dominant myofibrillar myopathy with arrhythmogenic right ventricular cardiomyopathy linked to
chromosome 10q. Ann Neurol 1999; 46: 684–692.
171 Norgett EE, Hatsell SJ, Carvajal-Huerta L et al. Recessive mutation in desmoplakin disrupts desmoplakinintermediate filament interactions and causes dilated
cardiomyopathy, woolly hair and keratoderma. Hum
Mol Genet 2000; 9: 2761–2766.
172 Laitinen PJ, Brown KM, Piippo K et al. Mutations of
the cardiac ryanodine receptor (RyR2) gene in familial
polymorphic ventricular tachycardia. Circulation 2001;
103: 485–490.
173 Marks AR: Ryanodine receptors, FKBP12, and heart
failure. Front Biosci 2002; 7: D970–977.
174 Marx SO, Ondrias K, Marks AR. Coupled gating
between individual skeletal muscle Ca2+ release channels (ryanodine receptors). Science 1998; 281: 818–
821.
175 Brillantes AB, Ondrias K, Scott A et al. Stabilization of
calcium release channel (ryanodine receptor) function
by FK506-binding protein. Cell 1994; 77: 513–523.
176 Mallat Z, Tedgui A, Fontaliran F, Frank R, Durigon M,
Fontaine G. Evidence of apoptosis in arrhythmogenic
right ventricular dysplasia. N Engl J Med 1996; 335:
1190–1196.
177 d’Amati G, Bagattin A, Bauce B et al. Juvenile sudden
death in a family with polymorphic ventricular arrhythmias caused by a novel RyR2 gene mutation: evidence of
specific morphological substrates. Hum Pathol 2005; 36:
761–767.
178 Rampazzo A, Nava A, Malacrida S et al. Mutation in
human desmoplakin domain binding to plakoglobin
causes a dominant form of arrhythmogenic right ventricular cardiomyopathy. Am J Hum Genet 2002; 71:
1200–1206.
179 Cheong JE, Wessagowit V, McGrath JA. Molecular
abnormalities of the desmosomal protein desmoplakin
in human disease. Clin Exp Dermatol 2005; 30: 261–266.
180 Payne AS, Hanakawa Y, Amagai M, Stanley JR. Desmosomes and disease: pemphigus and bullous impetigo.
Curr Opin Cell Biol 2004; 16: 536–543.
181 Bauce B, Basso C, Rampazzo A et al. Clinical profile
of four families with arrhythmogenic right ventricular
cardiomyopathy caused by dominant desmoplakin
mutations. Eur Heart J 2005; 26: 1666–1675.
182 Michalodimitrakis M, Papadomanolakis A, Stiakakis J,
Kanaki K. Left side right ventricular cardiomyopathy.
Med Sci Law 2002; 42: 313–317.
183 Armstrong DK, McKenna KE, Purkis PE et al.
Haploinsufficiency of desmoplakin causes a striate subtype of palmoplantar keratoderma. Hum Mol Genet
1999; 8: 143–148.
184 Whittock NV, Wan H, Morley SM et al. Compound heterozygosity for non-sense and mis-sense mutations in
desmoplakin underlies skin fragility/woolly hair syndrome. J Invest Dermatol 2002; 118: 232–238.
185 Mertens C, Hofmann I, Wang Z et al. Nuclear particles
containing RNA polymerase III complexes associated
with the junctional plaque protein plakophilin 2. Proc
Natl Acad Sci USA 2001; 98: 7795–7800.
186 Mertens C, Kuhn C, Franke WW. Plakophilins 2a and
2b: constitutive proteins of dual location in the karyoplasm and the desmosomal plaque. J Cell Biol 1996; 135:
1009–1025.
187 Chen X, Bonne S, Hatzfeld M, van Roy F, Green KJ.
Protein binding and functional characterization of
plakophilin 2. Evidence for its diverse roles in desmosomes and beta-catenin signaling. J Biol Chem 2002;
277: 10512–10522.
188 Azhar M, Schultz Jel J, Grupp I et al. Transforming
growth factor beta in cardiovascular development and
function. Cytokine Growth Factor Rev 2003; 14: 391–407.
189 Beffagna G, Occhi G, Nava A et al. Regulatory mutations in transforming growth factor-beta3 gene cause
arrhythmogenic right ventricular cardiomyopathy type
1. Cardiovasc Res 2005; 65: 366–373.
190 Leask A, Abraham DJ: TGF-beta signaling and the
fibrotic response. FASEB J 2004; 18: 816–827.
191 Kapoun AM, Liang F, O’Young G et al. B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac
fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation. Circ Res 2004; 94: 453–461.
192 Coonar AS, Protonotarios N, Tsatsopoulou A et al.
Gene for arrhythmogenic right ventricular cardiomyopathy with diffuse nonepidermolytic palmoplantar
keratoderma and woolly hair (Naxos disease) maps to
17q21. Circulation 1998; 97: 2049–2058.
CHAPTER 4
193 McKoy G, Protonotarios N, Crosby A et al. Identification of a deletion in plakoglobin in arrhythmogenic
right ventricular cardiomyopathy with palmoplantar
keratoderma and woolly hair (Naxos disease). Lancet
2000; 355: 2119–2124.
194 Sacco PA, McGranahan TM, Wheelock MJ, Johnson
KR. Identification of plakoglobin domains required for
association with N-cadherin and alpha-catenin. J Biol
Chem 1995; 270: 20201–20206.
195 Knudsen KA, Wheelock MJ. Plakoglobin, or an 83-kD
homologue distinct from beta-catenin, interacts with Ecadherin and N-cadherin. J Cell Biol 1992; 118: 671–679.
196 Saffitz JE. Dependence of electrical coupling on mechanical coupling in cardiac myocytes: insights gained
from cardiomyopathies caused by defects in cell-cell
connections. Ann N Y Acad Sci 2005; 1047: 336–344.
197 Fatkin D, Graham RM. Molecular mechanisms of
inherited cardiomyopathies. Physiol Rev 2002; 82: 945–
980.
198 Abelmann WH. Classification and natural history of
primary myocardial disease. Prog Cardiovasc Dis 1984;
27: 73–94.
199 Kushwaha SS, Fallon JT, Fuster V. Restrictive cardiomyopathy. N Engl J Med 1997; 336: 267–276.
200 Asher CR, Klein AL. Diastolic heart failure: restrictive
cardiomyopathy, constrictive pericarditis, and cardiac
tamponade: clinical and echocardiographic evaluation.
Cardiol Rev 2002; 10: 218–229.
201 Child JS, Perloff JK. The restrictive cardiomyopathies.
Cardiol Clin 1988; 6: 289–316.
202 Benotti JR, Grossman W, Cohn PF. Clinical profile of
restrictive cardiomyopathy. Circulation 1980; 61: 1206–
1212.
203 Fitzpatrick AP, Shapiro LM, Rickards AF, Poole-Wilson
PA. Familial restrictive cardiomyopathy with atrioventricular block and skeletal myopathy. Br Heart J 1990; 63:
114–118.
204 Ishiwata S, Nishiyama S, Seki A, Kojima S. Restrictive
cardiomyopathy with complete atrioventricular block
and distal myopathy with rimmed vacuoles. Jpn Circ J
1993; 57: 928–933.
205 Siegel RJ, Shah PK, Fishbein MC. Idiopathic restrictive
cardiomyopathy. Circulation 1984; 70: 165–169.
206 Katritsis D, Wilmshurst PT, Wendon JA, Davies MJ,
Webb-Peploe MM. Primary restrictive cardiomyopathy: clinical and pathologic characteristics. J Am Coll
Cardiol 1991; 18: 1230–1235.
207 Hughes SE, McKenna WJ. New insights into the pathology of inherited cardiomyopathy. Heart 2005; 91:
257–264.
208 Fauci AS, Harley JB, Roberts WC, Ferrans VJ, Gralnick
HR, Bjornson BH. NIH conference. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic, and
209
210
211
212
213
214
215
216
217
218
219
220
221
222
Dilated cardiomyopathy 79
therapeutic considerations. Ann Intern Med 1982; 97:
78–92.
Schaffer SW, Dimayuga ER, Kayes SG. Development
and characterization of a model of eosinophil-mediated
cardiomyopathy in rats infected with Toxocara canis.
Am J Physiol 1992; 262: H1428–1434.
Boustany CW Jr, Murphy GW, Hicks GL Jr. Mitral valve
replacement in idiopathic hypereosinophilic syndrome.
Ann Thorac Surg 1991; 51: 1007–1009.
Gudmundsson GS, Ohr J, Leya F, Jacobs WR, Godwin
JE, Schwartz J. An unusual case of recurrent Loffler
endomyocarditis of the aortic valve. Arch Pathol Lab
Med 2003; 127: 606–609.
Yazdani K, Maraj S, Amanullah AM. Differentiating
constrictive pericarditis from restrictive cardiomyopathy. Rev Cardiovasc Med 2005; 6: 61–71.
Chinnaiyan KM, Leff CB, Marsalese DL. Constrictive
pericarditis versus restrictive cardiomyopathy: challenges in diagnosis and management. Cardiol Rev 2004;
12: 314–320.
Demir M, Paydas S, Cayli M, Akpinar O, Balal M,
Acarturk E. Tissue Doppler is a more reliable method in
early detection of cardiac dysfunction in patients with
AA amyloidosis. Ren Fail 2005; 27: 415–420.
Hancock EW. Differential diagnosis of restrictive cardiomyopathy and constrictive pericarditis. Heart 2001;
86: 343–349.
Casset-Senon D, Secchi V, Arbeille P, Cosnay P.
Localization of myocardial amyloid deposits in cardiac
amyloidosis by Tc-99m pyrophosphate myocardial
SPECT: implication for medical treatment. Clin Nucl
Med 2005; 30: 496–497.
Hesse A, Altland K, Linke RP et al. Cardiac amyloidosis:
a review and report of a new transthyretin (prealbumin)
variant. Br Heart J 1993; 70: 111–115.
Olson LJ, Gertz MA, Edwards WD et al. Senile cardiac
amyloidosis with myocardial dysfunction. Diagnosis by
endomyocardial biopsy and immunohistochemistry.
N Engl J Med 1987; 317: 738–742.
Arbustini E, Merlini G, Gavazzi A et al. Cardiac
immunocyte-derived (AL) amyloidosis: an endomyocardial biopsy study in 11 patients. Am Heart J 1995;
130: 528–536.
Huang XP, Du JF. Troponin I, cardiac diastolic dysfunction and restrictive cardiomyopathy. Acta Pharmacol
Sin 2004; 25: 1569–1575.
Rivenes SM, Kearney DL, Smith EO, Towbin JA,
Denfield SW. Sudden death and cardiovascular collapse
in children with restrictive cardiomyopathy. Circulation
2000; 102: 876–882.
Rapezzi C, Ortolani P, Binetti G, Picchio FM, Magnani
B. Idiopathic restrictive cardiomyopathy in the young:
report of two cases. Int J Cardiol 1990; 29: 121–126.
80
PART I
Cardiovascular single gene disorders
223 Cetta F, O’Leary PW, Seward JB, Driscoll DJ. Idiopathic
restrictive cardiomyopathy in childhood: diagnostic
features and clinical course. Mayo Clin Proc 1995; 70:
634–640.
224 Lewis AB. Clinical profile and outcome of restrictive
cardiomyopathy in children. Am Heart J 1992; 123:
1589–1593.
225 Feld S, Caspi A. Familial cardiomyopathy with variable
hypertrophic and restrictive features and common HLA
haplotype. Isr J Med Sci 1992; 28: 277–280.
226 Zachara E, Bertini E, Lioy E, Boldrini R, Prati PL,
Bosman C. Restrictive cardiomyopathy due to desmin
accumulation in a family with evidence of autosomal
dominant inheritance. G Ital Cardiol 1997; 27: 436–442.
227 Zhang J, Kumar A, Stalker HJ et al. Clinical and molecular studies of a large family with desmin-associated
restrictive cardiomyopathy. Clin Genet 2001; 59: 248–
256.
228 Alpert NR, Mulieri LA, Warshaw D: The failing human
heart. Cardiovasc Res 2002; 54: 1–10.
229 Wilkinson JM, Perry SV, Cole HA, Trayer IP: The regulatory proteins of the myofibril. Separation and biological activity of the components of inhibitory-factor
preparations. Biochem J 1972; 127: 215–228.
230 Layland J, Solaro RJ, Shah AM. Regulation of cardiac
contractile function by troponin I phosphorylation.
Cardiovasc Res 2005; 66: 12–21.
231 Harada K, Morimoto S; Inherited cardiomyopathies as a
troponin disease. Jpn J Physiol 2004; 54: 307–318.
232 Milner DJ, Weitzer G, Tran D, Bradley A, Capetanaki Y.
Disruption of muscle architecture and myocardial
degeneration in mice lacking desmin. J Cell Biol 1996;
134: 1255–1270.
233 Capetanaki Y, Milner DJ, Weitzer G. Desmin in muscle
formation and maintenance: knockouts and consequences. Cell Struct Funct 1997; 22: 103–116.
234 Goldfarb LG, Park KY, Cervenakova L et al. Missense
mutations in desmin associated with familial cardiac
and skeletal myopathy. Nat Genet 1998; 19: 402–403.
235 Saraiva MJ: Transthyretin mutations in health and disease. Hum Mutat 1995; 5: 191–196.
236 Frigerio R, Fabrizi GM, Ferrarini M et al. An unusual
transthyretin gene missense mutation (TTR Phe33Val)
linked to familial amyloidotic polyneuropathy. Amyloid
2004; 11: 121–124.
237 Lafitte S, Lafitte M, Perron JM, Ennouchi D, Vital C,
Roudaut R. [Cardiac manifestations of amyloidosis by
deposits of transthyretin and apolipoprotein A1. Report
of 3 families]. Arch Mal Coeur Vaiss 2003; 96: 631–635.
238 Booth DR, Tan SY, Hawkins PN, Pepys MB, Frustaci A.
A novel variant of transthyretin, 59Thr⇒Lys, associated
with autosomal dominant cardiac amyloidosis in an
Italian family. Circulation 1995; 91: 962–967.
239 Moore DF, Scott LT, Gladwin MT et al. Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement
therapy. Circulation 2001; 104: 1506–1512.
240 Masson C, Cisse I, Simon V, Insalaco P, Audran M.
Fabry disease: a review. Joint Bone Spine 2004; 71:
381–383.
241 Revilla M, Obach V, Cervera A, Davalos A, Castillo J,
Chamorro A. A-174G/C polymorphism of the interleukin-6 gene in patients with lacunar infarction.
Neurosci Lett 2002; 324: 29–32.
242 Paradossi U, Ciofini E, Clerico A, Botto N, Biagini A,
Colombo MG. Endothelial function and carotid intimamedia thickness in young healthy subjects among
endothelial nitric oxide synthase Glu298⇒Asp and
T-786⇒C polymorphisms. Stroke 2004; 35: 1305–
1309.
243 Bertina RM, Koeleman BP, Koster T et al. Mutation in
blood coagulation factor V associated with resistance to
activated protein C. Nature 1994; 369: 64–67.
244 Frosst P, Blom HJ, Milos R et al. A candidate genetic risk
factor for vascular disease: a common mutation in
methylenetetrahydrofolate reductase. Nat Genet 1995;
10: 111–113.
245 Lichy C, Kropp S, Dong-Si T et al. A common polymorphism of the protein Z gene is associated with protein Z
plasma levels and with risk of cerebral ischemia in the
young. Stroke 2004; 35: 40–45.
246 Longstreth WT Jr, Rosendaal FR, Siscovick DS et al. Risk
of stroke in young women and two prothrombotic
mutations: factor V Leiden and prothrombin gene variant (G20210A). Stroke 1998; 29: 577–580.
247 DiMauro S, Schon EA. Mitochondrial respiratory-chain
diseases. N Engl J Med 2003; 348: 2656–2668.
248 Burgeois M, Goutieres F, Chretien D, Rustin P,
Munnich A, Aicardi J: Deficiency in complex II of
the respiratory chain, presenting as a leukodystrophy in
two sisters with Leigh syndrome. Brain Dev 1992; 14:
404–408.
249 Finsterer J: Mitochondriopathies. Eur J Neurol 2004; 11:
163–186.
250 Kearns TP, Sayre GP. Retinitis pigmentosa, external
ophthalmophegia, and complete heart block: unusual
syndrome with histologic study in one of two cases.
AMA Arch Ophthalmol 1958; 60: 280–289.
251 Sengers RC, Stadhouders AM, Trijbels JM. Mitochondrial myopathies. Clinical, morphological and biochemical aspects. Eur J Pediatr 1984; 141: 192–207.
252 DiMauro S, Schon EA. Mitochondrial DNA mutations
in human disease. Am J Med Genet 2001; 106: 18–26.
253 Smeitink J, van den Heuvel L, DiMauro S. The genetics
and pathology of oxidative phosphorylation. Nat Rev
Genet 2001; 2: 342–352.
CHAPTER 4
254 Hubner G, Grantzow R. Mitochondrial cardiomyopathy with involvement of skeletal muscles. Virchows
Arch A Pathol Anat Histopathol 1983; 399: 115–125.
255 Hodgson S, Child A, Dyson M. Endocardial fibroelastosis: possible X linked inheritance. J Med Genet 1987; 24:
210–214.
256 DiMauro S, Bonilla E, Zeviani M, Nakagawa M, DeVivo
DC. Mitochondrial myopathies. Ann Neurol 1985; 17:
521–538.
257 Guenthard J, Wyler F, Fowler B, Baumgartner R.
Cardiomyopathy in respiratory chain disorders. Arch
Dis Child 1995; 72: 223–226.
258 Gillis L, Kaye E. Diagnosis and management of mitochondrial diseases. Pediatr Clin North Am 2002; 49:
203–219.
259 McFarland R, Taylor RW, Turnbull DM. The neurology
of mitochondrial DNA disease. Lancet Neurol 2002; 1:
343–351.
260 Orstavik KH, Skjorten F, Hellebostad M, Haga P,
Langslet A. Possible X linked congenital mitochondrial
cardiomyopathy in three families. J Med Genet 1993; 30:
269–272.
261 Clarke L, Dimmick J, Da A. Pathology of inherited
metabolic diseases. In: Dimmick J, Kalousek D, eds.
Developmental Pathology of the Embryo and Fetus. JB
Lippincott, Philadelphia, 1992, 199–234.
262 Chinnery PF, Turnbull DM. Clinical features, investigation, and management of patients with defects of mitochondrial DNA. J Neurol Neurosurg Psychiatry 1997; 63:
559–563.
263 Anderson S, Bankier AT, Barrell BG et al. Sequence and
organization of the human mitochondrial genome.
Nature 1981; 290: 457–465.
264 Anan R, Nakagawa M, Miyata M et al. Cardiac involvement in mitochondrial diseases. A study on 17 patients
with documented mitochondrial DNA defects. Circulation 1995; 91: 955–961.
265 Laschi R, Govoni E, Cenacchi G, Trotta F. Calcium
pyrophosphate dihydrate microcrystal-associated arthropathy. Ultrastruct Pathol 1986; 10: 395–400.
266 Finsterer J, Jarius C, Eichberger H. Phenotype variability in 130 adult patients with respiratory chain disorders. J Inherit Metab Dis 2001; 24: 560–576.
267 Leonard JV, Schapira AH. Mitochondrial respiratory
chain disorders I: mitochondrial DNA defects. Lancet
2000; 355: 299–304.
268 Fadic R, Johns DR. Clinical spectrum of mitochondrial
diseases. Semin Neurol 1996; 16: 11–20.
269 Hug G, Bove KE, Soukup S. Lethal neonatal multiorgan
deficiency of carnitine palmitoyltransferase II. N Engl J
Med 1991; 325: 1862–1864.
270 Rocchiccioli F, Wanders RJ, Aubourg P et al. Deficiency of long-chain 3-hydroxyacyl-CoA dehydrogenase:
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
Dilated cardiomyopathy 81
a cause of lethal myopathy and cardiomyopathy in early
childhood. Pediatr Res 1990; 28: 657–662.
Kelly DP, Whelan AJ, Ogden ML et al. Molecular characterization of inherited medium-chain acyl-CoA dehydrogenase deficiency. Proc Natl Acad Sci USA 1990; 87:
9236–9240.
Bennett MJ, Rinaldo P, Strauss AW. Inborn errors of
mitochondrial fatty acid oxidation. Crit Rev Clin Lab Sci
2000; 37: 1–44.
Shoubridge EA. Cytochrome c oxidase deficiency. Am J
Med Genet 2001; 106: 46–52.
Robinson BH. Human cytochrome oxidase deficiency.
Pediatr Res 2000; 48: 581–585.
Mootha VK, Lepage P, Miller K et al. Identification of a
gene causing human cytochrome c oxidase deficiency by
integrative genomics. Proc Natl Acad Sci USA 2003; 100:
605–610.
Pavlakis SG, Phillips PC, DiMauro S, De Vivo DC,
Rowland LP. Mitochondrial myopathy, encephalopathy,
lactic acidosis, and strokelike episodes: a distinctive clinical syndrome. Ann Neurol 1984; 16: 481–488.
Schapira AH, Cock HR. Mitochondrial myopathies and
encephalomyopathies. Eur J Clin Invest 1999; 29: 886–
898.
Ingwall JS, Weiss RG. Is the failing heart energy starved?
On using chemical energy to support cardiac function.
Circ Res 2004; 95: 135–145.
Ishikawa K, Kimura S, Kobayashi A et al. Increased reactive oxygen species and anti-oxidative response in mitochondrial cardiomyopathy. Circ J 2005; 69: 617–620.
Levak-Frank S, Radner H, Walsh A et al. Muscle-specific
overexpression of lipoprotein lipase causes a severe
myopathy characterized by proliferation of mitochondria and peroxisomes in transgenic mice. J Clin Invest
1995; 96: 976–986.
Tokunaga M, Mita S, Sakuta R, Nonaka I, Araki S.
Increased mitochondrial DNA in blood vessels and
ragged-red fibers in mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes
(MELAS). Ann Neurol 1993; 33: 275–280.
Bonnet D, de Lonlay P, Gautier I et al. Efficiency of
metabolic screening in childhood cardiomyopathies.
Eur Heart J 1998; 19: 790–793.
Servidei S, Bertini E, DiMauro S: Hereditary metabolic
cardiomyopathies. Adv Pediatr 1994; 41: 1–32.
Towbin JA, Lipshultz SE. Genetics of neonatal cardiomyopathy. Curr Opin Cardiol 1999; 14: 250–262.
Kohlschutter A, Hausdorf G. Primary (genetic) cardiomyopathies in infancy. A survey of possible disorders
and guidelines for diagnosis. Eur J Pediatr 1986; 145:
454–459.
Hirschhorn R. storage disease type II: Acid alphaglucosidase (acid maltase) deficiency. In: Scriver C,
82
287
288
289
290
291
292
293
PART I
Cardiovascular single gene disorders
Beaudet A, Sly W, Valle D, eds. The Metabolic and
Molecular Bases of Inherited Disease. McGraw Hill, Inc.,
New York, 1995, 2443–2464.
Dincsoy MY, Dincsoy HP, Kessler AD, Jackson MA,
Sidbury JB Jr. Generalized glycogenosis and associated
endocardial fibroelastosis. Report of 3 cases with biochemical studies. J Pediatr 1965; 67: 728–740.
Chin TK, Perloff JK, Williams RG, Jue K, Mohrmann R.
Isolated noncompaction of left ventricular myocardium. A study of eight cases. Circulation 1990; 82:
507–513.
Murphy RT, Thaman R, Blanes JG et al. Natural history
and familial characteristics of isolated left ventricular
non-compaction. Eur Heart J 2005; 26: 187–192.
Ichida F, Hamamichi Y, Miyawaki T et al. Clinical features of isolated noncompaction of the ventricular
myocardium: long-term clinical course, hemodynamic
properties, and genetic background. J Am Coll Cardiol
1999; 34: 233–240.
Jenni R, Wyss CA, Oechslin EN, Kaufmann PA. Isolated
ventricular noncompaction is associated with coronary
microcirculatory dysfunction. J Am Coll Cardiol 2002;
39: 450–454.
Bleyl SB, Mumford BR, Thompson V et al. Neonatal,
lethal noncompaction of the left ventricular myocardium is allelic with Barth syndrome. Am J Hum Genet
1997; 61: 868–872.
Ichida F, Tsubata S, Bowles KR et al. Novel gene muta-
294
295
296
297
298
299
300
tions in patients with left ventricular noncompaction or
Barth syndrome. Circulation 2001; 103: 1256–1263.
Vatta M, Mohapatra B, Jimenez S et al. Mutations in
Cypher/ZASP in patients with dilated cardiomyopathy
and left ventricular non-compaction. J Am Coll Cardiol
2003; 42: 2014–2027.
Shou W, Aghdasi B, Armstrong DL et al. Cardiac defects
and altered ryanodine receptor function in mice lacking
FKBP12. Nature 1998; 391: 489–492.
Kenton AB, Sanchez X, Coveler KJ et al. Isolated left
ventricular noncompaction is rarely caused by mutations in G4.5, alpha-dystrobrevin and FK Binding
Protein-12. Mol Genet Metab 2004; 82: 162–166.
Sasse-Klaassen S, Gerull B, Oechslin E, Jenni R,
Thierfelder L. Isolated noncompaction of the left ventricular myocardium in the adult is an autosomal dominant disorder in the majority of patients. Am J Med Genet
A 2003; 119: 162–167.
Sasse-Klaassen S, Probst S, Gerull B et al. Novel gene
locus for autosomal dominant left ventricular noncompaction maps to chromosome 11p15. Circulation 2004;
109: 2720–2723.
Watkins H: Genetic clues to disease pathways in hypertrophic and dilated cardiomyopathies. Circulation 2003;
107: 1344–1346.
Seidman JG, Seidman C. The genetic basis for cardiomyopathy: from mutation identification to mechanistic
paradigms. Cell 2001; 104: 557–567.
5
CHAPTER 5
The long QT syndrome
Sabina Kupershmidt, PhD, Kamilla Kelemen, MD,
& Tadashi Nakajima, MD, PhD
Introduction
Cardiac arrhythmias are a major cause of morbidity
and mortality throughout the world. On average,
every day over 1000 individuals in the USA die suddenly because of fatal ventricular arrhythmias,
most often caused by underlying heart disease in
middle-aged to elderly patients. This chapter deals
with the long QT syndrome (LQTS), which has
evolved into a paradigm for arrhythmia studies,
where basic science and clinical research have
danced a well-choreographed pas de deux to yield
fundamental insights into arrhythmia mechanisms
and cardiac electrophysiology. We hope to demonstrate convincingly that these advances would have
been unthinkable without information gleaned
from the study of rare, hereditary ion-channel diseases, often called “channelopathies.”
In particular, recent advances in human molecular genetic research prepared the way for the
identification of genes responsible for a number of
inherited, potentially lethal arrhythmia syndromes,
including the LQTS [1–3], the Brugada syndrome
[4], catecholaminergic polymorphic ventricular
tachycardias [5], progressive cardiac conduction
defects [6], familial atrial fibrillation [7] and familial sick sinus syndrome [8]. As we shall discuss in
greater detail, the underlying cause of all of these
conditions was eventually traced to defects in ion
channels or channel-associated proteins. Among
those, the LQTS remains the best studied, and
identification and functional analysis of genes
responsible for LQTS form the basis for a better
understanding of the pathophysiology of arrhythmia syndromes in general.
By definition, LQTS is characterized by a prolongation of the QT interval on the surface electrocardiogram (ECG; Figs 5.1a and 5.2a). The QT interval
extends from the QRS complex, to the end of the
T wave representing ventricular depolarization
and repolarization, respectively (Fig. 5.2a). A ratecorrected QT interval (QTc) longer than 440 ms
is considered prolonged, although there is considerable variability due to age and sex (see “Diagnosis”). In addition to a prolonged QT interval,
other ECG parameters may also be affected.
Clinical manifestations of LQTS includes syncope
and a characteristic polymorphic ventricular tachycardia whose ECG tracing twists around the isoelectric line, called torsade de pointes (TdP), which
is often precipitated by physical or emotional stress
(Figs 5.1b and 5.2c) and can deteriorate into lifethreatening ventricular fibrillation. Significantly, it
occurs mostly in young individuals without underlying structural heart disease.
The LQTS exists in two forms, congenital and
acquired LQTS. Congenital LQTS is defined as an
inherited disorder, caused by gene mutations and
can be further subdivided according to locusspecific characteristics (Table 5.1). The various
congenital LQT syndromes show different phenotypes. Gene-specific differences have been reported
in terms of morphology of the ST-T wave complex [9], triggers for cardiac events [10–12] and
risk of cardiac events [13]. In the past few years,
genotype–phenotype studies have become one of
the most active areas of LQTS research.
The acquired LQTS is precipitated by co-factors
such as exposure to certain drugs (Table 5.2) and
electrolyte abnormalities, but it presents with
83
(a)
I
II
III
aVR
aVL
aVF
V1
V2
V3
V4
V5
V6
QT interval
550 ms
(b)
I
II
III
aVR
Figure 5.1 (a) Surface ECG of a patient
with the long QT syndrome (LQTS).
The QT interval measures 550 ms.
(b) Drug-induced TdP tachyarrhythmia
in a chronic AV block dog model.
The class III anti-arrhythmic agent
almokalant was applied to induce
torsade de pointes (TdP).
aVL
aVF
(a)
(b)
K+
K+
K+
Prolonged
Normal
QT interval
X
QRS
P
Normal Mutation
T
Drug block
K+ channels
(c)
EADs
TdP
Figure 5.2 (a) Schematic depiction of a
surface electrocardiograph (ECG) trace.
The QT interval is outlined. Below:
idealized depiction of a ventricular
action potential. The gray-shaded
area and the stippled lines denote a
prolongation of the QT interval. (b)
Tetrameric K+ channels are depicted
embedded within the lipid bilayer of the
membrane. K+ flows from the inside to
the outside of the cell. Normal: a wildtype channel conducts unimpeded
current. Mutants: a mutation within a
channel monomer prevents current
flow. Drug block: an anti-arrhythmic
drug or an unrelated drug (in the case of
the acquired long QT syndrome [LQTS])
blocks the flow of K+ by binding to the
inside of the channel pore. (c) Mutations
or drug block can lead to prolongation
of the QT interval, which, in turn, leads
to early afterdepolarizations (EADs) and
torsade de pointes (TdP).
CHAPTER 5
The long QT syndrome
85
Table 5.1 Genetics of the long QT syndrome (LQTS).
Phenotype
Genotype (protein)
Current
Localization
Inherited form
LQTS (%)
LQT1
KCNQ1 (KvLQT1)
IKs a-subunit
Chromosome 11p15.5
Autosomal dominant
60
LQT2
KCNH2 (HERG)
IKr a-subunit
Chromosome 7q35–36
Autosomal dominant
35
LQT3
SCN5A (Nav1.5)
INa
Chromosome 3p21–23
Autosomal dominant
3–4
LQT4
ANK2 (Ankyrin B)
–
Chromosome 4q25–27
Autosomal dominant
<1
LQT5
KCNE1 (minK)
IKs b-subunit
Chromosome 21q22.1
Autosomal dominant
<1
LQT6
KCNE2 (MiRP1)
IKr b-subunit
Chromosome 21q22.1
Autosomal dominant
<1
LQT7 (Andersen
KCNJ2 (Kir2.1)
IK1
Chromosome 17q23–24
Autosomal dominant
<1
CACNA1C (Cav1.2)
ICa-L
?
Sporadic?
<1
syndrome)
Timothy syndrome
(LQT8)
Autosomal recessive?
JLN1
KCNQ1 (KvLQT1)
IKs a-subunit
Chromosome 11p15.5
Autosomal recessive
<1
JLN2
KCNE1 (minK)
IKs b-subunit
Chromosome 21q22.1–22.2
Autosomal recessive
<1
JLN1, Jervell and Lange–Nielson syndrome 1; JLN2, Jervell and Lange–Nielson syndrome 2.
Table 5.2 Examples of drugs causing QT
prolongation and torsade de pointes
Anti-arrhythmics
Class IA
Quinidine, disopyramide, procainamide
(TdP).
Class III
Sotalol, amiodarone, almokalant, dofetilide
Class IV
Bepridil
Anti-infectious agents
Erythromycin, clarithromycin, clindamycin,
quinolone, amantadine, pentamidine, imidazole,
chloroquine, quinine, ketoconazole, halofantrine
Histamine antagonists
Terfenadine, astemizole, fexofenadine
Serotonine antagonists
Fluoxetine, zimelidine
Diuretics
Indapamide, triamterene
Antipsychotics
Haloperidol, droperidol, chlorpromazine,
desipramine, doxepin, lithium, maprotiline,
sertinole, imipramine
Anticholinergics
Cisapride, acetylcholine, terodiline
Inotropics
Amrinone, milrinone
symptoms similar to those of the congenital LQTS.
The acquired LQTS represents a significant clinical
problem because its manifestation is unpredictable
and it has been estimated that up to 3% of all therapeutic drug prescriptions may result in TdP as a
side effect. Indeed, the acquired LQTS has become
the leading cause for drug withdrawal from the
market [14,15].
Public and scientific awareness of the importance of the LQTS are reflected in the International
LQTS Registry, which was established in 1979
[16,17]. The registry constitutes a long-term project intended to promote a better understand-
ing and management of the LQTS. It encompasses
clinical phenotypes and family pedigrees, and has
played an important part in investigating this
arrhythmia syndrome.
In this chapter, we describe the latest molecular and pathophysiologic insights into LQTS
mechanisms.
Historical development
Historically, the LQTS has been divided into two
groups, the Jervell and Lange-Nielsen syndrome
(JLN syndrome) and the Romano–Ward syndrome
86
PART I
Cardiovascular single gene disorders
(RW syndrome). In 1957, Jervell and LangeNielsen formally reported a rare, inherited autosomal recessive disorder defined by prolongation
of the QT interval, congenital bilateral neural deafness, syncopal episodes and sudden death [18]. In
the early 1960s, Romano and Ward independently
reported a similar familial disorder, also associated
with QT prolongation but not with associated deafness and inherited in an autosomal dominant
fashion [19,20]. “Autosomal recessive” indicates
that both copies of a gene (alleles) must be altered
for a person to be affected. In this case, it is likely
that the patients’ parents are merely carriers of
the mutant gene and are themselves unaffected,
whereas in the “dominant” form, the mutation of a
single allele is sufficient to cause disease.
It is difficult to find exact figures for the incidence of the RW syndrome but estimates range
from 1 in 10,000 to 1 in 5000 [21,22] people. The
JLN syndrome is less common, and thought to
occur in approximately 1.6–6 in 1 million children.
Yet it is important to recognize that, in general, the
10-year mortality rate is very high (71%) in patients
who are left untreated. Precise estimates for the
incidence of the acquired LQTS are also not available, although it is known to be much more common than the congenital form.
Until the first genetic loci responsible for the syndrome were identified in the 1990s, clinical and
experimental studies suggested that LQTS might be
caused by an imbalance of sympathetic nerve activ-
(a)
HERG
and
KCNE2
Ikr
and
ITo
(b)
1
2
3
0
4
SCN5A
INa
ICa-L
CACNA1C
100 ms
INa
Ik1
KCNJ2
ICa,L
ITO
IKs
ity or by defects in cardiac ion channels. The “sympathetic imbalance” theory was initially favored
because of reports that the QT interval could be
prolonged by right stellate ganglionectomy or by
stimulating the left stellate ganglion [21,23], and
that left stellate ganglionectomy was an effective
therapy for patients unresponsive to drug treatment [21,24] (see “Clinical treatment”).
This hypothesis has been revised during the last
decade, when mutations in eight genes were identified that can cause the congenital LQTS. These
included the genes for the cardiac sodium current,
INa [1], multiple genes contributing to the rapid
and slow components of the delayed rectifier potassium currents, IKr and IKs, respectively [2,3,25,26],
the Kir2.1 channel (IK1) [27] and the L-type calcium channel (ICa-L) (Fig. 5.3) [28]. Providing a
novel twist, ankyrin B, a protein acting primarily
as an adapter between membrane proteins and
the cytoskeleton, was discovered to be the first nonion channel gene responsible for one form of the
LQTS [29].
Clinically silent ion channel gene mutations have
been characterized in families with cases of the
acquired LQTS, indicating that this form of the disorder also carries a genetic component [30–34].
Additional risk factors for the acquired LQTS
include individual differences in drug metabolism
caused by genetic mutations or polymorphisms
that alter the function of drug-metabolizing enzymes (CYP2D6, CYP3A) [34].
(c)
K+
Out
IKr
IK1
In
Na+
Ca2+
Iks
KCNQ1
and
KCNE1
Figure 5.3 (a) Top: The five phases of an
idealized action potential (AP). Bottom:
Schematized activation patterns of the
currents discussed in this chapter. Inward
currents are shown below the solid line
in gray, outward currents are above
the solid line, in black. (b) Shows the
currents associated with the various
phases of the AP. The gene names
corresponding to the currents are
denoted in capital letters. (c) Tetrameric
K+ channels are embedded within the
lipid bilayer of the membrane. Na+ and
Ca2+ are depolarizing and flow into the
cell, while K+ repolarizes and thus flows
to the outside of the cell.
CHAPTER 5
In the early 2000s, a molecular link between
sudden infant death syndrome (SIDS) and LQTS
was also proposed [35,36]. SIDS is a frequent cause
of unexplained death among otherwise healthy
infants. The pathophysiologic mechanisms responsible for SIDS may be multifactorial and remain
poorly understood. However, postmortem genetic
testing in some patients identified mutations/polymorphisms in LQT-associated genes (SCN5A,
KCNQ1 and KCNH2) [35,37,38].
Molecular mechanisms
Ionic currents involved in shaping the
cardiac action potential
The cardiac action potential (AP) reflects the integrated electrical activity of many ionic currents across
the cell membrane through voltage-gated ion channels, ionic pumps and ionic exchangers. Depolarizing currents convey positively charged ions into
the cell, whereas the repolarizing currents ferry
positively charged ions out of the cell (Fig. 5.3c).
This is illustrated with the help of an idealized AP,
which can be divided into five phases (Fig. 5.3a):
Phase 0 The cardiomyocyte membrane is depolarized by a rapid, transient influx of Na+ ions
through voltage-gated sodium channels
(INa). Because depolarization makes the
cytoplasmic side of the plasma membrane
more positive, this is reflected in electrophysiologic recordings as the upstroke of
the action potential.
Phase 1 During early repolarization, the transient
efflux of K+ through transient outward
(Ito) channels (Fig. 5.3b), which inactivate
rapidly, terminates the AP upstroke.
Phase 2 The prolonged plateau phase of the cardiac
action potential is maintained by a balance
between inward Ca2+ through L-type Ca2+
channels and efflux of repolarizing K+
(Fig. 5.3a,b).
Phase 3 During late repolarization the Ca2+ channels have inactivated and the outward K+
currents are unopposed to sustain the
downward stroke of the action potential
through the delayed rectifier K+ channels
(IKr, IKs) (Fig. 5.3a,b).
Phase 4 The resting membrane potential is maintained between the end of one AP and the
The long QT syndrome
87
beginning of the next by a balance between
Na+ and Ca2+ leak currents and the inward
rectifier (IK1) current (Fig. 5.3a,b). At rest,
there is no substantial electrochemical gradient for K+ to enter or exit the cell because
the reversal potential for K+ is close to the
resting membrane potential (−85 mV).
In healthy people, the AP progresses through its
five phases within 200–300 ms but in LQTS patients, it takes in excess of 440–460 ms. This implies
an imbalance of depolarizing and repolarizing currents which may, in theory, be brought about by
too much of the inward Na+ current or by inhibition of one or more of the outward K+ currents,
resulting in a delay in repolarization. Indeed, this
theory was proven correct by a series of seminal discoveries made in the 1990s which rapidly led to the
development of LQTS as a molecular paradigm for
arrhythmia development [39]. An important factor
in determining the success of these studies was the
availability of genetic material collected from families afflicted with the LQTS, by researchers working
in Salt Lake City, Utah, who had the foresight to
establish such DNA banks and use the power of
human genetics to usher in a new era of arrhythmia
research [40–42].
Cardiac ion channels
At this point, a short discussion of the profound
impact on human genetic diseases made by the
study of the model organism Drosophila is warranted. Voltage-gated potassium channels had first
been cloned from the central nervous system of
fruit flies in the 1980s and their structure and functional relationships had been worked out in some
detail [43,44]. The Shaker potassium channels were
the first to be cloned [45–47] and received their
moniker because flies carrying channel mutations
shake their legs under ether anesthesia [48]. A Ca2+
modulated, voltage-dependent potassium channel, called the ether-a-go-go-gene (eag) for similar
reasons, was also first cloned from fruit flies and
its biophysical behavior was studied in Xenopus
oocytes [49]. The mechanistic insights gained from
studying ion channels isolated from Drosophila
eventually converged with powerful genetic techniques applied to large families, to enable rapid
progress in the identification of the molecular
mechanisms underlying arrhythmias.
88
PART I
Cardiovascular single gene disorders
(a)
(b)
Pore
N terminus
Extracellular
S3
+
S4
+
+
+
S6
S5
×4
b-subunit
S2
S1
+b?
Cytoplasm
C terminus
C terminus
N terminus
a subunit
×
(c)
Pore
S1
S2
DI
S3
S4
S5
u
ub
ss
lu
1p
s
nit
Pore
S6
S1
S2
S3
S4
S5
Pore
S6
DII
S1
S2
S3
DIII
S4
S5
S6
Pore
S1
S2
S3
S4
S5
S6
DIV
Figure 5.4 (a) Schematic depiction of a voltage-gated
K+ channel embedded in the lipid bilayer. The cylinders
denote the membrane-spanning regions (S1–S6). The S4
domain contains a periodic array of positively charged
amino acid residue that act as the voltage sensor. A
function-modulating b subunit often co-assembles with the
pore forming a subunit. (b) Four individual monomers form
a functional pore-forming tetramer. In some cases,
modulatory b-subunits co-assemble at various and often
undetermined stoichiometries. (c) The Na+ and Ca2+
channels consist of a linked repeat of four individual K+
channel-like modules. The individual modules are denoted
domains I–IV (DI–DIV). Accessory subunits also assemble
with Na+ and Ca2+ channels, although they are not shown
in this figure.
Ion channel structure–function
relationships
The predicted structure of voltage-gated potassium
channels includes six membrane-spanning regions
termed S1–S6, a voltage sensing domain (S4) and a
pore region located between S5 and S6 (Fig. 5.4).
The S4 domain features a regular array of positively
charged amino acids at every third position, which
move across the membrane in response to depolarization [50]. The N and C terminal regions are
cytoplasmically located (Fig. 5.4a) and are involved
in regulating the channel’s response to the environment. Four monomers assemble to yield a tetrameric structure (also called the α subunit; Fig. 5.4)
forming a hydrophobic envelope which surrounds
a central cavity or pore, after traversing various
membranous intracellular checkpoints on their way
from the endoplasmic reticulum (ER) to the plasma
membrane [51,52]. The pore-forming α subunits
are known to be modulated in their biophysical
properties, pharmacologic responses, tissue distribution and intracellular trafficking by smaller
accessory (β) subunits which often have a single
membrane-spanning domain [53–57] (Fig. 5.4a).
The differential assortment of α–β associations may
also contribute to greater combinatorial diversity
of ion channel function [58]. It is not entirely clear
at which point function-modulating β subunits
assemble with their corresponding α subunits, or
whether such assemblies can be transient, although
work carried out in heterologous systems indicates
that this occurs early in the biosynthesis pathway
during transit through the ER [59].
The structure of the cardiac sodium and L-type
calcium channels, SCN5A and CACNA1C, is a bit
more complex than that of the K+ channels. These
channels consist of four homologous domains, each
of which contain six transmembrane domains,
CHAPTER 5
similar to the architecture of four linked potassium
channel modules (Fig. 5.4c).
Important aspects of voltage-gated K+ channel
structure have recently been worked out to considerably facilitate the investigation of structure–
function relationship of ion channels [60–69].
Dr. Roderick MacKinnon’s group achieved crucial
breakthroughs in this area by producing and purifying relatively large amounts of a bacterial potassium channel (KcsA, isolated from Streptomyces
lividans). They subsequently devised a method to
turn the protein into well-ordered crystals, a prerequisite for determining a molecule’s structure.
This led to an X-ray crystallographic structure of
the pore-forming region of a K+ channel for which
Dr. MacKinnon shared the 2003 Nobel Prize in
Chemistry with Dr. Peter Agre. The crystal structure showed that the four subunits are arranged
in the shape of an inverted teepee whose wide opening contains the selectivity filter or pore. The ions
must fit precisely into the pore and must pass
through it in single file. Ions other than K+ are
either too large or too small to align properly with
the sides of the pore, making the pore selective for
K+ [70]. Recently, the first structure of a mammalian Shaker-type voltage-gated ion channel was
published [71].
The congenital LQTS: Affected genes
A combination of two basic approaches was used to
identify LQTS-related genes:
1 The candidate gene approach, which posits a
likely mechanistic hypothesis based on existing
physiologic evidence; and
2 Positional cloning, where a disease-causing gene
is identified based on its relative chromosomal position with respect to previously defined DNA markers.
In addition to genetic methods, the molecular
basis of delayed cardiac repolarization was subsequently worked out through a combination of
electrophysiologic, molecular biologic and biochemical methods.
Initially, the analysis of a large kindred in Utah
who inherited the LQTS in an autosomal dominant
fashion led to the linkage of the LQT phenotype to
the Harvey ras-1 locus on chromosome 11 by positional cloning [40,41]. The locus was denoted as
LQT1, and although the Harvey ras-1 gene thus
became a candidate for LQT, it was subsequently
The long QT syndrome
89
demonstrated by direct sequence analysis and
further linkage studies that it was not, in fact, the
culprit gene [72]. Additional LQT loci were quickly
identified on other chromosomes: LQT2 was localized to chromosome 7, LQT3 to chromosome 3
and LQT4 to chromosome 4 (Table 5.1) [3,42,73,74].
Potassium channels
The first potassium channel gene shown to underlie
the LQTS was the human ether-a-go-go-related gene
(abbreviated as HERG), whose more recently
assigned gene name is KCNH2 [2]. Initially, five
unrelated kindreds of patients suffering from a prolonged QT interval, syncope, seizures and aborted
sudden cardiac death in an autosomal dominant
manner, were genetically linked to polymorphic
markers on chromosome 7q35–36 (Table 5.1), the
known site of the LQT2 locus. Subsequently,
KCNH2 was mapped to the same chromosomal
location, shown to harbor mutations in the affected
families and its mRNA was detected in human
heart. This led to the conclusion that KCNH2
mutations caused the LQT2 syndrome. Molecular
cloning of the KCNH2 cDNA soon permitted functional studies and the channel was expressed in
Xenopus oocytes and characterized biophysically
with the two-electrode voltage clamp technique
[75,76]. These studies revealed that KCNH2 encoded a channel protein that produced a voltagesensitive potassium-selective current nearly
identical to the cardiac delayed rectifier IKr. At the
functional level, many LQT2 mutations result in
reduced current levels or in dominant negative
suppression of IKr in heterologous expression systems. This implied that the molecular mechanism
of chromosome 7-linked LQT2 syndrome was a
malfunctioning IKr channel.
Within the same year, KCNQ1 (Fig. 5.3b) was
implicated as the underlying cause for LQT1.
Again, positional cloning was used to map the
offending gene to chromosome interval 11p15.5.
When a gene with a high degree of sequence similarity to K+ channels was identified in that position,
it was initially named KvLQT1, for “voltage-gated
K+ channel associated with the LQT1 locus” (the
gene name is now KCNQ1; Table 5.1) and examined for mutations in DNA samples from patients
with LQT1. Mutations in KCNQ1 were found to
co-segregate with the disease and the associated
90
PART 1
Cardiovascular single gene disorders
mRNA was found to be expressed in human heart
[3]. Similar to KCNH2, in vitro expression studies
of mutated KCNQ1 proteins suggested multiple
biophysical consequences to K+ current through
the channel, all of them ultimately inducing a
reduction of function [77,78]. At the time, it was
uncertain which specific cardiac ionic current was
affected in LQT1 patients. However, in the following year it became clear that a modulatory
β subunit, variably called IsK, minK and, most
recently, KCNE1 (gene name), when co-expressed
with KCNQ1 in heterologous systems, it generated
a current corresponding to the cardiac delayed
rectifier, IKs (Fig. 5.3b) [79,80].
Compared with α subunits, KCNE1 is a very
small protein with only a single membranespanning domain and lacking the classic pore region
characteristic of voltage-gated potassium channels
(Fig. 5.4a). However, it dramatically influences the
biophysical and pharmacologic properties of the
current mediated by its KCNQ1 α subunit to
resemble those of the cardiac myocyte current IKs.
In light of this information, a candidate gene
approach was used to sequence the KCNE1 gene in
LQTS families that had not yet been linked to any
other loci, and yielded missense mutations in
KCNE1 in affected members of two different families [81]. This finding was especially significant
because it lent credibility to the notion that the
genetics of the syndrome was partly determined by
factors that modulate ion channel proteins rather
than being limited to the pore-forming subunits
themselves. Since then, the search for genetic mutations in similar proteins that might also cause
arrhythmias has been ongoing.
In 1999, as the Human Genome Project-driven
deposition in public databases of human and mouse
genomic sequences neared completion, amino acid
sequence alignments revealed that the KCNE protein family was, in fact, comprised of five members
[26,82]. The second member to be cloned, KCNE2
(formerly called MiRP1, the MinK-related protein
1) was found to influence the biophysical and pharmacologic characteristics of the HERG-mediated
IKr current [26]. In the ensuing years, KCNE2 was
found to affect a number of other ionic currents
[83–89] making it difficult to determine its true
physiologic role [90]. Despite this uncertainty,
KCNE2 was found to carry mutations or polymorphisms in subjects with the congenital and acquired
(drug-associated) QT prolongation. One of the
KCNE2 variants, associated with clarithromycininduced arrhythmia, rendered the IKr channel more
susceptible to blockade by the antibiotic. This
revealed a mechanism for the acquired form of the
LQTS: genetic variants in ion channel associated
proteins can remain clinically silent until additional stressors such as drug challenge uncover the
disease phenotype [26,32]. When tested in heterologous expression systems, most mutations in K+
channel or subunits that cause the LQTS in patients
result in decreased K+ current, which is also called a
“loss-of-function” phenotype (although a “reduction of function” might be the more appropriate
terminology) [25,75,91,92]. Several molecular mechanisms are now known to result in decreased current levels:
1 Decreased channel number at the plasma membrane because of a mutation in one allele (haploinsufficiency).
2 Alterations in the gating process caused by a
change in the permeation pathway, which hinders
the movement of ions through the open pore, or
changes in the process whereby the channel opens
or inactivates [91,93–96].
3 Defective ‘trafficking’ of the channel through the
obligate cellular compartments to the cell surface
[97–100].
At the time of this writing, the Internet-based
Inherited Arrhythmias Database maintained by the
European Society of Cardiology listed 180 LQTSassociated mutations of the KCNQ1 and 197 of the
KCNH2 potassium channels and the list is steadily
growing. We have therefore confined ourselves to a
general discussion of their effects on repolarization.
The sodium channel
When the LQT3 locus was initially localized to
chromosome 3p21–24 by positional cloning, it was
discovered that this area of the genome comprised
several genes. However, the cardiac voltage-gated
sodium channel, SCN5A (Table 5.1; Fig. 5.4c) at
that location, had previously been cloned and characterized [1,101,102] and became a strong candidate because of its known functional properties.
Na+ channels open quickly in response to depolarization but within a few milliseconds the channels
cease to conduct via a process termed “fast inactivation” (Fig. 5.3a,b). During prolonged depolarizations, however, a small fraction of channels do not
CHAPTER 5
fully inactivate and still conduct Na+. Functional
analysis of LQT3-associated SCN5A mutations
revealed that most mutations produce “gain of
function” defects by slightly disrupting Na+ channel
fast inactivation thereby causing a small but persistent INa during the AP plateau, a property sufficient
to delay repolarization and increase vulnerability of
the heart to arrhythmias [103–106].
Interestingly, LQT3 patients carrying the SCN5A
1795insD mutation (i.e., the amino acid aspartate
[D] is inserted following amino acid 1795) exhibit
ECG features of both LQTS and Brugada syndrome: QT interval prolongation at slow heart rates
and ST segment elevations with exercise, respectively. Functional analysis revealed that this mutation disrupts fast inactivation, causing persistent
INa throughout the action potential plateau and
prolonging cardiac repolarization at slow heart
rates, while at the same time augmenting slow inactivation, delaying recovery of Na+ channel availability between stimuli and reducing INa at rapid
heart rates [107]. Thus, although sodium channel
mutations causing the LQTS generally result in a
“gain of function,” and potassium channel mutations result in “loss of function” phenotype, the
cellular consequences are comparable because
both types of defects lead to delayed repolarization
and increased cellular excitability. Although some
experts do not consider LQT4 or LQT7 and LQT8
to be representatives of the classic LQTS [17,108],
they are nevertheless associated with QT prolongation, and we will include them in our discussion.
Ankyrin mutations and LQT4
In 1995, Schott et al. [109] reported a large French
kindred with LQTS, sinus node dysfunction with
bradycardia, atrial fibrillation, polymorphic ventricular tachycardia, syncope and sudden cardiac
death. This was the first description of LQT4,
an autosomal dominant condition that mapped
to chromosome 4q25–27. Cardiac reoplarization
defects, as measured by QTc, in patients of this
genotype were not as severe as in other families
with previously described forms of the LQTS
[21,29,109,110]. Because of the large size of the
gene, it took several more years to pinpoint the
genetic defect of LQT4 to a loss of function mutation in ankyrin B, also known as ankyrin 2
[111,112]. Ankyrins were originally identified in
erythrocytes and, in addition to the heart, they are
The long QT syndrome
91
also expressed in brain, kidney, skeletal muscle,
liver and lung. Because the cellular function of
ankyrin B is to link membrane proteins to the
cytoskeleton, LQT4 became the first form of the
LQTS not caused by a defect in an ion channel protein. A total of three ankyrins (ankyrins R, B and G)
are encoded in the mammalian genome. Cardiomyocytes express the 220-kDa ankyrin B and the
190-kDa ankyrin G [29,113,114]. In LQT4 patients,
the E1425G mutation in ankyrin B was found to be
responsible for disease and a mouse model heterozygous for the E1425G mutation, the ankyrin B+/−
mouse, was generated. The homozygous mutation
is lethal but haploinsufficient ankyrin B+/− mice live
to adulthood and display 50% reduction of ankyrin
B in the heart. The mutant phenotype included
abnormal calcium homeostasis such as elevated
calcium transients and loss of cellular targeting of
the Na+/K+ ATPase, Na+/Ca+ exchanger and inositol 1,4,5 triphosphate receptor, all of them ankyrinbinding proteins, to the cell membrane. Thus, in
this model, calcium overload in the sarcoplasmic
reticulum indirectly caused by a Na+/K+ ATPase
deficiency may be the final trigger causing depolarizations that can initiate the arrhythmias. Like the
LQT4 kindred, the ankyrin B mutant mice show
catecholamine-induced polymorphic ventricular
tachycardia and sudden death.
Ankyrin G is associated with the principal
cardiac voltage-gated sodium channel, SCN5A
(Fig. 5.3b). As described above, gain of function
mutations in the SCN5A gene lead to long LQT3
[1]. In addition, SCN5A loss of function mutation
may also lead to the Brugada syndrome with right
bundle branch block, ventricular arrhythmia and
the risk of sudden cardiac death [107,115,116].
Wild-type SCN5A and ankyrin G interact directly
in biochemical assays, whereas the E1053K SCN5A
mutation isolated from a patient with Brugada
syndrome is no longer able to do so. The failure to
interact with ankyrin G leads to reduced membrane
expression of the sodium channel in cardiac
myocytes (albeit not other cell types) and its accumulation in intracellular compartments, resulting
in the Brugada syndrome phenotype [113]. Although the Brugada syndrome is independent of
the LQTS, it is of interest in this context because it
illustrates how mutations in ankyrin, which link to
the cytoskeleton, can influence the function of ion
channels at the cell surface. It is to be expected that
92
PART 1
Cardiovascular single gene disorders
other proteins that regulate ion channel trafficking
and intracellular processing will also be found to
cause LQTS, considering that 30–35% of patients
with a definite clinical diagnosis of LQTS remain to
be genotyped [117].
The Andersen syndrome (LQT7)
In 1963, Klein et al. [259] reported two girls with
cardiac arrhythmia and periodic paralysis. This was
the first description of Andersen syndrome, a rare
disease with potassium-sensitive periodic paralysis,
prolongation of the QT interval with ventricular
arrhythmias, clinodactyly, micrognathia and lowset ears [118–120]. The mean QTc was found to be
479–493 ms [121].
Andersen syndrome is inherited as an autosomal
dominant disorder with variable penetrance, exhibiting cardiac arrhythmias as a primary manifestation
[117,120,122,123]. In 2002, the Andersen syndrome
locus was mapped to chromosome 17q23 [27], and
subsequently a missense mutation (D71V) in the
potassium channel gene KCNJ2 was shown to cause
the phenotype. KCNJ2 encodes the inward rectifier
K+ channel Kir2.1, which is an important contributor to IK1. Kir 2.1 is expressed both in skeletal and
cardiac muscle [124] where it is a key determinant
of the cardiac resting potential and the terminal
phase of repolarization (Fig. 5.3a,b).
A major difference between LQT7 (Andersen
syndrome) and the other forms of the LQTS is
the low incidence of syncope and cardiac arrest.
LQT7-associated cardiac arrhythmias degenerate
only very rarely into TdP or ventricular fibrillation
[110], suggesting that the substrate for arrhythmia
susceptibility here differs from the other forms
of the LQTS. Reduced Kir2.1 prolongs the terminal phase of the cardiac action potential and, in
the setting of hypokalemia, induces Na+/Ca2+
exchanger-dependent delayed afterdepolarizations
and spontaneous arrhythmias. In patients with
Andersen syndrome a unique form of arrhythmia,
called bidirectional tachycardia, which is characterized by alternating polarity of the QRS axis, has
been reported [125,126]. Bidirectional tachycardia
is typically associated with digitalis toxicity and is
also characteristic for familial catecholaminergic
polymorphic ventricular tachycardia, which is not
related to LQTS [127]. In contrast, other forms of
LQTS are more commonly characterized by early
afterdepolarization (EAD)-induced TdP (see “Cellular mechanisms”).
Timothy syndrome (LQT8)
The first case of Timothy syndrome was described
in 1992 as a sporadic case of congenital heart disease, LQTS and syndactyly [128]. Several other
cases followed that presented with various forms of
arrhythmias including bradycardia, AV block, TdP,
ventricular fibrillation and sudden death in early
childhood [28,129]. Recently, a gain of function
missense mutation (G406R) in exon 8A of the cardiac L-type calcium channel CACNA1C (Cav1.2)
was found to be responsible for the diverse physiologic and developmental defects in Timothy syndrome (Fig. 5.3a,b and Fig. 5.4c). Because the
CACNA1C channel is widely expressed in organs
such as the heart, pancreas, brain, ectodermal cells
of developing digits, bladder, prostate, uterus,
stomach and smooth muscle, it is not surprising
that Timothy syndrome is a multisystem disorder
affecting heart (congenital heart disease, arrhythmia),
skin (syndactyly), eyes (myopia), teeth (cavities,
small teeth), immune system (immunodeficiency
with recurrent infections) and brain (autism, mental retardation). The cardiac phenotype known to
be associated with the syndrome includes patent
ductus arteriosus, patent foramen ovale, ventricular septal defects and tetralogy of Fallot. The average QTc in Timothy syndrome is 580 ms, but in
sporadic cases QTc ranges from 620–730 ms [28].
In addition, hypocalcemia and hypoglycemia are
also observed. The mechanism underlying the
arrhythmia phenotype is reduced CACNA1C channel inactivation, which results in maintained depolarizing Ca2+ currents during the plateau phase of
the cardiac action potential. Even modest changes
in inward calcium current can lead to significant
QT interval prolongation and may result in lifethreatening arrhythmia and sudden cardiac death.
Because the Timothy syndrome is the most recently
discovered syndrome associated with QT interval
prolongation it has been designated as LQT8.
Cellular mechanisms
The interaction of several membrane currents is
responsible for cardiac excitation and repolarization (Fig. 5.3) and the morphology of the cardiac
CHAPTER 5
93
midmyocardium, because of a low density of IKs,
whereas the endo- and epicardium show shorter
APD. Voltage gradients between the endocardium
and the M-cell layer and between the epicardium
and the M region during phase 2 and 3 of the ventricular AP determine the height and shape of the T
wave. However, to date, a functional role of M cells
in transmural dispersion of repolarization has not
been demonstrated in the human heart [135].
Electrophysiologically, a distinction is made
between global and local dispersion of refractoriness. In the ventricle, “global dispersion” denotes
dispersion in refractoriness over the whole ventricle, whereas “local dispersion” describes the inhomogeneity in refractoriness in a smaller, local area
of the ventricle. Local dispersion of refractoriness is
most arrhythmogenic in animal models [136,137]
as well as in humans. For example, a study by Misier
En
Block
EB
Figure 5.5 Temporal relationship
between action potentials (APs)
recorded from the three different layers
of the ventricular wall and the T wave
of the surface ECG. The three different
cardiac layers and the corresponding
APs are shown within a wedge of
ventricular tissue. APDs are shortest in
the epicardial or outer layer, longest
in the midmyocardium (M cells) and
of intermediate duration in the
endocardium. Repolarization of the
epicardium, midmyocardium and
endocardium coincides with the peak,
the end and the latter half of the T
wave, respectively. A re-entry circuit is
shown as a result of an early beat (EB)
and unidirectional block within the
wedge (see Fig. 5.6 for greater detail).
Epicardial
Midmyocardial
Endocardial
ECG
di
ar
ic
Ep
m
id
M
do
ca
rd
yo
ia
l
ca
rd
al
ia
l
action potential depends on the balance between
depolarizing and repolarizing currents which varies
in different regions of cardiac tissue. On the surface
ECG the QRS complex reflects the depolarization,
and the T wave reflects the repolarization phase of
the ventricle (Fig. 5.2). Typically, the T wave is
much longer than the QRS complex because repolarization takes longer than the fast upstroke of the
action potential. Inherent in the T wave is the electrical inhomogeneity of the ventricle during the
repolarization phase. This inhomogeneity is based
on the fact that the ventricular wall consists of three
different layers: epicardium, midmyocardium (or
M cell layer) and endocardium. Action potential
duration and configuration are different in each of
these layers [130,131] (Fig. 5.5). In the dog model,
Antzelevitch et al. [132–134] described that action potential durations (APD) are longest in the
The long QT syndrome
PART 1
Cardiovascular single gene disorders
et al. [138] showed that patients with ventricular
fibrillation after myocardial infarction have greater
local dispersion of refractoriness in the nonischemic part of the ventricle than patients with ventricular tachycardia that did not degenerate into
ventricular fibrillation.
Dispersion in APD has been related to dispersion
in QT interval duration [139,140]. In a clinical study,
Priori et al. [141] showed that LQTS patients, especially RW syndrome patients who were treated with
beta-blockade, and patients who underwent left
cardiac sympathectomy had similar levels of QT
dispersion, indicating that QT dispersion may be a
useful index for therapeutic efficacy.
A prolonged QT interval may give rise to lifethreatening ventricular tachyarrhythmias, especially TdP. Re-entry and triggered activity are the
two major mechanisms used to explain how the
TdP arrhythmia arises. In brief, dispersion of repolarization can lead to unidirectional block of a wave
of electrical excitation [137] and cause re-entry.
Conduction is temporarily blocked within an area
of refractory tissue. If conduction velocity is slowed
and re-entrant circuits occur in the refractory area,
this can create a substrate for arrhythmias (Fig.
5.6). However, unidirectional block is often not
sufficient to initiate life-threatening arrhythmias
and a triggering mechanism is still required. The
trigger for the LQTS seem to be EADs (Fig. 5.2c),
which set the stage for ectopic beats if the afterdepolarization is large enough to reach the threshold
potential for activation (Fig. 5.6).
The typical initiation of TdP is a “long–short”
sequence, where a premature ventricular beat is followed by a pause, then a supraventricular beat followed by a premature ventricular beat at short cycle
length, starting the ventricular tachyarrhythmia
that twists around the isoelectric line (Figs 5.1b and
5.2c) [142,143].
A more detailed look at the possible mechanisms of TdP reveals the likelihood that re-entry and
triggered activity are not completely separable and
that both mechanisms have a role. According to
this theory, EADs occur in specific areas of the
myocardium, prolonging the cardiac action potential and favouring the development of re-entry (Fig.
5.6). As a consequence, inhomogeneous repolarization and afterdepolarizations are both required
for the development and maintenance of TdP
(a)
EB
Fast conduction
pathway
Slow conduction
pathway
(b)
Blo
ck
94
(c)
Figure 5.6 Three conditions conspire to cause re-entry:
(a) A combination of slow and fast conducting pathways,
shown on the left and right sides of the figure, respectively.
(b) A unidirectional block in the fast conducting pathway.
(c) The conduction velocity in the slow conducting pathway
is slow enough to allow recovery of the refractory tissue
in the fast conducting pathway. The re-entry mechanism
is initiated by an extra beat (EB, part a) that meets a
refractory tissue where conduction is temporarily blocked
(unidirectional block, part b). Because it cannot enter the
fast conducting pathway, it advances along the slow
conducting pathway (b). When the EB arrives at the distal
end of the fast conducting pathway, which has in the
meantime recovered from refractoriness, it enters the fast
conduction pathway in a retrograde fashion, thus creating
the circuit movements that are called re-entry.
[144]. In most cases TdP is self-limiting, but it may
also deteriorate into life-threatening ventricular
fibrillation with the risk of sudden cardiac death.
Acquired LQTS
While drugs designed to treat arrhythmias can prevent disease and sudden cardiac death in some
patients, they can also unpredictably provoke serious adverse events, including fatal arrhythmias in
others [145]. The SWORD and CAST clinical trials
were conducted to evaluate the efficacy of anti-
CHAPTER 5
arrhythmic drugs based on the hypothesis that
altering either the refractory period (by using class
III drugs that block potassium currents) or the conduction velocity (by using class I drugs that block
sodium currents), respectively, would prevent tachycardia. Unfortunately, the trials became prime
examples of how an incomplete understanding of
drug effects on wave propagation can cost human
lives. Indeed, more patients died after taking the
drugs than after taking placebo and the trials had to
be discontinued [146–148].
Class III anti-arrhythmics (e.g. amiodarone,
sotalol and bretylium) were designed to delay cardiac repolarization and TdP is not an unexpected
side effect during treatment. However, for many
other therapeutic agents, AP prolongation is an
undesired side effect, which seriously diminishes
their intended use. The problem is so serious that
half of all drug withdrawals since 1998 were in
response to potential proarrhythmic effects [149].
The most common underlying mechanism is IKr
block, which causes the acquired or drug-induced
LQTS (e.g., the drugs that cause most acquired
LQTS such as quinidine, sotalol, erythromycin, terfenadine and astemizole all block HERG).
Examples of drugs that were withdrawn because
of HERG toxicity are Propulsid, a heart burn medication that was prescribed to 30 million US
residents since 1993 [150], and Seldane, an antihistamine which also totaled millions of dollars in
US sales [151]. Many of these drugs were prescribed for relatively benign or low-risk conditions
and for most of them, the potential to prolong the
QT interval and cause arrhythmias was not recognized until after approval and clinical use. To complicate matters, the metabolites of certain drugs
may also lead to QT prolongation and TdP. Typical
examples include procainamide [152] and astemizole [153].
Genetic factors also appear to contribute to the
acquired LQTS: a number of “silent” mutations
and functional polymorphisms in LQT-associated
genes (SCN5A, KCNQ1, KCNE1, KCNE2) have
been associated with an increased vulnerability for
the disease [15,30–34,154,155]. Some of the mutations identified, resulted in reduced current levels
when tested in in vitro assays, which could put the
patient at increased risk for the acquired LQTS
[155]. Additional risk factors for the acquired
The long QT syndrome
95
LQTS include underlying heart disease such as
cardiac hypertrophy or congestive heart failure
[154,156–164] where ion channel genes are no
longer expressed at normal levels thereby causing
prolonged myocardial repolarization, as well as individual differences in drug metabolism caused by
genetic mutations or polymorphisms that alter the
function of drug-metabolizing enzymes (CYP2D6,
CYP3A) [34].
Experimental models for the LQTS
Numerous studies have shown that there is not
always a correlation between prolongation of repolarization and the potentially lethal TdP arrhythmia [165–172]. The FDA now requires that any
new drug needs to be investigated with respect to its
potential to delay repolarization and proarrhythmic properties [173]. This can be difficult to
demonstrate because of a relatively low incidence
of provoked TdP in vivo because healthy animals
usually have adequate repolarization reserve, a
term that denotes a redundancy of repolarizing
currents or the abiltity of cardiomyocytes to maintain efficient repolarization in the face of reduced
net outward current. For example, IKs can function
as a reserve reservoir of repolarizing current if IKr is
impaired [174,175].
The dog model
Nevertheless, experimental animal models frequently used to study susceptibility for acquired
TdP are dogs with chronic complete atrioventricular (AV) nodal block created by radiofrequency
ablation [176–180]. The model is readily adapted to
study drug-induced arrhythmias because the electrophysiologic alterations show striking similarities
with those of humans [181].
The principle behind this model is that complete
AV block results in bradycardia-induced hemodynamic overload of the ventricles, thus initiating a
cascade of compensatory processes for decreased
cardiac output and increased end-diastolic pressure. This includes the development of hypertrophy [182], contractile alterations to preserve
cardiac output [183], prolongation of ventricular
repolarization and increased dispersion of repolarization (see “Cellular mechanisms”) [181] as well as
EAD-triggered arrhythmias and drug-induced TdP
96
PART 1
Cardiovascular single gene disorders
[184]. In this model, the blockade of IKs, in addition
to drug-induced IKr inhibition, seems to constitute
the underlying mechanism, because a downregulation of KCNQ1 and KCNE1 was demonstrated
[185]. Additionally, the canine wedge preparation
model was used to demonstrate that bifurcated T
waves and a U wave can occur in conjunction with
QT interval prolongation [133].
The rabbit model
A second animal model used to study the acquired
LQTS is anesthetized rabbits in which TdP is
evoked by administration of a test agent [165,
180,186], and the effects of test drugs on APD are
recorded from Purkinje fibers and ventricular cells.
Carlsson et al. [165] showed that almokalant and
other QT-prolonging agents, such as sematilide,
and cesium chloride induced a prolongation of the
QT interval, as well as EADs and TdP in a dosedependent manner.
The arterially perfused canine or rabbit transmural ventricular wedge preparation was initially
developed to study transmural repolarization heterogeneity across the ventricular wall (Fig. 5.5)
[133,187] but is also useful for the assessment of
cardiac safety of new compounds [188,189]. In this
model, transmural wedges are excised from the left
ventricle and the tissue is cannulated and arterially
perfused. The wedges are stimulated with bipolar silver electrodes and transmural ECGs are
recorded. In addition, intracellular floating electrodes can be used to measure transmembrane APs
from endocardial, midmyocardial and epicardial
layers of the ventricular wall. With this technique,
Shimizu et al. [189–191] were able to mimic LQT1
using the IKs-blocker chromanol, LQT2 using the
IKr-blocker d-sotalol, and LQT3 using ATX-II,
which increases sodium currents. To a large extent,
the insights about the role M cells have in setting up
the development of arrhythmias were generated
using this model (see “Cellular mechanisms”).
The mouse model
The drawback of the dog and rabbit models is that
they are not genetically tractable, a property that, in
addition to experimental accessibility, is highly
desirable in an ideal model organism. Over the last
two decades the mouse has grown into that particular role for several reasons:
1 The field of mouse genetics is comparatively well
developed because spontaneous and induced mouse
mutations have been studied, maintained, inbred,
genetically mapped and described at the Jackson
Laboratory in Bar Harbor, Maine, since 1929.
2 Techniques for manipulating gene function,
such as inactivating genes (“knockouts”) or turning
them on (transgenics) exist, which are not available
in any other model vertebrate.
3 The mouse genome is fully sequenced and 99%
of mouse genes have a direct human counterpart.
Genetically modified mouse models of ion channel diseases have been derived both in the form of
transgenics, where genetic coding material is added
to an otherwise (at least theoretically) undisturbed
genetic background, as well as in the form of
“knockouts,” where the function of the target gene
is disrupted by genetic means. As the salient characteristics of engineered arrhythmia mouse models
were recently summarized in a comprehensive
review [192], we will restrict ourselves to a short
discussion. Several genetically modified mouse
models were constructed before it was fully appreciated that the mouse is a useful but not ideal model
to study cardiac arrhythmias. Specialized techniques had to be developed to investigate mouse
cardiac electrophysiology [193–198]. For example,
changes in mouse ECGs can now be analyzed in
conscious animals with the help of implantable
telemetry devices and signal averaging to avoid the
confounding effects of anesthetic agents [199].
These investigations uncovered fundamental differences between the electrical activity of the hearts
of mice and humans. At rest, the mouse heart beats
at a rate approximately 10-fold that of humans
(600–700 beats/min) and there are clear differences in AP morphology. In adult mouse ventricular myocytes, a distinct plateau phase is missing
and repolarization is rapid, carried mainly by ITo
[198,200,201]. IKr and IKs, the currents most often
affected in the congenital LQTS, are generally
thought to be lacking in adult ventricular myocytes, although they may simply be exceedingly
rare, occurring only in specialized subpopulations
of mouse cardiocytes. For example, KCNE1, the
required β subunit for IKs formation, is restricted to
cells from the cardiac conduction system in the
adult mouse heart and one would not expect to
record IKs from a randomly selected mouse myo-
CHAPTER 5
cyte because conduction system-derived cells make
up an exceedingly small proportion of cardiocytes [202]. Spontaneous ventricular arrythmias
are rare in either wild-type mice, or in mice with
genetically altered levels of LQTS-associated genes.
However, this is not simply because of the small
size of the mouse heart, because both atrial and
ventricular arrhythmias can be generated in mice
[203–208].
Lower organisms
Some intrepid researchers are exploring simpler,
more genetically tractable model organisms such
as Caenorhabditis elegans, taking advantage of the
rhythmic contractility of the worm pharynx to
identify proteins that affect electrical excitability
in that organism and then relating it back to the
mammalian channels [209]. The zebrafish model is
discussed below. However, it is evident that the
ideal animal model in which to study integrated
cardiac myocyte biology is still lacking.
Theoretical models
Data derived from in vivo and in vitro experimental
models are now being incorporated systematically
into theoretical computer models of cardiac electrophysiology that are uniquely capable of simulating cardiac electrical function in a way that
is not possible experimentally. These models are
described by systems of ordinary differential equations approximating the dynamical behavior of ion
channels, pumps, exchangers, as well as Na+, Ca2+
and K+ concentrations during the AP [210,211].
Pioneering work in this respect was carried out in
the early 1990s by Luo and Rudy [211,212] who
established a mathematical model of the membrane action potential of mammalian ventricular
cells. Henry and Rappel [213] later extended the
dynamic Luo–Rudy model to investigate the role of
M cells with a special focus on LQT3.
Modifying factors
Adrenergic stimulation
Sympathetic stimulation is one of the most important factors in cardiac repolarization. Experimental
data reveal that β-adrenergic stimulation augments
a number of ionic currents in cardiac myocytes that
contribute to repolarization, including the delayed
The long QT syndrome
97
rectifier, IKs, the Ca2+ activated chloride current
(ICl(Ca)), the L-type Ca2+ current (ICa), and the
Na+/Ca2+ exchange current (INa-Ca), thus impacting
the balance of net outward (IKs, ICl(Ca)) and inward
(ICa) current [214]. Indeed, sympathetic stimulation is often the trigger for arrhythmic events, especially in LQT1 patients [12] (see “Symptoms”).
Clinical studies of LQTS patients infused with
epinephrine suggest that sympathetic stimulation
produces genotype-specific responses of the QT
interval [215]. Sympathetic stimulation remarkably prolongs the QTc interval at fast heart rates
and peak levels of epinephrine in LQT1 and LQT2
patients. The QTc continues to be prolonged in
LQT1 patients even at steady state conditions of
epinephrine, whereas in LQT2 patients it then
shortens to baseline levels. In LQT3 patients, the
QTc is less prolonged at peak levels and also returns
to baseline at steady state. Thus, in LQT1 patients
who have suffered a loss of function in IKs, β-adrenergic stimulation does not sufficiently augment the
current to hasten repolarization, resulting in persistent QTc interval prolongation. In contrast, in
LQT3 patients with a gain-of-function in INa, βadrenergic stimulation does not markedly prolong
the QTc, which is probably because of an increase
in IKs as well as a reduction in the INa-Ca because of
persistent INa.
Thus, patients with different genotypes carry
varying degrees of risk for arrhythmias in response
to adrenergic stimulation, which has raised the possibility of distinct therapeutic strategies in the management of patients with these LQTS variants (see
“Therapy”).
Electrolytes
Another factor impacting cardiac repolarization
is electrolyte imbalance. Hypokalemia is known
to prolong QT interval in healthy populations
[34,216], and hypokalemia, as well as severe hypomagnesemia constitute risk factors in the LQTS
[28]. The underlying reason appears to be, paradoxically, that the magnitude of IKr decreases with
reduced extracellular K+, despite an increase in the
chemical driving force [217,218]. This can be
explained by a relief of extracellular Na+-mediated
IKr block under high extracellular [K+] conditions
[219]. Thus, decreasing serum K+ prolongs repolarization by decreasing the repolarizing current,
98
PART 1
Cardiovascular single gene disorders
whereas an increase of serum K+ augments IKr magnitude. Indeed, it has been reported that long-term
oral potassium administration may be effective
therapy for LQT2 (see “Therapy”) [220,221].
Gender and sex hormones
The QTc interval is known to be age- and sexdependent in the normal population, with lower
values in adult males [222]. Male LQTS patients
have an earlier onset of adverse cardiac events and a
higher risk of first events in childhood than females,
with decreasing risk after puberty. In contrast,
females have a lower incidence of cardiac events in
childhood and higher incidence of events in adulthood; their risk of first cardiac events does not
decrease in adulthood [223]. The lower incidence
of cardiac events among adult males may be because of a shortening of the QTc interval post
puberty, which is more prominent in males than in
females. Analyses of genotyped families show that
LQT1 and LQT2 syndrome males have shorter QTc
intervals than females. In contrast, LQT3 syndrome
males have longer QTc intervals than females [224].
In the drug-induced LQTS, female gender is
associated with a greater incidence of cardiac events
than male gender [225]. Drug-induced QT prolongation in females occurs more often during menstruation and the ovulatory phase of the menstrual
cycle than during the luteal phase [226]. Although
sex hormones are probably implicated, the precise
mechanisms responsible for age and sex differences
in QTc interval are still unknown.
Symptoms
The major symptoms of LQTS patients are syncope, seizure-like activity and sudden cardiac arrest
resulting from TdP and ventricular fibrillation.
Tragically, death is the first symptom in 10–15% of
patients who die of complications, because LQTS
patients rarely feel palpitations.
Most clinical and basic studies on genotype–
phenotype correlation have been performed on
patients with either the LQT1, LQT2 or LQT3,
because this group comprises approximately 60%,
35% and 3–4% of all patients, respectively, compared with all other genotypes which represent less
than 1% of the total (Table 5.1) [22]. It was found
that triggers of cardiac events differ among the
genotypes: LQT1 patients experience the majority
of their events during exercise or conditions associated with elevated sympathetic activity but rarely
during rest or sleep. In contrast, this situation is
reversed in LQT2 and LQT3 patients. Swimming
as a trigger is particularly frequent in LQT1 patients, while auditory stimuli are relatively frequent
in LQT2 patients [12]. These characteristics can
mostly be explained through the differences in
response to adrenergic stimulation.
The incidence of first cardiac event (syncope,
cardiac arrest and sudden death) before the age of
40, and prior to initiation of therapy, also differs
among the genotypes. It is lower in LQT1 (30%)
than for LQT2 (46%) or LQT3 (42%). Moreover,
the genetic locus affects not only the clinical course
of the LQTS but also modulates the effects of the
QTc interval and gender on clinical manifestation.
A risk stratification scheme for LQTS patients,
according to length of QTc interval, genotype and
gender, has been proposed [13] and is depicted in
Table 5.3.
Diagnosis
The classic ECG feature of LQTS patients is prolongation of the rate-corrected QT interval (QTc),
as measured by Bazett’s formula (QTc = QT/√RR).
The benchmark QTc value of 440 ms was often
used in the past as an index for diagnosing LQTS.
However, the ECG changes in LQTS are not merely
limited to a prolongation of the QTc interval, but
may also include factors such as T and U wave
abnormalities, bradycardia and episodic polymorphic ventricular tachycardia. As a consequence,
diagnostic criteria for LQTS were refined based on
a scoring system of clinical characteristics including
ECG findings, clinical history and family history
[227] (Table 5.4).
Because the symptoms of LQTS patients often
look like those of patients with neurologic disorders,
clinical suspicion is a crucial element in diagnosing the LQTS. If healthy people experience unexplained syncope, cardiac arrest and sudden death,
LQTS should be on the list of differential diagnosis.
However, the diagnosis of LQTS can be quite
difficult in some “borderline” patients. In addition
to 12-lead ECGs and Holter monitoring, provocative tests such as epinephrine infusion or treadmill
CHAPTER 5
Table 5.3 Risk stratification of the long QT syndrome
The long QT syndrome
99
Table 5.4 Diagnostic criteria.
(LQTS).
Electrocardiographic findings
Low risk for
Intermediate risk
High risk for
cardiac event
for cardiac event
cardiac event
(<30%)
(30–50%)
(>50%)
QTc <500 ms
QTc <500 ms
QTc >500 ms
Male sex
Female sex, LQT2
Female sex, LQT
LQT1, LQT2
Points
QTc (calculated by Bazett formula*)
>480 ms
3
460–470 ms
2
450 ms in males
1
Tosade de pointes
2
Female sex, LQT3
T-wave alternans
1
Male sex, LQT3
Notched T-wave in 3 leads of the surface ECG
1
Low heart rate for age (resting heart rate below
0.5
QTc >500 ms
QTc >500 ms
Female sex, LQT3
LQT1
the second percentile for age)
LQT2
Clinical history
Male sex, LQT3
Syncope
with stress
2
without stress
1
Congenital deafness
exercises may be useful [215,228], especially in
latent KCNQ1 mutation carriers [229]. The results
may differ among LQTS genotypes (see “Modifying
factors”). In the absence of other indicators, invasive electrophysiologic study can be useful for diagnosing LQTS. If LQTS is clinically diagnosed or
suspected, family members should also be screened
by ECGs. Genetic testing is available and recommended as a final diagnosis (success rate, 50–70%)
and to direct genotype-specific therapy.
Clinical treatment
Clinical tratment of patients with congenital LQTS
is most effective if it is genotype-specific. Several
studies on drug-induced LQTS based on the wedge
preparation model support genotype-specific treatments for the different types of LQTS, with LQT3
being the best studied [189–191,230].
Treatment of LQT1
The first choice of therapy for LQT1 are beta-blockers. Schwartz et al. [12] reported that suppression
of cardiac events by beta-blockers is more frequent
in patients with LQT1 (81%) than in LQT2 (59%)
and LQT3 (50%). However, if beta-blockade is not
sufficient to suppress cardiac events, mexiletine, a
class IB anti-arrhythmic (sodium-channel blocker)
should be considered for treatment. It has been
shown experimentally that mexiletine is able to
suppress TdP [190,191]. An adjunct therapy may
be a calcium-channel blocker such as verapamil. A
0.5
Family history
Family members with definite LQTS
1
Unexplained sudden cardiac death before the
0.5
age of 30 among immediate family members
ECG, electrocardiogram; LQTS, long QT syndrome.
A score of 4 or more defines LQTS.
* Bazett formula: QTc = QT/√RR. Scoring: <1 point, low
probability; 2–3 points, intermediate probability; >4 points:
high probability.
study by Aiba et al. [231] showed positive effects
of verapamil in shortening the QT interval and
decreasing the risk for TdP. On the other hand,
potassium-channel openers such as nicorandil, available in Europe and Japan, are of lesser value,
because it has been demonstrated that a high intravenous dosage of nicorandil is required to abolish
EADs and TdP [230]. LQT1 patients are most sensitive to sympathetic stimulation, and left cardiac
sympathetic denervation is thought to be most
effective in LQT1 patients, if beta-blocker therapy
fails [232]. LQT1 patients should avoid exercise or
do so only under careful supervision, because cardiac events in LQT1 patients are most frequently
exercise-induced, and are especially associated with
swimming.
Treatment of LQT2
As for LQT1 patients, beta-blockers are also the
first choice of treatment for LQT2 patients.
100 PART 1 Cardiovascular single gene disorders
Additional therapies such as mexiletine and/or
verapamil might have a higher impact in LQT2
patients because they seem to have a higher recurrence rate of cardiac events when they are
exclusively on beta-blocker therapy [12,233]. It is
important to consider serum potassium levels in
LQT2 patients, because IKr, the defective current in
LQT2, is very sensitive to extracellular potassium
levels [133,217–219]. Etheridge et al. [234] found
that long-term oral administration of potassium
has beneficial effects, improving disturbances in
repolarization. Additionally, restricted exercise is
meaningful in LQT2 patients [235].
Treatment of LQT3
Because a gain of function defect in the sodiumchannel gene, SCN5A, is responsible for LQT3,
sodium-channel blockade with mexiletine is of special interest. Indeed, preliminary clinical and basic
experimental data suggest that the class Ib antiarrhythmic drug, mexiletine, is more effective in
abbreviating the QT interval in LQT3 than in LQT1
or LQT2 [191,236,237], possibly because of the
block of SCN5A mutation-associated persistent INa
by mexiletine [238].
In this context it is interesting to note that the
SCN5A D1790G mutation does not produce persistent INa during depolarization, but alters the
kinetics and voltage dependence of the inactivated
state, which can prolong ventricular repolarization
[239]. In this case, administration of the class Ic
anti-arrhythmic flecainide is more effective than
the class Ib mexiletine, possibly because of the high
sensitivity of this mutation to the use-dependent
block of INa by flecainide [240]. Based on preliminary clinical data, mexiletine should be applied with
beta-blockers or co-administered with an implantable cardioverter-defibrillator (ICD). LQT3 patients are not recommended for single beta-blocker
therapy because experimental studies show no protective or even harmful effects [189,235]. Pacemakers
seem to be of specific benefit for LQT3 patients.
Schwartz et al. [241] showed that an increase of
heart rate may effectively abbreviate the QT interval.
Treatment of LQT4–8
At present, genotype-specific treatment of LQT4–8
has not been determined because of the small number of cases. In general, beta-blockers should be the
first therapy of choice. In LQT5 the responsible
defect is a mutation in KCNE1, which is responsible
for IKs, thus the recommended therapy for LQT1
patients also applies to LQT5. Similarly, the therapy
scheme for LQT2 should be beneficial for LQT6
[242]. In all cases, additional prospective clinical
studies are needed to provide a better assessment of
LQT treatment other than beta-blockers.
ICD therapy
In general, ICD therapy is indicated in LQTS
patients who have experienced cardiac arrest or
repetitive episodes of syncope. In cases involving
young LQTS patients who have not themselves had
cardiac events but whose family members have
experienced episodes of syncope, cardiac arrest or
even sudden cardiac death, an ICD implantation
should be considered early in therapy. In an 8-year
follow-up study of 125 LQT patients, Zareba et al.
[243] and Welde [244] showed that incidence of
mortality was higher in those patients who did not
receive an ICD.
Pacemaker therapy
A study by Eldar et al. [245] showed that, in general,
a combination of beta-blocker and cardiac pacing
appears to be highly advantageous for LQTS patients. Especially patients with LQT3 derive great
benefit from pacemaker therapy [241]. Currently,
ICD and pacemaker are combined in one device,
which facilitates the use of a pacemaker as adjunct
therapy.
Because a large number of drugs have the potential to induce TdP tachyarrhythmias with the risk
of deteriorating into life-threatening ventricular
fibrillation, patients with congenital LQTS should
avoid taking those drugs. Examples of drugs with
torsadogenic potential are listed in Table 5.2. A
more comprehensive list of drugs that can cause
TdP can be found on the Internet at http://
www.qtdrugs.org [246].
A challenge for the pharmaceutical
industry
A major problem facing the pharmaceutical industry is the identification of potentially toxic effects
of drugs before those drugs reach the market and
endanger the health of patients. This is associated
CHAPTER 5
with an ever-escalating cost for drug development
which was estimated to be US$1.9 billion in 2005
[247]. In addition, only 21% of drugs entering phase
I clinical trials actually reach the market [248]. Thus,
the pharmaceutical industry considers it increasingly important to identify potential toxicities early
in the drug discovery process and the demand for
assays that can accurately predict the effect of compounds on the QT interval is great [249].
A number of screens exist for detecting druginduced repolarization abnormalities, although
most are not high-throughput and costly (i.e., of
limited use early in the drug discovery process).
Typical assays used to determine the QT prolonging potential of test compounds include the in vivo
dog model, as well as in vitro models including
the analysis of APD from freshly isolated rabbit
Purkinje fibers, or the Langendorff perfused ex vivo
heart model [249,250] (see “Experimental models
for the LQTS”). In vitro assays, such as the measurement of HERG channel activity in a cell culture system, can be adapted to high throughput formats
but are limited by their inherent biologic simplicity, high rate of false positives and the inability to
detect drug interactions [251].
An exciting new model that holds promise for
high throughput screening applications is the
zebrafish, Danio rerio. Zebrafish embryos are transparent which permits convenient monitoring of the
heart rate, “gene knockdown” approaches via morpholinos [252] allow for easy gene manipulation,
the culture of the embryos is easy and adaptable to
high throughput formats, small amounts of drugs
are sufficient for in vivo testing, and drugs can be
applied to the bath where they are taken up through
the embryo’s skin. Moreover, it is possible to stop
the heart beat in zebrafish embryos for days while
they survive by diffusion [253]. Although zebrafish
have two-chambered hearts, human and zebrafish
cardiac structure and function appear largely conserved. For example, hereditary cardiomyopathy in
humans has been linked to mutations in several
genes that also affect the heartbeat in zebrafish
[254–256]. A zebrafish ortholog of HERG/KCNH2,
zERG, was cloned and antisense knockdown of
this gene was shown to produce bradycardia and
arrhythmia [257]. The usefulness of zebrafish in
screening for QT prolonging drugs was demonstrated, when compounds associated with long
The long QT syndrome
101
QT and TdP in humans, such as terfenadine and
cisapride reduced heart rate and caused dosedependent AV nodal block in this model [257,258].
Conclusions
We hope that at this point the reader has developed
an appreciation that even a relatively rare genetic
syndrome can provide an impressive example of
the power of translational research. The LQTS
posed a challenge to basic scientists, clinicians and
industry alike. They responded by combining basic
science techniques including population genetics,
biochemistry, molecular biology, electrophysiology, with clinical studies to elucidate general
arrhythmia mechanisms and to improve therapies
for the betterment of public health.
References
1 Wang Q, Shen J, Splawski I et al. SCN5A mutations
associated with an inherited cardiac arrhythmia, long
QT syndrome. Cell 1995; 80: 805–811.
2 Curran ME, Splawski I, Timothy KW et al. A molecular
basis for cardiac arrhythmia: HERG mutations cause
long QT syndrome. Cell 1995; 80: 795–803.
3 Wang Q, Curran ME, Splawski I et al. Positional cloning
of a novel potassium channel gene: KVLQT1 mutations
cause cardiac arrhythmias. Nat Genet 1996; 12: 17–23.
4 Chen Q, Kirsch GE, Zhang D et al. Genetic basis and
molecular mechanism for idiopathic ventricular fibrillation. Nature 1998; 392: 293–296.
5 Priori SG, Napolitano C, Tiso N et al. Mutations in the
cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia.
Circulation 2001; 103: 196–200.
6 Tan HL, Bink-Boelkens MT, Bezzina CR et al. A
sodium-channel mutation causes isolated cardiac conduction disease. Nature 2001; 409: 1043–1047.
7 Chen YH, Xu SJ, Bendahhou S et al. KCNQ1 gain-offunction mutation in familial atrial fibrillation. Science
2003; 299: 251–254.
8 Benson DW, Wang DW, Dyment M et al. Congenital
sick sinus syndrome caused by recessive mutations in
the cardiac sodium channel gene (SCN5A). J Clin Invest
2003; 112: 1019–1028.
9 Moss AJ. T-wave patterns associated with the hereditary
long QT syndrome. Cardiac Electrophysiol Rev 2002; 6:
311–315.
10 Ackerman MJ, Tester DJ, Porter CJ. Swimming, a genespecific arrhythmogenic trigger for inherited long QT
syndrome. Mayo Clin Proc 1999; 74: 1088–1094.
102 PART 1 Cardiovascular single gene disorders
11 Moss AJ, Robinson JL, Gessman L et al. Comparison of
clinical and genetic variables of cardiac events associated
with loud noise versus swimming among subjects with
the long QT syndrome. Am J Cardiol 1999; 84: 876–879.
12 Schwartz PJ, Priori SG, Spazzolini C et al. Genotype–
phenotype correlation in the long-QT syndrome:
gene-specific triggers for life-threatening arrhythmias.
Circulation 2001; 103: 89–95.
13 Priori SG, Schwartz PJ, Napolitano C et al. Risk
stratification in the long-QT syndrome. N Engl J Med
2003; 348: 1866–1874.
14 Chiang CE. Congenital and acquired long QT syndrome. Current concepts and management. Cardiol Rev
2004; 12: 222–234.
15 Roden DM. Drug-induced prolongation of the QT
interval. N Engl J Med 2004; 350: 1013–1022.
16 Moss AJ, Schwartz PJ. 25th Anniversary of the International Long-QT Syndrome Registry: An ongoing
quest to uncover the secrets of long-QT syndrome.
Circulation 2005; 111: 1199–1201.
17 Schwartz PJ. Management of long QT syndrome.
Nature Clin Pract Cardiovasc Med 2005; 2: 346–351.
18 Jervell A, Lange-Nielsen F. Congenital deaf-mutism,
functional heart disease with prolongation of the Q-T
interval and sudden death. Am Heart J 1957; 54: 59–68.
19 Romano C, Gemme G, Pongiglione R. [Rare cardiac
arrythmias of the pediatric age. II. Syncopal attacks due
to paroxysmal ventricular fibrillation. (Presentation of
1st Case in Italian Pediatric Literature)]. Clin Pediatr
(Bologna) 1963; 45: 656–683.
20 Ward OC. A new familial cardiac syndrome in children.
J Ir Med Assoc 1964; 54: 103–106.
21 Chiang CE, Roden DM. The long QT syndromes:
genetic basis and clinical implications. J Am Coll Cardiol
2000; 36: 1–12.
22 Vincent GM. Romano-Ward syndrome. GeneReviews
at GeneTests: Medical Genetics Information Resource
(database online). Copyright, University of Washington, Seattle. 1997–2005. Available at http://www.
genetests.org
23 Yanowitz F, Preston JB, Abildskov JA. Functional distribution of right and left stellate innervation to the ventricles. Production of neurogenic electrocardiographic
changes by unilateral alteration of sympathetic tone.
Circ Res 1966; 18: 416–428.
24 Schwartz PJ, Periti M, Malliani A. The long Q-T syndrome. Am Heart J 1975; 89: 378–90.
25 Splawski I, Tristani-Firouzi M, Lehmann MH et al.
Mutations in the hminK gene cause long QT syndrome
and suppress IKs function. Nat Genet 1997; 17: 338–340.
26 Abbott GW, Sesti F, Splawski I et al. MiRP1 forms IKr
potassium channels with HERG and is associated with
cardiac arrhythmia. Cell 1999; 97: 175–187.
27 Plaster NM, Tawil R, Tristani-Firouzi M et al. Mutations
in Kir2.1 cause the developmental and episodic electrical phenotypes of Andersen’s syndrome. Cell 2001;
105: 511–519.
28 Splawski I, Timothy KW, Sharpe LM et al. Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell 2004; 119:
19–31.
29 Mohler PJ, Schott JJ, Gramolini AO et al. Ankyrin-B
mutation causes type 4 long-QT cardiac arrhythmia and
sudden cardiac death. Nature 2003; 421: 634–639.
30 Splawski I, Timothy KW, Tateyama M et al. Variant of
SCN5A sodium channel implicated in risk of cardiac
arrhythmia. Science 2002; 297: 1333–1336.
31 Paulussen AD, Gilissen RA, Armstrong M et al. Genetic
variations of KCNQ1, KCNH2, SCN5A, KCNE1, and
KCNE2 in drug-induced long QT syndrome patients.
J Mol Med 2004; 82: 182–188.
32 Sesti F, Abbott GW, Wei J et al. A common polymorphism associated with antibiotic-induced cardiac
arrhythmia. Proc Natl Acad Sci USA 2000; 97: 10613–
10618.
33 Kubota T, Horie M, Takano M et al. Evidence for a single nucleotide polymorphism in the KCNQ1 potassium
channel that underlies susceptibility to life-threatening
arrhythmias. J Cardiovasc Electrophysiol 2001; 12: 1223–
1229.
34 Aerssens J, Paulussen AD. Pharmacogenomics and
acquired long QT syndrome. Pharmacogenomics 2005;
6: 259–270.
35 Schwartz PJ, Priori SG, Dumaine R et al. A molecular
link between the sudden infant death syndrome and the
long-QT syndrome. N Engl J Med 2000; 343: 262–267.
36 Tester DJ, Ackerman MJ. Sudden infant death syndrome: How significant are the cardiac channelopathies?
Cardiovasc Res 2005; 67: 388–396.
37 Schwartz PJ, Priori SG, Bloise R et al. Molecular diagnosis in a child with sudden infant death syndrome.
Lancet 2001; 358: 1342–1343.
38 Christiansen M, Tonder N, Larsen LA et al. Mutations in
the HERG K+-ion channel: a novel link between long
QT syndrome and sudden infant death syndrome. Am J
Cardiol 2005; 95: 433–434.
39 Roden DM, Spooner PM. Inherited long QT syndromes: a paradigm for understanding arrhythmogenesis. J Cardiovasc Electrophysiol 1999; 10: 1664–1683.
40 Keating M, Atkinson D, Dunn C et al. Linkage of a cardiac arrhythmia, the long QT syndrome, and the Harvey
ras-1 gene. Science 1991; 252: 704–706.
41 Keating M, Dunn C, Atkinson D et al. Consistent linkage of the long-QT syndrome to the Harvey ras-1 locus
on chromosome 11. Am J Hum Genet 1991; 49: 1335–
1339.
CHAPTER 5
42 Jiang C, Atkinson D, Towbin JA et al. Two long QT syndrome loci map to chromosomes 3 and 7 with evidence
for further heterogeneity. Nat Genet 1994; 8: 141–147.
43 Jan LY, Jan YN. Cloned potassium channels from
eukaryotes and prokaryotes. Ann Rev Neurosci 1997; 20:
91–123.
44 Jan LY, Jan YN. Tracing the roots of ion channels. Cell
1992; 69: 715–718.
45 Papazian DM, Schwarz TL, Tempel BL et al. Cloning
of genomic and complementary DNA from Shaker,
a putative potassium channel gene from Drosophila.
Science 1987; 237: 749–753.
46 Pongs O, Kecskemethy N, Muller R et al. Shaker encodes
a family of putative potassium channel proteins in the
nervous system of Drosophila. EMBO J 1988; 7: 1087–
1096.
47 Iverson LE, Tanouye MA, Lester HA et al. A-type potassium channels expressed from Shaker locus cDNA. Proc
Natl Acad Sci USA 1988; 85: 5723–5727.
48 Kaplan WD, Trout WE III. The behavior of four neurological mutants of Drosophila. Genetics 1969; 61: 399–409.
49 Bruggemann A, Pardo LA, Stuhmer W et al. Ether-ago-go encodes a voltage-gated channel permeable to K+
and Ca2+ and modulated by cAMP. Nature 1993; 365:
445–448.
50 Jan LY, Jan YN. Structural elements involved in specific
K+ channel functions. Annu Rev Physiol 1992; 54:
537–555.
51 Roden DM, Kupershmidt S. From genes to channels:
normal mechanisms. Cardiovasc Res 1999; 42: 318–326.
52 Deutsch C. The birth of a channel. Neuron 2003; 40:
265–276.
53 Rhodes KJ, Strassle BW, Monaghan MM et al. Association and colocalization of the Kvbeta1 and Kvbeta2
beta-subunits with Kv1 alpha-subunits in mammalian
brain K+ channel complexes. J Neurosci 1997; 17: 8246–
8258.
54 Takumi T, Ohkubo H, Nakanishi S. Cloning of a membrane protein that induces a slow voltage-gated potassium current. Science 1988; 242: 1042–1045.
55 Trimmer JS, Rhodes KJ. Building (potassium) channels
to the 21st century. Trends Neurosci 1997; 20: 99–100.
56 England SK, Uebele VN, Shear H et al. Characterization
of a voltage-gated K+ channel beta subunit expressed
in human heart. Proc Natl Acad Sci USA 1995; 92:
6309–6313.
57 Nuss HB, Chiamvimonvat N, Perez-Garcia MT et al.
Functional association of the beta 1 subunit with human
cardiac (hH1) and rat skeletal muscle (mu 1) sodium
channel alpha subunits expressed in Xenopus oocytes.
J Gen Physiol 1995; 106: 1171–1191.
58 Pourrier M, Schram G, Nattel S. Properties, expression
and potential roles of cardiac K+ channel accessory sub-
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
The long QT syndrome
103
units: MinK, MiRPs, KChIP, and KChAP. J Membr Biol
2003; 194: 141–152.
Nagaya N, Papazian DM. Potassium channel alpha and
beta subunits assemble in the endoplasmic reticulum.
J Biol Chem 1997; 272: 3022–3027.
Jiang Y, Lee A, Chen J et al. X-ray structure of a voltagedependent K+ channel. Nature 2003; 423: 33–41.
Jiang Y, Lee A, Chen J et al. The open pore conformation
of potassium channels. Nature 2002; 417: 523–526.
Jiang Y, Lee A, Chen J et al. Crystal structure and mechanism of a calcium-gated potassium channel. Nature
2002; 417: 515–522.
Kreusch A, Pfaffinger PJ, Stevens CF et al. Crystal structure of the tetramerization domain of the Shaker potassium channel. Nature 1998; 392: 945–948.
Bezanilla F. The voltage-sensor structure in a voltagegated channel. Trends Biochem Sci 2005; 30: 166–168.
Long SB, Campbell EB, MacKinnon R. Voltage sensor of
Kv1.2: structural basis of electromechanical coupling.
Science 2005; 309: 903–908.
Cuello LG, Cortes DM, Perozo E. Molecular architecture of the KvAP voltage-dependent K+ channel in a
lipid bilayer. Science 2004; 306: 491–495.
Perozo E, Cortes DM, Cuello LG. Three-dimensional
architecture and gating mechanism of a K+ channel studied
by EPR spectroscopy. Nat Struct Biol 1998; 5: 459–469.
Gulbis JM, Zhou M, Mann S et al. Structure of the cytoplasmic beta subunit-T1 assembly of voltage-dependent
K+ channels. Science 2000; 289: 123–127.
Perozo E, Cortes DM, Cuello LG. Structural rearrangements underlying K+-channel activation gating. Science
1999; 285: 73–78.
Doyle DA, Cabral JM, Pfuetzner RA et al. The structure
of the potassium channel: molecular basis of K+ conduction and selectivity. Science 1998; 280: 69–77.
Long SB, Campbell EB, MacKinnon R. Crystal structure
of a mammalian voltage-dependent Shaker family K+
channel. Science 2005; 309: 897–903.
Roy N, Kahlem P, Dausse E et al. Exclusion of HRAS
from long QT locus. Nat Genet 1994; 8: 113–114.
Curran M, Atkinson D, Timothy K et al. Locus heterogeneity of autosomal dominant long QT syndrome. J
Clin Invest 1993; 92: 799–803.
Benhorin J, Kalman YM, Medina A et al. Evidence of
genetic heterogeneity in the long QT syndrome. Science
1993; 260: 1960–1962.
Sanguinetti MC, Jiang C, Curran ME et al. A mechanistic link between an inherited and an acquired cardiac
arrhythmia: HERG encodes the IKr potassium channel.
Cell 1995; 81: 299–307.
Trudeau MC, Warmke JW, Ganetzky B et al. HERG, a
human inward rectifier in the voltage-gated potassium
channel family. Science 1995; 269: 92–95.
104 PART 1 Cardiovascular single gene disorders
77 Huang LQ, Bitner-Glindzicz M, Tranebjaerg L et al.
A spectrum of functional effects for disease causing
mutations in the Jervell and Lange-Nielsen syndrome.
Cardiovasc Res 2001; 51: 670–680.
78 Li RA, Miake J, Hoppe UC et al. Functional consequences of the arrhythmogenic G306R KvLQT1 K+
channel mutant probed by viral gene transfer in cardiomyocytes. J Physiol (Lond) 2001; 533: 127–133.
79 Barhanin J, Lesage F, Guillemare E et al. K(V)LQT1 and
IsK (minK) proteins associate to form the I(Ks) cardiac
potassium current. Nature 1996; 384: 78–80.
80 Sanguinetti MC, Curran ME, Zou A et al. Coassembly of
K(V)LQT1 and minK (IsK) proteins to form cardiac
I(Ks) potassium channel. Nature 1996; 384: 80–83.
81 Splawski I, Tristani-Firouzi M, Lehmann MH et al.
Mutations in the hminK gene cause long QT syndrome
and suppress IKs function. Nat Genet 1997; 17: 338–
340.
82 Piccini M, Vitelli F, Seri M et al. KCNE1-like gene is
deleted in AMME contiguous gene syndrome: identification and characterization of the human and mouse
homologs. Genomics 1999; 60: 251–257.
83 Lewis A, McCrossan ZA, Abbott GW. MinK, MiRP1
and MiRP2 diversify Kv3.1 and Kv3.2 potassium channel gating. J Biol Chem 2003; 279: 7884–7892.
84 Decher N, Bundis F, Vajna R et al. KCNE2 modulates
current amplitudes and activation kinetics of HCN4:
influence of KCNE family members on HCN4 currents.
Pflugers Arch 2003; 446: 633–640.
85 Mazhari R, Greenstein JL, Winslow RL et al. Molecular interactions between two long-QT syndrome gene
products, HERG and KCNE2, rationalized by in vitro
and in silico analysis. Circ Res 2001; 89: 33–38.
86 Deschenes I, Tomaselli GF. Modulation of Kv4.3
current by accessory subunits. FEBS Lett 2002; 528:
183–188.
87 Zhang M, Jiang M, Tseng GN. minK-related peptide 1
associates with Kv4.2 and modulates its gating function:
potential role as beta subunit of cardiac transient outward channel? Circ Res 2001; 88: 1012–1019.
88 Yu H, Wu J, Potapova I et al. MinK-related peptide 1: A
beta subunit for the HCN ion channel subunit family
enhances expression and speeds activation. Circ Res
2001; 88: E84–E87.
89 Abbott GW, Goldstein SA. Disease-associated mutations in KCNE potassium channel subunits (MiRPs)
reveal promiscuous disruption of multiple currents and
conservation of mechanism. FASEB J 2002; 16: 390–400.
90 Weerapura M, Nattel S, Chartier D et al. A comparison
of currents carried by HERG, with and without coexpression of MiRP1, and the native rapid delayed rectifier
current. Is MiRP1 the missing link? J Physiol 2002; 540:
15–27.
91 Sanguinetti MC, Curran ME, Spector PS et al. Spectrum
of HERG K+-channel dysfunction in an inherited
cardiac arrhythmia. Proc Natl Acad Sci USA 1996; 93:
2208–2212.
92 Shalaby FY, Levesque PC, Yang WP et al. Dominantnegative KvLQT1 mutations underlie the LQT1 form of
long QT syndrome. Circulation 1997; 96: 1733–1736.
93 Lees-Miller JP, Duan Y, Teng GQ et al. Novel gain-offunction mechanism in K(+) channel-related long-QT
syndrome: altered gating and selectivity in the HERG1
N629D mutant. Circ Res 2000; 86: 507–513.
94 Nakajima T, Kurabayashi M, Ohyama Y et al. Characterization of S818L mutation in HERG C-terminus in
LQT2: Modification of activation–deactivation gating
properties. FEBS Letters 2000; 481: 197–203.
95 Chen J, Zou A, Splawski I et al. Long QT syndromeassociated mutations in the Per-Arnt-Sim (PAS)
domain of HERG potassium channels accelerate channel deactivation. J Biol Chem 1999; 274: 10113–10118.
96 Sanguinetti MC. Dysfunction of delayed rectifier potassium channels in an inherited cardiac arrhythmi. Ann N
Y Acad Sci 1999; 868: 406–413.
97 Delisle BP, Anson BD, Rajamani S et al. Biology of cardiac arrhythmias: Ion channel protein trafficking. Circ
Res 2004; 94: 1418–1428.
98 January CT, Gong QM, Zhou ZF. Long QT syndrome:
Cellular basis and arrhythmia mechanism in LQT2.
J Cardiovasc Electrophysiol 2000; 11: 1413–1418.
99 Kupershmidt S, Yang T, Chanthaphaychith S et al.
Defective human ether-a-go-go related gene trafficking
linked to an endoplasmic reticulum retention signal in the
carboxy terminus. J Biol Chem 2002; 277: 27442–27448.
100 Kanki H, Kupershmidt S, Yang T et al. A structural
requirement for processing the cardiac K+ channel
KCNQ1. J Biol Chem 2004; 279: 33976–33983.
101 George AL Jr, Varkony TA, Drabkin HA et al. Assignment of the human heart tetrodotoxin-resistant voltagegated Na+ channel alpha-subunit gene (SCN5A) to band
3p21. Cytogenet Cell Genet 1995; 68: 67–70.
102 Gellens ME, George AL Jr, Chen L et al. Primary structure and functional expression of the human cardiac
tetrodotoxin-insensitive voltage-dependent sodium channel. Proc Natl Acad Sci USA 1992; 89: 554–558.
103 Bennett PB, Yazawa K, Makita N et al. Molecular mechanism for an inherited cardiac arrhythmia. Nature 1995;
376: 683–685.
104 Dumaine R, Wang Q, Keating MT et al. Multiple mechanisms of Na+ channel-linked long-QT syndrome. Circ
Res 1996; 78: 916–924.
105 Makita N, Shirai N, Nagashima M et al. A de novo missense mutation of human cardiac Na+ channel exhibiting novel molecular mechanisms of long QT syndrome.
FEBS Lett 1998; 423: 5–9.
CHAPTER 5
106 Kambouris NG, Nuss HB, Johns DC et al. A revised view
of cardiac sodium channel “blockade” in the long-QT
syndrome. J Clin Invest 2000; 105: 1133–1140.
107 Veldkamp MW, Viswanathan PC, Bezzina C et al. Two
distinct congenital arrhythmias evoked by a multidysfunctional Na+ channel. Circ Res 2000; 86: 91–97.
108 Zhang L, Benson DW, Tristani-Firouzi M et al.
Electrocardiographic features in Andersen–Tawil syndrome patients with KCNJ2 mutations: Characteristic
T-U-wave patterns predict the KCNJ2 genotype. Circulation 2005; 111: 2720–2726.
109 Schott JJ, Charpentier F, Peltier S et al. Mapping of a
gene for long QT syndrome to chromosome 4q25–27.
Am J Hum Genet 1995; 57: 1114–1122.
110 Zareba W, Moss AJ, Schwartz PJ et al. Influence of genotype on the clinical course of the long-QT syndrome.
International Long-QT Syndrome Registry Research
Group. N Engl J Med 1998; 339: 960–965.
111 Mohler PJ, Schott JJ, Gramolini AO et al. Ankyrin-B
mutation causes type 4 long-QT cardiac arrhythmia and
sudden cardiac death. Nature 2003; 421: 634–639.
112 Mohler PJ, Splawski I, Napolitano C et al. A cardiac
arrhythmia syndrome caused by loss of ankyrin-B function. Proc Natl Acad Sci USA 2004; 101: 9137–9142.
113 Mohler PJ, Rivolta I, Napolitano C et al. Nav1.5 E1053K
mutation causing Brugada syndrome blocks binding to
ankyrin-G and expression of Nav1.5 on the surface of
cardiomyocytes. Proc Natl Acad Sci USA 2004; 101:
17533–17538.
114 Tuvia S, Buhusi M, Davis L et al. Ankyrin-B is required
for intracellular sorting of structurally diverse Ca2+
homeostasis proteins. J Cell Biol 1999; 147: 995–1008.
115 Baroudi G, Napolitano C, Priori SG et al. Loss of function associated with novel mutations of the SCN5A gene
in patients with Brugada syndrome. Can J Cardiol 2004;
20: 425–430.
116 Mok NS, Priori SG, Napolitano C et al. A newly characterized SCN5A mutation underlying Brugada syndrome
unmasked by hyperthermia. J Cardiovasc Electrophysiol
2003; 14: 407–411.
117 Ganelin R, Marks JF, Usher P et al. J Periodic paralysis
with cardiac arrhythmia. J Pediatr 1963; 62: 371–385.
118 Andersen ED, Krasilnikoff PA, Overvad H. Intermittent
muscular weakness, extrasystoles, and multiple developmental anomalies. A new syndrome? Acta Paediatr
Scand 1971; 60: 559–564.
119 Tawil R, Ptacek LJ, Pavlakis SG et al. Andersen’s syndrome: potassium-sensitive periodic paralysis, ventricular ectopy, and dysmorphic features. Ann Neurol 1994;
35: 326–330.
120 Sansone V, Griggs RC, Meola G et al. Andersen’s syndrome: a distinct periodic paralysis. Ann Neurol 1997;
42: 305–312.
The long QT syndrome
105
121 Kimbrough J, Moss AJ, Zareba W et al. Clinical implications for affected parents and siblings of probands with
long-QT syndrome. Circulation 2001; 104: 557–562.
122 Canun S, Perez N, Beirana LG. Andersen syndrome
autosomal dominant in three generations. Am J Med
Genet 1999; 85: 147–156.
123 Plaster NM, Tawil R, Tristani-Firouzi M et al. Mutations
in Kir2.1 Cause the developmental and episodic electrical phenotypes of Andersen’s syndrome. Cell 2001;
105: 511–519.
124 Kubo Y, Baldwin TJ, Jan YN et al. Primary structure and
functional expression of a mouse inward rectifier potassium channel. Nature 1993; 362: 127–133.
125 Stubbs WA. Bidirectional ventricular tachycardia in
familial hypokalaemic periodic paralysis. Proc R Soc
Med 1976; 69: 223–224.
126 Fukuda K, Ogawa S, Yokozuka H et al. Long-standing
bidirectional tachycardia in a patient with hypokalemic
periodic paralysis. J Electrocardiol 1988; 21: 71–75.
127 Grimm W, Ritter M, Alter P et al. Bidirectional ventricular tachycardia due to digitalis intoxication. Z Kardiol
2005; 94: 79–80.
128 Reichenbach H, Meister EM, Theile H. [The heart-hand
syndrome. A new variant of disorders of heart conduction and syndactylia including osseous changes in hands
and feet]. Kinderarztl Prax 1992; 60: 54–56.
129 Marks ML, Trippel DL, Keating MT. Long QT syndrome associated with syndactyly identified in females.
Am J Cardiol 1995; 76: 744–745.
130 Antzelevitch C. Transmural dispersion of repolarization
and the T wave. Cardiovasc Res 2001; 50: 426–431.
131 Belardinelli L, Antzelevitch C, Vos MA. Assessing predictors of drug-induced torsade de pointes. Trends
Pharmacol Sci 2003; 24: 619–625.
132 Antzelevitch C, Sicouri S, Litovsky SH et al. Heterogeneity within the ventricular wall. Electrophysiology
and pharmacology of epicardial, endocardial, and M
cells. Circ Res 1991; 69: 1427–1449.
133 Yan GX, Antzelevitch C. Cellular basis for the normal T
wave and the electrocardiographic manifestations of the
long-QT syndrome. Circulation 1998; 98: 1928–1936.
134 Liu DW, Antzelevitch C. Characteristics of the delayed
rectifier current (IKr and IKs) in canine ventricular epicardial, midmyocardial, and endocardial myocytes. A
weaker IKs contributes to the longer action potential of
the M cell. Circ Res 1995; 76: 351–365.
135 Taggart P, Sutton PM, Opthof T et al. Transmural
repolarisation in the left ventricle in humans during
normoxia and ischaemia. Cardiovasc Res 2001; 50:
454–462.
136 Allessie MA, Bonke FI, Schopman FJ. Circus movement
in rabbit atrial muscle as a mechanism of tachycardia. II.
The role of nonuniform recovery of excitability in the
106 PART 1 Cardiovascular single gene disorders
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
occurrence of unidirectional block, as studied with multiple microelectrodes. Circ Res 1976; 39: 168–177.
Kuo CS, Munakata K, Reddy CP et al. Characteristics
and possible mechanism of ventricular arrhythmia
dependent on the dispersion of action potential durations. Circulation 1983; 67: 1356–1367.
Misier AR, Opthof T, van Hemel NM et al. Dispersion of
“refractoriness” in noninfarcted myocardium of patients with ventricular tachycardia or ventricular fibrillation after myocardial infarction. Circulation 1995; 91:
2566–2572.
Zabel M, Portnoy S, Franz MR. Electrocardiographic
indexes of dispersion of ventricular repolarization: an
isolated heart validation study. J Am Coll Cardiol 1995;
25: 746–752.
Zabel M, Franz MR, Siedow A et al. QT dispersion as a
marker of risk in patients awaiting heart transplantation? J Am Coll Cardiol 1998; 31: 1442–1443.
Priori SG, Napolitano C, Diehl L et al. Dispersion of the
QT interval. A marker of therapeutic efficacy in the
idiopathic long QT syndrome. Circulation 1994; 89:
1681–1689.
Kay GN, Plumb VJ, Arciniegas JG et al. Torsade de
pointes: the long-short initiating sequence and other
clinical features: observations in 32 patients. J Am Coll
Cardiol 1983; 2: 806–817.
Roden DM, Woosley RL, Primm RK. Incidence and
clinical features of the quinidine-associated long QT
syndrome: implications for patient care. Am Heart J
1986; 111: 1088–1093.
Brugada P, Wellens HJ. Early afterdepolarizations:
role in conduction block, “prolonged repolarizationdependent reexcitation,” and tachyarrhythmias in the
human heart. Pacing Clin Electrophysiol 1985; 8: 889–896.
Roden DM. Risks and benefits of antiarrhythmic therapy. N Engl J Med 1994; 331: 785–791.
Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia
suppression after myocardial infarction. N Engl J Med
1989; 321: 406–412.
Waldo AL, Camm AJ, deRuyter H et al. Survival with
oral d-sotalol in patients with left ventricular dysfunction after myocardial infarction: Rationale, design, and
methods (the SWORD trial). Am J Cardiol 1995; 75:
1023–1027.
Tan LB. SWORD trial of d-sotalol. Lancet 1996; 348:
827–828.
Noble D. Modeling the heart: from genes to cells to the
whole organ. Science 2002; 295: 1678–1682.
Heartburn drug Propulsid pulled from US market.
Washington Post Friday, March 24, 2000; 2005, A11.
Defective Drugs. adrugrecall.com. 2005.
152 Lazzara R. Antiarrhythmic drugs and torsade de
pointes. Eur Heart J 1993; 14 (Supplement H): 88–92.
153 Zhou Z, Vorperian VR, Gong Q et al. Block of HERG
potassium channels by the antihistamine astemizole and
its metabolites desmethylastemizole and norastemizole.
J Cardiovasc Electrophysiol 1999; 10: 836–843.
154 Schulze-Bahr E, Haverkamp W, Eckardt L et al. Genetic
aspects in acquired long QT syndrome: a piece in the
puzzle. Eur Heart J Suppl 2001; 3: K48–K52.
155 Yang P, Kanki H, Drolet B et al. Allelic variants in longQT disease genes in patients with drug-associated torsades de pointes. Circulation 2002; 105: 1943–1948.
156 Nattel S, Khairy P, Schram G. Arrhythmogenic ionic
remodeling. Adaptive responses with maladaptive consequences. Trends Cardiovasc Med 2001; 11: 295–301.
157 Swynghedauw B, Baillard C, Milliez P. The long QT
interval is not only inherited but is also linked to cardiac
hypertrophy. J Mol Med 2003; 81: 336–345.
158 Kawasaki T, Azuma A, Kuribayashi T et al. Determinant
of QT dispersion in patients with hypertrophic cardiomyopathy. Pacing Clin Electrophysiol 2003; 26: 819–826.
159 Ramakers C, Vos MA, Doevendans PA et al.
Coordinated down-regulation of KCNQ1 and KCNE1
expression contributes to reduction of I(Ks) in canine
hypertrophied hearts. Cardiovasc Res 2003; 57: 486–496.
160 Dong D, Duan Y, Guo J et al. Overexpression of calcineurin in mouse causes sudden cardiac death associated with decreased density of K+ channels. Cardiovasc
Res 2003; 57: 320–332.
161 Ji S, Cesario D, Valderrabano M et al. The molecular
basis of cardiac arrhythmias in patients with cardiomyopathy. Curr Heart Fail Rep 2004; 1: 98–103.
162 McNair WP, Ku L, Taylor MR et al. SCN5A mutation
associated with dilated cardiomyopathy, conduction
disorder, and arrhythmia. Circulation 2004; 110: 2163–
2167.
163 Antzelevitch C. Molecular genetics of arrhythmias and
cardiovascular conditions associated with arrhythmias.
J Cardiovasc Electrophysiol 2003; 14: 1259–1272.
164 Boccalandro F, Velasco A, Thomas C et al. Relations
among heart failure severity, left ventricular loading
conditions, and repolarization length in advanced heart
failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 2003; 92: 544–547.
165 Carlsson L, Almgren O, Duker G. QTU-prolongation
and torsades de pointes induced by putative class III
antiarrhythmic agents in the rabbit: etiology and interventions. J Cardiovasc Pharmacol 1990; 16: 276–285.
166 Hondeghem LM, Carlsson L, Duker G. Instability and
triangulation of the action potential predict serious
proarrhythmia, but action potential duration prolongation is antiarrhythmic. Circulation 2001; 103: 2004–
2013.
CHAPTER 5
167 Hondeghem LM, Dujardin K, De Clerck F. Phase 2 prolongation, in the absence of instability and triangulation, antagonizes class III proarrhythmia. Cardiovasc
Res 2001; 50: 345–353.
168 van Opstal JM, Verduyn SC, Leunissen HDM et al.
Electrophysiological parameters indicative of sudden
cardiac death in the dog with chronic complete AVblock. Cardiovasc Res 2001; 50: 354–361.
169 Antzelevitch C, Belardinelli L, Zygmunt AC et al.
Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 2004; 110: 904–910.
170 Milberg P, Eckardt L, Bruns HJ et al. Divergent proarrhythmic potential of macrolide antibiotics despite
similar QT prolongation: Fast phase 3 repolarization
prevents early afterdepolarizations and torsade de
pointes. J Pharmacol Exp Ther 2002; 303: 218–225.
171 Thomsen MB, Verduyn SC, Stengl M et al. Increased
short-term variability of repolarization predicts dsotalol-induced torsades de pointes in dogs. Circulation
2004; 110: 2453–2459.
172 Thomsen MB, Volders PGA, Stengl M et al. Electrophysiological safety of sertindole in dogs with normal
and remodeled hearts. J Pharmacol Exp Ther 2003; 307:
776–784.
173 Morganroth J. A definitive or thorough phase 1 QT ECG
trial as a requirement for drug safety assessment. J Electrocardiol 2004; 37: 25–29.
174 Jost N, Virag L, Bitay M et al. Restricting excessive cardiac action potential and QT prolongation. A vital role
for IKs in human ventricular muscle. Circulation 2005;
112: 1392–1399.
175 Silva J, Rudy Y. Subunit interaction determines IKs participation in cardiac repolarization and repolarization
reserve. Circulation 2005; 112: 1384–1391.
176 Belardinelli L, Antzelevitch C, Vos MA. Assessing predictors of drug-induced torsade de pointes. Trends
Pharmacol Sci 2003; 24: 619–625.
177 Weissenburger J, Davy JM, Chezalviel F et al. Arrhythmogenic activities of antiarrhythmic drugs in conscious
hypokalemic dogs with atrioventricular block: comparison
between quinidine, lidocaine, flecainide, propranolol
and sotalol. J Pharmacol Exp Ther 1991; 259: 871–883.
178 Vos MA, de Groot SHM, Verduyn SC et al. Enhanced
susceptibility for acquired torsade de pointes arrhythmias in the dog with chronic, complete AV block is
related to cardiac hypertrophy and electrical remodeling. Circulation 1998; 98: 1125–1135.
179 Schreiner KD, Kelemen K, Zehelein J et al. Biventricular
hypertrophy in dogs with chronic AV block: effects of
cyclosporin A on morphology and electrophysiology.
Am J Physiol Heart Circ Physiol 2004; 287: H2891–
H2898.
The long QT syndrome
107
180 Chiba K, Sugiyama A, Hagiwara T et al. In vivo experimental approach for the risk assessment of fluoroquinolone antibacterial agents-induced long QT syndrome.
Eur J Pharmacol 2004; 486: 189–200.
181 Vos MA. Preclinical evaluation of antiarrhythmic drugs:
new drugs should be safe to be successful. J Cardiovasc
Electrophysiol 2001; 12: 1034–1036.
182 Vos MA, de Groot SH, Verduyn SC et al. Enhanced susceptibility for acquired torsade de pointes arrhythmias
in the dog with chronic, complete AV block is related
to cardiac hypertrophy and electrical remodeling. Circulation 1998; 98: 1125–1135.
183 de Groot SH, Schoenmakers M, Molenschot MM et al.
Contractile adaptations preserving cardiac output
predispose the hypertrophied canine heart to delayed
afterdepolarization-dependent ventricular arrhythmias.
Circulation 2000; 102: 2145–2151.
184 Verduyn SC, Vos MA, van der ZJ et al. Further observations to elucidate the role of interventricular dispersion
of repolarization and early afterdepolarizations in the
genesis of acquired torsade de pointes arrhythmias: a
comparison between almokalant and d-sotalol using the
dog as its own control. J Am Coll Cardiol 1997; 30:
1575–1584.
185 Ramakers C, Vos MA, Doevendans PA et al.
Coordinated down-regulation of KCNQ1 and KCNE1
expression contributes to reduction of I(Ks) in canine
hypertrophied hearts. Cardiovasc Res 2003; 57: 486–496.
186 Carlsson L, Abrahamsson C, Andersson B et al. Proarrhythmic effects of the class III agent almokalant:
importance of infusion rate, QT dispersion, and early
afterdepolarisations. Cardiovasc Res 1993; 27: 2186–
2193.
187 Yan GX, Shimizu W, Antzelevitch C. Characteristics
and distribution of M cells in arterially perfused canine
left ventricular wedge preparations. Circulation 1998;
98: 1921–1927.
188 Yan GX, Wu Y, Liu T et al. Phase 2 early afterdepolarization as a trigger of polymorphic ventricular tachycardia
in acquired long-QT syndrome: direct evidence from
intracellular recordings in the intact left ventricular
wall. Circulation 2001; 103: 2851–2856.
189 Shimizu W, Antzelevitch C. Differential effects of betaadrenergic agonists and antagonists in LQT1, LQT2 and
LQT3 models of the long QT syndrome. J Am Coll
Cardiol 2000; 35: 778–786.
190 Shimizu W, Antzelevitch C. Sodium channel block with
mexiletine is effective in reducing dispersion of repolarization and preventing torsade des pointes in LQT2 and
LQT3 models of the long-QT syndrome. Circulation
1997; 96: 2038–2047.
191 Shimizu W, Antzelevitch C. Cellular basis for the ECG
features of the LQT1 form of the long-QT syndrome:
108 PART 1 Cardiovascular single gene disorders
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
effects of beta-adrenergic agonists and antagonists and
sodium channel blockers on transmural dispersion of
repolarization and torsade de pointes. Circulation 1998;
98: 2314–2322.
Nerbonne JM. Studying cardiac arrhythmias in the
mouse: A reasonable model for probing mechanisms?
Trends Cardiovasc Med 2004; 14: 83–93.
Berul CI. Electrophysiological phenotyping in genetically engineered mice. Physiol Genomics 2003; 13:
207–216.
Gehrmann J, Berul CI. Cardiac electrophysiology in
genetically engineered mice. J Cardiovasc Electrophysiol
2000; 11: 354–368.
Berul CI, Aronovitz MJ, Wang PJ et al. In vivo cardiac
electrophysiology studies in the mouse. Circulation
1996; 94: 2641–2648.
London B. Cardiac arrhythmias: from (transgenic) mice
to men. J Cardiovasc Electrophysiol 2001; 12: 1089–1091.
Papadatos GA, Wallerstein PM, Head CE et al. Slowed
conduction and ventricular tachycardia after targeted
disruption of the cardiac sodium channel gene Scn5a.
Proc Natl Acad Sci USA 2002; 99: 6210–6215.
London B. Cardiac arrhythmias: from (transgenic) mice
to men. J Cardiovasc Electrophysiol 2001; 12: 1089–1091.
Mitchell GF, Jeron A, Koren G. Measurement of heart
rate and Q-T interval in the conscious mouse. Am J
Physiol 1998; 274: H747–H751.
Wang L, Duff HJ. Developmental changes in transient
outward current in mouse ventricle. Circ Res 1997; 81:
120–127.
Wang L, Feng ZP, Kondo CS et al. Developmental
changes in the delayed rectifier K+ channels in mouse
heart. Circ Res 1996; 79: 79–85.
Kupershmidt S, Yang T, Anderson ME et al. Replacement by homologous recombination of the minK gene
with lacZ reveals restriction of minK expression to the
mouse cardiac conduction system. Circ Res 1999; 84:
146–152.
Temple J, Frias P, Rottman J et al. Atrial fibrillation in
KCNE1-null mice. Circ Res 2005; 97: 62–69.
Cerrone M, Colombi B, Santoro M et al. Bidirectional
ventricular tachycardia and fibrillation elicited in a
knock-in mouse model carrier of a mutation in the cardiac ryanodine receptor. Circ Res 2005; 96: e77–e82.
Tanaka M, Berul CI, Ishii M et al. A mouse model of
congenital heart disease: cardiac arrhythmias and atrial
septal defect caused by haploinsufficiency of the cardiac
transcription factor Csx/Nkx2.5. Cold Spring Harb Symp
Quant Biol 2002; 67: 317–325.
Xiao HD, Fuchs S, Campbell DJ et al. Mice with cardiacrestricted angiotensin-converting enzyme (ACE) have
atrial enlargement, cardiac arrhythmia, and sudden
death. Am J Pathol 2004; 165: 1019–1032.
207 Gutstein DE, Morley GE, Vaidya D et al. Heterogeneous
expression of Gap junction channels in the heart leads to
conduction defects and ventricular dysfunction. Circulation 2001; 104: 1194–1199.
208 Gutstein DE, Morley GE, Tamaddon H et al. Conduction slowing and sudden arrhythmic death in mice with
cardiac-restricted inactivation of connexin 43. Circ Res
2001; 88: 333–339.
209 Petersen CI, McFarland TR, Stepanovic SZ et al. In vivo
identification of genes that modify ether-a-go-gorelated gene activity in Caenorhabditis elegans may also
affect human cardiac arrhythmia. Proc Natl Acad Sci
USA 2004; 101: 11773–11778.
210 Luo CH, Rudy Y. A dynamic model of the cardiac
ventricular action potential. II. Afterdepolarizations,
triggered activity, and potentiation. Circ Res 1994; 74:
1097–1113.
211 Luo CH, Rudy Y. A dynamic model of the cardiac ventricular action potential. I. Simulations of ionic currents
and concentration changes. Circ Res 1994; 74: 1071–
1096.
212 Luo CH, Rudy Y. A model of the ventricular cardiac
action potential. Depolarization, repolarization, and
their interaction. Circ Res 1991; 68: 1501–1526.
213 Henry H, Rappel WJ. The role of M cells and the long
QT syndrome in cardiac arrhythmias: simulation studies of reentrant excitations using a detailed electrophysiological model. Chaos 2004; 14: 172–182.
214 Roden DM, Lazzara R, Rosen M et al. Multiple mechanisms in the long-QT syndrome. Current knowledge,
gaps, and future directions. The SADS Foundation Task
Force on LQTS. Circulation 1996; 94: 1996–2012.
215 Noda T, Takaki H, Kurita T et al. Gene-specific response
of dynamic ventricular repolarization to sympathetic
stimulation in LQT1, LQT2 and LQT3 forms of congenital long QT syndrome. Eur Heart J 2002; 23: 975–983.
216 Nosworthy A. Images in clinical medicine. Hypokalemia. N Engl J Med 2003; 349: 2116.
217 Yang T, Roden DM. Extracellular potassium modulation of drug block of IKr. Implications for torsade de
pointes and reverse use-dependence. Circulation 1996;
93: 407–411.
218 Yang T, Snyders DJ, Roden DM. Rapid inactivation
determines the rectification and [K+]o dependence of
the rapid component of the delayed rectifier K+ current
in cardiac cells. Circ Res 1997; 80: 782–789.
219 Numaguchi H, Johnson JP Jr, Petersen CI et al. A sensitive mechanism for cation modulation of potassium
current. Nat Neurosci 2000; 3: 429–430.
220 Tan HL, Alings M, Van Olden RW et al. Long-term
(subacute) potassium treatment in congenital HERGrelated long QT syndrome (LQTS2). J Cardiovasc Electrophysiol 1999; 10: 229–233.
CHAPTER 5
221 Etheridge SP, Compton SJ, Tristani-Firouzi M et al.
A new oral therapy for long QT syndrome: long-term
oral potassium improves repolarization in patients with
HERG mutations. J Am Coll Cardiol 2003; 42: 1777–
1782.
222 Pham TV, Rosen MR. Sex, hormones, and repolarization. Cardiovasc Res 2002; 53: 740–751.
223 Locati EH, Zareba W, Moss AJ et al. Age- and sexrelated differences in clinical manifestations in patients
with congenital long-QT syndrome: findings from the
International LQTS Registry. Circulation 1998; 97:
2237–2244.
224 Lehmann MH, Timothy KW, Frankovich D et al. Agegender influence on the rate-corrected QT interval and
the QT-heart rate relation in families with genotypically
characterized long QT syndrome. J Am Coll Cardiol
1997; 29: 93–99.
225 Lehmann MH, Hardy S, Archibald D et al. Sex difference in risk of torsade de pointes with d,l-sotalol.
Circulation 1996; 94: 2535–2541.
226 Rodriguez I, Kilborn MJ, Liu XK et al. Drug-induced
QT prolongation in women during the menstrual cycle.
JAMA 2001; 285: 1322–1326.
227 Schwartz PJ, Moss AJ, Vincent GM et al. Diagnostic criteria for the long QT syndrome. An update. Circulation
1993; 88: 782–784.
228 Takenaka K, Ai T, Shimizu W et al. Exercise stress test
amplifies genotype–phenotype correlation in the LQT1
and LQT2 forms of the long-QT syndrome. Circulation
2003; 107: 838–44.
229 Shimizu W, Noda T, Takaki H et al. Epinephrine
unmasks latent mutation carriers with LQT1 form of
congenital long-QT syndrome. J Am Coll Cardiol 2003;
41: 633–642.
230 Shimizu W, Antzelevitch C. Effects of a K(+) channel
opener to reduce transmural dispersion of repolarization and prevent torsade de pointes in LQT1, LQT2, and
LQT3 models of the long-QT syndrome. Circulation
2000; 102: 706–712.
231 Aiba T, Shimizu W, Inagaki M et al. Cellular and ionic
mechanism for drug-induced long QT syndrome and
effectiveness of verapamil. J Am Coll Cardiol 2005; 45:
300–307.
232 Schwartz PJ, Priori SG, Cerrone M et al. Left cardiac
sympathetic denervation in the management of highrisk patients affected by the long-QT syndrome. Circulation 2004; 109: 1826–1833.
233 Priori SG, Napolitano C, Schwartz PJ et al. Association
of long QT syndrome loci and cardiac events among
patients treated with beta-blockers. JAMA 2004; 292:
1341–1344.
234 Etheridge SP, Compton SJ, Tristani-Firouzi M et al.
A new oral therapy for long QT syndrome: long-term
235
236
237
238
239
240
241
242
243
244
245
246
247
248
The long QT syndrome
109
oral potassium improves repolarization in patients with
HERG mutations. J Am Coll Cardiol 2003; 42: 1777–
1782.
Shimizu W. The long QT syndrome: Therapeutic implications of a genetic diagnosis. Cardiovasc Res 2005; 67:
347–356.
Schwartz PJ, Priori SG, Locati EH et al. Long QT syndrome patients with mutations of the SCN5A and
HERG genes have differential responses to Na+ channel
blockade and to increases in heart rate. Implications for
gene-specific therapy [see comments]. Circulation 1995;
92: 3381–3386.
Shimizu W, Antzelevitch C. Sodium channel block with
mexiletine is effective in reducing dispersion of repolarization and preventing torsade des pointes in LQT2 and
LQT3 models of the long-QT syndrome. Circulation
1997; 96: 2038–2047.
Wang DW, Yazawa K, Makita N et al. Pharmacological
targeting of long QT mutant sodium channels. J Clin
Invest 1997; 99: 1714–1720.
Abriel H, Wehrens XH, Benhorin J et al. Molecular
pharmacology of the sodium channel mutation D1790G
linked to the long-QT syndrome. Circulation 2000; 102:
921–925.
Benhorin J, Taub R, Goldmit M et al. Effects of
flecainide in patients with new SCN5A mutation:
mutation-specific therapy for long-QT syndrome?
Circulation 2000; 101: 1698–1706.
Schwartz PJ, Priori SG, Locati EH et al. Long QT syndrome patients with mutations of the SCN5A and
HERG genes have differential responses to Na+ channel
blockade and to increases in heart rate. Implications for
gene-specific therapy. Circulation 1995; 92: 3381–3386.
Shimizu W. The long QT syndrome: Therapeutic implications of a genetic diagnosis. Cardiovasc Res 2005; 67:
347–356.
Zareba W, Moss AJ, Daubert JP et al. Implantable cardioverter defibrillator in high-risk long QT syndrome
patients. J Cardiovasc Electrophysiol 2003; 14: 337–341.
Welde AA. Is there a role for implantable cardioverter
defibrillators in long QT syndrome? J Cardiovasc Electrophysiol 2002; 13: S110–S113.
Eldar M, Griffin JC, Van Hare GF et al. Combined use of
beta-adrenergic blocking agents and long-term cardiac
pacing for patients with the long QT syndrome. J Am
Coll Cardiol 1992; 20: 830–837.
Woosley RL. ArizonaCERT. University of Arizona
Health Sciences Center.
Mervis J. Productivity counts—but the definition is key.
Science 2005; 309: 726.
Kaitin KI. Post-approval R&D raises total drug development costs to $897 million. Tufts Center Study Drug Dev
Impact Rep 2003; 5: 1.
110 PART 1 Cardiovascular single gene disorders
249 Netzer R, Ebneth A, Bischoff U et al. Screening lead
compounds for QT interval prolongation. Drug Discov
Today 2001; 6: 78–84.
250 Padrini R, Speranza G, Nollo G et al. Adaptation of the
QT interval to heart rate changes in isolated perfused
guinea pig heart: influence of amiodarone and Dsotalol. Pharmacol Res 1997; 35: 409–416.
251 Brown AM. Drugs, hERG and sudden death. Cell
Calcium 2004; 35: 543–547.
252 Summerton J, Weller D. Morpholino antisense oligomers: design, preparation, and properties. Antisense
Nucleic Acid Drug Dev 1997; 7: 187–195.
253 Langheinrich U. Zebrafish: a new model on the pharmaceutical catwalk. Bioessays 2003; 25: 904–912.
254 Sehnert AJ, Stainier DY. A window to the heart: can
zebrafish mutants help us understand heart disease in
humans? Trends Genet 2002; 18: 491–494.
255 Sehnert AJ, Huq A, Weinstein BM et al. Cardiac troponin T is essential in sarcomere assembly and cardiac
contractility. Nat Genet 2002; 31: 106–110.
256 Chen JN, Fishman MC. Genetics of heart development.
Trends Genet 2000; 16: 383–388.
257 Langheinrich U, Vacun G, Wagner T. Zebrafish
embryos express an orthologue of HERG and are sensitive toward a range of QT-prolonging drugs inducing severe arrhythmia small star, filled. Toxicol Appl
Pharmacol 2003; 193: 370–382.
258 Milan DJ, Peterson TA, Ruskin JN et al. Drugs that
induce repolarization abnormalities cause bradycardia
in zebrafish. Circulation 2003; 107: 1355–1358.
259 Klein R, Gamelin R, Marks JF et al. Periodic paralysis
with cardiac arrhythmia. J Pediatr 1963; 62: 371–385.
II
PART II
Cardiovascular
polygenic disorders
Circulating cAMP⇑ + solute and water reabsorption (kidney)
pancreas
glucagon
hepatic cAMP
Angiotensinogen
Liver
Non-ACE pathway
7-TMD
β
α
α
+
β receptor GDP
GTP
GTP GDP
Direct: vasorelaxation
Renin
Insulin
Angiotensin I
Via endothelium
Bradykinin
ACE
Inactive peptides and
amino acids
Angiotensin II
Endothelins
Prostacyclin
Prostacyclin
ATIR vascular-adrenal
ANP
synthase
ELAM NO
NOS3
−
+
L-arginine
Blg ET-1 Endcthellal
Cell
ECE
Enzyme ATP cAMP
Adrenal cortex
+
ATP
R2C2 protein
+ 2C
CYP11B2
ADP
kinase
2R
Aldosterone
Enzyme-PO2
ET-1
ET G-proteins
Increased force of contraction,
Increased AV nodal conduction
velocity
Increase heart rate
HypothalamusPitoitary
ADH
Winteraklosterone – Salt and water retention
Kidney
Cardiac Output
Ca2+
vasoconstriction
Heart rate – Systemic resistance
Endothelin2
IPa
Smooth Muscle
contraction
Biologic effect
Heart
SAH
ANP
Vasoactivity
Variants of epithelial Na channel
Gene (Liddle syndrome)
Vessel smooth
muscles
Na-K ATPase
α β
Variants of
α-Adducin gene
Salt retention
Peripheral resistance
Network of pathways and genes postulated to be associated with blood pressure regulation.
ACE, angiotensin-converting enzyme; ADH, antidiuretlc hormone (vasopressin); ANP, atrial natriuretic peptide; AT1R,
angiotensin II type 1 receptor; AV, atrioventricular; ECE, endothelin-converting enzyme ELAM, endothelial leukocyte
adhesion molecule 1 (E-selectin); ET-1, endothelin-1; IP3, inositol tris-phosphate; NO, nitric oxide; NOS, nitric oxide synthase;
SAH, SA hypertension-associated homolog (rat); 7-TMD, seven-transmembrane domain. Reprinted from Marteau J-B, Zaiou
M, Siest G, Visvikis-Siest S. Genetic determinants of blood pressure regulation. J Hypertens 2005; 23: 2127–2143 with
permission from Lippincott Williams and Wilkins.
6
CHAPTER 6
Atherosclerosis
Päivi Pajukanta, MD, PhD, Kiat Tsong Tan, MD, MRCP, FRCR
& Choong-Chin Liew, PhD
Introduction
For hundreds of years observers have been interested in the unusual lesions of atherosclerosis.
Renaissance artist Leonardo da Vinci complained
of the “waxy fat” that made some arteries difficult
to draw and provided some early descriptions of
arteriosclerosis in elderly men. The first complete
and accurate description of intimal atheromatous
lesions is that of the eighteenth century Italian
anatomist Antonio Scarpa who wrote graphically of
the “slow, morbid ulcerated, steatomatous, fungus,
squamous degeneration of the internal coat of the
artery.” The word “atheroma” derives from the
Greek for gruel or porridge and was first used with
reference to human arteries by Swiss physiologist
Albrecht von Haller in 1755; the term “atherosclerosis” as we use it today to describe disease of the
coronary artery intima was coined in the first years
of the twentieth century by Leipzig pathologist,
Felix Marchand [1,2].
Data from previous clinical and epidemiologic
studies have shown that several risk factors, including age, male sex, family history of myocardial
infarction (MI), increased serum total and low density lipoprotein cholesterol (LDL-C), decreased
serum high density lipoprotein cholesterol (HDLC), smoking and diabetes mellitus, predict the risk
for atherogenesis [3–11]. More recently, inflammation linked with disadvantageous plasma lipoprotein profile and chronic infections were suggested
as risk factors for coronary artery disease (CAD)
[12–14]. It has become evident that atherosclerosis
is a complex multifactorial phenomenon. Furthermore, risk factors appear to cluster and interact in
individuals and families, making it challenging to
determine the level of risk. Evaluation of risk is
further hampered by the largely unknown relationship and interactions among the underlying genetic
and environmental factors. Currently, atherosclerosis is considered to be a highly complex heterogeneous disease involving the actions of more than
400 genes [15] and an ever increasing number of
genetic, environmental and endogenous risk factors continue to be identified as acting singly and
in combination to modify gene expression to contribute to or to protect against the development of
CAD. Today atherosclerosis, presenting as CAD,
stroke and peripheral artery disease, is the most
common cause of morbidity and mortality in western and westernizing societies. About half of all
people in the USA die from atherosclerosis-related
complications, and cardiovascular disease worldwide is expected to increase significantly over the
next 20 years [16].
Up until about 20 years ago, the lesions of
atherosclerosis were mainly regarded as degenerative by-products of the atherosclerotic process;
atherosclerosis itself was considered to be a build
up of bland degenerative lipid products, and angina
and thrombosis were thought to be the consequence of narrowing of the artery to occlusion as
a result of lipid accumulation. However, this view
has drastically changed. For the past 20 years researchers have been dissecting out the intricate cellular and molecular signaling and communication
pathways, the genetic, molecular and cellular activity that drives atherosclerotic lesion formation.
Thanks in large part to this work, atherosclerosis
today is regarded as a complex, ongoing inflammatory process. The lesions of atherosclerosis are
considered to have important roles in driving the
113
114 PART II Cardiovascular polygenic disorders
atheromatous process from initial endothelial injury to final plaque disruption and disease manifestations such as stroke and MI [17].
In this chapter we explore first the cellular and
tissue changes that initiate the process of lesion
formation in atherosclerosis and, second, the molecular and gene level changes as the disease advances
from benign to increasingly more dangerous.
Studies in the molecular biology of atherosclerosis
over the past two decades have provided numerous
clues to novel diagnostic, prognostic and therapeutic approaches to atherosclerosis and in the final
section we review how molecular biologic insights
can be translated into clinical applications for the
future.
Endothelial dysfunction and lesion
formation: A general view
Theories of the pathogenesis of atherosclerosis have
undergone considerable changes in the past few
decades. Earlier conceptualizations of atherosclerosis as for the most part a disorder of lipid storage
have given way to the “response to injury” hypothesis originally described by Ross and Glomset [18].
In this model, atherosclerosis is considered to be
essentially an inflammatory and immune response
process, triggered and maintained as a response to
ongoing systemic biochemical injury (reviewed in
[19,20]). This hypothesis focuses on the cardiovascular system not as a set of passive mechanical
structures but at the molecular biologic level as
active players in atherosclerotic events. Gimbrone
and Topper [21] have well described the blood vessel as a “community of cells.” It is by exploring the
microcomponents of this community and their
inter- and intracellular interactions and signals as
they work together to maintain homeostasis in
health and become maladaptive and ultimately
self-destructive in disease that we can best understand atherosclerosis.
The lesions of atherosclerosis start with vascular
endothelial dysfunction. The vascular endothelium
is the 700 m2, single-cell-thick luminal lining of the
vascular system. The healthy functioning of the
vascular endothelium is the first line of defense
against atherosclerosis and this highly interesting
tissue has lately received a great deal of research
attention [21–23].
The endothelium is most obviously a tissue of
structural importance. It is the innermost layer of
the artery and acts as a barrier between the blood
flowing in the intravascular space and the wall of
the artery itself. The endothelium is also a complex
and active tissue, even a cardiovascular organ in its
own right, with paracrine, endocrine and autocrine
functions [21]. The endothelial cells synthesize and
release vasoactive substances and have a number of
important functional properties. First, healthy
endothelial cells regulate the vascular tone of the
cardiovascular system; second, they are antithrombotic, inhibiting platelet aggregation and coagulation so that blood circulates through the arterial
vessels without clotting; and third, the endothelium
is nonadhesive. Endothelial cells are able to sense
changes in their microclimate; to signal these
changes to other cells and to respond to alterations
in order to maintain vascular homeostasis.
It is thus in specific areas of the vascular system
where the endothelium is functioning less well that
the first changes leading to atherosclerosis become
evident. In areas of endothelial dysfunction the
endothelial cells lose some protective function,
becoming pro- rather than anti-atherogenic. In
particular, in areas of altered function the endothelium becomes more permeable to plasma lipoproteins, shows increased monocyte adhesion, altered
vasoreactivity and other signs of inflammatory
changes begin to occur in the vessel wall.
It is at these areas of endothelial dysfunction that
the first lesions associated with atherosclerosis
develop, the so-called fatty streaks. Fatty streaks are
yellowish inflammatory lesions that develop in the
intima within the artery wall. Varying from the size
of a pinhead to covering large areas, fatty streaks are
to be found in the arteries of very young children
[24] and even in premature fetuses [25], and by the
age of 10–14 years some 50% of childhood autopsy
specimens show evidence of fatty streak lesions
[26]. In humans, fatty streaks can be found in the
aorta in the first few years of life; the coronary arteries in the teens; and cerebral arteries in third to
fourth decades of life [16].
Analysis of characteristic fatty streak lesions
finds them to contain inflammatory monocytes
and T lymphocyte cells as well as oxidized lipids
such as low density lipoprotein (LDL). Intralesional monocytes become macrophages, able to
CHAPTER 6
digest large amounts of the surrounding oxidated
lipoprotein particles. Such lipid laden macrophages, or foam cells, together with T cells form the
bulk of fatty streaks. It is these lipid filled foam cells
that account for the gruel- or cereal-like yellowish
substance that is observed in atheroma.
The next stage in development of atherosclerosis
is the formation of “intermediate or fibrofatty
lesions.” Similar in appearance to the fatty streaks,
intermediate lesions are more complex in composition. Ongoing inflammation stimulates smooth
muscle cells to migrate to the area of injury. Contractile smooth muscle cells undergo phenotypic
changes, becoming noncontractile and then fibrous.
Neither the fatty streaks nor the more complex
intermediate lesions are immediately harmful.
Such lesions can in fact be viewed as protective
responses to insult, as is wound healing in general
in the body. If the injury were a one time or occasional event, then these changes would be benign
and reversible. However, as Ross [26] observes, in
the atherogenic milieu the biochemical injury tends
to be constant and chronic, such as smoking, diabetes or hypercholesterolemia. Such ongoing insult
prevents the inflammatory process from ceasing,
becoming maladaptive and harmful as the lesions
continue to develop.
The next stage of atherogenesis is the formation
of arterial plaques. These are well-defined lesions
containing a lipid core, collagen, elastic fibres and
proteoglycans and covered with cap of fibrous
tissue, composed of smooth muscle cells and connective tissue. Patients with early atherosclerotic
plaques often do not exhibit symptoms of chronic
ischemia as the arterial lumen can be remarkably
normal at this stage, because of the phenomenon
of positive remodeling. However, the absence of
symptoms does not mean that these patients are
not at risk of acute atherothrombosis, as even the
smallest of plaques is liable to rupture. As the plaque
grows, the lesions may obtrude into the artery
lumen and it was long thought that it was this gradual and insidious narrowing of the lumen over time
that was the causal event in angina and coronary
thrombosis. However, it is now believed that although occlusion may have a role in some cases, it
is the physical disruption of plaques that is the
cause of acute coronary events. That is, the lesions
become unstable and either stimulate in situ throm-
Atherosclerosis
115
bosis or, more rarely, break off to form distal
emboli. Either of these events can cause obstruction
of the coronary arterial tree, which ultimately results
in the manifestation of acute cardiac ischemia.
Steps in lesion formation:
Molecular and gene levels
The challenge for the molecular biologist is to identify the genes and gene expression changes that
drive the pathologic process of lesion formation
from dysfunction of the normal healthy endothelium to fatty intimal deposits, plaque formation,
rupture and thrombosis [23].
The initiating events in endothelial dysfunction
have long been a subject of investigation. If endothelial dysfunction were solely a consequence of
biochemical risk factors such as smoking or high
cholesterol or homocysteine levels then we would
expect that blood vessels would be uniformly prone
to disease: that atheroma would be found throughout the length of the arteries. However, it has long
been known that atherosclerotic lesions do not
occur uniformly or randomly throughout the vascular system. On the contrary, atheroma is more
likely to be found in specific locations in the vasculature: in arterial branches and bifurcations;
straight vessels, by contrast, are less likely to
develop atherogenic lesions [27].
The most relevant geographical differences between vascular regions where atheromatous lesions
occur compared with where they do not occur is
that blood flow patterns are significantly altered in
arterial branches compared to straight arterial
regions. Hemodynamic shear stress forces such as
turbulence tends to affect curvatures in the arterial
landscape; straight vessels experience uniform, relatively constant laminar shear stress. Thus, shear
stress may act as a “local” risk factor, contributing
to endothelial dysfunction.
Are there genes whose expression may be altered
under conditions of altered shear stresses? One such
molecule is the nitric oxide synthase 3 (NOS3) gene
encoding the enzyme endothelial cell nitric oxide
synthase (eNOS). The NOS3 gene is a key factor
linking shear stress and endothelial dysfunction.
The biologically ubiquitous gas nitric oxide was
named molecule of the year by Science magazine in
1992 [28]. Nitric oxide was identified as the original
116 PART II Cardiovascular polygenic disorders
endothelium derived relaxant factor [29] and is
of crucial importance in maintaining healthy endothelium [30]. In vascular tissue, nitric oxide is
atheroprotective: it regulates vascular tone and
vasomotor function, it counteracts leukocyte adhesion to the endothelium, opposes vascular smooth
muscle proliferation and inhibits platelet aggregation. Nitric oxide is thus a major component of
defense against vascular injury, inflammation and
thrombosis [22].
Nitric oxide is synthesized in endothelial tissue
by eNOS encoded by NOS3. The NOS3 gene
expression is influenced by biomechanical fluid
shear stresses generated by local conditions of blood
flow. Cultured human endothelial cells undergo gene
expression changes under conditions of altered shear
stress. For example, Topper et al. [27] showed that
steady laminar blood flow, mimicking conditions
occurring as blood flows through straight vessels,
upregulates NOS3, as well as manganese superoxide dismutase and other atheroprotective genes.
By upregulating genes that are anti-oxidant, antithrombotic and anti-adhesive, laminar blood flow
creates conditions within the artery that are atheroprotective. Turbulent blood flow, by contrast,
which might occur at artery branches, does not
appear to upregulate NOS3. Thus, specific areas
within the artery may have decreased local nitric
oxide production, leading to endothelial dysfunction at these vulnerable areas.
Areas of altered endothelial function are also
characterized by increasing “stickiness” of the
endothelial cells to circulating monocytes. Normally, mononuclear leukocytes circulate freely through
the blood and do not adhere to the vascular endothelium. In conditions conducive to atherosclerosis
such as hypercholesterolemia, however, large numbers of mononuclear cells can be found attaching
to the endothelium in the specific areas prone to
atheroma [31,32].
Abnormal localized stickiness is a result of
endothelial cell activation or overexpression of
specific leukocyte adhesion molecules. Leukocyte
adhesion molecules are proteins which, when activated on the surface of the endothelial cells,
increase adherence of monocytes and T cells to
the endothelial surface [33]. Adhesion molecule
expression occurs at the specific focal sites that are
prone to develop atherosclerosis. Normal endothe-
lium shows little to no such expression of adhesion
molecules.
One of the first endothelial adhesion molecules
to be identified was vascular cell adhesion molecule
1 (VCAM-1). VCAM-1 is specialized to recruit
circulating leukocytes, specifically monocytes and
T lymphocytes. Early experiments showed that in
response to cholesterol feeding in rabbits, endothelial cells express mononuclear leukocyte selective
VCAM-1 in localized areas of the aorta close to
developing atheroma [34]. VCAM-1 expression is
increased in early stage disease [35] and is also
expressed in advanced atherogenic plaques [36].
Mice genetically engineered with defective VCAM1 expression showed reduced foam cell lesion
development [37]. Other adhesion molecules
upregulated in atherosclerosis include P selectin,
E selectin and intercellular adhesion molecule 1
(ICAM-1) [33].
Once monocytes and T cells attach to activated
endothelial cells via adhesion molecules, these cells
are able to effect passage through the single cell
layer of endothelium, between the endothelial cells
and into the coronary vessel intima. Little is known
about the process of transmigration. Specific
proinflammatory chemokines are expressed in
atheroma and have been identified, including monocyte chemoattractant protein 1 (MCP-1) [38] and
various T-cell chemoattractants [39].
Endothelial dysfunction is also characterized by
increased permeability to lipoproteins [21]. It is
now firmly established that cholesterol levels are
important contributors to atherogenesis, in particular levels of LDL. In endothelial dysfunction,
circulating LDL attaches itself to the wall of the
artery in the areas that endothelial cells have become altered because of shear stress. Via transcellular or pericellular mechanisms, LDL transmigrates
through the normally impermeable endothelial
barrier into the intima.
Although LDL circulating in plasma is nontoxic,
once trapped in the subendothelial matrix, LDL
seems to become more susceptible to enzymatic
induced oxidative changes, becoming oxidized
LDL (oxLDL), a proinflammatory substance [20].
For example, oxLDL contains bioactive lysophosphatidyl choline and other phospholipids, which
act to upregulate several genes including the adhesion molecules VCAM-1 and ICAM-1 and growth
CHAPTER 6
factors such as platelet derived growth factor
(PDGF) and heparin epidermal binding growth
factor-like protein (HB-EGF) [40,41]. Growth
factors are important mediators of smooth muscle
cell and fibroblast migration and proliferation.
The exact role of oxLDL and the relevance of this
modified lipoprotein to atherosclerosis continue to
be under investigation.
The combination of monocytes and oxLDL
within the arterial intima initiates a number of gene
changes driving the activation of monocytes. This
transformation involves the activation of molecular scavenger receptors on mononuclear cells.
Scavenger receptors are proteins structured to be
able to recognize and rapidly to accumulate oxLDL
[42]. Several molecules of this class have been
identified including scavenger receptors of the SRA
series and CD36 (reviewed in [20]). Genetically
engineered ApoE deficient mice lacking scavenger
receptor expression are less likely than control mice
to develop atherosclerosis [20].
Macrophages contribute to host cell defense by
acting as phagocytes, recognizing and removing
foreign or noxious substances, and it is thought
that initial macrophage removal of cytotoxic and
inflammatory oxLDL is a protective process [20,43].
Macrophages also act as signaling cells in the
inflammatory cascade and release cytokines such as
tumor necrosis factor α (TNF-α) [44,45]. Macrophage derived TNF-α has important proinflammatory autocrine and paracrine effects. Cell
stimulation by TNF-α leads to the downstream
activation of the proinflammatory transcription
factor nuclear factor κB (NF-κB) [46]. Activation
of NF-κB leads to the upregulation of various adhesion molecules (e.g. VCAM-1, E selectin), the production and release of proinflammatory cytokines
(e.g. interleukin-1β [IL-1β]) and the induction of
molecules that favor a prothrombotic state (e.g. tissue factor, plasminogen activator inhibitor 1) [47].
Therefore, TNF-α has a net effect of propagating
endothelial dysfunction as well as promoting the
influx of more inflammatory cells.
TNF-α increases expression of macrophageproduced iNOS. We have earlier spoken of NO as
atheroprotective when produced in small amounts
by endothelial cells. When produced in high levels
by macrophages, inducible NO (iNOS) is antimicrobial. However, antimicrobial NO is also athero-
Atherosclerosis
117
genic. The high levels of NO produced by iNOS
damages proteins and DNA [48].
Macrophages can also secrete IL-1β which is
another potent proinflammatory cytokine [49]. IL1β has similar effects to TNF-α as it also induces
NF-κB activation [47]. Indeed, the importance of
IL-1β in atherogenesis was illustrated by a study
that showed that the blockade of IL-1β in an ApoE
−/− mouse model of atherosclerosis attenuated the
formation of atherosclerotic plaques [50].
Macrophages that have taken up great quantities
of lipids are called foam cells, and lesions full of
foam cells are called fatty streaks. The initial pathologic changes in the fatty streak are fully reversible.
However, with persistence of the atherogenic stimuli, the fatty streak may progress to become an
atherosclerotic plaque. The conversion of the fatty
streak to the atherosclerotic plaque occurs as a
result of the death of foam cells and the influx of
vascular smooth muscle (SMC) cells to form the
characteristic lipid core and fibrous cap, respectively. The origin of the SMCs in atherosclerotic
plaques is currently a matter of debate. Classically,
plaque SMCs are believed to arise from the preexisting medial SMCs [51].
More recently, it has been proposed that at least
some of the plaque SMCs are derived from stem
cells [52]. Whatever the origin of the SMC in the
atherosclerotic plaque, their phenotypic characteristics are different from those of SMCs found in
healthy blood vessels. Normally, SMCs are quiescent, contractile and nonproliferative and act to
control artery tonus. Within the atherosclerotic
environment SMCs become noncontractile and
proliferative. SMCs become altered under the
influence of cytokines and growth factors from
leukocytes, platelets and endothelial cells. γInterferon (IFN-γ), which is secreted by CD4+ lymphocytes of the Th1 phenotype, has been shown
to promote vascular SMC proliferation [53,54].
Indeed, this effect has been suggested to be caused
by the induction of the PDGF receptor in SMCs
[54]. Another molecule, macrophage inhibitory
factor (MIF), a potent proinflammatory cytokine
secreted by SMCs, endothelium and macrophages,
has been shown to promote SMC proliferation
[55,56]. Indeed, MIF immunoreactivity has been
demonstrated to co-localize to areas of atherosclerosis [55]. In addition, MIF −/− mice are more
118 PART II Cardiovascular polygenic disorders
resistant to atherosclerosis than their MIF +/+ littermates [53]. Analysis of atherosclerotic lesions
from MIF −/− mice has shown decreased lipid
deposition and reduced smooth muscle proliferation and intimal thickening.
Conversely, some cytokines have been demonstrated to suppress SMC proliferation. The antiinflammatory cytokine, IL-10, has been observed to
inhibit the proliferation of SMC after vascular
injury [57]. In addition, IL-10 hyperexpression in a
murine model of atherosclerosis has been shown to
reduce plaque formation [58].
Many of the cytokine-induced SMC changes are
mediated by modification of gene expression.
Indeed, in vitro stimulation of SMCs by TNF-α
induced the upregulation of more than 50 genes
and the downregulation of around 20 others [59].
The genes whose expression are affected by TNF-α
treatment are diverse, and they range from those
involved in the immune response through those
encoding structural proteins to those involved in
cellular metabolism [59].
The next stage in atherosclerosis is the formation
of plaque [60]. It is now thought that it is the rupture of the plaque leading to thrombosis rather
than stenosis leading to occlusion that is the precipitating factor in the majority of acute atherosclerotic events [61,62]. Plaque rupture is now
suspected to be the cause of approximately 70% of
fatal MI and sudden coronary deaths [63].
The atherosclerotic lesion is composed of a mass
of fatty material and inflammatory cells overlaid
with a fibrous cap. The major question in considering plaque lesions is: What causes some lesions
to suddenly rupture and cause life-threatening
thrombosis? [64]. Gene expression changes and
other factors that contribute either to plaque stability or to plaque instability are subjects of increasing
interest in this regard (reviewed in [60,65]).
Stable and unstable plaques show striking dissimilarities in architecture and histology. The
unstable vulnerable plaque lesion has a large lipid
core, which can comprise some 40% and upwards
of the lesion, and a thin fibrous cap [66]. Stable
plaque comprises about 14% lipid and the stable
cap, which can occupy more than 70% of the lesion,
acts to protect against rupture [61]. The unstable
lesion also contains large numbers of inflammatory
macrophages and T cells [22]. By contrast, the
stable cap is relatively nonactivated and noninflammatory [60].
The stability of the fibrous cap is largely determined by its collagen content. Collagen and other
cap proteins such as elastin and glycosaminoglycans are in turn synthesized by the SMCs. In the
unstable inflammatory lesion, fibrous cap thinning
is caused, on the one hand, by increased collagen
breakdown by proteases and, on the other, by
decreased collagen synthesis by SMCs.
The formation of the calcified plaques is also
dependent on gene expression. Genes that are
active in bone formation are also activated during
plaque formation [67,68]. This may also contribute
to plaque stability.
It is now recognized that collagen and elastin
breakdown are affected by activated macrophages
that overproduce matrix metalloproteinases, in
particular collagenases and gelatinases, enzymes
that have a key role in breaking down collagen and
elastin [16]. Advanced plaque is also made up of
about 20% T cells, which produce the lymphokine
IFN-γ that inhibits the production of collagen
matrix by SMCs. Macrophage content in unstable
plaque is high and, in turn, macrophage expression
of these proteins is strongly induced by inflammatory cytokines such as TNF-α, PDGF and IL-1
[69–71].
The other important process occurring in plaque
destabilization is a reduction in SMCs. Cytokines
such as TNF-α and IFN-γ induce apoptosis of
SMCs. As a consequence, SMC synthesized collagen, elastin and glycosaminoglycans decrease and
large areas of necrotic and apoptotic SMCs begin to
accumulate in unstable plaques [72–74]. Increased
apoptosis of SMCs brings into play the Fas death
pathways and other cell death pathways. The lipid
cores of unstable plaque lesions have been described as a cemetery of cells and cell types [74].
Extracellular protein tenascin C, which regulates
cell adhesion, both induces metalloproteinase
expression and causes SMC apoptosis. It is not present in normal vessel but is expressed in unstable
plaque [75,76].
Plaque rupture usually occurs specifically at the
edges of the lesion. It is here that inflammatory
activity is the most intense, T lymphocytes and
lipid-filled macrophages predominate and SMCs
are less common. When the cap ruptures the con-
CHAPTER 6
tents of the lesion plaque lipids, tissue factor, collagen and other materials come into contact with
blood components, initiating platelet activation,
coagulation and thrombosis [64].
In addition to being prone to rupture, the
inflamed plaque has a prothrombotic effect. This
finding is not surprising, given that the thrombotic
and inflammatory pathways are intimately linked
[77]. Indeed, it is now believed that thrombosis can
play a vital part in the initiation of atherosclerosis.
The adhesion of platelets to seemingly normal
endothelium has been shown to promote the
formation of the atherosclerotic plaque in the apoE
−/− mouse [78]. The initial adhesion of the platelet
to the vessel wall has been shown to be mediated by
a member of the integrin family, GPIb/IX/V [78].
Indeed, this adhesion molecule may represent a
potential pharmacologic target as its inhibition can
attenuate the formation of the atherosclerotic
plaque in the mouse model of atherosclerosis [78].
GPIb/IX/V can bind von Willebrand factor (vWF)
adherent to the damaged vessel wall, thus allowing
the platelet to roll on the endoluminal surface of the
vasculature [79]. This interaction slows the passage
of the platelet in the blood stream, thus allowing
for other platelet adhesion molecules, such as
GPIIb/IIIa, to establish more permanent links to
the vessel wall. GPIIb/IIIa is another member of the
integrin family, whose main physiologic ligands are
fibrinogen and vWF [80]. The presence of multiple
GPIIb/IIIa binding sites on fibrinogen allows this
molecule to act as a cross-link between different
platelets, thus facilitating platelet aggregation [77].
GPIIb/IIIa binding to fibrinogen also mediates
various physiologic changes within the platelet leading to shape change and platelet granular release.
Thrombosis also has a vital role in the progression of atherosclerosis. Exposure of the subintima
to blood, through plaque rupture, disruption
of plaque microvessels or superficial endothelial
disruption, leads to activation of the coagulation
cascade as well as circulating platelets [17]. The
resulting thrombus can be integrated into the
atherosclerotic plaque, thus contributing to its size.
In addition, thrombus constituents, such as erythrocyte membrane cholesterol, may provide additional antigenic stimuli for plaque growth [81].
Platelets are also a rich source of proinflammatory
cytokines, such as RANTES, CD40L and IL-1β,
Atherosclerosis
119
which further promote inflammation [77]. CD40L
has an important role in plaque destabilization by
inducing the production of various metalloproteinases (MMPs) responsible for the breakdown of
the extracellular matrix in the plaque [82]. Indeed,
CD40L levels are associated with the presence of
lipid-rich plaques in humans [83]. It is therefore
not difficult to visualize a vicious cycle whereby the
inflamed plaque initiates local thrombosis, which
then promotes further inflammation and plaque
destabilization.
Genetic background of
atherosclerosis: Atherosclerosis
is a complex trait
Common DNA sequence variants which each may
have a small to moderate phenotypic effect have
been suggested to determine genetic susceptibility
to common complex traits such as atherosclerosis
[84–86]. Currently, however, the DNA sequence
variants, whether rare or common, conferring the
susceptibility to atherosclerosis in the general population are still largely unknown.
Atherosclerosis and other complex traits do not
follow a simple Mendelian mode of inheritance.
Instead, relatives of an affected individual are likely
to have disease-predisposing alleles, making the
disease more common among the first degree relatives of the proband and less common in less closely
related relatives, resulting in a familial aggregation
of the complex trait. However, the observed familial aggregation does not necessarily mean a strong
genetic contribution. It may be by chance alone
because atherosclerosis is common at the population levels or to great extent explained by shared
environmental factors but previous studies have
shown that family history of coronary heart disease
(CHD) significantly increases the risk for CHD
[3,87,88]. Heritability is also used to estimate the
degree of genetic involvement. Heritability is the
fraction of the total phenotypic variance of a trait
caused by genes. It is worth noting that heritability
does not reveal how many genes are involved or
how the different genes interact. For CHD the heritability has been estimated to be 56–63% [89].
Currently, a gene for a monogenic disease can be
mapped and identified, providing that there are
enough informative families available for analysis.
120 PART II Cardiovascular polygenic disorders
Unknown allelic spectra
Table 6.1 Gene identification in
Unknown mode of inheritance
Unknown allele frequencies of the diseasepredisposing alleles
atherosclerosis is hampered by several
factors.
Unknown risk associated with the disease
Epistasis
Locus and allelic heterogeneity
Phenotype
Difficulties in assessing the complex phenotype
(lack of unequivocal diagnostic criteria)
Late onset of the disease
Pleiotrophy
Phenocopies
Incomplete penetrance
Technical issues
Affordable large-scale genotyping methods
Statistical analyses
Multiple testing
Limited statistical power
However, the success in identifying genes for complex diseases including atherosclerosis has been
relatively modest (reviewed in [90]), and most progress has been made with rare familial (Mendelian)
forms of these complex traits [91]. Table 6.1 shows
some of the factors hampering gene identification
in atherosclerosis.
To increase the impact of genetic involvement
and thus the possibilities of identifying contributing genes for complex diseases, investigation of
cases with a likely familial component; families
with multiple affected individuals; subjects with an
early onset disease; and extreme phenotypes can be
utilized [92]. Importantly, study samples originating from genetically isolated populations such as
Sardinians and Finns, where genetic and environmental heterogeneity are reduced, have been very
successfully used to identify genes for rare monogenic diseases (reviewed in [93,94]). These populations may provide some advantages into gene
identification of complex traits as well, although
there are likely to be multiple predisposing alleles
for complex traits even in these population isolates.
An important advantage of population isolates may
turn out to be the relatively low environmental and
lifestyle variability that can be expected among
these populations. These are important factors
because they present less confounding factors into
the statistical analyses.
Alleles contributing to complex traits are also
suggested to have only a minor to moderate effect
on the phenotype [84–86]. Furthermore, in com-
plex traits such as atherosclerosis the underlying DNA sequence variants may differ from the
ones identified for typical monogenic diseases [94],
and they may mostly even represent noncoding
variants, residing in conserved regulatory regions.
For associated single nucleotide polymorphisms
(SNPs) in noncoding regions, the functional analyses are challenging, and currently they focus
on investigation of cross-species conservation
and/or identification of regulatory elements such
as transcription factor, RNA splicing factor and
microRNA binding sites using approaches of bioinformatics [95].
Two main projects facilitating gene
identification in atherosclerosis:
the Human Genome Project and
the International HapMap Project
The Human Genome Project (HGP) was started in
1988 first to map and then to sequence the human
genes. The initial emphasis was in building both
physical and genetic linkage maps of 22 human
autosomal chromosomes in order to provide dense
maps of microsatellites, expressed sequence tags
and sequence-tagged sites for mapping purposes.
The ultimate goal was to sequence the human
genome. The first version was available in 2001
[96,97] and, in 2003, the HGP announced the completion of the DNA reference sequence of Homo
sapiens. The HGP provided the essential tools for
gene identification of complex traits, including
CHAPTER 6
atherosclerosis. As a result of the successful HGP,
human genetics is expected to be one of the key
players in providing new insights and better understanding of diseases, not only of the rare monogenic disorders but also of common complex
diseases such as CAD, and other atherosclerosisrelated disorders including stroke, diabetes and
hypertension.
Meaningful analysis of the enormous amount of
data that the HGP produced is crucial for successful
genetic analysis of atherosclerosis and other complex traits [90]. To tackle the millions of SNPs
available for association tests, approaches identifying the causal variants among those in an associated
haplotype were recently developed [98–101]. The
important message of these studies was that most
of the human genome may consist of blocks of
variable length over which only a few common
haplotypes are detected. The mean size of blocks
was initially estimated to be 22 kb and ~80% of the
genome in blocks >10 kb in populations of European ancestry [102]. In African-Americans, the
mean size of blocks was initially estimated to be
11 kb and ~60% of the genome in blocks >10 kb
[102]. These observations led to the establishment
of the International HapMap Project which is
currently determining the linkage disequilibrium
(LD) patterns across the human genome in blood
samples taken from people in Japan, Nigeria and
China as well as from people of northern and western European ancestry in the USA in order to allow
the efficient selection of SNPs for regional and
genome-wide association studies [103]. The overall
aim is to provide a restricted number of tag SNPs
for genotyping to cover most of the common variation in the human genome without genotyping
redundant SNPs. The ultimate success of this project is to great extent dependent on the hypothesis
of common variants underlying common disorders
[84,86]. Using these data generated by the HapMap
project, the tag SNPs capturing most of the genetic
variation can be selected for regional and genomewide association analyses, hopefully providing a
powerful shortcut to gene identification of atherosclerosis among other complex traits. For example,
currently, the genotypes of millions of SNPs for
30 trios from Centre d’Etude du Polymorphisme
Humain (CEPH) subjects of north European ancestry
are available online (http://www.hapmap.org/).
Atherosclerosis
121
Previous data show that some genomic regions
fit better to the block theory than others [104].
Thus, the actual practical usefulness of the haplotype method will depend on the specific patterns
of LD in the region of interest [104] as well as on
the underlying LD structure of the study population. Furthermore, the haplotype-block strategy is
agnostic about types and location of functional
SNPs. However, in most Mendelian diseases the
identified causative mutations have turned out to
be coding variants (reviewed in [94]). Thus, an
alternative strategy, focusing on identification and
testing for association of SNPs in coding and regulative regions, has been proposed for association
testing of complex traits [94]. In this sequence
based approach, about 10 times smaller number of
SNPs need to be genotyped than when using the
haplotype-block strategy [94]. In addition, low frequency disease alleles could also be detected. This
may be of importance because rare DNA sequence
variants may have a role in individual families, and
because both rare and common variants seem to
confer for instance the susceptibility to low plasma
levels of HDL-C in the general population [105].
Candidate genes contributing to
the development of atherosclerosis
Genetic components of atherosclerosis can be
investigated using several strategies, including
genome-wide scans for novel genes (Table 6.2) and
candidate gene approaches (reviewed in [90]).
Candidate gene studies of known genes, mainly
using case–control study samples have been the
method of choice for several decades. In these studies, alleles of unrelated affected subjects are compared with alleles of unrelated unaffected subjects.
When an association is detected, however, it may
be difficult to demonstrate the direct causality.
Differences in age, sex or ethnicity between case
and control groups can contribute to the observed
association and cause stratification bias resulting in
false positive associations [106]. Therefore, careful
selection of a control group is crucial for a meaningful case–control study. Multiple testing can also
lead to false positive results. These difficulties partly
explain the small number of findings replicated in
several study samples and populations. Replication in independent study samples is of utmost
122 PART II Cardiovascular polygenic disorders
Table 6.2 Genome-wide screens for myocardial infarction (MI), coronary artery disease (CAD) or coronary artery
calcification using linkage or association analysis [90]. After Lusis et al. 2004 [90].
Trait
MI
Chromosome Lod score
Population (number
(gene)
or P value
of subjects)
6p21 (LTA)
0.0000003
Japanese (94 cases/
Method
Reference
Association
Ozaki et al. 2002 [135]
Linkage: Allele sharing
Helgadottir et al. 2004
658 controls)
MI
13q12–13
2.9 0.000002 Icelandic (multiple
study samples; 779
(ALOX5AP)
(Allegro); and association [114]
cases and 6624
controls for ALOX5AP)
MI
14qter
3.9
German (1406)
Linkage: Variance
Broeckel et al. 2002 [132]
component (SOLAR)
MI
1p34–36
11
USA (1163)
Linkage: Allele sharing
Wang et al. 2004 [213]
(SAGE)
CAD
CAD
2q21–22,
3.2
Xq23–26
3.5
3q13
3.3
Finnish (364)
Linkage: Allele sharing
Pajukanta et al. 2000 [129]
(MAPMAKER/SIBS)
USA (1168)
Linkage: Allele sharing
Hauser et al. 2004 [133]
and parametric
(Genehunter Plus)
CAD
Coronary
16p13-pter
10q21.3
3
3.2
North-Eastern Indian
Linkage: Allele sharing
(535)
(MAPMAKER/SIBS)
USA (94)
Linkage: Allele sharing
artery
Francke et al. 2001 [130]
Lange et al. 2002 [134]
(MLS)
calcification
LTA indicates lymphotoxin-alpha and ALOX5AP arachidonate 5-lipoxygenase-activating protein gene.
importance when evaluating the significance of
association results.
Genes suggested to contribute to CAD risk include apolipoprotein E, apolipoprotein (a), methyltetrahydrofolate reductase, angiotensin-converting
enzyme and NOS3 genes [107–111]. The size and
nature of these and other CAD susceptibility genes
are largely unknown. An autosomal dominant form
of CAD was recently shown to be caused by a mutation in the myocyte enhancer factor-2 (MEF2A)
transcription factor gene [91], implicating the
MEF2A signaling pathway in the pathogenesis of
myocardial infarction (MI). However, subsequent
studies showed that mutations in this gene are not a
common cause of CAD at the population level
[112,113]. Recently, the gene encoding 5-lipoxygenase activating protein was also shown to confer
risk of MI and stroke in subjects from Iceland and
UK [114], and the finding was replicated in
Japanese [115]. Table 6.3 shows the currently
known common DNA variations contributing to
CAD and its risk factors (reviewed in [90]).
Example of a candidate gene for
atherosclerosis: NOS3
Identifying polymorphisms that may indicate increased susceptibility to atherosclerosis and heart
disease is an area of active research interest. A major
contender for prognostic polymorphisms is the NOS3
gene. NOS3 (or the endothelial isoform of nitric
oxide synthase) is expressed primarily in vascular
endothelium [116]. The nitric oxide synthesized by
this enzyme has antiplatelet effects as well as promoting smooth muscle relaxation. Indeed, nitric
oxide is the predominant vasodilator found in the
healthy vasculature. Therefore, loss of nitric oxide
activity would promote vasoconstriction and platelet activation. Impairment of nitric oxide activity
has been described in many conditions that predispose to atherosclerosis, including hypertension,
hypercholesterolemia and diabetes [117–119].
Theoretically, genetically controlled subtle disturbances in nitric oxide synthesis caused by perturbations in the NOS3 gene might predispose
CHAPTER 6
Atherosclerosis
123
Table 6.3 Common DNA sequence variations contributing to coronary heart disease (CHD) and its risk factors. After Lusis
et al. 2004 [90]. Only genes showing evidence of linkage or association in multiple studies are cited.
Trait
Gene
Variation
Reference
LDL/VLDL
LDL receptor
Many mutations
Goldstein et al. 1995 [192]
PCSK9
Many mutations
Abifadel et al. 2003 [193]
ApoE
Three common missense alleles
Sing et al. 1985 [194]
explain ~5% of variance of
cholesterol
HDL levels
FCHL
ApoAI-CIII-AIV-AV cluster
Multiple polymorphisms
Talmud et al. 2002 [195]
Hepatic lipase
Promoter polymorphism
Shohet et al. 2002 [196]
ABCA1
Many polymorphisms
Frikke-Schmidt et al. 2004 [197]
Upstream transcription
Intronic and 3′UTR polymorphims Pajukanta et al. 2004 [167]
factor 1
Lp(a)
Apo(a)
Many alleles of apo(a) explain
Boerwinkle et al. 1992 [198]
>90% variance
Homocysteine
Methylene tetrahydrofolate
Missense polymorphism
reductase
Coagulation
Kang et al. 1993 [199]
Ma et al. 1996 [200]
Fibrinogen B
Promoter polymorphism
Hamsten et al. 1993 [201]
Plasminogen activator
Promoter polymorphism
Hamsten et al. 1993 [201]
Factor VIII
Common missense
Hamsten et al. 1993 [201]
Angiotensinogen
Missense and promoter
inhibitor type 1
Thomas et al. 1995 [202]
Blood pressure
Caulfield et al. 1995 [203]
polymorphisms
b2-Adrenergic receptor
Missense polymorphism
Lusis et al. 2002 [204]
Alpha-adducin
Missense polymorphism; support
Lusis et al. 2002 [204]
from studies in rats
CAD
Angiotensin converting
Insertion-deletion polymorphism
Staessen et al. 1997 [205]
enzyme
Serum paraoxonase
Missense polymorphism affecting Shih et al. 2001 [206]
enzymatic activity; animal studies Tward et al. 2002 [207]
support
Toll-like receptor 4
Missense polymorphism
Kiechl et al. 2002 [208]
Arachidonate 5-lipoxygenase-
Haplotype of 4 SNPs
Helgadottir et al. 2004 [114]
activating protein
Stroke
Phosphodiesterase 4D
Diabetes, obesity and PPARg
insulin resistance
Regulatory polymorphism
Gretarsdottir et al. 2003 [209]
Missense polymorphism
Altshuler et al. 2000 [210]
Calpain 10
Horikawa et al. 2000 [211]
Hepatocyte nuclear factor-4a
Promoter polymorphism
Silander et al. 2004 [212]
Transcription factor 7-like 2
Intronic
Grant et al. 2006 [214]
CAD, coronary artery disease; FCHL, familial combined hyperlipidemia; HDL, high density lipoprotein; LDL, low density
lipoprotein; PPAR, peroxisome proliferator activated receptor; SNP, single nucleotide polymorphism; VLDL, very low
density lipoprotein.
individuals to develop atherosclerosis, given some
environmental or endogenous upset to uncover the
effects of the gene alteration [111]. There is some
evidence that certain polymorphisms in this gene
may affect atherosclerosis development. Among
several polymorphisms found in the NOS3 gene
(reviewed in [111]), the Glu298Asp polymorphism
is of especial interest. This polymorphism, which is
located in a coding region of the gene, exon 7, could
alter mature protein activity, thus affecting enzyme
activity and reducing local nitric oxide synthesis.
Hingorani et al. [120] investigated Glu298Asp in an
124 PART II Cardiovascular polygenic disorders
English study sample. They found a strong association between the Glu298Asp polymorphism and
the risk for coronary heart disease. Studies have also
linked Glu298Asp to essential hypertension, resistance to therapy [121] and to coronary spasms
[122]. However, the relevance of the data remains
uncertain, as other investigators have not been able
to replicate these findings [123].
Other polymorphisms have also been found in
the NOS3 gene. Polymorphisms in the promoter may influence mRNA transcription; intronic
polymorphisms are less likely to have functional
roles. In Japanese, the promoter polymorphism T786C was shown to be linked to vasospasm, which
in turn is linked to low endothelial NO [124].
T-786C is also associated with MI [125] and diabetes [126]. Wang et al. [127] reported that risk of
CAD was increased in smokers with a 27 base pair
repeat polymorphism in intron 4 of NOS3.
The evidence linking NOS3 polymorphisms to
clinical states is still inconsistent [30]. With increasing availability of large scale genotyping techniques such as microarray technology, the search
for interesting diagnostic or prognostic polymorphisms will be made easier, as thousands of gene
variants can be searched simultaneously.
Polymorphisms related to identifying individuals at risk of unstable plaque and plaque rupture are also under investigation. For example,
MMP gene expression is regulated at the transcriptional level and responds to variety of factors such
as TNF-α. Genetic variations in the MMP promoter regions may act to affect extracellular matrix
degradation, thereby increasing susceptibility to
atherosclerosis [74,128]. A polymorphism in MMP3 promoter was also linked to MI independently
of other risk factors, suggesting a susceptibility to
plaque rupture (reviewed in [128]). Several SNPs in
thrombospondin genes, deficiencies of which are
associated with increases in MMP-2, have been
associated with premature familial MI [74].
Genomic approaches to identify
genes for atherosclerosis
During the last decade, a genome-wide scan has
become a popular approach to identify novel genes
for complex traits, and several scans have been performed for MI, CAD [129–133] as well as for coron-
ary artery calcification [134], mainly using linkage
analysis of families or affected sib-pairs (Table 6.2)
(reviewed in [90]). For this approach no a priori
knowledge of disease pathophysiology is required,
thus enabling identification of novel genes and
pathways for atherosclerosis. In 1996 the idea of
genome-wide association studies was introduced
[85]. Association analysis has been shown to be
more powerful than linkage analysis for detecting
alleles of complex traits with only modest effects
[85]. However, searching the whole genome using
an association approach requires genotyping of
hundreds of thousands of SNPs [94]. So far, only a
few such studies have been completed for complex
traits, because of the technical demands related
to genotyping of such a large number of SNPs
[135,136]. In one such study, analyses of 92,788
gene-based SNPs showed that functional SNPs in
the lymphotoxin-alpha gene are associated with
susceptibility to MI [135]. In another study, over
100,000 SNPs were genotyped and the human complement factor H gene was identified to be associated with age-related macular degeneration [136].
Advances in genotyping technologies have recently
made this approach both more affordable and feasible. However, genome-wide association analyses
are still facing a number of challenges, including
problems related to multiple testing, suitable study
design, SNP selection and interactions between
polymorphisms [137,138]. Selecting the tag SNPs,
produced by the HapMap Project, instead of random, evenly spaced SNPs may turn out to be the
most effective way to cover most of the genetic variation in the human genome. However, it is difficult
to detect rare causative SNPs using this approach,
suggesting that substantial resequencing of genes is
warranted to identify rare causative variants.
DNA microarrays provide a practical and economic tool for studying gene expression in atherosclerosis on a genomic scale [90]. Complementing
classic linkage and association studies, expression
arrays can relate changes in gene expression to
atherosclerosis and have great potential to identify
novel genes, their pathways and networks associated
with atherosclerosis. Recently, when atherosclerotic
plaques of patients with stable and unstable angina
were investigated for gene expression differences,
several genes previously linked to hemostasis, such
as the protein S (PROS1) gene, the cyclo-oxygenase
CHAPTER 6
1 (COX-1) gene, the IL-7 gene, and the MCP-1 and
MCP-2 genes, were shown to be expressed at significantly lower levels in samples from unstable
angina patients [139]. These findings suggest that
these genes may have a role in plaque rupture.
The limitations of expression arrays are often
related to the relevant tissues and small sample sizes
available for investigation in humans. Small sample
sizes typically available for microarrays as well as
increased genetic heterogeneity can make distinguishing statistically significant differential
expression between cases and controls especially
challenging. Furthermore, atherosclerosis is likely
to result from small quantitative differences in
multiple genes, rather than major expression
changes in a few genes. This phenomenon is exemplified by a recent study of type 2 diabetic males
[140], where analysis of co-regulated sets of genes
rather than individual genes identified metabolic
pathways that are altered in diabetic individuals. In
more detail, Mootha et al. [140] used the Gene Set
Enrichment Analysis (GSEA) to identify a set of
PGC-1α responsive genes involved in oxidative
phosphorylation that were coordinately downregulated by approximately 20% in the muscle of diabetic individuals, with no single gene showing
significant differential expression between diagnostic categories.
As a result of the successful HGP, recent progress
of the HapMap Project and advancing genotyping
and microarray technologies, it is finally possible to
identify the DNA sequence variants conferring susceptibility to atherosclerosis using whole-genome
approaches where information obtained from linkage, association, gene expression and functional
analyses are combined to verify the signals.
Genes, lipids and atherosclerosis
Stein et al. [141] point out that some people are
unlikely to develop atherosclerosis and CHD even
in the face of high dietary cholesterol intake or frank
hypercholesterolemia. Individuals show a wide variety of responses to dietary cholesterol, about 9% of
populations studied are hyper-responders and 9%
are hypo-responders. For example of the latter, a
case was reported of one man who ate about 25 eggs
a day (about 6 g cholesterol) and yet remained normocholesterolemic at 88 years of age [142]. It has
Atherosclerosis
125
been known for some time that genetic variation
can have dramatic effects in causing inter-individual variation in cholesterol levels. Some of the genes
implicated in lipid metabolism are discussed below.
Familial hypercholesterolemia is one of the most
common inborn errors of metabolism and is most
often a result of mutations of the low density lipoprotein receptor (LDL-R) gene [143]. Although
countless loss of function mutations have been
described in the LDL-R gene (these can be viewed at
http://www.ucl.ac.uk/fh), these can generally be
classified into one of five categories:
1 Those that do not produce a detectable LDL-R
(e.g. ‘null alleles’);
2 Those that code for a protein that cannot be
transported from the endoplasmic reticulum to the
Golgi body and hence to the cell surface;
3 LDL-R that cannot bind the corresponding
ligand;
4 LDL-R that binds LDL normally but cannot be
internalized; and
5 LDL-R that cannot be recycled to the cell surface
after transporting cholesterol into the cell [143].
Individuals who are heterozygous for a mutant
allele have a two- to threefold increase in LDL-C
and develop premature CHD after the age of 35.
Homozygotes exhibit 6–8 times above normal
levels of cholesterol and develop ischemic heart
disease in their teenage years. Therefore, it is
important to identify individuals who suffer from
familial hypercholesterolemia in order to institute
early lipid lowering treatment.
Apolipoprotein E (ApoE), found in various
classes of lipoproteins, binds to LDL-R and mediates the uptake of the lipoprotein by the cell [144].
ApoE is believed to have a protective effect against
the development of atherosclerosis. Mice that are
−/− for the ApoE gene are severely hypercholesterolemic and are prone to early onset atherosclerosis [145]. Numerous polymorphisms of the gene
coding for ApoE have been described [144]. Of the
three common alleles, ε2, ε3 and ε4 at a single
locus, ε3 and ε2 are the most and least common
alleles, respectively [144,146]. ε2 homozygosity can
give rise to type III hyperlipoproteinemia [146], a
condition that is associated with premature
atherosclerosis brought about by the defective cellular uptake of lipoprotein remnants [147,148].
Based on the finding that the majority of cases of
126 PART II Cardiovascular polygenic disorders
type III hyperlipoproteinemia are homozygous for
ε2, it is perhaps surprising to find that ε2 heterozygosity is not associated with CHD [149]. However,
ε3/4 heterozygosity is associated with an increased
risk of ischemic heart disease when compared with
ε3/3 homozygotes, with an odds ratio of 1.30 (95%
confidence interval [CI], 1.18–1.44) [149]. The
mechanism by which ε4 heterozygosity affects
atherogenesis is unclear at present.
Lipoprotein lipase is important in the regulation
of triglyceride-rich lipoproteins such as VLDL and
chylomicrons. Impairment of lipoprotein lipase
activity may delay the clearance of these lipoproteins from the circulation [150]. An Asp9Asn
mutation in the lipoprotein lipase gene may be
associated with disease progression while some
other variations are believed have a protective effect
against MI [150,151].
Lipoprotein (a) levels appear to be a marker of
the risk of disease progression in atherosclerosis
and cardiovascular risk, although not all studies
have shown consistent results [152–154]. Genetic
variation seems to have an effect on plasma
lipoprotein (a) levels, although the significance of
this remains to be determined [155].
Cholesteryl ester transfer protein (CETP) mediates the transfer of cholesteryl esters from HDL to
LDL and VLDL, therefore promoting the transport
of cholesterol to the hepatocyte [156]. Inhibition of
CETP has been shown to protect against atheroma
formation in rabbits [157]. A recent meta-analysis
of over 13,000 patients has shown that the so-called
Taq1B polymorphism of the CETP gene can be
related to cardiovascular risk [158].
Sitosterolemia is an autosomal recessive condition in which there is excessive intestinal uptake but
decreased biliary secretion of plant sterols and
cholesterol [159]. Patients with this condition usually have hypercholesterolemia and are at risk of
developing premature atherosclerosis. Sitosterolemia has been found to be caused by mutations in
the genes coding for ABCG5 and ABCG8 [160].
These genes belong to the ATP-binding cassette
(ABC) superfamily of transmembrane transporters
that are responsible for the movement of a diverse
range of substances [161]. ABCG5 and ABCG8 are
expressed in the liver and intestines and have been
shown to be responsible for the secretion of cholesterol into the bile [162].
Another member of the ABC superfamily,
ABCA1, controls the efflux of intracellular cholesterol to lipid-poor ApoA-I, the major apolipoprotein of HDL [161]. Impairment of ABCA1 activity
leads to an autosomal recessive condition known as
Tangier disease [163]. Patients with this condition
have accumulation of cholesterol in various tissues,
leading to a multisystem disorder featuring premature atherosclerosis, hepatosplenomegaly, polyneuropathy and epidermal lesions. In a mouse
model of atherosclerosis, overexpression of the
ABCA1 gene attenuated atherogenesis and increased
HDL levels [164]. These findings suggest that HDL
levels may reflect ABCA1 activity [165]. Indeed,
certain mutations in the ABCA1 genes have been
shown to be associated with reduced HDL levels
and an increased risk of developing CHD [165,166].
Upstream transcription factor 1 (USF1), residing
on chromosome 1q21, regulates several genes of lipid
and glucose metabolism. Variants of USF1 were
recently associated with a common familial dyslipidemia, familial combined hyperlipidemia (FCHL)
in Finnish [167], Mexican [168] and Caucasian
families [169]. As FCHL predisposes the affected
individuals to CAD, it is of importance that a recent
study implicated USF1 variants in CAD [170] and
that the 1q21 region has also been linked to MI [133].
Taken together these studies suggest that USF1
should be further investigated as a potential candidate gene conferring the susceptibility to CAD.
Genetic polymorphisms,
inflammation and atherosclerosis
There is great interest in elucidating the role played
by polymorphisms of the genes regulating inflammation. Early studies on a rodent model have
shown that a genetic predisposition to inflammation co-segregates with the tendency to form
atherosclerotic plaques [171].
5-Lipoxygenase is an enzyme involved in the
production of the leukotrienes, and thus has a
major role in promoting inflammation. A recent
study showed that 6% of an American population
sample possess two minor variant alleles in the promoter polymorphism of the 5-lipoxygenase gene
[172]. It was found that individuals with the variant
alleles have higher intima-media thickness measurements and a greater degree of systemic inflam-
CHAPTER 6
Atherosclerosis
127
mation (as measured by high-sensitivity C-reactive
protein [CRP]). Indeed, the 5-lipoxygenase gene
has been shown to be associated with adverse cardiovascular events in both Icelandic and Scottish
subjects [114,173]. In addition, LDLR −/− mice
that had one copy of their 5-lipoxygenase gene
removed showed a dramatic reduction in plaque
formation when compared with “normal” LDLR
−/− controls [174]. However, this finding has not
been replicated in LDL −/− 5-LO −/− and ApoE
−/− 5-LO −/− mice [175].
A genome-wide association study of Japanese
subjects has found a polymorphism in the lymphotoxin-α (also known as TNF-β) gene to be associated with susceptibility to MI [135]. However, the
result of this study was not replicated in another
publication from another Japanese group [176]. A
study performed in a German population similarly
failed to reveal an association between the lymphotoxin-α polymorphism and CHD [177]. Similarly,
studies on polymorphisms of TNF-α gene provided conflicting results [177,178].
Plasminogen activator inhibitor-1 (PAI-1) is the
major circulating inhibitor of tissue-type plasminogen activator (t-PA). PAI-1 acts to regulate
thrombolytic activity by preventing excessive systemic fibrinolysis. Therefore, PAI-1 can be considered to be a procoagulant molecule. Indeed, plasma
levels of PAI-1 can be related to the risk of developing adverse cardiovascular events [183]. However,
it is unclear if elevated PAI-1 levels are a cause or
effect of atherosclerosis. In addition, the fact that
the elevations of PAI-1 levels are accompanied by
rises in t-PA further complicates matters. Most
studies on the PAI-1 gene have focused on the
4G/5G insertion/deletion polymorphism at position -675 in the promoter region of the gene [184].
The 4G (deletion) allele is associated with higher
PAI-1 levels and it is conceivable that patients with
this allele may be more prone to thrombosis.
Because studies on the 4G/5G polymorphism have
yielded conflicting results, a meta-analysis was performed which showed a weak association between
the 4G allele and the risk of atherothrombosis [185].
Genes, coagulation, fibrinolysis
and atherosclerosis
Other genes
Variations in genes controlling the coagulation
pathway may also play a part in influencing the natural history of atherosclerosis. A high plasma level
of fibrinogen has been associated with an increased
risk of developing adverse cardiovascular events
[179]. Fibrinogen is the precursor of fibrin. In addition, its numerous binding sites for the platelet
GPIIb/IIIa receptor enables it to act as a cross-link
during platelet aggregation [77]. A recent study has
suggested that genetic variation may play a part in
determining plasma fibrinogen levels and that the
genes responsible for this are located on chromosomes 2 and 10 [180]. A -455G/A polymorphism
in the β-fibrinogen gene has also been shown to
affect plasma fibrinogen levels [181]. However, at
present, it is unclear if this polymorphism may influence the risk of atherothrombosis, as some studies have reported a positive association between
the two while others have not [181,182]. At present, there is no strong evidence to suggest that
genetic polymorphisms in genes coding for the
other components of the coagulation pathway
would influence atherothrombosis.
An autosomal dominant form of CHD has been
linked to a 21-bp deletion in the transcription factor MEF2A [91]. MEF2A is known to be involved in
vasculogenesis but the pathophysiologic pathway
by which the MEF2A polymorphism may influence
the atherogenesis is uncertain at present. Some of
the other candidate genes that may be related to the
development of atherosclerotic disease are summarized in Table 6.3.
The future in atherosclerosis
Atherosclerosis is no longer thought of as a lipid
accumulation or passive degeneration but as an
active process of cells signaling and actively participating in atherosclerotic remodeling. Hundreds
of genes are likely to be involved in this process as
well as alterations in cell–cell communication [186].
Increased understanding of the molecular and cell
biologic events underlying the atherosclerotic process has led to new concepts to develop the necessary
prognostic indicators, diagnostic tests and targeted
therapies for atherosclerosis and CHD. Plaque stabilization and identification of vulnerable patients
128 PART II Cardiovascular polygenic disorders
is also emerging as an important goal to prevent
complications of atherosclerosis [63].
The concept of atherosclerosis as inflammation
has led to several new insights into novel, clinically
applicable, risk factor markers. For example, measurement of inflammatory markers such as plasma
CRP or serum amyloid A could provide a noninvasive method for assessing cardiovascular risk.
Large increases in levels of these proteins can be discerned in plasma following inflammatory stimuli.
CRP, produced in the liver and possibly in cells
in atheromatous plaque in response to upstream
proinflammatory cytokines, is being developed as a
potentially important risk factor with predictive
power for cardiovascular events [187].
In addition, because early endothelial changes
may herald the development of later disease development, tests to assess the health of endothelium
may serve as markers for disease and as targets for
therapy [21,33]. For example, methods to detect
marker “activation antigens” such as the endothelial leukocyte adhesion molecules, E selectin,
ICAM-1 and VCAM-1, could be developed as
biomarkers in tissues or circulating blood to identify inflammatory endothelial cell changes for early
diagnosis [21]. Because VCAM-1 is an important
early step in atherosclerotic processes, targeting
this protein might be of therapeutic value, and several animal studies have suggested that blocking
VCAM-1 acts to reduce neointimal hyperplasia [33].
Novel therapies for suppressing endothelial activation could provide new means of preventing
atherosclerotic changes. For example, the peroxisome proliferator activated receptor (PPAR) subfamily appears to have anti-inflammatory properties
and can reduce VCAM-1 and tissue factor gene
expression by cells in atheroma [19].
The atherosclerosis as inflammation hypothesis
has also led to new understanding of the mechanisms by which several existing pharmaceuticals
are effective in reducing the complications of CAD.
Angiotensin-converting enzyme (ACE) inhibitors
promote bradykinin a nitric oxide stimulus, and
decreased angiotensin increases nitric oxide bioavailability [22]. Thus, these agents appear to have
effects on improving endothelial function beyond
blood pressure decreases. The important role of the
unstable plaque and plaque rupture in thrombosis
has also increased interest in mechanisms that may
effect plaque stabilization, by lipid lowering, ACE
inhibition and antibiotics (reviewed in [60,188]).
Gene therapy
Gene therapeutic technologies might be used to
remedy eNOS deficits (reviewed in [189]). Rabbits
that are fed a high cholesterol diet are prone to
develop endothelial dysfunction and atherosclerosis [189]. Impairment of nitric oxide activity has
been shown to be a key factor behind this observation. Enhancement of NOS activity in these rabbits
by the use of an adenovirus-mediated NOS gene
transfer restored endothelial derived relaxing factor
activity [190]. The use of the adenovirus-mediated
NOS gene therapy was also shown to reduce
macrophage infiltration of the carotid arteries of
cholesterol-fed animals [191]. In addition, the
expression of adhesion molecules such as ICAM-1
and VCAM-1 are significantly downregulated in
the carotid arteries of the treated rabbit [191].
Therefore, it is possible that NOS3 gene therapy may be useful in the treatment of human
atherosclerosis.
Other gene therapy targets include MMP
inhibitors (reviewed in [128]). Tissue inhibitors of
MMPs might be increased at the local tissue level by
administration of exogenous recombinant tissue
inhibitors or by stimulating increased endogenous
expression via gene therapy. Synthetic MMP
inhibitors have also been investigated, including
antibiotics such as doxycycline [128]. In addition,
the apoptosis of fibroblasts on the surface of
plaques would increase the likelihood of plaque
rupture, and blocking apoptosis would be another
approach to preventing complications of atherosclerosis [15]. It might also be possible to interfere
with important transcription factors that regulate
groups of genes involved in atherosclerosis. For
example, NF κB, a key inflammation regulator in
the vessel wall, PPARs and Sp/XKLF family of zinc
finger genes may all prove to be important targets
(reviewed in [186]).
Conclusions
Many highly intriguing genes have been discovered
to be active in the progress of atherosclerosis. Furthermore, identification of genes contributing to
CHAPTER 6
susceptibility to atherosclerosis and other complex
traits is expected to accelerate rapidly because the
Human Genome Project and the HapMap Project
have made the sequence of the human genome and
human genome sequence variation data publicly
available. Even so, we need more detailed knowledge about the numerous genes and gene targets
involved in various stages of development of complex atherosclerotic lesions. New genomic technologies such as microarray chip technologies are
beginning to be used to identify novel genes and
pathways as well as to understand gene–gene and
gene–environment interactions. For example, recent studies comparing gene expression in stable
and ruptured plaque, as well as various responses of
macrophages to oxLDL are pioneering the way to
the fuller utilization of genomic technology in
exploring the complexities of atherosclerosis.
References
1 Schwartz CJ, Mitchell JR. The morphology, terminology
and pathogenesis of arterial plaques. Postgrad Med J
1962; 38: 25–34.
2 Gotto AM Jr. Some reflections on arteriosclerosis past,
present and future. Circulation 1985; 72: 8–17.
3 Rose G. Familial patterns in ischaemic heart disease. Br J
Prev Soc Med 1964; 18: 75–80.
4 Kannel WB, Castelli WP, Gordon T, McNamara PM.
Serum cholesterol, lipoproteins, and the risk of coronary heart disease: the Framingham study. Ann Intern
Med 1971; 74: 1–12.
5 Pooling Project Research Group. The relationship of
blood pressure, serum cholesterol, smoking habit, relative weight and ECG abnormalities to incidence of
major coronary events. 1978; Monograph 60, American
Heart Association, Dallas.
6 Keys A. Seven Countries: A Multivariate Analysis of
Death and Coronary Heart Disease. Harvard University
Press, Cambridge, 1980.
7 Pyörälä K, Laakso M, Uusitupa M. Diabetes and
atherosclerosis: an epidemiologic view. Diabetes Metab
Rev 1987; 3: 463–542.
8 Grundy SM, Wilhelmsen L, Rose G et al. Coronary heart
disease in high risk populations: lessons from Finland.
Eur Heart J 1990; 11: 462–471.
9 Grundy SM, Balady GJ, Criqui MH et al. Primary prevention of coronary heart disease: guidance from
Framingham. A statement for healthcare professionals
from the AHA Task Force on Risk Reduction. Circulation 1998; 97: 1876–1887.
Atherosclerosis
129
10 Genest J Jr, Cohn JS. Clustering of cardiovascular risk
factors: targeting high-risk individuals. Am J Cardiol
1995; Supplement 76: 8A–20A.
11 Wilson PW, D’Agostino RB, Levy D et al. Prediction of
coronary heart disease using risk factor categories.
Circulation 1998; 97: 1837–1847.
12 Ridker PM, Buring JE, Shih J et al. Prospective study of
C-reactive protein and the risk of future cardiovascular
events among apparently healthy women. Circulation
1998; 98: 731–733.
13 Saikku P, Leinonen M, Mattila K et al. Serological evidence of an association of a novel chlamydia, TWAR,
with chronic coronary heart disease and acute myocardial infarction. Lancet 1998; 2: 983–986.
14 Noll G. Pathogenesis of atherosclerosis: a possible relation
to infection. Atherosclerosis 1998; 140 (Supplement 1):
S3–S9.
15 Doevendans PA, Jukema W, Spiering W et al. Molecular
genetics and gene expression in atherosclerosis. Int J
Cardiol 2001; 80: 161–172.
16 Lusis AJ. Atherosclerosis. Nature 2000; 407: 233–241.
17 Libby P. Inflammation in atherosclerosis. Nature 2002;
420: 868–874.
18 Ross R, Glomset JA. The pathogenesis of atherosclerosis. N Engl J Med 1976; 295: 369–377.
19 Libby P, Ridker PM, Maseri A. Inflammation and
atherosclerosis. Circulation 2002; 105: 1135–1143.
20 Glass CK, Witztum JL. Atherosclerosis: the road ahead.
Cell 2001; 104: 503–516.
21 Gimbrone MA, Topper JN. Biology of the vessel wall:
endothelium. In: Chien KR, ed. Molecular Basis of
Cardiovascular Disease. WB Saunders, Philadelphia,
1999: 331–348.
22 Behrendt D, Ganz P. Endothelial function: from vascular biology to clinical applications. Am J Cardiol 2002;
90: 40L–48L.
23 Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction, a marker of atherosclerotic risk. Arterioscler
Thromb Vasc Biol 2003; 23: 168–175.
24 Stary HC. Evolution and progression of atherosclerotic
lesions in coronary arteries of children and young adults.
Arteriosclerosis 1989; 9: 19–32.
25 Napoli C, Lerman L. Involvement of oxidationsensitive mechanisms in the cardiovascular effects of
hypercholesterolemia. Mayo Clinic Proc 2001; 76: 619–
631.
26 Ross R. The pathogenesis of atherosclerosis a perspective for the 1990s. N Engl J Med 1993; 362: 801–809.
27 Topper JN, Cai J, Falb D, Gimbrone MA Jr. Identification of vascular endothelial genes differentially
responsive to fluid mechanical stimuli: cyclooxygenase2, manganese superoxide dismutase, and endothelial
cell nitric oxide synthase are selectively up-regulated by
130 PART II Cardiovascular polygenic disorders
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
steady laminar shear stress. Proc Nat Acad Sci USA 1996;
93: 10417–10422.
Humphries SE, Ordovas JM. Genetics and atherosclerosis: broadening the horizon. Atherosclerosis 2001; 154:
517–519.
Henderson AH. It all used to be so simple in the old
days. Eur Heart J 2001; 22: 648–653.
Albrecht EWJA, Stegeman CA, Heeringa P et al.
Protective role of endothelial nitric oxide synthase.
J Pathol 2003; 199: 8–17.
Gerrity RG, Naito HK, Richardson M, Schwartz CJ.
Dietary induced atherogenesis in swine. Morphology of
the intima in prelesion stages. Am J Pathol 1979; 95:
775–792.
Joris I, Zand T, Nunnari JJ. Studies on the pathogenesis
of atherosclerosis. I. Adhesion and emigration of
mononuclear cells in the aorta of hypercholesterolemic
rats. Am J Pathol 1983; 113: 341–358.
Blankenberg S, Barbaux S, Tiret L. Adhesion molecules
and atherosclerosis. Atherosclerosis 2003; 170: 191–203.
Cybulsky M, Gimbrone MA. Endothelial expression of a
mononuclear adhesion molecule during atherogenesis.
Science 1991; 251: 788–791.
Li H, Cybulsky MI, Gimbrone MA et al. An atherogenic
diet rapidly induces VCAM-1 a cytokine regulatable mononuclear leukocyte adhesion molecule in rabbit aortic
endothelium Arterioscler Thromb 1993; 13: 197–204.
O’Brien KD, Allen MD, McDonald TO et al. Vascular
cell adhesion molecule 1 is expressed in human coronary atherosclerotic plaques. J Clin Invest 1993; 92:
945–951.
Cybulsky MI, Iiyama K, Li H, et al. A major role for
VCAM-1 but not ICAM-1 in early atherogenesis J Clin
Invest 2001; 107: 1255–1262.
Boring L, Gosling J, Cleary M, Charo IF. Decreased
lesion formation in CCR2−/− mice reveals a role for
chemokines in the initiation of atherosclerosis. Nature
1998; 394: 894–897.
Mach F, Sauty A, Iarossi AS et al. Differential expression
of three T lymphocyte activating CXC chemokines by
human atheroma-associated cells. J Clin Invest 1999;
104: 1041–1050.
Kume N, Cybulsky MI, Gimbrone MA Jr. Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion
molecules in cultured human and rabbit arterial
endothelial cells. J Clin Invest 1992; 90: 1138–1144.
Kume N, Gimbrone MA Jr. Lysophosphatidylcholine
transcriptionally induces growth factor gene expression
in cultured human endothelial cells. J Clin Invest 1994;
93: 907–911.
Kodama T, Freeman M, Rohrer L et al. Type 1
macrophage scavenger receptor contains alpha helical
and collaged like coiled cells. Nature 1990; 343: 531–535.
43 Krieger M, Action A, Ashkenas J et al. Molecular flypaper, host defense, and atherosclerosis. J Biol Chem
1993; 68: 4569–4572.
44 Hayes AL, Smith C, Foxwell BM et al. CD45-induced
tumor necrosis factor alpha production in monocytes is
phosphatidylinositol 3-kinase-dependent and nuclear
factor kappa-B independent. J Biol Chem 1999; 274:
33455–33461.
45 Koike J, Nagata K, Kudo S et al. Density-dependent
induction of TNF-alpha release from human monocytes
by immobilised P-selectin. FEBS Lett 2000; 477: 84–
88.
46 Thommesen L, Sjursen W, Gasvik K et al. Selective
inhibitors of cytosolic or secretory phospholipase A2
blocks TNF induced activation of transcription factor
nuclear factor-kappaB and expression of ICAM-1.
J Immunol 1998; 161: 3421–3430.
47 de Martin R, Hoeth M, Hofer-Warbinek R et al. The
transcription factor NFkB and the regulation of vascular
cell function. Arterioscler Thromb Vasc Biol 2000; 20:
e83–88.
48 Beckman JS, Koppenol WH. Nitric oxide, superoxide,
and peroxynitrite: the good, the bad, and ugly. Am J
Physiol Cell Physiol 1996; 271: C1424–C1437.
49 Dinarello CA, JG Cannon, Wolff SM et al. Tumour
necrosis factor is an endogenous pyrogen and induces
production of interleukin 1. J Exp Med 1986; 163:
1433–1450.
50 Elhage R, Maret A, Pieraggi MT et al. Differential effects
of interleukin-1 receptor antagonist and tumour necrosis factor binding protein on fatty streak formation
in apolipoprotein E-deficient mice. Circulation 1998;
97: 242–244.
51 Campbell GR, Campbell JH, Manderson JA et al.
Arterial smooth muscle. A multifunctional mesenchymal cell. Arch Pathol Lab Med 1988; 112: 977–986.
52 Religa P, Bojakowski K, Maksymowicz M et al. Smooth
muscle progenitor cells of bone marrow origin contribute to the development of neointimal thickenings in
rat aortic allografts and injured rat carotid arteries.
Transplantation 2002; 74: 1310–1315.
53 Buono C, Come G, Stavrakis GF et al. Influence of interferon-gamma on the extent and phenotype of diet
induced atherosclerosis in the LDLR-deficient mouse.
Arterioscler Thromb Vasc Biol 2003; 23: 454–460.
54 Tellides GD, Tereb A, Kirkiles-Smith NC et al.
Interferon-gamma elicits arteriosclerosis in the absence
of leukocytes. Nature 2000; 403: 207–211.
55 Burger-Kentischer A, Goebel H, Seiler R et al. Expression of macrophage migration inhibitory factor in different stages of human atherosclerosis. Circulation 2002;
105: 1561–1566.
56 Pan JH, Sukhova GK, Yang JT et al. Macrophage migration inhibitory factor deficiency impairs atherosclerosis
CHAPTER 6
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
in low density lipoprotein receptor deficient mice.
Circulation 2004; 109: 3149–3153.
Feldman LJ, Aguirre L, Ziol M et al. Interleukin-10
inhibits intimal hyperplasia after angioplasty or stent
implantation in hypercholesterolaemic rabbits. Circulation 2000; 101: 908–916.
Pinderski LJ, Fischbein MP, Subbanagounder G et al.
Overexpression of interleukin-10 by activated T lymphocytes inhibits atherosclerosis in LDL receptor deficient mice by altering lymphocyte and macrophage
phenotypes. Circ Res 2002; 90: 1064–1071.
Jang WG, Kim HS, Park KG et al. Analysis of proteome
and transcriptome of tumor necrosis factor alpha stimulated vascular smooth muscle cells with or without alpha
lipoic acid. Proteomics 2004; 4: 3383–3393.
Forrester JS. Prevention of plaque rupture: a new paradigm of therapy. Ann Intern Med 2002; 137: 823–833.
Falk E. Plaque rupture with severe pre-existing stenosis
precipitating coronary thrombosis. Characteristics of
coronary atherosclerotic plaques underlying fatal occlusive thrombi. Br Heart J 1983; 50: 127–134.
Davies MJ, Thomas A. Plaque fissuring: the cause of
acute myocardial infarction, sudden ischaemic death,
and crescendo angina. Br Heart J 1985; 53: 363–373.
Naghavi M, Libby P, Falk E et al. From vulnerable
plaque to vulnerable patient. Circulation 2003; 108:
1664–1672.
Falk E, Shah PK, Fuster V. Coronary plaque disruption.
Circulation 1995; 92: 657–671.
Davies MJ. The composition of coronary artery plaques.
N Engl J Med 1997; 336: 1312–1314.
Felton CV, Crook D, Davies MJ, Oliver MF. Relation of
plaque lipid composition and morphology to the stability of human aortic plaques. Arterioscler Thromb Vasc
Biol 1997; 17: 1337–1345.
Davies PF. Endothelium as a signal transduction interface for flow forces: cell surface dynamics. Thromb
Haemost 1993; 70: 124–128.
Watson KE, Demer LL. The atherosclerosis-calcification
link? Curr Opin Lipid 1996; 7: 101–104.
Saren P, Welgus HG, Kovanen P. TNF-alpha and
IL-1beta selectively induce expression of 92-kDa gelatinase by human macrophages. J Immunol 1996; 157:
4159–4165.
Kol A, Sukhova GK, Lichtman AH, Libby P. Chlamydial
heat shock protein 60 localizes in human atheroma and
regulates macrophage tumor necrosis factor-alpha and
matrix metalloproteinase expression. Circulation 1998;
98: 300–307.
Rajavashisth TB, Xu TP, Jovinge S et al. Membrane type
1 matrix metalloproteinase expression in human atherosclerotic plaques. Circulation 1999; 99: 3103–3109.
Bennett MR, Evan GI, Schwartz SM. Apoptosis of
human vascular smooth muscle cells derived from nor-
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
Atherosclerosis
131
mal vessels and coronary atherosclerotic plaques. J Clin
Invest 1995; 95: 2266–2274.
Henderson EL, Geng YJ, Sukhova GK et al. Death of
smooth muscle cells and expression of mediators of
apoptosis by T lymphocytes in human abdominal aortic
aneurysms. Circulation 1999; 99: 96–104.
Lopes N, Vasudevan SS, Alvarez RJ et al. Pathophysiology of plaque instability insights at the genomic level.
Prog Cardiovasc Dis 2002; 44: 323–328.
Wallner K, Li C, Shah PK MD et al. Tenascin-C is
expressed in macrophage-rich human coronary atherosclerotic plaque Circulation 1999; 99: 1284–1289.
LaFleur DW, Chiang J, Fagin JA. Aortic smooth muscle
cells interact with tenascin C through its fibrinogen like
domain. J Biol Chem 1997; 52: 32798–32803.
Tan KT, Lip GY. Platelets, atherosclerosis and the endothelium: new therapeutic targets? Expert Opin Invest
Drugs 2003; 12: 1765–1776.
Massberg S, Brand K, Gruner S et al. A critical role of
platelet adhesion in the initiation of atherosclerotic
lesion formation. J Exp Med 2002; 196: 887–896.
Savage B, Almus-Jacobs F, Ruggeri ZM. Specific synergy
of multiple substrate-receptor interactions in platelet
thrombus formation under flow. Cell 1998; 94: 657–666.
Hynes RO. Integrins: Versatility, modulation, and signalling in cell adhesion. Cell 1992; 69: 11–25.
Kolodgie FD, Gold HK, Burke AP et al. Intraplaque
haemorrhage and progression of coronary atheroma.
N Engl J Med 2003; 349: 2316–2325.
Schonbeck U, Mach F, Sukhova GK et al. Regulation of
matrix metalloproteinase in human smooth muscle cells
by T lymphocytes: A role for CD40L in plaque rupture?
Circ Res 1997; 81: 448–451.
Blake GJ, Ostfeld RJ, Yucel EK et al. Soluble CD40 ligand
levels indicate lipid accumulation in carotid atheroma:
an in vivo study with high resolution MRI. Arterioscler
Thromb Vasc Biol 2003; 23: E11–E14.
Lander ES. The new genomics: global views of biology.
Science 1996; 274: 536–539.
Risch N, Merikangas K. The future of genetic studies of
complex human diseases. Science 1996; 273: 1516–1517.
Collins FS, Guyer MS, Chakravarti A. Variations on a
theme: cataloging human DNA sequence variation.
Science 1997; 278: 1580–1581.
Sholtz RI, Rosenma RH, Brand RJ. The relationship of
reported parental history to the incidence of coronary
heart disease in Western Collaborative Group Study.
Am J Epidemiol 1975; 102: 350–356.
Jousilahti P, Puska P, Vartiainen E, Pekkanen J,
Tuomilehto J. Parental history of premature coronary
heart disease: an independent risk factor of myocardial
infarction. J Clin Epidemiol 1996; 49: 497–503.
Nora JJ, Lortscher RH, Spangler RD, Nora AH, Kimberling WJ. Genetic-epidemiologic study of early-onset
132 PART II Cardiovascular polygenic disorders
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
ischemic heart disease. Circulation 1980; 61: 503–
508.
Lusis AJ, Mar R, Pajukanta P. Genetics of atherosclerosis. Annu Rev Genomics Hum Genet 2004; 5: 189–218.
Wang L, Fan C, Topol SE et al. Mutation of MEF2A in
an inherited disorder with features of coronary artery
disease. Science 2003; 302: 1578–1581.
Lander ES, Schork NJ. Genetic dissection of complex
traits. Science 1994; 265: 2037–2048.
Peltonen L, Palotie A, Lange K. Use of population isolates for mapping complex traits. Nat Rev Genet 2000; 1:
182–190.
Botstein D, Risch N. Discovering genotypes underlying
human phenotypes: past successes for mendelian disease, future approaches for complex disease. Nat Genet
2003; Supplement: 228–237.
Xie X, Lu J, Kulbokas EJ et al. Systematic discovery
of regulatory motifs in human promoters and 3′ UTRs
by comparison of several mammals Nature 2005; 434:
338–345.
Lander ES, Linton LM, Birren B et al. Initial sequencing
and analysis of the human genome. Nature 2001; 409:
860–921.
Venter JC, Adams MD, Myers EW et al. The sequence of
the human genome. Science 2001; 291: 1304–1351.
Daly MJ, Rioux JD, Schaffner SF et al. High-resolution
haplotype structure in the human genome. Nat Genet
2001; 29: 229–232.
Patil N, Berno AJ, Hinds DA et al. Blocks of limited
haplotype diversity revealed by high-resolution scanning of human chromosome 21. Science 2001; 294:
1719–1723.
Reich DE, Cargill M, Bolk S et al. Linkage disequilibrium in the human genome. Nature 2001; 411: 199–204.
Rioux JD, Daly MJ, Silverberg MS et al. Genetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohn disease. Nat Genet 2001; 29: 223–228.
Gabriel SB, Schaffner SF, Nguyen H et al. The structure
of haplotype blocks in the human genome. Science 2002;
296: 2225–2229.
The International HapMap Project. Nature 2003; 426:
789–796.
Wall JD, Pritchard JK. Haplotype blocks and linkage
disequilibrium in the human genome. Nat Rev Genet
2003; 4: 587–597.
Cohen JC, Kiss RS, Pertsemlidis A et al. Multiple rare
alleles contribute to low plasma levels of HDL cholesterol. Science 2004; 305: 869–872.
Weeks DE, Lathrop GM. Polygenic disease: methods for
mapping complex disease traits. Trends Genet 1995; 11:
513–519.
Kraft HG, Lingenhel A, Kochl S et al. Apolipoprotein(a)
kringle IV repeat number predicts risk for coronary
108
109
110
111
112
113
114
115
116
117
118
119
120
121
heart disease. Arterioscler Thromb Vasc Biol 1996; 16:
713–719.
Cambien F, Poirier O, Lecerf L et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is
a potent risk factor for myocardial infarction. Nature
1992; 359: 641–644.
Boushey CJ, Beresford SA, Omenn GS, Motulsky AG.
A quantitative assessment of plasma homocysteine as
a risk factor for vascular disease: probable benefits of
increasing folic acid intakes. JAMA 1995; 274: 1049–
1057.
Wilson PW, Schaefer EJ, Larson MG, Ordovas JM.
Apolipoprotein E alleles and risk of coronary disease A
meta-analysis. Arterioscler Thromb Vasc Biol 1996; 16:
1250–1255.
Hingorani AD. Polymorphisms in endothelial nitric
oxide synthase and atherogenesis: John French Lecture
2000. Atherosclerosis 2000; 154: 521–527.
Weng L, Kavaslar N, Ustaszewska A. Lack of MEF2A
mutations in coronary artery disease. J Clin Invest 2005;
115: 1016–1020.
Kajimoto K, Shioji K, Tago N et al. Assessment of
MEF2A mutations in myocardial infarction in Japanese
patients. Circ J 2005; 69: 1192–1195.
Helgadottir A, Manolescu A, Thorleifsson G et al. The
gene encoding 5-lipoxygenase activating protein confers
risk of myocardial infarction and stroke. Nat Genet 2004;
36: 233–239.
Kajimoto K, Shioji K, Ishida C et al. Validation of the
association between the gene encoding 5-lipoxygenaseactivating protein and myocardial infarction in a
Japanese population. Circ J 2005; 69: 1029–1034.
Moncada S. Nitric oxide: discovery and impact on clinical medicine. J R Soc Med 1999; 92: 164–169.
Cardillo C, Kilcoyne CM, Quyyumi AA et al. Selective
defect in nitric oxide synthesis may explain the impaired endothelium-dependent vasodilation in patients
with essential hypertension. Circulation 1998; 97: 851–
856.
Zeiher AM, Drexler H, Saubier B, Just H. Endotheliummediated coronary blood flow modulation in humans.
Effects of age, atherosclerosis, hypercholesterolaemia,
and hypertension. J Clin Invest 1993; 92: 652–662.
Saenz de Tejada I, Goldstein I, Azadzoi K et al. Impaired
neurogenic and endothelium-mediated relaxation of
penile smooth muscle from diabetic men with impotence. N Engl J Med 1989; 320: 1025–1030.
Hingorani AD, Liang CF, Fatibene J et al. A common variant of the endothelial nitric oxide synthase
(Glu298→Asp) is a major risk factor for coronary artery
disease in the UK Circulation 1999; 100: 1515–1520.
Jachymova M, Horky K, Bultas J et al. Association of
the Glu298Asp polymorphism in the endothelial nitric
CHAPTER 6
122
123
124
125
126
127
128
129
130
131
132
133
134
oxide synthase gene with essential hypertension resistant to conventional therapy. Biochem Biophys Res Commun 2001; 284: 426–430.
Yoshimura M, Yasue H, Nakayama M et al. A missense
Glu298Asp variant in the endothelial nitric oxide synthase gene is associated with coronary spasm in the
Japanese. Hum Genet 1998; 103: 65–69.
Cai H, Wilcken DEL, Wang XL. The glu298→asp
(894G-T) mutation at exon 7 of the endothelial nitric
oxide synthase gene and coronary artery disease. J Mol
Med 1999; 77: 511–514.
Nakayama M, Yasue H, Michihiro Y et al. T-786→C
Mutation in the 5′-flanking region of the endothelial
nitric oxide synthase gene is associated with coronary
spasm Circulation 1999; 99: 2864–2870.
Nakayama M, Yasue H, Yoshimura M et al. T-786→C
mutation in the 5′-flanking region of the endothelial
nitric oxide synthase gene is associated with myocardial
infarction, especially without coronary organic stenosis
Am J Cardiol 2000; 86: 628–634.
Zanchi A, Moczulski DK, Hanna LS et al. Risk of
advanced diabetic nephropathy in type 1 diabetes is
associated with endothelial nitric oxide synthase gene
polymorphism. Kidney Int 2000; 57: 405–413.
Wang XL, Sim AS, Badenhop RF et al. A smokingdependent risk of coronary artery disease associated
with a polymorphism of endothelial nitric oxide synthase gene. Nat Med 1996; 2: 41–45.
Loftus IM, Naylor AR, Bell PRF, Thompson MM.
Matrix metalloproteinases and atherosclerotic plaque
instability. Br J Surg 2002; 89: 680–694.
Pajukanta P, Cargill M, Viitanen L et al. Two loci on
chromosomes 2 and X for premature coronary heart
disease identified in early- and late-settlement populations of Finland. Am J Hum Genet 2000; 67: 1481–1493.
Francke S, Manraj M, Lacquemant C et al. A genomewide scan for coronary heart disease suggests in IndoMauritians a susceptibility locus on chromosome 16p13
and replicates linkage with the metabolic syndrome on
3q27. Hum Mol Genet 2001; 10: 2751–2765.
Harrap SB, Zammit KS, Wong ZY et al. Genome-wide
linkage analysis of the acute coronary syndrome suggests a locus on chromosome 2. Arterioscler Thromb
Vasc Biol 2002; 22: 874–878.
Broeckel U, Hengstenberg C, Mayer B et al. A comprehensive linkage analysis for myocardial infarction and
its related risk factors. Nat Genet 2002; 30: 210–214.
Hauser ER, Vrossman DC, Granger CB et al. A genomewide scan for early-onset coronary artery disease in
438 families: the GENECARD Study. Am J Hum Genet
2004; 75: 436–447.
Lange LA, Lange EM, Bielak LF et al. Autosomal
genome-wide scan for coronary artery calcification loci
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
Atherosclerosis
133
in sibships at high risk for hypertension. Arterioscler
Thromb Vasc Biol 2002; 22: 418–423.
Ozaki K, Ohnishi Y, Iida A et al. Functional SNPs in the
lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction. Nat Genet 2002; 32:
650–654.
Klein RJ, Zeiss C, Chew EY et al. Complement factor H
polymorphism in age-related macular degeneration.
Science 2005; 308: 385–389.
Carlson CS, Eberle MA, Kruglyak L, Nickerson DA.
Mapping complex disease loci in whole-genome association studies. Nature 2004; 429: 446–452.
Hirschhorn JN, Daly MJ. Genome-wide association
studies for common diseases and complex traits. Nat
Rev Genet 2005; 6: 95–108.
Randi AM, Biguzzi E, Falciani F et al. Identification of
differentially expressed genes in coronary atherosclerotic plaques from patients with stable or unstable angina
by cDNA array analysis. J Thromb Haemost 2003; 1:
829–835.
Mootha VK, Lindgren CM, Eriksson KF et al. PGC1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human
diabetes. Nat Genet 2003; 34: 267–273.
Stein O, Thiery J, Stein Y. Is there a genetic resistance to
atherosclerosis? Atherosclerosis 2002; 160: 1–10.
Kern F Jr. Normal plasma cholesterol in an 88-year-old
man who eats 25 eggs a day. Mechanisms of adaptation.
N Engl J Med. 1991; 28: 896–899.
Hobbs HH, Brown MS, Goldstein JL. Molecular genetics
of LDL receptor gene in familial hypercholesterolaemia.
Hum Mutat 1992; 1: 445–466.
Greenow K, Pearce NJ, Ramji D. The key role of
apolipoprotein E in atherosclerosis. J Mol Med 2005; 83:
342–392.
Plump AS, Smith JD, Hayek T et al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein Edeficient mice created by homologous recombination in
ES cells. Cell 1992; 71: 343–353.
Mahley RW, Rall SC. Apolipoprotein E: far more than a
transport protein. Annu Rev Genomics Hum Genet 2000;
1: 507–537.
Schaefer EJ, Gregg RE, Ghiselli G et al. Familial
apolipoprotein E deficiency. J Clin Invest 1986; 78:
1206–1219.
Mahley RW, Huang Y, Rall SC. Pathogenenesis of type
III hyperlipoproteinaemia. J Lipid Res 1999; 40:
1933–1949.
Song Y, Stampfer MJ, Liu S. Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease.
Ann Intern Med 2004; 141: 137–147.
Jukema JW, van Boven AJ, Groenmeijer B et al. The
Asp9 Asn mutation in the lipoprotein lipase gene is
134 PART II Cardiovascular polygenic disorders
151
152
153
154
155
156
157
158
159
160
161
162
163
associated with increased progression of coronary
atherosclerosis. REGRESS Study Group, Interuniversity
Cardiology Institute, Utrecht, the Netherlands. Regression Growth Evaluation Statin Study. Circulation 1996;
94: 1913–1918.
Humphries SE, Nicaud V, Margalef J. Lipoprotein lipase
gene variation is associated with a paternal history
of premature coronary artery disease and fasting and
postprandial plasma triglycerides: the European Atherosclerosis Research Study (EARS). Arterioscler Thromb
Vasc Biol 1998; 18: 526–534.
Kronenberg F, Kronenberg MF, Kiechl S et al. Role
of lipoprotein(a) and apolipoprotein(a) phenotype in
atherogenesis: prospective results from the Bruneck
study. Circulation 1999; 100: 1154–1160.
Ridker PM, Hennekens CH, Stampfer MJ. A prospective
study of lipoprotein(a) and the risk of myocardial
infarction. JAMA 1993; 270: 2195–2199.
Rosengran A, Wilhelmsen L, Eriksen E et al. Lipoprotein(a) and coronary heart disease: a prospective
case–control study in a general population sample of
middle-aged men. Br Med J 1990; 301: 1248–1251.
Kim JH, Kim KH, Nam SM. The apolipoprotein(a) size,
pentanucleotide repeat, C/T(+93) polymorphisms of
apolipoprotein(a) gene, serum lipoprotein(a) concentrations and their relationship in a Korean population.
Clin Chim Acta 2001; 314: 113–123.
Barter BJ, Brewer HB, Chapman J et al. Cholesteryl ester
transfer protein. Arterioscler Thromb Vasc Biol 2003; 23:
160–167.
Okamoto H, Yonemori F, Wakitani K et al. A cholesteryl
ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 2000; 406: 203–206.
Boekholdt S, Sacks FM, Jukema JW et al. Cholesteryl
ester transfer protein TaqIB variant, high-density
lipoprotein cholesterol levels, cardiovascular risk, and
efficacy of pravastatin treatment. Circulation 2005; 111:
278–287.
Salen G, Shefer S, Nguyen L. Sitosterolemia. J Lipid Res
1992; 33: 945–955.
Berge KE, Tian H, Graf GA et al. Accumulation of
dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science 2000; 290:
1771–1775.
Stefkova J, Poledne R, Hubacek JA. ATP-binding cassette (ABC) transporters in human metabolism and
diseases. Physiol Res 2004; 53: 235–243.
Graf GA, Li WP, Gerard RD et al. Coexpression of ATPbinding cassette proteins ABCG5 and ABCG8 permits
their transport to the apical surface. J Clin Invest 2002;
110: 659–669.
Oram JF. Molecular basis of cholesterol homeostasis:
lessons from Tangier disease and ABCA1. Trends Mol
Med 2002; 8: 168–173.
164 Joyce CW, Amar MJ, Lambert G et al. The ATP binding
cassette transporter A1 (ABCA1) modulates the development of aortic atherosclerosis in C57BL/6 and apoEknockout mice. Proc Natl Acad Sci USA 2002; 99: 407–412.
165 Alrasadi K, Ruel IL, Marcil M et al. Functional mutations of the ABCA1 gene in subjects of French-Canadian
descent with HDL deficiency. Atherosclerosis 2006; 188:
281–291.
166 Frikke-Schmidt R, Noordesgardt BG, Schnohr P et al.
Mutation in ABCA1 predicted risk of ischemic heart
disease in the Copenhagen City Heart Study Population.
J Am Coll Cardiol 2005; 46: 1516–1520.
167 Pajukanta P, Lilja HE, Sinsheimer J et al. Familial combined hyperlipidemia is associated with upstream transcription factor 1 (USF1). Nat Genet 2004; 36: 371–376.
168 Huertas-Vazquez A, Aguilar-Salinas C, Lusis AJ. Familial combined hyperlipidemia in Mexicans: Association
with upstream transcription factor 1 and linkage on
chromosome 16q24.1. Arterioscler Thromb Vasc Biol
2005; 25: 1985–1991.
169 Coon H, Xin Y, Hopkins PN et al. Upstream stimulatory
factor 1 associated with familial combined hyperlipidemia, LDL cholesterol, and triglycerides. Hum Genet
2005; 117: 444–451.
170 Komulainen K, Alanne M, Auro K et al. Risk alleles of
USF1 gene predict cardiovascular disease of women in
two prospective studies. PLoS Genet 2006; 2 : e69 [Epub
ahead of print].
171 Liao F, Andalibi A, Qiao JH et al. Genetic evidence for a
common pathway mediating oxidative stress, inflammatory gene induction, and aortic fatty streak formation in mice. J Clin Invest 1994; 94: 877–884.
172 Dwyer JH, Allayee H, Dwyer KM et al. Arachidonate 5lipoxygenase promoter genotype, dietary arachidonic
acid, and atherosclerosis. N Engl J Med 2004; 350: 29–37.
173 Helgadottir A, Gretarsdottir S, St Clair D et al. Association between the gene encoding 5-lipoxygenaseactivating protein and stroke replicated in a Scottish
population. Am J Hum Genet 2005; 76: 505–509.
174 Mehrabian M, Allayee H, Wong J et al. Identification of
5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice. Circ Res 2002; 91:
120–126.
175 Lotzer K, Funk CD, Habenicht AJ. The 5-lipoxygenase
pathway in arterial wall biology and atherosclerosis.
Biochim Biophys Acta 2005; 1736: 30–37.
176 Yamada A, Ichihara S, Murase Y et al. Lack of association of polymorphisms of the lymphotoxin alpha gene
with myocardial infarction in Japanese. J Mol Med 2004;
82: 477–483.
177 Koch W, Kastrati A, Bottiger C et al. Interleukin-10 and
tumor necrosis factor gene polymorphisms and risk of
coronary artery disease and myocardial infarction.
Atherosclerosis 2001; 159: 137–144.
CHAPTER 6
178 Elghannam H, Tavackoli S, Ferlic L et al. A prospective
study of genetic markers of susceptibility to infection
and inflammation, and the severity, progression and
regression of coronary atherosclerosis and its response
to therapy. J Mol Med 2000; 78: 562–568.
179 Maresca G, DiBlasio A, Marchioli R et al. Measuring
plasma fibrinogen to predict stroke and myocardial
infarction: an update. Arterioscler Thromb Vasc Biol
1999; 19: 1368–1377.
180 Yang Q, Tofler GH, Cupples LA et al. A genome-wide
search for genes affecting circulating fibrinogen levels in
the Framingham Heart Study. Thromb Res 2003; 110:
57–64.
181 Folsom AR, Aleksic N, Ahn C et al. Beta-fibrinogen gene
-455G/A polymorphism and coronary heart disease
incidence: the Atherosclerosis Risk in Communities
(ARIC) Study. Ann Epidemiol 2001; 11: 166–170.
182 Lee AJ, Fowkes FG, Lowe GD et al. Fibrinogen, factor
VII and PAI-1 genotypes and the risk of coronary and
peripheral atherosclerosis: Edinburgh Artery Study.
Thromb Haemost 1999; 81: 553–560.
183 Thogersen AM, Jansson JH, Boman K et al. High plasminogen activator inhibitor and tissue plasminogen
activator levels in plasma precede a first acute myocardial infarction in both men and women. Circulation
1998; 98: 2241–2247.
184 Dawson SJ, Wiman B, Hamsten A et al. The two allele
sequences of a common polymorphism in the promoter
of the plasminogen activator inhibitor-1 (PAI-1) gene
respond differently to interleukin-1 in HepG2 cells.
J Biol Chem 1993; 268: 10739–10745.
185 Iacoviello L, Burzotta F, Di Castelnuovo A et al. The
4G/5G polymorphism of PAI-1 promoter gene and the
risk of myocardial infarction: a meta-analysis. Thromb
Haemost 1998; 80: 1029–1030.
186 Monajemi H, Arkenbout EK, Pannekoek H. Gene
expression in atherogenesis. Thromb Haemost 2001; 86:
404–412.
187 Libby P, Ridker PM. Inflammation and atherosclerosis:
role of C-reactive protein in risk assessment. Am J Med
2004; 116 (Supplement 6A): 9S–16S.
188 Libby P. What have we learned about the biology of
atherosclerosis? The role of inflammation. Am J Cardiol
2001; 88 (7B): 3J–6J.
189 Zuckerbraun BS, Tzeng E. Vascular gene therapy: a
reality of the 21st century. Arch Surg 2002; 137:
854–861.
190 Channon KM, Qian H, Nephlioeva V et al. In vivo gene
transfer of nitric oxide synthase enhances vasomotor
function in carotid arteries from normal and cholesterol-fed rabbits. Circulation 1998; 98: 1905–1911.
191 Qian H, Nephlioeva V, Shetty GA et al. Nitric oxide synthase gene therapy rapidly reduces adhesion molecule
expression and inflammatory cell infiltration in carotid
192
193
194
195
196
197
198
199
200
201
202
203
204
205
Atherosclerosis
135
arteries of cholesterol-fed rabbits. Circulation 1999; 99:
2979–2982.
Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS,
Valle D, eds. Metabolic Basis of Inherited Disease.
McGraw Hill, New York. 1995; 1267–1282.
Abifadel M, Varret M, Rabes JP et al. Mutations in
PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003; 34: 154–156.
Sing CF, Davignon J. Role of the apolipoprotein E polymorphism in determining normal plasma lipid and
lipoprotein variation. Am J Hum Genet 1985; 37:
268–285.
Talmud PJ, Hawe E, Martin S et al. Relative contribution of variation within the APOC3/A4/A5 gene cluster
in determining plasma triglycerides. Hum Mol Genet
2002; 11: 3039–3046.
Shohet RV, Vega GL, Bersot TP et al. Sources of variability in genetic association studies: insights from the analysis of hepatic lipase (LIPC). Hum Mutat 2002; 19:
536–542.
Frikke-Schmidt R, Nordestgaard BG, Jensen GB,
Tybjaerg-Hansen A. Genetic variation in ABC transporter A1 contributes to HDL cholesterol in the general
population. J Clin Invest 2004; 114: 1343–1353.
Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G,
Hobbs HH. Apolipoprotein(a) gene accounts for
greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest 1992; 90: 52–60.
Kang SS, Passen EL, Ruggie N et al. Thermolabile defect
of methylenetetrahydrofolate reductase in coronary
artery disease. Circulation 1993; 88: 1463–1469.
Ma J, Stampfer MJ, Hennekens CH et al. Methylenetetrahydrofolate reductase polymorphism, plasma
folate, homocysteine, and risk of myocardial infarction
in US physicians. Circulation 1996; 94: 2410–2416.
Hamsten A. The hemostatic system and coronary heart
disease. Thromb Res 1993; 70: 1–38.
Thomas AE, Green FR, Lamlum H, Humphries SE. The
association of combined alpha and beta fibrinogen
genotype on plasma fibrinogen levels in smokers and
non-smokers. J Med Genet 1995; 32: 585–589.
Caulfield M, Lavender P, Newell-Price J et al. Linkage of
the angiotensinogen gene locus to human essential
hypertension in African Caribbeans. J Clin Invest 1995;
96: 687–692.
Lusis AJ, Weinreb A, Drake TA, Allayee H. Genetics
of atherosclerosis. In: Topol E, ed. Textbook of Cardiovascular Medicine, 2nd edn. Lippincott Williams and
Wilkins, Philadelphia, 2002.
Staessen JA, Wang JG, Ginocchio G et al. The deletion/
insertion polymorphism of the angiotensin converting
enzyme gene and cardiovascular-renal risk. J Hypertens
1997; 15: 1579–1592.
136 PART II Cardiovascular polygenic disorders
206 Shih DM, Reddy S, Lusis AJ. CHD and atherosclerosis: human epidemiological studies and trangenic
mouse models. In: Costa LG, Furlong C, eds. Paraoxonase (PON1) in Health and Disease. Kluwer, Boston,
2001.
207 Tward A, Xia YR, Wang XP et al. Decreased atherosclerotic lesion formation in human serum paraoxonase
transgenic mice. Circulation 2002; 106: 484–490.
208 Kiechl S, Lorenz E, Reindl M et al. Toll-like receptor 4
polymorphisms and atherogenesis. N Engl J Med 2002;
347: 185–192.
209 Gretarsdottir S, Thorleifsson G, Reynisdottir ST et al.
The gene encoding phosphodiesterase 4D confers risk of
ischemic stroke. Nat Genet 2003; 35: 131–138.
210 Altshuler D, Hirschhorn JN, Klannemark M et al. The
common PPARgamma Pro12Ala polymorphism is
211
212
213
214
associated with decreased risk of type 2 diabetes. Nat
Genet 2000; 26: 76–80.
Horikawa Y, Oda N, Cox NJ et al. Genetic variation in
the gene encoding calpain-10 is associated with type 2
diabetes mellitus. Nat Genet 2000; 26: 163–175.
Silander K, Mohlke KL, Scott LJ et al. Genetic variation
near the hepatocyte nuclear factor-4 alpha gene predicts
susceptibility to type 2 diabetes. Diabetes 2004; 53:
1141–1149.
Wang Q, Rao S, Shen GQ et al. Premature myocardial
infarction novel susceptibility locus on chromosome
1P34-36 identified by genomewide linkage analysis. Am
J Hum Genet 2004; 74: 262–271.
Grant SFA, Thorleifsson G, Reynisdottir I et al. Variant
of transcription factor 7-like 2 (TCF7L2) gene confers
risk of type 2 diabetes. Nat Genet 2006; 38: 320–323.
7
CHAPTER 7
Heart failure
Markus Meyer, MD, & Peter VanBuren, MD
Overview
Introduction
Major advances in the treatment of cardiovascular
diseases in general (e.g., coronary artery disease and
sudden cardiac death) have resulted in improved
overall mortality but ultimately contribute to the
increasing incidence and prevalence of heart failure. Currently more than 550,000 new cases of
heart failure are diagnosed in the USA each year
[1]. Based on a 2002 estimate, the prevalence of
heart failure in the US is approximately 5 million,
with many more cases of preclinical heart failure
uncounted in the population at large [2]. Once
diagnosed with heart failure, an individual’s 1 year
mortality is approximately 20%, with 80% and
70% 8-year mortalities in men and women, respectively. Since 1992, the number of deaths from heart
failure has increased by 35%. Nearly 1,000,000
patients were hospitalized in the USA with heart
failure in 2002. Currently (2005), the estimated cost
of heart failure in the USA is approximately 28 billion dollars [1].
These staggering statistics underscore the fact
that this disease is a major public health burden
which warrants active and broad based research to
discover novel therapies. While some patients presenting with heart failure have inherited disorders
where a single gene is the cause, the majority of
heart failure cases are acquired and involve the
interaction of multiple genes. Thus, by definition,
acquired forms of heart failure are polygenic disorders. Gene regulation and expression are the cornerstones of understanding the processes that
govern the pathophysiology of heart failure.
It is now well understood that heart failure is
generally triggered by a direct insult to the myo-
cardium. The source of the insult can be broadly
categorized as ischemic/infarction, toxic metabolic
(e.g., diabetes, alcohol, chemotherapy), inflammatory (e.g., myocarditis), hemodynamic (e.g., valvular heart disease, hypertension) or inherited (e.g.,
dilated cardiomyopathy, hypertrophic cardiomyopathy). Furthermore, the underlying conditions
of diabetes, hypertension, renal disease, obesity and
sleep apnea can contribute in an additive fashion to
other myocardial insults. Following an insult, the
heart hypertrophies seen as an increase in cardiac
mass as well as an increase in myocyte length and
width at the cellular level. In most cardiomyopathies, if the inciting insult (or its sequel) persists
the left ventricle will dilate, which is then followed
by further deterioration of systolic function (Fig. 7.1).
In end-stage cardiomyopathy, the gross phenotype
of the heart is strikingly similar irrespective of the
initial etiology. The process of hypertrophy, dilation and dysfunction is termed ventricular remodeling or, more aptly, adverse remodeling. The
progression of heart failure is a dynamic process
where adverse remodeling can be partially reversed
or at least halted with the initiation of therapies
and/or removal of the insult. In the following pages,
we review the stages of heart failure and probe
known and probable changes in gene expression as
a function of the progression of the disease.
Polygenic factors in the development
of heart failure
Acquired heart failure is a polygenic disorder and
several predisposing medical conditions increase
the risk of developing heart failure. For example,
hypertension, diabetes and renal disease are associated with altered hemodynamic stress, neurohormonal and inflammatory signaling which trigger
137
138 PART II Cardiovascular polygenic disorders
Initial insult
CAD
Hypertension
Infection
Adaptive response
Diabetes
Hemodynamic response
Neurohormonal stimulation
Compensation
Continued insult
Cardiac growth (Fetal program)
Continued neurohormonal stimulation
Decompensation
Maladaptive response
Wall stress, remodeling
Dysfunctional calcium cycling
Sarcomere dysfunction
Apoptosis, oxidative stress
Metabolic dysfunction
the development of heart failure. These diseases
increase the risk of developing heart failure, both
as indirect sequelae of the disease process and as
a result of direct modulation of cardiac gene
expression.
A patient’s race and sex are important factors in
the pathogenesis of heart failure. The incidence of
heart failure is currently declining in women but
not in men [3]. After the onset of heart failure,
women demonstrate better survival when compared with men [3,4]. The proportion of women
with diastolic heart failure with preserved systolic
function is greater than in men [2], which may be a
factor in their improved prognosis. In response to
pressure overload, the pattern of hypertrophy tends
to be more concentric in woman and dilated in
men [5], indicating that there is a sex difference in
the remodeling of the left ventricle, a process that
is ultimately tied to myocardial gene expression.
Evidence of gender-specific responses to therapy is
seen in the subset analyses of the SOLVD and
CONSENSUS-1 studies which demonstrated that
men achieved a greater beneficial response to
angiotensin-converting enzyme inhibitors (ACE-I)
than women [6]. In contrast, the response to betablocker therapy in heart failure is greater in women
than in men [7,8].
Figure 7.1 Polygenic diseases leading
to heart failure. Intra- or extracardiac
insults trigger hemodynamic and
neurohormonal responses as an
adaptive response. The intracellular
pathways activated by prolonged
mechanical or hormonal stimuli mediate
cellular growth (hypertrophy), and have
additional effects on the transcriptional
control and post translational
modification of proteins involved in
contractility, metabolism, apoptosis and
the extracellular matrix. These changes
detrimental to cardiac function sustain
a vicious cycle of decompensation
and additional growth (maladaptive
response). CAD, coronary artery disease.
Estrogen is likely a major (but not the sole) factor
in the differential response of women to specific
therapies compared with men [9]. Estrogen has
shown attenuated hypertrophic response in animal
models of myocardial failure [10]. Estrogen can
directly affect transcription through two nuclear
hormone receptors (α and β). In addition, estrogen
appears to affect cell signaling through the phosphoinositide-3 kinase (PI3K)-Akt-dependent and
mitogen activated protein kinase (MAPK) pathways which are discussed in more detail below
[11,12]. In addition, estrogen is a potent vasodilator and increases nitric oxide and atrial natriuretic
peptide production. Furthermore, testosterone can
also affect cardiac function; thus, it may be the relative influence of sex hormones that is a determining
factor in the therapeutic response of heart failure
patients. However, more research needs to be conducted to better understand the effects of gender on
the remodeling process in heart failure.
Black patients have a greater prevalence of heart
failure and higher mortality compared with white
patients [1]. These differences may be related, in
part, to the increased incidence of hypertension
and renal disease in black patients [13]. Differences
in neurohormonal signaling may underlie the poor
prognosis and altered response to heart failure
CHAPTER 7
therapy [14]. Specifically, response rate to ACE-I in
patients with an African-American background is
less pronounced than in patients with a Caucasian
background [14,15], whereas the response to specific beta-blockers has been variable. Bucindolol
conferred a benefit in white patients but was associated with a trend toward higher mortality in black
patients [16]. In contrast, the benefit of carvedilol is
similar for black and white patients [17]. These differences likely underlie the different mechanisms of
action of specific beta-blockers. Taken together
these results suggest that there are fundamental differences in signaling pathways and genetic regulation in black and white populations. This was the
focus of the recently published African American
Heart Failure Trial (A-HeFT) trial, which revisited
the use of nitrates and hydralazine in black patients
with heart failure. A 43% reduction in mortality
was demonstrated in spite of the fact that many of
the patients were already being treated with betablockers and ACE-I or angiotensin receptor blockers [18]. Given that black patients have been found
to have lower bioavailability of nitric oxide than
white patients [19], the increased nitric oxide level
associated with the combined therapy of nitroglycerin and hydralazine may be uniquely suited to
benefit black patients with heart failure.
It is now understood that polymorphisms in specific genes can predispose patients to heart failure.
Gene polymorphisms are population variations in
DNA composition that occur at a frequency >1%.
In African-Americans these include polymorphisms
in the α2c and β1 adrenergic receptors, endothelial
nitric oxide synthase (eNOS), aldosterone synthase,
transforming growth factor β1 (TGF-β1) and G proteins [20,21]. In addition, polymorphisms in the
angiotensin-converting enzyme (deletion allele) has
been reported in the general population with relatively high frequency [22]. All of these polymorphisms may predispose a carrier to the development
of cardiomyopathy, impact prognosis or affect the
response to a specific treatment for heart failure.
In summary, differences in genetic make up or
alteration in genetic expression resulting from an
underlying condition can affect the risk of developing heart failure, its prognosis and response to
therapy. In the future, determining a patient’s
genetic profile may help tailor therapies in an effort
to optimize response.
Heart failure 139
Humoral and hemodynamic factors
in heart failure
Hemodynamic and mechanical
considerations
During most of the last century, heart failure was
understood as a disorder of cardiac ejection or systolic function. Only since the 1970s have we begun
to understand that impaired diastolic function also
contributes to most cases of heart failure. This is
most obvious in end stage dilated cardiomyopathy
where both systolic and diastolic function are
impaired. In other words, a ventricle that ejects
poorly in systole usually does not fill normally in
diastole, and a heart that fills poorly in diastole usually does not eject normally in systole [23]. The initial hemodynamic, morphologic and molecular
changes are acute adaptive responses that aim to
preserve cardiac output after a myocardial insult.
The earliest response involves adjustments of cardiac parameters including preload, afterload, heart
rate and changes in the speed of contraction and
relaxation. These early hemodynamic adaptations
are supported by intrinsic myocardial mechanisms
that control cardiac contractility and output. Such
mechanisms include preload and heart rate dependent inotropy first described more than a century
ago by Starling and Bowditch [24,25].
Many of these early adaptive processes are
regulated by neurohormonal factors such as catacholamines and angiotensin II, whose levels are
increased in the blood in an attempt to further
stabilize cardiac output and blood pressure. This
response is best exemplified in the activation of
the renin–angiotensin–aldosterone system, where
reduced renal perfusion leads to the renal release of
renin, aldosterone and vasopressin. The end result
is increased vasoconstriction and renal free water
reabsorption. Norepinephrine, released primarily
by the adrenal glands, increases heart rate and contractility through β1-adrenergic stimulation whereas
α-adrenergic stimulation in the peripheral vasculature leads to vasoconstriction. Thus, many effects of
initial neurohormonal stimulation appear to be
adaptive by attempting to maintain cardiac output
and blood pressure. However, in the past 20 years
we have come to understand that neurohormones,
when chronically activated, lead to detrimental
changes by creating unfavorable hemodynamic
140 PART II Cardiovascular polygenic disorders
conditions, such as increased cardiac afterload,
excessive preload and volume overload. Moreover,
neurohormones can induce cardiac growth in the
form of concentric and eccentric hypertrophy by
directly activating intracellular signaling pathways
that initiate a hypertrophy gene program, as discussed in greater detail below. This process of cardiac hypertrophy in the setting of myocardial stress
and failure is maladaptive, as evidenced by clinical
trials that demonstrate left ventricular hypertrophy
is an independent predictor of mortality. Such maladaptive hypertrophy contrasts with adaptive
hypertrophy (i.e., fetal cardiac development, cardiac growth into adulthood and cardiac growth as a
response to exercise) which is governed by many of
the same mechanisms. If cardiac remodeling results in ventricular dilatation, unfavorable chamber
geometry and increased wall stress results. This is
based on the Law of Laplace, where wall stress
is proportional to (pressure × radius) / (2 × wall
thickness). In concentric hypertrophy, where
chamber dimensions are preserved and wall thickness is increased, wall stress is usually not increased
(even with increased intracardiac pressures) and
thus is likely not a contributing factor in the pathologic processes of heart failure. However, in dilated
cardiomyopathy where chamber dimensions are
increased and wall thickness is largely unchanged
or even reduced, wall stress is markedly elevated
and thus believed to be a contributing factor to
heart failure.
Myocardial wall stress is now well recognized to
have direct effects on cardiac gene expression by
activating intracellular signaling cascades independent of neurohormonal stimulation [26,27]. The
clinically best known genes activated by wall stress
are the natriuretic hormones and in particular brain
natriuretic peptide (BNP). The natriuretic peptides
are known to decrease afterload and increase diuresis. However, despite the favorable hemodynamic
effects of natriuretic proteins, myocardial wall
stress is known to induce both physiologic and
pathologic myocardial hypertrophy through several mechanisms.
Surprisingly, while baseline cardiac output is
either unchanged or slightly reduced in most forms
of systolic heart failure, the intrinsic mechanisms
to control contractility in the myocardium are
markedly disturbed [28]. The Frank–Starling curve
is shifted to higher preloads in order to maintain
similar systolic pressures, and the heart rate dependent increase in cardiac output is blunted. This
explains why a severely dilated heart with low ejection fraction can have a normal stroke volume
but typically shows a reduced contractile reserve
compared with a normal heart, especially when
challenged by higher heart rates or circulatory
demands. This illustrates that ejection fraction is a
poor measure of contractile function which does
not correlate well with cardiac output and symptoms but has repeatedly proven to be a good predictor of survival in systolic heart failure [29,30].
Cardiac contractility is a much more complex and
poorly defined measure which integrates preload
and afterload, chamber size and shape, inotropy,
speed of cardiac relaxation and the speed and
sequence of cardiac excitation. The interplay of
these factors determines if cardiac output and
blood pressure are sufficient to maintain organ perfusion and provide reserve capacity in times of
higher circulatory needs. This supports the concept
that even a minor disturbance in this system over
time can induce cardiac hypertrophy as an adaptive
process which itself can worsen the imbalance leading to a vicious cycle of insult and maladaptive
changes which ultimately can result in symptoms
and a diagnosis of heart failure.
Neurohormonal and cytokine signaling
While the depressed contractility of the heart is
central to the clinical syndrome of heart failure,
there are several circulating neurohormones and
cytokines that, in addition to having early inotropic
effects, can directly or indirectly affect cardiac gene
regulation and thus alter cardiac function. The
neurohormones include catacholamines, angiotensin II, endothelin, aldosterone, vasopressin, estrogen,
testosterone and growth hormone.
Epinephrine and norepinephrine
Circulating catacholamine levels are markedly elevated in heart failure and positively correlate with
mortality [31]. Adrenergic stimulation of the heart
by norepinephrine and epinephrine occurs through
α and β adrenergic receptors. The β-adrenergic
receptor has three isoforms with the β1 isoform
demonstrating 75% predominance in the nonfailing human cardiac myocyte. Stimulation of the
CHAPTER 7
β-adrenergic receptor causes an acute increase in
myocardial contractility, but chronic adrenergic
stimulation results in contractile dysfunction,
adverse ventricular remodeling and increased mortality. The β-adrenergic receptor is a seven transmembrane, G protein coupled receptor (discussed
in more detail below). When stimulated it activates
adenylate cyclase through a Gαs protein coupled
mechanism to generate cyclic AMP to ultimately
activate protein kinase A (PKA) [32]. Many of the
acute increases in contractile response to β-adrenergic stimulation are mediated through PKA. In
contrast, chronic β-adrenergic receptor stimulation (β1 receptor subtype) is associated with the
induction of several signaling pathways (e.g. the cJun N terminal kinases [JNKs] and Ca2+ activated calmodulin [CAM] kinase II) that are involved
in ventricular remodeling and apoptosis [33]. In
chronic heart failure, the β-adrenergic receptor is
downregulated largely by reduced gene transcription [32]. Moreover, the chronic adrenergic stimulation of heart failure results in desensitization of
the β-adrenergic receptor [35]. Polymorphisms of
the β-adrenergic receptor gene have been reported
in patients with heart failure [20,36,37]. Many of
these polymorphisms have been shown to alter
function in vitro [38], and are implicated in the differential therapeutic responses of patients with
heart failure [39]. Finally, these polymorphism
have been associated with the development and
progression of heart failure [20,36].
The α-adrenergic receptor is much less abundant than the β receptor (1 : 10 ratio). The αadrenergic receptor is a G protein coupled receptor
(Gαq) which ultimately mediates the activation of
protein kinase C (PKC). Despite its lower abundance,
chronic stimulation of the α-adrenergic receptor
elicits a cardiac hypertrophic response through the
MAPK and calcineurin mediated pathways.
Angiotensin II
Renin is released by the kidney largely with the
activation of the sympathetic nervous system,
reduced renal perfusion and vasopressin release.
Renin converts angiotensinogen to angiotensin I.
The major source of angiotensinogen is the liver
but other organs such as the heart also produce angiotensinogen. Angiotensin I is converted to angiotensin II by angiotensin-converting enzyme which also
Heart failure 141
hydrolyzes bradykinin. Angiotensin II levels are
markedly elevated in heart failure because of the
activation of renin. Angiotensin II is a potent vasoconstrictor that also triggers aldosterone release
and stimulates renal tubular retention of sodium
and water and thus directly contributes to increased myocardial hemodynamic stress in heart
failure. The heart contains two cell membraneassociated angiotensin receptors. Stimulation of
the angiotensin II type 1 (AT1) receptor is associated with several pathologic changes in the myocardium. Stimulation of the AT1 receptor occurs
through a Gαq protein mediated mechanism to
activate PKC through the same pathways as for
α-adrenergic stimulation. Angiotensin II infusion
in rats induced a failing cardiac phenotype with
an increase in fetal gene program mRNA expression (e.g., α-skeletal actin, β myosin heavy chain,
atrial natriuretic peptide) and an increase in cardiac
mass [40]. Moreover, hypertrophy as measured
by the increase in myocyte size and the rate of protein synthesis is also induced by angiotensin II
[41,42]. Angiotensin II stimulation of the AT1
receptor is known to activate signaling pathways
directly involved in the induction of factors that
control gene transcription (i.e., the immediate early
genes: c-fos, c-jun, jun-B, Egr-1 and c-myc [41]).
Modulation of the immediate early gene expression
is implicated in the initial hypertrophic response.
In addition, angiotensin II (through the AT1 receptor) induces fibroblast hyperplasia and collagen
synthesis, with specific increases in fibronectin,
TGF-β and collagen type I and III expression
[40,43]. These data indicate the likely role of
angiotensin II in the extracellular matrix remodeling and myocardial fibrosis associated with
myocardial failure. Moreover, cardiac tissue can
produce endogenous angiotensin through cellular
angiotensin-converting enzyme and thus modulate
the above pathway through an autocrine–paracrine
type mechanism, the functional significance of
which is currently unknown. Increased cellular
necrosis and programmed cell death was noted
with angiotensin II infusion [44].
While the overall abundance of angiotensin II
receptors is low in the heart, the angiotensin II type
2 (AT2) receptor is expressed at a higher level than
AT1 receptor in the human heart [45,46]. Whereas
AT1 receptor protein expression is downregulated
142 PART II Cardiovascular polygenic disorders
in end stage failure, the relative abundance of the
AT2 receptor is unchanged or even upregulated
[46,47]. The functional effects of AT2 receptor
stimulation is not as well known but appears to be
protective. AT2 receptor overexpression in transgenic mice resulted in preserved left ventricular
function after myocardial infarction [48]. Furthermore, the downstream functional effects of the AT2
receptor appear distinct and largely opposite to the
effects of the AT1 receptor. Specifically, stimulation
of the AT2 receptor causes a relative suppression
of the hypertrophic response [45], likely through
the activation of phosphatases that inactivate the
MAPK growth cascade [49].
Aldosterone
In heart failure, aldosterone levels are increased as
much as 30-fold and are correlated with increased
mortality [50]. In addition, aldosterone is directly
linked to the induction of cardiac fibrosis and hypertrophy. Aldosterone is produced primarily by the
adrenal glands, stimulated by elevated angiotensin
II levels. However, other factors can trigger aldosterone release such as hyperkalemia, hyponatremia
and adrenocorticotrophic hormone. Aldosterone
modulates vascular tone and volume through
affecting epithelial sodium transport and possibly
through modulating vascular response through the
α-adrenergic receptor or by upregulation of angiotensin II receptors in the vasculature [51].
Aldosterone is known to cause cardiac fibrosis
and hypertrophy which largely appear to be independent of its vascular effects and is likely the direct
effect of stimulation of the myocardial mineralocorticoid receptor [52]. When aldosterone binds
the mineralocorticoid receptor (located in the cytoplasm), the receptor–ligand complex dimerizes,
is translocated to the nucleus and ultimately binds
to hormone response elements activating the transcription of target genes. Aldosterone increases
the cardiac expression of the AT1 receptor and
angiotensin-converting enzyme [53,54], thus contributing to the hypertrophic response through
angiotensin II stimulation. Moreover, aldosterone
has been linked to the upregulation in collagen I,
collagen III, matrix metalloproteinase (MMP)
expression as demonstrated in animal models of
heart failure, facilitating the observed fibrosis associated with aldosterone stimulation of the heart
[55,56]. However, while the induction of hypertrophy and fibrosis with aldosterone is well documented, the specific nuclear signaling mechanisms
are not completely understood. Activation (direct
or indirect) of the transcription factors: activating
protein 1, nuclear factor κB (NF κB) and nuclear
factor of activated T cells (NFAT) have been implicated [56,57].
In addition, the effects of aldosterone can be
observed over a number of minutes, which are
likely nongenomic effects, and appear to be mediated through inositol 1,4,5-triphosphate, PKC and
Ca2+ signaling [58]. Finally, local production of
aldosterone by the heart possibly has a significant
role in human heart failure [59]. Given the profound effect of mineralocorticoid receptor blockade on ventricular remodeling and mortality in
clinical trials [60], further research in this area will
likely yield more insight into the detrimental effects
of aldosterone in heart failure.
Arginine vasopressin
Arginine vasopressin, also known as antidiuretic
hormone (ADH) is released by the posterior pituitary and is known to facilitate free water reabsorption through the collecting ducts in the kidney.
In addition, it is a potent vasoconstrictor, and
thus through these two mechanisms can increase
circulating blood volume and blood pressure.
Vasopressin is elevated in heart failure [61]. There
are three vasopressin receptor isoforms. V1a is
located in the adrenal cortex, myocardium and the
vasculature. V2 is located predominantly in the
kidney and is responsible for its antidiuretic effect.
V1b is involved in the regulation of adrenocorticotropic hormone release from the pituitary gland
[60]. Vasopressin directly stimulates hypertrophy
and hyperplasia in cardiac myocytes and fibroblasts, respectively, as is demonstrated by increased
protein and DNA synthesis [63,64]. Studies in cultured myocytes suggests that the V1a receptor is G
protein coupled activating inositol 1,4,5-triphosphate, and diacylglycerol through phospholipase C
[65] ultimately triggering PKC, MAPK and mediated calcium signaling [63,64]. The nuclear transcription factors, c-Fos and c-Jun, are associated
with the hypertrophic response [64]. Vasopressin
receptor blockade is an area of active basic and clinical research.
CHAPTER 7
Endothelin
Endothelin was first discovered in 1988 as a very
potent vasoconstrictor. Endothelin 1 is the predominant isoform of endothelin in the cardiovascular system and is the cleavage product of
endothelin-converting enzyme. Endothelin 1 is
primarily produced from endothelial cells but also
can be produced by other cells including cardiac
myocytes and vascular smooth muscle cells [66]. In
the heart, endothelin works primarily by autocrine
and paracrine mechanisms with the majority of the
endothelin being produced locally [67]. There are
two isoforms of the endothelin (ET) receptor (A
and B). ETA and ETB receptors are located on cardiac myocytes and vascular smooth muscle cells,
whereas only ETB is located on endothelial cells.
The endothelin receptors are Gαq.
The acute effects of endothelin are an increase in
stroke volume and vascular resistance through
enhanced contractility of the myocardium and vascular smooth muscle. Circulating endothelin levels
are chronically elevated in human heart failure
[68]. It is likely that chronic elevation of endothelin
has deleterious effects on cardiovascular function
as endothelin blockade has been demonstrated to
improve myocardial contractility and survival in
animal models of heart failure [69]. While the acute
effects of endothelin are nongenomic, the longer
and deleterious effects of endothelin receptor
stimulation involve transcriptional changes that
contribute to adverse ventricular remodeling and
contractile dysfunction. Overexpression of endothelin in a transgenic mouse model induced a
dilated cardiac phenotype with activation of cytokines and transcription factor, NF κB [70]. Interestingly, endothelin-converting enzyme was found
to be differentially regulated in one gene array
study of human ischemic and nonischemic dilated
cardiomyopathy [71]. Despite mounting evidence
to invoke endothelin in the pathophysiology of
cardiac remodeling and failure, clinical trials using
endothelin blockers both nonspecific (i.e., blockade of ETA and ETB such as with bosentan) or
specific (e.g., ETA as with darusentan) have so far
yielded largely neutral or negative results.
Cytokines
While cytokines have traditionally been viewed as
systemic inflammatory modulators released by the
Heart failure 143
immune system, it is now understood that they
can be generated by a variety of cell types including cardiac myocytes, fibroblast and endothelium,
and can mediate inflammatory responses through
an autocrine or paracrine mechanism. The effects
of inflammatory modulators were confirmed in
several gene array studies which found that several genes involved in inflammatory responses
are upregulated in samples from failing human
hearts [72–74]. The proinflammatory cytokines,
tumor necrosis factor α (TNF-α), interleukin-1β
(IL-1β), IL-2, IL-6 and IL-18, have all been implicated in the pathophysiology of heart failure
[75,76]. Specifically, circulating cytokine levels correlate with the severity of myocardial dysfunction
and overall mortality [77,78]. In addition, infusion
of these cytokines in animal models is associated
with immediate improvement and delayed (sustained) suppression of myocardial contractile function implicating nongenomic and genomic effects,
respectively [79]. The immediate effect of cardiac
contractility appears to be through alterations in
calcium cycling through a variety of mechanisms
[80,81].
Cardiac nitric oxide synthase (cNOS) activation
resulting in increased nitric oxide production by
cytokines has been implicated in the delayed suppression of contractile function. Nitric oxide is
known to affect transcriptional gene regulation
through the activation of guanylate cyclase and
generation of cyclic GMP which in turn activates
protein kinase G (PKG). Through this process the
activities of several transcription factors, activating protein 1 (c-Fos, Jun B), NF κB and NFAT)
are increased in cardiocytes [82]. Furthermore,
activation of transcription factor GATA4 is
reported with IL-18 stimulation [75]. Of these
transcription factors, it appears that NF-κB may
be playing a dominant part [83]. The net effect
of chronic cytokine stimulation hypertrophy in
isolated myocytes and in transgenic overexpression models is a re-expression of a fetal gene program (e.g., ANP, BNP, skeletal α actin and β
myosin heavy chain), increased expression of the
MMPs and induction of apoptosis. Ultimately,
this leads to cellular hypertrophy, increased extracellular fibrosis, a dilated hypocontractile ventricular phenotype resulting in increased mortality
[76,79,84].
144 PART II Cardiovascular polygenic disorders
Intracardiac factors in heart
failure genomics
Sarcomeric proteins
There are two cardiac myosin heavy chain (MHC)
isoforms, designated as α and β MHC. These two
isoforms are functionally distinct as evidenced by
the threefold greater rate of ATP hydrolysis by α
MHC [85]. In response to hemodynamic overload,
small mammals (containing predominantly αMHC) rapidly increase the proportion of β-MHC
present in the left ventricle [86,87]. While normal
human myocardium contains predominantly βMHC, recent studies have demonstrated small
amounts of α-MHC in normal human myocardium, ranging from a few to as much as 14% of
the total MHC [88–90]. An increase in β-MHC
expression (and a corresponding decrease in αMHC expression) has been reported in failing
human myocardium using both standard methods
and gene arrays [88–93]. To determine if this small
myosin isoform shift is of any functional significance, myosin isolated from end stage failing
human myocardium and nonfailing control tissue
was directly compared in several studies [90,94–
96]. These in vitro experiments failed to demonstrate differences in ATPase or mechanical
performance, suggesting that a shift in myosin isoform is not of functional significance in human
heart failure. However, much larger changes in
MHC expression are seen at the mRNA level [97]
and thus can be used as an index of fetal gene program activation in human hypertrophy and failure.
The MHC contains two associated light chains
which provide structural support to the neck region
of the myosin molecule. There is an up to 10%
increase in expression of the atrial isoform of the
essential light chain in the left ventricle of patients
with heart failure [98]. While the functional implications of such shifts are not completely known, the
magnitude of this isoform shift correlated with a
change in the calcium sensitivity of the myofilament. However, a definitive role of changes in light
chain isoform in heart failure has not been established to date.
Titin is a very large structural protein of the sarcomere which integrates the thick filament and the
Z-disc. It is largely responsible for the passive tension of the myocyte. Two isoforms of titin are co-
expressed in the human heart. A shift to the more
compliant titin isoform has been described in end
stage human heart failure and correlated with
decreased passive stiffness [99]. The implication in
an actively beating heart is not known. Perhaps
more important is the fact that titin has recently
been recognized as a biomechanical sensor, and is
involved in increased expression of atrial natriuretic peptide (ANP) and B-type natriuretic peptide
(BNP) with mechanical stress [100].
The human heart α-cardiac and α-skeletal actin
isoforms. There is a large shift in actin isoform
expression (α-cardiac to α-skeletal) in the developing human heart [101]. In addition, increased
expression of α-skeletal actin mRNA has been
reported in a rat myocardial infarction model
[102,103]. An increase in α-skeletal actin expression is a common measure of fetal gene program
activation in animal models of heart failure. However, no changes in actin isoform protein expression levels have been demonstrated in end stage
human cardiomyopathy tissue compared with agematched controls [101,104].
Thin filament-associated regulatory proteins of
the sarcomere control cardiac contractility in a calcium dependent fashion. There is only one isoform
of cardiac troponin C. While tropomyosin, troponin I and troponin T manifest developmental
isoform variation, no isoform shifts of troponin I or
tropomyosin at the protein level have been detected
in human or experimental heart failure [105–107].
In contrast, there are now a number of reports
demonstrating altered troponin T isoform expression in cardiac failure. In most cases there is
increased expression of a fetal isoform in the disease state [108–110]. Anderson et al. [106] first
reported a troponin T isoform shift in human heart
failure with an 8% increase in expression of a fetal
isoform compared with normal human myocardium. However, two recent studies which directly
examined the effect of troponin T isoforms on thin
filament function found only modest functional
differences between the two isoforms [111,112].
Thus, it is unlikely that a troponin T isoform shift
represents the primary cause of myofibrillar dysfunction in human heart failure.
In summary, while changes in actin, MHC, myosin
light chain and troponin T isoform have been observed in animal models and human heart failure,
CHAPTER 7
these changes are likely the result of a re-expression
of a fetal gene program and to date have not been
shown to have any significant functional impact.
Myocardial calcium handling
In most forms of hypertrophy and heart failure,
alterations of intracellular calcium handling contribute to impaired contraction and relaxation
[113]. Regulation of intracellular calcium levels has
a central role in the contraction–relaxation cycle of
the mammalian heart. Calcium levels in cardiac
myocytes vary by a factor of 10 between diastole
and systole and are 10,000-fold lower than extracellular levels [114]. Changes in cytosolic calcium
concentrations are mechanically translated as contraction and relaxation through the activation of
sarcomeric proteins. This is a highly cooperative
system, where small changes in calcium levels result
in large changes in force.
To control these changes in intracellular calcium
concentration, cardiac myocytes have two interacting systems:
1 one system is located in the outer cell (sarcolemmal) membrane and regulates calcium movements
between the cytosol and the extracellular space; and
2 the other is a specialized intracellular calcium storing organelle, the sarcoplasmic reticulum (Fig. 7.2).
Upon depolarization of the sarcolemmal membrane, voltage gated L-type calcium channels (dihydropyridine receptors) release a small amount of
Figure 7.2 Calcium handling proteins
and sarcomeric proteins. Calcium enters
the cardiac cell via the dihydropyridine
channels (DHPR) to trigger calcium
release from the sarcoplasmic reticulum
calcium channel (RyR, ryanodine
receptor) into the cytoplasm. By binding
to troponin C (TnC) calcium leads to
actin–myosin interaction and
contraction. In diastole calcium is
sequestered into the sarcoplasmic
reticulum by the calcium pump of the
sarcoplasmic reticulum (SERCA) which is
inhibited by phospholamban (PLB), and
extruded to the extracellular space by
the Na/Ca exchanger (NCX). Both
phospholamban and troponin I are
important phosphorylation targets of
protein kinase A which results in
increased contractility and relaxation.
Heart failure 145
calcium into the cardiac myocyte. This in turn
triggers the release of calcium (calcium-induced
calcium release) from the sarcoplasmic reticulum.
The rate of calcium flux from the sarcoplasmic
reticulum is the major determinant of positive
dP/dT and peak ventricular pressure.
In contrast, myocardial relaxation is determined
by the kinetics of calcium removal from the
myofilaments. The calcium pump of the sarcoplasmic reticulum (SERCA) is an ATP consuming
pump that mediates the reuptake of calcium into
the sarcoplasmic reticulum. The pump activity of
SERCA is regulated by the small inhibitory protein
phospholamban. The inotropic effects of betaagonists are largely mediated by PKA dependent
phosphorylation of phospholamban leading to a
disinhibition of SERCA and therefore increased
calcium uptake into the sarcoplasmic reticulum
ultimately leading to stronger subsequent contractions. Because the capacity for calcium storage within
the sarcoplasmic reticulum is limited, a sodium gradient driven calcium exchanger (Na/Ca exchanger)
maintains a net balance between calcium influx and
efflux at the sarcolemmal membrane.
Gene expression during cardiac hypertrophy and
heart failure mimics in many aspects the fetal expression pattern, in which the sarcolemmal calcium transport proteins are abundantly expressed
and the calcium handling proteins of the sarcoplasmic reticulum show reduced expression [115].
NCX
Ca2+
Ca2+
Sarcoplasmic reticulum
RyR
Ca2+
DHPR
Ca2+
SERCA
T-Tubule
Ca2+
PLB
Ca2+
Actin
TnC
Myosin
146 PART II Cardiovascular polygenic disorders
It was first noted that calcium transients in heart
failure were prolonged mostly because of a slowing
of cytosolic calcium removal. This translates to
slowed relaxation and consequently reduced contractility. Analysis of the candidate genes and proteins revealed that in most models of cardiac
hypertrophy and heart failure, SERCA gene transcription and protein expression is markedly
downregulated [116]. This has been confirmed in
animal models of hypertrophy and heart failure
and in end stage human heart failure [113,117].
Conversely, Na/Ca exchanger gene transcription
and protein expression was found to be upregulated in heart failure [113,117,118]. Interestingly,
many single gene defects that result in hypertrophy
or heart failure lead to a similar change in expression pattern of calcium cycling proteins. The inciting factors that have been described to lead to these
changes in calcium transients include:
1 Neurohormonal signaling, which is elevated in
heart failure and acts in part to stimulate cardiac
myocyte growth similar to the fetal situation; and
2 Mechanical tension and stretch, which activates intracellular signaling cascades resulting in a
growth stimulus on cardiac myocytes.
SERCA is by far the most studied calcium cycling
protein in hypertrophy and heart failure. Reported
changes in the expression levels of the ryanodine
receptor (calcium channel of the sarcoplasmic
reticulum) and phospholamban are less consistent
but suggest lower expression levels as well. While
ryanodine receptor levels might be reduced, more
importantly, the ryanodine receptor appears to be
hyperphosphorylated in heart failure leading to a
small calcium leak which potentially increases the
probability for malignant ventricular tachyarrhythmias [119]. The changes in the expression pattern
of calcium cycling protein expression have been
demonstrated in failing hearts with nonischemic or
ischemic dilated cardiomyopathy and in animal
models of concentric hypertrophy, thus demonstrating a commonality across species and disease
etiology. Data from gene array experiments and
proteomics approaches confirmed a significant
downregulation of SERCA in ventricular tissue
from patients with hypertrophic and dilated cardiomyopathy [91,93,120–122]. The inability of the
gene array to detect other changes is likely a result
of the considerable variability within cardiomyo-
pathic hearts and the small absolute changes in
mRNA levels.
To summarize, the disequilibrium in calcium in
heart failure stems from a shift of systolic and diastolic calcium cycling towards the sarcolemmal
membrane and away from the sarcoplasmic reticulum which leads to decreased calcium release from
the sarcoplasmic reticulum, impaired reuptake of
calcium by the sarcoplasmic reticulum and possibly
elevated diastolic calcium levels. This is seen functionally in the intact heart as a delay in relaxation,
slowed systolic upstroke, reduced systolic pressures
and potentially increased end-diastolic ventricular
pressures (caused by incomplete sarcomeric calcium clearance resulting in residual cross-bridge
cycling).
The interstitium
The cardiac interstitium is comprised of the extracellular matrix and fibroblasts. The extracellular
matrix can be viewed as the scaffolding of the myocardium. Under normal physiologic conditions,
extracellular matrix remains under the control of
several signaling pathways that can affect extracellular matrix proteins synthesis and/or degradation.
The primary proteases that are responsible for the
degradation of the extracellular matrix are the
MMPs which constitute a large family of proteases
with isoform specific actions (e.g., fibrillar collagen
or basement membrane proteins). Remodeling
of the extracellular matrix has a key role in the
development of cardiac hypertrophy and in the
alteration of ventricular shape that is associated
with the progression to end stage cardiac failure.
Specifically, the deposition of collagen in the extracellular matrix leads to increased myocardial fibrosis and myocardial stiffness, where as activation of
MMPs leads to digestion of the extracellular matrix.
Increased MMP activity directly contributes to the
remodeling (e.g., chamber dilation) associated with
hypertrophy and myocardial failure in animal
models and humans [123]. Many large-scale gene
array studies have confirmed increased transcription of structural matrix proteins (e.g., collagen isoforms I and III) and the activation of genes involved
in the turnover of extracellular components (e.g.,
MMPs) [72–74,93,122,124,125].
Cytokines likely have a major role in activation
of the MMPs in myocardial hypertrophy and fail-
CHAPTER 7
ure. The inflammatory cytokines IL-1β, TNF-α
and IL-6 decrease collagen synthesis and procollagen mRNA levels in fibroblasts [126]. IL-1β and
TNF-α cause transcriptional increase in the expression of MMPs. Thus, these inflammatory cytokines
directly contribute to chamber dilatation in the cardiac remodeling process of myocardial failure.
Furthermore, reactive oxygen species, as is present
in end stage cardiac failure and ischemic heart disease, decrease transcriptional synthesis of collagen
[127], and thus likely contribute to the degradation
of the extracellular matrix by the inflammatory
cytokines. TGF-β increases synthesis of collagen,
decreases MMP activity and increases tissue inhibitors of MMPs [128], thus may limit chamber dilatation by counteracting some of the effects of the
inflammatory cytokines.
Neurohormonal signaling by catecholamines,
angiotensin II and endothelin all stimulate fibroblast synthesis of collagen. Angiotensin II stimulates
fibroblast proliferation and the expression of collagen and other extracellular matrix proteins such as
fibronectin and laminin [129]. The end result is
increased myocardial fibrosis which is attenuated
in animal models with angiotensin II blockade
[130]. In contrast, endothelin appears to increase
fibrosis through both activation of collagen synthesis and diminished MMP activity. Catecholamines likely stimulate myocardial fibrosis through a
decrease in MMP activity as well as the increase in
tissue inhibitors of MMPs [131]. Aldosterone has
been shown to induce myocardial fibrosis, a process in which sodium appears to be a co-factor
[132]. The mechanisms of aldosterone induced
fibrosis involve the induction of fibroblast proliferation [133] as well as an increase in collagen synthesis [130] and possibly the induction of MMP
activity [134].
Finally, the activation of collagen synthesis is
likely through c-Jun and c-Fos which dimerize to
form activating protein-1 which binds to specific
gene promoter sites. Similarly, the induction MMP
transcription is through the transcription factors,
activating protein-1 and NF-κB to the promoter
region of specific MMP genes [131]. Thus, the
integrity of the interstitium lies in the balance
between MMP activity and collagen synthesis, a
process that is governed by similar signaling pathways and likely similar transcription factors.
Heart failure 147
Receptors and signal transduction
Several neurohormonal signals through receptor
specific targeting directly affect the hypertrophy
and remodeling associated with heart failure. Many
of these receptors are members of the seven transmembrane family (the receptor spans the cell membrane seven times). Receptors in this class include
β1 and β2-adrenergic, α-adrenergic, endothelin,
AT1 and AT2 (angiotensin II receptor). Common
to all these receptors is the close association with
specific guanosine triphosphate (GTP) binding
proteins (also known as G proteins comprised
of three subunits α, β, γ) and an effector enzyme
(Fig. 7.3). When an agonist binds to the receptor,
GDP is released from the α subunit allowing GTP
to bind and leading to the disassociation of α-effector enzyme, and the β–γ subunit from the agonist
receptor. Typically, effector enzymes are associated
with the α subunit but certain effector enzymes are
associated with the β–γ subunit. G protein subunit
isoform variation allows association with specific
effector enzymes [135].
Gαs signal transduction
β-Adrenergic signaling employs the Gαs subunit
which is associated with adenlylate cylase to generate cyclic AMP from ATP. Cyclic AMP functions as
a second messenger to trigger the activation of
PKA. The immediate primary function of PKA is to
increase contractile function through enhanced calcium cycling by means of phosphorylating several
calcium channels or regulatory proteins (i.e., the
L-type calcium channel, sarcoplasmic reticulum
calcium release channel – the ryanodine receptor –
and phospholamban). However, with prolonged
β-adrenergic stimulation as seen in heart failure,
several likely genomically initiated mechanisms
come into play. Specifically, there is a downregulation of the β1-receptor and its mRNA in heart
failure (as large as 50%) which is partially restored
with beta-blockade, thus suggesting a direct βadrenergic mediated mechanism [32]. β-Adrenergic
receptor sensitivity is reduced in heart failure. This
is largely because of the increase of expression
of β-adrenergic receptor kinase (which through
phosphorylation inhibits G protein binding to the
β-adrenergic receptor), and the increased expression of an inhibitory G protein Gαi [136,137].
Chronic β-adrenergic stimulation in in vitro cell
148 PART II Cardiovascular polygenic disorders
Endothelin
a-agonists
Angiotensin II
? Mechanical stress
PI(4,5)P2
GgGb-Gaq
Gaq
DAG
PLCb
+
PKC
IP3
Ras
Ca2+
Calcineurin
NFAT•P
Raf
MEK
Pi
NFAT
+
+
Transcription factors
preparations and β1-adrenergic receptor overexpression in a mouse model lead to initial myocyte
hypertrophy followed by ventricular fibrosis and
failure [138,139]. Furthermore, β-adrenergic stimulation has been implicated in the induction of
apoptosis [32].
αq–Gα
α11 signal transduction
Gα
Signaling through the endothelin, α1-adrenergic
and angiotensin II receptors is largely mediated
through G protein subunits αq and α11 (Fig. 7.3).
Upon agonist activation of the receptor, Gα coupled phospholipase Cβ is activated, hydrolyzing the
membrane bound phospholipid, phosphatidylinositol 4,5 bisphosphate, to yield diacylglycerol
(DAG) and inositol 1,4,5-triphosphate. DAG is the
primary activator of most, but not all, PKC isoforms. In the hypertrophic response mediated by
Gαq/11 PKC isoforms α and ε appear to have
a prominent role based on increased expression
levels and changes in cellular distribution [140].
However, other isoforms likely have a role as is evidenced by the transgenic overexpression of PKC β1
which resulted in the induction of a hypertrophic
ERK1/2
Figure 7.3 Gaq–Ga11 signal
transduction. The seven transmembrane receptors for several
agonists, including endothelin,
catacholamines (a1 adrenergic) and
angiotensin II, are mediated through
G protein subunits aq and a11.
Phospholipase CbPLCb) is coupled to the
Gaq subunit. Upon receptor activation,
PLCb hydrolyses cell membrane bound
phosphatidylinositol, PI(4,5)P2 to yield
diacylglycerol (DAG) and inositol 1,4,5triphosphate (IP3). DAG in turn activates
PKC which ultimately activates the extra
cellular signal related kinases 1 and 2
(ERK 1/2) of the mitogen activated
protein kinase (MAPK) family. ERK 1/2 is
responsible for the induction of several
transcription factors. On the other hand,
IP3 triggers intracellular calcium release
activating calcineurin, leading to the
dephosphorylation of nuclear factor of
activated T cells (NFAT), permitting its
nuclear transport and activation of
genes associated with hypertrophy.
Finally, these pathways also appear to be
activated by mechanical stress.
gene program [141]. Overall, the mechanisms of
isoform specific PKC mediated hypertrophic response are not currently well understood, with likely
several isoforms being involved.
It is now recognized that PKC activates the extracellular signal related kinases 1 and 2 (ERK 1/2) of
the MAPK family. There are three MAPK cascades:
ERK, the c-Jun N terminal kinases (JNKs) and the
p38 MAPKs (the latter two are discussed below).
MAPK are regulated upstream by MAPK kinases
(MAPKK) which in turn are activated by MAPKK
kinases (MAPKKK). Activation of the ERK 1/2
pathway has been demonstrated to be a principal
mediator of the hypertrophic response in heart failure [142]. Current evidence indicates that the cascade is triggered by PKC mediated activation of the
“small” GTP binding protein Ras, although the
specific mechanisms of activation are not currently
understood. Ras in turn activates Raf (a MAPKKK)
which phosphorylates ERK 1/2, resulting in the
activation of several transcription factors and
inducing a hypertrophy gene program. Furthermore, the ERK 1/2 pathway has been shown to be
activated by several growth factors as well as mech-
CHAPTER 7
anical stress mediated signaling mechanisms [141].
Finally, ERK 1/2 signaling appears to have antiapoptotic properties with several potential mechanisms being implicated [142].
Gαq/Gα11 protein activation result in the production of inositol 1,4,5-trisphosphate. This in
turn promotes release of calcium from the endoplasmic reticulum. Elevation of calcium in turn
activates the phosphatase, calcineurin. The details
of how calcium activates calcineurin in the cardiocytes, where intracellular calcium levels increase at
least 10-fold with each cardiac contraction, are not
known. Through a series of elegant experiments
conducted over the past several years, calcineurin
has been firmly established as key mediator of the
hypertrophic response in heart failure [144].
Calcineurin is known to dephosphorylate the transcription factor NFAT, thus promoting its nuclear
transport.
β
Glycogen synthase 3β
Glycogen synthase 3β inhibits the activation of
several transcription factors involved in the hypertrophic response including GATA-4, β-catenin, Cmyc and c-Jun [140]. Moreover, glycogen synthase
3β phosphorylates NFAT blocking its nuclear
translocation and thus counteracting calcineurin
induced hypertrophy [145]. PKC, PKA and mechanical stress (by an unknown mechanism) phosphorylate glycogen synthase 3β and release its
inhibition on gene transcription and promote
hypertrophy by this mechanism.
Stress activated kinases
Both the MAPK p38 and JNK are activated by cellular stress by mechanisms that are not completely
understood. The activation of p38 in transgenic
models through the overexpression of upstream
effectors resulted in a dilated ventricular phenotype
with increased fibrosis and premature mortality
[146]. p38 is known to activate the transcription
factor GATA. It was later determined that p38
MAPK phosphorylates the transcription factor
NFAT promoting nuclear export and counteracting calcineurin mediated hypertrophy [147]. Thus,
it appears that p38 signaling results in the triggering
of gene expression which promotes ventricular
dilatation and fibrosis as is observed in end stage
myocardial failure. Interestingly, p38 activity have
Heart failure 149
been reported to be elevated in end stage human
heart failure, albeit not consistently. The JNK pathway is similar to p38 MAPK in that it likely blunts
the hypertrophic response through phosphorylation (deactivation) of NFAT [143]. There is evidence to suggest that both p38 and JNK induce
cellular apoptosis [148].
PI3K–Akt signal transduction
There are two PI3K isoforms directly involved in
the hypertrophic response. The tyrosine kinase
receptors (receptors for insulin, IGF-1 and other
growth factors) and integrins (i.e., mechanoreceptors) are thought to mediate normal physiologic
(adaptive) hypertrophy through the activation of
the PI3K isoform p110α (Fig. 7.4). In contrast, activation of PI3K p110γ through G protein coupled
receptors mediates a pathologic hypertrophic
response. However, while the above discussed
pathways are through the Gα subunit, signal transduction in this pathway is through the Gβγ subunit.
Activation of either of the p110 isoforms results
in phosphorylation of membrane bound phosphatidylinositols. This step leads to the downstream activation of Akt (also referred to as protein
kinase B) by 3-phosphoinositide-dependent protein kinase D (PKD). Akt is known to activate
mammalian target of rapamycin (mTOR), a transcription factor and a central mediator of protein
synthesis. In addition, Akt phosphorylates GSK-3,
thus blocking its inhibitory effects on transcription.
The net effect is the development of hypertrophy
through the activation of the Akt pathway. The
PI3K–Akt pathways are dominant signaling pathways in the hypertrophic response as is demonstrated by the phenotypic response in several
transgenic models. The mechanisms by which activation PI3K p110γ leads to pathologic hypertrophy
and PI3K p100α results in adaptive hypertrophy
are not currently known. It has been suggested that
the development of pathologic hypertrophy requires the co-activation PI3K–Akt with other signaling pathways such as calcineurin–NFAT [145].
In summary, the signaling pathways involved in
hypertrophy and failure are complex, and our
understanding of these processes and their relative
importance continues to evolve. Other pathways
not discussed likely play a contributing part (e.g.
janus kinases – signal transducers and activators of
150 PART II Cardiovascular polygenic disorders
Insulin
IGF-1
Integrins
Tyrosin
kinase
receptors
Ga
GgGb
P(4,5)P2
PI3K
p110a
PI3K
p110
GgGb
PI3K–p110g
P(3,4,5)P3
PKD
Akt (PKB)
PI3K–p110g
mTOR
GSK-3
Transcription
GSK-3-P
Translation
Figure 7.4 PI3K–Akt signal transduction. Phosphoinositide
3-OH kinase (PI3K) is activated by two mechanisms.
The PI3K–p110a isoform is activated by the tyrosine
kinase receptor via growth factors such as insulin
and insulin like growth factor 1 (IGF-1). In addition
integrins, trans-membrane proteins that function as
mechanoreceptors, also activate PI3K–p110a. Alternatively;
PI3K–p100g isoform is activated through G protein coupled
receptors by association with the G protein subunits bg.
Both activated PI3K–p110 isoforms phosphorylate the
membrane bound phosphatidylinositol (PI(4,5)P2 →
PI(3,4,5)P3). This permits the binding of both 3phosphoinositide-dependent protein kinase (PKD) and
Akt (as known as protein kinase B) to PIP3 (not shown).
PKD then phosphorylates Akt which is turn activates
mammalian target of rapamycin (mTOR). Furthermore,
Akt phosphorylates glycogen synthase kinase 3b (GSK-3)
thus blocking its inhibitory effects on transcription. mTOR
facilitates the transcription of hypertrophic response genes
as well as promoting ribosomal biosynthesis thus increasing
transcription. Tyrosine kinase receptor activation is
associated with adaptive hypertrophy whereas G protein
coupled receptor activation predominates in cardiac
failure. Thus both adaptive and pathologic hypertrophy
can in part be mediated through this pathway.
transcription [JAK-STAT]; for review see [149]).
The PIK3–Akt pathway is involved in both physiologic and pathologic hypertrophy. In contrast, ERK
1/2 and calcineurin–NFAT pathways have a dominant role in animal models of heart failure and
are likely central mechanisms in the transition to
failure in human cardiomyopathy. It should be
emphasized that it is the interplay of several signaling pathways that, in concert through numerous transcription factors, ultimately guide gene
transcription.
oxygen delivery has immediate contractile consequences which illustrates the very limited substrate
storage capacity of the myocyte and the high
dependency on mitochondrial oxidation [150].
Phosphocreatine is the most important energy
store for ATP. To satisfy hemodynamic demands, a
healthy adult heart depends mainly on two main
energy substrate groups. Fatty acid oxidation supplies 60–90% of the energy and the oxidation of
glucose and lactic acid supplies 10–40%. Only a
small amount of ATP can be generated via anaerobic glycolysis. Most of the ATP is spent on cardiac
contraction followed by calcium handling, maintenance of sarcolemmal ion gradients and other basic
housekeeping functions. Acute changes in cardiac
Energy metabolism
The contractile performance of a heart is very
dependent on oxygen supply. The impairment of
CHAPTER 7
workload induce rapid adaptations of substrate
uptake and activate the enzymatic cascades involved into ATP generation to satisfy myocardial
energy demands. Only within the last two decades
has it been recognized that chronic changes in cardiac workload as they occur in hypertrophy and
heart failure have an effect on substrate preference,
enzyme expression patterns and mitochondrial
oxidative capacity. Hypertrophy and heart failure
lead to a progressive decline in the activity of mitochondrial oxidative pathways, ultimately decreasing the capacity for ATP production [151]. Indeed,
animal and human studies reveal a 20–30% reduction in ATP concentration in failing hearts and a
reduced phosphocreatine : ATP ratio in hypertrophy and heart failure, indicating that myocardial
energy reserves are disproportionately reduced.
However, most ATP consuming cellular processes
at normal cardiac workloads are not affected by
these reductions in ATP levels and do not support
the hypothesis that cardiac energy deficiency is a
general cause of heart failure with the clinically
important exception of heart failure from ischemia.
Interestingly, myocardial substrate preference
has been shown to switch from predominantly fatty
acids to glucose and lactic acid in heart failure and
hypertrophy [152,153]. This mimics the metabolic
Figure 7.5 Energy metabolism in heart
failure. In heart failure and hypertrophy
glucose metabolism is activated and
fatty acid metabolism is attenuated.
This change is mediated by altered
transcriptional control of the metabolic
genes involved in both pathways.
One key regulating mechanism is the
activation or inhibition of the nuclear
factor peroxisome proliferator-activated
receptor (PPAR) and its co-activator
(PCG-1). Numerous pathways which are
activated in heart failure (e.g. betaadrenergic pathway, nitric oxide,
calcium dependent kinases) affect PCG-1
levels and activity. PPAR has additional
regulatory effects on mitochondrial
biogenesis. In heart failure, reduced
adenosine triphosphate and
phosphocreatine levels under baseline
hemodynamic conditions do not affect
cardiac function but become apparent
with increased work loads.
Heart failure 151
situation in the fetal heart which was first described
in animal models. Initially, this could be only indirectly demonstrated in cardiac tissue samples from
patients with heart failure by analysis of the expression patterns of enzymes involved in the two metabolic pathways [152,154,155]. Recently, metabolic
imaging studies with positron emission tomography (PET) in patients with hypertrophy and
heart failure provided direct evidence for decreased
fatty acid oxidation and increased glucose metabolism [156,157].
The molecular mechanism leading to this switch
in substrate preference is the subject of intensive
research. The role of key nuclear proteins involved
in the transcriptional control of metabolic pathways and mitochondrial production has been
recently delineated [158]. Peroxisome proliferatoractivated receptors (PPARs) and the transcriptional co-activator (PCG-1), which are activated by
an array of signal transduction pathways, have been
shown to be involved in regulating metabolic pathways, mitochondrial metabolism and mitochondrial synthesis (Fig. 7.5). As nuclear receptors
PPARs bind to DNA in the regulatory region of
genes and activate gene transcription, whereas
PCG-1 activates PPAR to augment gene transcription. Both proteins have been shown to promote
Heart failure
Hypertrophy
Ischemia
Fetal heart
Normal heart
+
PGC
PPAR
−
Fatty acid metabolism
Glucose metabolism
Normal
energy reserve
Reduced
energy reserve
152 PART II Cardiovascular polygenic disorders
the expression of genes involved in fatty acid oxidation and mitochondrial ATP-producing capacity.
Several PCG-1 activating signaling pathways have
been delineated that translate physiologic stimuli
such as stress and exercise into changes in gene
transcription. Alterations in expression levels of
PCG-1 and PPARs represent another mechanism
of how gene transcription can be affected. High
levels of PCG-1 and PPARs promote fatty acid
metabolism and low levels favor glucose oxidation.
Indeed, in the fetal heart and animal models of
hypertrophy and heart failure, PCG-1 and PPAR
levels were found to be depressed, providing a possible explanation of why glucose and lactic acid
oxidation is the dominant metabolic pathway in
heart failure.
Gene array studies have confirmed changes in
metabolic and mitochondrial gene expression in
human hearts with ischemic and nonischemic cardiomyopathy [71,73,74,91–93,120,122,124,125]. Furthermore, alterations in mitochondrial and energy
metabolism protein levels were also detected employing proteomic methodologies in a dog model
of heart failure and in human tissue samples from
patients with heart failure [121,159].
In summary, cardiac hypertrophy and heart failure result in a depressed fatty acid metabolism and
increased glucose and lactic acid oxidation, with
the later being the primary source for ATP. This
change in primary substrate preference is orchestrated by nuclear transcription factors which lead
to changes in cellular substrate uptake, expression
levels of pathway-specific metabolic enzymes and
changes in mitochondrial function. These changes
are part of a final pathway in heart failure involving
the activation of a fetal gene expression pattern
which favors glucose and lactic acid metabolism.
Cell death and regeneration
Apoptosis is an evolutionary, highly conserved, cellular suicide process which has a critical role in
embryogenesis and tissue remodeling. Conversely,
dysregulation of apoptosis resulting in increased or
diminished cell death can result in disease. Because
programmed cell death is an ubiquitous process,
the progressive loss of cardiomyocytes through
apoptosis has also emerged as an important issue in
heart failure research [160,161]. The two major
modes of cardiac cell death are apoptosis, which
occurs at a low rate in chronic heart failure, and
necrosis as the major mode of cell death in myocardial infarction. An important feature of apoptosis
compared to necrosis appears to be that dead cells
are cleared without a significant inflammatory
reaction, which leads to fibrosis [162].
The signaling pathways that lead to apoptosis are
the intrinsic pathway which integrates a broad
spectrum of cellular stresses, and the extrinsic pathway which is mediated by a cellular membrane
receptor. The intrinsic pathway of apoptosis has
been shown to be activated by many different stimuli such as oxidative stress, reoxygenation, metabolic substrate deprivation, radiation, metabolic
inhibition, neuroendocrine stimulation and mechanical stress. Because many of these factors are present in heart failure it is not surprising to find
increased rates of apoptosis. Whereas the normal apoptosis count in a healthy human heart is <2
cells per 100,000 cardiac myocytes, the apoptosis
count in heart failure is increased to 8–250 cells
[163–165]. In myocardial infarction, apoptosis was
demonstrated not only in the border zones but also
in necrotic areas [166].
The receptor mediated extrinsic pathway in
apoptosis involves the binding of a ligand to a cell
surface receptor (death receptor) which induces
apoptosis (Fig. 7.6). Such ligands can be membrane
proteins of other cells such as the CD95–Apo-1
(Fas) ligand or soluble factors such as TNF-α.
Activation of the death receptor activates caspace-8
which in turn activates caspase-3. This last enzymatic step is shared between the extrinsic and the
intrinsic pathway of apoptosis and leads to proteolysis of the cellular substrates. In the intrinsic pathway, cellular death signals such as oxidative stress,
neurohormones, stretch or hypoxia, are transmitted to the mitochondria and stimulate the release of
cytochrome c and other factors from the mitochondria. Cytosolic cytochrome c then assembles
with other proteins to form the apoptosome which
activates caspase-3, resulting in degradation of proteins and cell death. A large group of intracellular
proteins, which have been originally found in B-cell
lymphomas (Bcl-2 group) have been identified to
either activate or inhibit the intrinsic pathway at the
level of the mitochondria. The most prominent
proapoptotic proteins are called Bcl-2-associated X
protein (Bax) and Bcl-2-antagonist/killer (Bak).
CHAPTER 7
Figure 7.6 Apoptosis in heart failure.
The extrinsic pathway is activated by
tumor necrosis factor a (TNF-a) and by
cell surface receptors (Fas) activating
caspase-8 which in turn activates
caspase-3. This enzyme leads to
proteolysis of the intracellular proteins
and cell death. The intrinsic pathway is
activated by multiple stress induced
signals (both intra- and extracellular)
which are known to be activated in
heart failure. This leads to Bax and Bak
mediated mitochondrial release of
cytochrome c. This process can be
inhibited by the antiapoptotic Bcl-2 and
Bcl-x. Cytochrome c released from the
mitochondria forms multimeres with
other proteins to activate caspase-3.
The extrinsic pathway can modulate the
intrinsic pathway at the mitochondrial
level.
Extrinsic pathway
TNF-a
Fas
Heart failure 153
Intrinsic pathway
Oxidative stress
Neurohormones
Stretch, hypoxia
Death receptor
Either one of these proteins can trigger the release
of cytochrome c from the mitochondria to initiate
cell death. The proapoptotic subgroup of Bcl-2
proteins is comprised of many more proteins which
integrate specific upstream signals to then activate
Bax and Bak. The proapoptotic proteins are antagonized by the antiapoptotic proteins Bcl-2 and
Bcl-x which prevent the release of cytochrome c,
thus inhibiting apoptosis. In genetically engineered
mouse models it was demonstrated that infarct size
after occulation of the left anterior descending
artery (LAD) is reduced by promoting antiapoptotic signaling, providing additional support to the
role of apoptosis in myocardial infarction. Heart
failure was observed in mice in which proapoptotic signaling was induced. Novel cellular pathways and factors that affect apoptosis continue to
be described. This includes the control of apoptotic
protein expression by transcription factors such as
p53, or calcium mediated apoptosis, the role of
which is still ill defined in cardiac myocytes where
there are large cyclical changes in intracellular
calcium [167]. Clearly, work is required to further
delineate these factors, especially in human heart
failure. So far it remains controversial whether
apoptosis is cause or a consequence (or both) of
heart failure.
The direct contribution of apoptosis towards
heart failure is even more in question after it was
Bax, Bak
Bcl-2, Bcl-x
Caspase-8
Mitochondrium
Apoptosome
Cytochrome c
Caspase-3
Cell death
convincingly demonstrated that there is a significant turnover of myocardial cells. Cardiac
myocytes have been thought to be terminally differentiated and unable to divide. Moreover, it was
thought that there was a lack of undifferentiated
myocytes or stem cells that could develop into
cardiac myocytes. However, there is now good
evidence that there are undifferentiated cells that
can develop into cardiac myocytes, even in the
adult heart. Cardiac neomyogenesis in humans was
first demonstrated in sex-mismatched transplanted
hearts in which male patients with a female donor
heart ended up with a small number of Y chromosome containing cardiac myocytes, a mechanism
that only could be explained by the differentiation
and homing of male cells within the female donor
heart [168]. Some of the cell types that have been
shown to be able to differentiate into cardiac
myocytes are bone marrow stem cells, partly differentiated endothelial progenitor cells or a newly
found pool of cardiac stem cells in the myocardium
[169]. Since this steady turnover of cardiac myocytes was reported, basic scientists and clinicians
have been developing strategies to take advantage
of cardiac regeneration in both heart failure and
myocardial infarctions [170,171]. However, to
date, even in a nonfailing heart, we do not know the
net effect of cell death and cardiac regeneration,
and conflicting results complicate the issue. Gene
154 PART II Cardiovascular polygenic disorders
array analysis has yielded differential expression
patterns in some genes involved in apoptotic pathways in tissue samples from human hearts with
heart failure when compared with normal hearts
[91–93,122,124].
It is apparent that several genes that are implicated in apoptosis are activated in all stages of heart
failure. In addition, a number of factors that characterize the hypertrophic and failing heart (mechanical stress, calcium overload and neuroendocrine
stimulation) also trigger apoptotic pathways. Furthermore, reactive oxygen species induce apoptosis,
suggesting a mechanism by which oxidative stress
might contribute to heart failure. Regenerative,
cardioprotective and apoptotic mechanisms continue to be characterized and further our understanding of their role in heart failure.
Oxidative injury, hypoxia and
nitrous oxide
Although oxygen is a critical determinant of cardiac
function, it has become clear that oxygen can also
play a detrimental part because of the generation of
reactive oxide species. The same pathways of cellular metabolism and mitochondrial oxidative phosphorylation that are necessary to provide cardiac
myocytes with energy can lead to the generation of
reactive oxide species. The oxygen atom contains
two unpaired electrons in the outer shell, designating it as a free radical. In molecular oxygen (O2),
two oxygen atoms assemble to neutralize the
unpaired electrons which greatly reduce its chemical reactivity. The reaction leading from molecular
oxygen to carbon dioxide and water requires the
donation of four electrons which lead to the generation of intermediate reactive oxide species. The
donation of a single electron to molecular oxygen
(O2) results in the formation of a superoxide radical (O2−). The addition of a second electron yields
peroxide which then reacts with hydrogen to become
hydrogen peroxide (H2O2). Further donation of a
third electron yields the highly reactive hydroxyl
radical (OH) which yields water (H2O) after a
fourth electron is added. Reactive oxide species can
interact with other molecules to lead to secondary
radicals such as peroxynitrite (ONOO−) which is
formed from nitric oxide and superoxide. Reactive
oxide species formation is induced by many of the
neurohormones implicated in heart failure includ-
ing angiotensin II, catecholamines, endothelin, cytokines and other growth factors [172–174].
Several cellular mechanisms counterbalance the
production of reactive oxide species. Among the
best characterized is superoxide dismutase and glutathione peroxidase which catalyze the reaction
of O2− to H2O2 and H2O2 to water, respectively. In
addition to nonenzymatic antioxidant agents such
as vitamins C and E, cells have several enzymatic
pathways that provide and regenerate antioxidative substrates such as ubiquinon (Q10) or glutathione (the reducing substrate for the glutathione
peroxidase reaction). Whenever the cellular antioxidant defenses are overwhelmed, reactive oxide
species can react with structural proteins, enzymes,
lipids and DNA to cause cell damage, mutations
and potentially cell death via necrosis or apotosis.
The contribution of reactive oxide species in the
pathogenesis of vascular disease has been demonstrated in oxidized low density lipoprotein (LDL),
plaque development and rupture, endothelial dysfunction and the stimulation of smooth muscle
growth. These often subclinical processes are linked
to an inflammatory response which can be followed
by serum C-reactive protein levels which is now
accepted as an independent predictor of vascular
disease progression. However, the measurement of
urinary or blood levels of free radical-catalyzed
products of the arachidonic acid metabolism called
isoprostanes (iPs) allows a more direct measure
of oxidative stress [175]. At the level of the
myocardium and more specifically in heart failure,
reactive oxide species have been implicated to contribute to stunning, reperfusion injury and cardiac
remodeling after myocardial infarction. In animal
models of heart failure and cell culture experiments,
several heart failure activated signaling pathways
(e.g., angiotensin II, endothelin, catecholamines)
have been found to increase the cellular generation
of reactive oxygen species which can affect ion
channel function and excitation–contraction coupling by interference with calcium cycling and
contractile proteins. In human heart failure,
alcohol-mediated and anthrocycline-induced cardiomyopathy have been proposed to result from
oxidative damage [176,177]. In the recently published A-HEFT, which showed a marked decrease
in mortality by adding the combination of hydralazine and nitrates to an optimal heart failure
CHAPTER 7
regimen, it was speculated that the antioxidative
effects of hydralazine might contribute to the
reduction in mortality [178]. Furthermore, antioxidant properties of statins and carvedilol have been
suggested to have a role in their beneficial effects.
However, other oral antioxidants (most of them
vitamins) have not been found to be beneficial in
protecting from cardiovascular disease, including
heart failure [177,179–182].
Beyond the effects of oxygen on cellular function
and on gene expression by chemically reacting with
other molecules, it is now recognized that changes
in oxygen levels have a direct effect on gene expression. This is best studied in hypoxia which induces
hypoxia-inducible factor (HIF-1), a transcription
factor involved in angiogenesis, glucose metabolism and apoptosis. In myocardium from patients
with ischemic cardiomyopathy, this factor was
found to be elevated, suggesting a role in neovascularization and the metabolic switch from fatty acid
turnover to glucose metabolism [172,183].
The gas nitric oxide is an endothelium derived
vasodilator which can add to oxidative injury by the
formation of peroxynitrite and the formation of
covalent chemical bonds to cysteine residues of
proteins (S-nitrosylation). In addition, nitric oxide
can modulate cardiac contractility by interfering
with adrenergic signaling by changing cyclic AMP
levels. In patients with heart failure it has been
shown that the response to nitric oxide is attenuated, leading to increased vascular tone and increased
afterload, but direct evidence for a causal pathologic role in heart failure is lacking [184] and only a
few results from gene array studies suggest altered
gene expression in antioxidative pathways [93].
To summarize from existing clinical and experimental data, it can be concluded that reactive oxide
species can participate in the pathogenesis of heart
failure by affecting basic cellular functions in cardiac and vascular cells, resulting in contractile dysfunction and cardiac remodeling. The level of
contribution of reactive oxygen species towards the
disease progression is difficult to assess and therefore poorly defined.
Transcription factors in cardiac
hypertrophy and failure
Transcription factors are regulatory proteins that
control gene transcription. Thus, they are the ter-
Heart failure 155
minal effectors of most signaling pathways that
affect gene expression. Regulation of gene expression is highly complex involving several hundred
transcription factors through a variety of mechanisms. We discuss the major transcription factors
that have been more commonly observed to be
involved in gene transcriptional regulation in the
cardiac remodeling of failure.
GATA4
GATA4 is a transcription factor in the activation of
many cardiac specific genes under basal condition
including α-MHC, essential myosin light chain,
cardiac troponin I and troponin C. GATA4 is activated by several signaling pathways. The MAPK,
ERK 1/2 and p38 both activate GATA4 [185]. Thus,
neurohormones working through the Gqα coupled
receptor will activate GATA4. β-Adrenergic stimulation, mechanical stress and IL-18 have also been
shown to activate GATA4 [75,186]. Finally, GATA4
can also be activated through calcineurin–NFAT
signaling. Glycogen synthase kinase 3β negatively
regulates GATA4. Given this commonality of activation it is not surprising that GATA is a co-factor
in the upregulation of gene specific to myocardial
hypertrophy and failure including β-MHC, sodium
calcium exchanger, angiotensin II type 1 receptor,
brain natriuretic peptide and atrial natriuretic peptide [186].
Activating protein 1
This transcription factor is the result of dimerization of Jun and Fos protein family members. Thus,
activating protein 1 (AP-1) is capable of activating a
variety of genes depending on the dimerized combination of transcription factors. The increase in
expression of c-Fos and c-Jun in hypertrophy and
failure has been well documented [187]. c-Jun is
the terminal effector of the c-Jun N terminal kinase
(JNK), which is a MAPK pathway [188]. Both c-Jun
and c-Fos are proto-oncogenes and part of an
immediate early gene expression program. G protein coupled receptors, cellular stress and cytokines can all activate their transcription. Activation
of other Jun and Fos members is demonstrated
in hypertrophy models and thus are also likely
involved in AP-1 gene regulation. In general, AP-1
is associated with the overall increase in protein
synthesis and with the specific activation of several
156 PART II Cardiovascular polygenic disorders
genes including atrial natriuretic factor, brain
natriuretic peptide, MMP and collagen [131,188].
Interestingly, expression of a dominant negative cJun in cardiocytes blocked hypertrophy by Gαq
coupled agonists suggesting a centralized role in the
hypertrophic response [189].
Nuclear factor κB
NF κB can be activated by a variety of mechanisms.
Perhaps the best established is the indirect activation by cytokines (most notably TNF-α and IL-1).
However, other signaling pathways can activate NF
κB including angiotensin II, endothelin, oxidative
stress, aldosterone and catacholamines [188,189].
NF κB is directly involved in the inflammatory–
apoptotic response of the cell with the upregulated
expression of TNF-α, IL-1, caspase-8 and caspase11 [192]. Interestingly, NF κB also increases the
expression of antiapoptotic genes. NF κB likely in
conjunction with AP-1 modulates the expression of
MMPs, collagen and adhesion molecules, thus having a critical role in the adverse remodeling of
myocardial failure [191,193]. Finally, Gαq receptor
linked cellular hypertrophy appears to be mediated
in part by NF κB [190].
Nuclear factor of activated T cells
The calcineurin–NFAT pathway is one of the better
characterized mechanisms of the pathologic hypertrophic response. In contrast, calcineurin–NFAT
signaling does not appear to be involved in physiologic hypertrophy [145]. Calcineurin is a phosphatase that dephosphorylates NFAT, permitting
its transport into the nucleus. Glycogen synthase 3β
kinase functions in a counter-regulatory manner
through the phosphorylation of NFAT. Similarly,
JNK, p38 MAPK and PKA all inhibit nuclear localization of NFAT [144,194]. Many studies in animal
models of failure have demonstrated the attenuated hypertrophic response when the animals are
treated with the calcineurin inhibitor, ciclosporin
[144]. These studies demonstrated the integral role
of calcineurin and NFAT in the pathologic hypertrophic response.
mTOR
Thus far we have focused on transcription factors
that modulate gene expression. The mammalian
target of rapamyosin (mTOR) affects transcription
not only through increasing the transcription of hypertrophic response genes but also through the induction of the ribosomal biosynthesis, thus facilitating
the translation of mRNA [195]. mTOR is activated
in both physiologic and pathologic hypertrophy
[140]. The transcription factor mTOR is activated
primarily through the PI3K–Akt pathway but may
also be activated through the ERK pathway [195].
Gene array studies in heart failure
Over the past few years several studies using largescale gene arrays have been reported using both
commercial and custom made gene chip systems.
Most of these studies compare samples from nonfailing and failing human myocardium obtained at
the time of transplantation (see Table 7.1 for a list
of the large-scale high-density gene arrays studies
in heart failure). Some studies compared samples
before and after left ventricular assist device (LVAD)
implantation or compared right and left ventricles
from failing hearts [72,196]. Other groups investigated the feasibility of performing gene array studies
from percutaneously obtained right ventricular
endomyocardial biopsies [71,124].
Despite the difficulties in comparing studies
because of differences in approach and analysis
(e.g., variable cutoff values for differential expression), common findings have been reported in all
studies. For example, ANP and BNP have been
confirmed to be largely universally upregulated in
heart failure, further underscoring their value as
biomarkers in this disease. Another common
theme is the upregulation of extracellular matrix
genes including different isoforms of collagen and
several members of small leucin-rich repeat proteoglycans (SLRPs) which are involved in binding
and regulating collagen assembly. The previously
established changes in the expression of sarcomeric
genes and genes involved in calcium cycling have
been confirmed by many gene array studies and are
often used to validate their results. Most gene array
studies also report heart failure induced changes in
genes involving energy metabolism, antioxidative
and apoptotic pathways, signal transduction, cellcycle regulators and transcription factors. However, because of large variations between samples
from different patients and stringently applied statistical algorithms, the altered expression of other
genes, which is commonly accepted to be changed
CHAPTER 7
Heart failure 157
Table 7.1 List of large scale high density gene arrays in heart failure.
Year
Array design
2000
Affymetrix Hu6800 GeneChip
2001
Cardio Chip
Number of genes
Subject
Disease
Reference
7085
Human
ICM, DCM
Yang et al. [123]
10368
Human
HCM
Barrans et al. [118]
Rat
MI
Jin et al. [71]
Barrans et al. [89]
Affymetrix Rat U34A Array
2002
Cardio Chip
10848
Human
DCM
Custom-made Chip
10272
Human
DCM, HCM
Hwang et al. [120]
6606
Human
DCM
Tan et al. [72]
Affymetrix Hu6800Fl GeneChip
2003
2004
6800
Human
pre – post LVAD
Blaxall et al. [70]
Incyte Human UniGem V
Affymetrix Hu GeneFL Chip
10176
Human
DCM
Boheler et al. [195]
Agilent Human 1 Catalogue Array
12814
Human
pre – post LVAD
Chen et al. [194]
Human Uni Gene RZPD1
30336
Human
DCM
Grzeskowiak et al. [122]
Affymetrix HG-U95A
12626
Human
ICM, DCM
Steenman et al. [90]
Yung et al. [91]
Affymetrix HG-U133A
22283
Human
DCM
Incyte Rat Gem2/3 cDNA library
12336
Rat
Ren-2
Schroen et al. [206]
Affymetrix U133A
22283
Human
DCM, ICM
Kittleson et al. [69]
DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; ICM, ischemic cardiomyopathy; LVAD, ; MI, myocardial
infarction.
in heart failure, was not reported in some studies,
indicating that subtle changes in gene expression
may not be recognized by this approach, irrespective of the functional importance.
Studies that compared gene-expression in ischemic versus idiopathic dilated cardiomyopathy
indicate that most genes are similarly regulated in
both conditions, supporting the concept of a common final pathway in end stage heart failure.
However, a subset of genes was demonstrated to be
differentially regulated. [71,72,92], which may present an opportunity for diagnostic and/or therapeutic targets if confirmed in larger patient trials.
However, other studies caution that this will not be
easy to accomplish because age and sex appear to
have a significant effect on gene transcription, thus
further complicating the analysis of gene arrays
[197]. The expression of genes in right and left ventricular samples from patients with dilated cardiomyopathy revealed similar expression patterns
but a small number of genes were found to be differentially regulated between right and left ventricular samples [92]. There are limited array data
patients with concentric hypertrophy and little is
known on gene regulation as a function of the different stages of heart human failure [120,122,196].
In summary, the first results from large-scale
gene array studies are very promising and confirm
previous results using target gene approaches. This
suggests that diagnostic and prognostic fingerprinting might become a reality in heart failure.
However, so far the results are mostly hypothesis
generating by hinting at novel pathways and gene
regulation mechanisms involved in heart failure,
because all studies to date have used small patient
samples or analyzed pooled RNA from different
patients. The available data suggest that larger scale
patient trials will promote gene array technology to
an accepted diagnostic and possibly prognostic tool
in heart failure.
Gene expression as a function of the stages of
heart failure
Information regarding the changes in gene expression in the various stages of human heart failure is
limited at best. Studies are limited by biopsy sampling location (e.g., right versus left ventricle; endocardium versus epicardium; septal versus free wall),
the inherent variability in patient populations, and
accurately determining the stage of heart failure.
Furthermore, small animal studies may not reflect
the changes in gene expression inherent to human
cardiomyopathy. Despite these concerns there are a
small number of studies that indicate differential
activation of signaling pathways and gene as a function of disease stage. Molkentin and colleagues
158 PART II Cardiovascular polygenic disorders
demonstrated that calcineurin activity was increased in the human hypertrophied and failing
heart [198]. Furthermore, all three MAPK pathways (ERK 1/2, JNK and p38) and the PI3K–Akt are
increased in end stage failure but not in hypertrophied hearts. Recent evidence indicates that cytokine expression (TNF-α, IL-1β, IL-6) is greatest
in compensated pressure overload hypertrophy
(aortic stenosis) but decrease toward normal level
in more advanced stages of the disease [199], suggesting that cardiac expression of cytokines may
have an adaptive role in hypertrophy. In a recent
study in aortic stenosis patients with preserved or
impaired left ventricular function it was demonstrated that MMP activity was elevated in all stages
of heart failure but that fibroblast hyperplasia and
collagen synthesis was increased most markedly in
patients with left ventricular ejection fractions of
<30% [200], suggesting that the balance of MMP
activity to collagen synthesis allows for degradation
of the extracellular matrix in the earlier stages of the
disease, facilitating myocyte slippage and chamber
dilatation, whereas in the later stages of heart failure myocardial fibrosis is more prominent [201].
Effect of therapies on gene expression
Therapy with beta-blockers results in improved
mortality in systolic heart failure patients and is
associated with alterations of gene expression.
Specifically, increased expression of SERCA and αMHC, and decreased expression of the β-MHC has
been reported, indicating a reversal of the fetal gene
program that is activated in heart failure [202].
Interestingly, in this small study beta-blockers did
not independently affect the expression levels of the
β-adrenergic receptors over a 6-month period [202].
While to our knowledge there are no studies directly assessing the effect of ACE-I or angiotensin
receptor blockers on gene expression in human cardiomyopathy, several studies have demonstrated
that these therapies significantly affect gene expression. Most notably, treatment in animal models of
cardiac failure have demonstrated decreased myocardial fibrosis, hypertrophy, calcineurin activity
and decreased expression of collagen I, total collagen and TGF-β [203,204]. Mechanically unloading
the heart and decreasing neurohormonal stimulation with the LVAD is associated with altered
expression of numerous gene as elucidated by gene
array including decreased expression BNP, TNF-α,
MMP, collagen, IL-8 and GATA4 [72,205]. It is of
interest that the expression levels of many genes
increased with LVAD support indicating suppressed expression in heart failure. Wall stress in
either failing or dyssynchronous ventricles is
known to directly contribute to the altered gene
expression [206,207]. Attenuation of wall stress
with a passive restraint device (ACORN) was associated with a favorable change in MHC expression,
p38 MAPK, c-fos and attenuated myocyte hypertrophy [207].
Conclusions
This chapter presents an introduction into the
changes in gene regulation and expression that
occur through the development and progression of
heart failure. We have not been able to cover all
aspects of genomics in heart failure but have sought
to cover major pathways and mechanisms. As is
clear, many factors control gene regulation, thus
making it a highly regulated and complex process.
Furthermore, differences in the genetic composition of individuals can affect the pathophysiology
of heart failure. Thus, more studies need to be conducted to better define the primary mechanisms of
gene regulation and expression. It is through such
an approach that tailored and target therapeutic
approaches to heart failure can be implemented.
Acknowledgments
This work was funded by grants from the National
Institutes of Health, HL077637 and HL65586
(PVB). We thank Drs. Martin LeWinter and David
Maughan for their valuable comments on the
manuscript.
References
1 American Heart Association. Heart Disease and Stroke
Statistics, 2005 Update. American Heart Association,
Dallas, TX, 2005.
2 Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW,
Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA
2003; 289: 194–202.
3 Levy D, Kenchaiah S, Larson MG et al. Long-term
trends in the incidence of and survival with heart failure.
N Engl J Med 2002; 347: 1397–1402.
CHAPTER 7
4 Ho KK, Anderson KM, Kannel WB, Grossman W,
Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation
1993; 88: 107–115.
5 Krumholz HM, Larson M, Levy D. Sex differences in
cardiac adaptation to isolated systolic hypertension. Am
J Cardiol 1993; 72: 310–313.
6 Petrie MC, Dawson NF, Murdoch DR, Davie AP,
McMurray JJ. Failure of women’s hearts. Circulation
1999; 99: 2334–2341.
7 Ghali JK. Sex-related differences in heart failure and
beta-blockers. Heart Fail Rev 2004; 9: 149–159.
8 Yancy CW. Special considerations for carvedilol use in
heart failure. Am J Cardiol 2004; 93: 64B–68B.
9 Huang A, Kaley G. Gender-specific regulation of cardiovascular function: estrogen as key player. Microcirculation 2004; 11: 9–38.
10 Pelzer T, Loza PA, Hu K et al. Increased mortality and
aggravation of heart failure in estrogen receptor-beta
knockout mice after myocardial infarction. Circulation
2005; 111: 1492–1498.
11 Patten RD, Pourati I, Aronovitz MJ et al. 17betaestradiol reduces cardiomyocyte apoptosis in vivo and in
vitro via activation of phospho-inositide-3 kinase/Akt
signaling. Circ Res 2004; 95: 692–699.
12 Schwartzbauer G, Robbins J. Matters of sex: sex matters.
Circulation 2001; 104: 1333–1335.
13 Smith GL, Shlipak MG, Havranek EP et al. Race and
renal impairment in heart failure: mortality in blacks
versus whites. Circulation 2005; 111: 1270–1277.
14 Carson P, Ziesche S, Johnson G, Cohn JN. Racial differences in response to therapy for heart failure: analysis
of the vasodilator-heart failure trials. VasodilatorHeart Failure Trial Study Group. J Card Fail 1999; 5:
178–187.
15 Dries DL, Exner DV, Gersh BJ, Cooper HA, Carson PE,
Domanski MJ. Racial differences in the outcome of left
ventricular dysfunction. N Engl J Med 1999; 340: 609–
616.
16 The Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients
with advanced chronic heart failure. N Engl J Med 2001;
344: 1659–1667.
17 Sackner-Bernstein JD, Skopicki HA. Racing away from
bias. J Am Coll Cardiol 2004; 43: 785–786.
18 Taylor AL, Ziesche S, Yancy C et al. Combination of
isosorbide dinitrate and hydralazine in blacks with heart
failure. N Engl J Med 2004; 351: 2049–2057.
19 Kalinowski L, Dobrucki IT, Malinski T. Race-specific
differences in endothelial function: predisposition of
African Americans to vascular diseases. Circulation
2004; 109: 2511–2517.
20 Small KM, Wagoner LE, Levin AM, Kardia SL, Liggett
SB. Synergistic polymorphisms of β1- and α2C-adrener-
21
22
23
24
25
26
27
28
29
30
31
32
33
34
Heart failure 159
gic receptors and the risk of congestive heart failure.
N Engl J Med 2002; 347: 1135–1142.
Yancy CW. Does race matter in heart failure? Am Heart J
2003; 146: 203–206.
Andersson B, Sylven C. The DD genotype of the
angiotensin-converting enzyme gene is associated with
increased mortality in idiopathic heart failure. J Am Coll
Cardiol 1996; 28: 162–167.
Katz AM. Heart Failure: Pathophysiology, Molecular
Biology and Clinical Management. Lippincott, Williams
& Wilkins, 2000.
Starling EH. The Linacre Lecture on the Law of the
Heart, London, UK: Longmans, Green and Co; 1918.
Bowditch HP. Über die Eigenthümlichkeiten der
Reizbarkeit, welche die Musklefasern des Herzens
zeigen. Berichte der Kön Sächs Gesellschaft der
Wissenschatten Mathematisch Physische Classe. 1871; 23:
652–689.
Mann DL. Basic mechanisms of left ventricular remodeling: the contribution of wall stress. J Card Fail 2004; 10
(6 Suppl): S202–S206.
Wiese S, Breyer T, Dragu A et al. Gene expression of
brain natriuretic peptide in isolated atrial and ventricular human myocardium: influence of angiotensin II
and diastolic fiber length. Circulation 2000; 102: 3074–
3079.
Houser SR, Margulies KB. Is depressed myocyte contractility centrally involved in heart failure? Circ Res
2003; 92: 350–358.
Franciosa JA, Park M, Levine TB. Lack of correlation
between exercise capacity and indexes of resting left
ventricular performance in heart failure. Am J Cardiol
1981; 47: 33–39.
Quinones MA, Greenberg BH, Kopelen HA et al.
Echocardiographic predictors of clinical outcome in
patients with left ventricular dysfunction enrolled in the
SOLVD registry and trials: significance of left ventricular hypertrophy. Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 2000; 35: 1237–1244.
Francis GS, Cohn JN, Johnson G, Rector TS, Goldman
S, Simon A. Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival
and the effects of therapy in V-HeFT II. The V-HeFT
VA Cooperative Studies Group. Circulation 1993; 87
(Supplement): VI40–VI48.
Lohse MJ, Engelhardt S, Eschenhagen T. What is the
role of beta-adrenergic signaling in heart failure? Circ
Res 2003; 93: 896–906.
Communal C, Colucci WS. The control of cardiomyocyte apoptosis via the beta-adrenergic signaling
pathways. Arch Mal Coeur Vaiss 2005; 98: 236–241.
Port JD, Bristow MR. Altered beta-adrenergic receptor
gene regulation and signaling in chronic heart failure.
J Mol Cell Cardiol 2001; 33: 887–905.
160 PART II Cardiovascular polygenic disorders
35 Hata JA, Williams ML, Koch WJ. Genetic manipulation
of myocardial beta-adrenergic receptor activation and
desensitization. J Mol Cell Cardiol 2004; 37: 11–21.
36 Forleo C, Resta N, Sorrentino S et al. Association of betaadrenergic receptor polymorphisms and progression to
heart failure in patients with idiopathic dilated cardiomyopathy. Am J Med 2004; 117: 451–458.
37 Kaye DM, Smirk B, Finch S, Williams C, Esler MD.
Interaction between cardiac sympathetic drive and heart
rate in heart failure: modulation by adrenergic receptor
genotype. J Am Coll Cardiol 2004; 44: 2008–2015.
38 Small KM, McGraw DW, Liggett SB. Pharmacology and
physiology of human adrenergic receptor polymorphisms. Annu Rev Pharmacol Toxicol 2003; 43: 381–411.
39 Pasotti M, Repetto A, Tavazzi L, Arbustini E. Genetic
predisposition to heart failure. Med Clin North Am
2004; 88: 1173–1192.
40 Kim S, Ohta K, Hamaguchi A, Yukimura T, Miura K,
Iwao H. Angiotensin II induces cardiac phenotypic
modulation and remodeling in vivo in rats. Hypertension
1995; 25: 1252–1259.
41 Sadoshima J, Izumo S. Molecular characterization of
angiotensin II-induced hypertrophy of cardiac myocytes
and hyperplasia of cardiac fibroblasts. Critical role of the
AT1 receptor subtype. Circ Res 1993; 73: 413–423.
42 Schunkert H, Sadoshima J, Cornelius T et al. Angiotensin II-induced growth responses in isolated adult rat
hearts. Evidence for load-independent induction of cardiac protein synthesis by angiotensin II. Circ Res 1995;
76: 489–497.
43 Manabe I, Shindo T, Nagai R. Gene expression in
fibroblasts and fibrosis: involvement in cardiac hypertrophy. Circ Res 2002; 91: 1103–1113.
44 Kajstura J, Cigola E, Malhotra A et al. Angiotensin II
induces apoptosis of adult ventricular myocytes in vitro.
J Mol Cell Cardiol 1997; 29: 859–870.
45 Regitz-Zagrosek V, Friedel N, Heymann A et al. Regulation, chamber localization, and subtype distribution of
angiotensin II receptors in human hearts. Circulation
1995; 91: 1461–1471.
46 Wharton J, Morgan K, Rutherford RA et al. Differential
distribution of angiotensin AT2 receptors in the normal
and failing human heart. J Pharmacol Exp Ther 1998;
284: 323–336.
47 Haywood GA, Gullestad L, Katsuya T et al. AT1 and AT2
angiotensin receptor gene expression in human heart
failure. Circulation 1997; 95: 1201–1206.
48 Yang Z, Bove CM, French BA et al. Angiotensin II type 2
receptor overexpression preserves left ventricular function after myocardial infarction. Circulation 2002; 106:
106–111.
49 Fischer TA, Singh K, O’Hara DS, Kaye DM, Kelly RA.
Role of AT1 and AT2 receptors in regulation of MAPKs
50
51
52
53
54
55
56
57
58
59
60
61
62
63
and MKP-1 by ANG II in adult cardiac myocytes. Am J
Physiol 1998; 275: H906–H916.
Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L.
Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group.
Circulation 1990; 82: 1730–1736.
Connell JM, Davies E. The new biology of aldosterone.
J Endocrinol 2005; 186: 1–20.
Young M, Head G, Funder J. Determinants of cardiac
fibrosis in experimental hypermineralocorticoid states.
Am J Physiol 1995; 269: E657–E662.
Harada E, Yoshimura M, Yasue H et al. Aldosterone
induces angiotensin-converting-enzyme gene expression in cultured neonatal rat cardiocytes. Circulation
2001; 104: 137–139.
Robert V, Heymes C, Silvestre JS, Sabri A, Swynghedauw B, Delcayre C. Angiotensin AT1 receptor subtype
as a cardiac target of aldosterone: role in aldosteronesalt-induced fibrosis. Hypertension 1999; 33: 981–986.
Qin W, Rudolph AE, Bond BR et al. Transgenic model
of aldosterone-driven cardiac hypertrophy and heart
failure 1. Circ Res 2003; 93: 69–76.
Matsumoto R, Yoshiyama M, Omura T et al. Effects of
aldosterone receptor antagonist and angiotensin II type
I receptor blocker on cardiac transcriptional factors and
mRNA expression in rats with myocardial infarction.
Circ J 2004; 68: 376–382.
Takeda Y, Yoneda T, Demura M, Usukura M, Mabuchi
H. Calcineurin inhibition attenuates mineralocorticoid-induced cardiac hypertrophy. Circulation 2002;
105: 677–679.
Takeda Y. Pleiotropic actions of aldosterone and the
effects of eplerenone, a selective mineralocorticoid
receptor antagonist. Hypertens Res 2004; 27: 781–789.
Mizuno Y, Yoshimura M, Yasue H et al. Aldosterone
production is activated in failing ventricle in humans.
Circulation 2001; 103: 72–77.
Zannad F, Alla F, Dousset B, Perez A, Pitt B. Limitation
of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in
patients with congestive heart failure: insights from the
randomized aldactone evaluation study (RALES). Rales
Investigators 4. Circulation 2000; 102: 2700–2706.
Goldsmith SR, Francis GS, Cowley AW Jr, Levine TB,
Cohn JN. Increased plasma arginine vasopressin levels
in patients with congestive heart failure. J Am Coll
Cardiol 1983; 1: 1385–1390.
Chatterjee K. Neurohormonal activation in congestive
heart failure and the role of vasopressin. Am J Cardiol
2005; 95: 8B–13B.
Fukuzawa J, Haneda T, Kikuchi K. Arginine vasopressin
increases the rate of protein synthesis in isolated per-
CHAPTER 7
64
65
66
67
68
69
70
71
72
73
74
75
76
77
fused adult rat heart via the V1 receptor. Mol Cell
Biochem 1999; 195: 93–98.
Nakamura Y, Haneda T, Osaki J, Miyata S, Kikuchi K.
Hypertrophic growth of cultured neonatal rat heart cells
mediated by vasopressin V(1A) receptor. Eur J Pharmacol 2000; 391: 39–48.
Xu Y, Hopfner RL, McNeill JR, Gopalakrishnan V.
Vasopressin accelerates protein synthesis in neonatal
rat cardiomyocytes. Mol Cell Biochem 1999; 195: 183–
190.
Rich S, McLaughlin VV. Endothelin receptor blockers in
cardiovascular disease. Circulation 2003; 108: 2184–2190.
Boerrigter G, Burnett JC. Endothelin in neurohormonal
activation in heart failure. Coron Artery Dis 2003; 14:
495–500.
Stewart DJ, Cernacek P, Costello KB, Rouleau JL. Elevated
endothelin-1 in heart failure and loss of normal response
to postural change. Circulation 1992; 85: 510–517.
Zolk O, Quattek J, Sitzler G et al. Expression of endothelin-1, endothelin-converting enzyme, and endothelin
receptors in chronic heart failure. Circulation 1999; 99:
2118–2123.
Yang LL, Gros R, Kabir MG et al. Conditional cardiac
overexpression of endothelin-1 induces inflammation
and dilated cardiomyopathy in mice. Circulation 2004;
109: 255–261.
Kittleson MM, Ye SQ, Irizarry RA et al. Identification of
a gene expression profile that differentiates between
ischemic and nonischemic cardiomyopathy. Circulation
2004; 110: 3444–3451.
Blaxall BC, Tschannen-Moran BM, Milano CA, Koch
WJ. Differential gene expression and genomic patient
stratification following left ventricular assist device support. J Am Coll Cardiol 2003; 41: 1096–1106.
Jin H, Yang R, Awad TA et al. Effects of early
angiotensin-converting enzyme inhibition on cardiac
gene expression after acute myocardial infarction.
Circulation 2001; 103: 736–742.
Tan FL, Moravec CS, Li J et al. The gene expression
fingerprint of human heart failure. Proc Natl Acad Sci
USA 2002; 99: 11387–1192.
Chandrasekar B, Mummidi S, Claycomb WC, Mestril R,
Nemer M. Interleukin-18 is a pro-hypertrophic cytokine
that acts through a phosphatidylinositol 3-kinasephosphoinositide-dependent kinase-1-Akt-GATA4 signaling pathway in cardiomyocytes. J Biol Chem 2005;
280: 4553–4567.
Mann DL. Inflammatory mediators and the failing
heart: past, present, and the foreseeable future. Circ Res
2002; 91: 988–998.
Deswal A, Petersen NJ, Feldman AM, Young JB,
White BG, Mann DL. Cytokines and cytokine receptors
in advanced heart failure: an analysis of the cytokine
78
79
80
81
82
83
84
85
86
87
88
89
90
91
Heart failure 161
database from the Vesnarinone trial (VEST). Circulation 2001; 103: 2055–2059.
Torre-Amione G, Kapadia S, Benedict C, Oral H, Young
JB, Mann DL. Proinflammatory cytokine levels in
patients with depressed left ventricular ejection fraction:
a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 1996; 27: 1201–1206.
Mehra VC, Ramgolam VS, Bender JR. Cytokines and
cardiovascular disease. J Leukoc Biol 2005; 78: 805–818.
Yokoyama T, Vaca L, Rossen RD, Durante W, Hazarika
P, Mann DL. Cellular basis for the negative inotropic
effects of tumor necrosis factor-alpha in the adult mammalian heart. J Clin Invest 1993; 92: 2303–2312.
Prabhu SD. Cytokine-induced modulation of cardiac
function. Circ Res 2004; 95: 1140–53.
Pilz RB, Casteel DE. Regulation of gene expression by
cyclic GMP. Circ Res 2003; 93: 1034–1046.
Kawamura N, Kubota T, Kawano S et al. Blockade of
NF-kappaB improves cardiac function and survival
without affecting inflammation in TNF-alpha-induced
cardiomyopathy. Cardiovasc Res 2005; 66: 520–529.
Yokoyama T, Nakano M, Bednarczyk JL, McIntyre BW,
Entman M, Mann DL. Tumor necrosis factor-alpha
provokes a hypertrophic growth response in adult cardiac myocytes. Circulation 1997; 95: 1247–1252.
VanBuren P, Harris DE, Alpert NR, Warshaw DM.
Cardiac V1 and V3 myosins differ in their hydrolytic
and mechanical activities in vitro. Circ Res 1995; 77:
439–444.
Kameyama T, Chen Z, Bell SP, VanBuren P, Maughan D,
LeWinter MM. Mechanoenergetic alterations during the
transition from cardiac hypertrophy to failure in Dahl
salt-sensitive rats. Circulation 1998; 98: 2919–2929.
Alpert NR, Mulieri LA. Increased myothermal economy
of isometric force generation in compensated cardiac
hypertrophy induced by pulmonary artery constriction
in the rabbit. A characterization of heat liberation in
normal and hypertrophied right ventricular papillary
muscles. Circ Res 1982; 50: 491–500.
Miyata S, Minobe W, Bristow MR, Leinwand LA.
Myosin heavy chain isoform expression in the failing
and nonfailing human heart. Circ Res 2000; 86: 386–390.
Reiser PJ, Portman MA, Ning XH, Schomisch MC.
Human cardiac myosin heavy chain isoforms in fetal
and failing adult atria and ventricles. Am J Physiol Heart
Circ Physiol 2001; 280: H1814–H1820.
Noguchi T, Camp P, Alix SL et al. Myosin from failing
and non-failing human ventricles exhibit similar contractile properties. J Mol Cell Cardiol 2003; 35: 91–97.
Barrans JD, Allen PD, Stamatiou D, Dzau VJ, Liew CC.
Global gene expression profiling of end-stage dilated
cardiomyopathy using a human cardiovascular-based
cDNA microarray. Am J Pathol 2002; 160: 2035–2043.
162 PART II Cardiovascular polygenic disorders
92 Steenman M, Chen YW, Le CM et al. Transcriptomal
analysis of failing and nonfailing human hearts. Physiol
Genomics 2003; 12: 97–112.
93 Yung CK, Halperin VL, Tomaselli GF, Winslow RL.
Gene expression profiles in end-stage human idiopathic
dilated cardiomyopathy: altered expression of apoptotic
and cytoskeletal genes. Genomics 2004; 83: 281–297.
94 Nguyen TT, Hayes E, Mulieri LA et al. Maximal actomyosin ATPase activity and in vitro myosin motility are
unaltered in human mitral regurgitation heart failure.
Circ Res 1996; 79: 222–226.
95 Pagani ED, Alousi AA, Grant AM, Older TM, Dziuban
SWJ, Allen PD. Changes in myofibrillar content and
Mg-ATPase activity in ventricular tissues from patients
with heart failure caused by coronary artery disease,
cardiomyopathy, or mitral valve insufficiency. Circ Res
1988; 63: 380–385.
96 Alousi AA, Grant AM, Etzler JR, Cofer BR, Van dB,
Melvin D. Reduced cardiac myofibrillar Mg-ATPase
activity without changes in myosin isozymes in patients
with end-stage heart failure. Mol Cell Biochem 1990; 96:
79–88.
97 Nakao K, Minobe W, Roden R, Bristow MR, Leinwand
LA. Myosin heavy chain gene expression in human heart
failure. J Clin Invest 1997; 100: 2362–2370.
98 Morano I, Hadicke K, Haase H, Bohm M, Erdmann E,
Schaub MC. Changes in essential myosin light chain isoform expression provide a molecular basis for isometric
force regulation in the failing human heart. J Mol Cell
Cardiol 1997; 29: 1177–1187.
99 Makarenko I, Opitz CA, Leake MC et al. Passive stiffness
changes caused by upregulation of compliant titin isoforms in human dilated cardiomyopathy hearts. Circ
Res 2004; 95: 708–716.
100 Granzier HL, Labeit S. The giant protein titin: a major
player in myocardial mechanics, signaling, and disease.
Circ Res 2004; 94: 284–295.
101 Boheler KR, Carrier L, de la Bastie D et al. Skeletal actin
mRNA increases in the human heart during ontogenic
development and is the major isoform of control and
failing adult hearts. J Clin Invest 1991; 88: 323–330.
102 Meggs LG, Tillotson J, Huang H, Sonnenblick EH,
Capasso JM, Anversa P. Noncoordinate regulation of
alpha-1 adrenoreceptor coupling and reexpression of
alpha skeletal actin in myocardial infarction-induced
left ventricular failure in rats. J Clin Invest 1990; 86:
1451–1458.
103 Hanatani A, Yoshiyama M, Kim S et al. Inhibition by
angiotensin II type 1 receptor antagonist of cardiac phenotypic modulation after myocardial infarction. J Mol
Cell Cardiol 1995; 27: 1905–1914.
104 Schwartz K, Carrier L, Lompre AM, Mercadier JJ,
Boheler KR. Contractile proteins and sarcoplasmic
reticulum calcium-ATPase gene expression in the hyper-
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
trophied and failing heart. Basic Res Cardiol 1992; 87
(Supplement 1): 285–290.
Gao L, Kennedy JM, Solaro RJ. Differential expression
of TnI and TnT isoforms in rabbit heart during the perinatal period and during cardiovascular stress. J Mol Cell
Cardiol 1995; 27: 541–550.
Hunkeler NM, Kullman J, Murphy AM. Troponin I isoform expression in human heart. Circ Res 1991; 69:
1409–1414.
Sasse S, Brand NJ, Kyprianou P et al. Troponin I gene
expression during human cardiac development and in
end-stage heart failure. Circ Res 1993; 72: 932–938.
Anderson PA, Malouf NN, Oakeley AE, Pagani ED,
Allen PD. Troponin T isoform expression in the normal
and failing human left ventricle: a correlation with
myofibrillar ATPase activity. Basic Res Cardiol 1992; 87
(Supplement 1): 117–127.
Wolff MR, Buck SH, Stoker SW, Greaser ML, Mentzer
RM. Myofibrillar calcium sensitivity of isometric tension is increased in human dilated cardiomyopathies:
role of altered beta-adrenergically mediated protein
phosphorylation. J Clin Invest 1996; 98: 167–176.
Molina MI, Kropp KE, Gulick J, Robbins J. The
sequence of an embryonic myosin heavy chain gene and
isolation of its corresponding cDNA. J Biol Chem 1987;
262: 6478–6488.
VanBuren P, Alix SL, Gorga JA, Begin KJ, LeWinter
MM, Alpert NR. Cardiac troponin T isoforms demonstrate similar effects on mechanical performance in a
regulated contractile system. Am J Physiol Heart Circ
Physiol 2002; 282: H1665–H1671.
Gomes AV, Guzman G, Zhao J, Potter JD. Cardiac troponin T isoforms affect the Ca2+ sensitivity and inhibition of force development. Insights into the role of
troponin T isoforms in the heart. J Biol Chem 2002; 277:
35341–35349.
Bers DM. Cardiac excitation–contraction coupling.
Nature 2002; 415: 198–205.
Bers DM. Calcium fluxes involved in control of cardiac
myocyte contraction. Circ Res 2000; 87: 275–281.
Wankerl M, Schwartz K. Calcium transport proteins in
the nonfailing and failing heart: gene expression and
function. J Mol Med 1995; 73: 487–496.
Hasenfuss G, Meyer M, Schillinger W, Preuss M, Pieske B,
Just H. Calcium handling proteins in the failing human
heart. Basic Res Cardiol 1997; 92 (Supplement 1): 87–93.
Meyer M, Schillinger W, Pieske B et al. Alterations of
sarcoplasmic reticulum proteins in failing human
dilated cardiomyopathy. Circulation 1995; 92: 778–784.
Studer R, Reinecke H, Bilger J et al. Gene expression of
the cardiac Na+-Ca2+ exchanger in end-stage human
heart failure. Circ Res 1994; 75: 443–453.
Wehrens XH, Lehnart SE, Huang F et al. FKBP12.6
deficiency and defective calcium release channel (ryan-
CHAPTER 7
120
121
122
123
124
125
126
127
128
129
130
131
132
133
odine receptor) function linked to exercise-induced
sudden cardiac death. Cell 2003; 113: 829–840.
Barrans JD, Stamatiou D, Liew C. Construction of a
human cardiovascular cDNA microarray: portrait of the
failing heart. Biochem Biophys Res Commun 2001; 280:
964–969.
Heinke MY, Wheeler CH, Chang D et al. Protein
changes observed in pacing-induced heart failure using
two-dimensional electrophoresis. Electrophoresis 1998;
19: 2021–2030.
Hwang JJ, Allen PD, Tseng GC et al. Microarray gene
expression profiles in dilated and hypertrophic cardiomyopathic end-stage heart failure. Physiol Genomics
2002; 10: 31–44.
Chapman RE, Spinale FG. Extracellular protease activation and unraveling of the myocardial interstitium:
critical steps toward clinical applications. Am J Physiol
Heart Circ Physiol 2004; 286: H1–H10.
Grzeskowiak R, Witt H, Drungowski M et al. Expression
profiling of human idiopathic dilated cardiomyopathy.
Cardiovasc Res 2003; 59: 400–411.
Yang J, Moravec CS, Sussman MA et al. Decreased
SLIM1 expression and increased gelsolin expression in
failing human hearts measured by high-density oligonucleotide arrays. Circulation 2000; 102: 3046–3052.
Siwik DA, Chang DL, Colucci WS. Interleukin-1beta
and tumor necrosis factor-alpha decrease collagen synthesis and increase matrix metalloproteinase activity
in cardiac fibroblasts in vitro. Circ Res 2000; 86:
1259–1265.
Siwik DA, Pagano PJ, Colucci WS. Oxidative stress regulates collagen synthesis and matrix metalloproteinase
activity in cardiac fibroblasts. Am J Physiol Cell Physiol
2001; 280: C53–C60.
Seeland U, Haeuseler C, Hinrichs R et al. Myocardial
fibrosis in transforming growth factor-beta(1) (TGFbeta(1)) transgenic mice is associated with inhibition
of interstitial collagenase. Eur J Clin Invest 2002; 32:
295–303.
Rosenkranz S. TGF-beta1 and angiotensin networking in cardiac remodeling. Cardiovasc Res 2004; 63:
423–432.
Weber KT, Brilla CG, Campbell SE, Guarda E, Zhou G,
Sriram K. Myocardial fibrosis: role of angiotensin II and
aldosterone. Basic Res Cardiol 1993; 88 (Supplement 1):
107–124.
Tsuruda T, Costello-Boerrigter LC, Burnett JC Jr.
Matrix metalloproteinases: pathways of induction by
bioactive molecules. Heart Fail Rev 2004; 9: 53–61.
Brilla CG, Weber KT. Mineralocorticoid excess, dietary
sodium, and myocardial fibrosis. J Lab Clin Med 1992;
120: 893–901.
Stockand JD, Meszaros JG. Aldosterone stimulates proliferation of cardiac fibroblasts by activating Ki-RasA
134
135
136
137
138
139
140
141
142
143
144
145
146
147
Heart failure 163
and MAPK1/2 signaling. Am J Physiol Heart Circ Physiol
2003; 284: H176–H184.
Rude MK, Duhaney TA, Kuster GM et al. Aldosterone
stimulates matrix metalloproteinases and reactive oxygen species in adult rat ventricular cardiomyocytes.
Hypertension 2005; 46: 555–561.
Rockman HA, Koch WJ, Lefkowitz RJ. Seventransmembrane-spanning receptors and heart function.
Nature 2002; 415: 206–212.
Qiu Z, Wang J, Perreault CL, Meuse AJ, Grossman W,
Morgan JP. Effects of endothelin on intracellular Ca2+
and contractility in single ventricular myocytes from
the ferret and human. Eur J Pharmacol 1992; 214:
293–296.
Feldman AM, Cates AE, Veazey WB et al. Increase of
the 40,000-mol wt pertussis toxin substrate (G protein)
in the failing human heart. J Clin Invest 1988; 82:
189–197.
Engelhardt S, Hein L, Wiesmann F, Lohse MJ.
Progressive hypertrophy and heart failure in beta1adrenergic receptor transgenic mice. Proc Natl Acad Sci
USA 1999; 96: 7059–7064.
Simpson PC, Kariya K, Karns LR, Long CS, Karliner JS.
Adrenergic hormones and control of cardiac myocyte
growth. Mol Cell Biochem 1991; 104: 35–43.
Dorn GW, Force T. Protein kinase cascades in the regulation of cardiac hypertrophy. J Clin Invest 2005; 115:
527–537.
Wakasaki H, Koya D, Schoen FJ et al. Targeted overexpression of protein kinase C beta2 isoform in myocardium causes cardiomyopathy. Proc Natl Acad Sci
USA 1997; 94: 9320–9325.
Bueno OF, Molkentin JD. Involvement of extracellular
signal-regulated kinases 1/2 in cardiac hypertrophy and
cell death. Circ Res 2002; 91: 776–781.
Liang Q, Molkentin JD. Redefining the roles of p38 and
JNK signaling in cardiac hypertrophy: dichotomy
between cultured myocytes and animal models. J Mol
Cell Cardiol 2003; 35: 1385–1394.
Wilkins BJ, Molkentin JD. Calcium-calcineurin signaling in the regulation of cardiac hypertrophy. Biochem
Biophys Res Commun 2004; 322: 1178–1191.
Wilkins BJ, Dai YS, Bueno OF et al. Calcineurin/
NFAT coupling participates in pathological, but not
physiological, cardiac hypertrophy. Circ Res 2004; 94:
110–118.
Liao P, Georgakopoulos D, Kovacs A et al. The in vivo
role of p38 MAP kinases in cardiac remodeling and
restrictive cardiomyopathy. Proc Natl Acad Sci USA
2001; 98: 12283–12288.
Gomez del AP, Martinez-Martinez S, Maldonado JL,
Ortega-Perez I, Redondo JM. A role for the p38 MAP
kinase pathway in the nuclear shuttling of NFATp. J Biol
Chem 2000; 275: 13872–13878.
164 PART II Cardiovascular polygenic disorders
148 Baines CP, Molkentin JD. STRESS signaling pathways
that modulate cardiac myocyte apoptosis. J Mol Cell
Cardiol 2005; 38: 47–62.
149 Booz GW, Day JNE, Baker KM. Interplay between the
cardiac renin angiotensin system and JAK-STAT signaling: Role in cardiac hypertrophy, ischemia/reperfusion
dysfunction, and heart failure. J Mol Cell Cardiol 2002;
34: 1443–1453.
150 Taegtmeyer H. Energy metabolism of the heart: from
basic concepts to clinical applications. Curr Probl
Cardiol 1994; 19: 59–113.
151 Ingwall JS, Weiss RG. Is the failing heart energy starved?
On using chemical energy to support cardiac function.
Circ Res 2004; 95: 135–145.
152 Bishop SP, Altschuld RA. Increased glycolytic metabolism in cardiac hypertrophy and congestive failure. Am J
Physiol 1970; 218: 153–159.
153 Taegtmeyer H, Overturf ML. Effects of moderate hypertension on cardiac function and metabolism in the rabbit. Hypertension 1988; 11: 416–426.
154 Razeghi P, Young ME, Alcorn JL, Moravec CS, Frazier
OH, Taegtmeyer H. Metabolic gene expression in fetal
and failing human heart. Circulation 2001; 104: 2923–
2931.
155 Sack MN, Rader TA, Park S, Bastin J, McCune SA, Kelly
DP. Fatty acid oxidation enzyme gene expression is
downregulated in the failing heart. Circulation 1996; 94:
2837–2842.
156 De Las FL, Herrero P, Peterson LR, Kelly DP, Gropler
RJ, vila-Roman VG. Myocardial fatty acid metabolism: independent predictor of left ventricular mass in
hypertensive heart disease. Hypertension 2003; 41: 83–
87.
157 vila-Roman VG, Vedala G, Herrero P et al. Altered
myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy. J Am Coll Cardiol 2002;
40: 271–277.
158 Huss JM, Kelly DP. Mitochondrial energy metabolism
in heart failure: a question of balance. J Clin Invest 2005;
115: 547–555.
159 McGregor E, Dunn MJ. Proteomics of heart disease.
Hum Mol Genet 2003; 12: R135–R144.
160 Kang PM, Izumo S. Apoptosis in heart: basic mechanisms and implications in cardiovascular diseases.
Trends Mol Med 2003; 9: 177–182.
161 Crow MT, Mani K, Nam YJ, Kitsis RN. The mitochondrial death pathway and cardiac myocyte apoptosis. Circ
Res 2004; 95: 957–970.
162 Olivetti G, Quaini F, Sala R et al. Acute myocardial
infarction in humans is associated with activation of
programmed myocyte cell death in the surviving portion of the heart. J Mol Cell Cardiol 1996; 28: 2005–2016.
163 Olivetti G, Abbi R, Quaini F et al. Apoptosis in the failing human heart. N Engl J Med 1997; 336: 1131–1141.
164 Saraste A, Pulkki K, Kallajoki M et al. Cardiomyocyte
apoptosis and progression of heart failure to transplantation. Eur J Clin Invest 1999; 29: 380–386.
165 Guerra S, Leri A, Wang X et al. Myocyte death in the failing human heart is gender dependent. Circ Res 1999; 85:
856–866.
166 Fliss H, Gattinger D. Apoptosis in ischemic and reperfused rat myocardium. Circ Res 1996; 79: 949–956.
167 Marks AR. Calcium and the heart: a question of life and
death. J Clin Invest 2003; 111: 597–600.
168 Quaini F, Urbanek K, Beltrami AP et al. Chimerism of
the transplanted heart. N Engl J Med 2002; 346: 5–15.
169 Dimmeler S, Zeiher AM, Schneider MD. Unchain my
heart: the scientific foundations of cardiac repair. J Clin
Invest 2005; 115: 572–583.
170 Perin EC, Dohmann HF, Borojevic R et al.
Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure.
Circulation 2003; 107: 2294–2302.
171 Strauer BE, Brehm M, Zeus T et al. Repair of infarcted
myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans.
Circulation 2002; 106: 1913–1918.
172 Giordano FJ. Oxygen, oxidative stress, hypoxia, and
heart failure. J Clin Invest 2005; 115: 500–508.
173 Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury: Part I: basic mechanisms and in vivo
monitoring of ROS. Circulation 2003; 108: 1912–1916.
174 Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury: Part II: animal and human studies.
Circulation 2003; 108: 2034–2040.
175 Roberts LJ, Morrow JD. Products of the isoprostane
pathway: unique bioactive compounds and markers of
lipid peroxidation. Cell Mol Life Sci 2002; 59: 808–820.
176 Jaatinen P, Saukko P, Hervonen A. Chronic ethanol
exposure increases lipopigment accumulation in human
heart. Alcohol Alcohol 1993; 28: 559–569.
177 Maack C, Kartes T, Kilter H et al. Oxygen free radical
release in human failing myocardium is associated with
increased activity of rac1-GTPase and represents a target
for statin treatment. Circulation 2003; 108: 1567–1574.
178 Taylor AL, Ziesche S, Yancy C et al. Combination of
isosorbide dinitrate and hydralazine in blacks with heart
failure. N Engl J Med 2004; 351: 2049–2057.
179 Packer M, Coats AJ, Fowler MB et al. Effect of carvedilol
on survival in severe chronic heart failure. N Engl J Med
2001; 344: 1651–1658.
180 Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P.
Vitamin E supplementation and cardiovascular events
in high-risk patients. The Heart Outcomes Prevention
Evaluation Study Investigators. N Engl J Med 2000; 342:
154–160.
181 Hennekens CH, Buring JE, Manson JE et al. Lack of
effect of long-term supplementation with beta carotene
CHAPTER 7
182
183
184
185
186
187
188
189
190
191
192
193
194
on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996; 334: 1145–1149.
De CR, Cipollone F, Filardo FP et al. Low-density
lipoprotein level reduction by the 3-hydroxy-3-methylglutaryl coenzyme-A inhibitor simvastatin is accompanied by a related reduction of F2-isoprostane formation
in hypercholesterolemic subjects: no further effect of
vitamin E. Circulation 2002; 106: 2543–2549.
Lee SH, Wolf PL, Escudero R, Deutsch R, Jamieson SW,
Thistlethwaite PA. Early expression of angiogenesis factors in acute myocardial ischemia and infarction. N Engl
J Med 2000; 342: 626–633.
Kubo SH, Rector TS, Bank AJ, Williams RE, Heifetz SM.
Endothelium-dependent vasodilation is attenuated in
patients with heart failure. Circulation 1991; 84: 1589–
1596.
Akazawa H, Komuro I. Roles of cardiac transcription
factors in cardiac hypertrophy. Circ Res 2003; 92:
1079–1088.
Pikkarainen S, Tokola H, Kerkela R, Ruskoaho H.
GATA transcription factors in the developing and adult
heart. Cardiovasc Res 2004; 63: 196–207.
Iwaki K, Sukhatme VP, Shubeita HE, Chien KR. Alphaand beta-adrenergic stimulation induces distinct patterns of immediate early gene expression in neonatal rat
myocardial cells. fos/jun expression is associated with
sarcomere assembly; Egr-1 induction is primarily an
alpha 1-mediated response. J Biol Chem 1990; 265:
13809–13817.
Clerk A, Cullingford TE, Kemp TJ, Kennedy RA,
Sugden PH. Regulation of gene and protein expression
in cardiac myocyte hypertrophy and apoptosis. Adv
Enzyme Regul 2005; 45: 94–111.
Omura T, Yoshiyama M, Yoshida K et al. Dominant
negative mutant of c-Jun inhibits cardiomyocyte hypertrophy induced by endothelin 1 and phenylephrine.
Hypertension 2002; 39: 81–86.
Purcell NH, Tang G, Yu C, Mercurio F, DiDonato JA,
Lin A. Activation of NF-kappa B is required for hypertrophic growth of primary rat neonatal ventricular cardiomyocytes. Proc Natl Acad Sci USA 2001; 98: 6668–6673.
Valen G, Yan Zq, Hansson GK. Nuclear factor kappa-B
and the heart. J Am Coll Cardiol 2001; 38: 307–314.
Purcell NH, Molkentin JD. Is nuclear factor κB an
attractive therapeutic target for treating cardiac hypertrophy? Circulation 2003; 108: 638–640.
Takemoto Y, Yoshiyama M, Takeuchi K et al. Increased
JNK, AP-1 and NF-kappa B DNA binding activities in
isoproterenol-induced cardiac remodeling. J Mol Cell
Cardiol 1999; 31: 2017–2030.
Fiedler B, Wollert KC. Interference of antihypertrophic
molecules and signaling pathways with the Ca2+-calcineurin-NFAT cascade in cardiac myocytes. Cardiovasc
Res 2004; 63: 450–457.
Heart failure 165
195 Proud CG. Ras, PI3-kinase and mTOR signaling in cardiac hypertrophy. Cardiovasc Res 2004; 63: 403–413.
196 Chen MM, Ashley EA, Deng DX et al. Novel role for the
potent endogenous inotrope apelin in human cardiac
dysfunction. Circulation 2003; 108: 1432–1439.
197 Boheler KR, Volkova M, Morrell C et al. Sex- and agedependent human transcriptome variability: implications for chronic heart failure. Proc Natl Acad Sci USA
2003; 100: 2754–2759.
198 Haq S, Choukroun G, Lim H et al. Differential activation of signal transduction pathways in human hearts
with hypertrophy versus advanced heart failure. Circulation 2001; 103: 670–677.
199 Vanderheyden M, Paulus WJ, Voss M et al. Myocardial
cytokine gene expression is higher in aortic stenosis than
in idiopathic dilated cardiomyopathy. Heart 2005; 91:
926–931.
200 Polyakova V, Hein S, Kostin S, Ziegelhoeffer T, Schaper
J. Matrix metalloproteinases and their tissue inhibitors
in pressure-overloaded human myocardium during
heart failure progression. J Am Coll Cardiol 2004; 44:
1609–1618.
201 Spinale FG. Matrix metalloproteinases: regulation and
dysregulation in the failing heart. Circ Res 2002; 90:
520–530.
202 Lowes BD, Gilbert EM, Abraham WT et al. Myocardial
gene expression in dilated cardiomyopathy treated with
beta-blocking agents. N Engl J Med 2002; 346: 1357–
1365.
203 Nagata K, Somura F, Obata K et al. AT1 receptor blockade reduces cardiac calcineurin activity in hypertensive
rats. Hypertension 2002; 40: 168–174.
204 Yu CM, Tipoe GL, Wing-Hon Lai K, Lau CP. Effects of
combination of angiotensin-converting enzyme inhibitor and angiotensin receptor antagonist on inflammatory cellular infiltration and myocardial interstitial
fibrosis after acute myocardial infarction. J Am Coll
Cardiol 2001; 38: 1207–1215.
205 Hall JL, Grindle S, Han X et al. Genomic profiling of
the human heart before and after mechanical support
with a ventricular assist device reveals alterations in
vascular signaling networks. Physiol Genomics 2004; 17:
283–291.
206 Spragg DD, Leclercq C, Loghmani M et al. Regional
alterations in protein expression in the dyssynchronous
failing heart. Circulation 2003; 108: 929–932.
207 Sabbah HN, Sharov VG, Gupta RC et al. Reversal of
chronic molecular and cellular abnormalities due to
heart failure by passive mechanical ventricular containment. Circ Res 2003; 93: 1095–1101.
208 Schroen B, Heymans S, Sharma U et al. Thrombospondin-2 is essential for myocardial matrix integrity: increased expression identifies failure-prone
cardiac hypertrophy. Circ Res 2004; 95: 515–522.
8
CHAPTER 8
The implications of genes on the
pathogenesis, diagnosis and
therapeutics of hypertension
Kiat Tsong Tan, MD, MRCP, FRCR & Choong-Chin Liew, PhD
Introduction
Hypertension is a major cause of mortality and
morbidity in the developed world and affects up to
60–75% of Americans over the age of 60. Genetic
factors account for 30–60% of an individual’s risk
for developing hypertension [1]. However, elucidation of the genes involved in hypertension has
proven to be difficult. Blood pressure is inherited in
a polygenic fashion, with multiple genes contributing to the final phenotype. Environmental factors
also make a major contribution to blood pressure,
further complicating the understanding and investigation of the molecular and genetic aspects of hypertension. For example, increased salt intake has been
linked to hypertension. Other environmental factors that may influence the development of hypertension include smoking, excessive alcohol intake,
psychologic stress, lack of aerobic exercise and central obesity. In addition, there is some evidence that
developmental factors may also predispose to high
blood pressure. A low birth weight is associated
with the later development of hypertension. It has
been hypothesized that this is related to a congenital reduction of nephrons, which may subsequently
impair salt excretion [2]. Unfortunately, it is not
always possible to dissect out the role of nature versus
nurture in the etiology of hypertension. For example, genetic causes may predispose towards smoking and excessive alcohol intake, which may then
contribute to the development of hypertension.
166
However, the role of genetics in hypertension
is not limited to the determination of its etiology;
advances in the understanding of the genetics and
molecular biology of hypertension may also improve the diagnosis and treatment of the disorder.
A large proportion of hypertensive patients do not
have adequate blood pressure control on their
current medication [3,4]. Although poor patient
medication compliance is likely to account for a
proportion of these, suboptimal drug efficacy may
also contribute to this number. In addition, 10–
20% of treatment failures are a result of drug side
effects.
Thus, pharmacogenomic-based strategies for
rationalizing treatment in hypertension would be a
highly desirable goal. To some extent, clinicians are
already matching patient profiles with drug treatment. For example, a hypertensive patient with left
ventricular hypertrophy is likely to benefit from
angiotensin-converting enzyme (ACE) inhibition,
while patients with concurrent ischemic heart
disease are better treated with a beta-blocker. However, much of the current treatment for hypertension is carried out on an empirical basis. A recent
study suggests that there is great variation in patient
response to antihypertensive drugs and selection of
the best drug for a given patient is currently a matter of trial and error, a costly and time-consuming
process [5]. In addition, the efficient control of
hypertension can decrease the risk of blood pressure induced target organ damage, the prevalence
CHAPTER 8
of which increases with the length of time in which
blood pressure remains uncontrolled. An improved understanding of the genes of hypertension
may therefore enable the physician to better tailor
medication to the patient with hypertension.
Pathophysiology of hypertension
The regulation of extracellular fluid volume by
sodium excretion renal is responsible for the control of blood pressure. This mechanism is made
possible by the ability of the kidneys to vary renal
tubular sodium excretion in accordance with renal
perfusion pressure [6]. In the healthy individual,
any increase in mean arterial blood pressure would
lead to a proportional rise in renal perfusion pressure, which would increase renal sodium excretion.
The loss of sodium leads to shrinkage of extracellular fluid volume, causing a drop in cardiac output,
thus normalizing the blood pressure. A drop in
renal perfusion pressure has the opposite effect and
would result in sodium retention. Therefore, in
order to maintain blood pressure homeostasis in
the healthy individual, the kidney has to match
sodium excretion to sodium intake.
Hypertension results from the inability of the
kidneys to excrete enough sodium to match intake
or the inability of kidneys to excrete sufficient
sodium in response to raised mean arterial pressure. Impairment of renal perfusion by renal artery
stenosis, for example, results in a drop in renal perfusion pressure, leading to a rise in mean arterial
pressure in order to maintain kidney perfusion. A
similar mechanism accounts for the hypertensive
change observed in coarctation of the aorta. Other
causes of hypertension include renal failure, where
the remaining nephrons are unable to excrete
enough sodium to match blood pressure, Conn and
Cushing syndromes, and the various monogenetic
forms of hypertension discussed below.
However, up to 90% of patients with hypertension do not have a discernible cause for their high
blood pressure. These patients are described as having “essential hypertension.” There is often no histologic abnormality in the kidneys of patients in the
early stages of essential hypertension. However, a
proportion of patients with essential hypertension,
often referred to as salt-sensitive hypertensives,
Hypertension 167
have a blunted natriuretic response to a rise in
blood pressure.
Molecular pathways and
hypertension
Although the following discussion classifies the
molecular pathways involved in the pathogenesis of
hypertension into neat systems for the sake of clarity, it should be remembered that these systems are
closely interrelated. Changes in one system may
have profound effects on others.
The adrenergic system
The sympathetic nervous system is important in
the pathogenesis of hypertension [7]. Qi et al. [7]
have hypothesized that an increase in sodium
intake increases sodium plasma concentration,
which then triggers an increase in sympathetic
activity. The increase in sympathetic activity causes
a rise in blood pressure by increasing cardiac output and/or total peripheral resistance. Sympathetic
activity also blunts the rise in natriuresis induced
by increased mean arterial pressure, resulting in
hypertension. The mechanism behind this blunting of pressure natriuresis may be the stimulation
of renal arterial vasoconstriction by sympathetic
activity, which could result in a decrease in renal
perfusion. In addition, a reduction in renal perfusion would also result in the secretion of renin by
the kidney, which would further increase systemic
blood pressure. Indeed, there is evidence to suggest
that there is an increase in renal sympathetic activity in early hypertension and that renal denervation
may attenuate the rise in blood pressure in renal
hypertension [8].
The adrenergic system is involved in the regulation of blood pressure both centrally and peripherally. The genomic revolution has allowed the
identification of nine subtypes of adrenergic receptors [9]. Most of our knowledge of the adrenoceptors is centered upon the four major subgroups of
the receptor: α1, α2, β1 and β2. However, the study
of the physiology of the adrenergic system is complicated by interspecies and intertissue variation
of the distribution of the receptors. For example,
the exposure of the dog saphenous vein to epinephrine results in vasoconstriction while the effect
168 PART II Cardiovascular polygenic disorders
of epinephrine on the rabbit facial vein is one of
relaxation.
The α1-adrenoceptor has an important role in
regulating vascular tone. The receptor stimulates
smooth muscle contraction and proliferation on
exposure to adrenergic stimulation. Indeed, α1blockers, such as doxazosin, are in widespread clinical use in the treatment of hypertension.
α2-Adrenoceptors are involved in both the central
and peripheral regulation of blood pressure. Stimulation of central α2-adrenoceptors causes a drop in
blood pressure and in sedation [9]. α2-Adrenoceptors
are also found in vascular smooth muscle cells.
Stimulation of peripheral α2-adrenoceptors is associated with vasoconstriction. Therefore, the administration of the clinically used α2-agonist, clonidine,
elicits a transient hypertensive response before its
central hypotensive effect predominates.
The development of knockout mice has allowed
further elucidation of the function of the α2adrenoceptor subtypes. α2-Adrenoceptors can be
further subclassified into α2A, α2B and α2C subtypes. The initial hypertensive response to α2 stimulation is abolished in α2B knockout mice. The
deletion of the α2B-adrenoceptor gene did not
affect the hypotensive effect of clonidine. These
findings suggest that the α2B-adrenoceptor is responsible for the initial pressor effect of α-agonists.
In addition to their lack of pressor response to the
administration of clonidine, it has been shown that
α2B-adrenoceptor knockout mice are resistant to
the development of salt-sensitive hypertension.
Inhibition of the translation α2B-adrenoceptor
mRNA by the use of antisense oligonucleotides also
has a hypotensive effect. It is believed that the
hypotensive effect of α2B antagonism is mediated
centrally. Therefore, it is likely that selective inhibition of the α2B-adrenoceptor is a promising target
for antihypertensive agents.
In contrast to the α2B knockout mice, mice with
defective α2A-adrenoceptors have a normal initial
pressor response to clonidine but do not demonstrate a hypotensive response. Indeed, α2A-adrenoceptor represents the most common receptor
subtype in central cardiovascular regulatory centers.
The β-adrenoceptors are found in the myocardium, vascular smooth muscle and visceral
smooth muscle. β1-Adrenoceptors in the heart mediate positive chrono- and inotropic effects. β2-
Adrenoceptors in vascular and bronchial smooth
muscle mediates relaxation. However, the hypertensive effects of β stimulation usually predominates, which accounts for the use of beta-blockers
in the treatment of hypertension. It is also not
surprising that peripheral vasoconstriction and
bronchospasm can very occasionally complicate
beta-blockade. β3-Adrenoceptor mediates vascular
smooth muscle relaxation in some species. It is also
believed to have an important role in lipolysis. However, its exact role in human disease is uncertain.
Renin–angiotensin system
The renin–angiotensin system (RAS) has a vital
role in the regulation of blood pressure [10]. The
production of renin is the mechanism by which a
fall in renal perfusion pressure causes sodium and
water retention. Renin is secreted by the juxtaglomerular cells of the kidneys in response to a fall
in the delivery of sodium ions to the distal renal
tubules. In addition, a fall in intra-arteriolar pressure at the site of the juxtaglomerular cells results in
increased renin production and vice versa. Increased
sympathetic tone also acts to enhance renin secretion. Renin acts on angiotensinogen, secreted by
the kidney, to produce the angiotensin I.
Angiotensin I is then converted to angiotensin II
by ACE, which occurs predominantly in the lungs.
ACE also inactivates bradykinin (see below). Angiotensin II has a half-life of approximately 2 minutes
and has a potent hypertensive effect. Angiotensin
II type 1 receptor (AGTR1) which is coupled via a G
protein to phospholipase C. Therefore, stimulation of AGTR1 by angiotensin II stimulates an
increase in intracellular calcium. AGTR1 mediates
vasoconstriction; increased secretion of aldosterone,
adrenocorticotrophic hormone, norepinephrine and
vasopressin; decreased glomerular filtration rate and
increased water intake. Angiotensin II and vasopressin provides negative feedback to inhibit renin
secretion.
Angiotensin II is converted to the less vasoactive
angiotensin III by enzymes termed angiotensinases.
Angiotensin III is then broken down to biologically
inactive metabolites.
The importance of the RAS in the regulation of
blood pressure is clearly illustrated in many animal
studies. Rodent models show that the number of
copies of functional angiotensinogen genes can be
CHAPTER 8
related to the plasma concentration of angiotensinogen, which can then be connected to blood
pressure [11]. Knockout of the angiotensinogen
gene produces hypotension.
AGTR1 expression has also been shown to be
important in blood pressure regulation. AGTR1
−/− mice have a lower blood pressure than AGTR1
−/+ mice, which are hypotensive when compared
with their AGTR +/+ wild-type littermates [12].
Transplantation of a kidney derived from an AGTR
−/− mouse into an AGTR1 +/+ recipient had a
hypotensive effect, which illustrates the importance
of renal AGTR1 in blood pressure regulation.
Therefore, it is not surprising that AGTR1 inhibition is used clinically in the treatment of human
hypertension.
Inhibition of ACE has also been shown to be
effective in treating hypertension. It is therefore
surprising that genetically influenced plasma level
of ACE does not have an effect on blood pressure.
In humans, the presence of an insertion/deletion
(I/D) polymorphism of the ACE gene can have dramatic effects on the plasma level of ACE [13].
However, the I/D polymorphism in humans is not
associated with blood pressure differences. In the
mouse, ACE activity increases with the number of
copies of the ACE gene [14]. However, blood pressure is not affected by the concentration of ACE in
the blood. It is believed that a slight impairment of
ACE activity, as seen in a mouse with one copy of
the ACE gene, results in the build-up of angiotensin
I, which then drives the production of angiotensin
II. However, more complete inhibition of ACE, as
occurs during ACE inhibitor therapy, will impair
angiotensin II production and lower blood pressure.
Dopaminergic system
The dopaminergic system is an important regulator
of blood pressure through renal, adrenal, central
and gastrointestinal functions [15]. Proximal renal
tubular cells can secrete dopamine, which then acts
in an autocrine/paracrine fashion to reduce sodium
uptake from the renal tubule. This mechanism may
account for an increase in sodium excretion of more
than 50% during periods of increased salt intake. In
a similar manner, the jejunal cells can also produce
dopamine to reduce intestinal uptake of sodium.
Dopaminergic receptors can be classified into
two families, which are both coupled to G proteins.
Hypertension 169
The D1-like receptors comprise the D1 and D5
subtypes. These receptors increase intracellular
cAMP via stimulatory G proteins Gαs and Gαolf.
The D2-like receptors consist of D2, D3 and D4.
Stimulation of D2-like receptors results in the activation of the inhibitory G proteins Gαi and Go, and
leads to the inhibition of adenylyl cyclase.
Activation of the D1-like receptors in the renal
tubular cells leads to the inhibition of sodium reabsorption by various transporters, including NHE1,
NHE3, NA/HCO3 and the Na+/K+ ATPase. The
importance of the D1 receptor in the regulation of
blood pressure is illustrated by many studies. Mice
lacking at least one copy of the D1 receptor gene
show raised blood pressure. In addition, there is an
uncoupling of the D1 receptor from its effector G
protein in some rat models of hypertension, leading to increased sodium reabsorption.
Abnormalities in the dopaminergic system may
be responsible for abnormal high blood pressure in
some patients. There may be reduced synthesis
of renal dopamine in a subset of hypertensives. In
others, the renal production of dopamine may actually be normal or increased. This suggests that there
may be a defect in dopaminergic signal induction
in some hypertensives. Experimental studies with
the use of the D1 receptor agonist, fenoldopam,
showed that renal tubular cells from some patients with hypertension have an attenuated cAMP
response to D1 stimulation. The impaired coupling
of D1 stimulation to intracellular responses can be
brought about by excessive phosphorylation of the
receptor by a G protein coupled receptor kinase.
GRK4 is the most important member of the G protein coupled receptor kinase family in the regulation of D1 activity in the proximal renal tubule.
GRK4 activity accounts for the desensitization of
renal D1 in some hypertensives. Indeed, the use of
antisense oligonucleotides directed against GRK4
can attenuate the development of hypertension in
the spontaneously hypertensive rat (SHR).
Disruption of the D5 dopaminergic receptor also
causes hypertension, possibly because of increased
sympathetic outflow [16]. There is also a reduction
in the expression of D5 receptors in the renal cortex
of SHR. However, the significance of this is incompletely understood.
Stimulation of D2-like receptors can inhibit the
secretion of renin by the juxtaglomerular cells. The
170 PART II Cardiovascular polygenic disorders
D3 receptor is found in rat juxtaglomerular cells
and its selective inhibition results in an increase in
renin secretion. In addition, −/− D3 mice have high
renin salt-sensitive hypertension [17].
The D4 −/− mouse also has a hypertensive phenotype [18]. This observation is hypothesized to be
a result of its influence on angiotensin II type 1
receptor expression in the brain and kidney.
Nitric oxide
Nitric oxide (NO) is produced by nitric oxide synthase (NOS) and is an important mediator of
vasodilatation [19]. NOS exists in three isoforms:
endothelial (eNOS), neuronal (nNOS) and inducible (iNOS). As the name implies, eNOS is the isoform that is primarily involved in the regulation of
arterial tone. Inhibition of the production of arterial nitric oxide results in vasoconstriction, leading
to an increase in systemic resistance, which then
leads to a rise in blood pressure [20]. In addition,
eNOS −/− mice have higher blood pressure than
wild-type controls. There is also evidence to suggest
that NO activity is impaired in hypertension [21].
eNOS may provide the link between arterial
hypertension and its thrombotic complications,
such as stroke and myocardial infarction. NO has
important antiplatelet effects. Inhibition of NOS in
humans can reduce bleeding time, which is a clinical measure of platelet function. In addition, mice
that lack a functional copy of the eNOS gene have
decreased bleeding times and platelets that are
more easily activated.
Mice that are deficient in eNOS demonstrate the
triad of hypertension, insulin resistance and dyslipidaemia: the “metabolic syndrome” [22]. eNOS
may contribute to glucose uptake into striated
muscle by promoting muscular blood flow. It may
also have a direct effect in promoting the uptake of
glucose by striated muscle. The mechanism by
which eNOS disruption can result in dyslipidaemia
is uncertain.
Natriuretic peptides
The natriuretic peptides are molecules that regulate
sodium balance, vascular tone and have important
effects on cellular proliferation [23]. The beneficial
effects of natriuretic peptides have resulted in the
introduction of recombinant natriuretic peptides
in the treatment of heart failure.
Natriruretic peptides include:
1 Atrial natriuretic peptide (ANP);
2 Brain natriuretic peptide (BNP);
3 C-type natriuretic peptide (CNP).
More recently, denroaspis natriuretic peptide
(DNP) has been described.
There are three main classes of natriuretic receptors: natriuretic peptide receptor-A (NPRA), which
preferentially binds to ANP and BNP; natriuretic
peptide receptor-B (NPRB), which has a predilection for CNP; and natriuretic peptide receptor-C
(NPRC), which binds all natriuretic peptides [24].
NPRA and NPRB can be found in the vasculature,
kidneys, lungs and adrenals. NPRB is the predominant natriuretic peptide receptor in the brain.
NPRC can be found in most tissues and acts as a
clearance receptor. Ligand binding to NPRA and
NPRB results in the production of cGMP via the
activation of guanylate cyclase.
ANP and BNP are produced by the atria and
ventricles, respectively, in response to cardiac wall
tension. CNP is produced by vascular endothelium
and is believed to regulate vascular tone. Alternative processing of the ANP precursor yields urodilantin in the kidney. This molecule is secreted
into the lumen of the distal nephron and promotes
natriuresis.
The natriuretic peptides cause both venous and
arterial dilatation. This effect leads to an immediate
reduction in both preload (and hence cardiac output) and peripheral resistance, changes that can
result in a fall in arterial blood pressure. In addition, the reflex increase in sympathetic output that
usually accompanies a fall in blood pressure is
suppressed.
Natriuretic peptides also promote the excretion
of sodium. These molecules relax the afferent renal
arterioles while causing the efferent arterioles to
contract thus increasing glomerular filtration. They
also block the reabsorption of sodium in the renal
tubules. Natriuretic peptides antagonize the effects
of antidiuretic hormone and angiotensin II. ANP
−/− mice have exaggerated left ventricular hypertrophy and high renin salt-sensitive hypertension. In addition, the disruption of the NPRA gene
leads to hypertension. Indeed, blood pressure is
decreased by increasing the number of copies of the
functional NPRA gene in mice [25].
In addition to their beneficial hemodynamic
effects in hypertension, natriuretic peptides also
have a positive influence on cardiac remodeling
CHAPTER 8
and may have a cardioprotective effect. Therefore,
they may attenuate target organ damage by high
blood pressure.
Endothelin
The endothelin (ET) family consists of three closely
related peptides made up of 21 amino acid residues.
The constituents of the endothelin family are
referred to as ET-1, ET-2 and ET-3 [26]. ET-1 represents the most important subtype of the family.
The molecule is a potent mediator of vasoconstriction, vascular inflammation and cell proliferation.
The precursor of ET-1, preproendothelin, is produced by the endothelial cells. Preproendothelin is
cleaved to form proendothelin, which can subsequently be converted to bigET-1. bigET-1 is then
further cleaved by endothelin-converting enzyme
to ET-1. The production of ET-1 is believed to be
stimulated by angiotensin II. It has been shown in
rats that chronic angiotensin II induced hypertension is associated with increases in preproendothelin mRNA and ET-1 expression. In addition, the
administration of endothelin antagonists attenuates the hypertension resulting from chronic angiotensin II infusion.
ET-1 mediates its effects through two G protein
coupled receptors, ETA and ETB, which are encoded
by different genes and have different biologic functions. ETA is found in cardiac myocytes and vascular smooth muscle cells. Activation of ETA leads to
an increase in intracellular calcium via the phospholipase C pathway, leading to vasoconstriction.
ETB is found in endothelial cells, the inner
medullary collecting duct and the medullary thick
ascending limb [27]. This receptor also mediates its
effects through the phospholipase C pathway. In
addition, ETB may also activate inhibitory G protein. Renal ETB activation is associated with a
hypotensive effect. Indeed, chronic ETB receptor
blockade is associated with hypertension. In addition, ETB knockout mice become hypertensive on a
high salt diet. Therefore, it is believed that ETB is a
regulator of sodium excretion in the kidneys.
Kallikrein–kinin system
The Kallikrein–kinin system (KKS) mediates a
wide range of physiologic functions, from inflammation through cell proliferation to salt balance
[28]. The KKS is composed of kininogens, kallikreins and the active kinins.
Hypertension 171
Kinins, such as bradykinin and lysylbradykinin,
are formed from kininogens by the action of
kallikreins. Kininogens are coded for by a single
gene and circulating kininogen is synthesized primarily by the liver. Tissue kininogens can be found
in various tissues, such as the kidney, and are synthesized locally.
Kallikreins can be classified into plasma kallikrein, which circulates with the blood in an inactive
form, and tissue kallikrein, circulates within the
bloodstream found in cells involved in electrolyte
transport. Inactive plasma kallikrein is activated by
activators derived from fragments of clotting factor
XII. Conversely, plasma kallikrein can also activate
factor XII. Therefore, kallikreins provide a vital link
between the coagulation pathway and a myriad of
physiologic functions.
Kinins are inactivated by peptidases such as
kininase I and ACE (also referred to as kininase II).
Kinins exert their effects via two receptors, termed
“B1” and “B2”. B1 expression is usually only detectable in pathologic conditions such as inflammation. In contrast, B2 is expressed constitutively in
most tissues. It regulates renal sodium transport
and mediates the release of nitric oxide and prostacyclin by vascular endothelium. Administration of
bradykinin elicits natriuresis.
The urinary excretion of kallikreins is found to
be reduced in patients with essential hypertension and in rodent models of hypertension. The
overexpression of human kallikrein in genetically
engineered mice results in hypotension. In addition, the introduction of the kallikrein as gene
therapy in rats attenuates the development of
hypertension [29]. Rats that were inbred for low
kallikrein activity also had raised blood pressure,
providing further evidence for the role of kallikrein
in hypertension.
B2 receptor −/− mice have an exaggerated pressor response to salt loading [30]. They also have
an enhanced response to antidiuretic hormone
(ADH), suggesting that kinins may antagonize the
effects of ADH. Conversely, mice overexpressing
the B2 receptor are hypotensive.
Oxidative stress
Vascular oxidative stress has been shown to be
increased in experimental models of hypertension
[31]. SHRs have increased NADPH driven production of superoxide in their arteries. Patients with
172 PART II Cardiovascular polygenic disorders
severe hypertension also have increased levels of
plasma thiobarbituric acid-reactive substances and
8-epi-isoprostanes, which represent markers of
increased oxidative stress.
Oxidative stress may contribute to the development of hypertension by the destruction of nitric
oxide. Increased reactive oxygen species also contributes to inflammation, vascular smooth muscle
proliferation and the deposition of matrix proteins.
These processes have an important role in the
development of vascular damage associated with
hypertension. Therefore, it is not surprising that
the use of inhibitors of reactive oxygen species production or the use of free radical scavengers may
attenuate the development of hypertension in animal models. However, the large trials on the use of
antioxidant supplements in the management of
human cardiovascular disease have mostly yielded
negative results.
Inflammation and hypertension
There is an association between inflammation and
hypertension. The plasma level of C-reactive protein (CRP), as determined by the high-sensitivity
(hs) method, is higher in patients with hypertension when compared with healthy controls [32].
A raised hsCRP level is also associated with an
increased future risk of developing hypertension
[33]. Many risk factors that are associated with vascular inflammation, such as central obesity and
smoking, are also linked to hypertension. Indeed,
the presence of inflammation may also aggravate
the increase in peripheral resistance observed in
hypertension. For example, inflammation is associated with a decrease in vascular nitric oxide and an
increase in isoprostanes, which are conditions that
promote vascular smooth muscle constriction [21].
In addition, many of the complications of hypertension, such as stroke and myocardial infarction, often occur with the pro-thrombotic state
associated with significant inflammation. A more
detailed discussion on inflammation and the prothrombotic state is given in Chapter 7.
Approaches to the study of
essential hypertension
Currently there is controversy as to the best method
for investigating the genes involved in the etiology
of hypertension. Although there are numerous
studies in this area of research, virtually all have
provided conflicting results. It is likely that in
addition to the part played by the environment,
epistatic interactions (i.e., interactions among various genes) may influence the final phenotype, large
sample sizes are required if these interactions are to
be studied in detail. In addition, the effect of age on
the pathogenesis of hypertension should not be
ignored. As hypertension is more common in older
people, it is possible that the influence of genes on
blood pressure may also vary with age, or that gene
changes related to aging may be among the risk factors for hypertension.
Identification of the genes involved in
hypertension
The search for the genes involved in the causation
of hypertension can be classified as methods that
utilize:
1 The candidate gene approach;
2 Genome-wide linkage screens;
3 The study of monogenic hypertension; and
4 Animal models of hypertension.
Candidate genes
This approach investigates particular genes that are
believed to be involved in blood pressure regulation. Most of the early studies on the genes involved
in the etiology of hypertension were based in a traditional candidate gene approach and were often
dependent on prior knowledge of the gene product in question. However, genes whose products
are unknown or believed to be “unimportant” in
the pathogenesis of hypertension are likely to be
ignored.
Genome-wide linkage screens
Genome-wide linkage screens utilize genetic markers spread throughout the genome. The use of
densely spread markers in the genome allows the
identification of quantitative trait loci (QTL) associated with hypertension. QTL refers to a position
in the chromosome that may influence the trait
of interest. This approach eliminates the need for
prior knowledge of gene function and allows the
identification of loci that may not previously have
been suspected to be involved in blood pressure
regulation.
CHAPTER 8
Although genome-wide scans are useful in
detecting loci that may be responsible for hypertension, it should be noted that the possible pathophysiologic role(s) of these sites remain to be
determined. A potential source of error in the use of
genome-wide linkage screens is the absence of linkage disequilibrium between the gene of interest
and the marker, because of recombination during
meiosis. As the risk of recombination increases
with the distance between the two loci, it follows
that genome-wide scans require the use of closely
spaced markers in order to produce a meaningful
result.
The simultaneous study of large numbers of loci
increases the chance of obtaining a false positive
result. Therefore, the conventional threshold of
significance of P <0.05 may be inappropriate in
many genetic studies. Indeed, the independent
replication of a positive result is of particular
importance in the study of the genes of hypertension.
Study of monogenic hypertension
The identification of monogenic (Mendelian)
forms of hypertension has contributed greatly to
our understanding of the pathophysiology of hypertension. These forms of hypertension are rare but
their Mendelian pattern of inheritance has greatly
facilitated their study. However, studies aimed at
determining whether the genes identified by this
modality are involved in essential hypertension
have often yielded conflicting results.
Molecular tools in animal models of
hypertension
Since the classic studies of Goldblatt et al. [34] in
1934, animal models of hypertension have been
crucial in advancing our understanding of the
pathogenesis of this disorder. The use of animal
studies overcomes many of the problems associated
with human studies. For example, environmental
conditions (e.g., salt intake) and genetic homogeneity can be strictly controlled. The identification
of QTL or candidate genes in the rodent models of
hypertension can lead to the study of homologous
loci or genes in humans. Indeed, the public availability of genomic sequences in rats, mice and
humans has greatly facilitated this process in recent
times.
Hypertension 173
The selective breeding of animals displaying
elevated blood pressure has resulted in the development of useful rodent models of hypertension,
such as the SHR, Dahl salt-sensitive and Lyon
strains [35]. Indeed, Dahl was one of the first
researchers to show that the pressor effect of salt
could be related to genetic factors through his work
on the rat strain that bears his name [36]. Crosses
between inbred rodent strains can yield valuable
information on the QTLs associated with blood
pressure.
A congenic strain can be defined as the strain in
which the chromosomal region featuring the QTL
of interest in one strain, the recipient, has been
replaced by that of another, the donor. A difference in blood pressure between the recipient and
congenic strains would indicate that the QTL in
question is associated in the regulation of blood
pressure.
The use of genetically engineered animals in the
study of the genetics of hypertension was introduced in the late 1980s and has become increasingly
widespread. This approach, often referred to as
physiologic genomics, usually involves the use
of animals in which the gene of interest is overexpressed, underexpressed or deleted. The RAS has
been studied extensively in genetically engineered
rodent strains. For example, the overexpression of
the rat angiotensinogen gene in the mouse results
in hypertension [37]. In addition, angiotensinogen
knockout mice are hypotensive [38]. The application of this approach is of particular use in the study
of complex diseases such as hypertension, as it
allows the detailed dissection of the various (patho-)
physiologic pathways. However, the results of
experiments with knockout mice should be interpreted with care, as some of the functions of the
deleted gene may be taken over by other genes.
The introduction of techniques to “silence” a
specific gene, without the manipulation of the
host genome, are also useful in the study of
hypertension. This can be achieved by one of two
mechanisms:
1 The use of antisense molecules; or
2 By the introduction of RNA interference.
Antisense technology refers to the use of oligonucleotide molecules that possess a complementary
sequence to the mRNA sequence being targeted
[39]. This allows the antisense oligonucleotide to
174 PART II Cardiovascular polygenic disorders
form a double-stranded complex with the target
mRNA, which is then broken down by the host cell.
Indeed, the admininistration of antisense oligonucleotides directed against the constituents of the
RAS has resulted in hypotensive effects in rats.
RNA interference refers to an evolutionarily
conserved mechanism by which gene expression is
suppressed by the presence of homologous RNA
[40]. In RNA interference, the presence of short
segments of double-stranded mRNA of 21–23
nucleotide pairs has been shown to block the
expression of homologous mRNA for a period of
up to 3 weeks [41]. RNA interference has an advantage over the use of knockout mice in that it allows
the blockade of the expression of one or more genes
without the need for time-consuming crosses.
Interfering RNA has been used successfully to
demonstrate the role of WNK-1 gene, which has a
major effect on blood pressure, in influencing the
ERK-5 pathway (see section on “Monogenic hypertension” for a more detailed discussion on the
WNK-1 gene) [42].
In addition, it is possible that RNA interference
may be exploited as a therapeutic tool in the treatment of hypertension. For example, it has been
shown that a single dose of interfering mRNA has
beneficial effects on blood pressure and renal function in a rat model of hypertension [41].
Methods used to determine the
involvement of the gene or QTL in
human hypertension
Linkage analysis
Linkage analysis refers to the use of the link
between the presence of the trait in question (e.g.,
hypertension) and the inheritance of a particular
allele as studied either in sibling-pairs or in two to
three generations of affected families. Linkage analysis has good specificity but poor sensitivity for the
detection of genes involved in hypertension, and
many of the linkage studies published over the past
10 years have been inconclusive because of the large
sample size required [43].
Association studies
Association studies are based on a case–control
design, which allows the recruitment of cases that
are unrelated to the healthy controls. In contrast to
linkage studies, association studies have good sens-
itivity but are prone to false positive results. Another problem with many association studies is that
such studies concentrate on each candidate gene
individually, disregarding other candidate genes.
Indeed, most of the association studies published to
date have been used to test the involvement of candidate genes. This approach may be inappropriate,
as it ignores the complex interactions between the
genes involved in hypertension. Williams et al. [44]
showed that interactions between the various alleles of different genes may be more important than
allelic variation at a single locus in the determination of blood pressure. Potential confounding factors (e.g., linkage disequilibrium both within a gene
and between neighboring genes) are also frequently
ignored in most association studies. These shortcomings may explain the inconsistent and often
contradictory results generated by the various studies on the genes involved in the etiology of hypertension. Another criticism of association studies in
polygenic disorders is that many of these are of a
poor quality [45]. Finally, an association between a
particular allele and high blood pressure does not
imply “cause.”
Epistatic interactions and haplotype analysis
Epistatic interactions refer to interactions between
the allele of one particular gene and that of another.
Studies on epistatic interactions may be of particular use in polygenic disorders such as essential
hypertension and are often based on a modification
of the association study. For example, a study by
Staessen et al. [46] has shown a strong association
between hypertension and the presence of a DD
homozygosity of the ACE gene, a CC homozygosity
of the aldosterone synthase gene and a Gly460Trp
heterozygosity of the α-adducin gene.
Haplotype analysis refers to the simultaneous
study of multiple allelic variations of a QTL or candidate gene [47]. In a modified association study,
Brand-Herrmann et al. [47] studied four different
polymorphisms of the angiotensinogen gene – C532T, A-20C, C-18T and G-6A – to determine
which of these represented the best gene for functional analysis. They found that C-532T and G-6A
had the strongest associations with blood pressure.
The complexity of epistatic studies and haplotype
analysis means that large numbers of patients are
required for a meaningful result to be obtained.
CHAPTER 8
Combination of the above
The most convincing evidence for the involvement
of a particular genes in the etiology of hypertension
has come from combining the methods and models
mentioned above. As the studies below illustrate,
such combinations of methods using different
models have proven to be of greatest effectiveness
in developing an understanding of the genes underlying and influencing essential hypertension, and in
developing therapies for hypertension.
Study of monogenic hypertension
and genes related to essential
hypertension
Some rare forms of hypertension are caused by the
mutation of a single gene. Many single gene forms
of hypertension have been extensively studied, and
this research has greatly contributed to our understanding of the pathophysiology and pharmacogenomics of hypertension. To date, all known forms
of monogenic hypertension are caused by mutations
of the genes involved in renal sodium handling.
Mutations of genes encoding epithelial
sodium channel
Liddle syndrome is an autosomal dominant disorder characterized by low renin hypertension
with hypokalemic alkalosis [48,49]. The disease is
caused by mutations affecting the epithelial sodium
channel (ENac), which is made up of α-, β- and γsubunits on chromosomes 12p13 (α-subunit) and
16p12–p13 (β- and γ-subunits) [50,51]. Mutations
that either delete or cause a frameshift mutation in
the last 45–76 amino acids of the C-terminal end of
either the β- or γ-subunits of the ENac can cause
Liddle syndrome. These mutations reduce clearance of ENac from the cell surface, leading to an
increased reabsorption of sodium [48]. In addition,
an Asn530Ser mutation of the γ-subunit has been
described in a Finnish patient with Liddle syndrome [52]. The Asn530Ser mutation is believed to
increase the probability of the sodium channel
being open, with consequent increase in renal
sodium reabsorption.
As Liddle syndrome is brought about by a defect
in the sodium channel, the condition responds to
sodium channel antagonists such as triamterene and
amiloride but not to spironolactone, an aldoster-
Hypertension 175
one antagonist [49]. Salt restriction is also important in the management of patients with Liddle
syndrome. Thiazide and loop diuretics may be
useful therapies but, as these agents can aggravate
hypokalaemia, serum potassium needs to be monitored closely.
A T594M polymorphism of the β-subunit of
ENac has also been reported to be associated with
(non-Liddle) essential hypertension [53]. Lymphocyte ENac coded by the 594M variant shows greater
response to cAMP stimulation when compared
with wild-type controls, an effect possibly brought
about by loss of protein kinase C inhibition [54].
It is interesting to note that amiloride is capable
of inhibiting the 594M variant [54]. Whether
some subset of hypertensives might benefit especially from amiloride, however, remains to be
demonstrated.
Hypertensives of African descent often present
with increased sodium sensitivity, low plasma renin
activity and respond better to diuretic treatment
[55,56]. The urine aldosterone : potassium ratio –
low in Liddle syndrome – tends also to be lower in
those of African descent compared to other ethnic
groups [56]. Aldosterone secretion is also lower in
children of African descent [57]. These observations are consistent with a hypothesis of increased
ENac activity. Of interest in this context, it has been
proposed that increased ENac activity, and hence
enhanced sodium retention, may be beneficial in
ancestral habitats where sodium is relatively scarce.
A G442V polymorphism has been shown to be
associated with a lower aldosterone : potassium
ratio in healthy young people of African descent.
This polymorphism, however, has not been shown
to be associated with hypertension [56].
ACE inhibitors are often ineffective when used to
treat hypertensives of African descent. Lack of
efficacy is attributed to the low plasma renin activity associated with this group of patients. Diuretics
are often very useful in lowering the blood pressure
of hypertensives of African descent. These observations are again consistent with increased ENac
activity in this population.
Mutations of aldosterone
synthase gene
Glucocorticoid suppressible hypertension (GSH)
is a form of autosomal dominant hypertension
176 PART II Cardiovascular polygenic disorders
characterized by decreased renin activity and normal or increased levels of aldosterone [48,58]. The
disorder is associated with hypokalemia and metabolic alkalosis. Aldosterone levels in GSH can be
suppressed by the administration of exogenous
glucocorticoid. GSH is caused by a chimeric gene
on chromosome 8q21–22 with the regulatory
region of 11b-hydroxylase and the coding portion
of aldosterone synthase, presumably the result of
an unequal cross-over during meiosis. This gene
is regulated by adrenocorticotrophic hormone
(ACTH) but codes for aldosterone synthase. Therefore, adrenal production of aldosterone is stimulated by the presence of endogenous ACTH. Excess
circulating aldosterone stimulates salt and water
retention, which results in hypertension. The
condition is treated with glucocorticoids, which
suppresses ACTH production, with or without
the addition of a conventional antihypertensive.
Thiazide or loop diuretics should be used with care
because of the risk of precipitating hypokalaemia.
The discovery of GSH has led to an interest in the
role of the aldosterone synthase gene in the etiology
of essential hypertension. A T-344C polymorphism
in the promoter region of the gene may be associated with increased aldosterone levels [59–62].
However, studies on the role of the T-344C polymorphism in the etiology of hypertension have
been conflicting [59–62]. Some researchers have
found an association between the T allele and
hypertension [60,62], while others believe the C
allele is more important in the pathophysiology of
the disease [59,61,63]. The fact that the T-344C single nucleotide polymorphism (SNP) is in complete
linkage disequilibrium with another polymorphism, Lys173Arg, further complicates matters. It
is uncertain which of these polymorphisms are of
clinical importance [64]. Recently, a small Japanese
study has shown the additive beneficial effect of
spironolactone in the regression of left ventricular
hypertrophy in hypertensive patients treated with
ACE inhibition [65]. This observation provides
supplementary evidence of the benefit of mineralocorticoid antagonism in cardiac hypertrophy/
failure, a treatment that was recently shown to be
beneficial in severe heart failure patients by the
Randomized Aldactone Evaluation Study (RALES)
[66]. Another study of Chinese and Japanese hypertensives detected through serendipity a significant
association between two SNPs in the aldosterone
synthase gene (one in T-344C and one resulting in a
lysine/argenine substitution at amino acid 173) and
plasma glucose levels and patients’ diabetes status,
an intriguing finding suggesting an unexpected link
between aldosterone and glucose homeostasis [64].
11-b Hydroxylase deficiency and 17ahydroxylase deficiency
11-β Hydroxylase deficiency (11βHD) is a rare
cause of congenital adrenal hyperplasia [58,67].
Classic 11βHD patients present with masculinization of the female external genitalia, precocious
pseudopuberty in both sexes and hypertension.
Nonclassic forms may produce menstrual abnormalities, hirsutism and acne. The prevalence
of nonclassic 11βHD is unknown, but the condition may affect as many as 8.4% and 0.6–6.5% of
women with polycystic ovary syndrome and hirsutism, respectively [68,69].
11-β Hydroxylase is responsible for the production of cortisol. Multiple nonsense, missense and
insertion mutations have been described in patients
with 11βHD [69]. Defects in this enzyme result in
an accumulation of steroid precursors which are
shunted into the androgenic pathway, resulting in
masculinization. Hypertension results from the elevated levels of steroid precursors with aldosteronelike actions (e.g., deoxycorticosterone).
Milder forms of 11βHD may well represent
an intermediate hypertensive phenotype [70,71].
Indeed, there is some evidence to suggest that 11-β
hydroxylase activity may be impaired in some
essential hypertensives [70–72].
Cytochrome P450c17 has both 17α-dehydroxylase and 17,20-lyase activity. Defects in cytochrome
P450c17 are another cause of congenital adrenal
hyperplasia. The pathophysiology of this condition
is similar to that of 11βHD in that there is impairment of secretion of cortisol, with compensatory
hypersecretion of ACTH, which stimulates the production of large quantities of deoxycorticosterone
by the adrenal glands. In addition, as 17,20-lyase is
required for the synthesis of gonadal sex hormones,
affected males are usually born with female genitalia. Females affected by the condition have primary amenorrhoea and hypogonadism. Multiple
mutations of the P450c17 gene have been described
to cause the disease [73,74].
CHAPTER 8
Apparent mineralocorticoid excess
Patients with the autosomal recessive condition,
apparent mineralocorticoid excess (AME), usually
present with hypertension, hypokalaemic alkalosis,
an increased cortisol : cortisone ratio, and reduced
plasma renin activity [48,75]. AME is caused by
mutations affecting the gene coding for the enzyme
11β-hydroxysteroid dehydrogenase type 2 isozyme
(11βHsD2). This enzyme is responsible for converting cortisol to cortisone in the kidney. This process protects the distal tubular mineralocorticoid
receptor from activation by endogenous cortisol,
which has the same affinity as aldosterone for the
mineralocorticoid receptor. Mutations that deactivate or reduce the activity of 11βHsD2 will result in
excessive activation of the mineralocorticoid receptor, leading to salt retention. The clinical picture is
virtually identical to hypertension that is caused by
the chronic ingestion of liquorice, an inhibitor of
11βHsD2.
AME is treated with the aldosterone antagonist, spironolactone [75]. Sodium channel blockade with amiloride and triamterene are effective
alternatives.
Mild forms of AME resemble essential hypertension [75]. Li et al. [76] described the heterozygote
father of a child with AME with mineralocorticoid
hypertension. This has given rise to the hypothesis
that some cases of essential hypertension may be
caused by defects of the 11βHsD2 [77].
Studies of essential hypertension have shown
that the half-life of cortisol is significantly prolonged in hypertensive patients [72]. An impairment in the conversion of cortisol to inactive
metabolites has also been reported in young men
with hypertension [75]. Lovati et al. [78] have
found that salt-sensitivity and 11βHsD2 activity is
associated with a polymorphic CA repeat in the
11βHsD2 gene. A G534A mutation of the 11βHsD2
may also be important in determining salt sensitivity, the G allele being associated with a greater
increase in blood pressure with a salt load [78].
These findings may account for the observation
that spironolactone may be a useful add-on therapy
in the treatment of some hypertensives with low
renin hypertension who are resistant to conventional antihypertensives [79]. The relationship
between the polymorphic CA repeat and hypertension, however, remains controversial and a recent
Hypertension 177
study failed to find an association between them
[80].
Mutation in the mineralocorticoid
receptor
A missense mutation that results in the substitution
of leucine for serine at position 810 of the mineralocorticoid receptor has recently been described
[81]. Individuals heterozygous for the mutant
receptor develop hypertension at a young age. The
mutant receptor shows activity in the absence of
added steroid, but normal activation by aldosterone. This receptor is also activated by the mineralocorticoid receptor antagonists, progesterone
and spironolactone. The former explains the pregnancy-induced exacerbation of hypertension in
some of these patients. The mutation may also be
related to the early onset of heart failure, providing
more evidence in support of the role of mineralocorticoids in heart failure. As spironolactone activates the mutant receptor, unlike in the wild-type
receptor where it acts as an antagonist, its use is
likely to cause deterioration in these patients. The
exact prevalence of this mutation is unknown,
although it is likely to be extremely rare.
Mutations in the peroxisome
proliferator-activated receptor g
Peroxisome proliferator-activated receptor γ
(PPARγ) is one of the three members of the PPAR
family of nuclear receptors, and acts by modifying
the transcription of various target genes [82].
PPARγ mRNA is abundant in adipose tissue and
is downregulated in starvation and in insulindeficient states (i.e., untreated type I diabetes).
PPARγ activation is associated with increased
insulin sensitivity and growth of adipose tissue. The
newest class of oral hypoglycaemic agents, thiazolinediones, are potent PPARγ agonists.
Barroso et al. [83] described a syndrome of type 2
diabetes and hypertension linked to dominant missense PPARγ gene mutations, which act to decrease
the activity of the gene product. They postulate
that PPARγ mutations may result in hypertension
through effects on vascular tone [83]. PPARγ is
expressed in endothelial cells [84]. Indeed, thiazolinediones have been shown to have a blood pressure
lowering effect in rats and appears to have a similar
effect in hypertensive diabetics [85]. More studies
178 PART II Cardiovascular polygenic disorders
are needed to study the role of thiazolinediones in
hypertension.
Gordon syndrome
Gordon syndrome (pseudohypoaldosteronism
type II) is characterized by low-renin hypertension,
hyperkalaemia, hyperchloremic metabolic acidosis
and normal or high plasma aldosterone levels, all
of which respond well to thiazide diuretics [86–88].
Some forms of this syndrome have been ascribed to
mutations in either WNK1 or WNK4 genes [89],
which belong to the WNK family of serine/threonine kinases [90]. Wild-type WNK4 is an inhibitor
of the tubular thiazide-sensitive sodium-chloride
co-transporter, an activity that is absent in the
mutant variant associated with Gordon syndrome
[91].
WNK1 is believed to inhibit WNK4 activity [92].
Therefore, gain of function mutations in the
WNK1 gene would result in inhibition of WNK4
activity, leading to increased sodium and chloride
reabsorption.
An SNP near the promoter region of the WNK1
gene has been shown to be associated with blood
pressure [93]. It has therefore been suggested
that increased expression of WNK1 may have a
role in the pathogenesis of essential hypertension [93]. Indeed, a recent study suggests that
a common WNK1 polymorphism can predict
response to treatment with thiazide diuretics [94].
However, further studies are required to confirm
this finding before any definite conclusions can be
made.
Hypertension with brachydactyly
An autosomal dominant form of salt-resistant
hypertension associated with brachydactyly has
been described in Turkish, US and Canadian kindreds [95]. The condition appears to be related to
genetic changes in the short arm of chromosome
12 [95]. Indeed, a study has recently found a locus
for essential hypertension on chromosome 12p in
Chinese patients [96].
nomas [97]. The genetic cause of this condition is
not known.
Although single-gene disorders have led to
intriguing clues to hypertension, most of the
research on essential hypertension has involved
association and linkage studies focused on candidate genes. Although some gene variants appear to
be associated with hypertension, results have not
been consistently reproducible. Some of the candidate genes are listed in Table 8.1 [98–155]. A few of
the genes that have been studied in detail are discussed in the following section.
Table 8.1 Candidate genes that may have a role in essential
hypertension.
Genes involved in hypertension
Reference
Aldosterone synthase
[59–62]
Alpha-adducin
[98–102]
a2-Adrenoceptor
[106–108]
Alpha subunit of Gs protein
[111]
Angiotensin II receptor type I
[139–141,205]
Angiotensin converting enzyme (ACE)
[142–145,205]
Angiotensinogen
[130–138]
Atrial natriuretic peptide
[119–121]
Beta-adducin
[206]
b2-Adrenoceptor
[106,146–152]
b3-Adrenoceptor
[109,110]
b2-Bradykinin receptor gene
[124,125]
11b-Hydroxysteroid dehydrogenase
[207]
Chemokine receptor 2 gene
[208]
Dopamine D2 receptor
[209]
Endothelial nitric oxide synthase
[103–105]
Endothelin-1
[112]
Endothelin-2
[113]
Epithelial sodium channel beta-subunit
[53]
Glucagon receptor
[128,129]
Glucokinase
[127]
Human natriuretic peptide receptor type A
[210]
Human natriuretic peptide receptor type B
[211]
Insulin receptor
[116]
Lipoprotein lipase
[122,123]
Pertussis toxin sensitive G protein b-subunit [153–155]
Familial hyperaldosteronism type II
This disorder has an autosomal dominant inheritance and is characterized by nonglucocorticoid remediable hyperaldosteronism with bilateral
adrenal hyperplasia or aldosterone producing ade-
Renin
[114,115]
Transforming growth factor b1
[117,118]
Tyrosine hydroxylase
[126]
WNK1
[93]
WNK4
[212]
CHAPTER 8
Candidate genes and essential
hypertension
a-Adducin
Studies in the Milan hypertensive rat (MHR) suggested that alterations in the renal tubular absorption of salt may account for the raised blood pressure
found in this strain of rat [156]. It was subsequently
found that cytoskeletal proteins are involved in
mediating the increased salt reabsorption. Crossimmunization techniques between the MHR and
its normotensive control revealed differences in
the cDNA of the α-subunit of the adducin molecule. α-Adducin is a cytoskeletal protein involved
in the regulation of the assembly of the actin
cytoskeleton in renal tubular cells [156]. As the
actin cytoskeleton may be able to influence the surface expression of the Na-K-ATPase, it is possible
that disordered regulation of actin assembly may
lead to increased sodium reabsorption. In addition,
α-adducin has been shown to have a direct effect on
the Na-K-ATPase responsible for the tubular reabsorption of salt [156]. Indeed, in the MHR, mutations of the α-adducin gene have been linked to
hypertension and to increased Na-K pump activity.
In humans, a Gly460Trp mutation in α-adducin
has been associated with increased sodium retention, probably secondary to increased numbers of
renal tubular Na-K pumps [157,158]. The 460Trp
allele may be associated with lower plasma renin
activity and with a better response to thiazide
diuretics, consistent with the increased sodium
retention [98,159]. This finding could be of particular relevance in antihypertensive therapy as
the 460Trp allele is present in 20% of European
Caucasians. Unfortunately, an increase in Na-K
pump activity has not been associated with the
460Trp allele in some studies [99]. Similarly, the
460Trp allele has been related to hypertension in
some populations but not others [98–102].
Angiotensinogen
Multiple SNPs have been described in the angiotensinogen gene [130–132,160]. The M235T variant has been studied extensively. The T235 allele
is associated with raised plasma angiotensinogen
[130], which in turn may be correlated with blood
pressure [161]. T235 has been associated with hypertension in some studies, but not in others [131–
Hypertension 179
135]. M235T is in linkage disequilibrium with the
G-6A and A-20C polymorphisms in the promoter
region of the angiotensinogen gene [130,131]. The
G-6 allele is associated with a lower transcription
rate for angiotensinogen, while the presence of a
-20C allele can increase angiotensinogen transcription [130,162]. M235T is also in linkage disequilibrium with at least three other polymorphisms:
T+68C, C–18T and T+31C [131,160,163].
Another polymorphism, M174T, may be involved
in hypertension in some populations [136–138],
but not others [134,135]. Other angiotensinogen gene polymorphisms include C-532T, which
is in linkage disequilibrium with G-6A, and an
Arg-30Pro substitution in the signal peptide of
angiotensinogen [164,165]. These polymorphisms
may also influence plasma angiotensinogen levels.
Hunt et al. [166] showed that individuals with
the -6A allele are more salt sensitive and more likely
to benefit from salt restriction. Patients with the
-6A allele may demonstrate a larger fall in blood
pressure following weight loss when compared
with -6G homozygotes. As Hunt et al. [166] point
out, there may be a particular genotype that would
especially benefit from increased vigilance in salt
intake and/or weight monitoring. However, Giner
et al. [167] failed to find an association between salt
sensitivity and the M235T allele.
Hypertensives with at least one T235 allele have
been shown to require a higher dosage level of antihypertensive medication compared with M235
homozygotes [168]. The angiotensinogen gene
locus may influence an individual’s response to
ACE inhibition [169]. However, more studies are
required to confirm the pharmacogenomic role of
the angiotensinogen locus.
Angiotensin II receptor type I
Multiple single nucleotide polymorphisms have
been found in the angiotensin II receptor type I
(AGTRI) gene [139,170]. An A1166C polymorphism has been associated with hypertension in
some studies, but not in others [139–141]. The
mechanism by which this polymorphism affects
blood pressure remains to be elucidated [171].
Angiotensin-converting enzyme
Plasma ACE levels are linked to the D allele of an
I/D polymorphism of the ACE gene [172]. Linkage
180 PART II Cardiovascular polygenic disorders
and association data from the Framingham Heart
Study supports a relationship between the D variant and hypertension in males [142]. This hypothesis is supported by Fornage et al. [143] and
Higaki et al. [144]. However, it should be noted that
many studies fail to demonstrate a relationship
between the ACE I/D polymorphism and hypertension [145].
The effects of the ACE I/D polymorphism and
the response to ACE inhibition have been studied
extensively. Some studies have found an association between the blood pressure response to ACE
inhibition and ACE genotype, whereas others have
not [145,173–175]. Moreover, even the results of
the positive association studies are inconsistent,
with some studies showing a greater blood pressure
response in the DD group and others in the II genotype [173–175].
Left ventricular hypertrophy is an independent risk factor for mortality and morbidity from
hypertension [176]. In addition, left ventricular
hypertrophy in normotensive individuals is a risk
factor for the later development of hypertension
[176]. Evidence for the role of angiotensin and aldosterone comes from the observation that the intravenous administration of these agents can cause left
ventricular hypertrophy and fibrosis [177]. In addition, blockade of the RAS with ACE inhibitors can
cause regression of left ventricular hypertrophy
[178]. The role of the ACE I/D polymorphism in
hypertensive left ventricular hypertrophy has been
studied, with inconclusive results [179,180].
b2-Adrenoceptor
The β2-adrenoceptor locus has been linked to hypertension [106,146]. Two polymorphisms, Arg16Gly
and Gln27Glu, have been studied in detail [147–
152]. The Gly16 variant of the receptor demonstrates increased downregulation after stimulation
by isoproterenol compared to the Arg16 isoform
[146]. Such a response can lead to impaired vasodilatation to β2-adrenergic stimulation. Kotanko et
al. [148] found an association between the Gly16
allele and hypertension. However, Timmerman et
al. [149] discovered that the Gly16 allele is associated with lower blood pressure. Other studies have
also shown conflicting results [150–152].
Atenolol and other beta-blockers used to treat
hypertension can cause or aggravate bronchocon-
striction. Therefore, it is of great clinical interest
that the β2-adrenoceptor polymorphisms may have
a role in determining airway reactivity. Patients homozygous for the Glu27 allele have decreased bronchial sensitivity to methacholine compared to those
with at least one Gln27 allele [128]. The presence of
the Gly16 allele may be associated with increased
downregulation, resulting in agonist desensitization when the patient is treated with beta-agonists
[129]. Indeed, asthmatic children with the Arg16
allele are more likely to respond to albuterol compared to Gly16 homozygotes [130]. A better understanding of the interaction between beta-blockers,
β2-adrenoceptor polymorphisms and bronchoconstriction could lead to the identification of a subset
of patients who are likely to suffer from this adverse
effect. However, it is premature to comment on the
implications of the β2-adrenoceptor polymorphisms on the treatment of hypertension.
A critical evaluation of genes in
essential hypertension
Although many of the candidate genes have genuine pathophysiologic effects on blood pressure, no
single gene has consistently been shown to influence the development of hypertension in humans
in classic linkage and association studies. However, the lack of consistent results from association and linkage studies should not be viewed in
isolation. For example, in spite of the poor reproducibility of the association studies on the role of
allelic variation of α-adducin in human essential
hypertension, there is strong evidence from animal
as well as pharmacologic and physiologic studies
on its role in the regulation of blood pressure.
Therefore, even though the Gly460Trp polymorphism has not been shown conclusively to be associated with hypertension, much has been learnt on
the physiologic role of adducin on the regulation of
blood pressure using genomic technology. There
are many reasons as to the poor reproducibility
of genetic studies of essential hypertension in humans. Poor study design, laboratory errors and/or
lack of statistical power could partially account
for poor reproducibility between the various
association and linkage studies. The complexity of
gene–gene and gene–environment interactions
should not be discounted.
CHAPTER 8
In addition, studies on the genes involved in the
regulation of blood pressure should also be viewed
in the context of the target population. For example,
results from a study performed in the Japanese may
not be extrapolable to a European population.
Similarly, age and gender differences should be
taken into account when interpreting the results of
these studies.
Another cause of confusion is the presence of
multiple polymorphisms within the same gene that
are in linkage disequilibrium with one another, an
example typified by the multiple polymorphisms
found in the angiotensinogen gene. Therefore,
differences in blood pressure associated with a
particular polymorphism may, in fact, be brought
about by variation elsewhere in the gene. In addition, the effects (if any) of intragene interactions
between various polymorphisms should be thoroughly investigated before any definite conclusions
can be drawn.
Recently, many investigators have tried to get
around many of these problems by performing
meta-analyses of previous studies in well-defined
ethnic groups [133,181]. Indeed, these studies
appear to show that the 235T allele of the angiotensinogen gene is associated with hypertension.
However, reporting and positive publication biases
can result in erroneous results in meta-analyses. In
addition, because of design variation, not all studies
can be compared satisfactorily. For example, the
authors of one of these meta-analyses concluded
that many of the studies they used had considerable
heterogeneity, and the evidence was borderline.
Many believe that genome screens involving
large numbers of subjects will provide definitive
evidence for the genes involved in hypertension.
The results from the BRIGHT study of 2010 sibling-pairs in a white British population suggests
that a few loci on chromosomes 2q, 5q, 6q and 9q
may be involved in blood pressure regulation
[182]. Chromosomes 6q and 9q may have particularly strong influences on blood pressure, with
LOD scores of 3.21 and 2.24, respectively. Results
from the HyperGen, GENOA and GenNet studies
indicated some – extremely weak – influences on
blood pressure from loci in chromosomes 2p, 1p
and 1, respectively, providing further evidence on
the polygenic nature of hypertension [183–185].
Data from HyperGen also suggests that genetic
Hypertension 181
variation may be a more important determinant
of early onset hypertension in African-Americans
than in white population [186]. However, the
results from the large genome screens remain to
be replicated. Indeed, it is possible that the relative
importance of the individual genetic polymorphism in essential hypertension will never be conclusively shown and that future efforts should
concentrate on the elucidation of the role of these
polymorphisms.
Genomics and risk stratification
The main objective for the identification and treatment of hypertension is to prevent the development or progression of target organ damage [187].
In addition, secondary hypertension should be
identified in order for the underlying cause of the
high blood pressure to be treated. In current clinical practice, a combination of clinical, biochemical
and imaging data are obtained in order to achieve
these aims. The growth of genomics has great
potential to aid risk stratification. Some of the data
from basic science studies are already being used
for this purpose. For example, the use of ANP and
hsCRP in risk stratification have arisen as a direct
result of our knowledge of the disease process.
In addition, there is great interest in the use of
gene expression profiling in risk stratification
[188]. This process has been greatly aided by the
development of microarray technology, where the
simultaneous analysis of the expression profile of
the entire genome can be carried out. The gene
expression profile of an individual is the result of
a complex interplay between genetic and environmental factors. Changes in the gene expression
profile usually accompany phenotypic change.
Moreover, changes in gene expression patterns may
occur before the occurrence of any phenotypic
change. Indeed, the gene expression profile of circulating monocytes from patients with carotid
atherosclerosis is different from that of normal
controls [189].
Genes and the treatment of
hypertension
Advances in our understanding of genetics has contributed to the development of new strategies of
182 PART II Cardiovascular polygenic disorders
treating hypertension, namely in the fields of pharmacogenetics and gene therapy.
Pharmacogenomics
Pharmacogenomics can be defined as the application of genomic technology, such as gene sequencing and microarray technology, to the development
of a pharmacologic agent. The term thus encompasses the fields of “pharmacogenetics” and “gene
therapy,” which fields refer, respectively, to the
study of the effects of genotype on the response to a
particular drug and the use of genetic material as a
treatment for a disorder.
Pharmacogenomic technology can therefore
potentially be applied to any stage in drug development: from the initial development of the pharmacologic agent, through the preclinical tests, to the
final clinical trials. In addition, it is hoped that the
application of pharmacogenomics can result in the
development of personalized medicine, in which
the use of a particular drug or drug combination
can be tailored to the genotype of a patient. This is
particularly true for a condition such as hypertension, for which a bewildering array of medications
are available and which shows considerable interindividual variation to treatment by any given drug.
Drug isolation
Ferrari et al. [190] have shown that a digitoxigenin
derivative, PST 2238, can decrease the blood pressure and Na-K pump activity in the MHR but has
no effect on normotensive controls. This agent also
has more effect in the Na-K pump of cell lines
expressing mutant α-adducin compared with wildtype controls. These observations are of great interest, as they suggest PST2238 (or related compounds)
may potentially be used in the future in the subgroup of hypertensives with the 460Trp allele.
Interindividual response to treatment
Early pharmacogenetic studies mostly focused on
the effects of genetic variation on the metabolism
(i.e., pharmacokinetics) of antihypertensive drugs.
Cytochrome P450 CYP2D6 (CYP2D6) metabolizes
many of the commonly used agents (including the
beta-blocker, metoprolol), and polymorphisms in
this enzyme can affect drug plasma levels and halflife. A clinically important polymorphism of the
CYP2D6 enzyme was first noticed during a trial
involving the adrenergic ganglion-blocking antihypertensive drug debrisoquine [191]. It was found
that patients who are poor metabolizers of debrisoquine have an exaggerated hypotensive effect to
treatment by the drug, which is one of the reasons
why debrisoquine is not widely used in clinical
practice. However, although individuals who are
poor metabolizers of debrisoquine also have prolonged elimination half-life of metoprolol, they do
not appear to have an increased incidence of
adverse effects at therapeutic doses of the betablocker [192,193].
Catechol-O-methyltransferase (COMT) is responsible for the methylation of catecholamines
and drugs containing the catechol group (e.g.,
levodopa and methyldopa) [194]. Variation in
COMT activity is most commonly because of two
different alleles, one of which codes for an enzyme
with high activity while the other has low activity.
Individuals who have the high activity form of
COMT exhibit enhanced breakdown of methyldopa [195]. Therefore, these individuals may need
a higher dose of the drug for the desired pharmacologic effect. Conversely, individuals with the low
activity form of the enzyme may be more susceptible to the toxic effects of the drug.
Another enzyme, acetyltransferase, is responsible for the acetylation of the drug hydralazine
[195]. Patients who are slow acetylators of the drug
are at higher risk of developing hydralazineinduced systemic lupus erythematosus.
More recently, efforts have been made to identify
polymorphisms in the genes involved in blood
pressure regulation that may be implicated in the
interindividual variation to treatment by antihypertensive drugs. In other words, these studies aim
to research the direct interaction (i.e., the pharmacodynamic relationship) between drugs and polymorphisms of these genes. Genes that have been
evaluated for their pharmacodynamic effects include α-adducin, angiotensinogen, pertussis toxin
sensitive G protein β-subunit, ACE I/D polymorphism, β1-adrenergic receptor, WNK1 and AGTR1
[94,196,197]. However, at present, there is no consensus as to the effect (if any) of polymorphisms of
these genes on the pharmacodynamics of essential
hypertension.
CHAPTER 8
Hypertension 183
Gene therapy
Table 8.2 Some of the genes which have been targeted
The recent advances in our understanding of hypertension have stimulated interest into gene therapy
for hypertension, although research in this field is
still restricted to animal studies. Research into gene
therapy in hypertension can be classified into studies based on the overexpression of a gene known to
have a hypotensive effect and those suppressing the
effect of genes that have pressor effect on blood
pressure. Both of these approaches require a thorough knowledge of the genetic sequence of the gene
of interest.
An example of the latter approach is the use of
antisense oligonucleotides against the mRNA of the
gene of interest. Antisense oligonucleotides are
short segments of DNA which are designed to bind
to the corresponding parts of the target mRNA
[198]. This interaction prevents the translation of
the target mRNA by ribosomes and stimulates its
breakdown by RNAse H. The use of antisense therapy has so far focused on the mRNA of genes of the
RAS. Animal models have shown a marked reduction of blood pressure in rats after the injection
of antisense DNA directed against AGTR1 [198].
In addition, the hypotensive effect was prolonged,
with a reduction in blood pressure for up to 9
weeks. However, it should be borne in mind that
the study was carried out by the injection of the
DNA-containing viral vector into the cerebral ventricles or the hypothalamus. More recently, it was
shown that the use of intravenous antisense oligonucleotides directed against AGTR1 can reduce the
blood pressure effectively for 9 days after a single
injection [199]. Table 8.2 summarizes some of the
other genes that have been targeted successfully by
the antisense approach.
The overexpression of genes known to have a
hypotensive effect has also been shown to be successful in lowering blood pressure in animal models. The administration of the human kallikrein
gene using an adenovirus vector resulted in a
marked reduction in blood pressure in the deoxycorticosterone acetate salt-sensitive (DOCA) rat
[200]. In addition, the use of kallikrein gene therapy may prevent end organ damage in this rat
model of hypertension [201]. It has been hypothesized that the protective effect of kallikrein is
mediated by the prevention of end organ fibrosis
with antisense oligonucleotides in animal models of
hypertension.
Target
Reference
Angiotensinogen
[213]
AGTR1
[198,199]
b1-Adrenergic receptor
[214]
c-fos
[215]
CYP4A1
[216]
Thyrotropin releasing hormone
[217]
Thyrotropin releasing hormone receptor
[218]
Urinary kininase
[219]
and the suppression of free radical production [201].
Other genes whose overexpression has led to a
decrease in blood pressure include the adrenomedullin gene [202], atrial natriuretic peptide [203] and
parathyroid hormone-related protein [204].
Drug synthesis
For the past few hundred years, the medical treatment of disease has been by the use of chemical
agents that are either extracted from natural
sources or synthesized chemically. In the last
decade, the use of recombinant biologic agents in
the treatment of disease has become increasingly
common. This is a development that would not
have been possible without the use of genomic
technology. An example of this class of agent is the
use of the natriuretic peptides.
Future perspectives
The use of genomic technology has not led to the
detection of a genetic polymorphism that may lead
to essential hypertension in humans. However,
there have been great advances in our understanding of the role of various genes in blood pressure
regulation. Indeed, this has been marked by the
increasing use of genetically engineered animals
and inhibition of gene expression to investigate
the effect of modulating the effect of the gene of
interest.
It is likely that a better knowledge of the molecular pathophysiology of hypertension will provide
novel targets for pharmacologic intervention, such
184 PART II Cardiovascular polygenic disorders
as PST 2238. In addition, better understanding may
facilitate the development of gene therapy for the
treatment of hypertension. Gene therapy for hypertension provides a potential route for effective prolonged blood pressure control with a single course
of treatment, thus overcoming the problem of
treatment failure resulting from poor compliance
[198]. Finally, a better understanding of the interaction between genes, the environment and drugs
may facilitate the matching of a particular drug to
the clinical requirements of the individual patient.
References
1 Kaplan NM. Systemic hypertension: mechanisms and diagnosis. In: Braunwald E, Zipes DP, Libby P, eds. Heart
Disease: A Textbook of Cardiovascular Medicine, 6th edn.
WB Saunders Company, Philadelphia, 2001: 941–971.
2 Brenner BM, Garcia DL, Anderson S et al. Glomeruli
and blood pressure. Less of one, more the other? Am J
Hypertens 1988; 1: 335–347.
3 Weber MA. Unsolved problems in treating hypertension: rationale for new approaches. Am J Hypertens
1998; 11: 145S–149S.
4 Berlowitz DR, Ash AS, Hickey EC et al. Inadequate management of blood pressure in a hypertensive population.
N Engl J Med 1998; 339: 1957–1963.
5 Dickerson JE, Hingorani AD, Ashby MJ, Palmer CR,
Brown MJ. Optimisation of antihypertensive treatment
by crossover rotation of four major classes. Lancet 1999:
353: 2008–2013.
6 Guyton AC. The surprising kidney-fluid mechanism for
pressure control – its infinite gain! Hypertension 1990;
16: 725–730.
7 Qi N, Rapp JP, Brand PH et al. Body fluid expansion is
not essential for salt-induced hypertension in SS/Jr rats.
Am J Physiol Regul Integr Comp Physiol 1999; 277:
R1392–R1400.
8 DiBona GF, Kopp UC. The neural control of renal function. Physiol Rev 1997; 77: 75–197.
9 Guimaraes S, Moura D. Vascular adrenoceptors: an
update. Pharmacol Rev 2001; 53: 319–356.
10 Paul M, Poyan Mehr A, Kreutz R. Physiology of local
renin-angiotensin systems. Physiol Rev 2006; 86: 747–
803.
11 Kim HS, Krege JH, Kluckman KD et al. Genetic control
of blood pressure and the angiotensinogen locus. Proc
Natl Acad Sci USA 1995; 92: 2735–2739.
12 Crowley SD, Gurley SB, Oliverio MI et al. Distinct roles
for the kidney and systemic tissues in blood pressure
regulation by the renin-angiotensin system. J Clin Invest
2005; 115: 1092–1099.
13 Rigat B, Hubert C, Alhenc-Gelas F et al. An insertion/
deletion polymorphism in the angiotensin I-converting
enzyme gene accounting for half the variance of serum
enzyme levels. J Clin Invest 1990; 86: 1343–1346.
14 Smithies O, Kim HS, Takahashi N et al. Importance of
quantitative genetic variations in the etiology of hypertension. Kidney Int 2000; 58: 2265–2280.
15 Zeng C, Sanada H, Watanabe H et al. Functional
genomics of the dopaminergic system in hypertension.
Physiol Gen 2004; 19: 233–246.
16 Hollon TR, Bek MJ, Lachowicz JE et al. Mice lacking
D5 dopamine receptors have increased sympathetic tone
and are hypertensive. J Neurosci 2002; 22: 10801–10810.
17 Asico LD, Ladines C, Fuchs S et al. Disruption of the
dopamine D3 receptor gene produces renin-dependent
hypertension. J Clin Invest 1998; 102: 493–498.
18 Bek MJ, Wang X, Asico LD et al. Angiotensin-II type 1
receptor-mediated hypertension in D4 dopamine receptordeficient mice. Hypertension 2006; 47: 288–295.
19 Huang PL, Huang Z, Mashimo H et al. Hypertension in
mice lacking the gene for endothelial nitric oxide synthase. Nature 1995; 377: 196–197.
20 Stamler JS, Loh E, Roddy MA et al. Nitric oxide regulates
basal systemic and pulmonary vascular resistance in
healthy humans. Circulation 1994; 89: 2035–2040.
21 Tan KT, Lip GY. Platelets, atherosclerosis and the
endothelium: new therapeutic targets? Expert Opin
Investig Drugs 2003; 12: 1765–1776.
22 Duplain H, Burcelin R, Sartori C et al. Insulin resistance, hyperlipidemia, and hypertension in mice lacking
endothelial nitric oxide synthase. Circulation 2001; 104:
342–345.
23 Silver MA. The natriuretic peptide system: kidney and
cardiovascular effects. Curr Opin Nephrol Hypertens
2006; 15: 14–21.
24 Matsukawa N, Grzesik WJ, Takahashi N et al. The natriuretic peptide clearance receptor locally modulates the
physiological effects of the natriuretic peptide system.
Proc Natl Acad Sci USA 1999; 96: 7403–7408.
25 Oliver PM, John SW, Purdy KE et al. Natriuretic peptide
receptor 1 expression influences blood pressures of mice
in a dose-dependent manner. Proc Natl Acad Sci USA
1998; 95: 2547–2551.
26 Levin ER. Endothelins. N Engl J Med 1995; 333: 356–363.
27 Pollock DM. Endothelin, angiotensin, and oxidative
stress in hypertension. Hypertension 2005; 45: 477–480.
28 Emanueli C, Madeddu P. Role of the kallikrein-kinin
system in the maturation of cardiovascular phenotype.
Am J Hypertens 1999; 12: 988–999.
29 Zhao C, Wang P, Xiao X et al. Gene therapy with human
tissue kallikrein reduces hypertension and hyperinsulinemia in fructose-induced hypertensive rats.
Hypertension 2003; 42: 1026–1033.
CHAPTER 8
30 Alfie ME, Sigmon DH, Pomposiello SI et al. Effect of
high salt intake in mutant mice lacking bradykinin-B2
receptors. Hypertension 1997; 29: 483–487.
31 Touyz R. Reactive oxygen species, vascular oxidative
stress, and redox signalling in hypertension. Hypertension 2004; 44: 248–252.
32 Schillaci G, Pirro M, Gemelli L et al. Increased Creactive protein concentrations in never-treated hypertension: the role of systolic and pulse pressures. J
Hypertens 2003; 21: 1841–1846.
33 Sesso HD, Buring JE, Rifai N et al. C-reactive protein
and the risk of developing hypertension. JAMA 2003;
290: 2945–2051.
34 Goldblatt H, Lynch J, Hanzal RF, Summerville WW.
Studies of experimental hypertension I: Production of
persistent elevation of systolic blood pressure by means
of renal ischaemia. J Exp Med 1934; 59: 347–379.
35 Okamoto K, Akoi K. Development of a strain of spontaneously hypertensive rat. Jpn Circ J 1963; 27: 282–293.
36 Dahl LK, Heine M, Thompson K. Genetic influence of
the kidneys on blood pressure. Circ Res 1974; 34:
94–101.
37 Kimura S, Mullins JJ, Bunneman B, Metzger R,
Hilgenfeldt U. High blood pressure in transgenic mice
carrying the rat angiotensinogen gene. EMBO J 1992; 11:
821–827.
38 Kim HS, Krege JH, Kluckman KD et al. Genetic control
of blood pressure and the angiotensinogen locus. Proc
Natl Acad Sci USA 1995; 92: 2735–2739.
39 Raizada MK, DerSakissian S. Potential of gene therapy
strategy for the treatment of hypertension. Hypertension
2006; 47: 6–9.
40 Zamore PD, Tuschl T, Sharp PA et al. RNAi: doublestranded RNA directs the ATP-dependent cleavage of
mRNA at 21 to 23 nucleotide intervals. RNAi: doublestranded RNA directs the ATP-dependent cleavage of
mRNA at 21 to 23 nucleotide intervals. Cell 2000; 101:
25–33.
41 Wang X, Skelley L, Cade R et al. AAV delivery of mineralocorticoid receptor shRNA prevents progression of
cold-induced hypertension and attenuates renal damage. Gene Ther 2006; 13: 1097–1103.
42 Xu BE, Stippec S, Lenertz L et al. WNK1 activates ERK5
by an MEKK2/3-dependent mechanism. J Biol Chem
2004; 279: 7826–7831.
43 Jones HB. The relative power of linkage and association
studies for the detection of genes involved in hypertension. Kidney Int 1998; 53: 1446–1448.
44 Williams SM, Addy JH, Phillips JA et al. Combinations
of variations in multiple genes are associated with
hypertension. Hypertension 2000; 36: 2–6.
45 Bonnici F, Keavney B, Collins R, Danesh J. Angiotensin
converting enzyme insertion or deletion polymorphism
46
47
48
49
50
51
52
53
54
55
56
57
58
59
Hypertension 185
and coronary restenosis: meta-analysis of 16 studies. Br
Med J 2002; 325: 517–520.
Staessen JA, Wang JG, Brand E et al. Effects of three candidate genes on the prevalence and incidence of hypertension in a Caucasion population. J Hypertens 2001; 19:
1349–1358.
Brand-Herrmann SM, Kopke K, Reichenberger F et al.
Angiotensinogen promoter haplotypes are associated
with blood pressure in untreated hypertensives. J Hypertens 2004; 22: 1289–1297.
Lifton RP, Gharavi AG, Geller DS. Molecular mechanisms of hypertension. Cell 2001; 104: 545–556.
Warnock DG. Liddle syndrome: An autosomal dominant form of human hypertension. Kidnet Int 1998; 53:
18–24.
Voilley N, Lingueglia E, Champigny G et al. The lung
amiloride-sensitive Na+ channel: biophysical properties,
pharmacology, ontogenesis, and molecular cloning.
Proc Natl Acad Sci USA 1994; 91: 247–251.
Voilley N, Bassilana F, Mignon C et al. Cloning,
chromosomal localization and physical linkage of the
beta and gamma subunits of the human epithelial
amiloride-sensitive sodium channel. Genomics 1994; 29:
560–565.
Hiltunen TP, Hannila-Handelberg T, Petajaniemi N
et al. Liddle’s syndrome associated with a point mutation in the extracellular domain of the epithelial sodium
channel gamma subunit. J Hypertens 2002; 20: 2383–
2390.
Baker EH, Dong YB, Sagnella GA et al. Association of
hypertension with T594M mutation in beta subunit of
epithelial sodium channels in black people resident in
London. Lancet 1998; 351: 1388–1392.
Cui Y, Su YR, Rutkowski M, Reif M, Menon AG, Pun
RY. Loss of protein kinase C inhibition in the betaT594M variant of the amiloride-sensitive sodium channel. Proc Natl Acad Sci USA 1997; 94: 9962–9966.
Hall WD. A rational approach to the treatment of
hypertension in special populations. Am Fam Phys 1999;
60: 156–162.
Ambrosius WT, Bloem LJ, Zhou L et al. Genetic variants
in the epithelial sodium channel in relation to aldosterone and potassium excretion and risk for hypertension. Hypertension 1999; 34: 631–637.
Pratt JH, Jones JJ, Miller JZ, Wagner MA, Fineberg NS.
Racial differences in aldosterone excretion and plasma
aldosterone concentrations in children. N Engl J Med
1989; 321: 1152–1157.
White PC. Inherited forms of mineralocorticoid hypertension. Hypertension 1996; 28: 927–936.
Tamaki S, Iwai N, Tsujita Y, Kinoshita M. Genetic polymorphism of CYP11B2 gene and hypertension in
Japanese. Hypertension 1999; 33: 266–270.
186 PART II Cardiovascular polygenic disorders
60 Brand E, Chatelain N, Mulatero P et al. Structural analysis and evaluation of the aldosterone synthase gene in
hypertension. Hypertension 2005; 32: 198–204.
61 Komiya I, Yamada T, Takara M et al. Lys(173)Arg and
-344T/C variants of CYP11B2 in Japanese patients
with low-renin hypertension. Hypertension 2005; 35:
699–703.
62 Davies E, Holloway CD, Ingram MC et al. Aldosterone
excretion rate and blood pressure in essential hypertension are related to polymorphic differences in the aldosterone synthase gene CYP11B2. Hypertension 1999; 33:
703–707.
63 Kupari M, Hautanen A, Lankinen L et al. Association
between human aldosterone synthase (CYP11B2) gene
polymorphisms and left ventricular size, mass and function. Circulation 1998; 97: 569–575.
64 Ranade K, Wu KD, Risch N et al. Genetic variation in
aldosterone synthase predicts plasma glucose levels.
Proc Natl Acad Sci USA 2001; 98: 13219–13224.
65 Sato A, Suzuki Y, Saruta T. Effects of spironolactone and
angiotensin-converting enzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension. Hypertens Res 1999; 22: 17–22.
66 Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with
severe heart failure. Randomized Aldactone Evaluation
Study Investigators. N Engl J Med 1999; 341: 709–717.
67 Deaton MA, Glorioso JE, McLean DB. Congenital
adrenal hyperplasia: Not really a zebra. Am Fam Physician 1999; 59: 1190–1199.
68 Joehrer K, Geley S, Strasser-Wozak EM et al. CYP11B1
mutations causing non-classic adrenal hyperplasia due
to 11 beta-hydroxylase deficiency. Hum Mol Genet 1997;
6: 1829–1834.
69 Sahin Y, Kalestimur F. The frequency of late-onset
21-hydroxylase and 11 beta-hydroxylase deficiency in
women with polycystic ovarian syndrome. Eur J Endocrinol 1997; 137: 670–674.
70 Geley S, Kapelari K, Johrer K et al. CYP11B1 mutations
causing congenital adrenal hyperplasia due to 11 betahydroxylase deficiency. J Clin Endocrinol Metab 1996;
81: 2896–2901.
71 de Simone G, Tommaselli AP, Rossi R et al. Partial
deficiency of adrenal 11-hydroxylase. A possible cause
of primary hypertension. Hypertension 1985; 7: 204–
210.
72 Valentino R, Tommaselli AP, Savastano S et al.
Dysregulation of adrenal 11 beta-hydroxylase activity in
hypertensive subjects: usefulness of the ACTH 1–17
stimulation test. Nutr Metab Cardiovasc Dis 1999; 9:
192–195.
73 Lam CW, Arlt W, Chan CK et al. Mutation of Proline
409 to Arginine in the meander region of cytochrome
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
P450c17 causes severe 17-alpha hydroxylase deficiency.
Mol Genet Metab 2001; 72: 254–259.
Auchus RJ. The genetics, pathophysiology and management of human deficiencies of P450c17. Endocrinol
Metab Clin North Am 2001; 30: 101–119.
Connell JM, Kenyon CJ, Ingram M et al. Corticosteroids
in essential hypertension: multiple loci and phenotypic variation. Clin Exp Pharmacol Physiol 1996; 23:
369–374.
Li A, Li KX, Marui S et al. Apparent mineralocorticoid
excess in a Brazilian kindred: Hypertension in the heterozygote state. J Hypertens 1997; 15: 1397–1402.
Ferrari P, Krozowski Z. Role of 11beta-hydroxysteroid
dehydrogenase type 2 in blood pressure regulation.
Kidney Int 2000; 57: 1374–1381.
Lovati E, Ferrari P, Dick B et al. Molecular basis of
human salt sensitivity: the role of the 11beta-hydroxysteroid dehydrogenase type 2. J Clin Endocrinol Metab
1999; 84: 3745–3749.
Pratt JH. Low-renin hypertension: more common than
we think. Cardiol Rev 2000; 8: 202–206.
Brand E, Kato N, Chatelain N et al. Structural analysis
and evaluation of the 11beta-hydroxysteroid dehydrogenase type 2 (11beta-HSD2) gene in human essential
hypertension. J Hypertens 2005; 16: 1627–1633.
Geller DS, Farhi A, Pinkerton N et al. Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science 2000; 289: 119–123.
Auwerx J. PPARγ, the ultimate thrifty gene. Diabetologia
1999; 42: 1033–1049.
Barroso I, Gurnell M, Crowley VE et al. Dominant negative mutations in human PPARgamma associated with
severe insulin resistance, diabetes mellitus and hypertension. Nature 1999; 402: 880–883.
Iijima K, Yoshizumi M, Ako J et al. Expression of peroxisome proliferator-activated receptor gamma (PPARγ)
in rat aortic smooth muscle cells. Biochem Biophys Res
Commun 1998; 247: 353–356.
Kotchen TA. Attenuation of hypertension by insulinsensitizing agents. Hypertension 1996; 28: 219–223.
Disse-Nicodeme S, Achard JM, Desitter I et al. A new
locus on chromosome 12p13.3 for pseudohypoaldosteronism type II, an autosomal form of hypertension.
Am J Hum Genet 2000; 67: 302–310.
O’Shaughnessy KM, Fu B, Johnson A, Gordon RD.
Linkage of Gordon’s syndrome to the long arm of
chromosome 17 in a region recently linked to familial
essential hypertension. J Hum Hypertens 1998; 12:
675–678.
Mansfield TA, Simon DB, Farfel Z et al. Multilocus linkage of familial hyperkalaemia and hypertension, pseudohypoaldosteronism type II, to chromosomes 1q31–42
and 17p11–q21. Nat Genet 1997; 16: 205.
CHAPTER 8
89 Wilson FH, Disse-Nicodeme S, Choate KA et al. Human
hypertension caused by mutations in WNK kinases.
Science 2001; 293: 1107–1112.
90 Xu B, English JM, Wilsbacher JL, Stippec S, Goldsmith
EJ, Cobb MH. WNK1, a novel mammalian serine/
threonine protein kinase lacking the catalytic lysine in
subdomain II. J Biol Chem 2000; 275: 16795–16801.
91 Wilson FH, Kahle KT, Sabath E et al. Molecular pathogenesis of inherited hypertension with hyperkalaemia:
the Na-Cl cotransporter is inhibited by wild-type but
not mutant WNK4. Proc Natl Acad Sci USA 2003; 100:
680–684.
92 Yang CL, Zhu X, Wang Z, Subramanya AR, Ellison DH.
Mechanisms of WNK1 and WNK4 interaction in the
regulation of thiazide-sensitive NaCl cotransport. J Clin
Invest 2005; 115: 1379–1387.
93 Newhouse SJ, Wallace C, Dobson R et al. Haplotypes of
the WNK1 gene associate with blood pressure variation
in severely hypertensive population from the British
Genetics of Hypertension study. Hum Mol Genet 2005;
14: 1805–1814.
94 Turner ST, Schwartz GL, Chapman AB, Boerwinkle E.
WNK1 kinase polymorphism and blood pressure response to a thiazide diuretic. Hypertension 2005; 46:
758–765.
95 Bahring S, Rauch A, Toka O et al. Autosomal dominant
hypertension with type E brachydactyly is caused by
rearrangement on the short arm of chromosome 12.
Hypertension 2004; 43: 471–476.
96 Gong M, Zhang H, Schulz H et al. Genome-wide linkage
reveals a locus for human essential hypertension on
chromosome 12p. Hum Mol Genet 2003; 12: 1273–1277.
97 Stowasser M, Gordon RD. Primary aldosteronism: from
genesis to genetics. Trends Endocrinol Metab 2003; 14:
310–317.
98 Cusi D, Barlassina C, Azzani T et al. Polymorphism of
alpha-adducin and salt sensitivity in patients with essential hypertension. Lancet 1997; 349: 1353–1357.
99 Kamitani A, Wong ZY, Fraser R et al. Human alphaadducin gene, blood pressure, and sodium metabolism.
Hypertension 1998; 32: 138–143.
100 Province MA, Arnett DK, Hunt SC et al. Association
between the alpha-adducin gene and hypertension in
the HyperGEN Study. Am J Hypertens 2000; 13: 710–
718.
101 Bray MS, Li L, Turner ST, Kardia SL, Boerwinkle E.
Association and linkage analysis of the alpha-adducin
gene and blood pressure. Am J Hypertens 2000; 13:
699–703.
102 Schork NJ, Chakravarti A, Thiel B et al. Lack of association between a biallelic polymorphism in the adducin gene and blood pressure in whites and African
Americans. Am J Hypertens 2000; 13: 693–698.
Hypertension 187
103 Kato N, Sugiyama T, Morita H et al. Lack of evidence
for association between the endothelial nitric oxide
synthase gene and hypertension. Hypertension 1999; 33:
933–936.
104 Lacolley P, Gautier S, Poirier O, Pannier B, Cambien F,
Benetos A. Nitric oxide synthase gene polymorphisms,
blood pressure and aortic stiffness in normotensive and
hypertensive subjects. J Hypertens 1998; 16: 31–35.
105 Miyamoto Y, Saito Y, Kajiyama N et al. Endothelial
nitric oxide synthase gene is positively associated with
essential hypertension. Hypertension 1998; 27: 3–8.
106 Svetkey LP, Timmons PZ, Emovon O, Anderson NB,
Preis L, Chen YT. Association of hypertension with
beta2- and alpha2c10-adrenergic receptor genotype.
Hypertension 1996; 27: 1210–1215.
107 Lockette W, Ghosh S, Farrow S et al. Alpha 2-adrenergic
receptor gene polymorphism and hypertension in
blacks. Am J Hypertens 1995; 8: 390–394.
108 Umemura S, Hirawa N, Iwamoto T et al. Association
analysis of restriction fragment length polymorphism
for alpha 2-adrenergic receptor genes in essential hypertension in Japan. Hypertension 1994; 23: 203–206.
109 Fujisawa T, Ikegami H, Yamato E et al. Trp64Arg mutation of beta3-adrenergic receptor in essential hypertension: insulin resistance and the adrenergic system. Am J
Hypertens 1997; 10: 101–105.
110 Bendlova B, Mazura I, Vcelak J et al. Is a mutation of the
beta-3-adrenergic receptor gene related to NIDDM and
juvenile hypertension in the Czech population. Ann NY
Acad Sci 1997; 827: 135–143.
111 Jia H, Hingorani AD, Sharma P et al. Association of
the G(s)alpha gene with essential hypertension and
response to beta-blockade. Hypertension 1999; 4: 8–14.
112 Stevens PA, Brown MJ. Genetic variability of the ET-1
and the ETA receptor genes in essential hypertension.
J Cardiovasc Pharmacol 1995; 26S: S9–S12.
113 Sharma P, Hingorani A, Jia H, Hopper R, Brown MJ.
Quantitative association between a newly identified
molecular variant in the endothelin-2 gene and human
essential hypertension. J Hypertens 1999; 17: 1281–1287.
114 Frossard PM, Lestringant GG, Malloy MJ, Kane JP.
Human renin gene BglI dimorphism associated with
hypertension in two independent populations. Clin
Genet 1999; 56: 428–433.
115 Chiang FT, Hsu KL, Tseng CD, Lo HM, Chern TH,
Tseng YZ. Association of the renin gene polymorphism
with essential hypertension in a Chinese population.
Clin Genet 1997; 51: 370–374.
116 Morris BJ. Insulin receptor gene in hypertension. Clin
Exp Hypertens 1997; 19: 551–565.
117 Cambien F, Ricard S, Troesch A et al. Polymorphisms of
the transforming growth factor-beta 1 gene in relation
to myocardial infarction and blood pressure. The Etude
188 PART II Cardiovascular polygenic disorders
118
119
120
121
122
123
124
125
126
127
128
129
130
131
Cas-Temoin de l’Infarctus du Myocarde (ECTIM)
Study. Hypertension 1996; 28: 881–887.
Li B, Khanna A, Sharma V, Singh T, Suthanthiran M,
August P. TGF-beta1 DNA polymorphisms, protein levels,
and blood pressure. Hypertension 1999; 33: 271–275.
Rutledge DR, Sun Y, Ross EA. Polymorphisms within
the atrial natriuretic peptide gene in essential hypertension. J Hypertens 1995; 13: 953–955.
Kato N, Sugiyama T, Morita H et al. Genetic analysis of
the atrial natriuretic peptide gene in essential hypertension. Clin Sci 2000; 98: 251–258.
Daniel HI, Munroe PB, Kamdar SM et al. The atrial
natriuretic peptide gene and essential hypertension in
African-Caribbeans from St Vincent and the Grenadines. J Hum Hypertens 1997; 11: 113–117.
Wu DA, Bu X, Warden CH et al. Quantitative trait locus
mapping of human blood pressure to a genetic region at
or near the lipoprotein lipase gene locus on chromosome 8p22. J Clin Invest 1996; 97: 2111–2118.
Hunt SC, Province MA, Atwood LD et al. No linkage
of the lipoprotein lipase locus to hypertension in
Caucasians. J Hypertens 1997; 17: 39–43.
Gainer JV, Brown NJ, Bachvarova M et al. Altered frequency of a promoter polymorphism of the kinin B2
receptor gene in hypertensive African-Americans. Am J
Hypertens 2000; 13: 1268–1273.
Mukae S, Aoki S, Itoh S et al. Promoter polymorphism
of the beta2 bradykinin receptor gene is associated with
essential hypertension. Jpn Circ J 1999; 63: 759–762.
Sharma P, Hingorani A, Jia H et al. Positive association
of tyrosine hydroxylase microsatellite marker to essential hypertension. Hypertension 1998; 32: 676–682.
Chiang FT, Chiu KC, Tseng YZ, Lee KC, Chuang LM.
Nucleotide(-258) G-to-A transition variant of the liver
glucokinase gene is associated with essential hypertension. Am J Hypertens 1997; 10: 1049–1052.
Morris BJ, Chambers SM. Hypothesis: glucagon receptor glycine to serine missense mutation contributes to
one in 20 cases of essential hypertension. Clin Exp
Pharmacol Physiol 1996; 23: 1035–1037.
Brand E, Bankir L, Plouin PF, Soubrier F. Glucagon
receptor gene mutation (Gly40Ser) in human essential
hypertension: the PEGASE study. Hypertension 1999;
34: 15–17.
Inoue I, Nakajima T, Williams CS et al. A nucleotide
substitution in the promoter of human angiotensinogen
is associated with essential hypertension and affects
basal transcription in vitro. J Clin Invest 1997; 99:
1786–1797.
Sato N, Katsuya T, Rakugi H et al. Association of variants in critical core promoter element of angiotensinogen gene with increased risk of essential hypertension in
Japanese. Hypertension 1997; 30: 321–325.
132 Kunz R, Kreutz R, Beige J, Distler A, Sharma AM.
Association between angiotensinogen 235T variant and
essential hypertension in whites: a systematic review and
methodological appraisal. Hypertension 1997; 30: 1331–
1337.
133 Staessen JA, Kuznetsova T, Wang JG, Emelianov D,
Vlietinck R, Fagard R. M235T angiotensinogen gene
polymorphism and cardiovascular risk. J Hypertens
1999; 17: 9–17.
134 Niu T, Chen C, Yang J et al. Blood pressure and the
T174M and M235T polymorphisms of the angiotensinogen gene. Ann Epidemiol 1999; 9: 245–253.
135 Rotimi C, Cooper R, Ogunbiyi O et al. Hypertension,
serum angiotensinogen, and molecular variants of the
angiotensinogen gene among Nigerians. Circulation
1997; 95: 2348–2350.
136 Tiret L, Ricard S, Poirier O et al. Genetic variation at the
angiotensinogen locus in relation to high blood pressure and myocardial infarction: the ECTIM study. J
Hypertens 1995; 13: 311–317.
137 Hegele RA, Brunt JH, Connelly PW. A polymorphism of
the angiotensinogen gene associated with variation in
blood pressure in a genetic isolate. Circulation 1994; 90:
2207–2212.
138 Jeunemaitre X, Soubrier F, Kotelevtsev YV et al.
Molecular basis of human hypertension: role of angiotensinogen. Cell 1992; 71: 169–180.
139 Bonnardeaux A, Davies E, Jeunemaitre X et al. Angiotensin II type 1 receptor gene polymorphisms in human
essential hypertension. Hypertension 1994; 24: 63–69.
140 Wang WY, Zee RY, Morris BJ. Association of
angiotensin II type 1 receptor gene polymorphism with
essential hypertension. Clin Genet 1997; 51: 31–34.
141 Schmidt S, Beige J, Walla-Friedel M, Michel MC,
Sharma AM, Ritz E. A polymorphism in the gene for the
angiotensin II type 1 receptor is not associated with
hypertension. J Hypertens 1997; 15: 1385–1388.
142 O’Donnell CJ, Lindpaintner K, Larson MG et al.
Evidence for association and genetic linkage of the
angiotensin-converting enzyme locus and blood pressure in men but not women in the Framingham Heart
Study. Circulation 1998; 97: 1766–1772.
143 Fornage M, Amos CI, Kardia S, Sing CF, Turner ST,
Boerwinkle E. Variation in the region of the
angiotensin-converting enzyme gene influences interindividual differences in blood pressure levels in young
white males. Circulation 1998; 97: 1773–1779.
144 Higaki J, Baba S, Katsuya T et al. Deletion allele of
angiotensin-converting enzyme gene increases risk of
essential hypertension in Japanese men: the Suita Study.
Circulation 2000; 101: 2060–2065.
145 Dudley C, Keavney B, Casadei B, Conway J, Bird R,
Ratcliffe P. Prediction of patient responses to antihyper-
CHAPTER 8
146
147
148
149
150
151
152
153
154
155
156
157
158
159
tensive drugs using genetic polymorphisms: investigation of renin-angiotensin system genes. J Hypertens
1996; 14: 259–262.
Bray MS, Krushkal J, Li L et al. Positional analysis
identifies the beta-2-adrenergic receptor gene as a susceptibility locus for human hypertension. Circulation
2000; 101: 2877–2882.
Cockcroft JR, Gazis AG, Cross DJ et al. Beta(2)-adrenergic receptor polymorphism determines vascular reactivity in humans. Hypertension 2000; 36: 371–375.
Kotanko P, Binder A, Tasker J et al. Essential hypertension in African Caribbeans associates with a variant of
the beta-2-adrenoceptor. Hypertension 1997; 30: 773–
776.
Timmermann B, Mo R, Luft FC et al. Beta-2-adrenoceptor genetic variation is associated with genetic predisposition to essential hypertension: The Bergen Blood
Pressure Study. Kidney Int 1998; 53: 1455–1478.
Jia H, Sharma P, Hopper R, Dickerson C, Lloyd DD,
Brown MJ. Beta2-adrenoceptor gene polymorphisms
and blood pressure variations in East Anglia caucasians.
J Hypertens 2000; 18: 687–693.
Herrmann V, Buscher R, Go MM et al. Beta2-adrenergic
receptor polymorphisms at codon 16, cardiovascular
phenotypes and essential hypertension in whites and
African Americans. J Hypertens 2000; 13: 1021–1026.
Kato N, Sugiyama T, Morita H et al. Association analysis
of beta(2)-adrenergic receptor polymorphisms with
hypertension in Japanese. Hypertension 2001; 37: 286–
292.
Siffert W, Rosskopf D, Siffert G et al. Association of a
human G-protein beta3 subunit variant with hypertension. Nat Genet 1998; 18: 45–48.
Beige J, Hohenbleicher H, Distler A, Sharma AM. GProtein beta3 subunit C825T variant and ambulatory
blood pressure in essential hypertension. Hypertension
1999; 33: 1049–1051.
Brand E, Herrmann SM, Nicaud V et al. The 825C/T
polymorphism of the G-protein subunit beta3 is not
related to hypertension. Hypertension 1999; 33: 1175–
1178.
Ferrandi M, Salardi S, Tripodi G et al. Evidence for an
interaction between adducin and Na-K-ATPase: relation to genetic hypertension. Am J Physiol Hear Circ
Physiol 1999; 277: 338–349.
Manunta P, Cusi D, Barlassina C et al. Alpha-adducin
polymorphisms and renal sodium handling in essential
hypertension patients. Kidney Int 1998; 53: 1471–1478.
Barlassina C, Citterio L, Bernardi L et al. Genetics of
renal mechanisms of primary hypertension: the role of
adducin. J Hypertens 1997; 15: 1567–1571.
Glorioso N, Manunta P, Filigheddu F et al. The role of
alpha-adducin polymorphism in blood pressure and
160
161
162
163
164
165
166
167
168
169
170
171
172
Hypertension 189
sodium handling regulation may not be excluded by
a negative association study. Hypertension 1999; 34:
649–654.
Ishikawa K, Baba S, Katsuya T et al. T+31C polymorphism of angiotensinogen gene and essential hypertension. Hypertension 2001; 37: 281–285.
Walker WG, Whelton PK, Saito H, Russell RP,
Hermann J. Relation between blood pressure and renin,
renin substrate, angiotensin II, aldosterone and urinary
sodium and potassium in 574 ambulatory subjects.
Hypertension 1979; 1: 287–291.
Zhao YY, Zhon J, Narayanan CS, Cui Y, Kumar A. Role
of C/A polymorphism at -20 on the expression of
human angiotensinogen gene. Hypertension 1999; 33:
108–115.
Ishigami T, Tamura K, Fujita T et al. Angiotensinogen
gene polymorphism near transcription start site and
blood pressure: role of a T-to-C transition at intron I.
Hypertension 1999; 34: 430–434.
Paillard F, Chansel D, Brand E et al. Genotype–
phenotype relationships for the renin-angiotensinaldosterone system in a normal population. Hypertension
1999; 34: 423–429.
Nakajima T, Cheng T, Rohrwasser A et al. Functional
analysis of a mutation occurring between the two inframe AUG codons of human angiotensinogen. J Biol
Chem 1999; 274: 35749–35755.
Hunt SC, Cook NR, Oberman A et al. Angiotensinogen
genotype, sodium reduction, weight loss, and prevention of hypertension: trials of hypertension prevention,
phase II. Hypertension 1998; 32: 393–401.
Giner V, Poch E, Bragulat E. Renin-angiotensin genetic
polymorphism and salt sensitivity in essential hypertension. Hypertension 2000; 35: 512.
Schunkert H, Hense HW, Gimenez-Roqueplo AP. The
angiotensinogen T235 variant and the use of antihypertensive drugs in a population based cohort. Hypertension 1997; 29: 628–633.
Hingorani AD, Jia H, Stevens PA, Hopper R, Dickerson
JE, Brown MJ. Renin-angiotensin system gene polymorphisms influence blood pressure and the response to
angiotensin converting enzyme inhibition. J Hypertens
1995; 13: 1602–1609.
Rolfs A, Weber-Rolfs I, Regitz-Zagrosek V, Kallisch H,
Riedel K, Fleck E. Genetic polymorphisms of the
angiotensin II type 1 (AT1) receptor gene. Eur Heart J
1994; 15D: 108–112.
Hilgers KF, Langenfeld MR, Schlaich M, Veelken R,
Schmieder RE. 1166 A/C polymorphism of the
angiotensin II type 1 receptor gene and the response to
short-term infusion of angiotensin II. Circulation 1999;
100: 1394–1399.
Tiret L, Rigat B, Visvikis S et al. Evidence, from
190 PART II Cardiovascular polygenic disorders
173
174
175
176
177
178
179
180
181
182
183
184
combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene
controls plasma ACE levels. Am J Hum Genet 1992; 51:
197–205.
Stavroulakis GA, Makris TK, Krespi PG et al. Predicting
response to chronic antihypertensive treatment with
fosinopril: the role of angiotensin-converting enzyme
gene polymorphism. Cardiovasc Drugs Ther 2000; 14:
427–432.
Ueda S, Meredith PA, Morton JJ, Connell JM, Elliott
HL. ACE (I/D) genotype as a predictor of the magnitude
and duration of the response to an ACE inhibitor drug
(enalaprilat) in humans. Circulation 1998; 98: 2148–
2153.
Ohmichi N, Iwai N, Uchida Y, Shichiri G, Nakamura Y,
Kinoshita M. Relationship between the response to the
angiotensin converting enzyme inhibitor imidapril and
the angiotensin converting enzyme genotype. Am J
Hypertens 1997; 10: 951–955.
Lip GY, Felmeden DC, Li-Saw-Hee FL, Beevers DG.
Hypertensive heart disease. A complex syndrome or a
hypertensive “cardiomyopathy”? Eur Heart J 2000; 21:
1653–1665.
Sun Y, Weber KT. Angiotensin II and aldosterone
receptor binding: response to chronic angiotensin II or
aldosterone adminstration. J Lab Clin Med 1993; 122:
404–411.
Pitt B. Regression of left ventricular hypertrophy in
patients with hypertension: Blockade of the reninangiotensin-aldosterone system. Circulation 1998; 98:
1987–1999.
Schunkert H, Hense HW, Holmer SR et al. Association
between a deletion polymorphism of the angiotensinconverting-enzyme gene and left ventricular hypertrophy. N Engl J Med 1994; 330: 1634–1638.
Lindpainter K, Lee M, Larson MG et al. Absence of association or genetic linkage between the angiotensinconverting enzyme gene and left ventricular mass.
N Engl J Med 1996; 334: 1023–1028.
Kato N, Sugiyama T, Morita H, Kurihara H, Yamori Y,
Yazaki Y. Angiotensinogen gene and essential hypertension in the Japanese: extensive association study and
meta-analysis on six reported studies. J Hypertens 1999;
17: 757–763.
MRC British Genetics of Hypertension Study. Genomewide mapping of human loci for essential hypertension.
Lancet 2003; 361: 2118–2123.
Thiel BA, Chakravarti A, Cooper R et al. A genome-wide
linkage analysis investigating the determinants of blood
pressure in whites and African Americans. Am J Hypertens 2003; 16: 151–153.
Kardia SL, Rozek LS, Krushkal J et al. Genome-wide
linkage analyses for hypertension genes in two ethnically
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
and geographically diverse population. Am J Hypertens
2003; 16: 154–157.
HyperGen Network. A genome-wide affected sibpair
linkage analysis of hypertension: the HyperGen network. Am J Hypertens 2003; 16: 148–150.
Wilk JB, Djousse L, Arnett DK et al. Genome-wide linkage analyses for age at diagnosis of hypertension and
early onset hypertension in the HyperGen study. Am J
Hypertens 2004; 17: 839–844.
Erdine S, Ari O. ESH-ESC Guidelines for the management of hypertension. Herz 2006; 31: 331–338.
Liew CC. Expressed genome molecular signatures of
heart failure. Clin Chem Lab Med 2005; 43: 462–469.
Patino WD, Mian OY, Kang JG et al. Circulating transcriptome reveals markers of atherosclerosis. Proc Natl
Acad Sci USA 2005; 102: 3423–3428.
Ferrari P, Ferrandi M, Torielli L, Tripodi G, Bianchi G.
PST 2238: A new antihypertensive compound that
modulates Na,K-ATPase in genetic hypertension.
J Pharmacol Exp Ther 1999; 288: 1074–1083.
Gonzalez FJ, Skoda RC, Kimura S et al. Characterisation of the common genetic defect in humans deficient
in debrisoquine metabolism. Nature 1988; 331: 442–
446.
Zineh I, Beitelshees AL, Gaedigk A, Walker JR, Pauly
DF. Pharmacokinetics and CYP2D6 genotypes do not
predict metoprolol adverse events or efficacy in hypertension. Clin Pharm Ther 2004; 76: 536–544.
Kirchheiner J, Heesch C, Bauer S et al. Impact of the
ultrarapid metabolizer genotype of cytochrome P450
2D6 on metoprolol pharmacokinetics and pharmacodynamics. Clin Pharm Ther 2004; 76: 302–312.
Weinshilboum RM. Human pharmacogenetics of
methyl comjugation. Fed Proc 1984; 43: 2303–2307.
West WL, Knight EM, Pradhan S, Hinds TS. Interpatient variability: Genetic predisposition and other
genetic factors. J Clin Pharm 1997; 37: 635–648.
Mellen PB, Herrington DM. Pharmacogenomics of
blood pressure response to antihypertensive treatment.
J Hypertens 2005; 23: 1311–1325.
Koopmans RP, Insel PA, Michel MC. Pharmacogenetics
of hypertension treatment: a structured review. Pharmacogenetics 2003; 13: 705–713.
Phillips MI, Mohuczy-Dominiak D, Coffey M et al.
Prolonged reduction of high blood pressure with an
in vivo, nonpathogenic, adeno-associated viral vector
delivery of AT1-mRNA antisense. Hypertension 1997;
29: 374–380.
Galli SM, Phillips MI. Angiotensin II AT receptor antisense lowers blood pressure in acute 2 kidney, 1-clip
hypertension. Hypertension 2001; 38: 674–678.
Dobrzynski E, Yoshida H, Chao J, Chao L. Adenovirusmediated kallikrein gene delivery attenuates hyperten-
CHAPTER 8
201
202
203
204
205
206
207
208
209
210
sion and protects against renal injury in deoxycorticosterone-salt rats. Immunopharmacology 1999; 44: 57–65.
Xia CF, Beldsoe G, Chao L, Chao J. Kallikrein gene
transfer reduces renal fibrosis, hypertrophy and proliferation in DOCA-salt hypertensive rats. Am J Physiol
Renal Physiol 2005; 289: F622–F631.
Dobrzynski E, Wang C, Chao J, Chao L. Adrenomedullin. gene delivery attenuates hypertension,
cardiac remodelling, and renal injury in deoxycorticosterone acetate-salt hypertensive rats. Hypertension
2000; 36: 995–1001.
Schillinger KJ, Tsai SY, Taffet GE et al. Regulatable atrial
natriuretic peptide gene therapy for hypertension. Proc
Natl Acad Sci USA 2005; 102: 13789–13794.
Landa MS, Garcia SI, Liberjen L et al. Parathyroid
hormone-related protein overexpression decreases
blood pressure in spontaneously hypertensive rats. Clin
Exp Hypertens 2005; 27: 343–354.
Tiret L, Blanc H, Ruidavets JB et al. Gene polymorphisms of the renin-angiotensin system in relation to
hypertension and parental history of myocardial infarction and stroke: the PEGASE study. Projet d’Etude des
Genes de l’Hypertension Arterielle Severe a moderee
Essentielle. J Hypertens 1998; 16: 37–44.
Wang JG, Staessen JA, Barlassina C et al. Association
between hypertension and variation in the alpha- and
beta-adducin genes in a white population. Kidney Int
2002; 62: 2152–2159.
Agarwal AK, Giachetti G, Lavery G et al. CA-repeat
polymorphism in intron 1 of HSD11B2: effects on gene
expression and salt sensitivity. Hypertension 2000; 36:
187–194.
Izawa H, Yamada Y, Okada T et al. Prediction of genetic
risk for hypertension. Hypertension 2003; 41: 1035–
1040.
Thomas GN, Tomlinson B, Critchley JA. Modulation of
blood pressure and obesity with the dopamine D2
receptor gene TaqI polymorphism. Hypertension 2000;
36: 177–182.
Nakayama T, Soma M, Mizutani Y et al. A novel missense mutation of exon 3 in the type A human natri-
211
212
213
214
215
216
217
218
219
Hypertension 191
uretic peptide receptor gene: possible association with
essential hypertension. Hypertens Res 2002; 25: 395–401.
Rehemudula D, Nakayama T, Soma M et al. Structure of
the type B human natriuretic peptide receptor gene and
association of a novel microsatellite polymorphism with
essential hypertension. Circ Res 1999; 84: 605–610.
Kokubo Y, Kamide K, Inamoto N et al. Identification of
108 SNPs in TSC, WNK1 and WNK4 and their association with hypertension in a japanese general population. J Hum Genet 2004; 49: 507–515.
Makino N, Sugano M, Ohtsuka S, Sawada S. Intravenous injection with antisense oligonucleotides against
angiotensinogen decreases blood pressure in spontaneously hypertensive rats. Hypertension 1998; 31: 1166–
1170.
Zhang YC, Bui JD, Shen L, Phillips MI. Antisense inhibition of beta-1-adrenergic receptor mRNA in a single
dose produces a profound and prolonged reduction in
high blood pressure in spontaneously hypertensive rats.
Circulation 2000; 101: 682–688.
Suzuki S, Pilowsky P, Minson J et al. c-fos antisense in
rostral ventral medulla reduces arterial blood pressure.
Am J Physiol 1994; 266: R1418–R1422.
Wang MH, Zhang F, Marji J et al. CYP4A1 antisense
oligonucleotide reduces mesenteric vascular reactivity
and blood pressure in SHR. Am J Physiol Regul Integr
Comp Physiol 2001; 280: R255–R261.
Garcia SI, Alvarez AL, Porto PI, Garfunkel VM,
Finkielman S, Pirola CJ. Antisense inhibition of thyrotropin-releasing hormone reduces arterial blood pressure
in spontaneously hypertensive rats. Hypertension 2001;
37: 365–70.
Suzuki S, Pilowsky P, Minson J, Arnolda L, LlewellynSmith I, Chalmers J. Antisense to thyrotropin releasing
hormone receptor reduces arterial blood pressure in
spontaneously hypertensive rats. Circ Res 1995; 77:
679–683.
Hayashi I, Majima M, Fujita T et al. In vivo transfer
of antisense oligonucleotide against urinary kininase
blunts deoxycortisterone active-salt hypertension in
rats. Br J Pharmacol 2000; 131: 820–826.
III Therapies and
PART III
applications
Pedigree
I
II
III
IV
male
Female
Heredity
External
RNA
Microarray
Blood
Internal
9
CHAPTER 9
Gene therapy for cardiovascular
disease: inserting new genes,
regulating the expression of
native genes, and correcting
genetic defects
Ion S. Jovin, MD & Frank J. Giordano, MD
Introduction
Gene delivery
Genes are the blueprints that tell cells how to build
specific proteins. Thus, the ultimate goal of all gene
therapy is to either replace a defective or missing
protein, or to alter the amount of one or more specific proteins produced by a cell. Despite this convergence of purpose, the manner in which genes
accomplish this can be quite diverse and complex.
When “gene therapy” was first conceived it was envisioned primarily as a treatment for hereditary diseases caused by a missing or defective gene [1–3].
The missing gene would be “replaced” with exogenous DNA encoding a copy of the normal gene. Since
then, the definition has expanded considerably and
now encompasses a formidable array of new technology, including novel approaches to turn on or
off a patient’s own genes, and methods to repair an
individual’s own defective DNA within a chromosome [4–6]. This chapter tours the various aspects of
gene therapy and discuss how they may be applied
to cardiovascular diseases. We begin, however, by
laying a foundation of fundamental concepts relevant to gene therapy, including discussions of:
1 How therapeutic genes can be delivered into cells
and tissues;
2 Factors that determine how long a therapeutic
gene is expressed; and
3 Potential dangers of gene therapy.
Methods to deliver genes to cells, tissues, and
organs can be broadly categorized as either viral or
nonviral [7–9]. Viral methods of gene delivery
depend upon the use of viral vectors. These are naturally occurring viruses that have been altered such
that they are “defective” and can no longer either
cause disease or replicate themselves. This generally
involves the deletion of genetic material from the
virus that is required by the virus for its normal
replication cycle. Deletion of this genetic material
also makes space available within the capsid of the
virus for the inclusion of therapeutic genes. The
success of this approach requires that the virus
retain the ability to enter cells and carry the genetic
information it contains to the nucleus. Several
viruses have been altered in this manner (see Fig.
9.1 for depiction of general scheme). The most
widely used of these viral vectors include adenovirus, retrovirus, lentivirus and adeno-associated
virus vectors [10–16]. Each of these has unique
properties, advantages and limitations that are discussed below and summarized in Table 9.1.
Adenovirus vectors
Adenovirus vectors have been the most commonly
used viral vectors for clinical trials of gene therapy
for cardiovascular disease [17–19]. Adenoviruses
195
196 PART III Therapies and applications
Viral genome
VG1
VG2
Wild-type virus
VG3
VG4
VG5–7
1. Deletion of essential viral gene(s) (VG1–2)
VG3
VG4
VG5–7
TG
2. Insertion of therapeutic gene (TG)
TG
VG3
VG2
VG5–7
4. Deliver viral vector to target cells,
organ, or tissue (because VG1–2 are
not expressed in these cells and
tissues the virus in nonreplicative)
3. Replicate viral vector in
specialized cells into which the
deleted genes have been inserted
VG1
VG4
Viral vector
containing TG
Figure 9.1 General scheme for the construction and
production of viral gene therapy vectors. Although many
different naturally occurring (wild-type) viruses have been
used to make gene therapy vectors to carry therapeutic
genes into cells and tissues, the general scheme for
engineering these vectors is based on a common principle.
Essential viral genes (VG) are deleted from the wild-type
virus genome, rendering the virus nonreplicating and
incapable of causing human disease (1). This also creates
space within the viral genome to insert foreign genetic
material, such as a therapeutic gene (TG; 2). Once the
therapeutic gene is inserted the viral vector is replicated
in specialized cells that express the essential wild-type viral
genes that are required by the virus (3). After purification
steps the viral vector is introduced into targeted cells,
organs or tissues into which it carries the TG (4). These
normal human cells do not contain the essential viral genes
that are missing from the vector, thus the vector cannot
replicate in these cells. The TG, however, is expressed in
these cells.
are double-stranded DNA viruses that do not insert
into the host cell genome and that can infect nondividing cells, such as cardiac myocytes. The family of
adenoviridae contains over 40 serotypes, including
adenoviruses 2 and 5 which are most commonly
used to produce gene therapy vectors. In humans,
adenoviral infection is associated with conjunctivitis and upper respiratory track infections. Wildtype adenovirus has also been associated with
myocarditis. The “first generation” adenovirus vectors were based on deletion of the E1 gene from the
virus [20]. This gene encodes proteins that are
normally expressed early after the virus enters a
cell, and without which normal replication cannot
occur. In normal human cells these E1 deficient
vectors cannot replicate. To produce adenovirus
vectors for research and clinical use, they must be
replicated in specialized cell lines that provide the
missing E1 gene product.
The advantages of adenovirus vectors include
that they can carry genes into most known cell types
efficiently, they do not insert into the host DNA,
they allow the insertion of relatively large therapeutic genes and are relatively easy to produce at titers
high enough to allow clinical use [21,22]. Their disadvantages include that they can induce a signific-
CHAPTER 9
Gene therapy 197
Table 9.1 Viral vectors used in gene delivery.
Vector
Description
Associated
Advantages
Disadvantages
Relatively easy to produce in high
Inflammatory/immunogenic;
titers; able to transduce most cell
early generation vectors in
types; do not integrate into host
common use mediate only
genome
short term gene expression
Relatively noninflammatory/
More difficult to produce in
human disease
(wild-type virus)
Adenovirus
dsDNA virus;
Upper respiratory
~90 nm diameter infection;
conjunctivitis
Adeno-
ssDNA virus;
associated
~25 nm diameter diseases for AAV-2 immunogenic; small size facilitates
No known human
virus
high titer; require synthesis
egress from blood stream into tissues;
of second DNA strand to
mediates long-term gene expression
express transgene (delay in
without requirement for genomic
expression); small capsid
insertion; current vector of choice for
with limited space for
long-term gene expression in skeletal
genetic material
muscle and heart
Retrovirus
Enveloped
Relatively noninflammatory/
dsRNA virus
immunogenic; mediate long-term
and heritable transgene expression
because of genomic insertion
Lentivirus
Enveloped
Acquired immune
Relatively noninflammatory/
dsRNA virus
deficiency
immunogenic; able to transduce
syndrome (HIV)
nondividing cells; mediate long-term
and heritable transgene expression
because of genomic insertion
ant inflammatory response and generally only allow
for short-term expression of therapeutic genes (e.g.,
days to a few weeks) [23]. Some of these disadvantages may be overcome by the use of advanced generation adenovirus vectors, but these vectors have
not generally been validated clinically. These include
vectors with larger deletions of the viral DNA, the
most extreme example being the “gutless” adenovirus vectors that retain only minimal viral genetic
sequence [22,24]. Adenovirus vectors have been
used clinically to carry angiogenic genes to heart
muscle and skeletal muscle to stimulate the growth
of new blood vessels [17,25–27]. For this application their ability to transduce nondividing cardiac
muscle cells, and the relatively short-term gene
expression they mediate has been advantageous.
Adeno-associated viruses
Adeno-associated viruses (AAV) belong to a subset of Parvoviruses called the Dependoviruses.
They contain single-stranded DNA and are much
smaller than adenoviruses (~95 nm vs. ~25 nm
diameter for adenovirus and AAV, respectively).
AAV-2, the serotype of AAV upon which the first
AAV vectors were based, causes no known human
disease. The life cycle of naturally occurring (wildtype) AAV depends on “helper” viruses to allow
AAV to replicate. Adenovirus or herpes viruses can
each provide this helper function. In the absence
of helper viruses, AAV does not replicate and
can integrate into the host cell genome, although
the efficiency of integration is apparently low.
Interestingly, wild-type AAV has a proclivity to
integrate within a specific region of human chromosome 19. AAV-based vectors generally do not
share this property, and it is generally held that they
do not mediate efficient integration of therapeutic
genes into the host cell DNA [28], although they
can integrate more efficiently at sites of DNA strand
breaks [29].
198 PART III Therapies and applications
Because AAV is a single-stranded DNA virus it
must form a second DNA strand in the cell in order
to replicate or, in the case of gene therapy, to
express a therapeutic gene. This process can be
inefficient in some cells, and thus the full extent of
AAV-mediated gene therapy often takes several
weeks to manifest [30]. This issue may have been
solved, however, with the recent development of
AAV vectors that contain complementary DNA
strands that can assemble into a double-stranded
complex without the requirement for synthesis of a
second strand [31]. The advantages of AAV vectors
are that they transduce nondividing cells (e.g., cardiac muscle), are relatively noninflammatory, can
mediate long-term expression of a therapeutic gene
and are the smallest of the most widely used vectors
(this may provide advantages for gene delivery)
[15,32–34]. That AAV vectors are not efficient at
integrating into the host cell genome is in some
ways an additional advantage. The reason is because this decreases the possibility that during
insertion the new DNA will cause a mutation in the
host genome, a phenomenon known as mutational
mutagenesis [28]. This is discussed in more detail
in the description of retrovirus and lentivirus vectors. The disadvantages of AAV vectors include that
their small viral capsid limits the size of the therapeutic gene that can be inserted into the vector, and
that AAV is more difficult to make in high titer than
adenovirus, although this latter limitation has been
markedly improved [35]. Initially, AAV vectors
were produced using adenovirus to provide the
required adenoviral “helper” function, requiring
removal of the contaminating adenovirus from the
AAV vectors after production. This is no longer
necessary as the essential adenovirus helper genes
required for AAV replication are now known and
can be supplied during AAV vector production
without the need for helper virus. AAV vectors have
been shown capable of long-term high efficiency
gene delivery to the heart, and so have been the
focus of efforts to develop gene-based therapies to
treat heart failure [36,37].
Retrovirus vectors
Retrovirus vectors were one of the earliest vectors to be used for gene therapy [38]. Retroviruses
are enveloped double-stranded RNA viruses that
require a special enzyme, reverse transcriptase, to
make complementary double-stranded DNA from
the viral RNA template [39]. This double-stranded
DNA is flanked by palindromic regions called long
terminal repeats (LTRs) that, in conjunction with
an integrase enzyme and other proteins that form a
“pre-integration complex,” facilitates insertion of
this complementary double-strand DNA into the
host cell genome [40]. Insertion is required for the
expression of the therapeutic gene.
The advantages of retroviral vectors include that
they are capable of carrying therapeutic genes into
stem cells and that they mediate sustained gene
transfer. Once inserted into the host cell genome,
the therapeutic gene will be transferred to the
daughter cells resulting from replication of the host
cell. Thus, after retrovirous-mediated gene delivery
to a hematopoietic stem cell, for example, all the
progeny cells will contain the therapeutic gene over
successive generations. This property of retrovirus
vectors led to their use in treating children with
X-linked severe combined immune deficiency
syndrome (SCIDS-X). The corrective gene was
inserted into bone marrow-derived stem cells with
a retrovirus vector ex-vivo, and the stem cells were
then given back to the children. The results of this
therapy were initially one of the biggest successes in
the field of gene therapy and these children were
able to live normal lives outside of the sterile environments they required prior to gene therapy
[41]. Tragically, several children latter developed
an uncommon T-cell leukemia caused by the activation of a proto-oncogene by the insertion of the
retrovirus [42,43]. This phenomenon of insertional
mutagenesis remains a significant concern of all
gene therapy vectors that integrate randomly into
the host genome (Table 9.1). Thus, the ability to
direct insertion of a therapeutic gene into the host
genome is both an advantageous and disadvantageous property of retroviral vectors.
Other drawbacks of retroviral vectors include
that they cannot transduce nondividing cells, and
their ability to transduce many cell types is limited
unless the vectors are manipulated to change the
character of their envelope proteins (pseudotyping)
[44,45]. Their use in cardiovascular medicine has
been limited, although they have been used in
clinical trials to replace defective low density
lipoprotein (LDL) receptor genes in the liver of
patients with familial hypercholesterolemia [46],
CHAPTER 9
and experimentally for delivering genes to the vessel wall to alter vascular remodeling [47].
Lentiviruses
Lentiviruses are enveloped double-stranded RNA
viruses that, like retroviruses, require reverse transcription of the RNA to DNA, and then insertion
of the double-stranded DNA into the host cell
genome. Unlike retroviruses, however, lentivirus
vectors can transduce nondividing cells and are
thus capable of gene delivery to heart muscle
[11,12,45,48]. Given that these vectors are based
primarily on human, simian or feline immunodeficiency viruses, there has been concern that
recombination could produce wild-type HIV.
There is also concern that interaction of an HIVbased lentiviral vector and wild-type HIV in a cell
could result in a hybrid virus. Finally, lentivirus
vectors, like retrovirus vectors, mediate insertion
into the host genome and thus engender the same
concerns for insertional mutagenesis. These cumulative concerns have led to the development of
newer generations of retrovirus and lentivirus vector systems with modifications to make them safer,
including self-inactivating vectors, and vectors that
do not integrate into the host genome [49,50]. In
fact, a lentivirus vector carrying an antisense gene
against HIV is now in clinical trial in the USA [51].
Nonviral gene delivery
Nonviral gene delivery includes a number of
approaches, most frequently centered on plasmid
DNA [9,52–55]. Plasmids are circularized doublestranded DNA that are best known for carrying
antibiotic resistance genes into bacteria. For gene
therapy an expression cassette encoding the therapeutic gene is inserted into the plasmid, and a large
number of copies of this plasmid are made within
bacteria. After isolation from the bacteria and
purification to remove endotoxin and other contaminating bacterial products the plasmid is ready
for delivery to human cells. Some cells, such as cardiac and skeletal myocytes, are able to efficiently
take up plasmid DNA that is simply injected, in
solution, into the heart or skeletal muscle bed. This
approach has been used frequently in clinical trials
to induce therapeutic blood vessel growth in the
heart or ischemic limbs [55,56]. Other cell types
require additional measures to facilitate plasmid
Gene therapy 199
entry into the cell. These include combining the
plasmid DNA with lipid formulations (lipofection),
polymers (e.g., hydrogels) or precipitates (e.g., calcium phosphate-DNA co-precipitation) to facilitate entry through the cell membrane [9,57,58].
This type of DNA delivery to cells is designated transfection, as opposed to viral transduction of cells.
Other methods of nonviral gene delivery include receptor-mediated endocytosis and a variety
of “mechanical” methods. Receptor-mediated gene
delivery is based upon linking a natural ligand for a
specific cell membrane receptor to DNA encoding
a therapeutic gene [59,60]. Binding of the ligand to
the receptor results in endocytosis of the receptor–
ligand complex, along with the DNA that is
attached to the ligand. An example is the use of
asialoglycoproteins to target gene delivery to the
liver [61]. Mechanical methods include electroporation, ultrasound-mediated gene delivery and
methods based upon altered pressure gradients.
Electroporation is the application of a brief electrical impulse to cells (or tissues) to disrupt the cell
membrane long enough to allow the entry of new
genetic material. It can be performed on cells in
vitro (e.g., stem cells) and on tissues in vivo [62]. It
is a standard method used to deliver genetic material to stem cells, and has been considered for the
delivery of plasmid DNA to skeletal muscle to facilitate therapeutic angiogenesis [63].
Ultrasound-mediated gene delivery is generally
performed in conjunction with lipid “microbubbles” that can be loaded with, or attached to, the
genetic material [64,65]. These microbubbles are
injected into the general circulation and then
destroyed selectively by ultrasound energy applied
directly at the desired site, thus depositing the
genetic material there.
Methods based on altered pressure gradients are
exemplified by retrograde coronary venous delivery
(RCVD), and by a specific method developed to
deliver oligonucleotides to segments of veins used
for coronary artery bypass surgery [66]. RCVD is
predicated on the principle that injecting genes or
drugs retrograde under pressure into the coronary
venous system facilitates the bulk movement of
these agents out of the circulation and into the
myocardium via the postcapillary venules [67]. It
is easier to achieve an effective pressure gradient
across the venules by retrograde perfusion because
200 PART III Therapies and applications
in this manner the resistance vessels (i.e., arterioles)
are bypassed.
Gene delivery considerations
specific to the cardiovascular
system
There are a wide variety of potential cardiovascular
indications for gene therapy. These include treatment of heart failure, ischemic heart and peripheral vascular disease, dyslipidemias, inherited or
acquired genetic diseases such as glycogen or lipid
storage disorders, atherosclerosis, pulmonary hypertension and many others. For each of these there
are unique considerations for how best to deliver
the therapeutic gene, how many cells need to receive the gene and how long it needs to be expressed. A fundamental consideration is whether
the protein encoded by the therapeutic gene is
secreted or retained within the cell in which it was
produced. Secreted proteins produced in a relatively small number of cells can have significant
biologic effects by diffusing into surrounding tissues or by entering the systemic circulation. Gene
therapy involving a gene that encodes a secreted
protein can thus be effective even if a relatively
small number of cells receive the therapeutic gene.
An example is angiogenic gene therapy in which the
therapeutic gene encodes a secreted protein that
promotes the growth of new blood vessels. Conversely, for genes that encode nonsecreted proteins
that function within the cell in which they are produced, a relatively large percentage of cells must
receive the therapeutic gene in order to mediate
a meaningful clinical effect (e.g., genes encoding calcium regulatory proteins such as SERCA2
which influence cardiac contractility). This section
addresses the various routes by which genes can
be delivered to the heart, skeletal muscle and the
vasculature.
Gene delivery to the heart
Gene delivery to the heart can be accomplished
either by the direct intramyocardial injection of
plasmid DNA or viral vectors, or by an intravascular route [19,21,68]. The intramyocardial (IM)
route is efficient and generally reproducible, but
gene delivery is limited to the area into which the
DNA or viral vector is administered. Injection
volumes vary, but generally are in the range of
100–300 µL per site, with a few milliliters maximum
injected into the entire heart. The area of gene
delivery achieved by this method is limited largely
by the relatively small amount of myocardium that
can be infiltrated by this volume. This method,
therefore, delivers genes to a small percentage of the
total cells in the heart. This limited number of cells
may be sufficient, however, to produce a therapeutic effect when the gene product is a secreted
factor that can diffuse to adjacent areas of the
myocardium. This has been the reasoning behind
using IM gene delivery to stimulate angiogenesis in
the heart.
IM gene delivery can be accomplished directly
with a needle and syringe during open chest surgery
with direct visualization of the myocardium, or via
a thoroscopic approach [69–71]. IM injection can
be accomplished percutaneously by specialized
catheters that cross the aortic valve retrograde from
the aorta and allow endocardial/myocardial injection of plasmid DNA, or viral vectors, via a needle
at the end of the catheter [69]. Examples include
the Stiletto catheter (no specialized guidance system; Boston Scientific, Inc.) [72], and the NOGA
system (guided by electromagnetic mapping;
Biosense Webster of J&J, Inc.) [56,73]. Further
enhancements of the IM approach include the
use of polymers or specific carrier peptides to augment delivery, and specialized needles to promote
infiltration of a larger myocardial area.
The intravascular route for gene delivery to the
heart is theoretically the most effective route to
introduce a therapeutic gene to the largest number
of cardiac muscle cells. This is because there is generally at least one capillary per cardiac myocyte.
The caveat to this is that the endothelium of the
coronary microvasculature is a continuous endothelium that rivals the cerebral microcirculation in
its barrier function. Macromolecules, like viral vectors, have limited ability to traverse coronary capillaries and venules to gain access to the myocardium
[74,75]. This issue became particularly relevant in
recent clinical efforts to stimulate therapeutic
blood vessel growth in the hearts of patients with
severe ischemic heart disease. These clinical trials
were based on an experimental study of intracoronary (IC) infusion of adenovirus in a pig model of
myocardial ischemia. This study demonstrated that
CHAPTER 9
IC delivery of adenovirus encoding the angiogenic
gene FGF-5 relieved ischemia by stimulating new
blood vessel growth (therapeutic angiogenesis)
[21]. On the basis of these data and confirmatory
animal studies Phase I and II clinical trials were performed in patients with advanced ischemic heart
disease [17,26]. Although the approach appeared
safe and there was evidence of a biologic signal, the
therapeutic results in patients were significantly less
robust than hoped. In addition, there was an indication of systemic distribution of adenovirus after
IC injection, as evidenced by episodes of elevated
liver transaminases after viral vector delivery to the
coronary circulation. While it is not clear that
inefficient gene delivery to the human heart was
responsible for the disappointing clinical results, it
is now widely accepted that simple IC administration of viral vectors is an inefficient method of gene
delivery to the myocardium.
Nonetheless, IC administration remains the
most promising approach to achieve widespread
therapeutic gene delivery to the heart. Realization
of the full potential of intravascular gene delivery to
the heart and other target organs, however, requires
the development of clinically feasible methods to
overcome the endothelial barrier function of the
microvasculature. Several diverse approaches have
been pursued to accomplish this, including mechanical, pharmacologic and molecular methods.
Mechanical methods include RCVD in which a
catheter is inserted into the coronary sinus of the
heart, a balloon inflated to block venous outflow
from the coronary sinus, and then a solution containing either viral vector or plasmid DNA is
injected under pressure retrograde into the coronary venous system. The theory behind this
approach, as discussed briefly above, is that retrograde delivery in this manner bypasses the coronary resistance vessels (i.e., the arterioles) and thus
efficiently increases the driving pressure across
the coronary venules and capillaries, forcing viral
vector or DNA out of the vasculature and into the
myocardium by bulk flow [67,76].
Other mechanical methods include the slowing
or cessation of coronary flow to increase the dwelltime of the viral vector in the coronary circulation,
or recirculating the vector through the coronary
circulation to increase the time of exposure of the
vasculature to the vector [75,77]. When combined
Gene therapy 201
with pharmacologic agents that increase vascular
permeability (e.g., histamine) these methods can be
very effective, achieving gene delivery to >80% of
the cardiac myocytes in the heart [75,78]. Interestingly, in the setting of acute myocardial infarction (MI) the coronary microvasculature serving
the peri-infarction zone becomes quite hyperpermeable to macromolecules [79]. Viral vectors can
thus be delivered efficiently to the peri-infarction
myocardium by IC infusion into the infarct-related
coronary artery in this setting. This fact may facilitate post-MI gene therapy by IC administration,
and also illustrates how important altering vascular
permeability can be in achieving efficient gene
delivery to the heart by the IC route.
Molecular approaches to increase gene delivery
to the heart are also under development. Many of
these approaches are predicated on the fact that
certain macromolecules can efficiently traverse the
microvascular endothelium, in some cases by using
specific transport pathways. It has recently been
discovered that certain serotypes of AAV (e.g.,
AAV-6, AAV-8 and AAV-9) have a greatly enhanced ability to cross endothelial barriers and
mediate gene delivery to the heart and skeletal
muscle [36,80,81]. It is assumed that this property
is a result of unique configurations of the capsid
proteins of these AAV serotypes that direct them to
cross biologic barriers via specific molecular transport pathways. This principle is also driving efforts
to engineer capsid mutants in AAV, adenovirus and
other vectors that will facilitate transendothelial
passage of these vectors and allow them to carry
genes efficiently from the blood stream into targeted
organs and tissues [16]. Similarly, this principle is
being applied in attempts to develop nonviral vectors that have the capacity to transport out of the
blood stream and target specific tissues. The ultimate application of this approach would be the
ability to inject viral or nonviral vectors into the
general circulation after which they would “home”
to specific organs and tissues and deliver their
genetic cargoes there exclusively.
Gene delivery to the vasculature
Gene delivery to the vasculature can be directed to
many clinical indications, including the regression
or prevention of atherosclerosis, the inhibition of
vein graft disease, prevention of post intervention
202 PART III Therapies and applications
restenosis, prevention of transplant vasculopathy
and inhibition of vascular inflammation. A variety
of catheter-based methods for delivering genes to
blood vessels have been devised. Only a few representative catheter systems are discussed here.
The simplest catheter system uses two occlusive
balloons, between which are delivery ports through
which viral vectors or DNA–lipid complexes can
be administered [82,83]. The space between the
two balloons is sequestered from blood flow, thus
increasing the duration of contact between the gene
delivery vectors and the vessel wall. As one can
imagine, branching vessels create problems for this
catheter, and the ability of genes to penetrate the
vessel wall and reach the media by this method is
limited.
In an attempt to further increase the delivery of
therapeutic genes into the vessel wall, alternative
catheters were developed that used either porous
balloons or polymer (e.g., hydrogel) coated balloons that decreased the diffusion area from the
catheter to the vessel wall and prolonged contact.
The hydrogel balloon catheter (Boston Scientific,
Inc.) is one example, and was used for a short
period of time to deliver plasmid DNA encoding
VEGF to the wall of arteries to stimulate therapeutic angiogenesis [84,85].
Another type of catheter uses either highpressure fluid jets or fine needles to inject genes
deeper into the vessel wall. There have been many
iterations of this type of device [86–89], although
the safety and efficacy of this approach in atherosclerotic and/or calcified vessel segments remains
unclear.
One of the newest approaches is the use of
transvenous needle catheters that obviate the issue
of atherosclerosis and calcification. These catheters
are directed into the coronary venous system via
the coronary sinus, and then a needle is deployed
through a thin-walled coronary vein, thus allowing
peri-adventitial gene delivery to coronary arteries
[90]. None of these catheter systems has yet
achieved significant clinical use.
A relatively straightforward gene delivery system
predicated on inducing a pressure gradient within
the vessel lumen was used successfully to delivery
decoy oligonucleotides to human vein segments,
ex vivo, which were then used for coronary by
pass surgery [91]. This clinical trial, and the decoy
oligonucleotide therapeutic approach, is discussed
later in this chapter.
Gene delivery to skeletal muscle
Gene delivery to skeletal muscle has been used in
cardiovascular medicine primarily to stimulate
therapeutic angiogenesis in patients with severe
peripheral vascular disease. This has been performed primarily by direct intramuscular injection of plasmid DNA, although adenoviral vectors
have also been used [27,92–94]. Variations of this
approach include the use of specific polymers, electroporation, ultrasound energy, lipid formulations
and specialized needle designs to augment gene
delivery [93,95–98]. More global gene delivery to
skeletal muscle has been achieved with specific
serotypes of AAV vectors, and the use of these vectors is being pursued to treat muscular dystrophy
[36,81,99]. Recently, there has also been experimentation in the use of artificial vascular matrices
generated by culturing vascular cells or progenitor
cells in collagen gels. The cells orient themselves
into a vascular network, and when implanted under
the skin these engineered vascular networks connect to the native circulation [100,101]. By genetically engineering these cells to secrete specific factors
into the blood stream they can be used as finite
molecular factories. There is ongoing research
investigating the ability of these gels to increase
skeletal muscle vascularization in ischemic limbs.
Ex vivo gene delivery
Finally, mention should be made of ex vivo gene
delivery to stem cells and other cell types, with subsequent reintroduction of these cells into the circulation or into a specific organ or tissue. This has
been largely an experimental approach, and has yet
to make it to the clinic in the realm of cardiovascular disease, but it does have significant appeal for
specific conditions. For example, endothelial progenitor cells (EPC) are bone marrow-derived cells
found in the peripheral blood which are thought to
home to areas of angiogenesis and participate in the
formation of new blood vessels [102]. Introducing
an angiogenic gene into EPC and then reinfusing
them might lead to the delivery of the angiogenic
gene to the area of active angiogenesis, augmenting
the process [103]. There are innumerable settings
such as this in which gene delivery to stem cells or
CHAPTER 9
other cell types could be part of a viable therapeutic
strategy [104], including strategies for gene correction [6], discussed below. Current concerns and
limitations to this approach include that some
“stem cells” are more difficult to deliver genes to
than other cell types, and that genetic manipulation
of stem cells carries significant safety concerns,
given the pluripotency of these cells.
Determinants of the duration of
therapeutic gene expression
For some gene therapy applications it is desirable
to maintain the expression of a therapeutic gene
indefinitely. Examples include the replacement of a
defective LDL receptor gene to ensure an enduring
effect on lipid metabolism, or replacement gene
therapy for patients with hemophilia. For other
gene therapy applications, such as the stimulation
of blood vessel growth (therapeutic angiogenesis), it
may be desirable to express the therapeutic gene for
a shorter period of time to avoid deleterious effects
(e.g., formation of hemangiomas).
Several factors contribute to how long a therapeutic gene will be expressed in a host cell:
1 Whether or not the transgene is inserted into the
host cell genome;
2 The susceptibility of the transgene DNA to
degradation by cellular enzymes;
3 The propensity of the gene delivery vector to
elicit an immune response;
4 The propensity for the transgene promoter (activating regulatory sequences) to undergo “silencing”
(e.g., via “chemical alterations” of DNA, such as
DNA methylation); and
5 The immunogenicity of the transgene product.
For long-term “stable” gene expression that will
be transferred to all the progeny of the host cell that
received the therapeutic gene, the best approach is
to use a gene delivery method that results in insertion into the host genome. Retroviral and lentiviral
vectors are well-established gene delivery vehicles
for achieving genomic insertion, albeit with the
potential risk of “insertional mutagenesis,” discussed above and in the section below on potential
dangers associated with gene therapy.
Mammalian cells, and indeed prokaryotic cells,
have evolved mechanisms to eradicate foreign
DNA, including cellular enzymes that degrade DNA
Gene therapy 203
not inserted into the host genome. These represent
a significant barrier against the sustained presence of therapeutic genes that do not undergo
genomic insertion [105]. AAV vectors overcome
this limitation, in part, via the effects of their
inverted terminal repeats (ITRs). ITRs are palindromic sequences located at each end of the linear
DNA of AAV viruses. They are retained in AAV
gene therapy vectors, and flank the therapeutic
genes that have been inserted into these AAV vectors. Although not definitively understood, it is
thought that the ITRs protect the therapeutic DNA
from degradation in the host cell, possibly via the
formation of circular episomal DNA [105,106].
Whatever the mechanism, AAV-mediated gene
transfer into heart and skeletal muscle can mediate
long-term expression of therapeutic genes, and
thus AAV vectors have generated significant interest as vehicles for gene therapy of heart failure
[107,108]. It should be noted that without integration, AAV-mediated gene therapy does not ensure
that the therapeutic gene will be transferred to
progeny cells produced by cell division. Although
this limits the usefulness of AAV gene therapy for
stem cells, it is not a problem for nondividing (or
infrequently dividing) cells such as heart and skeletal muscle.
AAV vectors also have the advantage of being
small (~25 nm in diameter) and relatively nonimmunogenic. Larger nonenveloped viruses, such
as adenoviruses (~90 nm diameter), do elicit an
immune response, and this has led to issues with
inflammation, limited duration of therapeutic
gene expression and potentially problems with redosing (i.e., repeat administration of these vectors)
[109]. The safety issues engendered by this issue
are discussed further below. This dichotomy in
immune responses to adenovirus and AAV correlates with the duration of therapeutic gene expression that they mediate, and thus the applications to
which they are best suited. Adenovirus vectors
mediate limited duration of gene expression (for
first generation adenovirus vectors this is on the
order of 1–3 weeks), and thus are favored for applications such as gene therapy to stimulate angiogenesis. A separate, but related issue is the immune
response, if any, to the protein product of the therapeutic gene. This is a significant consideration when
gene therapy is being used to express a protein that
204 PART III Therapies and applications
is not present at all at baseline, or is significantly
mutated from its normal form. In this setting, tolerance to the normal protein has not been established during development, and thus the body sees
the normal protein as foreign. It is not yet known
how significant a hurdle this issue will be to successful gene therapy, and it is likely that its importance will vary for different genes.
The expression of therapeutic genes is dependent
in part on the regulatory sequences (e.g., promoter
elements) that activate them. The most common
promoter used for gene therapy applications has
been the cytomegalovirus (CMV) promoter. There
are reports that this promoter can become
“silenced” by DNA methylation [110,111]. If this
happens, gene expression will cease irrespective of
the presence of the therapeutic gene. It is possible
that similar events, perhaps directed to the therapeutic gene itself, or other regulatory sequences,
have a significant role in defining the longevity of
therapeutic gene expression in certain situations.
All of these issues are considerations when deciding which gene delivery method, or vector, to use.
Table 9.1 delineates the general longevity of gene
expression, and the inflammation-inducing properties of the most widely used gene delivery vectors.
Gene therapy by controlling a
patient’s own genes
As gene therapy has moved into areas such as therapeutic angiogenesis in which the biology is complex
and the optimal gene or genes to use is not clear, the
possibility of modeling complex biology by regulating the expression of a patient’s own genes has generated significant interest. Efforts to develop this
approach have focused primarily on regulating
the transcription of genes from DNA to mRNA.
We discuss two related methods that are used to
achieve this transcriptional control:
1 The use of known naturally occurring transcription factors; and
2 The de novo engineering of specifically targeted
transcription factors.
To understand these approaches most clearly, it
helps to consider what transcription factors actually are, and how they regulate gene expression.
Although the instruction set for making all of the
proteins required by a particular type of cell is con-
tained within that cell’s DNA, how those instructions are “interpreted” is a crucial determinant of
what a cell will be. Bear in mind that all cells have
the same instruction set, yet some become rod cells
in the retina, some become neurons and others
become heart muscle. In each of these cell types
some genes are active and some are silent. The
manner in which this occurs is complex and
remains incompletely understood. However, it is
known that the configuration of the protein coat of
chromosomal DNA, the chromatin structure, is a
critical control point [112–115]. If the protein coat
around a particular gene is not tightly packed (the
“open” chromatin configuration), the gene is accessible to the “transcription machinery” and more
easily expressed. If tightly packed in a “closed”
chromatin configuration, gene expression is conversely repressed. The chromatin configuration of a
neuron is distinct from that of a cardiac myocyte,
and this contributes significantly in determining
the differences in gene expression that distinguish
these two cell types.
Transcription factors work, in part, by binding
to DNA in the regulatory region of a particular gene
and directing the reconfiguration of the chromatin
at that location [116–118]. “Activating” transcription factors promote a looser chromatin structure, thus allowing access of RNA polymerase and
the rest of the transcriptional machinery to the
gene. They may also participate in the recruitment
of other co-factors that support transcription.
“Repressor” transcription factors, and the cofactors they recruit, induce a more tightly packed
chromatin and thus decrease the transcription of
a particular gene. Transcription factors generally
contain:
1 A DNA binding domain that binds to a specific
DNA sequence; and
2 A functional domain that directs chromatin
reconfiguration, recruits transcription co-factors,
or both.
The biology of transcription factors can be considerably more complex than this, but for purposes of
understanding how they can be used in gene therapy this modular concept is helpful. It is the DNA
sequence to which it is targeted that determines
what gene or genes a particular transcription factor regulates, and the character of its functional
domain that determines the type of regulation. This
CHAPTER 9
Finger 3
Finger 2
(b)
Finger 1
(a)
Gene therapy 205
5′GCAAGCATCGAAGGGCGC
ZFP DNA
binding
‘fingers’
Activation domain
Repression domain
Nuclease
Integrase
CGTTCGTAGCTTCCCGCG5′
Each zinc finger binds three bases on
the sense strand and interacts with a
fourth base on the antisense strand. By
combining multiple fingers longer DNA
sequences can be targeted, potentially
increasing specificity
By fusing the DNA-binding zinc fingers to a functional
domain, ZFPs can be engineered to activate or repress
the expression of specific genes, direct integration into
specific genomic sites, and to create specifically
targeted cuts in the DNA to facilitate the repair of
defective genes
1. Activating the transcription of a specific endogenous gene results in the
expression of all the natural splice variants of that particular gene
2. ZFPs can be engineered to repress the transcription of a chosen gene and
turn off its expression with single-gene specificity
3. When fused to an endonuclease domain ZFPs can be designed to cut DNA
in high specific sites, faciliating the repair of defective genes
4. The ability to engineer ZFPs to bind specific genomic DNA sites with
highly-specificity allows the potential use of engineered ZFPs to direct
gene insertion into safe sites in the genome
Figure 9.2 The modular structure of zinc finger proteins
can be exploited to engineer highly specific transcription
factors or endonucleases. Transcription factors generally
contain a DNA-binding domain that defines what gene(s)
the factor will regulate, and a “functional” domain that
defines what the nature of that regulation will be. Each
“finger” of a zinc finger protein (ZFP) transcription factor
binds a specific 3 base pair (bp) sequence on the sense
strand of the targeted gene (a). By combining multiple
fingers together longer and longer DNA sequences can be
specifically targeted (e.g., a six finger ZFP will target an
18-bp sequence). By genetically fusing this DNA-binding
domain to a specific functional domain (b), the ZFP fingers
can be used to either turn on (activate) gene expression, or
turn off (repress) gene expression. This same DNA-binding
domain can be used to direct other functions such as DNA
cutting (endonuclease function that can be used to repair
defective genes) or site-specific insertion of genetic
material (integrase function).
is illustrated in Fig. 9.2 in the context of zinc finger
proteins.
One reason transcriptional control of endogenous genes has generated significant interest for
gene therapy is that often a particular transcription
factor controls a number of distinct genes that
are all involved in one way or another in the same
biologic process. An example of this is the hypoxia-inducible basic helix-loop-helix transcription
factor HIF-1α. HIF-1α is an interesting transcription factor which regulates the expression of a
broad repertoire of genes involved in angiogenesis,
metabolism, hematopoiesis, apoptosis, inflammation and several other processes [119–122]. Levels
of HIF-1α rise as tissue oxygen tension decreases,
thus HIF-1α levels are elevated during ischemia.
The fact that it is an “upstream” regulator of several
known angiogenic genes and that it may control the
expression of still other unknown angiogenesisassociated genes, has led to clinical testing of HIF1α in patients with ischemic heart and peripheral
vascular disease [123]. In this approach, the gene
encoding HIF-1α is contained within an adenovirus vector, and constitutive expression of HIF1α, independent of tissue oxygen levels, leads to the
expression of multiple genes that are normally activated during hypoxia. It is hoped that this approach
will recapitulate natural biology more effectively
than standard gene therapy that leads to the expression of a single biologically active protein. Whether
this “upstream” approach will prove superior to
standard cDNA-based gene therapy remains unclear
at this point.
The HIF-1α approach is an example of using a
naturally occurring transcription factor to control a
native gene or genes. A potential drawback of using
206 PART III Therapies and applications
endogenous transcription factors in this manner is
that the number of genes they control can be quite
high, thus raising the possibility of undesired biologic effects. HIF-1α, for example, can alter cellular
metabolism and promote erythropoiesis, in addition to stimulating blood vessel growth [4,119–121,
124]. These effects of HIF-1α may actually be
beneficial, but they are nonetheless somewhat “collateral” to the targeted biologic process of angiogenesis. One reason natural transcription factors
regulate a wide repertoire of genes is because they target relatively short DNA sequences that are shared
by multiple genes. This may be the result of coordinated co-evolution of these genes and their regulatory factors, and the ability of a single transcription
factor to regulate the expression of multiple genes is
biologically more efficient than having separate factors for each of tens of thousands individual genes.
Although biologically more efficient, this nonspecificity of native transcription factors can be a
significant limitation for their use as therapeutics.
Zinc finger proteins
A novel way around this limitation is to engineer
unique transcription factors that bind with high
affinity and specificity to a single chosen gene, or a
few biologically related genes [4,125–131]. The
most straightforward way to accomplish this is to
use a naturally occurring DNA binding protein as a
starting point. However, this requires an intricate
knowledge of how the structure of that protein
directs sequence-specific DNA binding. Of all the
known transcription factor classes that could be
used for this purpose, it is the zinc finger protein
backbone that has proven the most useful for retargeting DNA binding and creating novel engineered transcription factors [126,129,132–135]. Zinc
finger proteins (ZFPs) are among the most highly
represented protein motifs encoded in the entire
mammalian genome. Further, the structure of
ZFPs has been solved, and the relationship between
ZFP protein configuration and DNA binding
specificity is now understood well enough to allow
the de novo design and engineering of ZFPs that will
bind virtually any chosen DNA sequence with high
affinity and specificity [4,129,135].
Each “finger” of a ZFP binds a 3 base pair (bp)
DNA sequence in the major groove of DNA. This
property of ZFPs, with certain limitations, allows
for a modular design such that multiple fingers can
be combined to bind specific DNA sequences of
variable lengths (i.e., a three-finger ZFP binds a
9 bp DNA sequence, a six-finger ZFP an 18 bp
sequence). Further, these ZFP fingers can then be
fused to specific “functional” protein domains to
direct a variety of biologic processes. To create, for
example, a novel transcription factor that activates
expression of the native erythropoietin gene, one
would engineer a ZFP DNA-binding domain that
targeted the regulatory region of the erythropoietin
gene, and then link this to a transcription activation
domain (TAD), such as the viral TAD VP16. To
turn off erythropoietin expression one would use a
repression domain, such as the KRAB domain of
the naturally occurring transcription repressor
KOX1, as the functional domain. In fact, the ability
to target ZFP DNA binding very specifically allows
the creation of multiple types of new therapeutic
DNA-binding proteins. The ZFP motif has thus
been exploited successfully to create ZFPs that activate specific native genes, repress specific native
genes and to target specific DNA loci for the correction of deleterious gene mutations [4,6,136,137].
This is shown schematically in Figs 9.2 and 9.3,
and discussed in further detail in the sections below
on splicing, gene correction, angiogenesis, heart
failure and targeted transcriptional repression.
The importance of splicing
The principle of one gene – one protein is not accurate. A single gene can encode many different proteins, either by using alternative transcriptional
start-sites or, more commonly, by alternative splicing. As discussed elsewhere in this book, most genes
contain several exons (the segment of the gene that
encodes protein) and introns (noncoding). Premessenger RNA, the unprocessed RNA produced
initially by transcription, undergoes a process of
splicing in which introns are looped out and the
exons are arranged next to one another. Depending
upon what exons are including in this splicing process, a significant number of highly related but biologically distinct proteins can be produced by a
single gene. The crucial biologic importance of these
diverse splice variants is only recently becoming
fully appreciated [4,138], and it is now recognized
CHAPTER 9
Gene therapy 207
Disease-associated
Point mutation in gene
(a)
Endonuclease
domain
FOK1 FOK1
DNA binding
domain
ZFP-endonucleases
create double-strand
DNA break
(b)
X
X
Small segment of
dsDNA containing
corrected gene repairs
DNA break
(c)
Corrected gene mutation
(d)
Figure 9.3 Correcting gene defects with engineered
endonucleases. Many cardiovascular diseases are caused by
or associated with gene mutations. The ability to engineer
DNA-binding proteins that can bind with high specificity to
targeted DNA sequences allows the creation of enzymes
that will cut DNA at only the point specified. Two separate
DNA-binding proteins are targeted to separate specific
DNA sequences around a point mutation in a defective
gene (a and b). These DNA-binding proteins are fused to
the FOK1 endonuclease domain to create engineered site-
specific DNA-cutting enzymes. FOK1 requires dimerization
with a second FOK1 domain to become functional. Thus,
DNA cutting will not occur unless both engineered
endonucleases bind to their closely separated and unique
targeted sites (b). Creation of a site-specific double-strand
break in the DNA facilitates recruitment of the cellular DNA
repair machinery (b,c). A small double-strand DNA segment
encoding the normal (corrected) gene sequence is provided
during DNA repair, and the repair process results in
incorporation of this corrected gene sequence (c,d).
that defective gene splicing causes several specific
human diseases [139,140].
From a gene therapy perspective, splice variants
have taken on increasing importance. Gene therapy, until recently, primarily involved the delivery
of a single cDNA construct encoding a single splice
variant of a particular gene. For example, the gene
encoding vascular endothelial growth factor A
(VEGF) can produce at least four major VEGF proteins via alterative splicing [138]. Two of these,
VEGF121 and VEGF165, were used separately in
distinct clinical trials to produce therapeutic angiogenesis in the heart [18,69]. The reasoning for using
only one of the major four splice variants included
the assumption that each of these splice variants
could produce near equivalent results. Several lines
of evidence challenge this assumption and strongly
suggest that the angiogenic process mediated by the
combination of all the naturally occurring VEGF
splice variants is distinct and potentially superior to
that produced by a single splice variant. To produce
all the naturally occurring splice variants in their
optimal stoichiometry, however, requires the delivery of a relatively large sequence of DNA that
contains the genetic information for all the splice
variants, or the transcriptional activation of the
endogenous gene in the target cell genome.
The two most feasible current methods for activating the expression of a patient’s own genes, and
thus inducing the expression of all that gene’s splice
variants, are the use of naturally occurring transcription factors, or the engineering of gene specific
transcription factors de novo using the ZFP backbone as discussed above. Each of these approaches
can effectively activate expression of a targeted
endogenous gene but, as also discussed, using naturally occurring transcription factors can lead to
the activation of a significant number of collateral genes, raising concerns of off-target effects.
In the case of VEGF-A, both the ZFP and the
208 PART III Therapies and applications
natural transcription factor (HIF-1α in this case)
approaches have been used experimentally and
clinically to activate the endogenous gene and
induce expression of all the natural VEGF-A splice
variants [4,123,125,141,241,242]. Most interestingly, the experimental studies indicated that
activation of the endogenous VEGF-A gene led to
a biologically distinct angiogenic response in which
the new blood vessels that formed appeared to
be more physiologically mature [4]. Whether this
approach will prove superior in ongoing clinical
studies awaits the completion of these clinical
assessments.
Turning genes ‘off’
In some circumstances reducing the expression of a
particular gene, or its protein product, can be therapeutic. Examples include genes involved in deleterious inflammation, apoptosis, heart failure and
in malignancies genes that promote angiogenesis.
There are several methods available to accomplish
this, including the use of repressor transcription
factors, siRNA, antisense, ribozymes, transcription
decoys and targeted genomic disruption. Each of
these approaches are described briefly here.
siRNA, antisense and ribozymes
The term siRNA refers to small inferring RNA
molecules; double-stranded RNA sequences that
are ~20–25 bp in length. There is a natural mechanism in mammalian cells wherein double-stranded
RNA is recognized as foreign and is targeted for
destruction by the cell. This is termed RNA interference (RNAi) and also results in degradation of
single-stranded RNA that has the same sequence
as the double-stranded RNA. siRNA, although
predicated on much smaller double-stranded RNA
sequences, induces the same process. Using the
siRNA approach therapeutically, siRNA specific for
the mRNA of a targeted gene is introduced into a
cell and induces the cell to degrade the singlestranded mRNA of that particular gene, effectively
reducing the expression of that gene [142–145].
Antisense is a similar approach that generally uses
longer single-stranded nucleic acid sequences designed to hybridize with specific mRNAs in the
cell and prevent the translation of these mRNAs
into protein. This can be accomplished with either
single-stranded DNA or RNA. The DNA is introduced into cells as single-stranded DNA oligonucleotides (relatively short DNA sequences), and
antisense RNA is introduced as the transcriptional
product of an antisense gene (this can be simply
the reversed cDNA for a particular gene that
then encodes a full-length antisense RNA strand)
[146–148]. Ribozymes are catalytic RNA-based
molecules that have the capacity to hybridize to
specific mRNAs and cut them, thus preventing the
translational expression of the gene from which
these mRNAs were transcribed [149].
The net effect of all the above methodologies is to
reduce the amount of a specific protein a cell makes,
without turning off the transcription of the gene
encoding that protein. The newest and potentially
most powerful of these approaches is currently
thought to be the siRNA approach. However, questions remain regarding the specificity of these approaches and safety concerns regarding potential
effects on off-target genes. Of note, all of the above
modalities can be delivered to cells by viral vectors,
by plasmid DNA or in some cases as oligonucleotides.
Targeted transcriptional repression and
targeted genomic disruption
One of the primary mechanisms used by mammalian cells to limit the expression of specific genes
is transcriptional repression mediated by specific
DNA-binding factors [5,150–152]. Most naturally
occurring repressor transcription factors have
effects on multiple genes, and therefore have limited use as therapeutic agents. The ability to engineer highly specific ZFPs has led to the ability to
make, in turn, highly specific repressor transcription factors that work with essentially single gene
specificity [5,150,151]. Currently, this approach
is being used to develop a repressor ZFP that turns
off a major calcium regulatory gene in cardiac
myocytes and thus increases their contractility. The
specificity of this approach makes it applicable to
a wide variety of cardiovascular targets, and this
approach represents a strong rival alternative to
siRNA technology.
Using a similar DNA-targeting approach, ZFPs
can be engineered to bind a specific gene, create a
double-strand break at that point and induce a
frameshift that effectively silences the gene. This
type of approach is heritable and would thus be
CHAPTER 9
passed on to all the progeny cells of the cell harboring the altered gene. If applied to stem cells, for
instance, the silencing of a particular diseaseassociated gene would be maintained in each subsequent generation of cells produced. This type of
approach can also be used for gene correction, and
is discussed further below in that context.
Decoys
Another novel method to decrease gene expression
is by using decoy oligonucleotides [153–156]. An
example of this approach is the use of oligonucleotide decoys that contain DNA-binding sites for
specific essential transcription factors. Naturally
occurring transcription factors recognize and bind
specific DNA sequences that occur in the regulatory
regions of particular genes. When they bind genes
at these specific sites they act in concert with co-factors and the general cellular transcription machinery to turn on (or repress) the expression of these
specific genes. Thus, the levels of specific transcription factors in a cell are a major determinant of
which genes are expressed, and at what level. Decoy
oligonucleotides that contain copies of the specific
binding site for a particular transcription factor can
compete for that transcription factor and thus
reduce its availability to the gene or genes it usually
binds, thus altering their expression. This strategy
was used in clinical trial to prevent vein graft failure
after bypass surgery, and is discussed further in the
section on clinical applications of gene therapy
[157–159].
Gene correction
Many human diseases that directly involve or indirectly affect the cardiovascular system are caused by
single gene mutations. Examples include Marfan’s
syndrome, heart failure caused by mutations in
the gene for phospholamban, long Q-T syndrome,
hemochromatosis, specific dyslipidemias and sickle
cell anemia, among many others. An emerging
approach to treat these types of genetic diseases is
to correct, in situ within the chromosome, the
causative gene defect. For diseases such as sickle cell
anemia, correcting the defective gene in stem cells
could be curative after a single intervention. Several
approaches have been proposed to achieve in situ
gene correction, including the use of triple-helix
Gene therapy 209
forming oligonucleotides (TFOs) [160,161], and
most recently the use of engineered ZFP endonucleases [6].
The triple-helix approach is based on the ability
of specifically targeted TFOs to bind DNA in the
major groove, thus forming triplex DNA. Areas
of triplex formation promote nucleotide excision
repair and can be used to insert corrective DNA
sequences into targeted genes. Several hurdles
remain for the effective use of TFOs in gene correction, however, and to date the efficiency of
gene correction achieved with this approach has
remained low. Conversely, over the past several
years advances in ZFP-based technology has greatly
increased the achievable efficiency of in situ gene
correction. Porteus [162] and Porteus and
Baltimore [163] showed that by designing pairs of
ZFPs that could bind with high affinity to DNA
sequences flanking a specific site in a target gene, it
was possible to specifically direct the cutting of
double-stranded DNA at this site. This was accomplished by fusing the ZFP DNA-binding domains
to the FOK1 endonuclease domain, which effectively created engineered DNA-cutting enzymes.
The FOK1 endonuclease domain must form a
homodimer with another FOK1 domain to be able
to cut DNA. Taking advantage of this, the ZFP gene
correction approach requires that two FOK1 ZFP
endonucleases bind close to one another on the
target gene in order to facilitate dimerization and
DNA cutting. This markedly increases the specificity of the approach in that both ZFP constructs
must bind with high affinity to their target sites in
order for DNA cutting to occur. Once a doublestrand break has been induced, the DNA repair
machinery is attracted to the site and attempts to
repair the break. If at the same time a complementary corrective double-stranded donor DNA oligonucleotide is provided to the cell, this oligo can
recombine with the native gene at the site of the
double-strand break and replace the defective gene
segment. Currently, the efficiency of this approach
in vitro has reached 15–30%, which is orders of
magnitude greater than other approaches and is
high enough to be in the range of required to “cure”
genetic diseases. While there are still several issues
to be addressed, this advancement has raised hopes
that clinically feasible gene correction is within reach
[6]. This approach can also be used to “silence”
210 PART III Therapies and applications
targeted genes by inducing mutations in them.
Figure 9.3 illustrates the use of the ZFP approach
to achieve gene correction and gene silencing.
Potential dangers of gene therapy
Unlike drugs, which have a short and finite duration of action in the body, gene therapy can have
much longer term consequences, especially when
using gene therapy approaches that mediate genomic insertion. Nonetheless, even nonintegrating
gene therapies can cause serious deleterious effects.
Two of the most infamous and tragic outcomes
from gene therapy include the death of a young
man in Pennsylvania who received adenovirusmediated gene therapy to the liver [164,165], and
the development of T-cell leukemia in several
young children who were administered stem cells
from their own bone marrow after these cells had
been genetically altered using retroviral vectors
[43,166]. In the first case, the delivery of a high titer
of adenovirus to the liver resulted in severe liver
inflammation, consequent multiorgan system
failure and death. Although there were additional
contributing factors in this particular case, the
potential for adenovirus vectors to cause serious
inflammation was confirmed by this tragic event.
In the case of the children who developed T-cell
leukemia, this was the first clinical manifestation of
a gene therapy complication that had been a theoretical concern until that time; insertional mutagenesis. As discussed above briefly in the sections on
retroviral and lentiviral vectors, insertional mutagenesis is the process in which a therapeutic gene is
inserted into the host cell genome in a place that
inadvertently alters the expression of an important
gene or genes that are near that site. This includes
the possible activation of proto-oncogenes and the
induction of malignancy. Insertional mutagenesis
is a particular concern when transferring genes to
stem cells. Currently, efforts are underway to
develop vectors that will integrate specifically
in areas of the human genome that do not harbor
sensitive genes.
Other concerns include that the therapeutic gene
will cause undesirable effects. This has been a
concern in the use of gene therapy to stimulate
angiogenesis. Stimulation of angiogenesis can be
deleterious in several settings, including when the
recipient patient has a vascular proliferative retinopathy or an occult malignancy. Thankfully, to
date no clear evidence of a deleterious angiogenic
effect has been observed in any of the clinical trials
of therapeutic angiogenesis that have been performed. Still, the possibility that a therapeutic gene
could have unanticipated and deleterious effects in
patients remains a serious concern that must be
addressed and assessed carefully for each individual
gene therapy application.
Clinical application of gene
therapy to cardiovascular disease
Probably the first attempted cardiovascular application of gene therapy was the use of retroviral
vectors to treat hyperlipidemia brought about by
LDL receptor deficiency [167,168]. Today gene
therapy is well established in cardiac and cardiovascular disease research and several studies testing
the efficacy and safety of various gene therapy
modalities in humans have been reported or are
underway (Table 9.2) [169,170]. The scope of cardiovascular gene therapy clinical targets is quite
broad, and includes the stimulation of blood vessel
growth in ischemic heart and peripheral vascular
disease (therapeutic angiogenesis), treatment of
heart failure, post-MI cardiac repair, atherosclerosis,
restenosis, vein graft disease, myocardial protection, cardiac rhythm disturbances, amongst others.
Angiogenesis
Gene therapy to stimulate blood vessel growth
(angiogenesis and/or arteriogenesis) in the heart
and in the periphery is the cardiovascular application that has been the most visible and intensely
studied, and a relatively large amount of data
regarding the efficacy and safety of this approach
has accumulated [19,171]. Although no significant
safety issues have emerged, the clinical efficacy of
angiogenic gene therapy has been modest at best,
despite the high expectations that marked the initial preclinical and clinical experiences. There has
been much speculation as to why the clinical results
have been less robust than hoped. One of the most
compelling explanations is that the biology of what
controls blood vessel growth is not sufficiently
understood to facilitate an optimal gene therapy
approach. For example, until fairly recently the
CHAPTER 9
Gene therapy 211
Table 9.2 Clinical gene therapy trials in patients with cardiovascular diseases.
Trial/clinical target
Gene
Vector/delivery route
Phase
Patients
Results (controlled
enrolled
trials only)
Therapeutic angiogenesis
Losordo et al. [182]
VEGF165
Naked plasmid/direct myocardial injection
I
5
CAD
Rosengart et al. [70]
VEGF121
Adenovirus/direct myocardial injection
I
21
CAD
Vale et al. [56]
VEGF-2
Naked plasmid/direct myocardial injection
I/II
6
CAD
Rajagopalan et al. [239]
VEGF121
Adenovirus/direct injection into lower
I
5
PVD
extremity muscle
Rajagopalan et al.
Del1
Plasmid-poloxamer/injection into lower
II
PVD
extremity muscle
Negative (? Effect
of poloxamer)
Morishita et al. [92]
HGF
Naked plasmid/injection into lower
PVD
extremity muscle
Sarkar et al. [240]
VEGF165
Naked plasmid/direct myocardial injection
I
7
CAD
Grines et al. [17]
FGF4
Adenovirus/intracoronary infusion
I/II
79
CAD
VEGF-2
Naked plasmid/percutaneous
I/II
16
(AGENT)
Losordo et al. [69]
Equivocal
intramyocardial injection
Grines et al. [26]
Positive
FGF4
Adenovirus/intracoronary infusion
II
52
VEGF165
Adenovirus or plasmid liposomes/to
I/II
103
(AGENT-2)
Hedman et al. [184]
CAD
CAD
Equivocal
(KAT)
CAD
+/− for AdVEGF,
coronary vessel wall after PTCA
negative for
plasmid liposomes
Kastrup et al. [68]
VEGF165
(Euroinject One)
Naked plasmid/percutaneous
II
80
intramyocardial injection
CAD
Equivocal
Prevention of restenosis
Laitinen et al. [82]
VEGF
Restenosis
Plasmid liposome/to coronary vessel
I/II
15
Equivocal
III
3014
Negative
wall after PTCA
Prevention of coronary artery bypass graft failure
Alexander et al. [229]
E2F Decoy
Oligonucleotide E2F decoy delivered
(PREVENT IV) Coronary
to vein graft by pressure at coronary
bypass vein grafts
bypass surgery
CAD, coronary artery disease; FGF, fibroblast growth factor; hVEGF, human vascular endothelial growth factor; mVEGF,
mouse vascular endothelial growth factor; PVD, peripheral vascular disease.
term “angiogenesis” was used to describe the
growth of capillaries and larger vessels. It is now
accepted that “arteriogenesis,” the development of
larger blood vessels of the type that can be seen on
an angiogram “bypassing” occluded vascular segments, is distinct from angiogenesis [172–174]. In
this review the term “angiogenesis” refers to both
types of vascular growth.
Currently, there are hundreds of proteins purported to have a role in regulating blood vessel
growth, and likely many more will be defined as
research continues. The earliest angiogenic gene
therapy approaches were based on the expression
of a single angiogenic growth factor alone, somewhat ignoring the complexity of the biology
[17,18,69,175–177]. Nonetheless, these approaches
212 PART III Therapies and applications
did yield significant biologic results in preclinical
animal models, and there have been indications of
biologic activity and therapeutic effects in patients.
Several representative preclinical and clinical studies, using different genes and different delivery
approaches, are addressed below and in Table 9.2.
The first clinical experience with angiogenic gene
therapy was initiated by Isner et al. [175] who
incorporated plasmid DNA encoding the gene for
VEGF into the hydrogel matrix of a coated balloon
catheter. The balloon was inflated in the femoral
arteries of patients with severe peripheral vascular
disease, resulting in the transfer of the plasmid into
the artery wall where it was taken up and VEGF
expressed. Although safe, Isner et al. quickly determined that more efficient gene delivery, and consequently higher levels of VEGF, could be obtained
by injecting the plasmid DNA directly into the
skeletal muscle of the ischemic limb [178,179].
These initial clinical trials, based on a large body of
preclinical studies in hindlimb ischemia models,
were all Phase I trials without control groups, but
they were critically important in launching the
field, demonstrating safety and provided compelling early evidence that a biologic effect could be
achieved. Since then several clinical trials of gene
therapy for peripheral vascular disease have been
performed, with a number of different genes, including VEGF, fibroblast growth factor 1 (aFGF),
hypoxia-inducible factor 1α (HIF-1α), hepatocyte
growth factor, Del-1 (developmentally regulated
endothelial locus-1), and an engineered transcription factor designed to turn on the endogenous
VEGF gene. To date, no published double-blind
study has shown definitive efficacy in peripheral
vascular disease, but there has been evidence of a
biologic effect in Phase I studies, and the results
from several clinical studies have not yet been publically reported. One exception is the Del-1 trial
that did not reach the pre-determined end-points
for clinical efficacy [93,180].
Angiogenic gene therapy for coronary artery disease has also been the subject of a great deal of preclinical and clinical research. Preclinical studies
with plasmid DNA and adenoviral vectors demonstrated efficacy in porcine models of coronary
ischemia, and paved the way for clinical studies
[18,21,70,181]. In one of the first clinical applications of gene therapy to the heart, Losordo et al.
[182] studied five patients with coronary disease
who did not respond to conventional anti-anginal
therapy and reported that direct intramyocardial
delivery of naked plasmid encoding VEGF165 directly into the myocardium led to a reduction of
anginal symptoms and an improvement in left ventricular function concomitant with reduced ischemia. In the first clinical trial of adenoviral gene
therapy in the heart, Rosengart et al. [70] reported
significant improvement in regional ventricular
function and wall motion in the region of vector
administration after intramyocardial delivery of
adenovirus encoding VEGF121 in patients undergoing conventional coronary artery bypass grafting
compared to patients receiving placebo. Using
catheter-based delivery of naked VEGF165 assisted
by electromechanical NOGA mapping of the left
ventricle in patients with chronic myocardial ischemia, Vale et al. [56] reported significant reductions in the frequency of anginal attacks after gene
delivery in the treated patients compared to patients receiving placebo.
Despite these encouraging early clinical experiences, attempts to validate angiogenic gene therapy in controlled clinical trials have yielded mixed
results. In a placebo-controlled, double blind clinical trial headed by the same group that pioneered
plasmid-based cardiac and peripheral vascular gene
therapy, catheter-mediated intramyocardial injection of plasmid DNA encoding VEGF-2 resulted in
a significant improvement in anginal symptom
class. However, although there were strong trends
towards improvement in exercise capacity and myocardial perfusion, the results for these end-points
did not reach statistical significance [69]. Despite
robust results in the initial proof-of-concept study
[21], three separate clinical trials of intracoronary
infusion of adenovirus encoding FGF-4 yielded
only mixed results [17]. Despite promising trends
toward improvement in exercise performance in
the two smaller FGF-4 studies [17,183], a large
controlled trial of intracoronary Ad-FGF-4 was
stopped early when interim analysis indicated efficacy end-points would not be reached. In a Phase II
trial designed to test the effects of VEGF gene
therapy on restenosis, neither plasmid nor adenovirus-based VEGF165 gene transfer into the wall
of the coronary artery at the time of angioplasty
had any effect on restenosis, but patients receiving
CHAPTER 9
Ad-VEGF165 demonstrated smaller perfusion defects on nuclear scans [184].
The most recently reported trial is the EUROINJECT II trial which compared the effects of intramyocardial plasmid VEGF165 gene transfer with
placebo on myocardial perfusion, left ventricular
function and clinical symptoms. Whereas VEGF
gene transfer did not significantly improve stressinduced myocardial perfusion abnormalities compared to placebo, it did result in improved regional
wall motion, as assessed both by electromechanical mapping (NOGA) and ventriculography,
thus suggesting a favorable anti-ischemic effect
[68]. Other controlled trials are currently in
progress [93].
Although the failure, thus far, to achieve consistent robust results in clinical trials is disappointing,
there have been encouraging indications of biologic
and therapeutic effects, and the concept of angiogenic gene therapy remains highly promising. It is
hoped that as the biology of blood vessel growth
is better understood, more advanced angiogenic
therapies will be devised. The trend in this field has
been toward a greater appreciation of the differences between angiogenesis yielding capillarization
and small vessels, and arteriogenesis yielding larger
vessels such as the collaterals noted on coronary
angiograms. Heil and Schaper [172,173] and Scholz
et al. [174] were the first to investigate the differential biology of these processes, and much work is
currently underway to further delineate this biology. Other advancements in the field have also been
driven by a deeper appreciation of the complex
biology controlling blood vessel growth. Examples
include combining multiple “complementary” genes,
and the use of engineered or endogenous transcription factors that activate the expression of multiple
angiogenic genes or splice variants [125,185]. The
marriage of angiogenic gene therapy with cell therapy using endothelial progenitor cells and other cell
types is also very promising. The field remains
young, and it is likely that many iterations of this
therapeutic approach will be tested prior to achieving optimal clinical results.
Heart failure
Heart failure is another biologically complex and
diverse condition that is nonetheless an extremely
attractive gene therapy target. The prevalence of
Gene therapy 213
heart failure is high and growing. The morbidity
and mortality associated with heart failure rival
malignancies, the costs of treatment are high and
current treatment options have limited efficacy.
Many mechanistic links to heart failure have been
established, including alterations in calcium handling [186–188], desensitization of the contractile
apparatus to calcium [189], adrenergic receptor
downregulation and desensitization [190–192],
increased oxidative stress [193], inflammation,
alterations in the extracellular matrix, and several
others [194–200]. Accordingly, in contrast to the
angiogenesis gene therapy trials where the choice of
target genes was relatively limited, for heart failure
the gamut of potential target genes is virtually
unlimited and ranges from β-adrenergic receptors [201] to various metabolically active proteins
[197], to proteins regulating calcium handling
[202–206]. Despite this plethora of potential target
genes, and experimental studies demonstrating the
ability to augment contractility by gene therapy,
there is to date no published clinical trial on gene
therapy for heart failure. The approaches that are
probably nearest to clinical testing are those directed to either cardiomyocyte calcium handling, or
adrenergic signaling.
To augment contractility by altering calcium
handling, the main targets have been the sarcoplasmic reticulum calcium pump SERCA2, and
phospholamban (PLN), an inhibitor of SERCA2
function. SERCA2 is responsible for uptake of
calcium into the sarcoplasmic reticulum (SR), and
thus is responsible for lowering cytosolic calcium
levels during myocyte relaxation, and loading the
SR with calcium for release during the next excitation–contraction coupling event [202,203,206]. As
such, SERCA2 has crucial effects on both systole
and diastole. Overexpression of SERCA2 in transgenic mice, or as a consequence of gene delivery,
alters cardiac calcium handling and augments contractility [204,206,207]. Abrogating or diminishing PLN expression by gene deletion, antisense or
other approaches also increases cardiac contractility, as does interference of PLN interactions with
SERCA2 by using PLN dominant negative mutants
[78,208–210]. Currently, clinical trials of gene therapy using SERCA2 overexpression, or an engineered
transcription factor that represses PLN expression,
are in the planning stages.
214 PART III Therapies and applications
Strategies targeted to adrenergic signaling include gene therapy to increase adrenergic receptor
number or activity [211–213] and a strategy to
increase cAMP levels via overexpression of adenylate cyclase [214,215]. Adenoviral transduction of a
peptide inhibitor of β-adrenergic receptor kinase 1
(ARK1) was performed in an infarct model of heart
failure in rabbits [216]. Despite unchanged βadrenergic receptor (AR) density or βARK1 levels
in the treated or control groups, a significantly
higher βAR-stimulated adenyl cyclase activity was
found in the treated group compared to the control
group. Adenovirus-mediated intracoronary delivery of the gene encoding β2-AR led to improvements in basal and isoproterenol-stimulated left
ventricle contractility and hemodynamic function in rabbits [211]. Moreover, this approach was
shown to restore β-adrenergic signaling in cardiac
myocytes from failing hearts [217]. Bypassing the
adrenergic receptor and targeting camp levels
directly, overexpression of adenylate cyclase was
also shown capable of augmenting contractility
in vivo [214,215]. Plans are also underway to clinically evaluate this strategy. Ultimately, irrespective of the target gene, one of the most important
determinants of the success of any of these approaches is the ability to achieve gene transfer to
a sufficient number of cardiac muscle cells to alter
contractility.
Cardiac rhythm disturbances
Management of cardiac rhythm disturbances is
now very heavily device oriented. Whereas genetic
manipulation of complex re-entrant arrhythmias
presents challenges that make gene therapy approaches unlikely to become clinically useful in the
near future, there are instances in which gene therapy could very conceivably be used as either an
adjunct to or replacement for device-based therapies [218]. One of the most intriguing is the development of biologic pacemakers. In a pioneering
study by Miake et al. [219], cardiac myocytes were
transduced with a gene encoding the K inward
rectifier channel (Kir) 2.1AAA. This induced the
electrophysiologic properties of cardiac pacemaker
cells into ventricular myocytes in vivo, increasing
their automaticity and resulting in spontaneous
rhythmic electrical activity in the heart. Another
group demonstrated that focal gene therapy-based
expression of β-adrenergic receptors in the atria
increased the heart rates of pigs [220]. Still another
group has shown the feasibility of using hyperpolarization activated cyclic nucleotide-gated potassium
channel 2 (HCN2) gene transfer to create biologic
pacemakers [221]. This group has recently shown
that stem cells can be altered in this manner to produce cells with pacemaker activity [222].
Another arrhythmia related application of gene
therapy in which proof-of-concept has been
demonstrated is rate control for supraventricular
arrhythmias; in particular, atrial fibrillation. In a
porcine model of atrial fibrillation, investigators
used adenovirus vectors to deliver to the AV node a
gene encoding the inhibitory G protein Gαi2. Gene
delivery to the AV node was very efficient and
resulted in increased refractoriness of the node
accompanied by a reduction in ventricular heart
rate [223]. Thus, gene therapy for cardiac rhythm
disturbances is both feasible and attainable using
currently available gene delivery technology. The
fact that a therapeutic effect can be obtained with
focal gene transfer makes this target particularly
appealing. If effective, biologic pacemakers could
have a marked impact on the cost of cardiac care by
reducing the numbers of device implantations.
Myocardial protection
Myocardial protection as a target for gene therapy
has been an appealing concept to reduce necrosis
and apoptosis associated with myocardial infarction, reduce the myocyte loss that is purported to
contribute to the development and progression of
heart failure, and to provide protection to the heart
during cardiac and noncardiac surgery. To date, the
field has concentrated primarily on heart shock
protein genes and antiapoptotic genes. The ability of heart shock protein expression to prevent
myocardial necrosis was definitively demonstrated
in transgenic mice constitutively expressing the
inducible heat shock protein 70 (HSP-70i). In these
mice, expression of HSP-70i reduced experimentally induced infarct size by 40% and preserved
ventricular function [224]. That similar cardioprotective effects could be achieved by a gene
therapy approach was demonstrated by adenovirusmediated gene transfer [225], and by a unique gene
delivery system that efficiently delivered the HSP70
gene to the heart by intracoronary infusion of a
CHAPTER 9
virus–liposome complex (hemagglutinating virus
of Japan; HVJ) [226].
Chatterjee et al. [227] studied the effect of the
antiapoptotic factor Bcl-2 in a rabbit model of
ischemia followed by reperfusion. The experimental group treated with adeno-Bcl-2 was compared
with a control group receiving empty vector adenonull. Animals that received Bcl-2 maintained
higher ejection fractions at 2, 4 and 6 weeks compared to controls. The Bcl-2 group had superior
preservation of LV geometry with less ventricular
dilatation and wall thinning. There was also reduced apoptosis compared to the controls [227].
The serine-threonine kinase Akt is activated by several ligand-receptor systems previously shown to
be cardioprotective. Matsui et al. [228] examined
the effects of a constitutively active mutant of Akt
(myr-Akt) in a rat model of cardiac ischemiareperfusion injury. In vivo gene transfer of myr-Akt
reduced infarct and the number of apoptotic cells.
Ischemia-reperfusion injury decreased regional cardiac wall thickening as well as the maximal rate of
left ventricular pressure rise and fall (+dP/dt and
−dP/dt). Akt activation restored regional wall
thickening and +dP/dt and −dP/dt to levels seen in
sham-operated rats.
These representative studies demonstrate that
cardiac protection can indeed be achieved by gene
transfer. Several major issues remain, however,
prior to bringing this concept to clinical fruition.
One major issue, shared with many other cardiovascular gene therapy targets, is the requirement
for a safe and efficient method of delivering cardioprotective genes to a large enough percentage
of cardiac muscle cells to be clinically meaningful. Another major issue is that of timing.
Conceptually, one would have to know beforehand
when a patient was going to have a major ischemic
event so that gene transfer could be performed preemptively; or one would have to express these cardioprotective genes chronically in the heart so that
they would be there prior to insult. Neither of these
approaches is feasible, and if one knew when precisely a patient would have a major ischemic event
there are numerous established clinical approaches
that could be used to prevent this event. However, there are instances in which pre-emptive gene
therapy-based cardioprotection would be both
feasible and appealing, including cardiac surgery in
Gene therapy 215
high-risk patients (possibly including children with
complex congenital heart disease) and noncardiac
surgery in patients with advanced pre-existing
heart disease.
Gene therapy directed to
atherosclerosis and vascular
remodeling
Gene therapy directed to vascular remodeling has
focused on post intervention restenosis and on prevention of vein graft failure. In an elegant approach
directed to saphenous vein bypass grafts, a oligonucleotide decoy targeting the E2F cell-cycle regulatory pathway was developed to prevent intimal
hyperplasia and accelerated atherosclerosis in these
grafts. In a small Phase I study, the E2F decoy
decreased the cumulative number of graft occlusions, revisions or critical stenoses [91], demonstrating the feasibility and potential efficacy of the
decoy approach. Disappointingly, the results of the
PREVENT IV trial, a larger multicenter randomized trial testing the efficacy of E2F decoy in the prevention of coronary bypass saphenous vein disease,
were negative, showing no advantage of the decoy
over placebo in patients undergoing coronary
artery bypass grafting [229].
Post intervention restenosis has been the type of
vascular remodeling most intensely targeted by
gene therapy. The repertoire of genes, vectors and
approaches investigated has been quite diverse, and
many of these approaches have been successful in
animal models. These include gene therapy
approaches directed to the cell cycle [230,231],
extracellular matrix [232,233], and re-endothelialization [234]. To date, there have been relatively
few clinical trials of gene therapy for restenosis, and
none of these has shown a significant clinical
improvement. On the other hand, drug-eluting
stents have been enormously successful. It would
seem then that restenosis is not a high priority target for gene therapy. It is possible that stents could
be designed that deliver genes to the site of intraarterial deployment and prevent restenosis, and concomitantly thrombosis, and thus have an advantage
over the current iterations of drug eluting stents.
The development of gene therapy for the treatment of atherosclerosis and plaque rupture is
complicated by the fact that atherosclerosis is a
216 PART III Therapies and applications
multifactorial multistep process and that existing
animal models do not faithfully reproduce human
atherosclerosis, including coronary plaque rupture
and local thrombosis. Nonetheless, several potential strategies have been put forth and tested in animal models [202,235–238]. With the tremendous
therapeutic success of statin therapy, and the
potential for various pharmacologic agents now in
the pipeline to have an equal or greater impact, the
impetus for the development of a gene-based therapy for atherosclerosis has probably diminished
somewhat. However, the advent of new gene therapy technologies could revive enthusiasm. For
example, gene-based expression of the Milano
apolipoprotein [237] could be an important strategy for those patients who do not respond to
pharmacologic therapies, or could be used as an
adjunct for patients with advanced atherosclerotic
disease to promote stabilization and regression.
Also, specific genetic mutations that have been
identified as associated with an increased risk of
developing atherosclerosis or plaque rupture could
potentially be targets for gene correction. As with
all other disease processes that have been considered as possible targets for gene therapy, as the
biology of the atherosclerotic process is better
understood, more and more potential gene therapy
targets will likely be identified.
The future
Gene therapy is only just beyond its infancy. The
field has changed dramatically in just the past
decade, and now includes such advanced technologies as targeted correction of genomic DNA mutations, engineered transcription factors to regulate
endogenous gene expression, a diverse array of
technologies to repress or silence the expression
of pathology related genes, and a tremendous
advancement in vectors. Although the clinical studies of gene therapy for cardiovascular disease conducted thus far have generally not yielded robust
therapeutic results, there have been encouraging
evidences of beneficial biologic activity. These can
be taken as encouraging early steps along the way
to the realization of the full potential of genebased therapies, for cardiovascular disease and
other indications.
References
1 Grosshans H. Gene therapy: when a simple concept
meets a complex reality. Review on gene therapy. Funct
Integr Genomics 2000; 1: 142–145.
2 Friedmann T. A brief history of gene therapy. Nat Genet
1992; 2: 93–98.
3 Friedmann T, Roblin R. Gene therapy for human
genetic disease? Science 1972; 175: 949–955.
4 Rebar EJ, Huang Y, Hickey R et al. Induction of angiogenesis in a mouse model using engineered transcription factors. Nat Med 2002; 8: 1427–1432.
5 Snowden AW, Zhang L, Urnov F et al. Repression of
vascular endothelial growth factor A in glioblastoma
cells using engineered zinc finger transcription factors.
Cancer Res 2003; 63: 8968–8976.
6 Urnov FD, Miller JC, Lee YL et al. Highly efficient
endogenous human gene correction using designed
zinc-finger nucleases. Nature 2005; 435: 646–651.
7 Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors for gene therapy. Nat
Rev Genet 2003; 4: 346–358.
8 De Laporte L, Cruz Rea J, Shea LD. Design of modular
non-viral gene therapy vectors. Biomaterials 2006; 27:
947–954.
9 Glover DJ, Lipps HJ, Jans DA. Towards safe, non-viral
therapeutic gene expression in humans. Nat Rev Genet
2005; 6: 299–310.
10 Anderson JL, Hope TJ. Intracellular trafficking of retroviral vectors: obstacles and advances. Gene Ther 2005;
12: 1667–1678.
11 Delenda C. Lentiviral vectors: optimization of packaging, transduction and gene expression. J Gene Med 2004;
6 (Supplement 1): S125–S138.
12 Lever AM, Strappe PM, Zhao J. Lentiviral vectors.
J Biomed Sci 2004; 11: 439–449.
13 Walther W, Stein U. Viral vectors for gene transfer: a
review of their use in the treatment of human diseases.
Drugs 2000; 60: 249–271.
14 Sadeghi H, Hitt MM. Transcriptionally targeted adenovirus vectors. Curr Gene Ther 2005; 5: 411–427.
15 Snyder RO, Francis J. Adeno-associated viral vectors for
clinical gene transfer studies. Curr Gene Ther 2005; 5:
311–321.
16 Choi VW, McCarty DM, Samulski RJ. AAV hybrid
serotypes: improved vectors for gene delivery. Curr
Gene Ther 2005; 5: 299–310.
17 Grines CL, Watkins MW, Helmer G et al. Angiogenic
Gene Therapy (AGENT) trial in patients with stable
angina pectoris. Circulation 2002; 105: 1291–1297.
18 Rosengart TK, Lee LY, Patel SR et al. Six-month assessment of a phase I trial of angiogenic gene therapy for
the treatment of coronary artery disease using direct
CHAPTER 9
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
intramyocardial administration of an adenovirus vector
expressing the VEGF121 cDNA. Ann Surg 1999; 230:
466–470; discussion 470–472.
Yeh JL, Giordano FJ. Gene-based therapeutic angiogenesis. Semin Thorac Cardiovasc Surg 2003; 15: 236–249.
Weitzman MD. Functions of the adenovirus E4 proteins
and their impact on viral vectors. Front Biosci 2005; 10:
1106–1117.
Giordano FJ, Ping P, McKirnan MD et al. Intracoronary
gene transfer of fibroblast growth factor-5 increases
blood flow and contractile function in an ischemic
region of the heart. Nat Med 1996; 2: 534–539.
Imperiale MJ, Kochanek S. Adenovirus vectors: biology,
design, and production. Curr Top Microbiol Immunol
2004; 273: 335–357.
Cotter MJ, Muruve DA. The induction of inflammation
by adenovirus vectors used for gene therapy. Front Biosci
2005; 10: 1098–1105.
Alba R, Bosch A, Chillon M. Gutless adenovirus:
last-generation adenovirus for gene therapy. Gene Ther
2005; 12 (Supplement 1): S18–S27.
Freedman SB. Clinical trials of gene therapy for atherosclerotic cardiovascular disease. Curr Opin Lipidol 2002;
13: 653–661.
Grines CL, Watkins MW, Mahmarian JJ et al. A randomized, double-blind, placebo-controlled trial of
Ad5FGF-4 gene therapy and its effect on myocardial
perfusion in patients with stable angina. J Am Coll
Cardiol 2003; 42: 1339–1347.
Mohler ER 3rd, Rajagopalan S, Olin JW et al.
Adenoviral-mediated gene transfer of vascular endothelial growth factor in critical limb ischemia: safety results
from a phase I trial. Vasc Med 2003; 8: 9–13.
McCarty DM, Young SM Jr, Samulski RJ. Integration of
adeno-associated virus (AAV) and recombinant AAV
vectors. Annu Rev Genet 2004; 38: 819–845.
Miller DG, Petek LM, Russell DW. Adeno-associated
virus vectors integrate at chromosome breakage sites.
Nat Genet 2004; 36: 767–773.
Ferrari FK, Samulski T, Shenk T, Samulski RJ. Secondstrand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors.
J Virol 1996; 70: 3227–3234.
Ren C, Kumar S, Shaw DR, Ponnazhagan S. Genomic
stability of self-complementary adeno-associated virus
2 during early stages of transduction in mouse muscle in
vivo. Hum Gene Ther 2005; 16: 1047–1057.
Blankinship MJ, Gregorevic P, Chamberlain JS. Gene
therapy strategies for duchenne muscular dystrophy
utilizing recombinant adeno-associated virus vectors.
Mol Ther 2006; 13: 241–249.
Zaiss AK, Muruve DA. Immune responses to adeno-associated virus vectors. Curr Gene Ther 2005; 5: 323–331.
Gene therapy 217
34 Flotte TR. Adeno-associated virus-based gene therapy
for inherited disorders. Pediatr Res 2005; 58: 1143–1147.
35 Merten OW, Geny-Fiamma C, Douar AM. Current
issues in adeno-associated viral vector production. Gene
Ther 2005; 12 (Supplement 1): S51–S61.
36 Zhu T, Zhou L, Mori S et al. Sustained whole-body functional rescue in congestive heart failure and muscular
dystrophy hamsters by systemic gene transfer. Circulation 2005; 112: 2650–2659.
37 Melo LG, Agrawal R, Zhang L et al. Gene therapy strategy for long-term myocardial protection using adenoassociated virus-mediated delivery of heme oxygenase
gene. Circulation 2002; 105: 602–607.
38 Barquinero J, Eixarch H, Perez-Melgosa M. Retroviral
vectors: new applications for an old tool. Gene Ther
2004; 11 (Supplement 1): S3–S9.
39 Katz RA, Skalka AM. The retroviral enzymes. Annu Rev
Biochem 1994; 63: 133–173.
40 Varmus H. Retroviruses. Science 1988; 240: 1427–1435.
41 Hacein-Bey-Abina S, Le Deist F, Carlier F et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 2002;
346: 1185–1193.
42 Engel BC, Kohn DB, Podsakoff GM. Update on gene
therapy of inherited immune deficiencies. Curr Opin
Mol Ther 2003; 5: 503–507.
43 Hacein-Bey-Abina S, Von Kalle C, Schmidt M et al.
LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302:
415–419.
44 Emi N, Friedmann T, Yee JK. Pseudotype formation of
murine leukemia virus with the G protein of vesicular
stomatitis virus. J Virol 1991; 65: 1202–1207.
45 Kafri T. Gene delivery by lentivirus vectors an overview.
Methods Mol Biol 2004; 246: 367–390.
46 Grossman M, Rader DJ, Muller DW et al. A pilot study
of ex vivo gene therapy for homozygous familial hypercholesterolaemia. Nat Med 1995; 1: 1148–1154.
47 Zhu NL, Wu L, Liu PX et al. Downregulation of cyclin G1
expression by retrovirus-mediated antisense gene transfer
inhibits vascular smooth muscle cell proliferation and
neointima formation. Circulation 1997; 96: 628–635.
48 Naldini L. Lentiviruses as gene transfer agents for delivery to non-dividing cells. Curr Opin Biotechnol 1998;
9: 457–463.
49 Terskikh AV, Ershler MA, Drize NJ, Nifontova IN,
Chertkov JL. Long-term persistence of a nonintegrated
lentiviral vector in mouse hematopoietic stem cells. Exp
Hematol 2005; 33: 873–882.
50 Cefai D, Simeoni E, Ludunge KM et al. Multiply attenuated, self-inactivating lentiviral vectors efficiently transduce human coronary artery cells in vitro and rat arteries
in vivo. J Mol Cell Cardiol 2005; 38: 333–344.
218 PART III Therapies and applications
51 Morris KV, Rossi JJ. Anti-HIV-1 gene expressing
lentiviral vectors as an adjunctive therapy for HIV-1
infection. Curr HIV Res 2004; 2: 185–191.
52 Tiera MJ, Winnik FO, Fernandes JC. Synthetic and natural polycations for gene therapy: state of the art and
new perspectives. Curr Gene Ther 2006; 6: 59–71.
53 van Drunen S, den Hurk LV. Novel methods for the
non-invasive administration of DNA therapeutics and
vaccines. Curr Drug Deliv 2006; 3: 3–15.
54 Labhasetwar V. Nanotechnology for drug and gene
therapy: the importance of understanding molecular
mechanisms of delivery. Curr Opin Biotechnol 2005; 16:
674–680.
55 Shah PB, Losordo DW. Non-viral vectors for gene
therapy: clinical trials in cardiovascular disease. Adv
Genet 2005; 54: 339–361.
56 Vale PR, Losordo DW, Milliken CE et al. Randomized,
single-blind, placebo-controlled pilot study of catheterbased myocardial gene transfer for therapeutic angiogenesis using left ventricular electromechanical mapping
in patients with chronic myocardial ischemia. Circulation 2001; 103: 2138–2143.
57 Dass CR. Lipoplex-mediated delivery of nucleic acids:
factors affecting in vivo transfection. J Mol Med 2004; 82:
579–591.
58 Kushibiki T, Tabata Y. A new gene delivery system based
on controlled release technology. Curr Drug Deliv 2004;
1: 153–163.
59 Stefanidakis M, Koivunen E. Peptide-mediated delivery
of therapeutic and imaging agents into mammalian
cells. Curr Pharm Des 2004; 10: 3033–3044.
60 Cristiano RJ, Curiel DT. Strategies to accomplish gene
delivery via the receptor-mediated endocytosis pathway. Cancer Gene Ther 1996; 3: 49–57.
61 Kim EM, Jeong HJ, Park IK et al. Asialoglycoprotein
receptor targeted gene delivery using galactosylated
polyethylenimine-graft-poly(ethylene glycol): in vitro
and in vivo studies. J Control Release 2005; 108: 557–567.
62 Jaichandran S, Yap ST, Khoo AB, Ho LP, Tien SL, Kon
OL. In vivo liver electroporation: optimization and
demonstration of therapeutic efficacy. Hum Gene Ther
2006; 17: 362–375.
63 Li S. Electroporation gene therapy: new developments
in vivo and in vitro. Curr Gene Ther 2004; 4: 309–316.
64 Oupicky D, Bisht HS, Manickam DS, Zhou QH.
Stimulus-controlled delivery of drugs and genes. Expert
Opin Drug Deliv 2005; 2: 653–665.
65 Unger EC, Hersh E, Vannan M, McCreery T. Gene
delivery using ultrasound contrast agents. Echocardiography 2001; 18: 355–361.
66 Dillmann WH. Calcium regulatory proteins and their
alteration by transgenic approaches. Am J Cardiol 1999;
83: 89H–91H.
67 Giordano FJ. Retrograde coronary perfusion: a superior
route to deliver therapeutics to the heart? J Am Coll
Cardiol 2003; 42: 1129–1131.
68 Kastrup J, Jorgensen E, Ruck A et al. Direct intramyocardial plasmid vascular endothelial growth
factor-A165 gene therapy in patients with stable severe
angina pectoris A randomized double-blind placebocontrolled study: the Euroinject One trial. J Am Coll
Cardiol 2005; 45: 982–988.
69 Losordo DW, Vale PR, Hendel RC et al. Phase 1/2
placebo-controlled, double-blind, dose-escalating trial
of myocardial vascular endothelial growth factor 2 gene
transfer by catheter delivery in patients with chronic
myocardial ischemia. Circulation 2002; 105: 2012–2018.
70 Rosengart TK, Lee LY, Patel SR et al. Angiogenesis gene
therapy: phase I assessment of direct intramyocardial
administration of an adenovirus vector expressing
VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 1999;
100: 468–474.
71 Reilly JP, Grise MA, Fortuin FD et al. Long-term (2year) clinical events following transthoracic intramyocardial gene transfer of VEGF-2 in no-option patients.
J Interv Cardiol 2005; 18: 27–31.
72 Naimark WA, Lepore JJ, Klugherz BD et al. Adenoviruscatheter compatibility increases gene expression after
delivery to porcine myocardium. Hum Gene Ther 2003;
14: 161–166.
73 Rutanen J, Rissanen TT, Markkanen JE et al. Adenoviral
catheter-mediated intramyocardial gene transfer using
the mature form of vascular endothelial growth factorD induces transmural angiogenesis in porcine heart.
Circulation 2004; 109: 1029–1035.
74 Wright MJ, Wightman LM, Latchman DS, Marber MS.
In vivo myocardial gene transfer: optimization, evaluation and direct comparison of gene transfer vectors.
Basic Res Cardiol 2001; 96: 227–236.
75 Ikeda Y, Gu Y, Iwanaga Y et al. Restoration of deficient
membrane proteins in the cardiomyopathic hamster by
in vivo cardiac gene transfer. Circulation 2002; 105:
502–508.
76 Hou D, Maclaughlin F, Thiesse M et al. Widespread
regional myocardial transfection by plasmid encoding
Del-1 following retrograde coronary venous delivery.
Catheter Cardiovasc Interv 2003; 58: 207–211.
77 Asfour B, Byrne BJ, Baba HA et al. Effective gene transfer in the rat myocardium via adenovirus vectors using a
coronary recirculation model. Thorac Cardiovasc Surg
1999; 47: 311–316.
78 Hoshijima M, Ikeda Y, Iwanaga Y et al. Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo
cardiac rAAV gene delivery. Nat Med 2002; 8: 864–871.
CHAPTER 9
79 Saeed M, van Dijke CF, Mann JS et al. Histologic
confirmation of microvascular hyperpermeability to
macromolecular MR contrast medium in reperfused
myocardial infarction. J Magn Reson Imaging 1998; 8:
561–567.
80 Kawamoto S, Shi Q, Nitta Y, Miyazaki J, Allen MD.
Widespread and early myocardial gene expression by
adeno-associated virus vector type 6 with a beta-actin
hybrid promoter. Mol Ther 2005; 11: 980–985.
81 Wang Z et al. Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat Biotechnol
2005; 23: 321–328.
82 Laitinen M, Hartikainen J, Hiltunen MO et al. Cathetermediated vascular endothelial growth factor gene transfer to human coronary arteries after angioplasty. Hum
Gene Ther 2000; 11: 263–270.
83 Rome JJ, Shayani V, Newman KD et al. Adenoviral
vector-mediated gene transfer into sheep arteries using
a double-balloon catheter. Hum Gene Ther 1994; 5:
1249–1258.
84 Isner JM, Walsh K, Symes J et al. Arterial gene transfer
for therapeutic angiogenesis in patients with peripheral
artery disease. Hum Gene Ther 1996; 7: 959–988.
85 Riessen R, Rahimizadah H, Blessing E et al. Arterial gene
transfer using pure DNA applied directly to a hydrogelcoated angioplasty balloon. Hum Gene Ther 1993; 4:
749–758.
86 Willard JE, Landau C, Glamann DB et al. Genetic
modification of the vessel wall. Comparison of surgical
and catheter-based techniques for delivery of recombinant adenovirus. Circulation 1994; 89: 2190–2197.
87 Enger C, Wolinsky H. Porous balloon catheters. Semin
Interv Cardiol 1996; 1: 28–29.
88 Wolinsky H. Historical perspective. Semin Interv Cardiol 1996; 1: 3–7.
89 Deiner C, Schwimmbeck PL, Koehler IS et al.
Adventitial VEGF(165) gene transfer prevents lumen
loss through induction of positive arterial remodeling
after PTCA in porcine coronary arteries. Atherosclerosis
2006; 189: 123–132.
90 Thompson CA et al. Percutaneous transvenous cellular
cardiomyoplasty. A novel nonsurgical approach for
myocardial cell transplantation. J Am Coll Cardiol 2003;
41: 1964–1971.
91 Mann MJ, Whittemore AD, Donaldson MC et al. Ex vivo
gene therapy of human vascular bypass grafts with E2F
decoy: the PREVENT single-centre, randomised, controlled trial. Lancet 1999; 354: 1493–1498.
92 Morishita R, Aoki M, Hashiya N et al. Safety evaluation
of clinical gene therapy using hepatocyte growth factor
to treat peripheral arterial disease. Hypertension 2004;
44: 203–209.
93 Rajagopalan S, Olin JW, Young S et al. Design of the
94
95
96
97
98
99
100
101
102
103
104
105
106
Gene therapy 219
Del-1 for therapeutic angiogenesis trial (DELTA-1), a
phase II multicenter, double-blind, placebo-controlled
trial of VLTS-589 in subjects with intermittent claudication secondary to peripheral arterial disease. Hum Gene
Ther 2004; 15: 619–624.
Baumgartner I, Pieczek A, Manor O et al. Constitutive
expression of phVEGF165 after intramuscular gene
transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 1998; 97:
1114–1123.
Mir LM, Moller PH, Andre F, Gehl J. Electric pulsemediated gene delivery to various animal tissues. Adv
Genet 2005; 54: 83–114.
Tjelle TE, Salte R, Mathiesen I, Kjeken R. A novel electroporation device for gene delivery in large animals and
humans. Vaccine 2006; 22: 4667–4670.
Dev SB, Dhar D, Krassowska W. Electric field of a sixneedle array electrode used in drug and DNA delivery in
vivo: analytical versus numerical solution. IEEE Trans
Biomed Eng 2003; 50: 1296–1300.
Zhang Q, Wang Z, Ran HX et al. Enhanced gene delivery
into skeletal muscles with ultrasound and microbubble
techniques. Acad Radiol 2006; 13: 363–367.
Cordier L, Hack AA, Scott MO et al. Rescue of skeletal muscles of gamma-sarcoglycan-deficient mice with
adeno-associated virus-mediated gene transfer. Mol
Ther 2000; 1: 119–129.
Schechner JS, Nath AK, Zheng L et al. In vivo formation
of complex microvessels lined by human endothelial
cells in an immunodeficient mouse. Proc Natl Acad Sci
USA 2000; 97: 9191–9196.
Enis DR, Shepherd BR, Wang Y et al. Induction, differentiation, and remodeling of blood vessels after transplantation of Bcl-2-transduced endothelial cells. Proc
Natl Acad Sci USA 2005; 102: 425–430.
Liew A, Barry F, O’Brien T. Endothelial progenitor cells:
diagnostic and therapeutic considerations. Bioessays
2006; 28: 261–270.
Iwaguro H, Asahara T. Endothelial progenitor cell culture and gene transfer. Methods Mol Med 2005; 112:
239–247.
Neff T, Beard BC, Kiem HP. Survival of the fittest: In
vivo selection and stem cell gene therapy. Blood 2006;
107: 1751–1760.
Musatov SA, Scully TA, Dudus L, Fisher KJ. Induction
of circular episomes during rescue and replication of
adeno-associated virus in experimental models of virus
latency. Virology 2000; 275: 411–432.
Duan D, Sharma P, Yang J et al. Circular intermediates
of recombinant adeno-associated virus have defined
structural characteristics responsible for long-term
episomal persistence in muscle tissue. J Virol 1998; 72;
8568–8577.
220 PART III Therapies and applications
107 Flierl A, Chen Y, Coskun PE, Samulski RJ, Wallace DC.
Adeno-associated virus-mediated gene transfer of the
heart/muscle adenine nucleotide translocator (ANT) in
mouse. Gene Ther 2005; 12: 570–578.
108 Bouchard S, MacKenzie TC, Radu AP et al. Long-term
transgene expression in cardiac and skeletal muscle following fetal administration of adenoviral or adeno-associated
viral vectors in mice. J Gene Med 2003; 5: 941–950.
109 Schaack J. Induction and inhibition of innate inflammatory responses by adenovirus early region proteins. Viral
Immunol 2005; 18: 79–88.
110 Loser P, Jennings GS, Strauss M, Sandig V. Reactivation of the previously silenced cytomegalovirus major
immediate-early promoter in the mouse liver: involvement of NF κB. J Virol 1998; 72: 180–190.
111 Krishnan M, Park JM, Cao F et al. Effects of epigenetic
modulation on reporter gene expression: implications
for stem cell imaging. FASEB J 2006; 20: 106–108.
112 Tchurikov NA. Molecular mechanisms of epigenetics.
Biochemistry (Mosc) 2005; 70: 406–423.
113 Roloff TC, Nuber UA. Chromatin, epigenetics and stem
cells. Eur J Cell Biol 2005; 84: 123–135.
114 Cho KS, Elizondo LI, Boerkoel CF. Advances in chromatin remodeling and human disease. Curr Opin Genet
Dev 2004; 14: 308–315.
115 Huang C, Sloan EA, Boerkoel CF. Chromatin remodeling and human disease. Curr Opin Genet Dev 2003; 13:
246–252.
116 Suzuki T, Matsumura T, Nagai R. Transcriptional regulation at the chromatin level in the cardiovasculature
through protein – protein interactions and chemical
modifications. Trends Cardiovasc Med 2005; 15: 125–129.
117 Jackson DA. The amazing complexity of transcription
factories. Brief Funct Genomic Proteomic 2005; 4: 143–
157.
118 Gilbert N, Ramsahoye B. The relationship between
chromatin structure and transcriptional activity in mammalian genomes. Brief Funct Genomic Proteomic 2005; 4:
129–142.
119 Huang Y, Hickey RP, Yeh JL et al. Cardiac myocytespecific HIF-1alpha deletion alters vascularization,
energy availability, calcium flux, and contractility in the
normoxic heart. Faseb J 2004; 18: 1138–1140.
120 Semenza GL. HIF-1, O2, and the 3 PHDs: how animal
cells signal hypoxia to the nucleus. Cell 2001; 107: 1–3.
121 Semenza GL. HIF-1 and mechanisms of hypoxia sensing. Curr Opin Cell Biol 2001; 13: 167–171.
122 Ryan HE, Lo J, Johnson RS. HIF-1 alpha is required for
solid tumor formation and embryonic vascularization.
Embo J 1998; 17: 3005–3015.
123 Genezyme. Genzyme Phase 2 Clinical Trial of HIF-1a
for peripheral vascular disease; Phase 1 clinical trial of
HIF-1a for ischemic heart disease. 2005.
124 Tang N et al. Loss of HIF-1alpha in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary
for tumorigenesis. Cancer Cell 2004; 6: 485–495.
125 Yu J, Lei L, Liang Y et al. An engineered Vegf-activating
zinc finger protein transcription factor improves blood
flow and limb salvage in advanced-age mice. FASEB J
2006; 20: 479–481.
126 Beerli RR, Barbas CF 3rd. Engineering polydactyl zincfinger transcription factors. Nat Biotechnol 2002; 20:
135–141.
127 Jantz D, Amann BT, Gatto GJ Jr, Berg JM. The design of
functional DNA-binding proteins based on zinc finger
domains. Chem Rev 2004; 104: 789–799.
128 Klug A. Zinc finger peptides for the regulation of gene
expression. J Mol Biol 1999; 293: 215–218.
129 Pabo CO, Peisach E, Grant RA. Design and selection of
novel Cys2His2 zinc finger proteins. Annu Rev Biochem
2001; 70: 313–340.
130 Segal DJ, Barbas CF 3rd. Custom DNA-binding proteins
come of age: polydactyl zinc-finger proteins. Curr Opin
Biotechnol 2001; 12: 632–637.
131 Urnov FD, Rebar EJ. Designed transcription factors as
tools for therapeutics and functional genomics. Biochem
Pharmacol 2002; 64: 919–923.
132 Klug A, Rhodes D. Zinc fingers: a novel protein fold for
nucleic acid recognition. Cold Spring Harb Symp Quant
Biol 1987; 52: 473–482.
133 Leon O, Roth M. Zinc fingers: DNA binding and
protein–protein interactions. Biol Res 2000; 33: 21–30.
134 Liu Q, Segal DJ, Ghiara JB, Barbas CF 3rd. Design of
polydactyl zinc-finger proteins for unique addressing
within complex genomes. Proc Natl Acad Sci USA 1997;
94: 5525–5530.
135 Pavletich NP, Pabo CO. Zinc finger-DNA recognition:
crystal structure of a Zif268-DNA complex at 2.1 A.
Science 1991; 252: 809–817.
136 Snowden AW, Gregory PD, Case CC, Pabo CO. Genespecific targeting of H3K9 methylation is sufficient for initiating repression in vivo. Curr Biol 2002; 12: 2159–2166.
137 Wolfe SA, Nekludova L, Pabo CO. DNA recognition by
Cys2His2 zinc finger proteins. Annu Rev Biophys Biomol
Struct 2000; 29: 183–212.
138 Grunstein J, Masbad JJ, Hickey R, Giordano F, Johnson
RS. Isoforms of vascular endothelial growth factor act in
a coordinate fashion To recruit and expand tumor vasculature. Mol Cell Biol 2000; 20: 7282–7291.
139 Nissim-Rafinia M, Kerem B. The splicing machinery is a
genetic modifier of disease severity. Trends Genet 2005;
21: 480–483.
140 Bonne G, Carrier L, Bercovici J et al. Cardiac myosin
binding protein-C gene splice acceptor site mutation is
associated with familial hypertrophic cardiomyopathy.
Nat Genet 1995; 11: 438–440.
CHAPTER 9
141 Elson DA, Thurston G, Huang LE et al. Induction of
hypervascularity without leakage or inflammation in
transgenic mice overexpressing hypoxia-inducible
factor-1alpha. Genes Dev 2001; 15: 2520–2532.
142 Geanacopoulos, M. An introduction to RNA-mediated
gene silencing. Sci Prog 2005; 88: 49–69.
143 Morris KV. siRNA-mediated transcriptional gene silencing: the potential mechanism and a possible role in the
histone code. Cell Mol Life Sci 2005; 62: 3057–3066.
144 Mahy BW. Therapeutic RNA? Rev Med Virol 2005; 15:
349–350.
145 Hammond SM. Dicing and slicing: the core machinery
of the RNA interference pathway. FEBS Lett 2005; 579:
5822–5829.
146 Costa FF. Non-coding RNAs: new players in eukaryotic
biology. Gene 2005; 357: 83–94.
147 Tamm I. Antisense therapy in malignant diseases: status
quo and quo vadis? Clin Sci (Lond) 2006; 110: 427–442.
148 Lu Y. Recent advances in the stereocontrolled synthesis
of antisense phosphorothioates. Mini Rev Med Chem
2006; 6: 319–330.
149 Sioud M, Iversen PO. Ribozymes, DNAzymes and small
interfering RNAs as therapeutics. Curr Drug Targets
2005; 6: 647–653.
150 Reynolds L, Ullman C, Moore M et al. Repression of the
HIV-1 5′ LTR promoter and inhibition of HIV-1 replication by using engineered zinc-finger transcription factors. Proc Natl Acad Sci USA 2003; 100: 1615–1620.
151 Tan S, Guschin D, Davalos A et al. Zinc-finger proteintargeted gene regulation: genomewide single-gene
specificity. Proc Natl Acad Sci USA 2003; 100: 11997–
12002.
152 Backs J, Olson EN. Control of cardiac growth by histone
acetylation/deacetylation. Circ Res 2006; 98: 15–24.
153 Cozzani M, Giovannini I, Naccari R et al. Transcription
factor decoy (TFD) as a novel approach for the control
of osteoclastic resorption. Prog Orthod 2005; 6: 238–247.
154 Da Ros T, Spalluto G, Prato M et al. Oligonucleotides
and oligonucleotide conjugates: a new approach for
cancer treatment. Curr Med Chem 2005; 12: 71–88.
155 Dzau VJ. Transcription factor decoy. Circ Res 2002; 90:
1234–1236.
156 Tomita N, Kim JY, Gibbons GH et al. Gene therapy with
an E2F transcription factor decoy inhibits cell cycle progression in rat anti-Thy 1 glomerulonephritis. Int J Mol
Med 2004; 13: 629–636.
157 Ehsan A, Mann MJ, Dell’Acqua G, Dzau VJ. Long-term
stabilization of vein graft wall architecture and prolonged resistance to experimental atherosclerosis after
E2F decoy oligonucleotide gene therapy. J Thorac
Cardiovasc Surg 2001; 121: 714–722.
158 Ehsan A, Mann MJ, Dell’Acqua G et al. Endothelial healing in vein grafts: proliferative burst unimpaired by
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
Gene therapy 221
genetic therapy of neointimal disease. Circulation 2002;
105: 1686–1692.
Mangi AA, Dzau VJ. Gene therapy for human bypass
grafts. Ann Med 2001; 33: 153–155.
Casey BP, Glazer PM. Gene targeting via triple-helix
formation. Prog Nucleic Acid Res Mol Biol 2001; 67:
163–192.
Seidman MM, Glazer PM. The potential for gene repair
via triple helix formation. J Clin Invest 2003; 112:
487–494.
Porteus MH. Mammalian gene targeting with designed
zinc finger nucleases. Mol Ther 2006; 13: 438–446.
Porteus MH, Baltimore D. Chimeric nucleases stimulate gene targeting in human cells. Science 2003; 300:
763.
Raper SE, Chirmule N, Lee FS et al. Fatal systemic
inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene
transfer. Mol Genet Metab 2003; 80: 148–158.
Carmen IH. A death in the laboratory: the politics of the
Gelsinger aftermath. Mol Ther 2001; 3: 425–428.
McCormack MP, Forster A, Drynan L, Pannell R,
Rabbitts TH. The LMO2 T-cell oncogene is activated via
chromosomal translocations or retroviral insertion during gene therapy but has no mandatory role in normal
T-cell development. Mol Cell Biol 2003; 23: 9003–9013.
Miyanohara A, Sharkey MF, Witztum JL, Steinberg D,
Friedmann T. Efficient expression of retroviral vectortransduced human low density lipoprotein (LDL)
receptor in LDL receptor-deficient rabbit fibroblasts in
vitro. Proc Natl Acad Sci USA 1988; 85: 6538–6542.
Chowdhury JR, Grossman M, Gupta S et al. Long-term
improvement of hypercholesterolemia after ex vivo gene
therapy in LDLR-deficient rabbits. Science 1991; 254:
1802–1805.
Melo LG, Pachori AS, Kong D et al. Gene and cell-based
therapies for heart disease. Faseb J 2004; 18: 648–663.
Quarck R, Holvoet P. Gene therapy approaches for cardiovascular diseases. Curr Gene Ther 2004; 4: 207–223.
Simons M. Angiogenesis: where do we stand now?
Circulation 2005; 111: 1556–1566.
Heil M, Schaper W. Influence of mechanical, cellular,
and molecular factors on collateral artery growth (arteriogenesis). Circ Res 2004; 95: 449–458.
Heil M, Schaper W. Cellular mechanisms of arteriogenesis. Exs 2005; 181–191.
Scholz D, Cai WJ, Schaper W. Arteriogenesis, a new
concept of vascular adaptation in occlusive disease.
Angiogenesis 2001; 4: 247–257.
Isner JM, Pieczek A, Schainfeld R et al. Clinical evidence of angiogenesis after arterial gene transfer of
phVEGF165 in patient with ischaemic limb. Lancet
1996; 348: 370–374.
222 PART III Therapies and applications
176 Kalka C, Masada H, Takahashi T et al. Vascular endothelial growth factor (165) gene transfer augments circulating endothelial progenitor cells in human subjects.
Circ Res 2000; 86: 1198–1202.
177 Simons M et al. Clinical trials in coronary angiogenesis:
issues, problems, consensus: An expert panel summary.
Circulation 2000; 102: E73–E86.
178 Rauh G, Pieczek A, Irwin W, Schainfeld R, Isner JM. In
vivo analysis of intramuscular gene transfer in human
subjects studied by on-line ultrasound imaging. Hum
Gene Ther 2001; 12: 1543–1549.
179 Tsurumi Y, Takeshita S, Chen D et al. Direct intramuscular gene transfer of naked DNA encoding vascular
endothelial growth factor augments collateral development and tissue perfusion. Circulation 1996; 94:
3281–3290.
180 News Release from Valentis, Inc. Valentis Reports
Results in Phase II Clinical Trial of Deltavasc (TM) in
Peripheral Arterial Disease. September 29, 2004. http://
salesandmarketingnetwork.com/news_release.php?ID=
2000806 (last accessed April 2007).
181 Lazarous DF, Shou M, Stiber JA et al. Adenoviral-mediated gene transfer induces sustained pericardial VEGF
expression in dogs: effect on myocardial angiogenesis.
Cardiovasc Res 1999; 44: 294–302.
182 Losordo DW, Vale PR, Symes JF et al. Gene therapy for
myocardial angiogenesis: initial clinical results with
direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 1998; 98:
2800–2804.
183 Grines C, Rubanyi GM, Kleiman NS, Marrott P,
Watkins MW. Angiogenic gene therapy with adenovirus
5 fibroblast growth factor-4 (Ad5FGF-4): a new option
for the treatment of coronary artery disease. Am J
Cardiol 2003; 92: 24N–31N.
184 Hedman M, Hartikainen J, Syvanne M et al. Safety and
feasibility of catheter-based local intracoronary vascular
endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in
the treatment of chronic myocardial ischemia: phase II
results of the Kuopio Angiogenesis Trial (KAT). Circulation 2003; 107: 2677–2683.
185 Dai Q, Huang J, Klitzman B et al. Engineered zinc
finger-activating vascular endothelial growth factor
transcription factor plasmid DNA induces therapeutic
angiogenesis in rabbits with hindlimb ischemia. Circulation 2004; 110: 2467–2475.
186 Babu GJ, Bhupathy P, Petrashevskaya NN et al. Targeted
overexpression of sarcolipin in the mouse heart decreases sarcoplasmic reticulum calcium transport and
cardiac contractility. J Biol Chem 2006; 281: 3972–3979.
187 Marks AR. Cardiac intracellular calcium release channels: role in heart failure. Circ Res 2000; 87: 8–11.
188 Zhao W, Frank KF, Chu G et al. Combined phospholamban ablation and SERCA1a overexpression result in
a new hyperdynamic cardiac state. Cardiovasc Res 2003;
57: 71–81.
189 MacGowan GA. The myofilament force–calcium relationship as a target for positive inotropic therapy in congestive heart failure. Cardiovasc Drugs Ther 2005; 19:
203–210.
190 Perrino C, Naga Prasad SV, Patel M, Wolf MJ, Rockman
HA. Targeted inhibition of beta-adrenergic receptor
kinase-1-associated phosphoinositide-3 kinase activity
preserves beta-adrenergic receptor signaling and prolongs survival in heart failure induced by calsequestrin
overexpression. J Am Coll Cardiol 2005; 45: 1862–1870.
191 Blaxall BC, Spang R, Rockman HA, Koch WJ. Differential myocardial gene expression in the development
and rescue of murine heart failure. Physiol Genomics
2003; 15: 105–114.
192 Koch WJ, Lefkowitz RJ, Rockman HA. Functional consequences of altering myocardial adrenergic receptor
signaling. Annu Rev Physiol 2000; 62; 237–260.
193 Giordano FJ. Oxygen, oxidative stress, hypoxia, and
heart failure. J Clin Invest 2005; 115: 500–508.
194 Kawada T, Masui F, Kumagai H et al. A novel paradigm
for therapeutic basis of advanced heart failure: assessment by gene therapy. Pharmacol Ther 2005; 107: 31–43.
195 Yu X, Burgess SC, Ge H et al. Inhibition of cardiac
lipoprotein utilization by transgenic overexpression of
Angptl4 in the heart. Proc Natl Acad Sci USA 2005; 102:
1767–1772.
196 Chiu HC, Kovacs A, Blanton RM et al. Transgenic expression of fatty acid transport protein 1 in the heart causes
lipotoxic cardiomyopathy. Circ Res 2005; 96: 225–233.
197 Park SY, Cho YR, Finck BN et al. Cardiac-specific overexpression of peroxisome proliferator-activated receptor-alpha causes insulin resistance in heart and liver.
Diabetes 2005; 54: 2514–2524.
198 Leotta E, Patejunas G, Murphy G et al. Gene therapy
with adenovirus-mediated myocardial transfer of vascular endothelial growth factor 121 improves cardiac
performance in a pacing model of congestive heart failure. J Thorac Cardiovasc Surg 2002; 123: 1101–1113.
199 Nayak L, Rosengart TK. Gene therapy for heart failure.
Semin Thorac Cardiovasc Surg 2005; 17: 343–347.
200 Rothermel BA, Vega RB, Williams RS. The role of modulatory calcineurin-interacting proteins in calcineurin
signaling. Trends Cardiovasc Med 2003; 13: 15–21.
201 Melo LG, Pachori AS, Gnecchi M, Dzau VJ. Genetic
therapies for cardiovascular diseases. Trends Mol Med
2005; 11: 240–250.
202 Giordano FJ, He H, McDonough P et al. Adenovirusmediated gene transfer reconstitutes depressed sarcoplasmic reticulum Ca2+-ATPase levels and shortens
CHAPTER 9
203
204
205
206
207
208
209
210
211
212
213
214
215
prolonged cardiac myocyte Ca2+ transients. Circulation
1997; 96: 400–403.
He H, Giordano F, Hilal-Dandan R et al. Overexpression of the rat sarcoplasmic reticulum Ca2+
ATPase gene in the heart of transgenic mice accelerates
calcium transients and cardiac relaxation. J Clin Invest
1997; 100: 380–389.
He H, Meyer M, Martin JL et al. Effects of mutant and
antisense RNA of phospholamban on SR Ca2+-ATPase
activity and cardiac myocyte contractility. Circulation
1999; 100: 974–980.
Minamisawa S, Hoshijama M, Chu G et al. Chronic
phospholamban–sarcoplasmic reticulum calcium ATPase
interaction is the critical calcium cycling defect in
dilated cardiomyopathy. Cell 1999; 99: 313–322.
Hajjar RJ, Schmidt U, Matsui T et al. Modulation of
ventricular function through gene transfer in vivo. Proc
Natl Acad Sci USA 1998; 95: 5251–5256.
del Monte F, Williams E, Lebeche D et al. Improvement
in survival and cardiac metabolism after gene transfer of
sarcoplasmic reticulum Ca2+-ATPase in a rat model of
heart failure. Circulation 2001; 104: 1424–1429.
Dieterle T, Meyer M, Gu Y et al. Gene transfer of a
phospholamban-targeted antibody improves calcium
handling and cardiac function in heart failure. Cardiovasc Res 2005; 67: 678–688.
Meyer M, Belke DD, Trost SU et al. A recombinant
antibody increases cardiac contractility by mimicking
phospholamban phosphorylation. Faseb J 2004; 18:
1312–1314.
Meyer M, Bluhm WF, He H et al. Phospholamban-toSERCA2 ratio controls the force–frequency relationship. Am J Physiol 1999; 276: H779–H785.
Maurice JP, Hata JA, Shah AS et al. Enhancement of
cardiac function after adenoviral-mediated in vivo intracoronary β2-adrenergic receptor gene delivery. J Clin
Invest 1999; 104: 21–29.
Shah AS, Lilly RE, Kypson AP et al. Intracoronary
adenovirus-mediated delivery and overexpression of
the β(2)-adrenergic receptor in the heart: prospects for
molecular ventricular assistance. Circulation 2000; 101:
408–414.
Jones JM, Petrofskia JA, Wilson KH et al. β2 Adrenoceptor gene therapy ameliorates left ventricular dysfunction following cardiac surgery. Eur J Cardiothorac
Surg 2004; 26: 1161–1168.
Lai NC, Roth DM, Gao MH et al. Intracoronary delivery
of adenovirus encoding adenylyl cyclase VI increases left
ventricular function and cAMP-generating capacity.
Circulation 2000; 102; 2396–2401.
Lai NC, Roth DM, Gao MH et al. Intracoronary adenovirus
encoding adenylyl cyclase VI increases left ventricular
function in heart failure. Circulation 2004; 110: 330–336.
Gene therapy 223
216 White DC, Hata JA, Shah AS et al. Preservation of
myocardial beta-adrenergic receptor signaling delays
the development of heart failure after myocardial
infarction. Proc Natl Acad Sci USA 2000; 97: 5428–5433.
217 Akhter SA, Skaer CA, Kypson AP et al. Restoration of
beta-adrenergic signaling in failing cardiac ventricular
myocytes via adenoviral-mediated gene transfer. Proc
Natl Acad Sci USA 1997; 94: 12100–12105.
218 Donahue JK. Gene therapy for cardiac arrhythmias. Ann
N Y Acad Sci 2004; 1015: 332–337.
219 Miake J, Marban E, Nuss HB. Biological pacemaker created by gene transfer. Nature 2002; 419; 132–133.
220 Edelberg JM, Huang DT, Josephson ME, Rosenberg RD.
Molecular enhancement of porcine cardiac chronotropy.
Heart 2001; 86; 559–562.
221 Qu J, Barbuti A, Protas L et al. Expression and function
of a biological pacemaker in canine heart. Circulation
2003; 107: 1106–1109.
222 Potapova I, Plotnikov IA, Lu Z et al. Human mesenchymal stem cells as a gene delivery system to create cardiac
pacemakers. Circ Res 2004; 94: 952–959.
223 Donahue JK, Heldman AW, Fraser H et al. Focal
modification of electrical conduction in the heart by
viral gene transfer. Nat Med 2000; 6: 1395–1398.
224 Marber MS, Mestri R, Chi SH et al. Overexpression of
the rat inducible 70-kD heat stress protein in a transgenic mouse increases the resistance of the heart to
ischemic injury. J Clin Invest 1995; 95: 1446–1456.
225 Mestril R, Giordano FJ, Conde AG, Dillmann WH.
Adenovirus-mediated gene transfer of a heat shock protein 70 (hsp 70i) protects against simulated ischemia.
J Mol Cell Cardiol 1996; 28: 2351–2358.
226 Suzuki K, Sawa Y, Kaneda Y et al. In vivo gene transfection with heat shock protein 70 enhances myocardial
tolerance to ischemia-reperfusion injury in rat. J Clin
Invest 1997; 99: 1645–1650.
227 Chatterjee S, Stewart AS, Bish LT et al. Viral gene transfer of the antiapoptotic factor Bcl-2 protects against
chronic postischemic heart failure. Circulation 2002;
106: I212–I217.
228 Matsui T, Tao J, del Monte F et al. Akt activation preserves cardiac function and prevents injury after transient cardiac ischemia in vivo. Circulation 2001; 104:
330–335.
229 Alexander JH, Hafley G, Harrington RA et al. Efficacy
and safety of edifoligide, an E2F transcription factor decoy,
for prevention of vein graft failure following coronary
artery bypass graft surgery: PREVENT IV: a randomized
controlled trial. JAMA 2005; 294: 2446–2454.
230 Chang MW, Barr E, Lu MM, Barton K, Leiden JM.
Adenovirus-mediated over-expression of the cyclin/
cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima
224 PART III Therapies and applications
231
232
233
234
235
formation in the rat carotid artery model of balloon
angioplasty. J Clin Invest 1995; 96: 2260–2268.
Chang MW, Barr E, Seltzer J et al. Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product.
Science 1995; 267: 518–522.
Kingston PA, Sinha S, Appleby CE et al. Adenovirusmediated gene transfer of transforming growth factorβ3, but not transforming growth factor-β1, inhibits
constrictive remodeling and reduces luminal loss after
coronary angioplasty. Circulation 2003; 108: 2819–2825.
Nili N, Cheema AN, Giordano FJ et al. Decorin inhibition of PDGF-stimulated vascular smooth muscle cell
function: potential mechanism for inhibition of intimal
hyperplasia after balloon angioplasty. Am J Pathol 2003;
163: 869–878.
Rutanen J, Turunen P, Rutanen J et al. Gene transfer
using the mature form of VEGF-D reduces neointimal
thickening through nitric oxide-dependent mechanism.
Gene Ther 2005; 12: 980–987.
Ishisaki A, Matsuno H. Novel ideas of gene therapy
for atherosclerosis: modulation of cellular signal transduction of TGF-β family. Curr Pharm Des 2006; 12:
877–886.
236 Liu Y, Li D, Chen J et al. Inhibition of atherogenesis in
LDLR knockout mice by systemic delivery of adenoassociated virus type 2-hIL-10. Atherosclerosis 2005; Nov
18 [Epub ahead of print].
237 Sharifi BG, Wu K, Wang L et al. AAV serotypedependent apolipoprotein A-I Milano gene expression.
Atherosclerosis 2005; 181: 261–269.
238 Lee KU, Lee IK, Han J et al. Effects of recombinant
adenovirus-mediated uncoupling protein 2 overexpression on endothelial function and apoptosis. Circ Res
2005; 96: 1200–1207.
239 Rajagopalan S, Shah M, Luciano A, Crystal R, Nabel EG.
Adenovirus-mediated gene transfer of VEGF(121) improves lower-extremity endothelial function and flow
reserve. Circulation 2001; 104: 753–755.
240 Sarkar N, Ruck A, Kallner G et al. Effects of intramyocardial injection of phVEGF-A165 as sole therapy in
patients with refractory coronary artery disease: 12month follow-up: angiogenic gene therapy. J Intern Med
2001; 250; 373–381.
241 Giordano FJ. Oxygen, oxidative stress, hypoxia, and
heart failure. J Clin Invest. 2005; 115(3): 500–508.
242 Giordano FJ. Therapeutic gene regulation: targeting
transcription. Circulation 2007; 115(10); 1180–1183.
10
CHAPTER 10
Stem cell therapy for
cardiovascular disease
Emerson C. Perin, MD, PhD, & Guilherme V. Silva, MD
Introduction
Coronary artery disease (CAD) remains a leading
cause of death and disability in the USA. Research
efforts have concentrated on treating acute myocardial infarction (AMI) so as to reduce mortality
rates. AMI can cause variable degrees of damage to
myocardial tissue depending on the amount of
necrosis and patency of the arterial bed. Myocardial
scarring may compromise myocardial performance, leading to remodeling of the left ventricle
in response to increased mechanical wall stress,
inadequate perfusion that compromises remaining
viable myocardial segments, and finally ischemic
heart failure.
Despite efforts to halt the progression to ischemic
heart failure by means of revascularization, ventricular remodeling remains a danger. Efforts to treat
severely compromised hearts refractory to medical
treatment have focused on heart transplantation
and, more recently, mechanical ventricular assistance [1]. Until recently, cardiologists believed that
beyond revascularization and medical therapy this
process was irreversible because the heart did not
have the capacity to renew itself.
However, new insights into the mechanisms of
cardiac repair have provided evidence that the
adult heart may repair itself and that vasculogenesis
may not occur solely during embryonic development, which has in turn sparked strong interest in
stem cell therapy [2,3]. Prompted by evidence that
adult bone marrow harbors a reservoir of enormously plastic cells [4], animal experiments have
generated a wide array of evidence supporting the
use of stem cells to repair cardiac tissue in diverse
clinical scenarios [5].
Stem cell therapy for cardiac diseases is a reality.
Several strategies have been tested with promising
initial results. This chapter, which is aimed at the
clinical cardiologist who will ultimately deliver
this investigational therapy to patients, outlines the
basic concepts of such therapy and reviews the clinical data available from Phase I and II trials.
The basics of stem cells
Definition
Stem cells are self-replicating cells capable of generating, sustaining and replacing terminally differentiated cells [6,7]. Stem cells can be subdivided into
two main groups: embryonic and adult. Embryonic
stem cells are present in the earliest stage of embryonic development – the blastocyst. Embryonic stem
cells are pluripotent. This means they are capable of
generating any terminally differentiated cell in the
human body that is derived from any one of the
three embryonic germ layers: ectoderm, mesoderm
or endoderm [8]. Through a series of divisions and
differentiations, all the organs of the human body
arise from the original embryonic stem cells that
form the blastocyst [3].
Adult stem cells are intrinsic to specific tissues
of the postnatal organism and are committed to
differentiate into those tissues [9]. Hematologists
have studied them for four decades, ever since the
successful clinical introduction of bone marrow
transplantation. Theoretically, adult stem cells selfrenew forever, yielding mature differentiated cells
225
226 PART III Therapies and applications
that are: (i) integrated into a particular tissue; and
(ii) capable of performing the specialized function,
or functions, of that tissue. Each type of differentiated cell has its own phenotype (i.e., observable
characteristics), including shape or morphology,
interactions with surrounding cells and extracellular matrix, expression of particular cell surface
proteins (receptors) and behavior [8]. Adult tissuespecific stem cells are present in self-renewable
organs including the liver, pancreas, skeletal muscle
and skin.
Identification
Each adult stem cell subtype can be identified by
cell surface receptors that selectively bind to particular signaling molecules. Differences in structure and
binding affinity allow for a remarkable multiplicity
of receptors. Normally, cells utilize these receptors
and the molecules that bind to them to communicate with other cells and perform the proper
function of the tissue to which they belong (e.g.,
contraction, secretion or synaptic transmission).
Each type of adult stem cell has a certain receptor or
combination of receptors (i.e., marker) that distinguishes it from other types of stem cells (Table 10.1).
Stem cell markers are often given letter and
number codes based on the molecules that bind to
them (Table 10.1). A cell presenting the stem cell
antigen-1 receptor is identified as Sca-1+. Cells
exhibiting Sca-1 but not CD34 antigen or lineagespecific antigen (Lin) are identified as CD34−Sca-1+
Lin−. This particular combination of surface receptors identifies mesenchymal stem cells (MSCs).
Unfortunately, the nomenclature can be confusing. Different researchers have given the same bone
marrow cells different names. In some cases, surface marker designations within cell subtypes overlap. Most surface markers do not adequately
identify stem cells because they may also be found
on nonstem cells. Moreover, some markers may be
expressed only under certain culture conditions or
at a certain stage of cell development. Bone marrow
stem cells are also highly plastic and may give rise to
several subtypes.
Role in cardiovascular repair
The field of stem cell therapy has benefited greatly
from the work of numerous basic and clinical
researchers whose studies have greatly improved
Table 10.1 Development of differentiated tissues from
embryonic germ layers.
Embryonic
Differentiated tissue
germ layer
Endoderm
Gastrointestinal tract lining
Larynx
Liver
Lung
Pancreas
Parathyroid gland
Respiratory tract lining
Thymus
Thyroid gland
Trachea
Urethra
Urinary bladder
Vagina
Mesoderm
Adrenal cortex
Bone marrow (blood)
Cardiac muscle
Connective tissues (cartilage, bone)
Heart and blood vessels (vascular system)
Lymphatic tissue
Skeletal muscle
Smooth muscle
Ectoderm
Adrenal medulla
Connective tissue of head and face
Ears
Eyes
Neural tissue (neuroectoderm)
Pituitary gland
Skin
our understanding of the processes involved in cardiac repair and neovascularization. The creation of
new blood vessels (neovascularization) requires the
formation of new mature endothelial cells. In this
process, the new endothelial cells migrate or proliferate from existing vessels (angiogenesis) or arise
from bone marrow-derived progenitor cells (vasculogenesis) [10]. Asahara et al. [2] were the first
to describe a unique population of bone marrowderived endothelial progenitor cells (EPCs) found
in the peripheral circulation. These EPCs share
similarities with bone marrow hematopoietic progenitor cells. Before EPCs were discovered, vasculogenesis was thought to occur only in the human
embryonic phase. In animal models of ischemia,
CHAPTER 10
however, EPCs participate in new vessel development, thus establishing a new paradigm of postnatal vasculogenesis [11–30].
The importance of postnatal vasculogenesis to
stem cell therapy has been highlighted by several
recent studies. Bone marrow-derived EPCs have
been shown to contribute functionally to vasculogenesis after AMI [1,13,14], during wound healing
[31] and in limb ischemia [12–14,19,20,27,30].
They have also been implicated in the endothelialization of vascular grafts [13,21,28]. The number of
circulating EPCs and their migratory capacity correlates inversely with risk factors for CAD, such as
smoking and hypercholesterolemia [31]. EPCs have
also been implicated in the pathogenesis of allograft
transplant vasculopathy and coronary restenosis
after stent implantation, after being recruited by
appropriate cytokines, growth factors and hormones
via autocrine, paracrine and endocrine mechanisms [32]. Endothelial progenitor cell mobilization
is a natural response to vascular trauma, as seen in
patients who undergo coronary artery bypass graft
surgery or suffer burns [16] or an AMI [1].
Endothelial progenitor cells also appear to be
crucial to vascular homeostasis. Werner et al. [33]
followed a series of 519 patients with CAD for up to
1 year after coronary angiography and found that
preprocedural EPC levels were prognostically valuable in predicting major cardiovascular events
(MACE) and death from cardiovascular causes.
Patients with higher EPC levels were less likely to
suffer these untoward events even after adjustment
for traditional prognostic and risk factors.
Adult tissue-specific stem cells are present in
other self-renewable organs such as the liver, pancreas, skeletal muscle and skin. The heart, which
until very recently was considered a terminally differentiated, post mitotic organ with a finite store
of myocytes established at birth, might now be
added to this list. It has recently been observed that
hematopoietic stem cells (HSCs) can transdifferentiate into cardiomyocytes [34,35] and that stem
cells may reside in the heart [36]. Such resident cardiac stem cells are thought to occupy niches in the
atria and apex and have been observed in the border zones of myocardial infarcts [37,38]. These
observations have in turn drastically changed our
understanding of the cardiac repair process. It now
appears that resident cardiac stem cells and possibly
Stem cell therapy 227
bone marrow-derived stem cells may be able to
repair the damaged heart. Once adequate signaling
is established with cytokines and growth factors,
bone marrow cells are mobilized [32]. This concept
is strengthened by evidence from animal studies
showing that AMI repair involves bone marrow
cells [39] and by evidence of chimerism in transplanted hearts [40].
Further evidence for a dynamic cardiac renewal
process in the adult heart comes from the recent
identification of a novel population of early tissuecommitted stem cells that may be part of a group of
circulating progenitor cells involved in cardiac
repair [41]. The particularities and interactions of
resident and circulating stem cells in this setting
continue to be delineated.
Together, these strands of evidence suggest that
stem cells have key roles in the adult heart’s ability
to dynamically repair itself and its vessels and in the
body’s ability to maintain homeostasis.
Stem cell types and characteristics
At present, most basic and clinical research concerns bone marrow-derived progenitor cells and
skeletal myoblasts.
Adult bone marrow-derived stem cells
Adult bone marrow-derived stem cells are the
cell type most widely utilized in cardiac stem cell
therapy. A very heterogeneous subset, termed autologous bone-marrow-derived mononuclear cells
(ABMMNCs), is composed of small amounts of
stromal or mesenchymal stem cells (MSCs), hematopoietic progenitor cells (HPCs), endothelial
progenitor cells (EPCs) and more committed cell
lineages such as natural killer lymphocytes, T and B
lymphocytes (Plate 10.1) [2].
Bone marrow stem cells are aspirated from
the patient’s iliac crest under local anesthesia. The
mononuclear subfraction of the aspirate is isolated
by means of Ficoll density centrifugation, filtered
through a 100-µm nylon mesh to remove cell
aggregates or bone spicules, and washed several
times in phospate-buffered saline solution before
being used immediately for therapy or expanded
in an endothelial cell-specific culture medium.
Endothelial progenitor cells can be harvested from
peripheral blood.
228 PART III Therapies and applications
So far, the most important bone marrow subtypes utilized for cardiac repair have been MSCs,
EPCs or, alternatively, the whole ABMMNC fraction. Newly described bone marrow cell subtypes
with therapeutic potential are discussed below.
Mesenchymal stem cells
An adult MSC is a cell from any adult tissue that can
be expanded in culture and can renew itself and differentiate into several specific mesenchymal cell
lineages. MSCs are present in different niches
throughout the body such as bone marrow and adipose tissue [42]. MSCs are extremely plastic, with
the potential to terminally differentiate in vitro
and in vivo into mesenchymal phenotypes such as
bone [43,44], cartilage [45], tendon [46,47], muscle
[34,48], adipose tissue [49,50] and hematopoiesissupporting stroma [50]. MSCs differentiate not
only into mesenchymal tissues but also into cells
derived from other embryonic layers, including
neurons [51] and epithelia in the skin, lung, liver,
intestine, kidney and spleen [52–54]. Their plasticity has increased interest in using them for cardiac
regeneration.
In a proof-of-concept study in which Saito et al.
[55] intravenously injected LacZ reporter genetransfected MSCs into healthy rats, the MSCs preferentially engrafted in the bone marrow. When
injected into rats subjected to several cycles of
ischemia-reperfusion, however, the MSCs engrafted
in the infarcted regions of the heart, where they
participated in angiogenesis and expressed cardiomyocyte-specific proteins. When injected into
rats 10 days after myocardial injury, MSCs preferentially homed in instead on the bone marrow, suggesting that in the first days after myocardial injury
a specific cell homing signal causes the MSCs to
home in on the damaged myocardium.
MSCs are CD45−CD34− bone marrow cells that
can be readily grown in culture. They are evidently
rare in the bone marrow (<0.01% of nucleated
cells, by some estimates) and thus 10 times less
abundant than HSCs. MSCs need to be cultured for
at least 20 days to obtain the numbers necessary for
therapy, which would directly affect any clinical
strategy for treating AMI that involves autologous
MSCs.
Adult bone marrow MSCs, which are easy to
manipulate genetically and weakly immunogenic,
represent a potential source of allogeneic stem
cells [56]. Allogeneic MSCs actually inhibit T cells
in culture [57], and several in vivo studies have
achieved good engraftment of allogeneic MSCs
without rejection [56].
Our group at the Texas Heart Institute was the
first to study mesenchymal cell injections in a largeanimal model of chronic myocardial ischemia [58].
In brief, we used ameroid constrictors to induce
ischemia in 12 dogs and a month later directly
injected the myocardium of each with 100 million
MSCs or a saline control. Subsequent two-dimensional echocardiography showed improved systolic function both at rest and during stress in
treated dogs (Fig. 10.1), and histopathologic studies showed that the MSCs had transdifferentiated
into endothelial and smooth muscle cells (Fig. 10.2;
Plate 10.2) and improved vascularization (Plate
10.3).
In light of the current evidence, MSCs should
have strong clinical potential, especially if human
safety studies confirm the lack of rejection seen so
far in preclinical studies.
Endothelial progenitor cells
Endothelial progenitor cells can be isolated from
the mononuclear fraction of the bone marrow or
peripheral blood, as well as from fetal liver or
umbilical cord blood [12,23,59,60]. In widely ranging animal models of ischemia, heterologous, homologous and autologous EPCs have been shown
to engraft at sites of active neovascularization
[60].
EPCs can differentiate into endothelial cells,
smooth muscle cells, or cardiomyocytes both in
vitro and in vivo. EPCs have been identified by different research groups using different methodologies [15,17,22,25]. The classic methods involve
culture of total peripheral blood mononuclear cells
or isolation via magnetic microbeads coated with
anti-CD133 or anti-CD34 antibodies. After isolation, the cells are cultured in medium containing
specific growth factors such as vascular endothelial
growth factor (VEGF) and fibroblast growth factor
to facilitate the growth of endothelial-like cells.
“Immature” or “primitive” EPCs have a profile
similar to that of HSCs; both cell types are thought
to result from a common precursor, the hemangioblast. Within the bone marrow, immature EPCs
CHAPTER 10
Ejection fraction at rest (%)
(a)
Stem cell therapy 229
P = 0.6
70
60
P = 0.4
P = 0.004
50
40
30
20
10
0
Before ameroid
30 days after ameroid 60 days after ameroid
placement/30 days
placement (baseline)
placement/before
after intramyocardial
intramyocardial
injection
injection
Control Group
P = 0.7
Ejection fraction with stress (%)
(b) 40
Figure 10.1 (a), LVEF at rest. Assessments
were made at baseline before ameroid
placement (left), 30 days later at time of
cell or saline injection (middle), and 60
days after ameroid placement (right).
(b), LVEF with stress. Assessments were
made before and 30 days after
intramyocardial injection.
Treatment Group
35
P = 0.01
30
25
20
15
10
5
0
30 days after ameroid
placement/before injection
and HSCs share common cell-surface markers:
CD34, CD133 and VEGF receptor 2 (VEGFR-2, also
known as KDR/FLK-1). Similarly, in the peripheral
circulation, the more primitive cell population with
the capacity of differentiating into EPCs expresses
CD34, VEGFR-2 and CD133. In the peripheral circulation, the more committed EPCs lose CD133
but retain CD34 and VEGFR-2 expression. Some
circulating EPCs and, to a greater extent, more differentiated EPCs start expressing the endothelial
lineage-specific marker vascular endothelial (VE)
cadherin or E selectin. However, when immature
EPCs follow the hematopoietic path, the surface
markers of CD133 and VEGFR-2 are extinguished
because stem/progenitor cell markers are not expressed on differentiated hematopoietic cells.
Control Group
60 days after ameroid
placement/30 days after
injection
Treatment Group
Recent studies have challenged the more traditional view that primitive bone marrow-derived
EPCs that lose CD133 become relatively committed
EPCs that may subsequently differentiate into
mature endothelial cells. EPCs (CD34/VEGF-2+
cells) appear to originate from peripheral blood
mononuclear cells that express the monocyte–
macrophage markers CD14, MAC-1 and CD11-c,
suggesting a possible monocyte–macrophage origin [61]. Harraz et al. [62] have observed, within
populations of mononuclear peripheral cells,
CD34− cells that are not only CD14+ but also differentiate into endothelial cells. Adding to the debate
is the recent description of “late” EPCs or outgrowth endothelial cells (OECs) that originate
from a CD14− monocyte population [63]. EPCs
230 PART III Therapies and applications
10000
Vascular density (µm2/mm2)
9000
8000
7000
6000
5000
4000
3000
2000
1000
0
Stem cells
Control
originating from the CD14+ monocyte population
(so-called “early” EPCs) were found to secrete
angiogenic peptides such as VEGF, IL-8 and other
enzymes such as matrix metalloproteinase 9
(MMP9). However, these “early” EPCs did not
proliferate well. On the other hand, OECs did proliferate well but secreted only MMP2. Taken
together, these findings argue for the plasticity of
EPCs (CD34+, VEGFR-2+ and CD133+), the different developmental stages of a common precursor
progenitor cell, and the existence of distinct cell
subtypes that might be further differentiated by
surface markers yet to be discovered.
EPC numbers appear to decrease in the presence
of risk factors for CAD and to correlate negatively
with Framingham cardiovascular risk factors [31].
Therefore, stem cell therapy with EPCs may prove
very useful in the clinical setting of cardiovascular
disease. The kinetic and biologic properties of EPCs
may be especially appropriate for autologous transplantation. EPCs may also be safe to use in elderly
and diabetic patients, populations in which they do
not tend to migrate as much or induce neovascularization [61].
Our ability to characterize EPCs and identify
those subtypes most useful for cardiac cell therapy
has advanced rapidly, but is still incomplete.
Nonetheless, as the positive results of initial preclinical and clinical studies have shown, EPCs show
great therapeutic promise.
Figure 10.2 (a), Fibrosis (as evaluated
by trichrome staining) in anterolateral
wall of animals treated with MSCs and
controls. There was a trend toward less
fibrosis in treated dogs that did not
reach statistical significance. (b),
Vascular density was statistically greater
in anterolateral walls of animals that
received stem cells.
Other bone marrow stem cells
Clearly, the bone marrow is a reservoir of cells
whose regenerative capacity extends beyond the
hematopoietic lineage. Identifying stem cells on the
basis of cell-surface markers is a limited method
that may delay the discovery of additional tissuespecific stem cell subtypes. Nevertheless, the stem
cell field is advancing quickly. Recently, Kucia et al.
[64] published the first evidence that postnatal
bone marrow harbors a nonhematopoietic cell
population that expresses markers for cardiac differentiation. This finding corroborates the early
work of Deb et al. [65], who isolated Y chromosome-positive cardiac myocytes from female recipients of male bone marrow. The percentage of
cardiomyocytes that harbored the Y chromosome
was quite small (only 0.23%), but there was no evidence of either pseudonuclei or cell fusion. Two
new bone marrow cardiac precursors have been
identified: ABMMNCs expressing cardiac markers within a population of nonhematopoietic
CXCR4+/Sca-1+/Lin−/CD45− ABMMNCs in mice
and within a population of nonhematopoietic
CXCR4+/CD34+/AC133+/CD45− ABMMNCs in
humans. These nonhematopoietic ABMMNCs expressing cardiac precursors are mobilized into the
peripheral blood after a myocardial infarction and
home in on the infarcted myocardium in an SDF1-CXCR4, HGF-c-Met and LIF-LIF-R dependent
manner [64].
CHAPTER 10
The identification of a direct cardiac precursor
within the bone marrow cell population opens up a
vast number of possibilities for the field of cardiac
regeneration. In theory, in vitro expansion of this
type of cell would be therapeutically attractive.
Skeletal myoblasts
Skeletal myoblasts are adult tissue-specific stem
cells [66] located between the basal lamina and the
sarcolemma on the periphery of the mature skeletal-muscle fiber [67]. Also known as muscle
satellite cells, these small, mononuclear cells are
activated by biochemical signals to divide and differentiate into fusion-competent cells after muscle
injury.
The use of skeletal myoblasts for cardiac repair
originated in earlier attempts to use fetal cardiomyocytes. When injected into the border zone of an
AMI, these cells are able to engraft and survive [68].
Despite initial encouraging results in animal models, clinical use of fetal cardiomyocytes has not been
pursued because of ethical issues and the limited
availability of these cells.
Skeletal myoblasts have emerged as an attractive
alternative [69]. The first therapeutic trials used
skeletal myoblasts obtained under sterile conditions and local anesthesia 0.5–5.0 g muscle biopsy
specimens. Individual cells were isolated by digestion with trypsin and collagenase, washed to remove
red blood cells and debris, plated and cultured to
obtain the numbers necessary for therapeutic use.
Skeletal myoblasts can survive prolonged periods of hypoxia [70]. They can also survive and
engraft when injected into infarcted areas.
Embryonic stem cells
As gradually revealed over the past two decades,
embryonic stem cells (ESCs) are derived from the
cell mass of blastocysts in mice and humans. In the
presence of leukemia inhibitor factor (LIF) or atop
a layer of mitotically inactivated mouse embryonic
fibroblasts, ESCs can proliferate indefinitely. Once
removed from these conditions and transferred
into a suspension culture, ESCs spontaneously form
multicellular aggregates that turn into endoderm,
mesoderm and ectoderm [70]. Murine ESC lines
have been shown in vitro to differentiate into cells
associated with each of these three layers: hematopoietic progenitors, adipocytes, hepatocytes, smooth
Stem cell therapy 231
muscle cells, endothelial cells, neurons and others
[71,72]. More importantly, they have been shown
to differentiate into cardiomyocytes [73] in response to appropriate stimuli and specific signaling
factors. Hepatocyte growth factor (HGF), epidermal growth factor (EGF), basic fibroblast growth
factor (bFGF), platelet-derived growth factor
(PDGF), retinoic acid, vitamin C and overexpression of GAT4 all enhance this differentiation process in vitro [74]. However, the ideal combination
of these factors for enhancing ESC differentiation
into cardiomyocytes remains unknown.
Because they are pluripotent and can proliferate
indefinitely, ESCs may have an important potential role in cardiac regeneration. Although ethical
issues involving the use of human ESCs has slowed
research in several countries including the USA,
enthusiasm about their future clinical utilization
remains high.
Resident cardiac stem cells
Myocyte replication is the failing heart’s attempt to
compensate for a limited capacity for hypertrophy.
When Urbanek et al. [38] used Ki-67 (a nuclear protein expressed during cell division) to assess the
mitotic activity of myocytes, they observed significantly greater mitotic activity at infarct border zones
than in distant myocardium or healthy control
hearts. The evidence that cardiac myocytes divide
shortly after a myocardial infarction led investigators to search for the origin of the dividing
myocytes [75]. This culminated in the description
of resident cardiac stem cells (CSCs) [36–38].
Resident CSCs were first isolated in murine
hearts. Characterization of these cells was based on
the expression of the stem cell-related surface antigens c-Kit and Sca-1. In the first study, freshly isolated c-Kit+/Lin− cells were shown to be clonogenic
and to differentiate into myocytes, smooth muscle
cells and endothelial lineage cells [36]. Those cells
generated functional myocardium when injected
into ischemic areas of the heart. The second study
characterized CSCs as Sca-1/c-Kit−. When treated
in culture with 5-azacytidine, those cells differentiated into a myogenic lineage. Subsequently,
intravenous injection of the cells in an ischemiareperfusion model resulted in infarct healing with
cardiomyocyte transdifferentiation [75]. In studies
involving atrial and ventricular biopsies in sheep
232 PART III Therapies and applications
and humans, Messina et al. [76] isolated a cardiac
progenitor cell that was c-Kit+ and capable of selfproliferating into a large number of cells. The
authors also showed that human CSCs could participate in infarct repair in the murine model.
A detailed and uniform characterization of CSCs
is still lacking, as are preclinical data from largeanimal models. As further studies are performed
and yield promising results, CSCs may be considered for utilization in clinical trials.
Alternative sources of stem cells
Despite successful preclinical and clinical utilization of bone marrow cells and skeletal myoblasts,
the search continues for an ethical, easily accessible,
high-yield source of stem cells. Mesenchymal stem
cells have been isolated from adipose tissue, placental tissue and umbilical cord blood. A number of
studies have shown adipose-derived mesenchymal
stem cells (AMSCs) to be pluripotent and capable
of differentiating into multiple cell lineages along
the myogenic, osteogenic, neurogenic and hematopoietic pathways [77–79]. Additionally, AMSCs
secrete VEGF, HGF, bFGF and transforming
growth factor β (TGF-β), which have a potential
angiogenic effect on ischemic myocardium [80].
These cells also express the cell-surface marker
CD34, but it is uncertain whether their pluripotency is limited to the subgroup of cells that express
this marker [81]. Research to better characterize
AMSCs and evaluate the safety and efficacy of this
stem cell type in preclinical studies is ongoing.
By means of dissection and proteinase digestion,
large numbers of viable mononuclear cells can be
harvested from the human placenta at term, and a
mesenchymal cell population with characteristic
expression of CD9, CD29 and CD73 can be
obtained in culture. The in vitro growth behavior of
such placenta-derived mesenchymal cells is similar
to that of human bone marrow mesenchymal progenitor cells [82]. Transdifferentiation experiments
have shown a potential for differentiation along
osteogenic, chondrogenic, adipogenic and myogenic lines [82]. The human placenta at term might
be an easily accessible, ample source of multipotent
mesenchymal progenitor cells and is also under
preclinical investigation.
Cord blood has long been used as a source of
MSCs for bone marrow transplantation. The stem
cell compartment is more abundant and less
mature in cord blood than in bone marrow.
Moreover, MSCs in cord blood have a higher proliferative potential because of their extended lifespan and longer telomeres [83–86]. Not only can
they be harvested without morbidity to the donor,
but they also display a robust in vitro capacity for
directed or spontaneous differentiation into mesodermal, endodermal and ectodermal cell fates.
Cord blood MSCs are CD45− and HLA-II− and can
be expanded without losing their pluripotency.
Therefore, cord blood is also undergoing preclinical evaluation as a possible easily accessible source
of multipotent cells.
Stem cell delivery methods
The current understanding of stem cell biology and
kinetics gives us important clues as to how we should
deliver them. The efficacy of therapeutic stem cells
will obviously depend largely on successful delivery. Stem cells have been delivered indirectly
through peripheral and coronary veins and coronary arteries. Alternatively, they have been delivered
directly by intramyocardial injections via surgical, transendocardial or transvenous approaches.
Another potential delivery strategy is the mobilization of stem cells from the bone marrow by means
of cytokine therapy with or without peripheral
harvesting.
The main objective of any cell delivery method is
to achieve the concentration of stem cells necessary
for repairing the damaged region being targeted.
To this end, the ideal modality should be safe;
easy to use; cost-effective; clinically useful in a wide
range of clinical disease settings and scenarios; easily, adequately and effectively targeted; and able to
exert a long-lasting therapeutic effect.
Stem cell mobilization
In humans, progenitor cells from the bone marrow
mobilize after an AMI. This suggests a “natural”
attempt at cardiac repair [3]. In theory, therapeutic
mobilization of bone marrow progenitor cells after
an AMI would amplify the existing healing response. Because of its simplicity, mobilization of
stem cells is therefore an attractive delivery strategy
[87,88]. It would not only obviate the need for
invasive harvesting or delivery procedures, but also
CHAPTER 10
take advantage of the clinical procedures already
established for the use of progenitor cell-mobilizing
granulocyte colony-stimulating factor (G-CSF) in
treating hematologic disorders. However, because
of the possibility of adverse events in a different
patient population and the theoretical possibility of
tumorigenesis, the safety of such “off-label” applications of G-CSF have been questioned.
Transvascular delivery
Peripheral (intravenous) infusion
Peripheral (intravenous) infusion of stem cells as
performed in bone marrow transplantation would
be a very convenient – not to mention simple, widely
available and inexpensive – way of delivering therapeutic stem cells to myocardial targets. A study in a
mouse model has confirmed that bone marrow
cells infused into the peripheral circulation do
indeed home in on peri-infarct areas [87]. However, the number of cells that reach the affected area
is very small, and the technique would be most
applicable only after an AMI, as it would rely on
physiologic homing signals alone. Moreover, because peripherally infused stem cells home in on
infarcted areas only when injected within a few days
after an AMI, this delivery strategy would be much
less suitable for treating chronic myocardial ischemia.
The major drawback to using an intravenous
route of cell delivery is the possibility that the therapeutic cells would become trapped in the microvasculature of the lungs, liver and lymphoid tissues.
This theoretical limitation of systemic transvenous
delivery of stem cells has been confirmed experimentally. In a study by Toma et al. [89], human
MSCs were injected into the left ventricular cavity
of experimental mice; 4 days later, an estimated
0.44% of the injected cells remained in the myocardium, and the rest had localized to the spleen,
liver and lungs. Other studies using the systemic
delivery approach have produced similar results,
with very low local cell retention rates of less than
5% [90,91]. Thus, the transvenous delivery route
appears unlikely to achieve the local cell concentration needed to produce a significant therapeutic
benefit.
Retrograde coronary venous delivery
Two methodologies have been described for delivering therapeutic agents via the coronary venous
Stem cell therapy 233
system. Low-pressure delivery aims to increase
the time that the agent is in contact with the
vessels without disrupting the venous endothelium
[92–94]. High-pressure delivery aims to create a
biologic reservoir of product by disrupting the tight
endothelial junctions of the venocapillary vasculature and mechanically driving cells across them
into the myocardial interstitium [95–97]. Another,
newer technique involves a new catheter that has
proximal and distal balloons that occlude coronary
flow and therefore theoretically allow greater contact between therapeutic cells and the coronary
venous system.
The clinical experience with retrograde venous
infusion is limited. Several key issues (i.e., optimal delivery pressure, volume and infusion time)
remain to be resolved.
Intracoronary infusion
Intracoronary infusion has been the most popular
method of delivering stem cells in the clinical
setting, especially after AMI. Intracoronary stem
cell delivery 4–9 days after AMI is relatively safe
[98–104]. The technique is similar to that for coronary angioplasty, which involves over-the-wire
positioning of an angioplasty balloon in a coronary
artery (Plate 10.4). Coronary blood flow is transiently stopped for 2–4 minutes while stem cells
are infused under pressure. This maximizes their
contact with the microcirculation of the infarctrelated artery, thereby optimizing their homing time.
Again, this delivery technique would be suitable
only in the setting of acute ischemia when adhesion
molecules and cytokine signaling are temporarily
upregulated.
Results of recent studies have challenged the safety
and effectiveness of intracoronary delivery. There is
growing evidence of very low retention of stem cells
in target regions and of increased restenosis rates
associated with this delivery method.
Intramyocardial injection
Intramyocardial injection has been performed in
the clinical setting of chronic myocardial ischemia.
It is the preferred delivery route in patients with
chronic total occlusion of coronary arteries and in
patients with chronic conditions (e.g., congestive
heart failure) that involve weaker homing signals.
In theory, intramyocardial injection should be the
234 PART III Therapies and applications
most suitable route for delivering larger cells such
as skeletal myoblasts and MSCs, which are prone to
microvascular “plugging.” Intramyocardial injection can be performed via transepicardial, transendocardial or transcoronary venous routes.
Transepicardial injection
Transepicardial injection of stem cells has been
performed during open surgical revascularization
procedures to deliver the cells to infarct border
zones or areas of infarcted or scarred myocardium.
Because a sternotomy is required, this approach is
highly invasive and associated with surgical complications. However, in the setting of a planned
open heart procedure, the ancillary delivery of cell
therapy in this fashion can be easily justified.
Interestingly, not all areas of the myocardium (e.g.,
the interventricular septum) can be reached via a
direct external approach.
The main advantages of direct surgical injection
are its proven safety in several preclinical and
human trials [39,58,105–110] and ease of use.
However, it is also costly and offers a very unsophisticated targeting opportunity. The surgeon
chooses to inject the border of the infarcted area or
scar tissue on the basis of visual assessment only. In
addition, the safety of direct surgical injection in
patients with recent AMI has not been tested in
clinical trials. Nevertheless, direct surgical injection
certainly might have a role in the future of stem cell
therapy. One can easily envision the cardiac surgeon, during coronary artery bypass grafting surgery, bypassing all areas in which it is technically
feasible to do so and then concomitantly injecting stem cells into those areas containing totally
occluded epicardial coronary arteries.
Transendocardial injection
Transendocardial injection is performed via a percutaneous femoral approach. An injection-needle
catheter is advanced in retrograde fashion across
the aortic valve and positioned against the endocardial surface. Stem cells are then injected directly
into targeted areas of the left ventricular wall. Three
catheter systems are currently available for transendocardial cell delivery: the Stilleto™ (Boston
Scientific, Natick, MA), the BioCardia™ (BioCardia
South San Francisco, CA) and the Myostar™
(Biosense Webster, Diamond Bar, CA).
The Stilleto is used under fluoroscopic (usually
biplanar) guidance. Drawbacks inherent in this
approach are the bidimensional orientation and
lack of precision associated with fluoroscopy.
Another drawback is the inability to characterize
the underlying or target myocardium. Nevertheless, this technology may be promising when used
in association with imaging technologies such as
magnetic resonance imaging (MRI) or when targeting of myocardial therapy is not necessary. To
this end, in preclinical experiments, the Stilleto
catheter has been coupled with real-time cardiac
MRI, which permits online assessment of fullthickness myocardium and perfusion. Although
still investigational and not currently practical in
terms of clinical application, the simultaneous use
of MRI offers three-dimensional spatial orientation. Few preclinical studies have been performed,
and no safety data from human studies have been
assessed [111]. Theoretically, the use of MRI also
provides a unique opportunity to track the intramyocardial retention of therapeutic cells after direct
injection. However, this will require the labeling
of cells (specifically mesenchymal stem cells) with
fluorescent iron particles that can be detected in the
beating heart.
The BioCardia delivery system uses a catheter
whose deflectable tip includes a helical needle for
infusion. Initial preclinical and clinical experience
with this system has provided preliminary evidence
of its safety and feasibility [112,113]. Unlike the
other two catheter delivery systems discussed here,
the BioCardia catheter does not offer any additional navigational or targeting tool. More extensive preclinical experience with this catheter is
needed before human trials can begin.
The Myostar injection catheter takes advantage of nonfluoroscopic magnetic guidance [114].
Injections are targeted with the help of a threedimensional left ventricular “shell,” or NOGA
electromechanical map (EMM), representing the
endocardial surface of the left ventricle. The shell is
constructed by acquiring a series of electrocardiogram-gated points at multiple locations on the
endocardial surface. Ultralow magnetic fields (10−
to 10−6 tesla) generated by a triangular magnetic
pad positioned beneath the patient intersect with
a sensor just proximal to the deflectable tip of a
7F mapping catheter, which helps determine the
CHAPTER 10
real-time location and orientation of the catheter
tip inside the left ventricle. The NOGA system algorithmically calculates and analyzes the movement
of the catheter tip or the location of an endocardial
point throughout systole and diastole. That movement is then compared with the movement of
neighboring points in an area of interest. The
resulting value, called linear local shortening (LLS),
is expressed as a percentage that represents the
degree of mechanical function of the left ventricular region at that endocardial point. Data are
obtained only when the catheter tip is in stable contact with the endocardium. This contact is determined automatically.
The mapping catheter also incorporates electrodes that measure endocardial electrical signals
(unipolar or bipolar voltage) [114]. Voltage values
are assigned to each point acquired during left
ventricular mapping, and an electrical map is constructed concurrently with the mechanical map.
Each data point has an LLS value and a voltage
value. When the map is complete, all the data
points are integrated by the NOGA workstation
into a three-dimensional color-coded map of the
endocardial surface, as well as 9- and 12-segment
bull’s-eye views that show average LLS and voltage
values in each myocardial segment. These maps can
be spatially manipulated in real time on a Silicon
Graphics workstation (Mountain View, CA). The
three-dimensional representations acquired during
the cardiac cycle can also be used to calculate left
ventricular volume and ejection fraction.
The three-dimensional EMM serves both therapeutic and diagnostic purposes. On the one hand, it
allows the catheter to be maneuvered through the
left ventricle and oriented for transendocardial
injections. On the other hand, it allows ischemic
areas (i.e., those with low LLS and preserved unipolar voltage [UniV]) to be distinguished from
infarcted areas (i.e., those with low LLS and low
UniV) [115]. Moreover, the Myostar catheter
allows myocardial viability to be assessed at each
specific injection site where the catheter touches the
endocardial surface. The operator is thus able to
target therapy to viable tissue (where neoangiogenesis may be possible) or nonviable tissue (where
the target of cell therapy may be a scarred area).
Because of the patchy nature of human ischemic
heart disease, the ability to characterize the under-
Stem cell therapy 235
lying myocardial tissue is important when delivering stem cells.
The EMM technology has been widely tested in
both animals and humans and has an excellent
safety profile [26,116–123]. Kornowski et al. [121]
have studied the dynamics of transendocardial
delivery using different needle extensions to inject
0.1 mL methylene blue dye as a tracer. A total of 152
injections were performed with needle extensions
varying from 3 to 4 mm in length. Two myocardial
regions were injected per animal, and injection sites
were located after the animals were sacrificed
acutely. Staining extended to a depth of 7.1 ± 2.1
mm (range, 2–11 mm) and to a width of 2.3 ± 1.8
mm (range, 1–9 mm). In 2.6% of cases (4 of 152),
the injected dye stained the epicardial surface, suggesting pericardial extravasation; more importantly, three of those four injections were made in
the apical area. There were no animal deaths, no
instances of pericardial effusion or tamponade, and
no episodes of sustained ventricular arrhythmia
associated with the transendocardial injections.
Despite the limitations of the animal model, this
preclinical experience has translated well into clinical trials. However, it is very important to note
that the clinical safety profile of transendocardial
delivery so far has entailed precise preinjection measurements of needle extension with the injection
catheter tip deflected (to 90°) and not deflected,
arbitrary insistence on a maximal needle : wall ratio
of 0.6, and a conscious decision not to inject stem
cells into cardiac walls that are less than 8 mm thick
or into the true apical segment.
Transcoronary venous injection
Transcoronary venous injection is performed with
a catheter system threaded percutaneously into the
coronary sinus. Initial studies in swine have confirmed the feasibility and safety of this approach
[112]. This delivery method has also been used to
deliver skeletal myoblasts to scarred myocardium
in cardiomyopathy patients [113]. With intravascular ultrasound guidance, this approach allows
the operator to extend a catheter and needle away
from the pericardial space and coronary artery
into the adjacent myocardium. To date, human
feasibility studies have had a good safety profile.
This technique is limited, however, by coronary
venous tortuosity, lack of site specific targeting and
236 PART III Therapies and applications
its own technically challenging nature. Unlike the
transendocardial approach, in which cells are
injected perpendicularly into the left ventricular
wall, the transcoronary venous approach allows
parallel cell injection, which may result in greater
cell retention.
Comparisons of delivery methods
The biodistribution of intravenously injected allogeneic MSCs has been recently described [124].
Oxine-labeled MSCs were injected intravenously
72 hours after occlusion/reperfusion in seven dogs.
Initially, cells were trapped in the lungs; within 24
hours after injection, they had been redistributed
into the liver and spleen. Focal uptake and persistence of the stem cells was observed in a mid anterior wall location corresponding to the infarcted
target area.
Few studies have compared the different modes
of cell delivery. Hou et al. [125] have described
the fate of peripheral blood mononuclear cells
(PBMNCs) 1 hour after direct surgical injection,
intracoronary infusion and retrograde venous infusion in an acute swine ischemia-reperfusion model.
Overall, PBMNCs concentrated significantly more
in the pulmonary vasculature and parenchyma
than in the myocardium. Direct surgical injection
resulted in significantly less pulmonary retention
(26%) than did either intracoronary infusion (47%)
or retrograde venous infusion (43%). Cells were
scarcely present in the liver and spleen. Myocardial
homing, even in a setting of intense homing signaling, was limited in all three approaches, although
direct intramyocardial injection (11.3%) achieved
better homing and engraftment than did either
intracoronary infusion (2.6%) or retrograde venous infusion (3.2%).
Together, these data suggest that none of these
three delivery strategies are more than modestly
efficient at delivering cells to targeted regions. This
is of special concern in the case of intracoronary
delivery, which is the stem cell delivery method
most widely used after AMI. This has several
important clinical implications for the future of
cardiac stem cell therapy: higher doses might be
needed to achieve desired therapeutic effects, new
(e.g., combined) delivery strategies need to be considered, myocardial homing and signaling must be
better understood, and recipients of systemically
delivered cells must be followed up carefully and
closely.
Clinical trials of cardiac stem
cell therapy
Clinical research with bone marrow-derived stem
cells has focused on the period immediately after an
AMI and on the chronic phase of ischemic heart
disease. In these clinical scenarios, therapy has been
targeted to viable myocardium with or without systolic heart failure. On the other hand, skeletal
myoblast therapy has been used to treat ischemic
heart failure involving nonviable myocardium or
scar tissue and compromised systolic left ventricular function. In simple terms, skeletal myoblasts
offer “myocyte replacement therapy” for scarred
myocardial segments, and bone marrow stem cells
offer “neoangiogenic and regenerative therapy” for
acute and chronic ischemic heart disease involving
viable myocardial tissue.
Most of the clinical experience gained with stem
cells has involved therapy for AMI, particularly intracoronary infusion of bone marrow cells because
skeletal myoblasts are too large for this purpose
[126]. Table 10.2 summarizes the experience to
date. In all of these trials, revascularization was performed promptly after the index myocardial infarction, and left ventricular systolic compromise was
minor (in the BOOST trial, the baseline left ventricular ejection fraction [LVEF] was 50%).
In the Transplantation of Progenitor Cells and
Regeneration Enhancement in Acute Myocardial
Infarction (TOPCARE-AMI) trial, patients were
randomized to receive either bone marrow-derived
mononuclear cells or EPCs via intracoronary infusion [98]. Compared with the nonrandomized control patients, treated patients had a significantly
improved global LVEF, as assessed by left ventricular angiography, regardless of cell type used. More
recently, in a subgroup of this study population,
LVEF was significantly increased on cardiac MRI
and infarct size was reduced on late enhancement
MRI [99]. Interestingly, the ability of infused cells to
migrate was the most important predictor of infarct
remodeling. Cell therapy also increased coronary
flow reserve, possibly suggesting neovascularization.
The 1-year results of TOPCARE-AMI reinforce
the notion that stem cells protect against ventricular
CHAPTER 10
Stem cell therapy 237
Table 10.2 Trials of intracoronary cell therapy in patients with acute myocardial infarction.
Study
[n]
Cell type
Dose
Therapeutic effects
Time after
AMI
Improved
No change
Regional wall motion†
Global LVEF,
Perfusion†
LVEDV†
Nonrandomized
Strauer et al. [103]
10 treated
ABMMNC
2.8 ± 2.2 × 107
5–9 days
10 controls*
↓ Infarct size
TOPCARE-
29 ABMMNC
ABMMNC,
2.1 ± 0.8 × 108
AMI [98,99,102]
30 CPC
CPC
1.6 ± 1.2 × 107
5 ± 2 days
Regional wall motion†
LVEDV†
Global LVEF†
↓ Infarct size†
11 controls*
Coronary flow†
Fernandez-
20 treated
Aviles et al. [101]
13 controls*
ABMMNC
7.8 ± 4.1 × 107
14 ± 6 days
Regional wall motion†
LVEDV†
Global LVEF†
Randomized
BOOST [104]
30 treated,
NC
2.5 ± 0.9 × 1010
6 ± 1 days
30 controls
Chen et al. [100]
34 treated
MSC
4.8 ± 6.0 × 1010
35 controls
18 days
Regional wall motion
LVEDV
Global LVEF
Infarct size
Regional wall motion
Global LVEF
↓ Infarct size
↓ LVEDV
ABMMNC, autologous bone-marrow-derived mononuclear cells; AMI, acute myocardial infarction; BOOST, Bone Marrow
Transfer to Enhance ST Elevation Infarct Regeneration; CPC, circulating blood-derived progenitor cells; LVEDV, left
ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; MSC, mesenchymal stem cells; NC, bonemarrow-derived nucleated cells; TOPCARE, Transplantation of Progenitor Cells and Regeneration Enhancement.
* Nonrandomized control groups.
† Effects reported only within cell therapy groups. Values are mean ± standard deviation.
remodeling. Despite the limited number of patients,
contrast-enhanced MRI revealed a significantly
increased LVEF (P <0.001), significantly reduced
infarct size (P <0.001) and the absence of reactive
hypertrophy, suggesting that the infarcted ventricles had been functionally regenerated. Scientific
criticism of this trial has focused on the cell delivery
method, which included transient coronary occlusion and flow cessation, and its potential for ischemic preconditioning. Such preconditioning has
been shown to improve outcomes during AMI and
may have contributed to the functional improvement noted in this trial. Moreover, the occurrence
of in-stent thrombosis in one patient 3 days after
undergoing cell therapy has raised safety concerns.
The results of the randomized BOOST trial [104]
– the most important clinical trial of intracoronary infusion to date – have recently been published.
Patients received either bone marrow-derived
ABMMNCs or no treatment at all (no placebo).
Stem cell therapy resulted in an increased LVEF
and a reduced end-systolic volume, as assessed by
MRI. This improvement was attributed principally
to increased contractility of the peri-infarct zones.
Unlike earlier nonrandomized trials, the BOOST
trial did not show a significant reduction in infarct
size.
In a study by Bartunek et al. [127], 35 patients
were infused with AC133+ bone marrow cells after
AMI. The mean dose was 12.6 million cells, and the
Table 10.3 Cell therapy trials in patients with ischemic cardiomyopathy.
Study
Menasche et al. [107]
Herreros et al. [106]
[n]
LVEF
10 treated
24 ± 4%
11 treated
36 ± 8%
Cell type
Dose
Myoblasts
8.7 ± 1.9 ×
Myoblasts
1.9 ± 1.2 ×
108
108
Time after MI
Delivery
Outcomes in treated groups
3–228 months
Transepicardial
↑ Regional wall motion
(during CABG)*
↑ Global LVEF
Transepicardial
↑ Regional wall motion
(during CABG)†
↑ Global LVEF
3–168 months
↑ Viability in infarct area
Siminiak et al. [108]
Chachques et al. [142]
10 treated
20 treated
25–40%
28 ± 3%
Myoblasts
Myoblasts
0.04–5.0 × 107
3.0 ± 0.2 × 108
4–108 months
Not reported
Transepicardial
↑ Regional wall motion
(during CABG)†
↑ Global LVEF
Transepicardial
↑ Regional wall motion
(during CABG)*
↑ Global LVEF
↑ Viability in infarct area
Smits et al. [143]
Stamm et al. [109,110]
5 treated
12 treated
36 ± 11%
36 ± 11%
Myoblasts
CD133+
2.0 ± 1.1 × 10
8
1.0–2.8 × 10
6
24–132 months
3–12 weeks
Transendocardial
↑ Regional wall motion
(guided by EMM)
↑ Global LVEF
Transepicardial
↑ Global LVEF
(during CABG)*
↑ Perfusion
↓ LVEDV
Assmus et al. [144]
51 ABMMNC
35 CPC
40 ± 11%
ABMMNC
1.7 ± 0.8 × 108
CPC
2.3 ± 1.2 × 107
3–144 months
IC
↑ Global LVEF (only in
ABMMNC group)
16 controls
* CABG of noninjected territories only.
† CABG of injected and noninjected territories.
Values are mean ± standard deviation.
ABMMNC, autologous bone marrow mononuclear cells; AMI, acute myocardial infarction; BM, bone marrow; CABG, coronary artery bypass grafting; CD133+, bone-marrow–derived
CD133+ cells; CPC, circulating blood-derived progenitor cells; EMM, electromechanical mapping; IC, intracoronary; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular
ejection fraction; MI, myocardial infarction; NYHA, New York Heart Association.
CHAPTER 10
mean infusion was 11.4 days after the index event.
At 4-month follow-up, treated patients had an
improved mean LVEF but higher rates of stent
restenosis, stent reocclusion and de novo coronary
artery lesions than did the controls.
The intracoronary route has also been used to
deliver autologous MSCs. Chen et al. [100] recently
reported the first randomized clinical trial of these
cells in 69 patients who underwent a primary percutaneous coronary intervention within 12 hours
after an AMI. Either MSCs or saline was injected
into the target coronary artery. At 3-month followup, left ventricular perfusion and the LVEF had
significantly improved in the treatment group.
The feasibility and efficacy of G-CSF therapy and
subsequent intracoronary infusion of collected
peripheral blood stem cells were prospectively
investigated in the MAGIC randomized clinical
trial [128,129], which showed improved cardiac
function and promotion of angiogenesis in myocardial infarction patients. However, the trial raised
important safety questions. Intracoronary infusion
of G-CSF-stimulated peripheral-blood stem cells
apparently aggravated restenosis after coronary
stenting, leading to early termination of the trial.
Meanwhile, no temporal association between increased restenosis rate and stenting near the time of
intracoronary cell administration has been noted in
studies that did not use G-CSF stimulation.
A different therapeutic strategy using G-CSF
involved mobilization of CD34+ cells from the bone
marrow to the peripheral blood [32]. Thirty patients in the superacute phase of MI underwent
primary percutaneous revascularization. Eightyfive minutes after revascularization, 15 patients
were randomized to begin receiving G-CSF stimulation for up to 6 days. At 1-year follow-up, the GCSF treated patients had significantly improved
LVEF and stable end-diastolic diameters.
Outside the AMI setting, stem cells have been
used to treat patients with ischemic heart disease
with or without systolic functional compromise and
patients unsuitable for myocardial revascularization (Tables 10.3 and 10.4). Autologous bone marrow stem cells have been used to treat patients with
chronic myocardial ischemia, including ischemic
heart failure with or without systolic functional
compromise, and patients ineligible for myocardial
revascularization (Table 10.5). The preliminary
Stem cell therapy 239
clinical evidence supports the efficacy of this new
therapy and, at this point, all the evidence appears
to substantiate its safety.
Tse et al. [123] have reported that transendocardial injection of ABMMNCs in eight patients with
severe ischemic heart disease led to preserved left
ventricular function. At 3-month follow-up, heart
failure symptoms and myocardial perfusion had
improved, especially in the ischemic region as shown
by cardiac MRI (Plate 10.2).
Fuchs et al. [117] studied the clinical feasibility of
transendocardial delivery of filtered unfractionated
autologous bone marrow-derived (not mononuclear) cells in 10 patients with severe symptomatic
chronic myocardial ischemia not amenable to
conventional revascularization. Twelve targeted
injections (0.2 mL each) were administered into
ischemic noninfarcted myocardium identified previously by single-photon emission computed tomography (SPECT) perfusion imaging. No serious
adverse effects (i.e., arrhythmia, infection, myocardial inflammation or increased scar formation)
were noted. Moreover, even though treadmill exercise duration results did not change significantly
(391 ± 155 vs. 485 ± 198 s; P = 0.11), there was
improvement in Canadian Cardiovascular Society
angina scores (3.1 ± 0.3 vs. 2.0 ± 0.94; P = 0.001)
and in stress scores in segments within the injected
regions (2.1 ± 0.8 vs. 1.6 ± 0.8; P <0.001).
Our group performed the first clinical trial of
transendocardial injection of ABMMCs to treat
heart failure patients [26]. This study, performed in
collaboration with physicians and scientists at the
Hospital Pro-Cardiaco in Rio de Janeiro, Brazil,
used EMM-guided transendocardial delivery of
stem cells. The results of 2- and 4-month noninvasive and invasive follow-up evaluations [26] and of
6- and 12-month follow-up evaluation [122] have
already been published.
A total of 21 patients were enrolled. The first 14
comprised the treatment group, and the last 7
patients the control group. Baseline evaluations
included complete clinical and laboratory tests,
exercise stress (ramp treadmill) studies, twodimensional Doppler echocardiography, SPECT
perfusion scanning and 24-hour Holter monitoring. ABMMNCs were harvested, isolated, washed
and resuspended in saline for injection via NOGA
catheter (15 injections of 0.2 mL, totalling 30 × 106
240 PART III Therapies and applications
Table 10.4 Cell therapy trials in patients with myocardial ischemia and no revascularization option.
Study
Hamano et al. [105]
[n]
5 treated
LVEF
–
Cell Type
Dose
ABMMNC
0.3–2.2 × 10
Outcomes
Delivery
9
Transepicardial
Subjective
Objective
–
↑ Perfusion†
↓ Angina†
↑ Perfusion†
(during CABG)
Tse et al. [123]
8 treated
58 ± 11%
ABMMNC
From 40 mL
Transendocardial
BM
(guided by EMM)
↑ Regional
wall motion†
Fuchs et al. [117]
10 treated
47 ± 10%
NC
7.8 ± 6.6 × 107
↓ Angina†
↑ Perfusion†
Transendocardial
↓ Angina
↑ Perfusion
(guided by EMM)
↓ NYHA
↑ Regional
class
wall motion†
Transendocardial
(guided by EMM)
Perin et al. [26,122]
14 treated
30 ± 6%
ABMMNC
7 controls*
3.0 ± 0.4 × 107
↑ Global LVEF
ABMMNC, autologous bone-marrow-derived mononuclear cells; BM, bone marrow; CABG, coronary artery bypass grafting;
EMM, electromechanical mapping; LVEF, left ventricular ejection fraction; NC, bone-marrow-derived nucleated cells;
NYHA, New York Heart Association.
* Nonrandomized control group.
↑ Effects reported only within cell therapy groups. Values are mean ± standard deviation.
cells per patient) in viable myocardium (unipolar
voltage ≥6.9 mV). All patients underwent noninvasive follow-up tests at 2 months, and the treatment group also underwent invasive studies at 4
months, using standard protocols and the same
procedures as at baseline. The demographic and
exercise test variables did not differ significantly
between the treatment and control groups. There
were no procedural complications. At 2 months,
there was a significant reduction in the total reversible defect in the treatment group and between the
treatment and control groups (P = 0.02) on quantitative SPECT analysis. At 4 months, the LVEF
improved from a baseline of 20–29% (P = 0.003)
and the end-systolic volume decreased (P = 0.03)
in the treated patients. Electromechanical mapping
revealed significant mechanical improvement in
the injected segments (P <0.0005). In our opinion,
this established the safety of transendocardial
injection of ABMMNCs and warranted further
investigation of this therapy’s efficacy end-points.
This trial was important because for the first time
myocardial perfusion and cardiac function were
observed to improve in a group of severely impaired patients treated solely with stem cells. The
significant improvement seen at 2 and 4 months
was maintained at 6 and 12 months, even as exercise capacity improved slightly (Table 10.3). Monocyte, B cell, hematopoietic progenitor cell and
early hematopoietic progenitor cell subpopulations correlated with improvement in reversible
perfusion defects at 6 months (Table 10.4).
Clinical trials of skeletal myoblasts have focused
on the treatment of patients with ischemic cardiomyopathy and systolic dysfunction. Overall,
these trials have resulted in improved segmental
contractility and global LVEF. The preferred delivery route has been surgical intramyocardial injection, and one feasibility trial of transendocardial
injection has been reported in the literature so far.
Stem cell-induced functional
improvement in chronic
myocardial ischemia
Preclinical studies
Preclinical experiments have provided solid evidence supporting the efficacy of cardiac ABMMNC
therapy; however, further investigation at the molecular level is needed to elucidate the mechanistic
Table 10.5 Comparison of clinical values for the treatment and control groups at baseline, 2 months, 6 months and 12 months.
Variable
Baseline
Rx
2 Months
Control
Rx
6 Months
Control
Rx
12 Months
P value*
Control
Rx
Control
8.8 ± 9
32.7 ± 37
11.3 ± 12.8
34.3 ± 30.8
0.01
38 ± 6.7
36.4 ± 12
38.2 ± 8.5
35.2 ± 9.3
0.3
17.3 ± 6
SPECT
Total reversible defect, %
14.8 ± 14.5
20 ± 25.4
4.45 ± 11.5
Total fixed defect (50%), %
42.6 ± 10.3
38 ± 12
39.8 ± 6.9
39.1 ± 11.2
23.2 ± 8
18.3 ± 9.6
37 ± 38.4
Ramp treadmill test
17.3 ± 8
17.5 ± 6.7
24.2 ± 7
25.1 ± 8.7
18.2 ± 6.7
0.03
METS
5.0 ± 2.3
5.0 ± 1.91
6.6 ± 2.3
5.2 ± 2.7
7.2 ± 2.4
4.9 ± 1.7
7.2 ± 2.5
5.1 ± 1.9
0.02
LVEF
30 ± 6
37 ± 14
37 ± 6
27 ± 6
30 ± 10
28 ± 4
35.1 ± 6.9
34 ± 3
0.9
NYHA
2.2 ± 0.9
2.7 ± 0.8
1.5 ± 0.5
2.4 ± 1.0
1.3 ± 0.6
2.4 ± 0.5
1.4 ± 0.7
2.7 ± 0.5
0.01
CCSAS
2.6 ± 0.8
2.9 ± 1.0
1.8 ± 0.6
2.5 ± 0.8
1.4 ± 0.5
2 ± 0.1
1.2 ± 0.4
2.7 ± 0.5
0.002
PVCs, n
2507 ± 6243
672 ± 1085
901 ± 1236
2034 ± 4528
3902 ± 8267
1041 ± 1971
–
–
0.4
VO2 max, mL/kg/min
Functional class
dQRS, ms
136 ± 15
145 ± 61
145.9 ± 25
130 ± 27
144.8 ± 25
140 ± 61
–
–
0.62
LAS 40, ms
50 ± 24
70 ± 76
54 ± 33
48 ± 20
25 ± 25
66 ± 79
–
–
0.47
RMS 40, mV
22.2 ± 22
23.3 ± 23
23.3 ± 19
24.6 ± 28
25 ± 25
30 ± 27
–
–
0.7
* P value for comparisons between the treatment and control groups, as assessed by ANOVA, relating to treatment over time.
CCSAS, Canadian Cardiovascular Society Angina Score; dQRS, filtered QRS duration; LAS 40, duration of terminal low-amplitude signal less than 40 mV; LEVF, left ventricular ejection
fraction; METS, metabolic equivalents; NYHA, New York Heart Association; PVC, premature ventricular contraction; RMS 40, root mean square voltage in the terminal 40 ms of the
QRS complex; Rx, treatment; SPECT, single-photon emission computer tomography; VO2 max, maximal rate of oxygen consumption.
242 PART III Therapies and applications
aspects of stem cell therapy – an area where more
questions than answers remain.
Numerous research groups, using various detection methods in diverse experimental settings, have
proposed different mechanisms for the apparent
transformation of stem cells into cells of a variety of
tissues [5]. Some investigators attribute the transformation to the transdifferentiation potential of
stem cells [58,130,131], while others have it to be a
result of cell fusion [132].
Initial evidence indicates that ABMMNCs transdifferentiate into endothelial cells and cardiac
myocytes. Recent studies in mice, however, have
controversially challenged this notion. In a recent
study, Murry et al. [132] could detect no ABMMNC
transdifferentiation into a cardiomyocyte phenotype, despite the use of sophisticated genetic techniques for following cell fate and engraftment. In
experimental models, ABMMNCs have been shown
to depend on external signals that trigger secretory
properties and differentiation [133]. The local
environment of viable myocardial cells may provide the milieu necessary for inducing ABMMNC
myocyte differentiation [134]. In recent studies of
occlusion-induced myocardial infarction in rats, few
(if any) ABMMNCs might be expected to differentiate and express specific cardiac myocyte proteins,
depending on the injection site. To further clarify
the issue of transdifferentiation versus fusion, Zhang
et al. [135] elegantly used flow cytometry analysis to
study heart cell isolates from mice that had received
human CD34+ cells. HLA-ABC and cardiac troponin
T or Nkx2.5 were used to identify cardiomyocytes
derived from human CD34+ cells, and HLA-ABC
and VE-cadherin were used to identify the transformed endothelial cells. The double-positive cells
were tested for the expression of human and mouse
X chromosomes. As a result, 73.3% of nuclei derived
from HLA+ and troponin T+ or Nkx2.5+ cardiomyocytes contained both human and mouse X chromosomes, and 23.7% contained only human X
chromosomes. In contrast, the nuclei of HLA−, troponin T+ cells contained only mouse X chromosomes.
Furthermore, 97.3% of endothelial cells derived from
CD34+ cells contained human X chromosomes
only. Thus, human CD34+ cells both fused with and
transdifferentiated into cardiomyocytes in this
mouse model. In addition, human CD34+ cells also
transdifferentiated into endothelial cells.
The transdifferentiation of HSCs into a mature
hematopoietic fate (e.g., endothelium) in the heart
is less controversial [136]. In animal models of stem
cell therapy in ischemic heart disease, the evidence
points toward increased neovascularization (with
reduced myocardial ischemia) and consequent improvement in cardiac function [137–139]. Bone
marrow stem cells may directly contribute to an
increase in contractility or, more likely, may passively limit infarct expansion and remodeling.
Unfortunately, the limitations of the present animal models leave this question unanswered.
According to the current understanding of bone
marrow stem cell engraftment, most cells die
within the first days after delivery. Arteriogenesis
and vasculogenesis have long been known to be
highly dependent on vascular growth factors. In
light of the notion, recently proposed by Kinnaird
et al. [126,129], that MSCs contribute to angiogenesis by means of paracrine mechanisms, it may be
that therapeutic bone marrow stem cells recruit circulating progenitor cells, activate resident cardiac
stem cells, or both, via such paracrine means, thus
triggering a cascade of events resulting in cardiac
repair. The important role of resident cardiac stem
cells in the process of cardiac repair should also be
considered [75]. Urbanek et al. [38] were the first to
describe evidence of myocyte formation from cardiac stem cells in human cardiac hypertrophy.
Clinical trials
We recently described the postmortem study of one
of our patients who received ABMMNCs [140].
Eleven months after performing the treatment, we
observed no abnormal or disorganized tissue growth,
no abnormal vascular growth and no enhanced
inflammatory reactions. Histologic and immunohistochemical findings from infarcted areas of the
anterolateral ventricular wall (areas that had received
bone marrow cell injections) were reported. The
histologic findings from the anterolateral wall
region were subsequently compared with findings
from within the interventricular septum (which
had normal perfusion in the central region and no
cell therapy) and findings from the previously
infarcted inferoposterior ventricular wall (which
had extensive scarring and no cell therapy).
The observed effects of cell therapy were quite
intriguing: first, the cell-treated infarcted areas of
CHAPTER 10
(a) 600
500
400
300
200
100
0
Anterolateral Posterior
wall
wall
Septal
wall
Anterolateral Posterior
wall
wall
Septal
wall
(b) 500
400
300
200
100
0
(c)
50
40
Stem cell therapy 243
this patient’s heart had a higher capillary density
than did the nontreated infarcted areas (Fig. 10.3).
Second, smooth muscle α-actin-positive pericytes
and mural cells proliferated exclusively in the celltreated area. Third, these pericytes and mural cells
expressed specific cardiomyocyte proteins.
The angiogenesis literature makes clear that
pericytes are essential for long-lasting physiologic
angiogenesis. In our postmortem study, the cellinjected wall had marked areas of pericyte and
mural cells hyperplasia. The observed hypertrophic
pericytes, although still located in the vascular wall,
expressed specific myocardial proteins and were
found in locations distant from the vessel walls,
suggesting detachment. Migratory pericytes and
mural cells were found in adjacent tissue (in the
vicinity of cardiomyocytes) either isolated or in
small clumps. Closer to cardiomyocytes, the expression of myocardial proteins was enhanced,
yielding brighter immunostaining throughout the
whole cytoplasm. Within the posterior wall, none
of this was seen and small blood vessels were rare.
Although it would be premature to arrive at any
definitive conclusions about ABMMNC efficacy on
the basis of one postmortem study, the above
findings in the cell-treated wall are consistent with
neoangiogenesis. If confirmed in future human
studies, these findings would corroborate most of
the preclinical studies in chronic myocardial
ischemia models.
Safety of stem cell therapy
With regard to left ventricular function, cardiac
stem cell therapy is well tolerated overall. No proarrhythmic effects have been observed to date with
ABMMNC therapy, although other deleterious
30
20
10
0
Anterolateral
wall
Posterior
wall
Figure 10.3 Number of capillaries per mm2 in anterolateral,
posterior, and septal walls of studied heart. (a), Anti-factor
VIII-associated antigen counterstained with hematoxylin.
(b), Anti-smooth muscle-actin antigen counterstained with
hematoxylin. (c), Capillaries reacted with anti-factor VIIIassociated antigen inside fibrotic areas only in
anterolateral and posterior walls. (n = 108 microscope
fields for (a); 96 microscope fields for (b); and 40 microscopic
fields for (c).) Differences were statistically significant
among all groups in pairwise comparisons (P <0.05,
Newman-Keuls method) for (a) and (b). Differences were
significantly different (P <0.05) between anterolateral
and posterior walls in Mann–Whitney rank-sum test for (c).
244 PART III Therapies and applications
effects are possible. Early concerns about abnormal
transdifferentiation and tumorigenesis have subsided, but the potential for accelerated atherogenesis
remains, given the limited clinical experience and
the small number of patients treated. Because
atherosclerosis is an inflammatory disease triggered
and sustained by cytokines, adhesion molecules
and cellular components such as monocytes and
macrophages, intracoronary delivery is potentially
risky. In addition, as already mentioned, post
myocardial infarction intracoronary infusion has
been associated with increased rates of restenosis
and stent thrombosis. Given the small number of
patients treated in all Phase I and II trials so far, this
is a particular point of concern.
Another potential deleterious effect of bone
marrow stem cell therapy is myocardial calcification. In a recent study, Yoon et al. [141] noted
that direct transplantation of unselected bone marrow cells into acutely infarcted myocardium could
induce significant intramyocardial calcification.
In the same study, however, ABMMNCs did not.
Myoblast therapy raises the possibility of arrhythmogenic effects. Consequently, many clinical
studies require the placement of cardiac defibrillators in patients receiving myoblasts.
Conclusions
Despite many unresolved issues related to treatment dose, timing and delivery, the clinical potential of stem cell therapy for cardiovascular disease is
enormous. The expectations of both patients and
clinicians for this new therapeutic modality, however, are high and will require continued cooperation and close collaboration between basic and
clinical researchers.
References
1 Radovancevic, B, Vrtovec B, Frazier OH. Left ventricular assist devices: an alternative to medical therapy for
end-stage heart failure. Curr Opin Cardiol 2003; 18:
210–214.
2 Asahara T, Murohara T, Sullivan A et al. Isolation of
putative progenitor endothelial cells for angiogenesis.
Science 1997; 275: 964–967.
3 Shintani S, Murohara T, Ikeda H et al. Mobilization of
endothelial progenitor cells in patients with acute myocardial infarction. Circulation 2001; 103: 2776–2779.
4 Krause DS. Plasticity of marrow-derived stem cells.
Gene Ther 2002; 9: 754–758.
5 Perin EC, Geng YJ, Willerson JT. Adult stem cell therapy
in perspective. Circulation 2003; 107: 935–938.
6 Blau HM, Brazelton TR, Weimann JM. The evolving
concept of a stem cell: entity or function? Cell 2001; 105:
829–841.
7 Weissman IL. Stem cells: units of development, units of
regeneration, and units in evolution. Cell 2000; 100:
157–168.
8 Available from: www.nih.org
9 Korbling M, Estrov Z. Adult stem cells for tissue repair –
a new therapeutic concept? N Engl J Med 2003; 349:
570–582.
10 Rumpold H, Wolf D, Koeck R et al. Endothelial progenitor cells: a source for therapeutic vasculogenesis? J Cell
Mol Med 2004; 8: 509–518.
11 Asahara T, Masuda H, Takahashi T et al. Bone marrow
origin of endothelial progenitor cells responsible for
postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 1999; 85: 221–228.
12 Asahara T, Takahashi T, Masuda H et al. VEGF contributes to postnatal neovascularization by mobilizing
bone marrow-derived endothelial progenitor cells.
EMBO J 1999; 18: 3964–3972.
13 Bhattacharya V, McSweeney PA, Shi Q et al. Enhanced
endothelialization and microvessel formation in polyester grafts seeded with CD34+ bone marrow cells. Blood
2000; 95: 581–585.
14 Edelberg JM, Tang L, Hattori K et al. Young adult bone
marrow-derived endothelial precursor cells restore
aging-impaired cardiac angiogenic function. Circ Res
2002; 90: E89–E93.
15 Gehling UM, Ergun S, Schumacher U et al. In vitro differentiation of endothelial cells from AC133-positive
progenitor cells. Blood 2000; 95: 3106–3112.
16 Gill M, Dias S, Hattori K et al. Vascular trauma induces
rapid but transient mobilization of VEGFR2+AC133+
endothelial precursor cells. Circ Res 2001; 88: 167–174.
17 Gunsilius E, Petzer AL, Duba HC et al. Circulating
endothelial cells after transplantation. Lancet 2001; 357:
1449–1450.
18 Hatzopoulos AK, Fokman J, Vasile E et al. Isolation and
characterization of endothelial progenitor cells from
mouse embryos. Development 1998; 125: 1457–1468.
19 Iwaguro H, Yamaguchi J, Kalka C et al. Endothelial progenitor cell vascular endothelial growth factor gene
transfer for vascular regeneration. Circulation 2002; 105:
732–738.
20 Kalka C, Masuda H, Takahashi T et al. Transplantation
of ex vivo expanded endothelial progenitor cells for
therapeutic neovascularization. Proc Natl Acad Sci USA
2000; 97: 3422–3427.
CHAPTER 10
21 Kaushal S, Amiel GE, Guleserian KJ et al. Functional
small-diameter neovessels created using endothelial
progenitor cells expanded ex vivo. Nat Med 2001; 7:
1035–1040.
22 Lin Y, Weisdorf DJ, Solovey A et al. Origins of circulating endothelial cells and endothelial outgrowth from
blood. J Clin Invest 2000; 105: 71–77.
23 Murohara T, Ikeda H, Duan J et al. Transplanted cord
blood-derived endothelial precursor cells augment
postnatal neovascularization. J Clin Invest 2000; 105:
1527–1536.
24 Nieda M, Nicol A, Denning-Kendall P et al. Endothelial
cell precursors are normal components of human
umbilical cord blood. Br J Haematol 1997; 98: 775–757.
25 Peichev M, Neiyer AJ, Pereira D et al. Expression of
VEGFR-2 and AC133 by circulating human CD34+ cells
identifies a population of functional endothelial precursors. Blood 2000; 95: 952–958.
26 Perin EC, Dohmann HF, Borojevic R et al. Transendocardial, autologous bone marrow cell transplantation
for severe, chronic ischemic heart failure. Circulation
2003; 107: 2294–2302.
27 Schatteman GC, Hanlon HD, Jiao C et al. Blood-derived
angioblasts accelerate blood-flow restoration in diabetic
mice. J Clin Invest 2000; 106: 571–578.
28 Shi Q, Rafii S, Wu MH et al. Evidence for circulating
bone marrow-derived endothelial cells. Blood 1998; 92:
362–367.
29 Springer ML, Chen AS, Kraft PE et al. VEGF gene delivery to muscle: potential role for vasculogenesis in adults.
Mol Cell 1998; 2: 549–558.
30 Takahashi T, Kalka C, Masuda H et al. Ischemiaand cytokine-induced mobilization of bone marrowderived endothelial progenitor cells for neovascularization. Nat Med 1999; 5: 434–438.
31 Vasa M, Fichtlscherer S, Aicher A et al. Number and
migratory activity of circulating endothelial progenitor
cells inversely correlate with risk factors for coronary
artery disease. Circ Res 2001; 89: E1–E7.
32 Iwami Y, Masuda H, Asahara T. Endothelial progenitor
cells: past, state of the art, and future. J Cell Mol Med
2004; 8: 488–497.
33 Werner N, Kosiol S, Schiegl T et al. Circulating endothelial progenitor cells and cardiovascular outcomes.
N Engl J Med 2005; 353: 999–1007.
34 Ferrari G, Cusella-De Angelis G, Coletta M et al. Muscle
regeneration by bone marrow-derived myogenic progenitors. Science 1998; 279: 1528–1530.
35 Graf T. Differentiation plasticity of hematopoietic cells.
Blood 2002; 99: 3089–3101.
36 Beltrami AP, Barlucchi L, Torella D et al. Adult cardiac
stem cells are multipotent and support myocardial
regeneration. Cell 2003; 114: 763–776.
Stem cell therapy 245
37 Oh H, Bradfute SB, Gallardo TD et al. Cardiac progenitor cells from adult myocardium: homing, differentiation, and fusion after infarction. Proc Natl Acad Sci
USA 2003; 100: 12313–12318.
38 Urbanek K, Quaini F, Tasca G et al. Intense myocyte
formation from cardiac stem cells in human cardiac
hypertrophy. Proc Natl Acad Sci USA 2003; 100: 10440–
10445.
39 Orlic D, Kajstura J, Chimenti S et al. Bone marrow cells
regenerate infarcted myocardium. Nature 2001; 410:
701–705.
40 Quaini F, Urbanek K, Beltrami AP et al. Chimerism of
the transplanted heart. N Engl J Med 2002; 346: 5–15.
41 Kucia M, Ratajczak J, Ratajczak MZ. Bone marrow as a
source of circulating CXCR4+ tissue-committed stem
cells. Biol Cell 2005; 97: 133–146.
42 Baksh D, Song L, Tuan RS. Adult mesenchymal stem
cells: characterization, differentiation, and application
in cell and gene therapy. J Cell Mol Med 2004; 8: 301–
16.
43 Bruder SP, Jaiswal N, Haynesworth SE. Growth kinetics,
self-renewal, and the osteogenic potential of purified
human mesenchymal stem cells during extensive subcultivation and following cryopreservation. J Cell Biochem
1997; 64: 278–294.
44 Bruder SP, Kurth AA, Shea M et al. Bone regeneration
by implantation of purified, culture-expanded human
mesenchymal stem cells. J Orthop Res 1998; 16: 155–
162.
45 Kadiyala S, Young RG, Thiede MA et al. Culture
expanded canine mesenchymal stem cells possess osteochondrogenic potential in vivo and in vitro. Cell
Transplant 1997; 6: 125–134.
46 Awad HA, Butler DL, Boivin GP et al. Autologous mesenchymal stem cell-mediated repair of tendon. Tissue
Eng 1999; 5: 267–277.
47 Young RG, Butler DL, Weber W et al. Use of mesenchymal stem cells in a collagen matrix for Achilles tendon
repair. J Orthop Res 1998; 16: 406–413.
48 Galmiche MC, Koteliansky VE, Briere J et al. Stromal
cells from human long-term marrow cultures are mesenchymal cells that differentiate following a vascular
smooth muscle differentiation pathway. Blood 1993; 82:
66–76.
49 Dennis JE, Merriam A, Awadallah A et al. A quadripotential mesenchymal progenitor cell isolated from the
marrow of an adult mouse. J Bone Miner Res 1999; 14:
700–709.
50 Prockop DJ. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 1997; 276: 71–74.
51 Barry FP. Mesenchymal stem cell therapy in joint disease. Novartis Found Symp 2003; 249: 86–96; discussion
96–102, 170–174, 239–241.
246 PART III Therapies and applications
52 Chapel A, Bertho JM, Bensidhoum M et al. Mesenchymal
stem cells home to injured tissues when co-infused with
hematopoietic cells to treat a radiation-induced multiorgan failure syndrome. J Gene Med 2003; 5: 1028–1038.
53 Deng Y, Guo X, Yuan Q et al. Efficiency of adenoviral
vector mediated CTLA4Ig gene delivery into mesenchymal stem cells. Chin Med J (Engl) 2003; 116: 1649–1654.
54 Ortiz LA, Gambelli F, McBride C et al. Mesenchymal
stem cell engraftment in lung is enhanced in response to
bleomycin exposure and ameliorates its fibrotic effects.
Proc Natl Acad Sci USA 2003; 100: 8407–8411.
55 Saito T, Kuang JQ, Bittira B et al. Xenotransplant cardiac chimera: immune tolerance of adult stem cells. Ann
Thorac Surg 2002; 74: 19–24; discussion 24.
56 Pittenger MF, Martin BJ. Mesenchymal stem cells and
their potential as cardiac therapeutics. Circ Res 2004; 95:
9–20.
57 Tse WT, Pendleton JD, Beyer WM et al. Suppression
of allogeneic T-cell proliferation by human marrow
stromal cells: implications in transplantation. Transplantation 2003; 75: 389–397.
58 Silva GV, Litovsky S, Assad JA, Sousa AL, Martin BJ,
Vela D, Coulter SC, Lin J, Ober J, Vaughn WK, Branco
RV, Oliverra EM, He R, Geng YJ, Willerson JT, Perin
EC. Mesenchymal stem cells differentiate into an endothelial phenotype, enhance vascular density, and improve
heart function in a canine chronic ischemia model.
Circulation 2005; 111(2): 150–156.
59 Quirici N, Soligo D, Caneva L et al. Differentiation and
expansion of endothelial cells from human bone marrow CD133+ cells. Br J Haematol 2001; 115: 186–194.
60 Thomson JA, Itskovitz-Eldor J, Shapiro SS et al. Embryonic stem cell lines derived from human blastocysts.
Science 1998; 282: 1145–1147.
61 Hristov M, Erl W, Weber PC. Endothelial progenitor
cells: mobilization, differentiation, and homing. Arterioscler Thromb Vasc Biol 2003; 23: 1185–1189.
62 Harraz M, Jiao C, Hanlon HD et al. CD34 blood-derived
human endothelial cell progenitors. Stem Cells 2001; 19:
304–312.
63 Yoon CH, Hur J, Park KW et al. Synergistic neovascularization by mixed transplantation of early endothelial
progenitor cells and late outgrowth endothelial cells: the
role of angiogenic cytokines and matrix metalloproteinases. Circulation 2005; 112: 1618–1627.
64 Kucia M, Dawn B, Hunt G et al. Cells expressing early
cardiac markers reside in the bone marrow and are
mobilized into the peripheral blood after myocardial
infarction. Circ Res 2004; 95: 1191–1199.
65 Deb A, Wang S, Skelding KA et al. Bone marrowderived cardiomyocytes are present in adult human
heart: A study of gender-mismatched bone marrow transplantation patients. Circulation 2003; 107: 1247–1249.
66 Dowell JD, Rubart M, Pasumarthi et al. Myocyte and
myogenic stem cell transplantation in the heart. Cardiovasc Res 2003; 58: 336–350.
67 Menasche P. Cellular transplantation: hurdles remaining before widespread clinical use. Curr Opin Cardiol
2004; 19: 154–161.
68 Leor J, Patterson M, Quinones MJ et al. Transplantation
of fetal myocardial tissue into the infarcted myocardium of rat. A potential method for repair of infarcted
myocardium? Circulation 1996; 94: II332–II336.
69 Tambara K, Sakakibara Y, Sakaguchi F et al. Transplanted skeletal myoblasts can fully replace the infarcted
myocardium when they survive in the host in large
numbers. Circulation 2003; 108: II259–II263.
70 Williams RL, Hilton DJ, Pease S et al. Myeloid
leukaemia inhibitory factor maintains the developmental potential of embryonic stem cells. Nature 1988;
336: 684–687.
71 Cowan CA, Klimanskaya I, McMahon J et al. Derivation
of embryonic stem-cell lines from human blastocysts.
N Engl J Med 2004; 350: 1353–1356.
72 Itskovitz-Eldor J, Schuldiner M, Karsenti D et al.
Differentiation of human embryonic stem cells into
embryoid bodies compromising the three embryonic
germ layers. Mol Med 2000; 6: 88–95.
73 Sachinidis A, Fleischmann BK, Kolossov E et al. Cardiac
specific differentiation of mouse embryonic stem cells.
Cardiovasc Res 2003; 58: 278–291.
74 Lovell MJ, Mathur A. The role of stem cells for treatment of cardiovascular disease. Cell Prolif 2004; 37:
67–87.
75 Anversa P, Sussman MA, Bolli R. Molecular genetic
advances in cardiovascular medicine: focus on the
myocyte. Circulation 2004; 109: 2832–2838.
76 Messina E, De Angelis L, Frati G et al. Isolation and
expansion of adult cardiac stem cells from human and
murine heart. Circ Res 2004; 95: 911–921.
77 Dragoo JL, Choi JY, Lieberman JR et al. Bone induction
by BMP-2 transduced stem cells derived from human
fat. J Orthop Res 2003; 21: 622–629.
78 Safford KM, Hicok KC, Safford SD et al. Neurogenic
differentiation of murine and human adipose-derived
stromal cells. Biochem Biophys Res Commun 2002; 294:
371–379.
79 Zuk PA, Zhu M, Ashjian P et al. Human adipose tissue is
a source of multipotent stem cells. Mol Biol Cell 2002;
13: 4279–4295.
80 Rehman J, Traktuev D, Li J et al. Secretion of angiogenic
and antiapoptotic factors by human adipose stromal
cells. Circulation 2004; 109: 1292–1298.
81 Gronthos S, Franklin DM, Leddy HA et al. Surface protein characterization of human adipose tissue-derived
stromal cells. J Cell Physiol 2001; 189: 54–63.
CHAPTER 10
82 Wulf GG, Viereck V, Hemmerlein B et al. Mesengenic
progenitor cells derived from human placenta. Tissue
Eng 2004; 10: 1136–1147.
83 Erices A, Conget P, Minguell JJ. Mesenchymal progenitor cells in human umbilical cord blood. Br J Haematol
2000; 109: 235–242.
84 Jaiswal RK, Jaiswal N, Bruder SP et al. Adult human
mesenchymal stem cell differentiation to the osteogenic
or adipogenic lineage is regulated by mitogen-activated
protein kinase. J Biol Chem 2000; 275: 9645–9652.
85 Sims DE. Diversity within pericytes. Clin Exp Pharmacol
Physiol 2000; 27: 842–846.
86 Zuk PA, Zhu M, Mizuno H et al. Multilineage cells from
human adipose tissue: implications for cell-based therapies. Tissue Eng, 2001; 7: 211–228.
87 Lew WY. Mobilizing cells to the injured myocardium: a
novel rescue strategy or an unwelcome intrusion? J Am
Coll Cardiol 2004; 44: 1521–1522.
88 Maekawa Y, Anzai T, Yoshikawa T et al. Effect of granulocyte-macrophage colony-stimulating factor inducer
on left ventricular remodeling after acute myocardial
infarction. J Am Coll Cardiol 2004; 44: 1510–1520.
89 Toma C, Pittenger MF, Cahill KS et al. Human mesenchymal stem cells differentiate to a cardiomyocyte
phenotype in the adult murine heart. Circulation 2002;
105: 93–98.
90 Aicher A, Brenner W, Zuhayra M et al. Assessment of
the tissue distribution of transplanted human endothelial progenitor cells by radioactive labeling. Circulation
2003; 107: 2134–2139.
91 Barbash IM, Chouraqui P, Baron J et al. Systemic delivery of bone marrow-derived mesenchymal stem cells to
the infarcted myocardium: feasibility, cell migration,
and body distribution. Circulation 2003; 108: 863–
868.
92 Boekstegers P, von Degenfeld G, Giehrl W et al. Myocardial gene transfer by selective pressure-regulated
retroinfusion of coronary veins. Gene Ther 2000; 7:
232–240.
93 Murad-Netto S, Moura R, Romeo LJ et al. Stem cell
therapy with retrograde coronary perfusion in acute
myocardial infarction. A new technique. Arq Bras
Cardiol 2004; 83: 352–354; 349–351.
94 von Degenfeld G, Raake P, Kupatt C et al. Selective
pressure-regulated retroinfusion of fibroblast growth
factor-2 into the coronary vein enhances regional
myocardial blood flow and function in pigs with chronic
myocardial ischemia. J Am Coll Cardiol 2003; 42:
1120–1128.
95 Herity NA, Lo ST, Oei F et al. Selective regional myocardial infiltration by the percutaneous coronary venous
route: A novel technique for local drug delivery.
Catheter Cardiovasc Interv 2000; 51: 358–363.
Stem cell therapy 247
96 Hou D, Maclaughlin F, Thiesse M et al. Widespread
regional myocardial transfection by plasmid encoding
Del-1 following retrograde coronary venous delivery.
Catheter Cardiovasc Interv 2003; 58: 207–211.
97 Raake P, von Degenfeld G, Hinkel R et al. Myocardial
gene transfer by selective pressure-regulated retroinfusion of coronary veins: comparison with surgical and
percutaneous intramyocardial gene delivery. J Am Coll
Cardiol 2004; 44: 1124–1129.
98 Assmus B, Schachinger V, Teupe C et al. Transplantation of progenitor cells and regeneration enhancement
in acute myocardial infarction (TOPCARE-AMI). Circulation 2002; 106: 3009–3017.
99 Britten MB, Abolmaali ND, Assmus B et al. Infarct
remodeling after intracoronary progenitor cell treatment in patients with acute myocardial infarction
(TOPCARE-AMI): mechanistic insights from serial
contrast-enhanced magnetic resonance imaging. Circulation 2003; 108: 2212–2218.
100 Chen SL, Fang WW, Ye F et al. Effect on left ventricular
function of intracoronary transplantation of autologous
bone marrow mesenchymal stem cell in patients with acute
myocardial infarction. Am J Cardiol 2004; 94: 92–95.
101 Fernandez-Aviles F, San Roman JA, Garcia-Frade J et al.
Experimental and clinical regenerative capability of
human bone marrow cells after myocardial infarction.
Circ Res 2004; 95: 742–748.
102 Schachinger V, Assmus B, Britten MB et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction: final one-year
results of the TOPCARE-AMI Trial. J Am Coll Cardiol
2004; 44: 1690–1699.
103 Strauer BE, Brehm M, Zeus T et al. Repair of infarcted
myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans.
Circulation 2002; 106: 1913–1918.
104 Wollert KC, Meyer GP, Lotz J et al. Intracoronary autologous bone-marrow cell transfer after myocardial
infarction: the BOOST randomised controlled clinical
trial. Lancet 2004; 364: 141–148.
105 Hamano K, Nishida M, Hirata K et al. Local implantation of autologous bone marrow cells for therapeutic
angiogenesis in patients with ischemic heart disease:
clinical trial and preliminary results. Jpn Circ J 2001; 65:
845–847.
106 Herreros J, Prosper F, Perez A et al. Autologous
intramyocardial injection of cultured skeletal musclederived stem cells in patients with non-acute myocardial infarction. Eur Heart J 2003; 24: 2012–2120.
107 Menasche P, Hagege AA, Vilquin JT et al. Autologous
skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction. J Am Coll Cardiol 2003;
41: 1078–1083.
248 PART III Therapies and applications
108 Siminiak T, Kalawski R, Fiszer D et al. Autologous
skeletal myoblast transplantation for the treatment of
postinfarction myocardial injury: phase I clinical study
with 12 months of follow-up. Am Heart J 2004; 148:
531–537.
109 Stamm C, Kleine HD, Westphal B et al. CABG and bone
marrow stem cell transplantation after myocardial
infarction. Thorac Cardiovasc Surg 2004; 52: 152–158.
110 Stamm C, Westphal B, Kleine HD et al. Autologous
bone-marrow stem-cell transplantation for myocardial
regeneration. Lancet 2003; 361: 45–46.
111 Hill JM, Dick AJ, Raman VK et al. Serial cardiac magnetic resonance imaging of injected mesenchymal stem
cells. Circulation 2003; 108: 1009–1014.
112 Thompson CA, Nasseri BA, Makower J et al. Percutaneous transvenous cellular cardiomyoplasty. A novel
nonsurgical approach for myocardial cell transplantation. J Am Coll Cardiol 2003; 41: 1964–1971.
113 Siminiak T, Fiszer D, Jerzykowska O et al. Percutaneous
trans-coronary-venous transplantation of autologous
skeletal myoblasts in the treatment of post-infarction
myocardial contractility impairment: the POZNAN
trial. Eur Heart J 2005; 26: 1188–1195.
114 Sarmento-Leite R, Silva GV, Dohman HF et al.
Comparison of left ventricular electromechanical mapping and left ventricular angiography: defining practical
standards for analysis of NOGA maps. Tex Heart Inst J
2003; 30: 19–26.
115 Perin EC, Silva GV, Sarmento-Liete R et al. Assessing
myocardial viability and infarct transmurality with left
ventricular electromechanical mapping in patients with
stable coronary artery disease: validation by delayedenhancement magnetic resonance imaging. Circulation
2002; 106: 957–961.
116 Fuchs S, Baffour R, Zhou YF et al. Transendocardial
delivery of autologous bone marrow enhances collateral
perfusion and regional function in pigs with chronic
experimental myocardial ischemia. J Am Coll Cardiol
2001; 37: 1726–1732.
117 Fuchs S, Satler LF, Kornowski R et al. Catheter-based
autologous bone marrow myocardial injection in nooption patients with advanced coronary artery disease:
a feasibility study. J Am Coll Cardiol 2003; 41: 1721–
1724.
118 Kamihata H, Matsubara H, Nishiue T et al. Improvement of collateral perfusion and regional function by
implantation of peripheral blood mononuclear cells
into ischemic hibernating myocardium. Arterioscler
Thromb Vasc Biol 2002; 22: 1804–1810.
119 Kawamoto A, Tkebuchava T, Yamaguchi J et al. Intramyocardial transplantation of autologous endothelial
progenitor cells for therapeutic neovascularization of
myocardial ischemia. Circulation 2003; 107: 461–468.
120 Kornowski R, Fuchs S, Tio FO et al. Evaluation of the
acute and chronic safety of the biosense injection
catheter system in porcine hearts. Catheter Cardiovasc
Interv 1999; 48: 447–453; discussion 454–455.
121 Kornowski R, Leon MB, Fuchs S et al. Electromagnetic
guidance for catheter-based transendocardial injection:
a platform for intramyocardial angiogenesis therapy.
Results in normal and ischemic porcine models. J Am
Coll Cardiol 2000; 35: 1031–1039.
122 Perin EC, Dohmann HF, Borojevic R et al. Improved
exercise capacity and ischemia 6 and 12 months after
transendocardial injection of autologous bone marrow
mononuclear cells for ischemic cardiomyopathy. Circulation 2004; 110: II213–II218.
123 Tse HF, Kwong YL, Chan JK et al. Angiogenesis in
ischaemic myocardium by intramyocardial autologous
bone marrow mononuclear cell implantation. Lancet
2003; 361: 47–49.
124 Kraitchman DL, Tatsumi M, Gilson WD et al. Dynamic
imaging of allogeneic mesenchymal stem cells trafficking to myocardial infarction. Circulation 2005; 112:
1451–1461.
125 Hou D, Youssef EA, Brinton TJ et al. Radiolabeled cell
distribution after intramyocardial, intracoronary, and
interstitial retrograde coronary venous delivery: implications for current clinical trials. Circulation 2005; 112:
I150–I156.
126 Kinnaird T, Stabile E, Burnett MS et al. Local delivery
of marrow-derived stromal cells augments collateral
perfusion through paracrine mechanisms. Circulation
2004; 109: 1543–1549.
127 Bartunek J, Vanderheyden M, Vandekerckhove B et al.
Intracoronary injection of CD133-positive enriched
bone marrow progenitor cells promotes cardiac recovery after recent myocardial infarction: feasibility and
safety. Circulation 2005; 112: I178–I183.
128 Kang HJ, Kim HS, Zhang SY et al. Effects of intracoronary infusion of peripheral blood stem-cells mobilised
with granulocyte-colony stimulating factor on left ventricular systolic function and restenosis after coronary
stenting in myocardial infarction: the MAGIC cell randomised clinical trial. Lancet 2004; 363: 751–756.
129 Kinnaird T, Stabile E, Burnett MS et al. Marrow-derived
stromal cells express genes encoding a broad spectrum
of arteriogenic cytokines and promote in vitro and in
vivo arteriogenesis through paracrine mechanisms. Circ
Res 2004; 94: 678–685.
130 Goodell MA. Stem-cell “plasticity”: befuddled by the
muddle. Curr Opin Hematol 2003; 10: 208–213.
131 Hocht-Zeisberg E, Kahnert H, Guan K et al. Cellular
repopulation of myocardial infarction in patients with
sex-mismatched heart transplantation. Eur Heart J
2004; 25: 749–758.
CHAPTER 10
132 Murry CE, Soonpaa MH, Reinecke H et al. Haematopoietic stem cells do not transdifferentiate into cardiac
myocytes in myocardial infarcts. Nature 2004; 428:
664–668.
133 Losordo DW, Dimmeler S. Therapeutic angiogenesis
and vasculogenesis for ischemic disease: part II: cellbased therapies. Circulation 2004; 109: 2692–2697.
134 Yeh ET, Zhang S, Wu HD et al. Transdifferentiation
of human peripheral blood CD34+-enriched cell population into cardiomyocytes, endothelial cells, and smooth
muscle cells in vivo. Circulation 2003; 108: 2070–2073.
135 Zhang S, Wang D, Estrov Z et al. Both cell fusion and
transdifferentiation account for the transformation
of human peripheral blood CD34-positive cells into
cardiomyocytes in vivo. Circulation 2004; 110: 3803–
3807.
136 Forrester JS, Price MJ, Makkar RR. Stem cell repair of
infarcted myocardium: an overview for clinicians. Circulation 2003; 108: 1139–1145.
137 Duan HF, Wu CT, Wu DL et al. Treatment of myocardial ischemia with bone marrow-derived mesenchymal
stem cells overexpressing hepatocyte growth factor. Mol
Ther 2003; 8: 467–474.
138 Kudo M, Wang Y, Wani MA et al. Implantation of bone
marrow stem cells reduces the infarction and fibrosis in
ischemic mouse heart. J Mol Cell Cardiol 2003; 35:
1113–1119.
139 Tang YL, Zhao Q, Zhang YC et al. Autologous mesenchymal stem cell transplantation induce VEGF and
neovascularization in ischemic myocardium. Regul Pept
2004; 117: 3–10.
140 Dohmann HF, Perin EC, Takiya CM et al. Transendocardial autologous bone marrow mononuclear cell
injection in ischemic heart failure: postmortem anato-
141
142
143
144
145
146
Stem cell therapy 249
micopathologic and immunohistochemical findings.
Circulation 2005; 112: 521–526.
Yoon YS, Park JS, Tkebuchava T et al. Unexpected
severe calcification after transplantation of bone marrow cells in acute myocardial infarction. Circulation
2004; 109: 3154–3157.
Chachques JC, Herreros J, Trainini J, Juffe A, Rendal E,
Prosper F, Genovese J. Autologous human serum for
cell culture avoids the implantation of cardioverterdefibrillators in cellular cardiomyoplasty. Int J Cardiol.
2004; 95(Suppl I): 29–33.
Smits PC, van Geuns RJ, Poldermans D, Bountioukos
M, Onderwater EE, Lee CH, Maat AP, Serruys PW.
Catheter-based intramyocardial injection of autologous
skeletal myoblasts as a primary treatment of ischemic
heart failure: clinical experience with six-month followup. J Am Coll Cardiol. 2003; 42: 2063-2069.
Assmus B, Honold J, Lehmaun R, Pistorius K, Hoffman
WK, Martin H, Schachinger V, Zeiher AM. Transcoronary transplantation of progenitor cells and recovery
of left ventricular function in patients with chronic
ischemic heart disease: results of a randomized, controlled trial. Circulation. 2004; 110 (Suppl III): 238.
Wollert KC, Drexler H. Clinical applications of stem
cells for the heart. Circ Res. 2005 Feb 4; 96 (2): 151–163.
(with permission)
Perin EC, Dohmann HF, Borojevic R, Silva SA, Sousa AL,
Silva GV, Mesquita CT, Belem L, Vaughn WK, Rangel
FO, Assad JA, Carvalho AC, Branco RV, Rossi MI,
Dohmann HJ, Willerson JT. Improved exercise capacity
and ischemia 6 and 12 months after transendocardial
injection of autologous bone marrow mononuclear cells
for ischemic cardiomyopathy. Circulation. 2004 Sep 14;
110(11 Suppl 1): II213–8. (with permission)
11
CHAPTER 11
Pharmacogenetics and
personalized medicine
Julie A. Johnson, PharmD, FCCP, BCPS, & Issam Zineh, PharmD
Introduction
Pharmacogenetics and pharmacogenomics aim
to provide an understanding of the genetic basis
for interpatient variability in drug response. Pharmacogenetics is an older term that has typically been
attributed to studies focused on genetic associations between drug response and a single gene (the
majority of studies to date). Pharmacogenetics and
pharmacogenomics are increasingly being used
synonymously, although some will argue that pharmacogenomics describes approaches that investigate
a plethora of genes or the entire genome, as it
relates to drug response. Because most of the studies in the literature to date focus on one or a few
genes, we will use the term pharmacogenetics.
Knowledge gained through pharmacogenetics
and pharmacogenomics research has numerous
potential benefits. For example, pharmacogenetics
may lead to a better understanding of the mechanisms by which drugs provide their benefit in various disease states. While the drug pharmacology
provides some of this understanding, there are
numerous examples of drugs (e.g., angiotensinconverting enzyme [ACE] inhibitors, statins)
where the benefits seem to extend beyond the purported primary pharmacologic mechanism. When
genetic polymorphisms are associated with variable
response to a given drug, this suggests that the
gene’s encoded protein has a role in the drug’s
mechanism. An example of this is the α-adducin
protein, whose genetic variability has been associated with diuretic response in several studies (discussed below). α-Adducin’s physiologic function is
consistent with involvement in the action of diur-
250
etics, but it is not a protein that has historically been
linked to the mechanism of action of diuretics. As
genome-wide approaches are more commonly
used in pharmacogenomics investigations, there
will be increasing numbers of such examples.
In similar ways, pharmacogenetics may help
provide insights into the genetic basis for disease.
For example, genes that are found to be associated
with drug response in a given disease state could
then be very strong candidates as disease genes,
assuming that the drug works by providing more
than just symptomatic benefit.
Pharmacogenomics may also be used in drug
discovery and/or drug development. In the case of
drug discovery, one approach is to use genomic
approaches in individuals with (cases) and without
(controls) the disease of interest. For those genes
with different signals between cases and controls,
their encoded proteins may represent rational drug
targets for that disease. It is estimated that there are
approximately 10,000 potential drug targets in the
body, but all of the currently available drugs use
only 500 of those targets. Thus, there is potential for
many additional drugs with unique mechanisms of
action, possibly identified through a pharmacogenomics approach. There are currently several cancer drugs that have been discovered in this way, but
no such examples yet among the cardiovascular
drugs.
Pharmacogenetics and pharmacogenomics may
also lead to improvements in drug development.
Within cardiovascular diseases, this is perhaps easiest to envision in heart failure. There are numerous heart failure drugs that have failed in late Phase
III clinical trials (e.g., vasopeptidase inhibitors,
CHAPTER 11
endothelin blockers, tumor necrosis factor α
[TNF-α] blockers), and so use of pharmacogenetics in the drug development process might be
beneficial in such situations. Specifically, it is
believed that in a broad population of heart failure
patients, additional neurohormonal blockade cannot achieve sufficient benefit across the population.
However, there is likely to be a smaller subpopulation that might benefit from such therapy. The
potential approach is that the genetic polymorphisms associated with response would be
identified in Phase II studies, and then the Phase III
studies would be enriched with patients with the
target genotypes. Although enrollment was not
based on genotype per se, this is in essence what led
to the successful clinical trial with isosorbide dinitrate (ISDN)–hydralazine (and the subsequent
Food and Drug Administration [FDA] approval of
the combination product) [1]. Whether companies
that were developing these drugs will go back and
attempt to resurrect them using pharmacogenetics
remains to be seen.
To the clinician, the greatest promise of pharmacogenetics is the potential to optimize drug therapy
for a specific patient based on their genetic information. In some cases this will mean using
genetic information to optimize efficacy, in others
to minimize adverse drug effects. Currently, drug
therapy of cardiovascular diseases is essentially
either empirical (e.g., trial and error approach to
hypertension, angina, dyslipidemia) or protocoldriven (e.g., acute coronary syndromes, heart failure, stroke prevention). In either approach, there
will be patients who will not derive the desired
benefit or will experience adverse effects from
a specific drug. In the case of diseases treated by
trial and error, use of genetic information might
streamline this process, such that more rapid
identification of the optimal therapy for a given
patient might be accomplished. In the case of diseases managed per protocol, use of genetic information might facilitate the decision not to treat a
certain patient with a given drug if it is predicted to
provide little benefit, so as to allow for other therapies that might be beneficial. This is easiest to envision in heart failure, where the list of standard or
recommended drugs continues to grow, and there
are increasing concerns about how these regimens
might be simplified.
Pharmacogenetics 251
Thus, the promise of pharmacogenetics is highlighted in Plate 11.1. In this paradigm, those likely
to have an efficacious response, no response or
toxicity can be predicted based on genetic information prior to initiation of therapy. This is in contrast to the current approach of prescribing the
drug, and then once the patient is on therapy,
determining to which of these three response
groups they belong.
Herein, we review the advances in pharmacogenetics in the various therapeutic areas of
cardiovascular medicine, highlighting studies in
the literature and future clinical potential of pharmacogenetics for the given area. Examples of genes
that have been studied with some significant associations between genotype and drug response are
shown in Table 11.1.
Pharmacogenetics of dyslipidemia
Dyslipidemia has been long recognized as an
important risk factor for cardiovascular disease.
Consequently, treatment of elevated low density
lipoprotein (LDL) cholesterol and mixed dyslipidemia (elevated LDL, low high density lipoprotein
[HDL] and elevated triglycerides) is a cornerstone
of both primary and secondary prevention strategies [2,3]. Despite an armamentarium of cholesterol-modifying drugs that includes HMG-CoA
reductase inhibitors (statins), fibric acid derivatives
(e.g., gemfibrozil, fenofibrate), bile acid sequestrants (e.g., colestyramine, colestipol, colesevelam),
niacin, intestinal cholesterol absorption inhibitors
(ezetimibe) and others, achieving consensus guideline-recommended lipoprotein levels in patients
remains challenging. The inability to routinely
achieve cholesterol goals may be related to multiple
biologic and nonbiologic factors, with variability in
pharmacokinetic and pharmacodynamic genes
perhaps contributing.
Pharmacogenetics of HMG-CoA
reductase inhibitors
Statin drugs are the most commonly used
cholesterol-modifying agents in clinical practice.
Furthermore, studies evaluating contribution of
genetic variability to differential cholesterol-lowering
response to drugs are most abundant for the statin
drug class [4]. To date, there have been approximately
252 PART III Therapies and applications
Table 11.1 Sample candidate pharmacokinetic and pharmacodynamic genes for statin pharmacogenetic studies.
Gene symbol
Common name of encoded protein
OMIM No.*
Drugs
Pharmacokinetics
ABCB1
P-glycoprotein
171050
Statins, digoxin, CCBs
CYP3A4
Cytochrome P450 3A4
124010
Statins, CCBs
CYP3A5
Cytochrome P450 3A5
605325
Statins, CCBs
CYP2C9
Cytochrome P450 2C9
601130
Statins, warfarin, ARBs
CYP2D6
Cytochrome P450 2D6
124030
Statins, beta-blockers, CCBs
SLCO1B1
OATP1B1 aka OATP-C
604843
Statins
Pharmacodynamics
ABCA1
ATP-binding cassette, subfamily A, member 1
600046
Statins
ABCG5
ATP-binding cassette, subfamily G, member 5
605459
Statins
ABCG8
ATP-binding cassette, subfamily G, member 8
605460
Statins
ACE
Angiotensin I-converting enzyme
106180
Statins, fibrates, ACE-I, spironolactone
APOB
Apolipoprotein B
107730
Statins
APOE
Apolipoprotein E
107741
Statins, fibrates
ADRB1
b1-adrenergic receptor
109630
Beta-blockers, b-agonists
ADRB2
b2-adrenergic receptor
109690
Beta-blockers, b-agonists
ADD1
a-adducin
102680
Diuretics
CETP
Cholesteryl ester transfer protein
118470
Statins, fibrates
FCGR2A
Immunoglobulin G Fc receptor II
14670
Heparin
GNB3
G protein b3 subunti
139130
Diuretics
HMGCR
HMG CoA reductase
142910
Statins
ITGB3
Platelet glycoprotein IIIa
173470
Statins, aspirin, GPIIb/IIIa blockers
LDLR
Low density lipoprotein receptor
606945
Statins
LPL
Lipoprotein lipase
238600
Statins, fibrates
NOS3
Endothelial nitric oxide synthase
163729
Hydralazine/nitrate
NPC1L1
Neimann-Pick C1-like 1 protein
608010
Ezetimibe
P2RY12
Platelet ADP receptor
600515
Clopidogrel
PPARA
Peroxisome proliferator-activated receptor a
170998
Statins, fibrates
PTGS1
COX-1
176805
Aspirin
SREBF1
Sterol regulatory element-binding transcription
184756
Statins
608547
Warfarin
factor 1 (SREBP1)
VKORC1
Vitamin K epoxide reductase complex, subunit 1
ACE-I, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blocker; ADP, adenosine diphosphate; CCB,
calcium channel blocker; COX, cyclo-oxygenase; GPIIb/IIIa, glycoprotein IIb/IIIa; OATP, organic anion transporter protein;
SREBP, sterol regulatory element-binding protein.
* OMIM, Online Mendelian Inheritance of Man (http://www.ncbi.nlm.nih.gov/omim/omimfaq.html).
50 statin pharmacogenetic studies involving polymorphisms in more than 30 genes. The phenotype
of interest is overwhelmingly lipoprotein response,
although phenotypes also include pharmacokinetics, drug tolerability and safety, compliance/adherence and clinical outcomes.
Candidate gene lists for statin pharmacogenetic
studies invariably include genes whose protein
products are thought to be important in statin
pharmacokinetics/drug disposition (Table 11.2).
The variability in response and tolerability to statins
may be related to variability in hepatic uptake and
metabolism of the drugs. To the extent that the liver
is the site of action for LDL-lowering effects of statins,
heterogeneity in hepatic uptake of these agents may
contribute to heterogeneity in patient responses
[5]. Furthermore, as many statins are metabolized
by the hepatic cytochrome P450 (CYP) isoenzyme
CHAPTER 11
Pharmacogenetics 253
Table 11.2 Select statin pharmacogenetics studies of involving genes related to pharmacodynamics.
Gene/protein
Drug
Polymorphism
End-point(s)
Genetic association with
Reference
end-point*
ACE
Fluvastatin
I/D
Lipids; CAD progression/
Yes (both outcomes)
[170]
No
[171]
Yes (D-dimer and CRP)
[172]
Yes (apoAI)
[173]
Yes (LDL, D19H of ABCG8;
[174,175]
regression
Pravastatin
I/D
Lipids; fatal CAD or
non-fatal MI
Atorvastatin
I/D
Fibrinolytic markers;
adhesion markers;
C-reactive protein (CRP)
ABCA1
Fluvastatin
-477C/T; -320G/C
Lipids; CAD progression/
regression
ABCG5/ABCG8
APOB
APOE
CETP
Atorvastatin
Fluvastatin
Q604E; D19H;
Lipids
Y54C; T400K;
effect enhanced in CYP7A1
A632V
-204A/A genotype)
I/D
Lipids
Yes (LDL, women)
[176]
XbaI; EcoRI
Lipids
No
[176]
Simvastatin
XbaI
Lipids
Yes
[177]
Lovastatin
XbaI
Lipids
No
[178]
Pravastatin
e2; e3; e4
Lipids
No
[179]
Atorvastatin
e2; e3; e4
Lipids
Yes (gender-specific)
[29]
Simvastatin
e2; e3; e4
Lipids; mortality
Yes
[31,34]
Lovastatin
e2; e3; e4
Lipids
Yes
[180]
Fluvastatin
e2; e3; e4
Lipids; CAD progression
Yes (lipids)
[30]
Atorvastatin
B1/B2 (TaqIB)
Lipids
Yes (HDL)
[181]
Pravastatin
B1/B2 (TaqIB)
Lipids; CAD progression;
Yes (angiographic changes)
[182]
fatal CAD or non-fatal MI
CAD incidence
No
[183,184]
Miscellaneous
B1/B2 (TaqIB)
Lipids, CVD events
Yes (events)
[185]
Fluvastatin
Various haplotypes
Lipids
Yes
[18]
HMGCR
Pravastatin
SNP 12A/T; 29T/G
Lipids
Yes (TC and LDL)
[27]
IL-6
Fluvastatin
-174G/C
Lipids; CAD progression;
Yes (Lp(a) concentrations)
[186]
Yes (both outcomes)
[187]
No
[187]
events
Pravastatin
-174G/C
Lipids; first fatal or
nonfatal CV event
-572G/C
Lipids; first fatal or
nonfatal CV event
SCAP
Pravastatin
Ile796Val
Lipids; coronary reactivity No
[188]
Fluvastatin
Ile796Val
Lipids; CAD progression;
No
[189]
Yes (TC and triglycerides)
[190]
events
Simvastatin
Ile796Val
Lipids
254 PART III Therapies and applications
Table 11.2 (cont’d)
Gene/protein
Drug
Polymorphism
End-point(s)
Genetic association
Reference
with end-point*
SREBF1
Fluvastatin
-36G+/−
Lipids; CAD progression;
Yes (apoAI concentrations)
[189]
events
TLR4
Simvastatin
-36G+/−
Lipids
No
[190]
Pravastatin
Asp299Gly
Lipids; CAD progression;
Yes (events)
[184]
No
[184]
events
Thr399Ile
Lipids; CAD progression;
events
ACE, angiotensin-converting enzyme; APOE, apolipoprotein E; CETP, cholesteryl ester transfer protein; HDL, high density
lipoprotein; HMGCR, HMG CoA reductase; IL-6, interleukin-6; LDL, low density lipoprotein; MI, myocardial infarction; SCAP,
SREBF cleavage activating protein; SNP, single nucleotide polymorphism; SREBF1, sterol regulatory element-binding
transcription factor; TLR, toll-like receptor.
* In the case of genetic associations with hard clinical end-points, the association may denote excess cardiovascular risk in a
genotype group given placebo is attenuated in the presence of statin therapy.
system, variability in drug metabolism may also
be an important factor in both statin efficacy and
toxicity [6].
Hepatic uptake of statins is an important first
step in the drug response pathway in that this step
results in statin transport to both their site of action
and elimination. The organic anion transporter
(OAT) group of proteins appears to be important
in various processes that could affect statin exposure in vivo including drug absorption, hepatic
uptake and renal elimination [7–9]. OATP-C
(encoded by the SLCO1B1 gene) is a transporter
protein found in hepatocytes, and is postulated to
influence the uptake of pravastatin, simvastatin,
atorvastatin and rosuvastatin.
SLCO1B1 is genetically polymorphic with at
least 14 non-synonymous (causing an amino acid
change) single nucleotide polymorphisms (SNPs)
and many other synonymous variants reported in
the literature [10]. Furthermore, many of these polymorphisms have been shown to affect the expression or activity of OATP-C [11]. The impact of
SLCO1B1 polymorphisms on differing statin phenotypes was initially investigated in pharmacokinetic studies of pravastatin [12–14]. SLCO1B1
genotypes and haplotypes were associated with
differences in pravastatin drug exposure (e.g., area
under the plasma concentration–time curve, nonrenal clearance and total clearance). However, it was
unclear as to whether this variability in drug exposure translates into differences in drug effect.
For example, if individuals carry variant SLCO1B1
alleles that reduce hepatic uptake of statins and
increase systemic exposure to these agents, it can
be hypothesized that these patients would perhaps
be more likely to experience reduced efficacy in
terms of cholesterol modulation and increased
systemic toxicity (e.g., myopathic syndromes)
when compared with their homozygous wild-type
counterparts.
In an attempt to answer this question, one study
evaluated the role of SLCO1B1 polymorphisms on
statin pharmacodynamics [15]. Forty-one healthy
Caucasian individuals were treated with a single
dose of 40 mg pravastatin, and surrogate markers
of hepatic HMG-CoA reductase inhibition (i.e.,
plasma cholesterol and lathosterol concentrations)
were measured 12 hours later. It was found that
pravastatin inhibition of in vivo cholesterol synthesis was attenuated among individuals with variant
SLCO1B1 alleles (n = 3) when compared with nonvariant carriers (n = 38). A retrospective analysis of
66 individuals treated with pravastatin, atorvastatin
or simvastatin also showed a genetic association
with drug response (total cholesterol changes from
baseline) [16].
It should be noted that the majority of studies
investigating SLCO1B1 genetic associations with
CHAPTER 11
variable statin pharmacokinetics and pharmacodynamics have had small sample sizes and have not
generally looked at long-term therapy. Nonetheless,
transport protein pharmacogenetics continues to
grow in number and sophistication of study design,
and these initial studies have undoubtedly formed a
foundation for continued investigation.
The impact of polymorphisms in transport protein genes other that SLCO1B1 has also been investigated [13,17,18]. Because transport proteins are
additionally found on the apical surfaces of the
intestines and kidneys, it is conceivable that variants in genes encoding such proteins as P-glycoprotein (ABCB1), multidrug resistance-associated
protein-2 (ABCC2), OATs in enterocytes and renal
tubules (SLCO2B1 and SLC22A8) and others could
influence statin responses in patients.
A major area of focus in statin pharmacogenetics
is hepatic drug metabolism. Specifically, five of the
six commonly used statins are metabolized predominantly through hepatic (and extrahepatic)
cytochrome P450 enzymes, a major pathway of drug
metabolism in general. Simvastatin, atorvastatin
and lovastatin are largely metabolized by CYP3A4/5,
while the predominant enzyme in fluvastatin and
rosuvastatin metabolism is CYP2C9. It has also
been submitted that various statins are additionally
substrates for other isoenzymes such as CYP2D6
and CYP2C8.
Studies have investigated the impact of polymorphisms in drug metabolizing enzymes on both
efficacy and tolerability to statins. The earliest study
of healthy volunteers suggested potential association between CYP2D6 polymorphisms and variable
lipid response to simvastatin [19]. In particular, it
was concluded that CYP2D6 variant carriers had
decreased clearance of active simvastatin metabolites, resulting in greater drug response in these
individuals. However, as other studies with larger
sample sizes were conducted, it became clear that
no consistent relationship between CYP polymorphisms and statin response could be discerned
[20,21]. In general, consideration of metabolizing
enzyme polymorphisms alone does not sufficiently
explain variability in statin responses [20–25].
There have been suggestive recent studies of
CYP3A5 that perhaps warrant further investigation. For example, in a retrospective analysis of 69
Caucasians with coronary disease treated with
Pharmacogenetics 255
statins known to be metabolized by CYP3A (i.e.,
simvastatin, atorvastatin or lovastatin), it was
shown that individuals with at least one functional
CYP3A5*1 allele had a 13% and 14% diminishment
of 1-year total cholesterol and LDL reduction,
respectively [24]. The attenuated response is hypothesized to be brought about by enhanced expression of CYP3A5 in *1 carriers, resulting in increased
statin metabolism. Interestingly, polymorphisms
in CYP3A5 have also been associated with severity
of atorvastatin-induced myopathy [26]. While incidence of atorvastatin-induced myopathy was not
related to CYP3A5 genotypes, the magnitude of
creatine kinase elevations among individuals experiencing myalgia with myopathy was higher in
those with the CYP3A5*3 allele. These findings will
need to be replicated and the gene-effect further
refined prior to use of genotyping for prediction of
myopathy severity. However, they are consistent
with the expected effects of these genotypes on
statin plasma drug concentrations.
One of the major limitations of pharmacogenetic
studies is that they generally do not simultaneously
investigate the associations between multiple
genes and drug response [4]. Two notable studies
have attempted to use a multiple candidate gene
approach to elucidate genetic contributions to variable statin lipoprotein responses [27,28]. Chasman
et al. [27] retrospectively evaluated whether any of
nearly 150 SNPs in 10 candidate genes were associated with response to pravastatin among over 1500
patients in the Pravastatin Inflammation/CRP
Evaluation (PRINCE) study [27]. After establishment of strict statistical criteria for significance, it
was found that two highly linked SNPs in the
HMG-CoA reductase gene (HMGCR) were associated with differences in pravastatin response.
Specifically, carriers of at least one variant allele at
either SNP locus had an approximately 20%
smaller relative reduction in total cholesterol and
LDL compared with wild-type homozygotes.
In another retrospective multigene study (43
SNPs in 16 candidate genes) of 2735 individuals
receiving statins from the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS)
database, Thompson et al. [28] did not replicate the
findings from PRINCE. In fact, while identifying
several gene polymorphisms related to variability
in statin responses, only one association (LDL
256 PART III Therapies and applications
response by apolipoprotein E [APOE] genotype)
was consistent with previous literature reports.
These data highlight the importance of conducting
multigene studies and considering methodologic
differences among these studies in pushing the field
of statin pharmacogenetics forward.
Genes involved in absorption, distribution, metabolism and excretion of statins represent one side
of the pharmacologic coin with respect to statin
pharmacogenetics. There is tremendous diversity
in the choice of pharmacodynamic (i.e., drug
action) candidate genes that may have a role in
disparate therapeutic responses between patients.
For example, nondrug metabolism genes investigated to date include those whose protein products are involved in cholesterol biosynthesis and
lipoprotein metabolism, nonlipoprotein related
enzyme targets and inflammatory processes (e.g.,
cytokines) [4]. Pharmacogenetic studies of statins
investigating select pharmacodynamic genes are
presented in Table 11.2.
One of the best studied nonpharmacokinetic
genes in statin pharmacogenetics is APOE. ApoE is
a surface ligand found on lipoproteins that include
very low density lipoprotein (VLDL) and HDL.
Individuals carry two (parental) copies of any of
three commonly occurring APOE alleles: ε2, ε3
(wild-type) and ε4. The majority of studies have
shown lipid-lowering response to statins is highest
among those with the ε2 allele and lowest among
those with the ε4 allele [29–33]. However, as a dramatic departure from this observation, it appears
that ε4 carriers are at the greatest risk of cardiovascular mortality, and that these individuals have
the greatest relative reduction in mortality when
treated with a statin [34]. Furthermore, while these
individuals in general are more likely to receive
statin benefits in the form of hard end-point reduction, they are also more likely to discontinue
therapy, possibly as a consequence of perceived
attenuated response of the LDL surrogate [35].
These data highlight the importance of consideration of appropriate phenotype in pharmacogenetic
studies. The clinical implications of each observed
genotype–phenotype relationship should be carefully considered, as there is undoubtedly a complex
interaction between genetics, changes in surrogate
end-points, variable hard end-point risks, physician prescribing and patient adherence.
Pharmacogenetics of nonstatin
cholesterol modulators
Pharmacogenetic studies of cholesterol-modulating agents other than statins have also been conducted. For example, data continue to accumulate
on relationships between fibrate response and polymorphisms in such genes as ACE, APOE, CETP
(cholesteryl ester transfer protein), LPL (lipoprotein lipase), PPARA (peroxisome proliferatoractivated receptor alpha) and FABP1 (liver fatty
acid binding protein) [36–45]. Because activation
of PPARα by fibrates is seen as the main pharmacologic catalyst for downstream lipoprotein modulation, PPARA represents the main candidate gene in
fibrate pharmacogenetic studies.
The data regarding associations between PPARA
polymorphisms and variability in fibrate response
are conflicting [38,41–43]. In a study of 32 abdominally obese men, carriers of the variant L162→V
allele (n = 6, 19% of the population) had a dramatically higher increase in the HDL2 subfraction
in response to gemfibrozil compared with L162
homozygotes (50% vs. 5.5%, P = 0.03); no differences in triglyceride responses were seen [43].
However, in a larger subset of patients, variability
in response by L162V genotypes was seen for both
triglycerides and HDL, although the exact contribution of PPARA polymorphisms to these phenotypes in this study is complicated by consideration
of additional genotypes (e.g., APOE and LPL), age,
sex and anthropometric factors [38].
Other polymorphisms in PPARA (e.g., intron 7
G→C) have also been positively associated with
variable triglyceride responses to fibrates [41].
However, whether or not PPARA polymorphisms
influence cardiovascular risk reduction by fibrates
is unclear. For example, in an analysis of the Lopid
Coronary Angiography Trial (LOCAT), while
PPARA polymorphisms were associated with differences in progression of atherosclerotic coronary
disease, there was no effect of these polymorphisms
on treatment outcomes [42]. As with the example
of statins and APOE, the use of surrogate markers
in fibrate pharmacogenetic studies must be corroborated by evidence from outcomes trials.
Pharmacogenetic data are emerging for newer
agents used in management of dyslipidemia. For
example, data suggest that genetic polymorphisms
might have a role in the ezetimibe response path-
CHAPTER 11
way. Ezetimibe is a relatively new compound that
prevents the intestinal absorption of cholesterol
and related dietary phytosterols [46]. It is available
alone or as a combination product with simvastatin. Genetic control of intestinal cholesterol
absorption is complex, and the exact molecular target of ezetimibe has been elusive [47]. However, it
has recently been shown that ezetimibe’s target of
action is the Niemann–Pick C1-like 1 protein
(NPC1L1) found in enterocytes [48]. The exact
function of this protein is unknown. Nonetheless,
contribution of genetic variability in NPC1L1 to
ezetimibe response has been recently described. In
particular, a case series of 52 patients receiving ezetimibe revealed a combination of variant genotypes
associated with nonresponse to drug therapy [49].
In a larger study (n = 101), NPC1L1 haplotype analyses revealed that individuals without two copies
of the most commonly occurring haplotype exhibited the most significant response to ezetimibe in
terms of LDL cholesterol (35% vs. 24% reduction;
P = 0.02) with trends toward significance for total
cholesterol (P = 0.07) [50].
Relevance of pharmacogenetics to
treatment of dyslipidemias
There are several limitations to pharmacogenetic
studies of cholesterol lowering agents. These include
use of surrogate rather than hard clinical endpoints, little control for genetic and nongenetic
confounders (e.g., population stratification, diet,
adherence) and variability in study design [4].
Furthermore, even in scenarios of genotype-associated diminishment of drug response (i.e., LDL lowering), the magnitude of the differences among
differing genotype groups may not be clinically
meaningful [51]. Nonetheless, pharmacogenetics
of lipid modulation is a relatively new field of
study. To the extent that dyslipidemia is a major
antecedent risk factor for vasculopathic manifestations of disease, and many patients receive cholesterol drugs, it is important to identify the sources of
patient-specific variability in drug response. While
many lipid modulators confer significant relative
risk reduction in adverse cardiovascular events
based on data from randomized clinical trials, there
is still a significant proportion of individuals that
experiences major morbidity and mortality at the
Pharmacogenetics 257
end of follow-up. As such, genetic and non-genetic
determinants of response to dyslipidemia management (both dietary and drug) are likely to be investigated further.
Pharmacogenetics of hypertension
Hypertension is the most common chronic disease
in adults, estimated to affect approximately 65 million Americans. Treatment of hypertension is a
trial and error process, with drug therapy typically
selected from among the five first line drug classes,
which include thiazide diuretics, beta-blockers,
ACE inhibitors, angiotensin receptor blockers
(ARBs) and calcium-channel blockers (CCBs).
There are a number of pharmacogenetics studies
for all of the first line drug classes in hypertension,
with the exception of CCBs, and this literature has
been recently reviewed [52]. Among the studies
published to date, there have been several genes
that have been extensively studied and in some
cases have shown positive associations with response in multiple studies. It is these on which we
will focus.
Diuretics in hypertension
The most extensively studied gene relative to the
diuretic response is the gene for α-adducin (ADD1),
which is a ubiquitously expressed cytoskeletal protein involved in ion transport. There is a nonsynonymous polymorphism in ADD1 (Gly460Trp),
and several studies have shown that carriers of the
Trp460 allele have greater blood pressure lowering
than Gly460 homozygotes [53–55]. Further adding
to the interest in this polymorphism was a
case–control study that suggested that the reduction in nonfatal myocardial infarction and stroke
with diuretics was limited to carriers of the Trp460
allele [56]. In a recent study of patients with cardiovascular disease and hypertension, we found the
Trp460 allele to be associated with adverse cardiovascular outcomes, but this was not influenced by
the presence or absence of diuretics [57]. Additionally, not all studies that have examined the relationship of Gly460Trp with the blood pressure
response have seen positive associations. Nonetheless, ADD1 appears to be an intersting gene/
polymorphism that may well have an important
role in the diuretic response.
258 PART III Therapies and applications
Beta-blockers in hypertension
For beta-blockers, the most extensively studied
gene is that for the β1-adrenergic receptor
(ADRB1). There are two common polymorphisms
in ADRB1 that change encoded amino acids
(Ser49Gly and Arg389Gly), and both have been
shown through in vitro studies to have functional
consequences, where the Ser49 and Arg389 forms
have greater responsiveness to receptor stimulation
by agonists (e.g., norepinephrine). Several studies
have suggested that Arg389 homozygotes have the
greatest blood pressure lowering with beta-blockers [58–60], although not all studies have found
this association [61,62]. Additionally, data from
our laboratory suggest that consideration of both
the codon 49 and codon 389 polymorphisms is
more informative than consideration of codon 389
alone. Specifically, our data suggested that consideration of baseline blood pressure and the
genotypes at the two sites explained 57% of the
antihypertensive response variabilty with metoprolol, with genotype at the two ADRB1 polymorphic sites explaining 20% of the variability [58]. It is
also interesting to note that these polymorphisms
may help to explain the well-recognized difference
in antihypertensive response between AfricanAmericans and white people. Specifically, the most
responsive diplotype (genotype considering both
codon 49 and 389) occurs in 45% of white people,
but only about 10% of African-Americans. This
highlights that pharmacogenetics may shed light
on some clinically recognized differences in response, and will allow clinicians to move away from
using race to help make clinical decisions. Thus,
while the data on the ADRB1 SNPs and antihypertensive response to beta-blockers are not to the
point of being useful in the clinical setting, they
highlight that it might be possible in the future to
predict antihypertensive response through use of
genetic and nongenetic information in a predictive model.
ACE inhibitors and angiotensin receptor
blockers in hypertension
The most extensively studied gene for the ACE
inhibitors and ARBs is the ACE gene, and its intron
11 insertion/deletion (I/D) polymorphism, with
studies numbering into the twenties. Several early,
smaller studies of this polymorphism showed positive associations, although were inconsistent in that
some showed the D allele to be associated with the
greatest response [63,64] while others showed the
I allele to have the greatest response [65,66].
However, many other studies, including more
recent large studies, have not shown this polymorphism to be associated with the antihypertensive
response to ACE inhibitors or ARBs [67–70]. Thus,
evaluating the body of literature on the ACE I/D
polymorphism leads to the conclusion that it does
not importantly influence the response to ACE
inhibitors or ARBs. This is not to say that ACE
genetic variability does not influence response to
these drugs. It is possible that study of other polymorphisms in the gene, or a haplotype tagging SNP
approach (which more comprehensively captures
the gene’s variability) might be strongly associated
with response to these drugs. However, the extensively studied I/D polymorphism is not likely to be
useful in the future for predicting responses to ACE
inhibitors or ARBs.
There are several other genes that have been
studied (some with positive associations) for the
antihypertensive drugs, but not with positive findings in more than one study.
Relevance of pharmacogenetics
to the treatment of hypertension
The ADD1 and ADRB1 genes appear to have future
potential for predicting antihypertensive response
to diuretics and beta-blockers, respectively. Additionally, there are other genes that appear to be
strong candidates, for which there are interesting
data that require validation. Based on the hypertension pharmacogenetics studies to date, it seems
clear that like hypertension, the antihypertensive
response is a complex phenotype, governed by a
large number of genes. The future challenge is to
identify the constellation of genes that contribute
to variability in response to the major antihypertensive drug classes. This might be accomplished
through either study of comprehensive lists of candidate genes, or through a genome-wide approach.
Studies utilizing both of these approaches are
underway, and are likely to yield important data for
hypertension pharmacogenetics in the future.
CHAPTER 11
Pharmacogenetics of heart failure
There is a mounting body of literature regarding
the influence of genetic polymorphisms on the
cornerstones of therapy for heart failure, namely
beta-blockers, ACE inhibitors, diuretics, digoxin,
spironolactone and the ISDN–hydralazine combination. The majority of these papers have been
published since 2003, highlighting the rapid pace of
accumulation of knowledge in this area. There are
also numerous studies that have addressed genetic
associations with risk of heart failure, or prognosis
in heart failure. As these are addressed in Chapters
3, 4 and 7, we will focus only on the pharmacogenetic studies in heart failure. There are few pharmacogenetics studies in the setting of acute myocardial
infarction, which is perhaps not surprising given
the limited clinical potential for genetically guided
therapy in the acute setting. However, there are
some pharmacogenetic data on post-myocardial
infarction therapies, and because one of their major
benefits is prevention of heart failure, we discuss
those here as well.
Beta-blockers in heart failure
Among the heart failure drugs, there are the most
pharmacogenetic data on beta-blockers. It is well
recognized that beta-blockers are beneficial in heart
failure through their ability to directly block the
detrimental effects of sympathetic nervous system
(SNS) activation, and the majority of the studies
center on the β-adrenergic receptor genes.
A number of different studies suggest that the
genes for the β1-adrenergic receptor (ADRB1) and
the β2-adrenergic receptor (ADRB2) influence the
response to beta-blockers in heart failure. These
studies have focused on genetic associations with
beta-blocker induced change in left ventricular
ejection fraction (LVEF), clinical outcomes and
early tolerability of beta-blockers (Table 11.3).
At least two studies have shown that the
improvement in LVEF with beta-blockade was
associated with ADRB1 genotype. Specifically, both
studies found Arg389 homozygotes had the greatest
improvement in LVEF [71,72]. These findings are
consistent with the in vitro data, as it was expected
that Arg389 homozygotes would have the greatest
harm from SNS activation and so might derive the
Pharmacogenetics 259
greatest benefit from beta-blockers. Another study
considered only ADRB2 polymorphisms and found
Gln27 homozygotes had much smaller improvements in LVEF than Glu27 carriers (heterozygotes
and Glu27 homozygotes), as assessed by percentage
of those who had a 10-unit increase in LVEF [73]. A
study similar in design to these others considered
both ADRB1 and ADRB2 SNPs, but did not show
such an association between any of the SNPs studied and the LVEF response [74]. One potential
explanation is that the patients in this latter study
were generally healthier than those in the positive
studies. For example, in the three studies with positive findings, baseline LVEFs were 26%, 23% and
21%, whereas in the negative study it was 30%.
Whether this difference in heart failure severity
explains the negative findings in the latter study can
only be resolved through further well-powered
studies.
The study from our laboratory that assessed the
relationship between genotype and reverse remodeling also tested the influence of ADRB1 and
ADRB2 genotypes on initial tolerability of betablockers, during the titration period [75]. This
study found that there were significant differences
by ADRB1 codon 49 and 389 genotype in the need
for an increase in diuretic dose during the titration
period. For example, in one diplotype group (combination of both polymorphisms), 52% of patients
required an increase in diuretic dose, whereas in
another, none of the individuals required this intervention. If these findings could be replicated, they
would suggest that a clinician might be able to
determine the aggressiveness of dose titration or
need for close follow-up based on genotype.
Focus of studies on LVEF is based on data suggesting that change in LVEF is a strong surrogate
for survival benefits of drug therapy in heart failure,
and several additional studies have looked at clinical outcomes with beta-blockers, relative to genotype. Two separate reports from Magnusson et al.
[76] and Borjesson et al. [77] provide evidence that
in the absence of beta-blocker therapy, the ADRB1
Ser49Ser genotype is associated with worse outcomes (death and transplant) than Gly49 carriers. Additionally, beta-blockers provide a greater
improvement in event-free survival for Ser49Ser
than Gly49 carriers. This does not mean that Gly49
260 PART III Therapies and applications
Table 11.3 Pharmacogenetic studies of beta-blockers in heart failure.
Gene
Drug
Polymorphism studied
End-point/findings
Reference
ADRB1
Carvedilol
Arg389Gly
Arg389Arg had greatest improvement in LVEF
[72]
Metoprolol CR/XL
Arg389Gly
Arg389Arg had greatest improvement in LVEF.
[71]
Ser49Gly
No association between Ser49Gly genotype and
LVEF change
Carvidolol or
Arg389Gly
LVEF change – NA
bisoprolol
Ser49Gly
LVEF change – NA
Metoprolol CR/XL
Arg389Gly
Arg389Arg had better initial tolerability;
Ser49Gly
Codon 49 and 389 haploptypes also
[74]
[75]
Associated with different initial tolerability
[80]
Arg389Gly
Death – NA
Ser49Gly
Death – NA
Metoprolol CR/XL
Arg389Gly
Death – NA
[79]
Various
Arg389Gly
Transplant-free survival. NA for Arg389 Gly; Ser49Ser
[76]
Ser49Gly
genotype on low dose beta-blocker associated with
Various
similar outcomes as no beta-blocker; those on high
dose beta-blocker derived significant benefit
ADRB2
Carvedilol
Carvedilol
Various
CYP2D6
Carvedilol
Gln27Glu
Gln27Gln less likely to have ≥10 unit increase in LVEF.
Arg16Gly
No association between LVEF change and Arg16Gly
Gln27Glu
Change in LVEF – NA
Arg16Gly
Change in LVEF – NA
Gln27Glu
Gln27Gln and Arg16Arg treated w/ beta-blockers
Arg16Gly
post-MI had lowest 2 year survival
EM/PM
PMs had significantly higher carvedilol plasma
[73]
[74]
[80]
[81]
concentrations; no assessment of clinical response
Metoprolol
EM/PM
PMs had significantly higher plasma metoprolol
[75]
concentrations; no difference by genotype in
adverse effects of initial tolerability
CR/XL, controlled release/extended release (Toprol XL®); EM, extensive metabolizer; LVEF, left ventricular ejection
fraction; MI, myocardial infarction; NA, no association; PM, poor metabolizer.
carriers fair worse, but that beta-blockers narrow
the disparity between the two genotype groups in
terms of clinical adverse events. Their more recent
report also shows a dose effect by genotype with the
beta-blockers. Specifically, for Ser49 homozygotes,
low dose beta-blocker was associated with similar
outcomes as no beta-blocker, while high dose betablocker in this group had significant improvements
in their event-free survival (Fig. 11.1) [76]. In con-
trast, Gly49 carriers derived similar benefit from
low and high dose beta-blockade. If these data are
replicated, they could have important clinical
implications for the use of beta-blockers in heart
failure, where genotype may help guide the need for
aggressive beta-blocker dosing.
Although not yet published in full, data have
been presented from the BEST trial [78], showing
that in ADRB1 Arg389 homozygotes, there was a
Pharmacogenetics 261
CHAPTER 11
(b) 50
Low dose of beta-blockers
40
Risk of end-point (%)
Risk of end-point (%)
(a) 50
Ser49
30
20
Gly49
10
High dose of beta-blockers
40
Ser49
30
20
10
Gly49
0
0
0
At risk
Ser49 55
Gly49 30
3
2
Follow-up (years)
44
28
35
26
4
33
23
5
30
22
15
16
(d) 50
Dose of beta-blockers
Ser49 patients
40
No beta-blocker
30
0
At risk
Ser49 43
Gly49 11
Risk of end-point (%)
Risk of end-point (%)
(c) 50
1
Low dose
20
High dose
10
1
40
10
3
2
Follow-up (years)
35
9
32
8
4
5
27
8
12
3
Dose of beta-blockers
Gly49 carriers
40
30
No b-blocker
20
High dose
10
Low dose
0
0
0
At risk
No beta-blocker
Low dose
High dose
94
55
43
1
79
45
40
2
3
Follow-up (years)
69
35
35
63
33
32
4
52
30
27
5
41
15
12
0
At risk
No beta-blocker 44
Low dose
30
High dose
11
1
37
28
10
2
3
Follow-up (years)
35
26
9
34
23
9
4
5
32
22
8
26
16
3
Figure 11.1 Influence of b1AR genotype on outcome in
relation to doses of beta-blockers. (a) Low dose of betablocker (≤50% of target dose) by codon 49 genotype. (b)
High dose of beta-blocker (>50% of target dose) by codon
49 genotype. (c) Influence of beta-blocker dose on
outcomes among Ser49 homozygotes. (d) Influence of
beta-blocker dose on outcomes among Gly49 carriers.
Reprinted from [76] with permission from American Society
for Clinical Pharmacology and Therapeutics.
significant benefit associated with bucindolol
therapy, but there was no such benefit in Gly389
carriers. These data are consistent with the studies
showing Arg389 homozygotes had the greatest
improvements in ejection fraction. However, a 600
subject substudy of MERIT-HF tested whether the
ADRB1 Arg389Gly polymorphism was associated
with different outcomes [79]. They did not see any
differences in outcomes by genotype in either the
metoprolol treated, or the placebo-treated groups,
but did not conduct an analysis that would have
allowed them to detect a genotype–drug (i.e., gene–
environment) interaction.
Finally, in a recent study a post-myocardial
infarction patient population was prospectively
enrolled during myocardial infarction hospitalization, then followed for all-cause 3-year mortality
[80]. It was found that ADRB2 Arg16 homozygotes,
Gln27 homozygotes and the Arg16/Gln27 haplotype were associated with a significantly increased
risk of death in beta-blocker treated patients. These
findings are consistent with the previous study that
found Gln27 homozygous heart failure patients
had smaller improvements in LVEF with betablocker therapy. Lanfear et al. [80] found no associations between the ADRB1 polymorphisms and
adverse outcomes.
Both carvedilol and metoprolol are extensively
metabolized by the drug metabolizing enzyme
CYP2D6, for which 7% of Causasians lack functional protein due to genetic polymorphisms in the
gene. Studies have clearly documented that plasma
drug concentrations of metoprolol and carvedilol
are significantly influenced by CYP2D6 genotype
262 PART III Therapies and applications
[75,81], with poor metabolizers having drug concentrations that are 3–5 times higher than extensive
metabolizers. However, a study from our laboratory suggests that these differences in plasma drug
concentration do not translate into important clinical differences in tolerability of the beta-blocker
[75]. Data similarly suggest that adverse effects
of metoprolol in hypertension are unrelated to
CYP2D6 genotype [82].
Relevance of beta-blocker
pharmacogenetics to practice
There are a number of studies that suggest the β1and β2-adrenergic receptor gene polymorphisms
may influence response to beta-blockers, including
initial tolerability, improvements in left ventricular
remodeling and clinical outcomes. While these
findings have not been replicated in all studies
where they have been tested, when there are positive findings, they are highly consistent across the
studies (e.g., ADRB1 Arg389Arg and Ser49Ser and
ADRB2 Glu27Glu genotypes having the greatest
benefits from beta-blocker therapy). These data are
not to the point of being utilized clinically, but several of the studies highlight the future clinical
potential, either in assessing those who will need
close follow-up during therapy initiation, those
who need to be treated aggressively or those in
whom beta-blockers might offer minimal benefit
and so alternative therapy could be considered. To
get to this point will require large clinical trials,
which is most efficiently accomplished by addressing pharmacogenetic hypotheses as substudies to
large clinical trials. It is not anticipated that there
will be numerous additional beta-blocker trials.
Thus, unless the recent beta-blocker trials (such as
COMET and COPERNICUS) included collection
of genetic samples, it may be difficult to achieve the
level of evidence that will be necessary to translate
this information into clinical practice.
ACE inhibitors in heart failure
While there are numerous pharmacogenetic studies of ACE inhibitors in hypertension, they are
more limited in the heart failure population. The
bulk of the data come from the laboratory of
McNamara et al. [83] who have established a heart
failure genetics study population that they are following prospectively. In this population (for whom
treatment at baseline included ACE inhibitor in
about 85%, ARB in about 10% and beta-blocker in
about 40%), they noted that the ACE I/D polymorphism was associated with event-free survival.
Specifically, those with the (D/D) genotype had the
worst event-free survival. This was most evident in
the subgroups on low-dose ACE inhibitor therapy,
or those not on beta-blocker therapy. Interestingly,
the presence of beta-blocker therapy, irrespective
of the presence or dosage of the ACE inhibitor therapy, negated any of the negative effects of the D/D
genotype on survival. This highlights that in the
presence of contemporary pharmacotherapy, the
genes/genotypes that may adversely affect prognosis in heart failure may be more difficult to discern, as the drug therapy may overcome the risk
associated with the genotype.
Pharmacogentics of other heart
failure drugs
Digoxin
Digoxin has been shown to be a substrate of the Pglycoprotein (P-gp) drug efflux pump. Because Pgp is responsible for ejection of xenobiotics from
cells in the intestine, liver, kidney, brain and other
highly sequestered tissues, it has been hypothesized
that polymorphisms in the gene that encodes P-gp
(ABCB1 aka MDR1) might affect digoxin absorption and distribution [84,85].
The vast majority of ABCB1-digoxin pharmacogenetic studies have investigated the impact of
the C3435T polymorphism (synonymous SNP in
exon 26) on digoxin pharmacokinetics [86–93].
While several studies have demonstrated a significant effect of the C3435T polymorphism on serum
digoxin concentrations and other measures of
drug exposure, data are conflicting. In fact, a metaanalysis of eight studies investigating the impact
of C3435T genotypes on oral digoxin pharmacokinetics revealed no significant associations
between genotype and either P-gp expression,
digoxin AUC0–4h, or AUC0–24h. Overall, borderline
significance was demonstrated between genotypes
and peak digoxin concentrations (Cmax) [94]. While
polymorphic ABCB1 represents a biologically
plausible mediator of digoxin response variability,
studies have not robustly established this gene as
clinically significant. Because of the predictable,
CHAPTER 11
linear nature of digoxin pharmacokinetics, considering ABCB1 genotype to guide use of digoxin is
unlikely to occur clinically.
Diuretics
There is a broad literature on the pharmacogenetics
of thiazide diuretics, particularly in hypertension,
as discussed above. The literature is far more limited for loop diuretics, with little information on
pharmacogenetics of loop diuretics in heart failure.
One group studied the association of the BP
response to furosemide, relative to the ADD1 polymorphism. Consistent with the findings on this
gene with thiazides, the Trp460 carriers had a
greater BP response than the Gly460 homozygotes
[53]. The clinical use of diuretics in heart failure is
relatively straightforward, and so it seems less likely
that there would be clinical value to guiding therapy with genetic information in this setting. This is
in contrast with the potential benefit of genetic
information to guide the use of diuretics in hypertension. Thus, this body of literature may remain
limited. However, it seems likely that the genetic
association studies of thiazides in hypertension
may still inform, to some degree, the genes that
contribute importantly to the loop diuretic efficacy
in heart failure (e.g., ADD1).
Spironolactone
Spironolactone is an old drug that has seen a recent
rebirth as an aldosterone antagonist, useful for preventing the progressive remodeling of the left ventricle (LV) and associated adverse outcomes in
heart failure. To our knowledge there is a single
study on spironolactone pharmacogenetics, which
investigated the relationship between ACE I/D
genotype and the LV remodeling with spironolactone [95]. In this study, the investigators found that
those with the ACE non-D/D genotype (i.e., I/D or
I/I) were the ones that showed significant improvements in LV reverse remodeling with spironolactone therapy. These data need to be replicated, but
are similar to some of the beta-blocker studies in
that they suggest that certain genotypes may derive
greater reverse remodeling effects than others.
Isosorbide dinitrate–hydralazine
The combination of ISDN and hydralazine represented the first vasodilators to be documented to
Pharmacogenetics 263
have survival benefits in heart failure (in V-HeFT),
although a few years later it was shown clearly
that ACE inhibitors were superior to the ISDN–
hydralazine combination [96]. Thus, the hydralazine–
nitrate combination has seen limited use in heart
failure. However, the original V-HeFT investigators
noted on post hoc analysis that the noted benefits
of this combination therapy seemed to be largely
confined to the African-American subjects. Thus,
they recently tested ISDN–hydralazine against
placebo in a population of African-American Class
III heart failure patients receiving standard pharmacotherapy [1]. This study showed significant
clinical benefits of the therapy in this population,
including an improvement in survival. This study
was fairly controversial for its exclusive focus in an
African-American population, and the fixed dose
combination product has since received FDA
approval, with the labeled indication being only in
African-Americans.
The proposed hypothesis surrounding this
therapy is that in some patients (particularly
African-Americans), oxidative stress and reduced
availability of nitric oxide may have an important
role in heart failure pathophysiology. Recently presented pharmacogenetic data may provide some
support for that hypothesis (see summary at
http://www.theheart.org/viewArticle.do?primaryKey
=570543&from=/searchLayout.do). Specifically,
genetic polymorphisms in the gene for nitric oxide
synthase (NOS3), which is the enzyme responsible
for nitric oxide production, were studied. It was
shown that Glu298 homozygotes derived benefits
from ISDN–hydralazine that nearly achieved statistical significance, while the Asp298 carriers had
no benefit from this therapy. Consistent with the
hypothesis that this therapy is more beneficial in
African-Americans, it was noted that about 70–
80% of African-Americans are Glu298 homozygotes, whereas only about 40% of Caucasians carry
this genotype. Thus, these data are compelling
for several reasons. First, they provide support for
the nitric oxide hypothesis surrounding ISDN–
hydralazine therapy. Secondly, they highlight that
with the increasing numbers of drugs available for
treatment of heart failure patients, it might be possible to optimize therapies in the future through use
of genetic information. Finally, they highlight (like
the beta-blocker in hypertension data) that use of
264 PART III Therapies and applications
genotype data at specific genes relevant to drug
pharmacology may be a much more appropriate
method of guiding therapy than making decisions
based on a patient’s skin color. For example, if these
data are correct, they suggest that 20–30% of
African-Americans might not benefit from ISDN–
hydralazine, whereas 40% of Caucasians might
benefit from such therapy. Whether this therapy
will be guided in the future with genetic information remains to be seen, but these data provide evidence that such an approach may be in store.
variations in essentially the same prothrombotic
processes, common pharmacologic agents are used
in prevention and treatment. Drug therapy for
thrombosis-related conditions include antiplatelet
agents (e.g., aspirin, clopidogrel and glycoprotein IIb/IIIa inhibitors), anthrombin agents (e.g.,
unfractionated and low molecular weight heparin)
and anticoagulants such as warfarin. Several studies
of antithrombotic agents are available in the pharmacogenetics literature.
Antiplatelet pharmacogenetics
Relevance of pharmacogenetics to
management of heart failure
As highlighted above, there are some interesting
pharmacogenetic data surrounding heart failure
therapies. However, to move these data to the point
of clinical utility will require much additional
research. This would be most effectively accomplished by having pharmacogenetic substudies of
large heart failure clinical trials. However, a concern in this regard is that large studies of our standard therapies are likely to be very limited in the
future, given their well-documented benefits. Thus,
achieving the potential for pharmacogenomics in
heart failure may present a particular challenge.
However, because of the routine practice of
polypharmacy in heart failure, this is a disease state
whose management could likely benefit greatly
from use of genetic information to help guide therapy. Over the last two decades, management of
heart failure has become increasingly complex,
such that nearly all patients are on a minimum of
four heart failure drugs, and some are on as many as
seven. However, we know with some certainty that
not all patients benefit from all of those drugs, and
so the challenge is to have a way to identify those
patients most likely to derive benefit from a particular therapy. Pharmacogenomics represents an
appealing manner of achieving this goal.
Pharmacogenetics of thrombosis
Dysregulation of hemostatic equilibrium can manifest in myriad pathologic conditions including
deep vein thrombosis of the extremities, pulmonary embolism, cerebrovascular events and acute
coronary syndromes. Because these conditions are
Aspirin
Aspirin remains a cornerstone of therapy for prevention and treatment of myriad thromboembolic
conditions. While beyond the scope of the current
discussion, there is a fair amount of data regarding
associations between various genetic polymorphisms and aspirin intolerance or hypersensitivity
in noncardiac, predominantly asthmatic populations. When focusing on cardiovascular pharmacogenetic studies of aspirin, data largely relate to a
handful of genes encoding pharmacodynamic proteins and their influence on surrogate markers of
aspirin antiplatelet activity.
Interest in genetic contribution to variable
aspirin response began to emerge in the 1990s.
Increasing interest has been paid to the phenomenon of “aspirin resistance”; that is, the observation that aspirin does not reduce ischemic
end-points in many individuals, and that aspirin
fails to inhibit platelet aggregation ex vivo in up to
25% of individuals [97]. As such, in the last decade
increasingly rigorous attempts have been made to
elucidate the impact of polymorphisms in genes
that encode such proteins as cyclo-oxygenase-1
(COX-1), subunits of the platelet glycoprotein
IIb/IIIa (GP IIb/IIIa) receptor, and the platetelet
adenosine diphosphate (ADP) receptor on aspirin
resistance [98–101].
COX-1 is an important upstream enzyme in the
eicosanoid production pathway, and is a pharmacodynamic target of aspirin therapy. A limited
number of studies have investigated COX-1 gene
(PTGS1) haplotypes on aspirin action (e.g., inhibition of platelet aggregation or eicosanoid production) [102,103]. In general, there appear to be at
least certain “at-risk” genotype combinations in
CHAPTER 11
which carriers of these haplotypes are differentially
responsive to aspirin.
A more often studied target in antithrombotic
pharmacogenetics is the platelet GP IIb/IIIa receptor. This receptor on the activated platelet’s surface
allows for fibrinogen binding with subsequent
platelet cross-linking and aggregation. A C→T SNP
at nucleotide 1565 of the IIIa subunit results in a
change from Leu→Pro at amino acid 33. The wildtype allele is designated PlA1 while the variant is
denoted PlA2. It has been suggested that carriers of
the A2 allele are at higher risk for cardiovascular
events as well as diminished response to aspirin.
Several small investigations have found aspirin’s
ability to inhibit thrombin generation and prolong
bleeding times is attenuated in those with the A2
allele [104–106]. However, results regarding the
A1/A2 polymorphism are not consistent, vary by
phenotype studied, and may be confounded by differential responses of A2-positive platelets to agonists ex vivo [107–111]. Further, the use of ex vivo
platelet aggregation studies to determine the contribution of this polymorphism to aspirin resistance in vivo remains under debate [112]. Despite
these limitations, the biologic plausibility of the GP
IIb/IIIa receptor as a candidate gene, the associations of the PlA1/A2 polymorphism with variable
cardiovascular risk and aspirin effects in some studies, and relatively high A2 variant allele frequency
(12–15% among Caucasians) make this polymorphism a likely candidate for continued study into
the mechanisms of aspirin resistance.
GP IIb/IIIa inhibitors
Predictably, the IIIa subunit of GP IIb/IIIa is a
major candidate gene for pharmacogenetic studies
of GP IIb/IIIa inhibitors such as abciximab, eptifibatide and tirofiban. In 87 individuals undergoing
coronary revascularization, Wheeler et al. [113]
investigated whether or not platelets from P1A2
carriers had diminished response to abciximab
compared with those from A1 homozygotes.
Indeed, A2 carriers exhibited a partially responsive
phenotype as defined by several ex vivo assays. The
diminished response may be explained by fewer
fibrinogen receptors seen in A2-positive platelets.
Similar findings of an attenuated drug response
have been demonstrated in A2-positive platelets in
the presence of eptifibatide [114]. However, it is
Pharmacogenetics 265
important to note that genotype–drug interactions
with regard to variability in platelet response (particularly with eptifibatide and tirofiban) have
recently been shown to be dependent on the type of
anticoagulant used, complicating interpretation of
association studies using platelet activity as a phenotypic measure [115]. Furthermore, consideration of surrogate markers for GP IIb/IIIa inhibitor
efficacy by genotype other than platelet activity
(e.g., infarct size, mortality) has revealed no
significant impact of PlA genotype on drug effect,
and studies of drug toxicity (i.e., bleeding) are limited [116,117].
Clopidogrel
Clopidogrel, an ADP receptor antagonist, has
emerged as a standard antiplatelet treatment
modality in acute coronary syndromes and coronary revascularization procedures. Because ADP
acts as a platelet activator by binding to P2Y12
receptors on the platelet’s surface, inhibition of
P2Y12 receptors by clopidogrel blocks an initial step
in platelet degranulation, upregulation of GP
IIb/IIIa expression and platelet aggregation.
As with aspirin, resistance to clopidogrel effects
have been described with an upper prevalence estimate of 30% [118]. It has been hypothesized that
polymorphisms in P2RY12 encoding for the pharmacodynamic target of clopidogrel action may be
an important determinant of drug response. Several fairly large studies have investigated P2RY12
polymorphisms and clopidogrel responses. Ziegler
et al. [119] studied whether either of two exonic
SNPs in P2RY12 (C34→T or G52→T) were associated with variability in clopidogrel response for secondary prevention of cerebrovascular events in
patients with peripheral arterial disease. After
adjustment for known risk factors for cerebrovascular events and statin use, it was found that clopidogrel users who were 34T variant carriers had
a fourfold higher risk of the primary end-point
when compared with 34C homozygotes (95% CI,
1.08–14.92; P = 0.04). The G52→T SNP was not
associated with variable response. Neither SNP was
associated with variable responses among aspirin
users. Of note, these SNPs have not been associated
with different responses to clopidogrel loading
doses in the setting of revascularization (platelet
aggregation phenotype) [120].
266 PART III Therapies and applications
A study by Angiolillo et al. [121] looked at the
effect of a different P2RY12 polymorphism
(T744→C) on ex vivo platelet aggregation and
activation in two groups of patients with coronary
disease: group 1 consisted of 36 individuals undergoing revascularization with stent placement who
received a 300-mg clopidogrel loading dose, while
group 2 consisted of 83 individuals on long-term
clopidgrel therapy (75 mg/day). There was no differential response to clopidogrel by genotype for
any phenotypic measure, and the authors conclude
that this SNP alone is not likely to significantly contribute to clopidgrel resistance.
While P2RY12 has been the most consistently
studied gene in clopidogrel pharmacogenetics, single studies exist for other candidate genes such
as those encoding protease-activated receptor-1
(PAR-1), GP IIb/IIIa (PlA polymorphism) and GP
Ia, all of which suggest a role of genotype in modulating antiplatelet effects of clopidogrel [122–124].
Furthermore, as CYP3A4 is responsible for conversion of clopidogrel to its pharmacologically active
metabolite, polymorphisms in this gene are likely
to be studied in the future.
Anticoagulants
Anticoagulation with warfarin is standard of care
for preventing thromboembolic events in most
patients with chronic atrial fibrillation, and is used
in numerous other populations for either shortor long-term thromboembolism prophylaxis.
However, warfarin has a narrow therapeutic window in which efficacy can be maximized and risk
for excessive bleeding minimized. Furthermore,
appropriate warfarin dosing to achieve target international normalized ratio (INR) is problematic
because of the myriad factors that contribute to
variability in drug exposure (e.g., age, drug interactions, vitamin K intake).
Warfarin pharmacogenetic studies have largely
focused on two candidate genes: CYP2C9, responsible for warfarin metabolism, and VKORC1, which
encodes vitamin K epoxide reductase, the site of
warfarin action. As such, studies in aggregate have
attempted to elucidate the association between
variants in these pharmacokinetic and pharmacodynamic genes and such phenotypes as warfarin
dosage requirements and risk for bleeding.
Major CYP2C9 alleles include the *1 wild-type,
and *2 and *3 variants. While the *1 allele confers
full metabolic activity, the *2 and *3 alleles are
associated with decreased CYP2C9 activity and
decreased clearance of S-warfarin (the more pharmacologically active enantiomer) [125–127]. Consequently, it has been shown that individuals with
these variant alleles require lower maintenance
doses of warfarin [128–130]. In addition, it takes
variant carriers longer to achieve therapeutic INRs,
and variant carriers are at increased risk of overanticoagulation upon initiation of therapy; in
particular, *2 or *3 carriers are more likely to have
supratherapeutic INRs (INR >4) and increased risk
for bleeding [131].
In an attempt to push pharmacogenetics a
step closer to clinical practice, Voora et al. [132]
prospectively tested a warfarin dosing algorithm
containing CYP2C9 genotype along with nongenetic variables to see whether 48 surgical patients
could achieve therapeutic INR without significant
delay. The equation to predict warfarin dosage
included inputs for age, race, sex, body surface area,
target INR, genotype and presence of amiodarone
and/or a statin. Use of genotype-guided therapy
resulted in equivalent effectiveness between CYP2C9
wild-type homozygotes and variant carriers (i.e.,
time to stable therapeutic INR). However, there
was still a greater incidence of overanticoagulation
(INR >4) among variant carriers, suggesting use of
CYP2C9 genotype alone to guide warfarin regimens
does not currently eliminate the need for traditional monitoring parameters such as INR. Further
prospective studies using CYP2C9 genotype to dose
warfarin are likely [133].
A limitation of most studies investigating genetic
associations with warafrin dosage requirements is
that they fail to account for variability in pharmacodynamic genes such as VKORC1. Two seminal
papers published in 2004 identified VKORC1 as the
target of warfarin therapy and suggested VKORC1
polymorphisms are important factors in warfarin
resistance [134,135]. Since then, several studies
have correlated polymorphisms in this gene to
warfarin dosage requirements [136–142]. Studies
have demonstrated that VKORC1 and CYP2C9
genotypes, along with known nongenetic predictors of warfarin dosage, account for over 50% of
the patient–patient variability in weekly warfarin
CHAPTER 11
dosage requirements [139,141]. It appears that
VKORC1 polymorphisms explain more of this variability than CYP2C9 variants [142,143]. Clotting
factor polymorphisms have also been considered
by some groups, and while some seem to exhibit
differences in warfarin sensitivity by genotype, they
contribute minimally to the variability, particularly
in relation to CYP2C9 and VKORC1. Regimen
algorithms utilizing both CYP2C9, VKORC1 and
nongenetic variables are under development. It
seems likely that genotype-guided warfarin therapy
will be the first example among cardiovascular
drugs to enter clinical practice within the next couple of years.
Antithrombin pharmacogenetics
Despite the well-studied relationship between variants in genes such as factor V and prothrombin and
hypercoagulable states, pharmacogenetics studies
of antithrombin agents such as unfractionated and
low molecular weight heparin are exceedingly
scarce. This may perhaps be because these agents
are usually used short term in acute settings. The
majority of studies are small investigations assessing whether a polymorphism in the Fcγ receptor
IIa (FCGR2A), which cross-links platelet factor 4,
heparin and IgG, contributes to heparin-induced
thrombocytopenia (HIT) [144–149]. In particular,
an Arg131→His polymorphism has been contradictorily implicated in various HIT phenotypes,
whereby both the 131His and 131Arg alleles have
been associated with HIT; furthermore, neutral
studies also exist.
In a particularly interesting study of HIT with
thromboembolic complications, Carlsson et al. [150]
employed a multigene approach to determine whether variant alleles in GP IIb/IIIa, GP Ia/IIa, GPIb/
IX/V, factor V, prothrombin and methyltetrahydrofolate reductase genes were overrepresented in
HIT patients with thromboembolic complications
(n = 79) compared with HIT patients without complications (n = 63). There were no significant
genetic associations with risk for thromboembolic
complications in patients with HIT. While sample
size and power are always of concern when conducting pharmacogenetic analyses of multiple
polymorphisms, the study represents an important
undertaking in trying to elucidate the contribution
Pharmacogenetics 267
of multiple genes to a potentially life-threatening
complication of heparin therapy.
Pharmacogenetic studies of antithrombin efficacy are even scarcer. In a biomarker study of acute
coronary syndromes, Ray et al. [151] determined
whether or not a variable number of tandem repeat
(VNTR) polymorphism in the interleukin-1 receptor antagonist gene (IL1RN) was associated with
responses to unfractionated heparin (UFH) or low
molecular weight heparin (LMWH). The marker of
response was change in circulating von Willibrand
factor (vWF) concentrations 24 and 48 hours after
treatment. It was found that LMWH was superior
over UFH in attenuating increased vWF concentrations overall. However, it appeared that the differential benefit of LMWH was largely limited to
carriers if the IL1RN *2 variant allele. Differences in
response between UFH and LMWH were not seen
among the majority non-*2 carriers (i.e., *1/*1
wild-type homozygotes). These data offer interesting insights as to how genotyping or molecular
profiling might be used in the future. For example,
understanding that treatment effects between UFH
and LMWH were only seen for *2 carriers (roughly
43% of the population) may help guide treatment
policy for agents such as LMWH that tend to be
more expensive than UFH. Further studies are
required.
Pharmacogenetics of arrhythmia
and proarrhythmia
Treatment strategies for the management of
arrhythmias have dramatically evolved since the
early 1990s, such that class I and III antiarrhythmic
drugs are now rarely used as first line therapy [152].
Thus, while pharmacologic rhythm control still
remains a therapeutic option, the risks often outweigh the benefits in chronic management and prevention of ventricular dysrhythmia.
It has been long appreciated that polymorphic
Phase I and II drug metabolism contribute to variable drug exposure and effects for antiarrhythmic
drugs such as procainamide, propafenone, flecainide, encainide and others [153,154]. Furthermore,
genetically mediated polymorphic drug metabolism may be responsible for enhancing pharmacodynamic activity (and presumably likelihood
for drug-induced arrhythmias) when multiple
268 PART III Therapies and applications
antiarrhythmics are used simultaneously [155–159].
As such, serum drug concentrations are used to
guide therapy for certain antiarrhythmics.
Potentially significant clinical implications lie in
the pharmacogenetics of drug-induced QT prolongation and torsades de pointes (TdP). The genetics
of acquired (i.e., drug-induced) long QT syndrome
have been well described [160,161]. The ability of
both cardiovascular and noncardiovascular drugs
(e.g., terfenadine, astemizole, fluoroquinolone
antibiotics and antispychotics) to prolong the QT
interval has been cited as a major contributor to
arrhythmogenicity of these agents.
Because of the phenotypical similarities between
acquired and congenital long QT syndromes (e.g., a
predominance in women over men and near identical ECG changes), polymorphisms in genes associated with congenital long QT syndrome have
served as candidate genes for the study of druginduced QT prolongation and TdP. For example,
in an analysis of a fairly large data set, genetic variants in protein subunits of the cardiac K+ channel
encoded by KCNQ1 (or KvLQT1), KCNH2 (or
HERG) and SCN5A, have been identified to occur
in roughly 5–10% of individuals experiencing druginduced prolongation of the QT interval [162].
These and other findings suggest that polymorphisms in pore-forming subunits of electrocurrentrelated proteins, as well as protein modifiers
subunit function (e.g., KCNE2 or MiRP1) may be
important in a priori risk assessment for arrhythmia in a patient or in the drug development process
[163–166].
Because intrinsic regulatory control of cardiac
rhythm is so complex, it has been promulgated that
no one set of genetic or nongenetic factors can predict the likelihood of an agent to cause QT prolongation or TdP. Rather, variants in drug metabolism
genes (CYP2D6, CYP2C9, CYP2C19, CYP3A4,
CYP3A5) should be considered in conjunction with
genes for proteins involved in potassium-related
action potentials (i.e., ITO, IKr and IKs) and sodium
channels, along with nongenetic factors (e.g., sex,
renal function, serum potassium and interacting
drugs) [167,168].
The usefulness of arrhythmia pharmacogenetics
does not lie solely in understanding the molecular
basis of drug-induced arrhythmias. Associations
between single polymorphisms, haplotypes and
sets of multiple polymorphisms with dysrhythmia
phenotypes and in vitro analyses could potentially
lead to:
1 Improved diagnosis of individuals with both
congenital and acquired long QT syndrome;
2 More rational use of existing medications (both
cardiac and non-cardiac); and
3 Enhancement of the drug development process
[169].
By genomically profiling novel compounds against
compounds with known QT prolonging effects,
comparative toxicogenomics can perhaps be used
to triage novel compounds with likely QT prolonging effects in the preclinical phases of drug discovery and development.
The potential clinical relevance of the work on
drug-induced QT prolongation is that it may
improve drug development for drugs with QT prolongation properties. Additionally, it might be possible to identify those patients at highest risk for
drug-induced arrhythmia, although reaching this
goal will be a significant challenge.
Future directions in cardiovascular
pharmacogenetics
The examples discussed above provide clear evidence that genetics contributes to the variable
efficacy and toxicity that is encountered across a
population of individuals given a certain drug. The
hope is that this information might someday be
used to optimize the pharmacotherapy management of patients, and of the examples provided,
warfarin is the first in this group for which the
promise might be realized. However, in most cases
it is likely to be another 10–15 years before there are
a large number of drugs for which their use can
be guided by genetic information, and even longer
for this to gain widespread use in the practice of
medicine.
To achieve the goals of pharmacogenetics
requires several steps, as highlighted in Fig. 11.2.
For many of the examples discussed in this chapter,
our knowledge is at the base of the pyramid – there
has been documentation that genetics contributes
to variable drug response. However, this knowledge must be built upon to move pharmacogenetics to the point of use in clinical practice. The
next step on the pyramid is to determine the group
CHAPTER 11
Moving pharmacogenetics to clinical practice
Document superiority of pharmacogenetics:
Pharmacogenetic-guided versus usual care
Develop and test predictive models
using genetic and nongenetic information
4
5
Explain sufficient degree of
response variability to be predictive clinically
Document proof of concept:
genetics contributes to response variability
Figure 11.2 Moving pharmacogenetics to clinical practice.
The pyramid of knowledge that will likely need to be built
for use of pharmacogenetic data to be translated into
practice. See text for details. Reprinted from [192] with
permission from Future Medicine Ltd.
of genes that will allow for a sufficient degree of the
response variability to be explained or predicted.
While we have probably reached this threshold for
warfarin, this is not yet the case for our other examples. Once the various genes that contribute to variable drug response are known, then mathematical
models that incorporate genetic and nongenetic
information to predict response must be developed
and tested. This is currently underway for warfarin.
Finally, to achieve the evidence base that will be
needed for wide adoption into practice, there will
need to be studies documenting that a pharmacogenetic-guided approach is superior to the usual
approach of treating diseases with drug therapy.
For those drugs where the level of evidence can be
accumulated to reach the top of this knowledge
pyramid, it seems likely that use of pharmacogenetics will be embraced in clinical practice.
References
1 Taylor AL, Ziesche S, Yancy C et al. the AfricanAmerican Heart Failure Trial Investigators. Combination of isosorbide dinitrate and hydralazine in blacks
with heart failure. N Engl J Med 2004; 351: 2049–2057.
2 Third Report of the National Cholesterol Education
Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in
Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143–3421.
3 Grundy SM, Cleeman JI, Merz CN et al. Implications
of recent clinical trials for the National Cholesterol
6
7
8
9
10
11
12
13
14
Pharmacogenetics 269
Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227–239.
Zineh I. HMG-CoA reductase inhibitor pharmacogenomics: overview and implications for practice. Clin
Cardiol 2005; 1: 191–206.
Kim RB. 3-Hydroxy-3-methylglutaryl-coenzyme A
reductase inhibitors (statins) and genetic variability
(single nucleotide polymorphisms) in a hepatic drug
uptake transporter: what’s it all about? Clin Pharmacol
Ther 2004; 75: 381–385.
Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R,
Bernini F. New insights into the pharmacodynamic and
pharmacokinetic properties of statins. Pharmacol Ther
1999; 84: 413–428.
Hsiang B, Zhu Y, Wang Z et al. A novel human hepatic
organic anion transporting polypeptide (OATP2).
Identification of a liver-specific human organic anion
transporting polypeptide and identification of rat and
human hydroxymethylglutaryl-CoA reductase inhibitor
transporters. J Biol Chem 1999; 274: 37161–37168.
Kobayashi D, Nozawa T, Imai K, Nezu J, Tsuji A, Tamai
I. Involvement of human organic anion transporting
polypeptide OATP-B (SLC21A9) in pH-dependent
transport across intestinal apical membrane. J Pharmacol
Exp Ther 2003; 306: 703–708.
Hasegawa M, Kusuhara H, Sugiyama D et al. Functional
involvement of rat organic anion transporter 3 (rOat3;
Slc22a8) in the renal uptake of organic anions. J Pharmacol Exp Ther 2002; 300: 746–753.
Tirona RG, Leake BF, Merino G, Kim RB. Polymorphisms in OATP-C: identification of multiple allelic
variants associated with altered transport activity among
European- and African-Americans. J Biol Chem 2001;
276: 35669–35675.
Kameyama Y, Yamashita K, Kobayashi K, Hosokawa M,
Chiba K. Functional characterization of SLCO1B1
(OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and
SLCO1B1*15+C1007G, by using transient expression
systems of HeLa and HEK293 cells. Pharmacogenet
Genomics 2005; 15: 513–522.
Mwinyi J, Johne A, Bauer S, Roots I, Gerloff T. Evidence
for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin Pharmacol Ther
2004; 75: 415–421.
Nishizato Y, Ieiri I, Suzuki H et al. Polymorphisms
of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes:
consequences for pravastatin pharmacokinetics. Clin
Pharmacol Ther 2003; 73: 554–565.
Niemi M, Schaeffeler E, Lang T et al. High plasma
pravastatin concentrations are associated with single
nucleotide polymorphisms and haplotypes of organic
anion transporting polypeptide-C (OATP-C, SLCO1B1).
Pharmacogenetics 2004; 14: 429–440.
270 PART III Therapies and applications
15 Niemi M, Neuvonen PJ, Hofmann U et al. Acute effects
of pravastatin on cholesterol synthesis are associated
with SLCO1B1 (encoding OATP1B1) haplotype *17.
Pharmacogenet Genomics 2005; 15: 303–309.
16 Tachibana-Iimori R, Tabara Y, Kusuhara H et al. Effect
of genetic polymorphism of OATP-C (SLCO1B1) on lipidlowering response to HMG-CoA reductase inhibitors.
Drug Metab Pharmacokinet 2004; 19: 375–380.
17 Kajinami K, Brousseau ME, Ordovas JM, Schaefer EJ.
Polymorphisms in the multidrug resistance-1 (MDR1)
gene influence the response to atorvastatin treatment
in a gender-specific manner. Am J Cardiol 2004; 93:
1046–1050.
18 Bercovich D, Friedlander Y, Korem S et al. The association of common SNPs and haplotypes in the CETP and
MDR1 genes with lipids response to fluvastatin in familial
hypercholesterolemia. Atherosclerosis 2006; 185: 97–107.
19 Nordin C, Dahl ML, Eriksson M, Sjoberg S. Is the
cholesterol-lowering effect of simvastatin influenced by
CYP2D6 polymorphism? Lancet 1997; 350: 29–30.
20 Mulder AB, van Lijf HJ, Bon MA, et al. Association of
polymorphism in the cytochrome CYP2D6 and the
efficacy and tolerability of simvastatin. Clin Pharmacol
Ther 2001; 70: 546–551.
21 Geisel J, Kivisto KT, Griese EU, Eichelbaum M. The
efficacy of simvastatin is not influenced by CYP2D6
polymorphism. Clin Pharmacol Ther 2002; 72: 595–596.
22 Kajinami K, Brousseau ME, Ordovas JM, Schaefer EJ.
CYP3A4 genotypes and plasma lipoprotein levels before
and after treatment with atorvastatin in primary hypercholesterolemia. Am J Cardiol 2004; 93: 104–107.
23 Wang A, Yu BN, Luo CH et al. Ile118Val genetic polymorphism of CYP3A4 and its effects on lipid-lowering
efficacy of simvastatin in Chinese hyperlipidemic patients. Eur J Clin Pharmacol 2005; 60: 843–848.
24 Kivisto KT, Niemi M, Schaeffeler E et al. Lipid-lowering
response to statins is affected by CYP3A5 polymorphism. Pharmacogenetics 2004; 14: 523–525.
25 Kirchheiner J, Kudlicz D, Meisel C et al. Influence of
CYP2C9 polymorphisms on the pharmacokinetics and
cholesterol-lowering activity of (−)-3S,5R-fluvastatin
and (+)-3R,5S-fluvastatin in healthy volunteers. Clin
Pharmacol Ther 2003; 74: 186–194.
26 Wilke RA, Moore JH, Burmester JK. Relative impact
of CYP3A genotype and concomitant medication on
the severity of atorvastatin-induced muscle damage.
Pharmacogenet Genomics 2005; 15: 415–421.
27 Chasman DI, Posada D, Subrahmanyan L, Cook NR,
Stanton VP Jr, Ridker PM. Pharmacogenetic study of
statin therapy and cholesterol reduction. JAMA 2004;
291: 2821–2827.
28 Thompson JF, Man M, Johnson KJ et al. An association
study of 43 SNPs in 16 candidate genes with atorvastatin
response. Pharmacogenomics J 2005; 5: 352–358.
29 Pedro-Botet J, Schaefer EJ, Bakker-Arkema RG et al.
Apolipoprotein E genotype affects plasma lipid
response to atorvastatin in a gender specific manner.
Atherosclerosis 2001; 158: 183–193.
30 Ballantyne CM, Herd JA, Stein EA et al. Apolipoprotein
E genotypes and response of plasma lipids and progressionregression of coronary atherosclerosis to lipid-lowering
drug therapy. J Am Coll Cardiol 2000; 36: 1572–1578.
31 Nestel P, Simons L, Barter P et al. A comparative study
of the efficacy of simvastatin and gemfibrozil in combined hyperlipoproteinemia: prediction of response
by baseline lipids, apo E genotype, lipoprotein(a) and
insulin. Atherosclerosis 1997; 129: 231–239.
32 Ordovas JM, Mooser V. The APOE locus and the pharmacogenetics of lipid response. Curr Opin Lipidol 2002;
13: 113–117.
33 O’Neill FH, Patel DD, Knight BL et al. Determinants of
variable response to statin treatment in patients with
refractory familial hypercholesterolemia. Arterioscler
Thromb Vasc Biol 2001; 21: 832–837.
34 Gerdes LU, Gerdes C, Kervinen K et al. The apolipoprotein ε4 allele determines prognosis and the effect on
prognosis of simvastatin in survivors of myocardial
infarction: a substudy of the Scandinavian simvastatin
survival study. Circulation 2000; 101: 1366–1371.
35 Maitland-van der Zee AH, Stricker BH, Klungel OH et
al. Adherence to and dosing of beta-hydroxy-betamethylglutaryl coenzyme A reductase inhibitors in the
general population differs according to apolipoprotein
E-genotypes. Pharmacogenetics 2003; 13: 219–223.
36 Sanllehy C, Casals E, Rodriguez-Villar C et al. Lack of
interaction of apolipoprotein E phenotype with the
lipoprotein response to lovastatin or gemfibrozil in
patients with primary hypercholesterolemia. Metabolism 1998; 47: 560–565.
37 Nemeth A, Szakmary K, Kramer J et al. Apolipoprotein
E and complement C3 polymorphism and their role in
the response to gemfibrozil and low fat low cholesterol
therapy. Eur J Clin Chem Clin Biochem 1995; 33: 799–804.
38 Brisson D, Ledoux K, Bosse Y et al. Effect of apolipoprotein E, peroxisome proliferator-activated receptor alpha
and lipoprotein lipase gene mutations on the ability of
fenofibrate to improve lipid profiles and reach clinical
guideline targets among hypertriglyceridemic patients.
Pharmacogenetics 2002; 12: 313–320.
39 Brousseau ME, O’Connor JJ Jr, Ordovas JM et al.
Cholesteryl ester transfer protein TaqI B2B2 genotype is
associated with higher HDL cholesterol levels and lower
risk of coronary heart disease end points in men with
HDL deficiency: Veterans Affairs HDL Cholesterol
Intervention Trial. Arterioscler Thromb Vasc Biol 2002;
22: 1148–1154.
40 Brousseau ME, Goldkamp AL, Collins D et al. Polymorphisms in the gene encoding lipoprotein lipase in
CHAPTER 11
41
42
43
44
45
46
47
48
49
50
51
52
53
54
men with low HDL-C and coronary heart disease:
the Veterans Affairs HDL Intervention Trial. J Lipid Res
2004; 45: 1885–1891.
Foucher C, Rattier S, Flavell DM et al. Response to
micronized fenofibrate treatment is associated with the
peroxisome-proliferator-activated receptors alpha G/C
intron7 polymorphism in subjects with type 2 diabetes.
Pharmacogenetics 2004; 14: 823–829.
Flavell DM, Jamshidi Y, Hawe E et al. Peroxisome
proliferator-activated receptor alpha gene variants influence progression of coronary atherosclerosis and risk of
coronary artery disease. Circulation 2002; 105: 1440–1445.
Bosse Y, Pascot A, Dumont M et al. Influences of the
PPAR alpha-L162V polymorphism on plasma HDL(2)cholesterol response of abdominally obese men treated
with gemfibrozil. Genet Med 2002; 4: 311–315.
Brouillette C, Bosse Y, Perusse L, Gaudet D, Vohl MC.
Effect of liver fatty acid binding protein (FABP) T94A
missense mutation on plasma lipoprotein responsiveness to treatment with fenofibrate. J Hum Genet 2004;
49: 424–432.
Bosse Y, Vohl MC, Dumont M et al. Influence of the
angiotensin-converting enzyme gene insertion/deletion
polymorphism on lipoprotein/lipid response to gemfibrozil. Clin Genet 2002; 62: 45–52.
Smart EJ, De Rose RA, Farber SA. Annexin 2-caveolin 1
complex is a target of ezetimibe and regulates intestinal
cholesterol transport. Proc Natl Acad Sci USA 2004; 101:
3450–3455.
Lammert F, Wang DQ. New insights into the genetic
regulation of intestinal cholesterol absorption. Gastroenterology 2005; 129: 718–734.
Garcia-Calvo M, Lisnock J, Bull HG et al. The target of
ezetimibe is Niemann–Pick C1-Like 1 (NPC1L1). Proc
Natl Acad Sci USA 2005; 102: 8132–8137.
Wang J, Williams CM, Hegele RA. Compound heterozygosity for two non-synonymous polymorphisms
in NPC1L1 in a non-responder to ezetimibe. Clin Genet
2005; 67: 175–177.
Hegele RA, Guy J, Ban MR, Wang J. NPC1L1 haplotype
is associated with inter-individual variation in plasma
low-density lipoprotein response to ezetimibe. Lipids
Health Dis 2005; 4: 16.
Zineh I. Genetic polymorphisms and statin therapy.
JAMA 2004; 292: 1302–1303.
Johnson JA, Turner ST. Hypertension pharmacogenomics: current status and future directions. Curr Opin
Mol Ther 2005; 7: 218–225.
Cusi D, Barlassina C, Azzani T et al. Polymorphisms of
alpha-adducin and salt sensitivity in patients with essential hypertension. Lancet 1997; 349: 1353–1357.
Glorioso N, Manunta P, Filigheddu F et al. The role of
alpha-adducin polymorphism in blood pressure and
sodium handling regulation may not be excluded by a
55
56
57
58
59
60
61
62
63
64
65
66
Pharmacogenetics 271
negative association study. Hypertension 1999; 34: 649–
654.
Sciarrone MT, Stella P, Barlassina C et al. ACE and
alpha-adducin polymorphism as markers of individual
response to diuretic therapy. Hypertension 2003; 41:
398–403.
Psaty BM, Smith NL, Heckbert SR et al. Diuretic therapy, the alpha-adducin gene variant, and the risk of
myocardial infarction or stroke in persons with treated
hypertension. JAMA 2002; 287: 1680–1689.
Gerhard T, Gong Y, Beitelshees AL et al. Cardiovascular
outcomes, diuretic therapy and the alpha-adducin polymorphism: Results for the International Verapamil
SR-Trandolapril Study Genetic Substudy (INVESTGENES) (Abstract). Circulation 2005; 112: II608.
Johnson JA, Zineh I, Puckett BJ, McGorray SP, Yarandi
HN, Pauly DF. β1-Adrenergic receptor polymorphisms
and antihypertensive response to metoprolol. Clin
Pharmacol Ther 2003; 74: 44–52.
Liu J, Liu ZQ, Tan ZR et al. Gly389Arg polymorphism
of β1-adrenergic receptor is associated with the cardiovascular response to metoprolol. Clin Pharmacol Ther
2003; 74: 372–379.
Sofowora GG, Dishy V, Muszkat M et al. A common
β1-adrenergic receptor polymorphism (Arg389Gly)
affects blood pressure response to beta-blockade. Clin
Pharmacol Ther 2003; 73: 366–371.
O’Shaughnessy KM, Fu B, Dickerson C, Thurston D,
Brown MJ. The gain-of-function G389R variant of the
β1-adrenoceptor does not influence blood pressure or
heart rate response to beta-blockade in hypertensive
subjects. Clin Sci (Colch) 2000; 99: 233–238.
Karlsson J, Lind L, Hallberg P et al. β1-Adrenergic receptor gene polymorphisms and response to β1-adrenergic
receptor blockade in patients with essential hypertension. Clin Cardiol 2004; 27: 347–350.
Ohmichi N, Iwai N, Uchida Y, Shichiri G, Nakamura Y,
Kinoshita M. Relationship between the response to
the angiotensin converting enzyme inhibitor imidapril
and the angiotensin converting enzyme genotype. Am J
Hypertens 1997; 10: 951–955.
Stavroulakis GA, Makris TK, Krespi PG et al. Predicting
response to chronic antihypertensive treatment with
fosinopril: the role of angiotensin-converting enzyme
gene polymorphism. Cardiovasc Drugs Ther 2000; 14:
427–432.
Li X, Du Y, Huang X. Correlation of angiotensinconverting enzyme gene polymorphism with effect of
antihypertensive therapy by angiotensin-converting
enzyme inhibitor. J Cardiovasc Pharmacol Ther 2003; 8:
25–30.
Kurland L, Melhus H, Karlsson J et al. Aldosterone synthase (CYP11B2) -344 C/T polymorphism is related
to antihypertensive response: result from the Swedish
272 PART III Therapies and applications
67
68
69
70
71
72
73
74
75
76
77
78
Irbesartan Left Ventricular Hypertrophy Investigation
versus Atenolol (SILVHIA) trial. Am J Hypertens 2002;
15: 389–393.
Yu H, Zhang Y, Liu G. Relationship between polymorphism of the angiotensin-converting enzyme gene
and the response to angiotensin-converting enzyme
inhibition in hypertensive patients. Hypertens Res 2003;
26: 881–886.
Harrap SB, Tzourio C, Cambien F et al. The ACE gene
I/D polymorphism is not associated with the blood
pressure and cardiovascular benefits of ACE inhibition.
Hypertension 2003; 42: 297–303.
Ortlepp JR, Hanrath P, Mevissen V, Kiel G, Borggrefe
M, Hoffmann R. Variants of the CYP11B2 gene predict
response to therapy with candesartan. Eur J Pharmacol
2002; 445: 151–152.
Arnett DK, Davis BR, Ford CE et al. Pharmacogenetic
association of the angiotensin-converting enzyme insertion/
deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment:
the Genetics of Hypertension-Associated Treatment
(GenHAT) study. Circulation 2005; 111: 3374–3383.
Terra SG, Hamilton KK, Pauly DF et al. Beta1-adrenergic
receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy.
Pharmacogenet Genomics 2005; 15: 227–234.
Mialet Perez J, Rathz DA, Petrashevskaya NN et al. β1Adrenergic receptor polymorphisms confer differential
function and predisposition to heart failure. Nat Med
2003; 9: 1300–1305.
Kaye DM, Smirk B, Williams C, Jennings G, Esler M,
Holst D. β2-Adrenoceptor genotype influences the
responses to carvedilol in patients with congestive heart
failure. Pharmacogenetics 2003; 13.
de Groote P, Helbecque N, Lamblin N et al. Association
between β1 and β1-adrenergic receptor gene polymorphisms and the response to beta-blockade in patients
with stable congestive heart failure. Pharmacogenet
Genomics 2005; 15: 137–142.
Terra SG, Pauly DF, Lee CR et al. β-Adrenergic receptor
polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure. Clin Pharmacol Ther 2005; 77: 127–137.
Magnusson Y, Levin MC, Eggertsen R et al. Ser49Gly of
β1-adrenergic receptor is associated with effective betablocker dose in dilated cardiomyopathy. Clin Pharmacol
Ther 2005; 78: 221–231.
Borjesson M, Magnusson Y, Hjalmarson A, Andersson
B. A novel polymorphism in the gene coding for the β1adrenergic receptor associated with survival in patients
with heart failure. Eur Heart J 2000; 21: 1853–1858.
Beta-Blocker Evaluation of Survival Trial Investigators.
A trial of the beta-blocker bucindolol in patients with
79
80
81
82
83
84
85
86
87
88
89
90
advanced chronic heart failure. N Engl J Med 2001; 344:
1659–1667.
White HL, de Boer RA, Maqbool A et al. An evaluation
of the β1-adrenergic receptor Arg389Gly polymorphism
in individuals with heart failure: a MERIT-HF substudy. Eur J Heart Fail 2003; 5: 463–468.
Lanfear DE, Jones PG, Marsh S, Cresci S, McLeod HL,
Spertus JA. β2-Adrenergic receptor genotype and survival among patients receiving beta-blocker therapy
after an acute coronary syndrome. JAMA 2005; 294:
1526–1533.
Giessmann T, Modess C, Hecker U et al. CYP2D6 genotype and induction of intestinal drug transporters by
rifampin predict presystemic clearance of carvedilol in
healthy subjects. Clin Pharmacol Ther 2004; 75: 213–222.
Zineh I, Beitelshees AL, Gaedigk A et al. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clin
Pharmacol Ther 2004; 76: 536–544.
McNamara DM, Holubkov R, Postava L et al.
Pharmacogenetic interactions between angiotensinconverting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in
patients with congestive heart failure. J Am Coll Cardiol
2004; 44: 2019–2026.
Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M,
Pastan I, Gottesman MM. Biochemical, cellular, and
pharmacological aspects of the multidrug transporter.
Annu Rev Pharmacol Toxicol 1999; 39: 361–398.
Hoffmeyer S, Burk O, von Richter O et al. Functional
polymorphisms of the human multidrug-resistance
gene: multiple sequence variations and correlation of
one allele with P-glycoprotein expression and activity in
vivo. Proc Natl Acad Sci USA 2000; 97: 3473–3478.
Becquemont L, Verstuyft C, Kerb R et al. Effect of grapefruit juice on digoxin pharmacokinetics in humans. Clin
Pharmacol Ther 2001; 70: 311–316.
Sakaeda T, Nakamura T, Horinouchi M et al. MDR1
genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects.
Pharm Res 2001; 18: 1400–1404.
Gerloff T, Schaefer M, Johne A et al. MDR1 genotypes
do not influence the absorption of a single oral dose of
1 mg digoxin in healthy white males. Br J Clin Pharmacol 2002; 54: 610–616.
Johne A, Kopke K, Gerloff T et al. Modulation of steadystate kinetics of digoxin by haplotypes of the Pglycoprotein MDR1 gene. Clin Pharmacol Ther 2002; 72:
584–594.
Kurata Y, Ieiri I, Kimura M et al. Role of human MDR1
gene polymorphism in bioavailability and interaction of
digoxin, a substrate of P-glycoprotein. Clin Pharmacol
Ther 2002; 72: 209–219.
CHAPTER 11
91 Morita Y, Sakaeda T, Horinouchi M et al. MDR1 genotype-related duodenal absorption rate of digoxin in
healthy Japanese subjects. Pharm Res 2003; 20: 552–556.
92 Verstuyft C, Schwab M, Schaeffeler E et al. Digoxin
pharmacokinetics and MDR1 genetic polymorphisms.
Eur J Clin Pharmacol 2003; 58: 809–812.
93 Verstuyft C, Strabach S, El-Morabet H et al.
Dipyridamole enhances digoxin bioavailability via Pglycoprotein inhibition. Clin Pharmacol Ther 2003; 73:
51–60.
94 Chowbay B, Li H, David M, Bun Cheung Y, Lee EJ.
Meta-analysis of the influence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1
gene expression. Br J Clin Pharmacol 2005; 60: 159–171.
95 Cicoira M, Rossi A, Bonapace S et al. Effects of ACE
gene insertion/deletion polymorphism on response to
spironolactone in patients with chronic heart failure.
Am J Med 2004; 116: 657–661.
96 Cohn JN, Johnson G, Ziesche S et al. A comparison of
enalapril with hydralazine-isosorbide dinitrate in the
treatment of chronic congestive heart failure. N Engl J
Med 1991; 325: 303–310.
97 Szczeklik A, Musial J, Undas A, Sanak M. Aspirin resistance. J Thromb Haemost 2005; 3: 1655–1662.
98 Cambria-Kiely JA, Gandhi PJ. Aspirin resistance and
genetic polymorphisms. J Thromb Thrombolysis 2002;
14: 51–58.
99 Schafer AI. Genetic and acquired determinants of individual variability of response to antiplatelet drugs.
Circulation 2003; 108: 910–911.
100 Rozalski M, Boncler M, Luzak B, Watala C. Genetic factors underlying differential blood platelet sensitivity to
inhibitors. Pharmacol Rep 2005; 57: 1–13.
101 Jefferson BK, Foster JH, McCarthy JJ et al. Aspirin resistance and a single gene. Am J Cardiol 2005; 95: 805–808.
102 Halushka MK, Walker LP, Halushka PV. Genetic variation in cyclooxygenase 1: effects on response to aspirin.
Clin Pharmacol Ther 2003; 73: 122–130.
103 Maree AO, Curtin RJ, Chubb A et al. Cyclooxygenase-1
haplotype modulates platelet response to aspirin.
J Thromb Haemost 2005; 3: 2340–2345.
104 Undas A, Sanak M, Musial J, Szczeklik A. Platelet glycoprotein IIIa polymorphism, aspirin, and thrombin generation. Lancet 1999; 353: 982–983.
105 Undas A, Brummel K, Musial J, Mann KG, Szczeklik A.
Pl(A2) polymorphism of beta(3) integrins is associated
with enhanced thrombin generation and impaired
antithrombotic action of aspirin at the site of microvascular injury. Circulation 2001; 104: 2666–2672.
106 Szczeklik A, Undas A, Sanak M, Frolow M, Wegrzyn W.
Relationship between bleeding time, aspirin and the
PlA1/A2 polymorphism of platelet glycoprotein IIIa. Br
J Haematol 2000; 110: 965–967.
Pharmacogenetics 273
107 Cooke GE, Bray PF, Hamlington JD, Pham DM,
Goldschmidt-Clermont PJ. PlA2 polymorphism and
efficacy of aspirin. Lancet 1998; 351: 1253.
108 Andrioli G, Minuz P, Solero P et al. Defective platelet
response to arachidonic acid and thromboxane A(2) in
subjects with Pl(A2) polymorphism of beta(3) subunit
(glycoprotein IIIa). Br J Haematol 2000; 110: 911–918.
109 Michelson AD, Furman MI, Goldschmidt-Clermont P
et al. Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists. Circulation 2000; 101:
1013–1018.
110 Morawski W, Sanak M, Cisowski M et al. Prediction of
the excessive perioperative bleeding in patients undergoing coronary artery bypass grafting: Role of aspirin
and platelet glycoprotein IIIa polymorphism. J Thorac
Cardiovasc Surg 2005; 130: 791–796.
111 Macchi L, Christiaens L, Brabant S et al. Resistance in
vitro to low-dose aspirin is associated with platelet PlA1
(GP IIIa) polymorphism but not with C807T(GP Ia/IIa)
and C-5T Kozak (GP Ibalpha) polymorphisms. J Am
Coll Cardiol 2003; 42: 1115–1119.
112 Szczeklik A, Musial J, Undas A. Reasons for resistance to
aspirin in cardiovascular disease. Circulation 2002; 106:
e181–182; author reply e-2.
113 Wheeler GL, Braden GA, Bray PF, Marciniak SJ,
Mascelli MA, Sane DC. Reduced inhibition by abciximab in platelets with the PlA2 polymorphism. Am
Heart J 2002; 143: 76–82.
114 Rozalski M, Watala C. Antagonists of platelet fibrinogen
receptor are less effective in carriers of Pl(A2) polymorphism of beta(3) integrin. Eur J Pharmacol 2002; 454:
1–8.
115 Aalto-Setala K, Karhunen PJ, Mikkelsson J, Niemela K.
The effect of glycoprotein IIIa PIA1/A2 polymorphism
on the PFA-100 response to GP IIbIIIa receptor
inhibitors: the importance of anticoagulants used. J
Thromb Thrombolysis 2005; 20: 57–63.
116 Gorchakova O, Koch W, Mehilli J et al. PlA polymorphism of the glycoprotein IIIa and efficacy of
reperfusion therapy in patients with acute myocardial
infarction. Thromb Haemost 2004; 91: 141–145.
117 O’Connor FF, Shields DC, Fitzgerald A, Cannon CP,
Braunwald E, Fitzgerald DJ. Genetic variation in glycoprotein IIb/IIIa (GPIIb/IIIa) as a determinant of the
responses to an oral GPIIb/IIIa antagonist in patients
with unstable coronary syndromes. Blood 2001; 98:
3256–3260.
118 Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol 2005;
45: 1157–1164.
119 Ziegler S, Schillinger M, Funk M et al. Association
of a functional polymorphism in the clopidogrel
target receptor gene, P2Y12, and the risk for ischemic
274 PART III Therapies and applications
120
121
122
123
124
125
126
127
128
129
130
131
132
cerebrovascular events in patients with peripheral artery
disease. Stroke 2005; 36: 1394–1399.
von Beckerath N, von Beckerath O, Koch W, Eichinger
M, Schomig A, Kastrati A. P2Y12 gene H2 haplotype is
not associated with increased adenosine diphosphateinduced platelet aggregation after initiation of clopidogrel therapy with a high loading dose. Blood Coagul
Fibrinolysis 2005; 16: 199–204.
Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al. Lack
of association between the P2Y(12) receptor gene polymorphism and platelet response to clopidogrel in
patients with coronary artery disease. Thromb Res 2005;
116: 491–497.
Smith SM, Judge HM, Peters G et al. PAR-1 genotype
influences platelet aggregation and procoagulant responses in patients with coronary artery disease prior
to and during clopidogrel therapy. Platelets 2005; 16:
340–345.
Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al. PlA
polymorphism and platelet reactivity following clopidogrel loading dose in patients undergoing coronary stent
implantation. Blood Coagul Fibrinolysis 2004; 15: 89–93.
Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al. 807
C/T Polymorphism of the glycoprotein Ia gene and
pharmacogenetic modulation of platelet response to
dual antiplatelet treatment. Blood Coagul Fibrinolysis
2004; 15: 427–433.
Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9
polymorphisms: a comprehensive review of the in-vitro
and human data. Pharmacogenetics 2002; 12: 251–263.
Takahashi H, Kashima T, Nomizo Y et al. Metabolism of
warfarin enantiomers in Japanese patients with heart
disease having different CYP2C9 and CYP2C19 genotypes. Clin Pharmacol Ther 1998; 63: 519–528.
Takahashi H, Echizen H. Pharmacogenetics of warfarin
elimination and its clinical implications. Clin Pharmacokinet 2001; 40: 587–603.
Furuya H, Fernandez-Salguero P, Gregory W et al.
Genetic polymorphism of CYP2C9 and its effect on
warfarin maintenance dose requirement in patients
undergoing anticoagulation therapy. Pharmacogenetics
1995; 5: 389–392.
Daly AK, Day CP, Aithal GP. CYP2C9 polymorphism
and warfarin dose requirements. Br J Clin Pharmacol
2002; 53: 408–409.
Daly AK, Aithal GP. Genetic regulation of warfarin
metabolism and response. Semin Vasc Med 2003; 3:
231–238.
Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of
polymorphisms in the cytochrome P450 CYP2C9 with
warfarin dose requirement and risk of bleeding complications. Lancet 1999; 353: 717–719.
Voora D, Eby C, Linder MW et al. Prospective dosing of
133
134
135
136
137
138
139
140
141
142
143
144
145
warfarin based on cytochrome P-450 2C9 genotype.
Thromb Haemost 2005; 93: 700–705.
Hillman MA, Wilke RA, Yale SH et al. A prospective,
randomized pilot trial of model-based warfarin dose
initiation using CYP2C9 genotype and clinical data.
Clin Med Res 2005; 3: 137–145.
Li T, Chang CY, Jin DY, Lin PJ, Khvorova A, Stafford
DW. Identification of the gene for vitamin K epoxide
reductase. Nature 2004; 427: 541–544.
Rost S, Fregin A, Ivaskevicius V et al. Mutations in
VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 2004; 427:
537–541.
D’Andrea G, D’Ambrosio RL, Di Perna P et al. A polymorphism in the VKORC1 gene is associated with an
interindividual variability in the dose-anticoagulant
effect of warfarin. Blood 2005; 105: 645–649.
Harrington DJ, Underwood S, Morse C, Shearer MJ,
Tuddenham EG, Mumford AD. Pharmacodynamic
resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit 1. Thromb Haemost 2005; 93: 23–26.
Pelz HJ, Rost S, Hunerberg M et al. The genetic basis of
resistance to anticoagulants in rodents. Genetics 2005;
170: 1839–1847.
Wadelius M, Chen LY, Downes K et al. Common
VKORC1 and GGCX polymorphisms associated with
warfarin dose. Pharmacogenomics J 2005; 5: 262–270.
Yuan HY, Chen JJ, Lee MT et al. A novel functional
VKORC1 promoter polymorphism is associated with
inter-individual and inter-ethnic differences in warfarin
sensitivity. Hum Mol Genet 2005; 14: 1745–1751.
Sconce EA, Khan TI, Wynne HA et al. The impact
of CYP2C9 and VKORC1 genetic polymorphism and
patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005;
106: 2329–2333.
Rieder MJ, Reiner AP, Gage BF et al. Effect of VKORC1
haplotypes on transcriptional regulation and warfarin
dose. N Engl J Med 2005; 352: 2285–2293.
Veenstra DL, You JH, Rieder MJ et al. Association of
vitamin K epoxide reductase complex 1 (VKORC1)
variants with warfarin dose in a Hong Kong Chinese
patient population. Pharmacogenet Genomics 2005; 15:
687–691.
Burgess JK, Lindeman R, Chesterman CN, Chong BH.
Single amino acid mutation of Fc gamma receptor is
associated with the development of heparin-induced
thrombocytopenia. Br J Haematol 1995; 91: 761–766.
Brandt JT, Isenhart CE, Osborne JM, Ahmed A,
Anderson CL. On the role of platelet Fc gamma RIIa
phenotype in heparin-induced thrombocytopenia.
Thromb Haemost 1995; 74: 1564–1572.
CHAPTER 11
146 Denomme GA, Warkentin TE, Horsewood P, Sheppard
JA, Warner MN, Kelton JG. Activation of platelets by
sera containing IgG1 heparin-dependent antibodies: an
explanation for the predominance of the Fc gammaRIIa
“low responder” (HIS131) gene in patients with
heparin-induced thrombocytopenia. J Lab Clin Med
1997; 130: 278–284.
147 Arepally G, McKenzie SE, Jiang XM, Poncz M, Cines
DB. Fc gamma RIIA H/R 131 polymorphism, subclassspecific IgG anti-heparin/platelet factor 4 antibodies
and clinical course in patients with heparin-induced
thrombocytopenia and thrombosis. Blood 1997; 89:
370–305.
148 Bachelot-Loza C, Saffroy R, Lasne D, Chatellier G, Aiach
M, Rendu F. Importance of the FcgammaRIIa-Arg/His131 polymorphism in heparin-induced thrombocytopenia diagnosis. Thromb Haemost 1998; 79: 523–528.
149 Carlsson LE, Santoso S, Baurichter G et al. Heparininduced thrombocytopenia: new insights into the
impact of the FcgammaRIIa-R-H131 polymorphism.
Blood 1998; 92: 1526–1531.
150 Carlsson LE, Lubenow N, Blumentritt C et al. Platelet
receptor and clotting factor polymorphisms as genetic risk factors for thromboembolic complications in
heparin-induced thrombocytopenia. Pharmacogenetics
2003; 13: 253–258.
151 Ray KK, Francis S, Crossman DC. A potential pharmacogenomic strategy for anticoagulant treatment in nonST elevation acute coronary syndromes: the role of
interleukin-1 receptor antagonist genotype. J Thromb
Haemost 2005; 3: 287–291.
152 Bauman JL, Schoen MD. Arrhythmias. In: Dipiro JT,
Talbert RL, Yee GC et al. eds. Pharmacotherapy: A
Pathophysiological Approach. McGraw Hill, New York,
2002: 273–303.
153 Wang T, Roden DM, Wolfenden HT, Woosley RL,
Wood AJ, Wilkinson GR. Influence of genetic polymorphism on the metabolism and disposition of encainide
in man. J Pharmacol Exp Ther 1984; 228: 605–611.
154 Lee JT, Kroemer HK, Silberstein DJ et al. The role of
genetically determined polymorphic drug metabolism
in the beta-blockade produced by propafenone. N Engl J
Med 1990; 322: 1764–1768.
155 Funck-Brentano C, Kroemer HK, Pavlou H, Woosley
RL, Roden DM. Genetically determined interaction
between propafenone and low dose quinidine: role of
active metabolites in modulating net drug effect. Br J
Clin Pharmacol 1989; 27: 435–444.
156 Funck-Brentano C, Turgeon J, Woosley RL, Roden DM.
Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic
polymorphism. J Pharmacol Exp Ther 1989; 249: 134–
142.
Pharmacogenetics 275
157 Turgeon J, Pavlou HN, Wong W, Funck-Brentano C,
Roden DM. Genetically determined steady-state interaction between encainide and quinidine in patients with
arrhythmias. J Pharmacol Exp Ther 1990; 255: 642–649.
158 Birgersdotter UM, Wong W, Turgeon J, Roden DM.
Stereoselective genetically determined interaction between chronic flecainide and quinidine in patients with
arrhythmias. Br J Clin Pharmacol 1992; 33: 275–280.
159 Morike KE, Roden DM. Quinidine-enhanced betablockade during treatment with propafenone in extensive metabolizer human subjects. Clin Pharmacol Ther
1994; 55: 28–34.
160 Chiang CE, Roden DM. The long QT syndromes:
genetic basis and clinical implications. J Am Coll Cardiol
2000; 36: 1–12.
161 Roden DM, Viswanathan PC. Genetics of acquired long
QT syndrome. J Clin Invest 2005; 115: 2025–2032.
162 Yang P, Kanki H, Drolet B et al. Allelic variants in
long-QT disease genes in patients with drug-associated
torsades de pointes. Circulation 2002; 105: 1943–1948.
163 Roden DM. Pharmacogenetics and drug-induced
arrhythmias. Cardiovasc Res 2001; 50: 224–231.
164 Donger C, Denjoy I, Berthet M et al. KVLQT1 Cterminal missense mutation causes a forme fruste
long-QT syndrome. Circulation 1997; 96: 2778–2781.
165 Napolitano C, Schwartz PJ, Brown AM et al. Evidence
for a cardiac ion channel mutation underlying druginduced QT prolongation and life-threatening arrhythmias. J Cardiovasc Electrophysiol 2000; 11: 691–696.
166 Sesti F, Abbott GW, Wei J et al. A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proc Natl Acad Sci USA 2000; 97:
10613–10618.
167 Roden DM. Genetic polymorphisms, drugs, and proarrhythmia. J Interv Card Electrophysiol 2003; 9:
131–135.
168 Roden DM. Proarrhythmia as a pharmacogenomic
entity: a critical review and formulation of a unifying
hypothesis. Cardiovasc Res 2005; 67: 419–425.
169 Roden DM. Human genomics and its impact on
arrhythmias. Trends Cardiovasc Med 2004; 14: 112–116.
170 Marian AJ, Safavi F, Ferlic L, Dunn JK, Gotto AM,
Ballantyne CM. Interactions between angiotensin-I converting enzyme insertion/deletion polymorphism and
response of plasma lipids and coronary atherosclerosis
to treatment with fluvastatin: the lipoprotein and coronary atherosclerosis study. J Am Coll Cardiol 2000; 35:
89–95.
171 Bray PF, Cannon CP, Goldschmidt-Clermont P et al.
The platelet Pl(A2) and angiotensin-converting enzyme
(ACE) D allele polymorphisms and the risk of recurrent
events after acute myocardial infarction. Am J Cardiol
2001; 88: 347–352.
276 PART III Therapies and applications
172 Potaczek DP, Undas A, Iwaniec T, Szczeklik A. The
angiotensin-converting enzyme gene insertion/deletion
polymorphism and effects of quinapril and atorvastatin
on haemostatic parameters in patients with coronary
artery disease. Thromb Haemost 2005; 94: 224–225.
173 Lutucuta S, Ballantyne CM, Elghannam H, Gotto AM Jr,
Marian AJ. Novel polymorphisms in promoter region
of ATP binding cassette transporter gene and plasma
lipids, severity, progression, and regression of coronary
atherosclerosis and response to therapy. Circ Res 2001;
88: 969–973.
174 Kajinami K, Brousseau ME, Ordovas JM, Schaefer EJ.
Interactions between common genetic polymorphisms
in ABCG5/G8 and CYP7A1 on LDL cholesterollowering response to atorvastatin. Atherosclerosis 2004;
175: 287–293.
175 Kajinami K, Brousseau ME, Nartsupha C, Ordovas JM,
Schaefer EJ. ATP binding cassette transporter G5 and
G8 genotypes and plasma lipoprotein levels before and
after treatment with atorvastatin. J Lipid Res 2004; 45:
653–656.
176 Ojala JP, Helve E, Ehnholm C, Aalto-Setala K, Kontula
KK, Tikkanen MJ. Effect of apolipoprotein E polymorphism and XbaI polymorphism of apolipoprotein B on
response to lovastatin treatment in familial and nonfamilial hypercholesterolaemia. J Intern Med 1991; 230:
397–405.
177 Guzman EC, Hirata MH, Quintao EC, Hirata RD.
Association of the apolipoprotein B gene polymorphisms with cholesterol levels and response to fluvastatin in Brazilian individuals with high risk for coronary
heart disease. Clin Chem Lab Med 2000; 38: 731–736.
178 Ye P, Shang Y, Ding X. The influence of apolipoprotein
B and E gene polymorphisms on the response to simvastatin therapy in patients with hyperlipidemia. Chin Med
Sci J 2003; 18: 9–13.
179 Pena R, Lahoz C, Mostaza JM et al. Effect of apoE genotype on the hypolipidaemic response to pravastatin in
an outpatient setting. J Intern Med 2002; 251: 518–525.
180 Carmena R, Roederer G, Mailloux H, Lussier-Cacan S,
Davignon J. The response to lovastatin treatment in
patients with heterozygous familial hypercholesterolemia is modulated by apolipoprotein E polymorphism. Metabolism 1993; 42: 895–901.
181 van Venrooij FV, Stolk RP, Banga JD et al. Common
cholesteryl ester transfer protein gene polymorphisms
and the effect of atorvastatin therapy in type 2 diabetes.
Diabetes Care 2003; 26: 1216–1223.
182 Kuivenhoven JA, Jukema JW, Zwinderman AH et al.
The role of a common variant of the cholesteryl ester
transfer protein gene in the progression of coronary
183
184
185
186
187
188
189
190
191
atherosclerosis. The Regression Growth Evaluation
Statin Study Group. N Engl J Med 1998; 338: 86–93.
de Grooth GJ, Zerba KE, Huang SP et al. The cholesteryl
ester transfer protein (CETP) TaqIB polymorphism in
the cholesterol and recurrent events study: no interaction with the response to pravastatin therapy and no
effects on cardiovascular outcome: a prospective analysis of the CETP TaqIB polymorphism on cardiovascular outcome and interaction with cholesterol-lowering
therapy. J Am Coll Cardiol 2004; 43: 854–857.
Boekholdt SM, Sacks FM, Jukema JW et al. Cholesteryl
ester transfer protein TaqIB variant, high-density
lipoprotein cholesterol levels, cardiovascular risk, and
efficacy of pravastatin treatment: individual patient
meta-analysis of 13,677 subjects. Circulation 2005; 111:
278–287.
Mohrschladt MF, van der Sman-de Beer F, Hofman
MK, van der Krabben M, Westendorp RG, Smelt AH.
TaqIB polymorphism in CETP gene: the influence on
incidence of cardiovascular disease in statin-treated
patients with familial hypercholesterolemia. Eur J Hum
Genet 2005; 13: 877–882.
Elghannam H, Tavackoli S, Ferlic L, Gotto AM Jr,
Ballantyne CM, Marian AJ. A prospective study of
genetic markers of susceptibility to infection and
inflammation, and the severity, progression, and regression of coronary atherosclerosis and its response to therapy. J Mol Med 2000; 78: 562–568.
Basso F, Lowe GD, Rumley A, McMahon AD,
Humphries SE. Interleukin-6 -174G→C polymorphism
and risk of coronary heart disease in West of Scotland
coronary prevention study (WOSCOPS). Arterioscler
Thromb Vasc Biol 2002; 22: 599–604.
Fan YM, Laaksonen R, Janatuinen T et al. Effects of
pravastatin therapy on serum lipids and coronary reactivity are not associated with SREBP cleavage-activating
protein polymorphism in healthy young men. Clin
Genet 2001; 60: 319–321.
Salek L, Lutucuta S, Ballantyne CM, Gotto AM Jr,
Marian AJ. Effects of SREBF-1a and SCAP polymorphisms on plasma levels of lipids, severity, progression and
regression of coronary atherosclerosis and response to
therapy with fluvastatin. J Mol Med 2002; 80: 737–744.
Fiegenbaum M, Silveira FR, Van der Sand CR et al.
Determinants of variable response to simvastatin treatment: the role of common variants of SCAP, SREBF-1a
and SREBF-2 genes. Pharmacogenomics J 2005; 5:
359–364.
Johnson JA. Use of pharmacogenetics in clinical medicine: hype or hope? Personalized Med 2005; 2: 279–
282.
12
CHAPTER 12
The potential of blood-based gene
profiling for disease assessment
Steve Mohr, PhD, & Choong-Chin Liew, PhD
Introduction
A major thrust in current biomedical research
involves the search for genes that can be used to
evaluate the onset, progression and severity of
human disease. Such genes are not necessarily the
cause of the condition, but markers that will help in
diagnosis and in risk assessment [1]. Discovering
disease genes, however, can be challenging for several reasons. First, many disease phenotypes are
difficult to ascertain, disease may be heterogeneous, and many disorders can be influenced by
environmental and behavioral factors. Second,
some diseases lack a known anatomic lesion or have
lesions that are difficult to sample. Finally, collecting human biologic samples may impose an unacceptable burden on the patient.
Human genetics has been extremely successful in
disease gene identification during the past 15 years.
Much of this success can be attributed in earlier
studies to the availability of genetic tools, such as
positional cloning via linkage analysis, and in later
research to the “candidate gene” approach in association studies [2–3]. Although mapping strategies have led to the isolation of a number of genes
associated with cardiovascular diseases (CVD)
(e.g., APO A-I, APO C-III and Leptin genes) such
approaches have proven most successful in exploring the monogenic diseases; that is, those caused
by a single-gene mutation with high-risk variant
alleles segregating in rare families. In cardiovascular medicine such inheritance can be observed in
familial forms of cardiomyopathies and hyperlipi-
demias [4]. However, in the more common cardiovascular disorders (e.g., atherosclerosis) and in
CVD related risk factors (e.g., hypertension, diabetes and obesity), causation involves a dynamic
interplay among multiple genetic and epigenetic
factors that make it difficult for researchers to narrow the focus to a single gene [5]. While some
progress has been made over the past decade in the
genetics of the polygenic and multifactorial cardiovascular disorders, gaps clearly remain.
It is likely that more information about these
complex disorders can be gathered from the continued analysis and characterization of changes at
the genomic scale. The recent completion of the
Human Genome Project [6–8] and innovative research coupling fundamental sciences with microtechnologies [9,10] has provided an unexpected
opportunity for researchers to identify disease
genes and biomarkers through genome-wide analyses: the use of technologies that integrate the
entire genome [11]. Microarrays in particular have
revolutionized transcriptomics (transcriptional or
messenger RNA [mRNA] profiling) by allowing the
simultaneous analysis of the expression of tens of
thousands of genes. The output is a molecular
“portrait” (or profile) describing which transcripts
are “turned-on” and which “turned-off” in the system under study [12]. Microarray data can then be
mined systematically to prioritize candidate genes
to be tested individually or collectively for their discriminative and predictive power in human diseases; analyzing genome-wide data sets may also
provide insight into disease mechanisms.
277
278 PART III Therapies and applications
Microarray studies are often limited by difficulty in obtaining human tissues and by the lack of
models that effectively capture clinically relevant
disease features. Blood is easily accessible and has
long been used for noninvasive biomedical investigations in laboratory medicine. Thus, it was
recently hypothesized in the Sentinel Principle™
[13] that circulating blood could be regarded as
“surrogate” tissue from which informative molecular signatures can be obtained safely. According to
this hypothesis, environmental, physiological or
disease perturbations anywhere in the body may
leave a molecular signature detectable by applying
genomic tools, especially microarrays, to profile
blood-derived RNA. Thus, transcriptional profiling from circulating blood cells provides an alternative to tissue biopsy in the search for new disease
genes and biomarkers (Plate 12.1).
In this chapter we present recent progress in utilizing and integrating blood genomics data to aid in
the search for human disease genes and biomarkers.
We begin with an overview of the basics of using
blood cells. Then we outline the methodology used
to develop blood cell expression profiles. Next we
review the data available and how they are being
used to identify disease genes (focusing mainly on
discoveries in CVD). Finally, we discuss validation
strategies and the potential of blood as a molecular
or genomic diagnostic tool.
The blood option: Concepts and
basics
The Sentinel Principle™
The human body is nourished by a dynamic circulatory system [14]. Blood is a circulating “connective” tissue composed of a fluid matrix, the
plasma (55%), and formed elements (45%): erythrocytes or red blood cells, leukocytes or white blood
cells, and platelets or thrombocytes. The main
function of blood is to supply nutrients and constitutional elements to tissues and to remove waste
products such as carbon dioxide and lactic acid.
Blood also enables circulating cells, such as leukocytes, and circulating substances, such as amino
acids, lipids, cytokines and hormones, to be transported among tissues and organs. As blood moves
through the body, it interacts and communicates with every cell, tissue and organ, providing
physiologic connectivity between systems. Thus,
circulating blood has a number of critical roles in
homeostasis, response to injury and hormonal
communication.
The dynamic and interactive properties of blood
give rise to the possibility that subtle changes
occurring within the body, such as changes in association with a disease process or in response to an
injury, may leave “marks” in the blood. The cascade
of events induced by temporal and individual
factors may alter the set of genes expressed in circulating blood cells, and consequently may be potentially detectable by RNA profiling techniques. We
thus hypothesize that circulating blood can act as a
biosensor that reflects the health or disease of the
body, a concept referred to as the Sentinel Principle™ [13]. We propose to capitalize on this property of blood in the hunt for new disease genes and
biomarkers, and ultimately for the diagnosis and
prognosis of human diseases.
Practical and biologic rationales
The Sentinel Principle™ reasons that the blood cells
that circulate throughout the body present an ideal
“surrogate” tissue for gene expression studies in
humans and for subsequent disease evaluation for
the following reasons.
1 Blood provides scientists with a relatively safe
and easily obtained source of samples to evaluate
human health and disease. For many years, peripheral blood measurements, such as cell types and
counts, and levels of cholesterol, glucose or hormones have been used in laboratory medicine to
guide clinical decision-making and to quantify
clinical outcomes [15]. In addition, drawing blood
is a procedure that does not depend on specific
preparations and causes little discomfort to patients. Therefore blood collection is much more
acceptable to the public than procedures such as
colonoscopy, which are perceived as unpleasant.
2 Blood sampling allows for the collection of larger
sample sizes with better patient matching (avoiding
some problems of statistical interpretation and
confounding factors that weaken interpretation),
and offers more opportunities to standardize the
technical procedures.
3 Blood cells express a substantial part of the
human genome, an important criterion for blood
as a “surrogate” tissue. In a recent study, we found
CHAPTER 12
The potential of blood-based gene profiling for disease assessment
that peripheral blood cells share more than 80% of
the transcriptome with each of the nine tissues we
tested: brain, colon, heart, kidney, liver, lung,
prostate, spleen and stomach [13]. Interestingly,
this analysis showed that blood cells also express
genes of specific systems such as genes encoding βmyosin heavy chain and insulin [13]. Other studies
have documented the expression in blood of genes
relevant to cardiomyocyte excitability and contractibility [16] and genes involved in neuroendocrine pathways [17].
4 Even more importantly, blood cells express
genes that are responsive to various signals or
stimuli. For example, we found that insulin mRNA
levels were significantly different between fasting
and nonfasting subjects [13], a responsiveness to
cellular changes that is another important criterion
for a “surrogate” tissue. Other examples of such
responsiveness are outlined later in this chapter.
5 Diseases such as chronic fatigue syndrome or
schizophrenia remain enigmas because of the lack
of a known or accessible anatomic lesion. In these
cases, blood would serve as a representative sample
of the systemic state allowing for evaluation and
profiling of multiple pathologic and physiologic
pathways.
The continuous interaction between blood and
the body’s tissues, together with the capacity of
peripheral blood cells to specifically respond to
various stimuli or signals, and the accessibility of
blood for obtaining samples suggests that the
“blood option” represents a convenient, rigorous
and high-throughput method of profiling human
disease and discovering new disease genes and
biomarkers (Plate 12.1) [18].
Blood and cardiovascular pathogenesis
Besides the technical and methodologic advantages
of using blood over traditional biopsy samples, blood
components have been implicated in the pathogenesis of a variety of disorders: immune disorders
such as asthma, rheumatoid arthritis, systemic lupus
erythematosus [19], hematologic malignancies [20]
in which peripheral blood cells have a central role,
and in many other diseases associated with inflammatory processes, such as cancer [21].
Circulating blood cells are in direct contact with
the cardiovascular system and therefore may play a
pathogenic role in many cardiovascular disorders.
279
For example, peripheral blood cells have been
implicated in vascular disorders such as ischemia/
reperfusion, atherosclerosis and vasculitis, and dysfunction of blood cells has been associated with
many of the risk factors for CVD such as hypertension, diabetes, obesity and hyperhomocysteinemia
[22–26]. An extensive discussion of these complex
phenomena is beyond the scope of this chapter;
rather, we provide epidemiologic and clinical evidence that attests to the association between blood
components and cardiovascular diseases and risk
factors.
Atherosclerosis is the major underlying cause of
myocardial infarction, stroke and other CVD.
Current evidence clearly indicates that atherosclerosis is not simply an inevitable consequence of
aging, but rather a chronic inflammatory fibroproliferative disease of the vessel wall [24,27]. The
paradigm emerging with this hypothesis incorporates biochemical cross-talk among blood cells,
their descendents such as tissue macrophages, and
the endothelial cells and vascular smooth muscle
cells [28,29]. Inflammatory cells are recruited to the
injured vessel wall initially as a reparative mechanism; however, the same inflammatory process are
also pivotal in the development of lesions [30].
Studies in both humans and animals show that
innate immunity – including phagocytic leukocytes, complement and proinflammatory cytokines
– is essential for atherogenesis, whereas adaptive
immunity – involving T and B cells, antibody and
immunoregulatory cytokine – is an important
modulator of disease activity and progression [31].
One of the earliest and most crucial steps in atherogenesis is the attachment of circulating monocytes
and T lymphocytes to the injured endothelium, followed by their migration into the intima. This
recruitment of blood-derived cells is a constant feature found in atherosclerotic lesions, with substantial numbers of cells in all stages [32].
Recent advances in our understanding of the
vascular biology of atherosclerosis and its clinical
manifestations make more attractive the hypothesis that white blood cells are major contributors
to microvascular injury and atherogenesis. According to Hoffman et al. [26] leukocytes may act by
plugging microvessels, impairing vascular flow
(altered rheologic properties of leukocytes) and
injuring endothelial cells. Leukocytes serve as the
280 PART III Therapies and applications
primary inflammatory cells, and we now know that
other blood elements also have an important,
although often under-recognized, role in CVD. For
example, new data from mouse models have indicated that platelets not only contribute to acute
thrombotic vascular occlusion, but also participate
in the inflammatory and matrix degrading processes of coronary atherosclerosis [33]. The pivotal
role of platelets in the pathogenesis of CVD is
further emphasized by the fact that platelet hyperaggregability is associated with risk factors for
coronary artery disease (CAD), such as smoking,
hypertension and hypercholesterolemia [34]. Both
thrombosis and inflammation are intrinsically
linked processes in which blood components are
key mediators [35].
Apart from local processes in the vessel wall, systemic signs of inflammation are also associated
with the development of cardiovascular lesions.
Plasma levels of several inflammatory proteins,
including proinflammatory cytokines and acutephase reactants, and indicators of cellular response
to inflammation, such as white blood cell counts,
have been positively correlated to the risk of future
cardiovascular events both in patients with CVD
and in healthy individuals [36,37]. It has been
shown that a chronic leukocytosis reflects ischemic
risk in a direct manner and that patients with elevated white blood cell counts are at higher risk of
developing acute myocardial infarction and acute
coronary and vascular events [26,38]. Circulating
markers may consist of cytokines directly released
from inflammatory cells present in the plaques and
tissues exposed to recurrent ischemia (IL-1, TNFα, IL-6, IL-8 and MCP1), as well as other reactants
produced in response to those cytokines such as
adhesion molecules (ICAM-1, VCAM-1, L, P and S
selectin) and acute phase proteins (CRP, SAA and
fibrinogen) [39]. Measurement of these molecules
in serum can provide information about an individual’s inflammatory status. Furthermore, adhesion molecules released in soluble form into the
peripheral blood stream can serve as markers of
vascular inflammation. In fact, it is possible to measure blood-based biomarkers at different levels of
atherosclerotic inflammatory reactions [39].
More generally, evidence is increasing that a
state of mild, chronic and systemic inflammation,
with abnormal leukocyte counts and inflammatory
biomarker levels, is present not only in atherothrombotic CVD but also in various cardiovascular
risk situations, including hypertension, diabetes
and obesity. For example, C-reactive protein (CRP)
level increases in the presence of a growing number of CVD risk factors constitutive of metabolic
syndrome abnormalities [40]. Interestingly, the
inflammatory state is not only present, but in fact
precedes and may predict the development of cardiovascular risk factors such as type 2 diabetes [41].
Similarly, inflammatory mechanisms may underlie the pathogenesis of many cardiovascular risk
conditions and associated lesion formation and
organ dysfunction [42]. A variety of additional
blood-based markers that reflect either lipoprotein
metabolism (i.e., lipoprotein [a]), or endothelial
dysfunction (i.e., homocysteine) have been linked
to an excess risk of cardiovascular disease [43,44],
suggesting that these circulating molecules could
also contribute to the pathogenic processes underlying abnormal metabolic and vascular profiles of
risk situations and their associated complications.
Consonant with the well-established inflammatory and immune nature of cardiovascular diseases
and risk factors, blood components are now viewed
as major contributors to the biochemical and clinical features of atherothrombotic CVD. Peripheral
blood cell gene expression profile studies in CVD
will be extremely valuable. Not only will such investigations directly assist in the discovery of cardiovascular disease genes and new targets for clinical
purpose, but they will also generate useful data to
enhance our understanding of the biology of the
disease process and to shed light on etiologic pathways. Therefore, the potential utility of peripheral
blood cell expression profiling as a new way to
probe cardiovascular disease and risk factors is even
more attractive.
Blood gene expression profiling:
Methodology
Gene expression profiling
The potential involvement of a gene in a disease can
be inferred from quantitative or functional analyses
of human genome data. One of the simplest clues
that a gene may be a “disease gene” is that its expression is altered in disease samples as compared
with healthy controls. Changes in gene expression
CHAPTER 12
The potential of blood-based gene profiling for disease assessment
have traditionally been monitored by a “candidate
gene” approach, in which molecules of interest
have been analyzed one or a few at a time using
techniques such as reverse-transcription polymerized chain reaction (RT-PCR) or Northern blot.
The early twenty-first century has seen the rise
of genomic technologies that examine the entire
genome of an organism. The goal of each of these
approaches is to measure gene expression profiles
of normal samples and of samples affected by a disease [45]. If many genes are monitored at once,
their combined expression pattern can be viewed as
a “molecular portrait” of the sample [12]. A comparison of these “portraits” in the two states (normal vs. abnormal) can identify a “gene expression
signature” that identifies and characterizes a specific physiological state [18,46].
So far, gene expression profiling has relied to
a large extent on technologies for analyzing the
composition of complex mRNA samples (the transcriptome) and, less frequently, on technologies
for analyzing protein samples (the proteome).
Investigation of the human transcriptome has
become particularly important in cardiovascular
medicine. Cardiovascular genomics began in the
late 1980s and early 1990s with the sequencing of
clones obtained from human heart cDNA libraries.
Named “expressed sequence tags” (EST) these clones,
which represent the coding part of the genome,
were an attempt to obtain directly “biologically
relevant” sequences and were an alternative to
sequencing DNA, which contains introns [47]. In
1997, Liew et al. [48] analyzed about 76,000 ESTs
from different cDNA libraries of the cardiovascular system. This study formed the basis for a
comprehensive, annotated inventory of the genes
expressed in the human cardiovascular system
[49], illustrating the potential of transcriptomic studies to detect genes and markers of human CVD.
Subsequent research established that up to 27,000
distinct genes are expressed in this system [50] and
that cardiovascular-related genes cluster at specific
chromosomal locations [51].
Other methods currently in use for the analysis
of RNA-based gene expression include differential
display, cDNA and oligonucleotide microarrays,
serial analysis of gene expression (SAGE), massively parallel signature sequencing (MPSS) and
total gene expression analysis (TOGA). An excel-
281
lent overview of these methods can be found in
Scheel et al. [52].
Microarray technologies
Since the mid-1990s, studies in genomics have
mainly involved microarray technologies. While
simple in theory and design – a microarray is essentially a high-throughput Southern blot on a very
small scale – this technology has revolutionized the
study of global gene expression. With the ability
to represent up to 60,000 distinct transcripts on a
single chip, microarray is a robust platform for
global expression profiling from genes all across the
genome.
Early microarrays used nylon membranes as a
solid support, mimicking traditional blotting strategies [53,54]. Today, the most common microarray
format uses defined sequences (cDNA or oligonucleotide) spotted or directly synthesized in a gridlike fashion on a solid support such as a glass or
silicone slide, and hybridized with a solution phase
containing labeled nucleic acids (cDNA or aRNA)
that represent the mRNA expressed in the biologic
sample tested. By monitoring the amount of label
(signal intensity) associated with each location, it
is possible to infer the abundance of each mRNA
species (Plate 12.2). (For further information about
microarray techniques, the reader is referred to the
The Chipping Forecast series of special issues published by Nature Genetics and highlighting microarray theory, concepts, manufacture, applications
and perspectives [55–57].)
Using microarrays, researchers may choose to
study the entire genome or to scan only a specific subset of the transcriptome. Those transcripts
that are particularly relevant to a disease (e.g., a
specific pathway or system) can be explored
using customized support containing sequences
that match only these transcripts. For example,
the “LymphoChip” [58] was designed to assess
gene expression in normal and malignant lymphocytes. More recently, Barrens et al. [59] constructed
a cardiac-specific cDNA microarray called the
“CardioChip” and containing more than 10,000
distinct transcripts derived from cardiac cDNA
libraries. Using this customized system, gene expression profiles were compiled from human fetal
and adult heart to draw specific “portraits” of gene
expression alteration in dilated and hypertrophic
282 PART III Therapies and applications
cardiomyopathy [60,61]. Since then, specific or
more general microarrays have been used in several other studies to characterize the human heart
transcriptome and investigate the cardiovascular
system [18,46,47].
Microarray technologies are a powerful method
whereby complex gene expression patterns can be
distilled to identify specific genes and pathways
involved in a given disease. A hierarchy of importance can be determined to prioritize disease genes
for subsequent biologic or clinical validation. In
general, microarray data can be used for three different purposes. First, gene expression profiles can
help to identify new “disease genes” and to characterize the basic molecular pathways regulated by
etiological disease processes. Second, gene expression profiling can provide clues about the mechanisms underlying the effects of an intervention.
Third, gene expression profiling can help to identify key genes that are altered in pre-disease states or
“at risk” phenotypes. Such early stage alterations
might therefore act as molecular biomarkers for
early disease detection. Microarray data quickly
yielded quite impressive results, mostly in cancer
research, with applications that range from molecular nosology to the identification of differentially
expressed genes, prospective markers and intervention targets [62,63].
From blood collection to disease gene
The protocol outlined here, typical of the protocol used in our laboratory, illustrates step by
step the method for determining gene expression
profile in blood using microarrays. While other
methods exist and may prove beneficial to the individual user, this protocol has offered consistent
results. We use the Affymetrix GeneChip systems,
currently the popular platform of choice for the
commercial oligonucleotide-based arrays consumer. With the most recent human array, the
HG-U133Plus 2.0 (Affymetrix; Santa Clara, CA),
the expression level of more than 47,000 human
transcripts and variants, including 38,500 wellcharacterized human genes, can be assessed in a
single experiment.
Step 1: Collect blood
Approximately 10 mL peripheral whole blood is
collected by standardized venipuncture in EDTA
Vacutainer™ tubes (Becton Dickinson, Franklin
Lakes, NJ), and immediately stored at 4°C until
processing (within 6 hours) for RNA isolation.
Step 2: Isolate total RNA
Upon centrifugation, the plasma is removed and
a hypotonic buffer (1.6 mmol/L EDTA, 10 mmol
KHCO3, 153 mmol/L NH4Cl, pH 7.4) is added at a
3 : 1 volume ratio to lyse the red blood cells. The
sample is spun at 1,400 rpm for 10 min at 4°C. The
resulting cell pellet is washed with the hemolysis
buffer several times and then resuspended into
1.0 mL TRIzol® Reagent (Invitrogen Corp., Carlsbad,
CA) and 0.2 mL chloroform to isolate total RNA
according to the manufacture’s instructions. The
quality of the total RNA (i.e., purity and integrity)
is assessed by microcapillary electrophoresis on an
Agilent 2100 Bioanalyzer using the RNA 6000
Nano Chip (Agilent Technologies, Palo Alto, CA)
according to the manufacturer’s instructions. Total
RNA quantity is determined by absorbance at
260 nm in a spectrophotometer.
Step 3: Make labeled RNA and apply to the chip
Five micrograms of each purified total RNA is
labeled and hybridized onto an Affymetrix HGU133Plus 2.0 GeneChip array (Affymetrix; Santa
Clara, CA) following the manufacturer’s instructions (see overview in Plate 12.2). Briefly, doublestranded cDNA is synthesized from 5 µg blood
total RNA using SuperScript RTII (Invitrogen) and
the T7-Oligo(dT) primer (GeneChip T7-Oligo(dT)
Promoter Primer kit, Affymetrix) as described in
the manual. In vitro transcription is performed
with the BioArray™ HighYield™ RNA Transcript
Labeling Kit (Enzo Life Sciences, Inc. for distribution by Affymetrix), followed by cRNA fragmentation, and hybridization overnight.
Step 4: Scan the chip and measure expression
The next day, the array is washed, stained with
streptavidin-phycoerythrin and biotinylated antistreptavidin antibody, and scanned using the
Affymetrix GeneChip Scanner 3000. Hybridization
signals are scaled in the Affymetrix GCOS software,
using a scaling factor determined by adjusting the
global trimmed mean signal intensity value to 500
for each array, and imported into GeneSpring software (Silicon Genetics, Redwood City, CA). For
CHAPTER 12
The potential of blood-based gene profiling for disease assessment
normalization, signal intensities are then centered
to the 50th percentile of each chip and, for each
individual gene, to the median intensity of each
specific subset first to minimize the possible technical bias, then to the whole sample set. Only genes
called “present” or “marginal” by the GCOS software in all samples are used for further analysis.
Step 5: Analyze the expression data
Based upon specific clinical information gathered
from the patients, correlations between a patient’s
clinical parameters (disease activity, stage, etc.) and
changes in gene expression are performed using
dedicated algorithms and statistical tools. From the
normalized microarray data the relative expression
level of each transcript is calculated as the ratio
of the mean signal in the two groups of samples
(normal vs. abnormal), and the genes differentially expressed are identified using the Wilcoxon–
Mann–Whitney nonparametric test (P <0.05).
Hierarchical cluster analysis is performed to assess
correlations among samples for each significant
gene set [64]. The output graphic representation
shows a colored matrix (typically, red and green)
in which each column represents an individual
sample and its measured gene expression levels,
and each row represents a gene and its expression
levels in all samples. The color and the intensity
represent the direction (up or down) and the magnitude of fold-change relative to the control group
(see Plate 12.2, for an example). On the left side is
the generated clustering tree (or gene dendrogram)
for the significant gene set used. A similar clustering tree is generated for the samples (or sample
dendrogram). Genes or samples in a tree are joined
by very short branches if they are very similar to
each other, and by increasingly longer branches as
their similarity decreases. The colored matrix itself
is arranged according to the result of the hierarchical clustering. Starting with an original set of more
than 35,000 genes, this number is typically reduced
to a few hundred using signal filtering and statistical analysis. These gene, are ranked based on foldchange (higher is better) and P value (lower is
better), and the top 50 genes are selected as initial
candidates to be evaluated by quantitative RT-PCR.
Other criteria such as known biologic function can
also be used at this step to prioritize genes for further analyses.
283
Step 6: Verify candidate gene expression using
quantitative real-time RT-PCR
The expression patterns of the selected candidate
genes are verified using quantitative real-time RTPCR (qRT-PCR). Forward and reverse primers are
designed for the selected genes, and an internal
control or housekeeping gene (e.g., beta-actin).
Total blood RNA (2 µg) is reversed-transcribed
into single-stranded complementary DNA (cDNA)
using High-Capacity cDNA Archive Kit (Applied
Biosystems, Foster City, CA) according to the manufacturer’s protocol. Then 5 ng cDNA is amplified
and quantified by the Quantitect SYBR Green®
PCR kit (Qiagen, Valencia, CA) using an ABI 7500
Real-time PCR System (Applied Biosystems, Foster
City, CA). The PCR reaction is performed in a 96well format with the following cycling parameters:
2 min at 50°C; 15 min at 95°C; 40 cycles of 15 s at
94°C, 35 s at 55°C and 30 s at 72°C; and measuring
melting curve at 60–95°C, at 0.2°C intervals.
An automatically calculated melting point dissociation curve is examined to ensure the specific
PCR amplification and the lack of primer-dimer
formation in each well. The amount of amplified
product is given as a calculated threshold cycle (Ct)
for each gene tested (see Plate 12.3). The Ct reflects
the cycle number at which the fluorescence generated within a reaction crosses the threshold. The Ct
value assigned to a particular well thus indicates the
point during the reaction at which a sufficient
number of amplicons have accumulated, in that
well, to be at a statistically significant point above
the baseline. Differences in gene expression are
then estimated using the “comparative Ct method”
of relative quantitation [65], normalizing the Ct
values relative to the housekeeping gene (Plate
12.3), beta-actin. To ensure reproducibility of the
results, all genes are tested in triplicate and the
averaged Ct value is used for relative expression
quantification.
For the “comparative Ct method” to be valid, the
efficiency of the target (candidate gene) amplification and the efficiency of the reference (housekeeping gene) amplification must be relatively similar.
Before the quantitation, a validation experiment
is performed to determine the amplification efficiency and specificity of the primer pairs using
serial dilution of a reference cDNA generated from
a normal blood RNA pool with confirmation by
284 PART III Therapies and applications
agarose gel electrophoresis to ensure that the values
were within linear range and the amplification
efficiency was approximately equal for each of the
target gene tested (for details of the strategies used
to analyze the results of qRT-PCR, please refer
to the section of this chapter entitled “Discovery
validation”).
Critical factors and issues
Microarrays are powerful tools for gene expression
profiling in blood, but researchers must be aware
that there are specific limitations and critical issues
when using leukocytes as tissue source and microarray as the analytical technology. Some major concerns are discussed below.
Microarray technology
First of all, microarrays have certain limitations,
crucially:
1 The presence of a large number of false positive
and false negative discovery rates, which can be
minimized – but not completely eliminated –
through careful experimental design to reduce
background noise generated by technologic and
biologic factors and by the use of appropriate statistical methods to estimate and control multiple
testing error rates [66,67].
2 The low reliability of conclusions drawn from
only a few microarray analyses, which leads to the
need to replicate measurements [68,69] and to validate the primary screening by alternative methods
such as real-time quantitative PCR [70].
3 The need for clear standards and consensus, in
particular to ensure reliable and consistent use of
results across different laboratories and platforms
[71–73].
Blood variability and confounding factors
Blood is one of the most variable tissues in the body
and displays both intra- and intersubject variations
[74]. Variations such as the number and relative
proportion of blood cell types at different times
because of hormonal or diurnal changes, and variations between donors, may give rise to differences
in the blood transcriptome that reflect differences
in cellular composition rather than differences underlying disease processes [75]. These issues can be
minimized by optimizing the study design (e.g., by
increasing the sample size, harmonizing collec-
tion time points and requesting that patients fast
before sample collection), and by developing approaches to deal with the blood cell count in parallel with gene expression analysis [76]. Another
factor that can make blood gene expression profiles
difficult to interpret is the presence of confounding variables such as age, sex or environmental
exposures [77,78]. For example, Whitney et al. [79]
reported significant gender bias in a number of genes.
In addition, Wang et al. [80] showed that smoking
status influences gene expression signatures from
whole blood and is an important confounder in the
toxicogenomic studies of particulate exposure. As
in most human studies, linking outcomes with
genomic markers can be biased if the populations
are not well characterized or the study is not well
designed. This wide range of variability also reinforces the need for a sufficient number of both normal donor as well as disease samples to generate a
representative gene expression profile [81].
Blood sample handling and processing
Peripheral blood cell preparation requires a time
delay before RNA stabilization. Such delay exposes
RNA to numerous pre-analytical factors that
potentially induce ex vivo changes in gene expression profiles – changes not relevant to the disease
status or the clinical response under study [80,
82–84]. Critical aspects of blood transcriptomics
concern blood collection devices, cell and RNA
isolation procedures, time and temperature [76,82,
85–88]. Currently, several blood sampling methods
are available for gene expression profiling, including PAXgene™ tube (PreanalytiX GmbH), TEMPUS™ tube (ABI) for whole blood, CPT™ tube
(BD) and Ficoll-Hypaque density gradient for
peripheral blood mononuclear cells. The benefits
and drawbacks of each of these methods have been
reviewed elsewhere [75,82,89,90]. Although some
methods might be more convenient for day-to-day
clinical use, others are more adapted to the study of
specific types of blood cells. Overall, no one of these
methods outperformed the others and therefore
users should choose the most suitable procedure
for their research goals. Requesting that subjects
fast 3 hours before venipuncture, storing blood at
4°C and isolating peripheral blood cells within 2
hours following venipuncture may help to minimize possible effects on gene expression caused by
CHAPTER 12
The potential of blood-based gene profiling for disease assessment
sample handling and processing [91]. RNA preparation and microarray hybridization are substantial
sources of additional variability in gene expression
[92]. The great diversity of instruments, reagents
and protocols available today should be taken into
account for the reproducibility, validity and generalizability of the results.
285
have important medical and health implications.
Tests of the Sentinel Principle™ in a number of
recent studies provide clear evidence that unique
gene expression patterns in peripheral blood reflect
both static (inherited) and dynamic (acquired)
changes that occur within the cells or tissues of the
body. Below we summarize the key findings, with
emphasis on CVD-related studies.
RNA quality
The key to successful microarray experiments is to
start with high-quality RNA. As variations in RNA
quality can alter the assumed relative expression
levels of many genes, the RNA must be rigorously
tested. Various methods have traditionally been used
to analyze RNA quality, including spectrophotometers to ensure an optical density (OD) ratio at
260–280 nm of at least 1.8, and formaldehyde gel
electrophoresis, in which clear 28S, 18S and 5S
bands should be visible with no genomic DNA contamination. The Agilent 2100 Bioanalyzer provides
more sensitive qualitative analysis from less RNA
than do traditional methods. This system uses a fluorescent assay involving electrophoretic separation
to evaluate RNA samples qualitatively and creates a
graph called an electropherogram, which diagrams
fluorescence over time. High-quality RNA electropherograms show clear 28S and 18S peaks, low
noise between the peaks and minimal low molecular weight contamination. Additional quality control criteria can be used to confirm the integrity of
the mRNA hybridized on the chip. For example,
the Affymetrix GeneChip system includes different
probe sets recognizing the 5′ and 3′ regions of such
housekeeping genes as glyceraldehyde dehydrogenase (GAPD), and if the mRNA is degraded the
ratio of the 5′ : 3′ signal drops dramatically.
To obtain the best results using blood as source
for gene expression analysis, experiments should be
carefully designed, the quality of the biologic materials must be strictly controlled and factors that
may cause variability in gene expression not related
to what is being analyzed should be assessed. In
fact, all steps from blood collection to RNA analysis
require standardization.
Biomedical applications
A demonstration of the utility of blood for gene
expression profiling and biomarker discovery would
Blood reflects individual factors
Expression profiling of peripheral blood cells in
healthy subjects was carried out in two studies,
both of which reported that stable patterns of
gene expression differentiate among individuals.
Whitney et al. [79] found variations associated with
the composition of the peripheral blood cell population and constitutive factors such as gender and
age. This group found a set of 340 genes that could
describe individual samples in 13 of 16 people,
sampled more than once over a 1-month period. In
a longitudinal study, Radich et al. [93] reported
stable variations of gene expression in peripheral
blood leukocytes, reflecting biologic differences
between individuals such as responsiveness in immunologic and/or inflammatory pathways. Such
individual-specific genes will be helpful in identifying or predicting a person’s status (drug response,
disease risk or environmental exposure).
Blood reflects environmental and
behavioral factors
Several studies have shown that behavioral and
environmental factors, such as drugs, diet, exercise, alcohol, tobacco and industrial pollutants,
alter gene expression in peripheral leukocytes. For
example, Lampe et al. [94] demonstrated in an
observational study that on the basis of mRNA
expression profiling in peripheral blood leukocytes
it was possible to distinguish between two groups of
85 people exposed and unexposed to tobacco smoke.
Furthermore, they observed a gene expression signature indicative of cigarette smoking, a promising
finding with regard to the need to monitor CVD
risk status and detect early biologic effects of
cigarette smoke exposure. Van Leeuwen et al. [95]
used cigarette smoke and some of its constituents
to exemplify the general applicability of peripheral
blood mononuclear cell expression profiling as a
toxicologic model to detect biomarkers for carcinogen
286 PART III Therapies and applications
exposure. Overall, the studies of external factors suggest that expression profiling in peripheral blood
cells can be extended to estimate environmental
exposures or to evaluate the host response to different forms of environmental exposures or behaviors
(e.g., tobacco smoke, alcohol intake, dietary, exercise and medication). Thus, it is reasonable to think
that by exploring peripheral blood cell transcriptomes in human observational studies, it may be
possible to identify and classify individuals according to their “environmental” status. Such differences may in turn help to determine the likelihood
of late effects of an exposure or a behavior, including disease susceptibility and outcomes.
Blood reflects disease factors
The most important evidence in support of using
peripheral blood cell profiles as surrogate markers
in human disease and disease risk derives from
studies of diseases. The most impressive examples
include microarray applications to hematologic
malignancies, such as large B-cell lymphoma,
chronic lymphocytic leukemia, acute leukocyte
leukemia and myeloma [20], in which peripheral
blood cells are the cells actually affected by the disease. These studies showed that peripheral blood
cells can display disease-specific gene expression
signatures that are accurate enough to identify relevant patient subgroups [96]. Gene expression
assays have also been used in peripheral blood to
diagnose nonhematologic tumors based on specific
transcripts derived from either circulating tumor
cells [97–99] or circulating cancer-related RNA
molecules [100,101].
Our laboratory and other groups are now
profiling gene expression of peripheral blood cells
in a wide range of nonhematologic disorders. The
general objective of these studies is to determine
whether peripheral blood cell gene expression can
distinguish between patients and healthy controls.
As a prerequisite for the use of peripheral blood
cell-based expression profile for disease detection,
Whitney et al. [79] found that temporal and individual variations in healthy subjects were different
from variations found in patients with cancer or
with bacterial infection. The latter finding was
subsequently confirmed by Cobb et al. [102], who
reported that traumatic injuries induced changes in
blood gene expression of a magnitude sufficiently
great to be distinuishable from analytical noise or
interindividual variations.
We have now demonstrated that monitoring
gene expression in blood results in distinct transcriptional signatures for more than 35 different
conditions in humans [13], including various types
of cancer (i.e., bladder [103], colorectal [104] and
prostate [105]), schizophrenia [106,107], osteoarthritis [108] and cardiovascular diseases (as
below). Other laboratories have also shown, independently, that blood gene expression can reveal
unique gene expression profiles in a range of diseases, disorders and injuries: for example, renal
carcinoma [109] and breast cancer [110]; chronic
fatigue syndrome [111]; acute ischemic stroke [112]
and other neurologic injuries [113–116]; asthma
[19,117]; severe lupus erythematosus [118,119];
kidney disease [74,120]; and Crohn’s disease [121].
Rather than discussing each of these studies in
detail, we present some studies investigating the
usefulness of peripheral blood cell gene expression
in cardiovascular disease and risk factors.
Our laboratory has taken advantage of our EST
resources and our custom-made cDNA microarrays, such as “CardioChip” [59], to design an
in-house “blood chip” from an EST database of
peripheral blood cells [122]. This specific 10 K
cDNA microarray was used to screen peripheral
blood samples from CAD patients, and we showed
that profound changes occur in CAD blood samples
compared with healthy controls. We found that
108 genes were differentially expressed in peripheral blood cells of patients with CAD, including 43
downregulated and 65 upregulated genes. Some
of these changes could be interpreted in terms of
earlier observations and in terms of the potential
contribution of peripheral blood cells to the pathogenesis of CVD. For example, we identified three
CAD-upregulated genes (PBP, F13A and PF4),
whose encoded protein levels had previously been
found to be elevated in CAD plasma [122]. This
preliminary study (four CAD patients and three
normal controls) has since been confirmed in 22
CAD patients vs. seven patients diagnosed with
Chagas’ heart disease and 33 normal controls (Liew
CC., unpublished data).
More recently, using SAGE technology on bloodderived monocytes, Patino et al. [123] compared
patients with atherosclerosis with normal controls
CHAPTER 12
The potential of blood-based gene profiling for disease assessment
and identified a disease expression signature compatible with stress response and inflammation.
This study paid particular attention to the FOS
gene, the expression of which was strongly increased in monocytes of atherosclerotic patients,
and was significantly associated with severe forms
of atherosclerosis.
CVD risk factors were investigated by Chon et al.
[124], who studied changes in mRNA levels in
pooled samples of leukocytes from untreated or
treated hypertensive patients. Their findings indicate that microarray gene expression profiling of
peripheral leukocytes can distinguish patients with
essential hypertension from age- and sex-matched
controls. Interestingly, the hypertension-specific
disturbances were missing in the expression profile
from hypertensive patients who had become normotensive with treatment. Microarray analysis of
peripheral blood cells is thus also a potentially
promising tool to assess drug efficacy and for individualizing therapy with maximal effects and minimal side effects (pharmacogenomics) [89].
In a recent study, our laboratory investigated
another well-known CVD risk factor: plasma lipids.
When we examined the correlative relationships
between plasma levels of high-density lipoprotein
(HDL), low-density lipoprotein (LDL) and Triglycerides (TG) and circulating leukocyte gene expression, we found that peripheral blood cells respond
to changing plasma lipid levels by regulating a network of genes, including genes involved in immune
responses and inflammation, and in lipid and fatty
acid metabolism [125]. We found for example that
total cholesterol, TG and LDL levels have a positive
correlation with genes involved in inflammatory
responses (NFE2L1 and MGLL), while HDL level
showed a negative correlation (NFATC3 and MGLL),
suggesting systemic inflammation as a potential
mechanism of CVD. Similarly, genes involved in
lipid metabolism were positively correlated with
plasma levels of TG and LDL, while the opposite
pattern was seen with plasma levels of HDL. This
study provides further data on the interrelationships between plasma lipid levels – atherogenic risk
factors – and leukocytes – inflammatory executors
– in the atherogenic process. As this study shows,
peripheral blood gene expression profiling is not
only useful for identifying biomarkers, but also
promises to shed light on etiologic pathways.
287
Finally, the applicability of blood gene expression signatures in human disease is well illustrated
in a recent study on cardiac transplant rejection.
Deng et al. [126] showed that an 11-blood gene
classifier accurately discriminates allograft recipients with moderate to severe rejection from a quiescent state. This predictive panel was subsequently
optimized into a kit format [127] bringing peripheral blood expression profiling even closer to
clinical application.
Overall, the findings presented here demonstrate that distinct subsets of genes are specifically
induced or inhibited in peripheral blood cells in
relation to specific physiologic, pathologic, behavioral and environmental factors. The studies also
confirm the hypothesis that peripheral blood cells
carry a gene expression signature that identifies the
presence of a disease, and therefore is a valuable
way to identify new disease genes and markers.
Validation strategies
Despite the many issues that remain to be resolved,
microarray expression profiling approaches have
identified a wealth of candidate genes and signaling
pathways correlated with biologic dysregulation
and disease. However, in most cases microarray
studies represent only a first line of screening and
require suitable validation strategies to select
potential disease candidate genes and biomarkers
for further in-depth analysis and for intervention
efforts.
Overall the validation process requires:
1 “discovery” validation: that the candidate gene
expression level is effectively associated with the
disease; and
2 “functional” validation: perhaps most important, that the alteration of this gene affects the relevant disease phenotype.
For genes selected as disease markers, validation
efforts focus on showing that the changes observed
are sufficiently specific enough and sensitive
enough to provide a test of predictive value better
than those currently implemented in clinical
medicine.
The next section provides clues in some validation strategies used to delineate the reliability and
the biologic significance of disease genes and markers
found in blood. In the case of blood, we focus on
288 PART III Therapies and applications
strategies used to validate disease genes in the sense
of biomarkers.
“Discovery” validation
Whole-genome mRNA profiling approaches used
in the discovery phase typically yield lists of tens to
hundreds of candidate genes requiring confirmation [128]. Confirmation is of critical importance
given the high rate of false discovery using such
techniques, especially microarrays. Therefore, the
first step in follow-up analysis involves validating
differential expression and distribution of the
potential disease gene by alternative, often singlegene techniques. Because microarrays are currently
not a mature enough technology for widespread
use as clinical tools, the validation step may also
serve to translate expression biomarkers to a platform for future clinical application.
Validation methods used vary depending on the
scientific question; one commonly used technique
for gene expression change validation is qRT-PCR
[129].
Quantitative RT-PCR basics
RT-PCR involves PCR amplification of segments of
mRNA that have been turned into cDNA by reverse
transcription. RT-PCR is the most sensitive and
the most flexible of the quantification methods.
Besides conventional RT-PCR, the application of
fluorescence techniques has led to the development
of automated real time RT-PCR methodologies,
which combine the process of amplification and
detection to permit the monitoring of the reaction
in real-time during the PCR [129]. Advantages
include ease and reliability of the quantification, a
broad dynamic range of detection (up to 5 logs),
the small amount of RNA required (5–500 ng total
RNA) and the number of samples (96 or 384 well
plate format) that can be processed in parallel. Real
time RT-PCR measures product amount after each
cycle of amplification, based on the association of
the fluorescence signal with the amount of amplicon accumulated during the PCR.
Real time RT-PCR formats
There are available three real-time chemistries
that detect amplified product with about the same
sensitivity [130]. The simplest method uses a
fluorescent dye (SYBR Green®) that binds non-
specifically to double-stranded DNA. During the
elongation phase of the PCR increased amounts of
dye bind to the nascent DNA, and fluorescence
increases proportionally (Plate 12.3). This assay
can suffer from lack of specificity, as the presence
of any double-stranded DNA (specific amplicon,
as well as primer dimers) generates fluorescence
and therefore will be detected and entered in the
quantification.
The two other methods rely on the hybridization
of target-specific fluorescent probes, thereby obviating the need for post-PCR Southern analysis or
sequencing to confirm the identity of the amplicon.
In the Taqman® system, a fluorescence resonance
energy transfer (FRET) oligonucleotide probe complementary to the target sequence is used as the
reporter system. The fluorescence of the reporter
molecule at the 5′ end of the oligonucleotide is
interfered with by a quencher molecule attached at
3′ end. This probe hybridizes to the specific target
amplicon after the denaturation step, and when
strand synthesis occurs the 5′-nuclease activity of
Taq DNA polymerase degrades the FRET probe
and releases the reporter from the quencher, producing fluorescence. Alternatively, the reporter and
the quencher dyes can be carried by two different
probes to maximize the specificity [130].
In the Molecular Beacon method, the 3′ quencher and 5′ reporter of FRET probes initially exhibit no fluorescence because the oligonucleotide
forms a hairpin loop that brings these two factors
into close proximity. At the annealing step of PCR,
the probe forms a hybrid with the target sequence
that separates the two fluorochromes, allowing
the reporter to fluoresce. The main drawback with
the molecular beacon method is associated with the
design of the hybridization probes. Straightforward
quantification is accomplished by any of the
methods described above.
The validation process: step by step
“Discovery” validation provides independent verification of the primary data and typically begins with
the same samples studied in the initial investigation.
The investigators extend their findings to additional samples in order to demonstrate that the gene
is a “universal” feature of the disease under study.
Differential expression and statistical significance do not necessarily mean that the disease genes
CHAPTER 12
The potential of blood-based gene profiling for disease assessment
identified in blood will translate to the clinic. In
defining the value of any novel disease gene, or
multiple disease genes, the evidence of its utility
must be critically assessed against criteria that define
potential clinical applicability (i.e., discriminatory
power and predictive performance). Such criteria
will be evaluated during the validation process.
Because the number of potential genes or combination of genes that have the power to discriminate
between “disease” and “control” (a gene expression
classifier) is extremely large, a major concern in the
validation analyses is overfitting; that is, if enough
classification rules are investigated then, by chance,
one of them is likely to perform well. To minimize
overfitting the data, the split-sample approach is a
common statistical practice that uses a training
sample set to formulate the classification rules and
a test sample set for evaluating the accuracy and the
reproducibility of the classifier. This “internal validation” can also be accomplished using a crossvalidation (e.g., leave-one-out method; for review
see [131]).
Step 1. Validation of differentially expressed genes
via real-time qRT-PCR: The Comparative
Ct method
For each sample, the expression level of a target
gene is quantified by its threshold cycle (Ct), which
is the PCR cycle number at which the increase in
fluorescent signal associated with the exponential
growth of PCR products becomes distinguishable over the background. To analyze the results of
qRT-PCR, the “comparative Ct method” is used
(Plate 12.3); thus, no standard curves are required
to run in each assay. This involves comparing the
Ct values of the disease samples with controls (normal samples). The Ct values of both the disease and
the normal samples are first normalized to an
appropriate endogenous housekeeping gene (e.g.,
beta-actin gene). This is done by calculating a
∆Ctsample = Ct (target gene) − Ct (housekeeping
gene). Then the relative fold changes (disease vs.
controls) is represented as 2−∆∆Ct where ∆∆Ct =
mean ∆Ct (disease samples) − mean ∆Ct (control
samples) (see Livak and Schmittgen [65] for a
review; and the ABI-7700 User Bulletin 2, Applied
Biosystems [132] for further details of quantitation
methods). A nonparametric Mann–Whitney test is
then used to evaluate the statistical significance of
289
the differences in mRNA levels between controls
and patients with disease.
Disease genes are validated on the basis of correlation with microarray results – in terms of differential expression (under- or overexpressed) and
statistical significance (P <0.05) – and selected to
evaluate their diagnostic discriminative power.
Step 2. Discriminatory power of blood biomarker
panel: Logistic regression and ROC curve
To test the discriminatory power of the validated
genes, a logistic regression analysis is performed for
the ∆Ct values of the validated disease genes (Plate
12.4). The goal of logistic regression is to find the
best fitting model to describe the relationship
between the outcome variable, “disease” or “control,” and a set of independent variables, the ∆Ct
values (the predictor variables). Logistic regression
generates the coefficients “bk” (and its standard
errors and significance levels) of a formula to
predict a logit transformation of the probability of
presence of the characteristic of interest: Logit
[p (“disease”)/p (“control”)] = b0 + b1•∆Ct1 +
b2•∆Ct2 + . . . + bk•∆Ctk [133]. In other words,
logistic regression analysis generates from the complete panel of validated disease genes, different gene
combinations or classifiers with the power to discriminate between “disease” and “control” samples.
To visualize the efficacy of each of these gene
combinations, the logistic regression data are summarized in a receiver operating characteristic
(ROC) curve [134]. This curve plots the sensitivity
(true positives, or cases with disease classified as
disease/all disease cases) on the y axis against “1 –
the specificity” (false positives, or “1 – control cases
classified as controls/all control cases”) on the x
axis, considering each value as a possible cutoff
value. The area under curves (AUC) is calculated as
a single measure for the discriminate efficacy of the
selected gene combination. When a gene set has no
discriminative value, the ROC curve will lie close to
the diagonal and the AUC will be close to 0.5. By
contrast, when a gene set has strong discriminative
value, the ROC curve will move up to the upper
left-hand corner and the AUC will be close to 1.0
(Plate 12.4).
An optimal ROC curve (highest AUC) is identified based on the sample from the training set, and
a “Logit cutoff value” is selected in order to get a
290 PART III Therapies and applications
consensus on sensitivity and specificity closest to
the targeted discriminatory power. For example,
if biomarkers are selected for early detection of a
disease, when a low false positive rate is required,
the “Logit cutoff value” would be set to target a high
sensitivity. However, in other situations, such as
detecting biomarkers to be used in conjunction
with other tests, a different part of the ROC curve
would be selected and the “Logit cutoff value”
would be set accordingly (e.g., high specificity; true
negative fraction).
Step 3. Predictive performance of the disease gene
panel: The blind test
To test the predictive performance of the optimal
disease gene panel, the corresponding Logit equation and cutoff value are evaluated in the test samples (Plate 12.4). Briefly, the mRNA level for these
genes is quantified by real-time qRT-PCR, using
the independent samples of the test set. The equation Logit [p (“disease”)/p (“control”)] generated
from the training set is used for the sample prediction. If the Logit value is less than the selected cutoff, then the sample is predicted as “control,” and if
the Logit value is more than the selected cutoff,
then the sample is predicted as “disease.” In addition to estimating the overall predictive accuracy,
the blind test creates a definitive ROC curve, which
allows the researcher to validate other important
operating characteristics of the test, such as sensitivity, specificity, and positive and negative predictive value.
Ultimately, if the predictive performance of the
disease gene panel fits the intended use, the expression biomarker panel requires further validation in
a setting that simulates broad clinical use: “external
validation,” ideally, in prospective, well-controlled
clinical studies of independent samples across
multiple sites with well-established standards for all
steps in the testing process [135].
“Functional” validation
“Functional” validation involves identifying the
function of individual disease genes or gene products, deducing their causal relationship to the disease under study, and defining the biochemical
mechanisms and pathways they could disrupt or
through which the genes could exert their influence
and participate in the disease process.
The “functional validation” of disease genes
selected as biomarkers raises the question: Does
an expression signature and its components need
to be understood mechanistically before it can be
concluded that the genes represent valid disease
biomarkers? RNA expression is not a biologic function; candidate genes are statistically associated
with the event in question but nothing is implied
thereby about potential mechanistic involvement.
Observed changes may be causative, coincidental
or may simply reflect cellular response to a perturbation. In fact, functional criteria are not usually
the basis of biomarker development, and the biologic plausibility of the candidate biomarker is considered only in retrospect [136]. In addition, in the
case of blood, little is know about the mechanisms
by which nonblood disorders such as schizophrenia leave their “marks” on blood cells such that the
disease state can readily be detected by peripheral
blood cell expression profiling. However, to more
thoroughly understand the mechanistic relationship and biologic meaning of the blood expression
signature, functional validation is encouraged.
The typical analysis of microarray expression
data is performed by clustering the expression
profiles (Plate 12.2). This approach allows for the
identification of coordinately expressed genes with
biologic or clinical associations. The challenge that
arises is how to weigh biologic relevance and to
measure the strength of the candidate gene or gene
panel issuing from microarray experiments. To
make microarray data powerful, it may be worthwhile to link microarray data to existing biomedical
data cataloged over past decades by previous experimentation (e.g., cloning and discovery of gene new
functions, protein expression analysis, RT-PCR,
and so forth), and retrieved from the most complete databases [137,138].
In the following section we present several complementary ways to functionally annotate microarray-derived disease genes, and thereby to expand
the dimensionality of the array data to encompass
functional and biologic validation of the bloodbased disease genes and biomarkers.
Chromosome analysis
Disease genes identified can be functionally evaluated in terms of their chromosomal location [51]
and possible overlap with regions of suggestive
CHAPTER 12
The potential of blood-based gene profiling for disease assessment
linkage or association highlighted by genetic approaches. In our recent work on the relationship
between plasma lipid levels and circulating leukocytes gene expression, we discovered that a number
of genes correlating with plasma lipid levels were
located in the chromosomal regions of known
quantitative trait loci (QTLs, often referred to as
“susceptibility” genes) associated with hyperlipemia [125]. These genes are thus excellent candidates
for eQTLs (i.e., the mapping of gene expression
levels as quantitative trait loci) of hyperlipemia
[139]. Indeed, it is highly conceivable that new candidate genes will be defined initially on the basis of
their differential expression in a disease state, and
subsequently will be determined to be new genetic
(susceptibility) markers. This approach is particularly suited to the study of complex polygenic
diseases, because it allows researchers to take a
genome-wide “snapshot” at different progressive
stages of a disease and then nail down the analysis
to specific region of the chromosomes.
Pathway analysis
Pathway analysis involves looking for changes in
gene expression by incorporating either pathway or
functional annotations. Different software packages can be used to annotate disease genes by crossreferencing to public biomedical databases.
One of these tools, david (Database for Annotation, Visualization, and Integrated Discovery)
[140], allows users to access a relational database of
functional annotation. Functional annotations are
derived primarily from LocusLink at the National
Center for Biotechnology Information (NCBI). david
then uses LocusLink accession numbers to link
gene accessioning systems like Genbank, Unigene
and Affymetrix identifiers to biologic annotations
including gene names and aliases, functional summaries, Gene Ontologies (controlled vocabularies that describe gene products in terms of their
associated biologic processes, cellular components
and molecular functions), protein domains and
biochemical and signal transduction pathways.
Annotation pedigrees and pathways maps are provided via direct links to the primary sources of
annotation, which also provide additional genespecific information.
In our case, the Affymetrix identifiers of the
blood-derived disease genes can directly be down-
291
loaded in the david software to observe the complex
changes that occur in known metabolic and regulatory pathways as tracked by the changing expression
levels of those candidate genes. This may lead to
identify potential mechanisms that underlie diseases and new avenues for investigation.
Literature analysis
The published literature is a major source of information about genes, and interpretation of gene
expression signatures relies largely on manual literature searches. To allow better surveying of the
literature, several authors have initiated literaturesearching tools to automatically retrieve, organize
and analyze the tremendous wealth of knowledge
stored in the scientific literature that enabled, for
example, automatic protein annotations or association of keywords related to diseases [141].
Such applications can be of use for researchers
to compare microarray data for differentially
expressed genes with literature data available in
Medline© (available through [142]) [143]. Jenssen
et al. [144] described a tool for automatic literature
extraction using co-citation index. Their hypothesis was that a “biological meaningful relationship”
between two genes exists if they were co-cited in the
MeSH descriptors of Medline©. The automatic
analysis of co-citations allowed them to establish a
virtual gene network, called Pubgene [145], and to
rank genes according to biologic processes. This
gene network can be used to find groups of genes
that had co-occurred in the literature together with
the disease genes identified by blood profiling, thus
providing another way to structure gene expression
data and extract potential biologically meaningful
relationships.
In addition, several databases containing inventories of genes expressed in different systems have
been made available publicly, such as Gene Expression Omnibus [146], Gene Expression Atlas
[147], SAGEmap [148], ONCOMINE [149] and
ArrayExpress [150]. Mining such repositories may
also help to construct informative and structured
networks among human disease genes and to validate candidate genes for specific conditions.
Animal and cell models
The above mentioned analyses clearly show that
by linking microarray data to existing scientific
292 PART III Therapies and applications
literature and to biomedical databases it is possible
to evaluate the disease gene expression signature
from a functional point of view. Successes using
these approaches usually rely on raising functional
hypotheses and confirming them by direct experimentation in model systems. These assays involve
manipulation of the candidate gene in cell or animal systems, with the aim of producing a modified
phenotype or behavior, which is then examined
using functional tests for detecting changes in the
disease-relevant phenotype. If the intervention
results in a disease phenotype or behavior, the
involvement of the target gene is further confirmed.
Several complementary strategies for manipulating
gene expression and activity have been developed.
Loss-of-function strategies focus on decreasing or
eliminated gene expression and activity, while gainof-function strategies focus on increasing gene
expression and activity. Below, we provide a brief
overview of the systems currently in use.
Cell cultures are extensively used to design in
vitro validation assays through modifying the expression or activity of a candidate gene in a cell type
of interest. Cell-based strategies to disrupt gene
expression mostly use RNA interference (RNAi)
(for review see Milhavet et al. [151]). Primary
cell-based approaches for gain-of-function (gene
overexpression) use a cDNA expression vector to
overexpress a gene in a cell type of interest. Alternatively, overexpression of endogenous gene can be
achieved by using insertional mutagenesis. In these
assays, a specialized plasmid or retroviral vector
containing a promoter is integrated in the genome
(by transfection or viral infection) resulting in the
transcriptional activation of the endogenous gene
of interest downstream of the insertion site [152].
Animal models, especially murine models, continue to be the option of choice in the functional
validation of human disease genes. Alteration of
a target gene can be achieved with different levels
of sophistication. Basic systems use knockout or
transgenic animals, either in isolation or in conjunction with disease models. The goal is to reproduce as precisely as possible the human gene
alteration in mice and to assess its phenotypic consequences. “Transgenic” refers to the introduction
(random integration) of a human gene, the transgene, into the genetic material of an animal, a technique used to create mice that express more than
normal amounts of the candidate gene product or
to introduce a different form of the gene in question. Transgenic technologies have made possible
great advances in numerous fields including CVD
research [153]. Knockout and knockin mice are
created by gene-targeting techniques (targeted mutagenesis) that produce animals in which a specific
gene has been deleted (knocked out) or mutated
(knocked in) [154].
In addition to the time required to produce
knockout or transgenic animals, the most significant problems this approach faces are embryonic
lethality and the induction of compensatory mechanisms during development. These problems can
be substantially overcome through the construction of conditional expression systems, which allow
spatial and temporal control over the expression of the introduced genotypic alteration. Such
inducible systems better mimic the type of gene
expression changes occurring in late-onset human
pathologies. With transgenic animals, several systems are available to regulate the expression of the
transgene using external inducers (e.g., tetracycline
and ecdysone), and the addition of the corresponding inducible promoter in front of the transgene
[155]. The Cre-lox system from bacteriophage P1
is the most popular current system to produce
conditional knockout mice. There are numerous
variations on this technique, and the Cre-lox system has been widely used to uncover gene function
[156,157].
It is important to note that these functional
approaches are not only useful in validation studies, but also open up opportunities in the discovery phase [158]. To this end, various approaches
to undertake genome-wide functional screens in
mouse models have been initiated in areas such as
cardiology, central nervous system and neurology,
metabolism and obesity, osteoporosis, reproductive biology and oncology [159]. Moreover, these
approaches can be used to identify new disease
models [66]. In this way, genome-wide model
screens specifically designed to identify disease
phenotypes are highly complementary to expression profiling and genetic studies.
Computational modeling
Deciphering biologic mechanisms and disease
pathways requires looking beyond the single-gene
CHAPTER 12
The potential of blood-based gene profiling for disease assessment
biologic context and the unidimensional view
of gene expression. Moreover, the intersection of
multiple datasets of diverse biologic and clinical
information provides higher dimensional views of
gene function and the clinical significance of gene
function. To achieve this aim, biomedical sciences,
including cardiology, have been moving towards
the integration of many disciplines formalized by
the emergence of systems biology [160]. Greater
benefits for mechanistic discoveries are expected
collecting and integrating complete datasets from
genetics (DNA level), transcriptomics (RNA level),
proteomics (protein level) and even metabolomics (metabolite level) measurements, and by
interpreting these data in the context of underlying
biologic systems and in conjunction with patient
information [161]. Using this integrated systems
biology approach, changes in transcript abundance and/or protein expression can be related to
modification in cellular function and to tissue
pathology. For example, Schadt et al. [162] combined microsatellite genotyping, 23,000 gene expression profiling and detailed phenotypic data
to identify the genetic loci controlling the mRNA
levels and phenotypic traits associated with common multigenic diseases such as obesity. This
method promises to be an order of magnitude
more efficient than conventional genetic (linkage)
analysis for finding alleles with a causal role in
disease.
This combinatorial approach to disease gene discovery and validation raises significant challenges
in term of compiling, warehousing and synergizing
the vast amount of data produced. Bioinformatics
and biostatistics will play a significant part in
addressing the abundance of data through developing new computerized methods (in silico analyses)
that maximize the information made available to
the researchers (data basing) and that integrate
diverse types of data at a deeper level in order to
better model cells, organs and ultimately the entire
body (data mining). The common theme here is
the integration of biochemical, anatomic, profiling
and physiologic information together with current
biomedical research in order to develop detailed
dynamic models and decision schemes. These
models in turn will be used:
1 to refine our understanding of the role of specific
genes in disease pathways;
293
2 to establish predictive rules based on key genes
and physiological parameters; and
3 to select the best point of intervention [163].
Because CVD involve a combination of bioactive
factors acting upon complex biologic systems, this
group of diseases is ideally positioned to profit from
developments in systems biology. Integrative approaches to model the human heart and cardiovascular function have been initiated in the Physiome
Project [164,165]. As applied to blood as a “surrogate” model for investigation into the biology of
the entire body, systems biology has the potential
to add to our current understanding of biologic
pathways in disease and in health.
Conclusions and perspectives
Microarray-based gene expression profiling is,
unquestionably, now established in the study of
human disease and merits consideration as a technique to assist in disease gene discovery. However,
few if any of the candidate genes identified using
microarray technology have yet been integrated
into clinical practice. In fact, it is much easier to
develop a disease gene or a multigene panel than it
is to translate such a disease signature into a robust
clinical tool that benefits medical practice [135].
In this chapter we have outlined an alternative
strategy that may have significant long-term implications for genomic research, clinical diagnostics
and disease management. The approach is based on
gene expression profiling in peripheral blood cells
to detect disease genes and biomarkers. First, we
use microarray platform and appropriate software
packages to profile mRNA expression in peripheral
blood cells and compile a comprehensive list of
candidate disease genes. Second, we explore those
candidates using an alternative technique to measure RNA expression, real-time qRT-PCR, and we
apply logistic regression analysis and the ROC curve
representation to score and rank the resulting gene
combinations and define a predictive expression
signature. Third, we apply (blind) the “locked-down”
panel of disease genes to a new set of independent
samples to evaluate the performance of the gene
expression classifier. Finally, we attempt to annotate the functions of each blood-based disease gene
according to information gleaned from existing
biologic databases and biomedical bibliography.
294 PART III Therapies and applications
This cycle of screening, molecular signature analysis, expression classifier generation and biologic
and clinical validation has become the standard
operating approach to disease gene discovery from
transcriptome assessment. The novelty described
in this chapter is in the use of peripheral blood cellderived RNA, as opposed to tissue biopsy as the
source of samples to detect disease-driven changes.
While we focus on CVD and associated risk factors as our major example in this chapter, our group
has confirmed the feasibility of this strategy and
identified disease genes and biomarkers from more
than 35 conditions in humans [13]. Our results
have affirmed our initial hypothesis, the Sentinel
Principle™, which holds that changes in circulating
leukocytes, a readily accessible tissue source, reflect
disease changes occurring in human body tissues
[166], and that such changes may have a potential
role in the disease process. Blood is thus an excellent model for both the characterization and the
monitoring of human disease.
One of the main goals of these types of studies is
to optimize the disease gene panels generated from
blood-based RNA profile into an accurate expression assays and to implement them as molecular
diagnostic tools to determine clinical outcomes
based on specific blood gene expression signatures
(Plate 12.1). The challenge will lie in the development of appropriate detection and monitoring
systems including quality control and standard
operating procedure for sample collection and processing, and data generation and analysis. Nonetheless, we anticipate that in the very near future
gene expression profiling in blood will became as
diagnostically routine as histologic examination
of tissue, and will be used in a wide range of diseases, delivering for the first time the promise of
genomics in human healthcare.
Blood genomics is in a position not only to make
important contributions in how disease can be
better diagnosed, but also to provide important new
insights into how disease develops. As we embark
on this exciting new era, other strategies emerging
in the field focus on circulating tumor cells and
endothelial cells [98,167], circulating DNA and RNA
[100], serum or plasma proteomics (protein profiling)
[168–170] to cover different levels of blood dynamics. Such strategies may prove complementary to
identify subtle changes that can be translated to
multimolecular measurements in blood to comprehensively evaluate disease. Hence we propose to
introduce the field of “bloodomics,” corresponding
to the “omics” investigations (i.e., genomic, transcriptomic, proteomic or metabolomic studies) of
blood components to search for molecular signatures and biomarkers that will define patients’
clinical features and guide decision-making.
Acknowledgments
The authors wish to thank Isolde Prince for her
efforts in editing this manuscript. Blood profiling
work reported in this paper was supported by
GeneNews Corp. (Toronto, Ontario, Canada).
References
1 Vasan RS. Biomarkers of cardiovascular disease: Molecular basis and practical considerations. Circulation 2006;
113: 2335–2362.
2 Giallourakis C, Henson C, Reich M et al. Disease gene
discovery through integrative genomics. Ann Rev Genomics Hum Genet 2005; 6: 381–406.
3 Hirschhorn JN, Daly MJ. Genome-wide association
studies for common diseases and complex traits. Nat
Rev Genet 2005; 6: 95–108.
4 Gibbons GH, Liew CC, Goodarzi MO et al. Genetic
markers: progress and potential for cardiovascular disease. Circulation 2004; 109 (Supplement IV): 47–58.
5 Stephens JW, Humphries SE. The molecular genetics of
cardiovascular disease: clinical implications. J Intern
Med 2003; 253: 120–127.
6 International Human Genome Sequencing Consortium. Finishing the euchromatic sequence of the human
genome. Nature 2004; 431: 931–945.
7 Lander ES, Linton LM, Birren B et al. Initial sequencing
and analysis of the human genome. Nature 2001; 409:
860–921.
8 Venter JC, Adams MD, Myers EW et al. The sequence of
the human genome. Science 2001; 291: 1304–1351.
9 Kopp MU, Crabtree HJ, Manz A. Developments in technology and applications of microsystems. Curr Opin
Chem Biol 1997; 1: 410–419.
10 Wang J. From DNA biosensors to gene chips. Nucleic
Acids Res 2000; 28: 3011–3016.
11 Sauer S, Lange BM, Gobom J et al. Miniaturization in
functional genomics and proteomics. Nat Rev Genet
2005; 6: 465–476.
12 Chung CH, Bernard PS, Perou CM. Molecular portraits
and the family tree of cancer. Nat Genet 2002; 32
(Supplement): 533–540.
CHAPTER 12
The potential of blood-based gene profiling for disease assessment
13 Liew CC, Ma J, Tang HC et al. The peripheral blood
transcriptome dynamically reflects system wide biology:
a potential diagnostic tool. J Lab Clin Med 2006; 147:
126–132.
14 Ogawa M. Differentiation and proliferation of hematopoietic stem cells. Blood 1993; 81: 2844–2853.
15 Frank R, Hargreaves R. Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov 2003; 2:
566–580.
16 Seiler PU, Stypmann J, Breithardt G et al. Real-time
RT-PCR for gene expression profiling in blood of heart
failure patients: a pilot study: gene expression in blood
of heart failure patients. Basic Res Cardiol 2004; 99:
230–238.
17 Nicholson AC, Unger ER, Mangalathu R et al.
Exploration of neuroendocrine and immune gene
expression in peripheral blood mononuclear cells. Brain
Res Mol Brain Res 2004; 129: 193–197.
18 Liew CC. Expressed genome molecular signatures of
heart failure. Clin Chem Lab Med 2005; 43: 462–469.
19 Gladkevich A, Nelemans SA, Kauffman HF et al. Microarray profiling of lymphocytes in internal diseases with
an altered immune response: potential and methodology. Mediators Inflamm 2005; 2005: 317–330.
20 Margalit O, Somech R, Amariglio N et al. Microarraybased gene expression profiling of hematologic malignancies: basic concepts and clinical applications. Blood
Rev 2005; 19: 223–234.
21 Coussens LM, Werb Z. Inflammation and cancer.
Nature 2002; 420: 860–867.
22 Chon H, Verhaar MC, Koomans HA et al. Role of circulating karyocytes in the initiation and progression of
atherosclerosis. Hypertension 2006; 47: 803–810.
23 Afshar-Kharghan V, Thiagarajan P. Leukocyte adhesion
and thrombosis. Curr Opin Hematol 2006; 13: 34–39.
24 Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685–1695.
25 Toker S, Rogowski O, Melamed S et al. Association
of components of the metabolic syndrome with the
appearance of aggregated red blood cells in the peripheral blood. An unfavorable hemorheological finding.
Diabetes Metab Res Rev 2005; 21: 197–202.
26 Hoffman M, Blum A, Baruch R et al. Leukocytes and
coronary heart disease. Atherosclerosis 2004; 172: 1–6.
27 Ross R. Atherosclerosis; an inflammatory disease. N
Engl J Med 1999; 340: 115–126.
28 Kher N, Marsh JD. Pathobiology of atherosclerosis: a
brief review. Semin Thromb Hemost 2004; 30: 665–672.
29 Osterud B, Bjorklid E. Role of monocytes in atherogenesis. Physiol Rev 2003; 83: 1069–1112.
30 Davis C, Fischer J, Ley K et al. The role of inflammation
in vascular injury and repair. J Thromb Haemost 2003; 1:
1699–1709.
295
31 Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 2006;
6: 508–519.
32 de Boer OJ, Becker AE, van der Wal AC. T lymphocytes
in atherogenesis-functional aspects and antigenic repertoire. Cardiovasc Res 2003; 60: 78–86.
33 Massberg S, Schulz C, Gawaz M. Role of platelets in the
pathophysiology of acute coronary syndrome. Semin
Vasc Med 2003; 3: 147–162.
34 Willoughby S, Holmes A, Loscalzo J. Platelets and cardiovascular disease. Eur J Cardiovasc Nurs 2002; 1:
273–288.
35 Wagner DD. New links between inflammation and
thrombosis. Arterioscler Thromb Vasc Biol 2005; 25:
1321–1324.
36 Tanigawa T, Iso H, Yamagishi K et al. Association of
lymphocyte sub-populations with clustered features of
metabolic syndrome in middle-aged Japanese men.
Atherosclerosis 2004; 173: 295–300.
37 Ohshita K, Yamane K, Hanafusa M et al. Elevated white
blood cell count in subjects with impaired glucose tolerance. Diabetes Care 2004; 27: 491–496.
38 Madjid M, Awan I, Willerson JT et al. Leukocyte count
and coronary heart disease: implications for risk assessment. J Am Coll Cardiol 2004; 44: 1945–1956.
39 Saadeddin SM, Habbab MA, Ferns GA. Markers of
inflammation and coronary artery disease. Med Sci
Monit 2002; 8: RA5–RA12.
40 Festa A, D’Agostino R Jr, Howard G et al. Chronic subclinical inflammation as part of the insulin resistance
syndrome: the Insulin Resistance Atherosclerosis Study
(IRAS). Circulation 2000; 102: 42–47.
41 Hu FB, Meigs JB, Li TY et al. Inflammatory markers and
risk of developing type 2 diabetes in women. Diabetes
2004; 53: 693–700.
42 Schmidt MI, Duncan BB. Diabesity: an inflammatory
metabolic condition. Clin Chem Lab Med 2003; 41:
1120–1130.
43 Tsimikas S, Willerson JT, Ridker PM. C-reactive protein
and other emerging blood biomarkers to optimize risk
stratification of vulnerable patients. J Am Coll Cardiol
2006; 47 (Supplement C): 19–31.
44 Fruchart JC, Nierman MC, Stroes ES et al. New risk factors for atherosclerosis and patient risk assessment.
Circulation 2004; 109 (Supplement 3): 15–19.
45 Liotta L, Petricoin E. Molecular profiling of human cancer. Nat Rev Genet 2000; 1: 48–56.
46 Kittleson MM, Hare JM. Molecular signature analysis:
using the myocardial transcriptome as a biomarker in
cardiovascular disease. Trends Cardiovasc Med 2005; 15:
130–138.
47 Barrans DB, Liew CC. “Chip”ing away at Heart Failure.
In: Kearns-Jonker M, ed. Methods in Molecular Medicine,
296 PART III Therapies and applications
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
Vol. 126: Congenital Heart Disease: Molecular Diagnostics, Humana Press Inc., Totowa NJ, 2006: 157–169.
Liew CC, Hwang DM, Wang RS et al. Construction
of a human heart cDNA library and identification of
cardiovascular-based genes (CvBest). Mol Cell Biochem
1997; 172: 81–87.
Hwang DM, Dempsey AA, Wang RX et al. A genomebased resource for molecular cardiovascular medicine:
Towards a compendium of cardiovascular genes. Circulation 1997; 96: 4146–4203.
Dempsey AA, Dzau VJ, Liew CC. Cardiovascular genomics: Estimating the total number of genes expressed
in the human cardiovascular system. J Mol Cell Cardiol
2001; 33: 1879–1886.
Barrans JD, Ip J, Lam CW et al. Chromosomal distribution of the human cardiovascular transcriptome.
Genomics 2003; 81: 520–525.
Scheel J, Von Brevern MC, Horlein A et al. Yellow
pages to the transcriptome. Pharmacogenomics 2002; 3:
791–807.
Bertucci F, Bernard K, Loriod B et al. Sensitivity issues in
DNA array-based expression measurements and performance of nylon microarrays for small samples.
Human Mol Genet 1999; 8: 1715–1722.
Granjeaud S, Nguyen C, Rocha D et al. From hybridization image to numerical values: a practical, high
throughput quantification system for high density filter
hybridizations. Genet Anal 1996; 12: 151–162.
The Chipping Forecast III. Nat Genet 2005; 37 (Supplement): 1–45.
The Chipping Forecast II. Nat Genet 2002; 32 (Supplement): 465–552.
The Chipping Forecast. Nat Genet 1999; 21 (Supplement): 1–60.
Alizadeh A, Eisen M, Davis RE et al. The lymphochip:
a specialized cDNA microarray for the genomic-scale
analysis of gene expression in normal and malignant
lymphocytes. Cold Spring Harbor Symp Quant Biol 1999;
64: 71–78.
Barrans JD, Stamatiou D, Liew C. Construction of a
human cardiovascular cDNA microarray: portrait of the
failing heart. Biochem Biophys Res Commun 2001; 280:
964–969.
Barrans JD, Sc MH, Allen PD et al. Global gene expression of end-stage dilated cardiomyopathy using a
human cardiovascular-based cDNA microarray. Am J
Pathol 2002; 160: 2035–2043.
Hwang JJ, Allen PD, Tseng GC et al. Microarray gene
expression profiles in dilated and hypertrophic cardiomyopathic end-stage heart failure. Physiol Genomics
2002; 10: 31–44.
Quackenbush J. Microarray analysis and tumor classification. N Engl J Med 2006; 354: 2463–2472.
63 Mohr S, Leikauf GD, Keith G et al. Microarrays as cancer keys: an array of possibilities. J Clin Oncol 2002; 20:
3165–3175.
64 Tsai TH, Milhorn DM, Huang SK. Microarray and
gene-clustering analysis. Methods Mol Biol 2006; 315:
165–174.
65 Livak KJ, Schmittgen TD. Analysis of relative gene
expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods 2001; 25:
402–408.
66 Lindsay MA. Target discovery. Nat Rev Drug Discov
2003; 2: 831–838.
67 Pounds SB. Estimation and control of multiple testing
error rates for microarray studies. Brief Bioinform 2006;
7: 25–36.
68 Le Meur N, Lamirault G, Bihouee A et al. A dynamic,
web-accessible resource to process raw microarray
scan data into consolidated gene expression values:
importance of replication. Nucleic Acids Res 2004; 32:
5349–5358.
69 Lee ML, Kuo FC, Whitmore GA et al. Importance
of replication in microarray gene expression studies:
statistical methods and evidence from repetitive cDNA
hybridizations. Proc Natl Acad Sci USA. 2000; 97: 98349839.
70 Dallas PB, Gottardo NG, Firth MJ et al. Gene expression
levels assessed by oligonucleotide microarray analysis
and quantitative real-time RT-PCR: how well do they
correlate? BMC Genomics 2005; 6: 59.
71 Tumor Analysis Best Practices Working Group.
Expression profiling: best practices for data generation
and interpretation in clinical trials. Nat Rev Genet 2004;
5: 229–237.
72 Allison DB, Cui X, Page GP et al. Microarray data analysis: from disarray to consolidation and consensus.
Nat Rev Genet 2006; 7: 55–65.
73 Bammler T, Beyer RP, Bhattacharya S et al. Standardizing global gene expression analysis between laboratories
and across platforms. Nat Methods 2005; 2: 351–356.
74 Alcorta D, Preston G, Munger W et al. Microarray studies of gene expression in circulating leukocytes in kidney
diseases. Exp Nephrol 2002; 10: 139–149.
75 Fan H, Hegde PS. The transcriptome in blood: challenges and solutions for robust expression profiling.
Curr Mol Med 2005; 5: 3–10.
76 Baechler EC, Batliwalla FM, Karypis G et al. Expression
levels for many genes in human peripheral blood cells
are highly sensitive to ex vivo incubation. Genes Immun
2004; 5: 347–353.
77 Bakay M, Chen YW, Borup R et al. Sources of variability
and effect of experimental approach on expression
profiling data interpretation. BMC Bioinformatics 2002;
3: 4.
CHAPTER 12
The potential of blood-based gene profiling for disease assessment
78 Anderson D. Factors that contribute to biomarker
responses in humans including a study in individuals
taking Vitamin C supplementation. Mutat Res 2001;
480–481: 337–347.
79 Whitney AR, Diehn M, Popper SJ et al. Individuality
and variation in gene expression patterns in human
blood. Proc Natl Acad Sci USA 2003; 100: 1896–1901.
80 Wang Z, Neuburg D, Li C et al. Global gene expression
profiling in whole-blood samples from individuals
exposed to metal fumes. Environ Health Perspect 2005;
113: 233–241.
81 Dobbin KK, Simon RM. Sample size planning for
developing classifiers using high dimensional DNA
microarray data. Biostatistics 2006; Apr 13 [Epub ahead
of print].
82 Debey S, Schoenbeck U, Hellmich M et al. Comparison
of different isolation techniques prior gene expression
profiling of blood derived cells: impact on physiological
responses, on overall expression and the role of different
cell types. Pharmacogenomics J 2004; 4: 193–207.
83 Pahl A, Brune K. Gene expression changes in blood after
phlebotomy: implications for gene expression profiling.
Blood 2002; 100: 1094–1095.
84 Pahl A, Brune K. Stabilization of gene expression profiles
in blood after phlebotomy. Clin Chem 2002; 48: 2251–
2253.
85 Marteau JB, Mohr S, Pfister M et al. Collection and
storage of human blood cells for mRNA expression
profiling: a 15-month stability study. Clin Chem 2005;
51: 1250–1252.
86 Feezor RJ, Baker HV, Mindrinos M et al. Whole blood
and leukocyte RNA isolation for gene expression analyses. Physiol Genomics 2004; 19: 247–254.
87 Tanner MA, Berk LS, Felten DL et al. Substantial
changes in gene expression level due to the storage temperature and storage duration of human whole blood.
Clin Lab Haematol 2002; 24: 337–341.
88 Hartel C, Bein G, Muller-Steinhardt M et al. Ex vivo
induction of cytokine mRNA expression in human
blood samples. J Immunol Methods 2001; 249: 63–71.
89 Burczynski ME, Dorner AJ. Transcriptional profiling of
peripheral blood cells in clinical pharmacogenomic
studies. Pharmacogenomics 2006; 7: 187–202.
90 Rainen L, Oelmueller U, Jurgensen S et al. Stabilization
of mRNA expression in whole blood samples. Clin
Chem 2002; 48: 1883–1890.
91 Campbell C, Vernon SD, Karem KL et al. Assessment of
normal variability in peripheral blood gene expression.
Dis Markers 2002; 18: 201–206.
92 Pahl A. Gene expression profiling using RNA extracted
from whole blood: technologies and clinical applications. Expert Rev Mol Diagn 2005; 5: 43–52.
93 Radich JP, Mao M, Stepaniants S et al. Individual-
94
95
96
97
98
99
100
101
102
103
104
105
106
107
297
specific variation of gene expression in peripheral blood
leukocytes. Genomics 2004; 83: 980–988.
Lampe JW, Stepaniants SB, Mao M et al. Signatures of
environmental exposures using peripheral leukocyte
gene expression: tobacco smoke. Cancer Epidemiol
Biomarkers Prev 2004; 13: 445–453.
van Leeuwen DM, Gottschalk RW, van Herwijnen MH
et al. Differential gene expression in human peripheral
blood mononuclear cells induced by cigarette smoke
and its constituents. Toxicol Sci 2005; 86: 200–210.
Ebert BL, Golub TR. Genomic approaches to hematologic malignancies. Blood 2004; 104: 923–932.
Nebozhyn M, Loboda A, Kari L et al. Quantitative PCR
on 5 genes reliably identifies CTCL patients with 5% to
99% circulating tumor cells with 90% accuracy. Blood
2006; 107: 3189–3196.
Smirnov DA, Zweitzig DR, Foulk BW et al. Global gene
expression profiling of circulating tumor cells. Cancer
Res 2005; 65: 4993–4997.
Bosma AJ, Weigelt B, Lambrechts AC et al. Detection of
circulating breast tumor cells by differential expression
of marker genes. Clin Cancer Res 2002; 8: 1871–1877.
Li Y, Elashoff D, Oh M et al. Serum circulating human
mRNA profiling and its utility for oral cancer detection.
J Clin Oncol 2006; 24: 1754–1760.
Wong SC, Lo SF, Cheung MT et al. Quantification of
plasma beta-catenin mRNA in colorectal cancer and
adenoma patients. Clin Cancer Res 2004; 10: 1613–1617.
Cobb JP, Mindrinos MN, Miller-Graziano C et al.
Application of genome-wide expression analysis to
human health and disease. Proc Natl Acad Sci USA 2005;
102: 4801–4806.
Osman I, Bajorin D, Sun TT et al. Novel blood biomarkers of human urinary bladder cancer. Clin Cancer
Res 2006; 12: 3374–3380.
Han M, Liew CT, Zhang HW et al. Novel blood
biomarker panel detects human colorectal cancer
(Poster Abstract). ASCO Meeting, Atlanta, Georgia,
June 2006.
Nam RK, Marshall KW, Zheng R et al. Blood-based
biomarkers for detecting aggressive prostate cancer
at time of biopsy (Poster Abstract). ASCO Meeting,
Atlanta, Georgia, June 2006.
Tsuang MT, Nossova N, Yager T et al. Assessing the
validity of blood-based gene expression profiles for the
classification of schizophrenia and bipolar disorder: a
preliminary report. Am J Med Genet B Neuropsychiatr
Genet 2005; 133: 1–5.
Glatt SJ, Everall IP, Kremen WS et al. Comparative
gene expression analysis of blood and brain provides
concurrent validation of SELENBP1 up-regulation in
schizophrenia. Proc Natl Acad Sci USA 2005; 102:
15533–15538.
298 PART III Therapies and applications
108 Marshall KW, Zhang H, Yager TD et al. Blood-based
biomarkers for detecting mild osteoarthritis in the
human knee. Osteoarthritis Cartilage 2005; 13: 861–
871.
109 Twine NC, Stover JA, Marshall B et al. Diseaseassociated expression profiles in peripheral blood
mononuclear cells from patients with advanced renal
cell carcinoma. Cancer Res 2003; 63: 6069–6075.
110 Sharma P, Sahni NS, Tibshirani R et al. Early detection
of breast cancer based on gene-expression patterns in
peripheral blood cells. Breast Cancer Res 2005; 7:
R634–R644.
111 Vernon SD, Unger ER, Dimulescu IM et al. Utility of the
blood for gene expression profiling and biomarker discovery in chronic fatigue syndrome. Dis Markers 2002;
18: 193–199.
112 Moore DF, Li H, Jeffries N et al. Using peripheral blood
mononuclear cells to determine a gene expression
profile of acute ischemic stroke: a pilot investigation.
Circulation 2005; 111: 212–221.
113 Du X, Tang Y, Xu H et al. Genomic profiles for human
peripheral blood T cells, B cells, natural killer cells,
monocytes, and polymorphonuclear cells: comparisons
to ischemic stroke, migraine, and Tourette syndrome.
Genomics 2006; 87: 693–703.
114 Tang Y, Gilbert DL, Glauser TA et al. Blood gene expression profiling of neurologic diseases: a pilot microarray
study. Arch Neurol 2005; 62: 210–215.
115 Tang Y, Nee AC, Lu A et al. Blood genomic expression
profile for neuronal injury. J Cereb Blood Flow Metab
2003; 23: 310–319.
116 Tang Y, Lu A, Aronow BJ et al. Blood genomic responses
differ after stroke, seizures, hypoglycemia, and hypoxia:
blood genomic fingerprints of disease. Ann Neurol 2001;
50: 699–707.
117 Hansel NN, Hilmer SC, Georas SN et al. Oligonucleotide-microarray analysis of peripheral-blood
lymphocytes in severe asthma. J Lab Clin Med 2005; 145:
263–274.
118 Rus V, Chen H, Zernetkina V et al. Gene expression
profiling in peripheral blood mononuclear cells from
lupus patients with active and inactive disease. Clin
Immunol 2004; 112: 231–234.
119 Baechler EC, Batliwalla FM, Karypis G et al. Interferoninducible gene expression signature in peripheral blood
cells of patients with severe lupus. Proc Natl Acad Sci
USA 2003; 100: 2610–2615.
120 Preston GA, Waga I, Alcorta DA et al. Gene expression
profiles of circulating leukocytes correlate with renal
disease activity in IgA nephropathy. Kidney Int 2004; 65:
420–430.
121 Burczynski ME, Peterson RL, Twine NC et al. Molecular
classification of Crohn’s disease and ulcerative colitis
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
patients using transcriptional profiles in peripheral
blood mononuclear cells. J Mol Diagn 2006; 8: 51–61.
Ma J, Liew CC. Gene profiling identifies secreted protein
transcripts from peripheral blood cells in coronary
artery disease. J Mol Cell Cardiol 2003; 35: 993–998.
Patino WD, Mian OY, Kang JG et al. Circulating transcriptome reveals markers of atherosclerosis. Proc Natl
Acad Sci USA 2005; 102: 3423–3428.
Chon H, Gaillard CA, van der Meijden BB et al. Broadly
altered gene expression in blood leukocytes in essential
hypertension is absent during treatment. Hypertension
2004; 43: 947–951.
Ma J, Dempsey AA, Stamatiou D, et al. Identifying
leukocyte gene expression patterns associated with
plasma lipid levels in human subjects. Atherosclerosis
2006; Jun 26; [Epub ahead of print].
Deng MC, Eisen HJ, Mehra MR et al. Noninvasive discrimination of rejection in cardiac allograft recipients
using gene expression profiling. Am J Transplant 2006;
6: 150–160.
http://www.allomap.com/
Chuaqui RF, Bonner RF, Best CJ et al. Post-analysis
follow-up and validation of microarray experiments.
Nat Genet 2002; 32 (Supplement): 509–514.
Bustin SA, Mueller R. Real-time reverse transcription
PCR (qRT-PCR) and its potential use in clinical diagnosis. Clin Sci (Lond) 2005; 109: 365–379.
Bustin SA. Absolute quantification of mRNA using realtime reverse transcription polymerase chain reaction
assays. J Mol Endocrinol 2000; 25: 169–193.
Simon R. Roadmap for developing and validating therapeutically relevant genomic classifiers. J Clin Oncol
2005; 23: 7332–7341.
http://docs.appliedbiosystems.com/pebiodocs/
04303859.pdf
Pampel FC. Logistic Regression: A Primer. Sage Publications (Quantitative applications in the social sciences;
no. 07-132), Thousand Oaks, California, 2000.
Baker SG. The central role of receiver operating characteristic (ROC) curves in evaluating tests for the early detection of cancer. J Natl Cancer Inst 2003; 95: 511–515.
Ludwig JA, Weinstein JN. Biomarkers in cancer staging,
prognosis and treatment selection. Nat Rev Cancer 2005;
5: 845–856.
Liu ET. Mechanism-derived gene expression signatures
and predictive biomarkers in clinical oncology. Proc
Natl Acad Sci USA 2005; 102: 3531–3532.
Masys DR. Linking microarray data to the literature.
Nat Genet 2001; 28: 9–10.
Gaasterland T, Bekiranov S. Making the most of
microarray data. Nat Genet 2000; 24: 204–206.
Hubner N, Wallace CA, Zimdahl H et al. Integrated
transcriptional profiling and linkage analysis for
CHAPTER 12
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
The potential of blood-based gene profiling for disease assessment
identification of genes underlying disease. Nat Genet
2005; 37: 243–253.
Dennis G Jr, Sherman BT, Hosack DA et al. DAVID:
Database for annotation, visualization, and integrated
discovery. Genome Biol 2003; 4: P3.
Andrade MA, Bork P. Automated extraction of information in molecular biology. FEBS Lett 2000; 476:
12–17.
Rihn BH, Vidal S, Nemurat C et al. From transcriptomics to bibliomics. Med Sci Monit 2003; 9: MT89–
MT95.
http://www.ncbi.nlm.nih.gov/PubMed/
Jenssen TK, Laegreid A, Komorowski J et al. A literature
network of human genes for high-throughput analysis
of gene expression. Nat Genet 2001; 28: 21–28.
http: //www.pubgene.uio.no
Barrett T, Suzek TO, Troup DB et al. NCBI GEO: mining millions of expression profiles: database and tools.
Nucleic Acids Res 2005; 33 (Database issue): D562–
D566.
Su AI, Cooke MP, Ching KA et al. Large-scale analysis of
the human and mouse transcriptomes. Proc Natl Acad
Sci USA 2002; 99: 4465–4470.
Lash AE, Tolstoshev CM, Wagner L et al. SAGEmap: a
public gene expression resource. Genome Res 2000; 10:
1051–1060.
Rhodes DR, Yu J, Shanker K et al. ONCOMINE: a cancer microarray database and integrated data-mining
platform. Neoplasia 2004; 6: 1–6.
Parkinson H, Sarkans U, Shojatalab M et al.
ArrayExpress: a public repository for microarray gene
expression data at the EBI. Nucleic Acids Res 2005; 33
(Database issue): D553–D555.
Milhavet O, Gary DS, Mattson MP. RNA interference
in biology and medicine. Pharmacol Rev 2003; 55:
629–648.
Jackson PD, Harrington JJ. High-throughput target discovery using cell-based genetics. Drug Discov Today
2005; 10: 53–60.
Carmeliet P, Collen D. Transgenic mouse models in
angiogenesis and cardiovascular disease. J Pathol 2000;
190: 387–405.
van der Weyden L, Adams DJ, Bradley A. Tools for targeted manipulation of the mouse genome. Physiol
Genomics 2002; 11: 133–164.
299
155 Albanese C, Hulit J, Sakamaki T et al. Recent advances in
inducible expression in transgenic mice. Semin Cell Dev
Biol 2002; 13: 129–141.
156 Tornell J, Snaith M. Transgenic systems in drug discovery: from target identification to humanized mice. Drug
Discov Today 2002; 7: 461–470.
157 Metzger D, Chambon P. Site- and time-specific gene
targeting in the mouse. Methods 2001; 24: 71–80.
158 Ilyin SE, Belkowski SM, Plata-Salaman CR. Biomarker
discovery and validation: technologies and integrative
approaches. Trends Biotechnol 2004; 22: 411–416.
159 Zambrowicz BP, Sands AT. Knockouts model the 100
best-selling drugs: will they model the next 100? Nat Rev
Drug Discov 2003; 2: 38–51.
160 Kitano H. Systems biology: a brief overview. Science
2002; 295: 1662–1664.
161 Liu ET. Systems biology, integrative biology, predictive
biology. Cell 2005; 121: 505–506.
162 Schadt EE, Lamb J, Yang X et al. An integrative
genomics approach to infer causal associations between
gene expression and disease. Nat Genet 2005; 37:
710–717.
163 Kramer R, Cohen D. Functional genomics to new drug
targets. Nat Rev Drug Discov 2004; 3: 965–972.
164 Hunter PJ, Borg TK. Integration from proteins to
organs: the Physiome Project. Nat Rev Mol Cell Biol
2003; 4: 237–243.
165 Noble D. Modeling the heart: from genes to cells to the
whole organ. Science 2002; 295: 1678–1682.
166 Liew CC, inventor; GeneNews, Inc., assignee. Method
for the detection of gene transcripts in blood and uses
thereof. United States patent US 20040014059. 2004 Jan
22 (priority date January 1999).
167 Cristofanilli M, Budd GT, Ellis MJ et al. Circulating
tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004; 351: 781–791.
168 Wang X, Yu J, Sreekumar A et al. Autoantibody signatures in prostate cancer. N Engl J Med 2005; 353:
1224–1235.
169 Thadikkaran L, Siegenthaler MA, Crettaz D et al. Recent
advances in blood-related proteomics. Proteomics 2005;
5: 3019–3034.
170 Veenstra TD, Conrads TP, Hood BL et al. Biomarkers:
mining the biofluid proteome. Mol Cell Proteomics
2005; 4: 409–418.
Index
Note: page numbers in italics refer to figures and those in bold refer to tables.
ACE inhibitors, pharmacogenetics
heart failure 262
hypertension 258
ACTA 34
actin mutations 60–1
activating protein I 155–6
Adams, Mark 5
α-adducin 179
adeno-associated viruses 197–8
adenovirus vectors 195–7, 196, 197
adipose-derived mesenchymal stem cells 232
adrenergic system 167–8
β2-adrenoceptor 180
adult bone marrow-derived stem cells 227–8
Affymetrix 291
Agre, Peter 89
aldosterone 142
aldosterone synthase, gene mutations 175–6
alkaptonuria 2
α-galactosidase A 36
Andersen syndrome 92
angiogenesis 210–13
therapeutic 203
angiotensin-converting enzyme 179–80
angiotensin II 141–2
angiotensin II receptor type I 179
angiotensinogen 179
animal models 291–2
hypertension 173–4
long QT syndrome 95–7
dog 95–6
lower organisms 97
mouse 96–7
rabbit 96
theoretical 97
ankyrin mutations 91–2
anticoagulants, pharmacogenetics 266–7
antiplatelet drugs, pharmacogenetics 264–6
antisense 208
antithrombin drugs, pharmacogenetics 267
apolipoprotein E 125
apoptosis 152–4, 153
apparent mineralocorticoid excess 177
arginine vasopressin 142
arrhythmias see cardiac arrhythmias
arrhythmogenic right ventricular cardiomyopathies 62–6,
64
cardiac ryanodine receptor 2 mutations 63–4
desmoplakin mutations 64–5
plakoglobin mutations 66
plakophilin-2 mutations 65
transforming growth factor-β3 mutations 65–6
aspirin, pharmacogenetics 264–5
atherosclerosis 113–36, 279
candidate genes 121–2, 122, 123
coagulation and fibrinolysis 127
endothelial dysfunction 114–15
gene identification 124–5
genes and lipids 125–6
gene therapy 128, 215–16
genetic polymorphisms 126–7
genetics 119–20, 120
Human Genome Project 120–1
inflammation 126–7
International HapMap Project 120–1
lesion formation 114–15
molecular and gene levels 115–19
NO53 122–4
atorvastatin 253
ATP-binding cassette superfamily 126
autosomal recessive hypercholesterolemia 25–6
Avery, Oswald 2
Baltimore, David 3
Barth syndrome 59–60
Bateson, William 1
Beadle, George 2
Becker muscular dystrophy 59
β-blockers 42
pharmacogenetics
heart failure 259–62, 260, 261
hypertension 258
301
302 Index
BioCardia delivery system 234
bisoprolol 260
blind test 290
blood
collection and handling 282, 284–5
role in cardiovascular pathogenesis 279–80
blood gene expression profiling 277–99
analysis of data 283
biomedical applications 285–7
disease factors 286–7
environmental and behavioral factors 285–6
individual factors 285
blood collection and handling 282, 284–5
candidate gene expression 283–4
critical factors 284–5
gene expression profiling 280–1
measurement of expression 282–3
microarrays 281–2
quantitative real-time RT-PCR 277–99
rationale for 278–9
RNA isolation 282
RNA labeling 282
RNA quality 285
validation 287–93
discovery 288–90
functional 290–3
blood pressure regulation 133
BOOST trial 237
brachydactyly, in hypertension 178
Bridges, Calvin 1
Britten, Roy 3
Brugada syndrome 83, 91
glycogen storage diseases 36, 70–1
Kearns-Sayre syndrome 37, 70
left ventricular noncompaction 71
Leigh syndrome 70
MELAS 70
mitochondrial 68–70
restrictive 66–8
carvedilol 260
CAV3 34
CD34 229, 232
CD36 deficiency 37
CD133 229
cDNA microarrays 6
cell death 152–4, 153
cell models 291–2
ceramide trihexosidase 36
channelopathies 83
Chase, Martha 2
cholesteryl ester transfer protein 19, 126
chromosome analysis 290–1
clopidogrel, pharmacogenetics 265–6
coagulation 127
computational modeling 292–3
cord blood stem cells 232
coronary artery calcification, genome-wide screens 122
coronary artery disease 280
DNA sequence variations 123
genome-wide screens 122
Correns, Carl 1
C-reactive protein 127, 280
Crick, Francis 2
cytokines 117–18, 143
calcineurin 149
calcineurin inhibitors 45
calcium handling proteins 145
candidate genes 277, 281, 283–4
atherosclerosis 121–2, 122, 123
expression 283–4
hypertension 172, 179–80
cardiac arrhythmias
gene therapy 214
pharmacogenetics 267–8
cardiac gene delivery 200–1
cardiac proarrhythmias, pharmacogenetics 267–8
cardiac ryanodine receptor 2 mutations 63–4
cardiac troponin I mutations 67
CardioChip 7, 281, 286
cardiomyopathies 55–82
arrhythmogenic right ventricular 62–6
characterization 65–7
classification 55–6
familial dilated 57–62, 58
Danon disease 37
DAVID tool 291
decoys 209
denroaspis natriuretic peptide 170
desmin mutations 67–8
desminopathy 58–9
desmoplakin mutations 64–5
de Vries, Hugo 1
digoxin, pharmacogenetics 262–3
discovery validation 288–90
disopyramide 42
diuretics, pharmacogenetics
heart failure 263
hypertension 257
DMPK 36
DMWD 36
DNA 10
dopaminergic system 169–70
dual chamber pacing 44
Duchenne muscular dystrophy 59
Index
dyslipidemia, pharmacogenetics 251–7
nonstatin cholesterol modulators 256–7
relevance to treatment 257
statins 251–6, 252–4
dystrophinopathies 59
electrocardiogram in long QT syndrome 84
electrolyte imbalance 97–8
electroporation 199
embryonic stem cells 231
Emery-Dreifuss muscular dystrophies 61–2
endothelial progenitor cells 226–7, 228–30, 229, 230
endothelin 143, 171
energy metabolism 150–2, 151
epinephrine 140–1
ether-a-go-go-gene 87
ether-a-go-go-related gene 89
ethnicity in heart failure 138–9
eukaryotes 3
exons 3
expressed sequence tags 5, 6, 281
expression cassette 199
Fabry disease 36, 68
familial atrial fibrillation 83
familial combined hyperlipidemia 126
familial defective apoB-100 23
familial dilated cardiomyopathies 57–62, 58
Barth syndrome 59–60
desminopathy 58–9
Duchenne and Becker muscular dystrophy 59
dystrophinopathies 59
Emery-Dreifuss muscular dystrophies 61–2
laminin-2 (merosin) mutations 61
myosin and actin mutations 60–1
sarcoglycanopathies 61
titin mutations 61
troponin mutations 60
X-linked 60
familial dilated cardiomyopathy 57–8, 58
familial hyperaldosteronism type II 178, 178
familial hypercholesterolemia 21–3, 22
familial sick sinus syndrome 83
fatty streaks 114–15
fibrinolysis 127
fluvastatin 253
FRDA 36
functional validation 290–3
GA IIb/IIIa inhibitors, pharmacogenetics 265
Garrod, Archibald 2
GATA4 155
Gaucher disease 37
genes 1–15
1960 onwards 2–4, 4
cardiac myosin heavy chain 9–10, 9
function 2
search for 1–2
structure 10
gene array studies 156–8, 157
gene expression 10
therapeutic, duration of 203–4
gene expression profiling 11
blood 277–99
gene silencing 203, 204
gene splicing 3
gene therapy 195–224
cardiovascular indications 200–3
atherosclerosis 128, 215–16
ex vivo gene delivery 202–3
heart 200–1
skeletal muscle 202
vasculature 201–2
clinical applications 210–15, 211
angiogenesis 210–13
cardiac rhythm disturbances 214
heart failure 213–14
myocardial protection 214–15
control of patient’s own genes 204–6, 205
duration of therapeutic gene expression 203–4
gene correction 209–10
gene delivery 195–200
adeno-associated viruses 197–8
adenovirus vectors 195–7, 196, 197
lentiviruses 199
nonviral gene delivery 199–200
retrovirus vectors 198–9
potential dangers of 210
splicing 206–8, 207
turning off genes 208–9
decoys 209
siRNA, antisense and ribozymes 208
targeted genomic disruption 208–9
targeted transcriptional repression 208–9
vascular remodeling 215–16
zinc finger proteins 206
genetics
atherosclerosis 119–20, 120
hypertrophic cardiomyopathy 34–7
long QT syndrome 85
genome 10
genome-wide screens
coronary artery calcification 122
hypertension 172–4
myocardial infarction 122
genomics 11
303
304 Index
Gilbert, Walter 3, 5, 8
GLA 36
glycogen storage diseases 36, 70–1
glycogen synthase 3β 149
Gordon syndrome 178
Gαq-Gα11 signal transduction 148–9
Gαs signal transduction 147–8
haplo-insufficiency 41
heart failure 137–65
gene therapy 213–14
hemodynamic and mechanical factors 139–40
intracardiac factors 144–58
cell death and regeneration 152–4, 153
energy metabolism 150–2, 151
gene array studies 156–8, 157
interstitium 146–7
myocardial calcium handling 145–6, 145
oxidative injury, hypoxia and nitrous oxide 154–5
receptors and signal transduction 147–50, 148
sarcomeric proteins 144–5
transcription factors 155–6
neurohormonal and cytokine signaling 140–3
aldosterone 142
angiotensin II 141–2
arginine vasopressin 142
cytokines 143
endothelin 143
epinephrine and norepinephrine 140–1
pharmacogenetics 259–64
ACE inhibitors 262
β-blockers 259–62, 260, 261
digoxin 262–3
diuretics 263
isosorbide dinitrate-hydralazine 263–4
relevance to treatment 262, 264
spironolactone 263
polygenic factors 137–9, 138
hemochromatosis 37
heparin epidermal binding growth factor-like protein
117
Hershey, Alfred 2
HMG-CoA reductase inhibitors see statins
housekeeping genes 283
Human Genome Project 4–8, 5, 10, 277
atherosclerosis 120–1
hydralazine, pharmacogenetics 263–4
hydrogels 199
11-β-hydroxylase deficiency 176
17α-hydroxylase deficiency 176
hypercholesterolemia
autosomal recessive 25–6
familial 21–3, 22
hypertension 166–91
animal models 173–4
association studies 174
candidate genes 172, 179–80
α-adducin 179
β2-adrenoceptor 180
angiotensin-converting enzyme 179–80
angiotensin II receptor type I 179
angiotensinogen 179
epistatic interactions and haplotype analysis 174
gene evaluation 180–1
genes and treatment 181–3, 183
genome-wide linkage screens 172–4
genomics and risk stratification 181
linkage analysis 174
molecular pathways 167–72
adrenergic system 167–8
dopaminergic system 169–70
endothelin 171
inflammation 172
kallikrein-kinin system 171
natriuretic peptides 170–1
nitric oxide 170
oxidative stress 171–2
renin-angiotensin system 168–9
monogenic 173, 175–8
aldosterone synthase gene mutations 175–6
apparent mineralocorticoid excess 177
familial hyperaldosteronism type II 178, 178
Gordon syndrome 178
11-β-hydroxylase deficiency 176
17α-hydroxylase deficiency 176
hypertension with brachydactyly 178
mineralocorticoid receptor mutations 177
mutations in sodium channel genes 175
PPAR γ mutations 177–8
pathophysiology 167
pharmacogenetics 257–8
ACE inhibitors and angiotensin receptor blockers
258
β-blockers 258
diuretics 257
relevance to treatment 258
hypertrophic cardiomyopathy 30–54
definition 31–2
genetic and non-genetic phenotype determinants 37–8,
37
genetic screening 38–9
molecular genetics 34–7
causal genes 34–5, 34
genetic basis of phenocopy 35–7, 36
modifier genes 35
new therapeutic approaches 44–5
Index
pathogenesis 39–41, 40, 41, 41
phenotypic manifestations 32–3
prevalence 32, 33
risk factors 33
treatment 41–4, 42
dual chamber pacing 44
surgical myectomy 43–4, 43
transcoronary septal ablation 43, 44
hypoxia 154–5
inborn errors of metabolism 2
inflammation in hypertension 172
Ingram, Vernon 2
innate immunity 279
insertional mutagenesis 203, 210
intercellular adhesion molecule 1 (ICAM-1) 116
International HapMap Project 120–1
introns 3
ion channels 87
potassium 89–90
sodium 90–1
structure-function 88–9, 88
ion currents 87
isosorbide dinitrate, pharmacogenetics 263–4
Itano, Harvey 2
Jacob, Francois 3
Johannsen, Wilhelm 1
junk DNA 3
kallikrein-kinin system 171
KCNE protein family 90
Kearns-Sayre syndrome 37, 70
Keller, Evelyn Fox 2, 9
kininogens 171
kinins 171
Kohne, David 3
laminin-2 (merosin) mutations 61
LAMP2 36
LDL see low-density lipoprotein
left ventricular noncompaction cardiomyopathy 71
Leigh syndrome 70
lentiviruses 199
leukocytes 279–80
Liddle syndrome 175
linkage analysis, hypertension 174
lipofection 199
lipoprotein (a) 126
lipoprotein lipase 126
5-lipoxygenase 126
logit cutoff value 289–90
logit transformation 289
long QT syndrome 83–110
acquired 94–5
cellular mechanisms 92–4, 93, 94
clinical treatment 99–100
ICD therapy 100
LQT1 99
LQT2 99–100
LQT3 100
LQT4-8 100
pacemaker therapy 100
diagnosis 98–9, 99
drugs causing 85
experimental models 95–7
dog 95–6
lower organisms 97
mouse 96–7
rabbit 96
theoretical 97
genetics 85
historical development 85–7, 86
modifying factors 97–8
adrenergic stimulation 97
electrolytes 97–8
gender and sex hormones 98
molecular mechanisms 87–92
affected genes 89
Andersen syndrome 92
ankyrin mutations 91–2
cardiac ion channels 87
ion channel structure-function 88–9, 88
ionic currents 87
potassium channels 89–90
sodium channel 90–1
Timothy syndrome 92
pharmaceutical challenges 100–1
risk stratification 99
surface ECG 84
symptoms 98
lovastatin 253
low-density lipoprotein 19
metabolism 19
low-density lipoprotein receptor 20–1
domain structure 19–20
mutations in familial hypercholesterolemia 22
LymphoChip 281
McCarty, Maclyn 2
McClintock, Barbara 3
MacKinnon, Roderick 89
MacLeod, Colin 2
macrophages 117
MAGIC trial 239
MAPK kinases 148
305
306 Index
MAPKK kinases 148
Marchand, Felix 113
Marfan’s syndrome 209
massively parallel signature sequencing (MPSS) 281
matrix metalloproteinases 119, 230
Mendel, Gregor 1
mesenchymal stem cells 228
metabolomics 11
metoprolol 260
mexiletine 100
microarrays 6–7, 11, 277
blood gene expression profiling 281–2
CardioChip 7, 281, 286
gene expression profiling 11
LymphoChip 281
microRNA 4
mineralocorticoid receptor, gene mutations 175–6
missense mutations 9
mitochondrial cardiomyopathies 68–70
modifier genes 35
Monod, Jacques 3
monogenic hypercholesterolemia 19–29, 20
autosomal recessive hypercholesterolemia 25–6
domain structure of LDL receptor 19–20
familial defective apoB-100 23
familial hypercholesterolemia 21–3, 22
LDL 19
LDL metabolism 19
LDL receptor 20–1
PCKS9 nonsense mutations 23–5, 24
sitosterolemia 26
Morgan, Thomas Hunt 1
MOY6 36
mTOR 156
MTTG 36
MTTI 36
Muller, Herman J 1
mutations 11
missense 9
MYBPC3 34
MYH6 34
MYH7 34
MYL2 34
MYL3 34
MYLK2 34
myocardial calcium handling 145–6, 145
myocardial infarction, genome-wide screens 122
myocardial ischemia, stem cell therapy 240–4
clinical trials 242–3, 243
preclinical studies 240–2, 241
safety 243–4
myocardial protection, gene therapy 214–15
myomectomy 43–4, 43
myopathy, encephalopathy, lactacidosis and stroke-like
episodes (MELAS) 70
myosin heavy chain
genes 9–10, 9, 17
isoforms 144
myosin mutations 60–1
Myostar delivery system 234
natriuretic peptides 170–1
natriuretic peptide receptor-A 170
natriuretic peptide receptor-B 170
Naxos disease 64
Neel, James 2
Niemann-Pick disease 37
nitric oxide 116, 170
nitric oxide synthase 143
nitrous oxide 154–5
noncoding RNA 4
nonprotein coding RNA 4
nonviral gene delivery 199–200
Noonan syndrome 36, 37
norepinephrine 140–1
NOS3 115, 116, 122–4
nuclear factor of activated T cells 156
nuclear factor κB 117, 156
nucleotides 10
null alleles 125
one-gene-one-enzyme hypothesis 2
operons 3
oxidative injury 154–5
oxidative stress 171–2
pacemaker therapy in long QT syndrome 100
pathway analysis 291
Pauling, Linus 2
PCKS9 nonsense mutations 23–5, 24
peroxisome proliferator-activated receptor 151–2,
151
mutations 177–8
personalized therapy see pharmacogenetics
pharmacogenetics 250–76
anticoagulants 266–7
antithrombin drugs 267
arrhythmia and proarrhythmia 267–8
dyslipidemia 251–7
nonstatin cholesterol modulators 256–7
relevance to treatment 257
statins 251–6, 252–4
future directions 268–9, 269
heart failure 259–64
ACE inhibitors 262
β-blockers 259–62, 260, 261
Index
digoxin 262–3
diuretics 263
isosorbide dinitrate-hydralazine 263–4
relevance to treatment 262, 264
spironolactone 263
hypertension 257–8
ACE inhibitors and angiotensin receptor blockers
258
β-blockers 258
diuretics 257
relevance to treatment 258
thrombosis 264
antiplatelet drugs 264–6
aspirin 264–5
clopidogrel 265–6
GP IIb/IIIa inhibitors 265
pharmacogenomics 250
PI3K-Akt signal transduction 149–50, 150
plakoglobin mutations 66
plakophilin-2 mutations 65
plaque 118
plasminogen activator inhibitor-1 127
platelet derived growth factor 117
platelets 119, 280
PLN 34
Pompe disease 37
potassion channels 89–90
PPAR see peroxisome proliferator-activated receptor
pravastatin 253
private mutations 35
PRKAG2 36
prokaryotes 3
protein 11
protein kinase A 141
proteomics 11
PTPN11 36
quantitative trait loci 291
Refsum disease 37
renin-angiotensin syndrome 168–9
resident cardiac stem cells 231–2
response to injury hypothesis 114
restrictive cardiomyopathies 66–8
cardiac troponin I mutations 67
desmin mutations 67–8
Fabry disease 36, 68
transthyretin (prealbumin) mutations 68
retrograde coronary venous delivery 199
retrovirus vectors 198–9
reverse transcriptase-polymerase chain reaction
see RT-PCR
ribozymes 208
RNA 12
micro 4
noncoding 4
nonprotein coding 4
RNA world hypothesis 8
Romano-Ward syndrome 85–6
RT-PCR
Molecular Beacon 288
quantitative real-time 283–4, 288
SYBR Green 288
Taqman system 288
sarcoglycanopathies 61
sarcomeric proteins 144–5
Sentinel Principle 278
SERCA protein 146
serial analysis of gene expression (SAGE) 281
Sharp, Phillip 3
sickle cell anemia 2
signal transduction 147–50, 148
glycogen synthase 3β 149
Gαq-Gα11 148–9
Gαs 147–8
PI3K-Akt 149–50, 150
stress activated kinases 149
simvastatin 253
single gene disorders 8
monogenic hypercholesterolemia 19–29
single nucleotide polymorphisms 12, 35, 120
siRNA 208
sitosterolemia 26, 126
skeletal muscle, gene delivery 202
skeletal myoblasts 231
sodium channel 90–1
gene mutations 175
spironolactone, pharmacogenetics 263
statins, pharmacogenetics 251–6, 252–4
candidate genes 252
stem cells 225–49
adipose-derived mesenchymal 232
adult bone marrow-derived 227–8
alternative sources 232
in cardiovascular repair 226–7
chronic myocardial ischemia 240–4
clinical trials 242–3, 243
prelinical studies 240–2, 241
safety 243–4
clinical trials 236–40, 237, 238, 240
cord blood 232
definition 225–6
delivery 232–6
comparison of methods 236
intracoronary infusion 233
307
308 Index
stem cells (cont’d)
intramyocardial injection 233–5
stem cell mobilization 232–3
transcoronary venous injection 235–6
transvascular delivery 233
embryonic 231
endothelial progenitor 228–30, 229, 230
identification 226, 226
mesenchymal 228
resident cardiac 231–2
skeletal myoblasts 231
Stilleto delivery system 234
stress activated kinases 149
Sturtevant, Alfred 1
sudden infant death syndrome 87
superoxide dismutase 116
syncope 42
Tangier disease 126
targeted genomic disruption 208–9
targeted transcriptional repression 208–9
Tatum, Edward 2
TCAP 34
Temin, Howard 3
The Chipping Forecast 281
thrombosis, pharmacogenetics 264
antiplatelet drugs 264–6
aspirin 264–5
clopidogrel 265–6
GP IIb/IIIa inhibitors 265
Timothy syndrome 92
tissue-type plasminogen activator 127
titin 144
mutations 61
TNNCI 34
TNNI 34
TNNT2 34
torsade de pointes 83
drugs causing 85
total gene expression analysis (TOGA) 281
TPM1 34
transcoronary septal ablation 43, 44
transcription factors 155–6, 204
activating protein I 155–6
GATA4 155
mTOR 156
nuclear factor of activated T cells 156
nuclear factor κB 156
transcriptomics 277
transforming growth factor-β3 mutations 65–6
transforming growth factor β 232
Transplantation of Progenitor Cells and Regeneration
Enhancement in Acute Myocardial Infarction
(TOPCARE-AMI) trial 236
transthyretin (prealbumin) mutations 68
trinucleotide repeat syndromes 36
troponin mutations 60
TTN 34
tumor necrosis factor-α 117, 143
tumor necrosis factor-β 127
ultrasound-mediated gene delivery 199
vascular cell adhesion molecule 1 (VCAM-1) 116
vascular endothelial growth factor 229, 232
vascular remodeling 215–16
vasculature, gene delivery 201–2
Venter, Craig 5
verapamil 42
very low-density lipoprotein 19
VLDL see very low-density lipoprotein
von Haller, Albrecht 113
von Tschermak, Erich 1
Watson, James 2
Wolff-Parkinson-White syndrome 32
X-linked dilated cardiomyopathy 60
zinc finger proteins 206
molecular structure 205
Plate 2.1 Overview of low density lipoprotein (LDL)
metabolism.The liver synthesizes and secretes very low
density lipoprotein (VLDL), which are triglyceride-rich
lipoproteins, containing one molecule of apoB. The
triglycerides and phospholipids of circulating VLDL are
hydrolyzed by lipases at vascular endothelial surfaces. Free
fatty acids may be taken up by adipose tissue and stored in
lipid droplets or oxidized in skeletal muscle or other tissues.
The remaining cholesterol-enriched intermediate density
lipoprotein (IDL) remnant may be removed directly by the
liver or converted to LDL, a process which involves
remodeling by hepatic lipase and cholesteryl ester transfer
protein (CETP). LDL are largely cleared from the circulation
by the liver after binding to LDL receptors by receptormediated endocytosis [5].
Plate 2.2 Domain organization of the
low density lipoprotein (LDL) receptor.
This receptor is a glycoprotein of 839
amino acids with a single transmembrane
domain. Seven LDL receptor type A (LA)
molecules at the amino terminal end are
responsible for lipoprotein binding via
apoB or apoE [7]. The ligand binding
domain is the most frequent site of
mutations leading to familial
hypercholesterolemia (FH). Mutations in
apoB (esp Arg3500Gln) impair the
interaction of LDL with the LDLr leading
to familial dysbetalipoproteinemia
(FDB). Adjacent to this is a region with
homology to the epidermal growth
factor precursor (EGFP) consisting of two
EGF-like repeats, a YWTD domain and a
third EGF repeat. This region of the LDLr
is implicated in the release of internalized
lipoproteins in acidic endosomes at low
pH [8]. Interspersed between the
epidermal growth factor receptor (EGFR)
and the plasma membrane is a region rich
in serine and threonine which undergoes
N-linked glycosylation. This O-linked sugar
domain is followed by the transmembrane
domain and a 50 AA cytoplasmic tail
required for receptor localization in
clathrin coated pits and a NPxY motif
required for receptor internalization [9]
(reviewed in [10]).
Liver
LDL receptors
LDL
IDL
VLDL
LPL
Adipose tissue
Glycerides,
free fatty acids
Muscle tissue
Repeat 4
Repeat 3
Repeat 5
Repeat 2
Repeat 6
Repeat 1
Repeat 7
1
Ligand-binding domain
residues 1–292
EGF A
EGF B
β-propeller
EGF precursor
homology domain
residues 293–692
EGF C
O-linked sugar domain
Transmembrane domain
NPxY
831
Cytoplasmic tail
ER
2
Golgi
1
LDL receptor
4
LDL
Coated
pit
3
5
Lysosome
Endosome
MUTATION
CLASS
1
2
3
4
5
Synthesis
Transport
Binding
Internalization
Recycling
X
X
X
X
Adapted from Hobbs et al. Ann. Rev. Genet. 1990; 24: 133–170.
X
Plate 2.3 Classification of low density
lipoprotein (LDL) receptor mutations
that cause familial hypercholesterolemia
(FH). Mutations of the LDL receptor that
result in FH have been classified based
on how they perturb LDL receptor
intracellular trafficking or function.
Class 1: The LDLr is not synthesized (e.g.,
deletions in the promoter region or
splice defects). Class 2: the receptor is
synthesized but not transported to the
cell surface (predominately mutations in
the EGF precursor homology domain).
Class 3: the receptor is presented on the
cell surface but cannot bind ligands
(mutations in the ligand-binding domain).
Class 4: the receptor cannot localize in
coated pits and, as a consequence,
cannot mediate endocytosis (mutations
or deletions in the cytoplasmic tail). Class
5: the LDL receptor–ligand complex fails
to undergo pH-dependent dissociation
and the LDL receptor does not recycle
(deletion of the EGF precursor homology
domain).
(b)
(a)
(c)
Plate 3.1 Gross anatomic and histologic phenotype
in HCM. (a) Coronal section of the myocardium showing
hypertrophic walls and small left ventricular cavity
(courtesy of Sidney S. Murphree, MD, University of
Louisville). (b) Low magnification view (× 6) of H&E stained
myocardial section, showing disorganized architecture.
(c) High magnification view of myocytes (× 60) on a H&E
stained section.
BONE
MARROW
BMEC
Adipocyte
Stromal cell
Erythroblast
EPC
Plate 10.1 Bone marrow derived cells.
Adapted from Bianco P, Cossu G. Uno,
nessuno e centromila: searching for the
identity of mesodermal progenitors. Exp
Cell Res. 1999 Sept 15; (2): 257–63.
BONE
HSC
Osteoclast
Osteoblast
Osteocyte
Plate 10.2 (Top) DiI-positive stem cells (red) in the midmyocardium of the anterolateral wall. (Middle) x-Smooth
muscle actin staining with Fitc (green) showing crosssection of vessel wall. (Bottom) Stained areas showing
colocalization (yellow) of stem cells and smooth muscle
cells, suggesting transformation of stem cells into smooth
muscle cells. The vessel shown is in the myocardial
interstitium. Arrows point to vessel media. Reprinted from
Circulation 2005; 111: 150–156 with permission.
Plate 10.3 (A) Factor VIII staining with Fitc (green) showing
a thin vessel wall. (B) DiI-positive mesenchymal stem cells
(red) in a vessel of the anterolateral wall. (c) Colocalization
(yellow) of MSCs and endothelial cells, indicating
transformation of MSCs into endothelial cells. (D) DAPI
stain showing labeled endothelial nuclei. Reprinted from
Circulation 2005; 111: 150–156 with permission.
a
b
Syringe containing
adult stem cells
LAD
Ballon catheter
Border zone
Infarcted zone
c
Patients with same diagnosis
Predicted good
response to
tested drug
Predicted poor or
nonresponse
Use different drug
Predicted increased
toxicity risk
Decrease dose or use
different drug
Plate 10.4 Technique for cardiac stem
cell transplantation as treatment for
myocardial infarction. (a) Balloon
catheterization of infarct-related artery
(LAD) above the infarct border zone
followed by high-pressure infusion of
stem cells into the artery. (b) Migration
of stem cells (red dots) into infarcted
zone via infarct-related blood vessels
along suggest the possible route of
migration. (c) Migration of cells to both
infarct and border zone via existing
blood flow within infarcted zone. From
Straver BE, Brehm M, Zeus T, et al. Repair
of infarcted myocardium by autologous
intracoronary mononuclear bone
marrow cell transplantation in humans.
Reprinted from Circulation 2002; 106:
1913–8, with permission.
Plate 11.1 Clinical potential of
pharmacogenetics. Patients with the
same diagnosis (e.g., hypertension,
dyslipidemia, heart failure) are typically
treated either empirically (trial and
error) or by a protocol-driven approach.
However, their responses to drug
therapy will not be the same, with some
having an efficacious response, some
having little to no response, and others
having an adverse response.
Pharmacogenetics has the potential to
provide a tool for predicting those
patients who are likely to have the
desired response to the drug, those who
are likely to have little or no benefit, and
those at risk for toxicity. This would
allow tailored therapy that should
reduce adverse reactions to drugs, and
increase efficacy rates. Reprinted from
[191] with permission from Elsevier.
Plate 12.1 Work flow for systematic blood-based RNA biomarker discovery, validation and application.
Plate 12.2 Disease gene discovery: Microarray gene expression profiling.
Plate 12.3 Disease gene validation: Real-time reverse transcriptase polymerase chain reaction (RT-PCR) relative
quantification.
Plate 12.4 Disease gene application: Multigene expression classifier.